-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MwJDUsXoABkFvuB+yzXG7YBkRkMJQo5QeLNdq8/z0IvsWrv1bXwr/wMXkb37aEQA +X2GSb2fbY113k5Xn0Rs2g== 0000739944-04-000011.txt : 20040318 0000739944-04-000011.hdr.sgml : 20040318 20040318165325 ACCESSION NUMBER: 0000739944-04-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20031231 FILED AS OF DATE: 20040318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTOX SCIENTIFIC INC CENTRAL INDEX KEY: 0000739944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 953863205 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11394 FILM NUMBER: 04678223 BUSINESS ADDRESS: STREET 1: 402 WEST COUNTY ROAD D CITY: ST PAUL STATE: MN ZIP: 55112 BUSINESS PHONE: 6126367466 MAIL ADDRESS: STREET 1: 402 WEST COUNTY ROAD D CITY: ST PAUL STATE: MN ZIP: 55112 FORMER COMPANY: FORMER CONFORMED NAME: EDITEK INC DATE OF NAME CHANGE: 19940902 FORMER COMPANY: FORMER CONFORMED NAME: ENVIRONMENTAL DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-K 1 form10k.htm 10-K 10-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2003

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission file number 1-11394

MEDTOX SCIENTIFIC, INC.
(Exact name of Registrant as specified in its charter)


Delaware	95-3863205
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)


402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, par value $.15 per share
(Title of Class)

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X]

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). Yes [ ] No [X]

The aggregate market value of Common Stock of the Registrant, $.15 par value (“Common Stock”), held by non-affiliates of the Registrant was approximately $28,433,635 as of the last business day of the Registrant’s most recently completed second fiscal quarter, based upon a price of $6.37, which price was equal to the closing price for the Common Stock on the American Stock Exchange.

The number of shares of Common Stock outstanding as of March 2, 2004, was 4,976,986.

Portions of the Registrant’s Proxy Statement for its 2004 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

MEDTOX SCIENTIFIC, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2003

Table of Contents

ITEM NO.		PAGE
Part I

1.	Business. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	5

2.	Properties. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	12

3.	Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	13

4.	Submission of Matters to a Vote of Security Holders . . . . . . . . . . . . . . . . . . . .	13

Part II

5.	Market for the Registrant's Common Equity
	and Related Stockholder Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	14

6.	Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	15

7.	Management's Discussion and Analysis
	of Financial Condition and Results of Operations . . . . . . . . . . . . . . . . . . . . .	16

7A.	Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . .	25

8.	Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . .	26

9.	Changes in and Disagreements With Accountants on
	Accounting and Financial Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	26

9A.	Controls and Procedures. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	26

Part III

10.	Directors and Executive Officers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	27

11.	Executive Compensation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	27

12.	Security Ownership of Certain Beneficial Owners and Management
	and Related Stockholder Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	27

13.	Certain Relationships and Related Transactions . . . . . . . . . . . . . . . . . . . . . . . .	27

14.	Principal Accountant Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	27

Part IV

15.	Exhibits, Financial Statement Schedule, and Reports on Form 8-K. . . . . . . . . .	28

	Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	34

PART I

CAUTIONARY STATEMENT IDENTIFYING IMPORTANT FACTORS
THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER
FROM THOSE PROJECTED IN FORWARD LOOKING STATEMENTS

In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, readers of this document and any document incorporated by reference herein, are advised that this document and documents incorporated by reference into this document contain both statements of historical facts and forward looking statements. Forward looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially from those indicated by the forward looking statements. Examples of forward looking statements include, but are not limited to (i) projections of revenues, income or loss, earnings or loss per share, capital expenditures, dividends, capital structure and other financial items, (ii) statements of the plans and objectives of the Company or its management or Board of Directors, including the introduction of new products, or estimates or predictions of actions by customers, suppliers, competitors or regulatory authorities, (iii) statements of future economic performance, and (iv) statements of assumptions underlying other statements and statements about the Company or its business.

This document and any documents incorporated by reference herein also identify important factors which could cause actual results to differ materially from those indicated by the forward looking statements. The factors that could affect our actual results include the following:

increased competition, including price competition

general economic and business conditions, both nationally and internationally

changes in business strategy or development plans

technological, evolving industry standards, or other problems that could delay the sale of our products

risks and uncertainties with respect to our patents and proprietary rights including:

lack of meaningful protection from claims of any patents issued to the Company

other companies challenging our patents

patents issued to other companies that may harm our ability to do business

other companies designing around technologies we have developed

our inability to obtain appropriate licenses from third parties

our inability to protect our trade secrets

risk of infringement upon the proprietary rights of others

our inability to prevent others from infringing on our proprietary rights

our inability to obtain sufficient financing to continue to expand operations

changes in demand for products and services by our customers

our failure to obtain and retain new customers and alliance partners, or a reduction in tests ordered or specimens submitted by existing customers

adverse results in litigation matters

our ability to attract and retain experienced and qualified personnel

failure to maintain our days sales outstanding levels

losses due to bad debt

The cautionary statements made pursuant to the Private Securities Litigation Reform Act of 1995 above and elsewhere by the Company should not be construed as exhaustive or as any admission regarding the adequacy of disclosures made by the Company prior to the effective date of such Act. Forward looking statements are beyond the ability of the Company to control, and in many cases the Company cannot predict what factors would cause results to differ materially from those indicated by the forward looking statements.

ITEM 1. BUSINESS.

1. General.

MEDTOX Scientific, Inc. (formerly EDITEK, Inc.), a Delaware corporation, was organized in September 1986. MEDTOX Scientific, Inc. and its subsidiaries, MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and New Brighton Business Center, LLC are referred to herein as “the Company.” The Company is engaged primarily in two distinct, but very much related businesses. The business of forensic and clinical laboratory services is conducted by MEDTOX Laboratories, Inc. at its facility in St. Paul, Minnesota, and the business of manufacturing and distribution of diagnostic devices is executed by MEDTOX Diagnostics, Inc. from its facility in Burlington, North Carolina. For the year ended December 31, 2003, sales from the forensic and clinical laboratory services conducted by MEDTOX Laboratories, Inc. accounted for 77% of the Company’s revenues. Revenue from the manufacture and distribution of diagnostic devices and other similar products, including some contract manufacturing conducted by MEDTOX Diagnostics, Inc., accounted for 23% of the total revenues of the Company for the year ended December 31, 2003.

2. Principal Services, Products, and Markets.

General. The Company has two reportable segments: “Laboratory Services” conducted by the Company’s wholly owned subsidiaries, MEDTOX Laboratories, Inc. and New Brighton Business Center, LLC and “Product Sales” conducted by the Company’s wholly owned subsidiary MEDTOX Diagnostics, Inc. Laboratory Services include forensic toxicology, clinical toxicology, clinical testing for the pharmaceutical industry (central laboratory services, bioanalytical and pharmacokinetic testing), and analysis of heavy and trace metals. In addition, the Laboratory Services segment provides logistical support, data management and overall program management services. Product Sales include sales of a variety of on-site screening products and contract manufacturing. For financial information relating to the Company’s segments, see Note 2 of Notes to the Consolidated Financial Statements.

Laboratory Services

A. Employment Drug Testing Laboratory Services. The primary source of revenue for the Company is derived from the provision of laboratory testing services for the identification of drugs-of-abuse. These tests are conducted using methodologies that include various immunoassays, gas liquid chromatography, gas chromatography/mass spectrometry and high performance liquid chromatography with tandem mass spectrometry (LC/MS/MS). MEDTOX Laboratories, Inc. was one of the charter laboratories to be certified by the federal government to perform drug testing of employees covered by the Federal Workplace Drug Testing Guidelines. The Company pioneered security and chain of custody procedures, including sample bar coding and automated sample handling as well as specific confirmation methods that assist in maintaining specimen integrity and the accuracy and confidentiality of test results.

The Company’s customers for substance abuse testing include public and private corporations. In addition to public and private corporations, substance abuse testing is also conducted on behalf of service firms such as drug treatment counseling centers, occupational health clinics, third party administrators and hospitals.

B. Clinical Toxicology. The Company has a fully certified clinical toxicology reference laboratory specializing in esoteric therapeutic drug monitoring and emergency toxicology. The tests performed in the clinical laboratory are conducted using methodologies such as various immunoassays, gas liquid chromatography, high performance liquid chromatography, gas chromatography/mass spectrometry and tandem mass spectrometry. The Company performs analytical testing for a wide variety of drug classes including: analgesic, antianxiety, anticholinergic, anticoagulant, anticonvulsant, antidepressant, antidiabetic, antiemetic, antihistamine, antiinflammatory, antimicrobial, antipsychotic, bronchodilator, cardiovascular, stimulant, decongestant, immunosuppressant, local anesthetic, muscle relaxant, narcotic analgesic, and sedative medications.

The Company’s clients for this market consist of hospitals, clinics and other laboratories. Laboratory specimens are delivered to the Company from clients throughout the country by the Company’s own couriers, contracted delivery services and commercial overnight couriers.

C. Clinical Testing for the Pharmaceutical Industry. The Company provides laboratory testing for Phase I-IV clinical trials, including general laboratory services, assay development, bio-analytical and pharmacokinetic testing. These tests are performed in the Company’s clinical and GLP (Good Laboratory Practices)-bioanalytical laboratories and are conducted using methodologies such as immunoassay, gas chromatography, high performance liquid chromatography, gas chromatography/mass spectrometry and tandem mass spectrometry.

The Company’s clients for this market are clinical trial sponsors (pharmaceutical and biotech Companies), clinical research organizations (CRO’s), site management organizations, and clinical trials sites.

D. Heavy Metal, Trace Element, and Solvent Analyses. The Company operates a laboratory in which blood and urine are tested for heavy metals, trace elements, and solvents. The tests are performed using methodologies such as inductively coupled plasma-mass spectrometry, and head space-gas chromatography.

The Company’s clients for this market are other laboratories, occupational health clinics, companies that are required to comply with OSHA (Occupational Safety and Health Administration) guidelines for monitoring occupational exposure to hazardous materials, and pediatricians who test children for exposure to lead.
E. Logistics, Data, and Program Management Services. The Company also provides services in the areas of logistics management, data management, and program management. These services support the Company’s underlying business of laboratory analysis and provide added value to its clients. Value-added services include courier services for medical specimen transportation, management programs for laboratory-based and on-site drug testing, coordination of specimen collection sites, and data collection/reporting services including the use of its WEBTOX^®internet-based reporting system.

Product Sales

The Company has taken a leadership role in the development and distribution of diagnostic drug screening devices. The demand for fast, inexpensive screening technology that detects the presence of a number of substances in human urine, blood samples and other biological specimens continues to increase.

In 1998, the Company received FDA 510(k) clearance on the first of its second-generation on-site test products, PROFILE^®-II. PROFILE^®-II is a five-drug, lateral flow device that detects drugs-of-abuse in human urine. This single-step, immunoassay device has been combined with the Company’s data delivery system and laboratory confirmation capability to produce the PROFILE-II Test System^®. This integrated, on-site testing system is currently marketed to occupational health clinics, corporate clients, third party administrators, and drug abuse counseling and treatment centers

In July 2000, the Company filed a 510(k) with the FDA (Food and Drug Administration) for an additional test strip that includes benzodiazepines, barbiturates, methadone and TCA (tricyclic antidepressants). The Company received pre-marketing approval for this strip in early 2001, incorporated this test strip with the PROFILE^®-II test strip, and created the PROFILE-II ER^®, a dual-window device that can test for nine substances in a single device. The PROFILE-II ER^®is marketed primarily to hospital laboratories.

In 2001, the Company brought to market the seven-panel PROFILE^®-II and the PROFILE^®-II LFAS, a five-panel device with an “on-board” lateral flow adulteration strip. The adulteration strip tests for pH, specific gravity, gluteraldehyde, nitrites and a variety of oxidants.

In 2003, the Company expanded the PROFILE^®-II A Test Systems to include the use of six and nine panel drug screening devices. The Company believes it has the most complete line of diagnostic screening devices available in the market.

The Company also manufactures and distributes the VERDICT^®-II line of diagnostic drug screening products within the criminal justice, temporary service and drug rehabilitation markets. These devices are sold in multiple assay configurations, providing clients with flexibility in terms of drug panel options and potential cost savings.

The Company continues to market the EZ-SCREEN^®tests. These tests are qualitative assays utilized in agricultural diagnostics to detect mycotoxins and antibiotic residues. Mycotoxins are hazardous substances produced by fungal growth and frequently contaminate corn, wheat, rye, barley, peanuts, tree nuts, cottonseed, milk, rice, and livestock feeds. The EZ-SCREEN^®agridiagnostic tests are marketed to regulatory authorities and producers of foodstuffs and feeds.

The Company distributes diagnostic tests for the detection of alcohol with the EZ-SCREEN^®Breath Alcohol Test. The test consists of a small tube containing chemically treated crystals that change color in the presence of alcohol. The Company purchases the EZ-SCREEN^®Breath Alcohol Test through a distribution agreement.

3. Marketing and Sales.

The Company believes that the combined operations of the Laboratory Services business and the on-site test kits manufactured by the Product Sales segment have created synergy in the marketing of comprehensive, on-site and laboratory testing programs to a common customer base. The Company is in a position to offer a full line of products and services for the substance abuse testing and occupational medicine marketplace, including (1) on-site tests for the detection of substance of abuse drugs; (2) SAMHSA (Substance Abuse Mental Health Services Administration) certified laboratory testing (screening and confirmation); (3) biological monitoring of occupational toxins; (4) consultation; and (5) logistic, data management and program management services.

The Company has expanded its sales effort in the pharmaceutical market by offering testing services for Phase I — IV clinical trials and working with sponsors and CROs on assay development and bio-analytical and pharmacokinetic studies. In addition, the Company has begun to market clinical chemistry testing services to clinics, hospitals and physician offices on a regional basis. With the acquisition of Leadtech in October 2001, the Company expanded its presence in the pediatric lead testing market.

Major Customers. The Company had no single customer whose sales amounted to more than 10% of consolidated revenues during 2003, 2002, or 2001.

4. New Products, Research and Development.

Laboratory Services. The research and development group for Laboratory Services develops assays for new drugs and compounds, develops new assays for existing drugs and other toxins, and improves existing assays with the goal of improving assay robustness, sensitivity, accuracy, precision, specificity, and efficiency. This group also investigates and develops assays for commonly tested compounds in alternative matrices and novel formats. Numerous new laboratory-based assays were developed during 2003 using immunochemistry, liquid chromatography (LC), gas chromatography (GC), gas chromatography with mass spectrometry (GC/MS), inductively coupled plasma mass spectrometry (ICP/MS), and LC with tandem mass spectrometry (LC/MS/MS). These activities continue to enhance the Company’s test menu and realize efficiencies of new technologies. A significant effort in 2003 was invested in the development of new tests and markers for the pharmaceutical industry and clinical trials.

The clinical toxicology laboratory menu was further expanded in 2003 to encompass additional diagnostic testing focused in specific areas such as bone metabolism and renal disease. These new tests are offered both as a part of the routine test menu and as an adjunct to clinical trials testing. Significant effort was also expended on the continued transfer of current technology to state of the art LC/MS/MS methodology. Development of multi-component assays with enhanced sensitivity and specificity continues to improve the efficiency and strengthen the market position of this core business unit.

Product Sales. The Company continues to develop new and innovative products and services while expanding its test menu to meet the demands of both the drug testing and clinical markets. In 2003, the Company expanded the number of diagnostic product configurations to a total of 56, and added new device configurations to the ER, corporate and government markets.

Research and Development Expenses. The Company incurred costs of $1.9 million, $1.2 million, and $1.3 million for research and development activities in 2003, 2002, and 2001, respectively.

5. Raw Materials.

Laboratory Services. The raw materials required by the laboratory for urine drug testing consist primarily of two types: specimen collection supplies and reagents for laboratory analysis. The collection supplies include drug testing custody and control forms that identify the specimen and the client, as well as document the chain-of-custody. Collection supplies also consist of specimen bottles and shipping supplies. Reagents for drug testing are primarily immunoassay screening products and various chemicals used for confirmation testing. The Company believes all of these materials are available at competitive prices from numerous suppliers.

Product Sales. The primary raw materials required for the immunoassay-based test kits produced by the Company consist of antibodies, antigens and other reagents, plastic molded devices, wicking materials, filter materials, absorbent materials, and packaging materials. The Company maintains an inventory of raw materials which, to date, has been acquired primarily from third parties. Currently, most raw materials are available from several sources. The Company possesses the technical capability to produce its own antibodies and antigens. It has initiated production of antibodies and antigens for certain tests. If the Company were to change certain raw materials used in a specific test, additional development, validation, and accompanying costs may be required to adapt the alternate material to the specific diagnostic test.

6. Patents, Trademarks, Licensing and Other Proprietary Information.

Laboratory Services. The Company believes that the basic technologies requisite to the production of antibodies are in the public domain and are not patentable. The Company intends to rely upon trade secret protection of certain proprietary information, rather than patents, where it believes disclosure could cause the Company to be vulnerable to competitors that could successfully replicate the Company’s techniques and processes.

Product Sales. The Company was issued a second patent on the system that it developed which integrates on-site scientific analysis with state-of-the-art data collection and delivery. The system is currently being utilized with the Company’s PROFILE^®-II and VERDICT^®-II product lines.

The Company was issued a patent on a lateral flow test strip and the integration of adulteration strip testing into on-site devices. This is currently being utilized with the Company’s PROFILE^®-II A and VERDICT^®-II A product lines.

The Company holds eight additional United States issued patents. Seven of these patents generally form the basis for the EZ-SCREEN^®and one-step technologies, which include PROFILE^®-II and VERDICT^®-II product lines. The other patent relates to methods of utilizing whole blood as a sample medium on its immunoassay devices. Applications have also been made for additional patents.

Of the seven U.S. patents mentioned above which generally form the basis for the EZ-SCREEN^®and one-step technologies, one expires in 2004, two expire in 2007, one expires in 2009, two expire in 2010 and one expires in 2013. The patent relating to the methods of utilizing whole blood as a sample medium expires in 2012.

There can be no guarantee that there will not be a challenge to the validity of one or more of the patents. In the event of such a challenge, the Company might be required to spend significant funds to defend its patents, and there can be no assurance that the Company would be successful in any such action.

General. As of December 31, 2003, the Company held 14 registered trade names and/or trademarks in reference to its products and corporate names. The trade names and/or trademarks of the Company range in duration from 10 years to 20 years with expiration dates ranging from 2004 to 2013. Applications have also been made for additional trade names.

7. Seasonality.

Laboratory Services. The Company believes that the laboratory testing business is subject to seasonal fluctuations in pre-employment screening. These seasonal fluctuations include reduced volume in the summer months, year-end holiday periods, and other major holidays. In addition, inclement weather may have a negative impact on volume thereby reducing net revenues and cash flow.

Product Sales. The Company does not believe that seasonality is a significant factor in the sale of its on-site immunoassay testing devices.

8. Backlog.

Laboratory Services. There exists a delay in recognition of revenues when setting up new accounts for Laboratory Services. The time from when an account becomes a client of the Company to the time the laboratory starts receiving specimens may be up to four months. The delay in receiving samples is primarily due to the necessity of establishing communication capabilities between the client and the Company, the requirement to ship out collection kits and forms, and the establishment of a collection site network. At December 31, 2003, the Company had several accounts, which were in the process of being set up where revenues are not expected to be realized until 2004.

Product Sales. At December 31, 2003, MEDTOX Diagnostics, Inc. did not have any significant backlog. The Company does not believe that sales backlog is a significant factor in the Product Sales segment of its business.

9. Competition.

Laboratory Services. As of December 31, 2003, 52 labs, including MEDTOX Laboratories, Inc., were certified by the Department of Health and Human Services as having met the standards for Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). Competitors and potential competitors include forensic testing units of large clinical laboratories and other independent laboratories, specialized laboratories, and in-house testing facilities maintained by hospitals.

Competitive factors include reliability and accuracy of tests, price structure, service, transportation and collection networks and the ability to establish relationships with hospitals, physicians, and users of drug abuse testing programs. It should be recognized, however, that many of the competitors and potential competitors have substantially greater financial and other resources than the Company.

The industry in which the Company competes is characterized by service issues including: turn-around time of reporting results, price, the quality and reliability of results, and an absence of patents or other proprietary protection. In addition, since tests performed by the Company are not protected by patents or other proprietary rights, any of these tests could be performed by competitors. However, there are proprietary assay protocols for the more specialized testing that are unique to the Company.

The Company’s ability to successfully compete in the future and maintain its margins will be based on its ability to maintain its quality and customer service strength while maintaining efficiencies and low operating costs. There can be no assurance that price competitiveness will not increase in importance as a competitive factor in the laboratory testing business.

Product Sales. The diagnostics market has become highly competitive with respect to the price, quality and ease of use of various tests, and is characterized by rapid technological and regulatory changes. The Company has designed its on-site tests as inexpensive and for use by unskilled personnel, and has not endeavored to compete with laboratory-based systems. Numerous large companies with greater research and development, marketing, financial, and other capabilities, as well as smaller research firms, are engaged in research, development and marketing of diagnostic assays for application in the areas for which the Company produces its products.

The Company has experienced increased competition with respect to its immunoassay tests from systems and products developed by others, many of whom compete solely on price. As the number of firms marketing diagnostic tests has grown, the Company has experienced increased price competition. A further increase in competition may have a material adverse effect on the business and future financial prospects of the Company.

10. Government Regulations.

The products and services of the Company are subject to the regulations of a number of governmental agencies as listed below. It is believed that the Company is currently in compliance with all regulatory authorities. The Company cannot predict whether future changes in governmental regulations might significantly increase compliance costs or adversely affect the time or cost required to develop and introduce new products.

A. Substance Abuse and Mental Health Services Administration (SAMHSA). MEDTOX Laboratories, Inc. has been certified by SAMHSA since 1988. SAMHSA certifies laboratories meeting strict standards under Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs. Continued certification is accomplished through periodic inspection by SAMHSA to assure compliance with applicable regulations.

B. Food and Drug Administration (FDA). Certain tests for human diagnostic purposes must be cleared by the FDA prior to their marketing for in vitro diagnostic use in the United States. The FDA regulated products produced by the Company are in vitro diagnostic products subject to FDA clearance through the 510(k) process which requires the submission of information and data to the FDA that demonstrates that the device to be marketed is substantially equivalent to a currently marketed device. This data is generated by performing clinical studies comparing the results obtained using the Company’s device to those obtained using an existing test product. Although no maximum statutory response time has been set for review of a 510(k) submission, as a matter of policy the FDA has attempted to complete review of 510(k) submissions within 90 days. To date, the Company has received 510(k) clearance for 18 different products. Products subject to 510(k) regulations may not be marketed for in vitro diagnostic use until the FDA issues a letter stating that a finding of substantial equivalence has been made.
10

As a registered manufacturer of FDA regulated products, the Company is subject to a variety of FDA regulations including the Good Manufacturing Practices (GMP) regulations which define the conditions under which FDA regulated products are to be produced. These regulations are enforced by the FDA and failure to comply with GMP or other FDA regulations can result in the delay of pre-market product reviews, fines, civil penalties, recalls, seizures, injunctions and criminal prosecution.

As an accredited laboratory performing testing for clinical trials, the laboratory is subject to FDA regulations including Good Laboratory Practices (GLP) and related requirements.

C. Canadian Medical Devices Conformity Assessment System (CMDCAS). MEDTOX Diagnostics, Inc. maintains a Quality System which satisfies the requirements for ensuring the safety and effectiveness of MEDTOX products and meeting the customer needs in accordance with FDA requirements as described in 21 CFR part 820 (Quality Systems), and that satisfies the requirements of the Canadian Medical Devices Regulations (CMDR) and CAN/CSA ISO 13485:1998 and ISO 9001:1994.

The policy on the Canadian Medical Devices Conformity Assessment System (CMDCAS) addresses the Quality System requirements found in the CMDR. To sell a medical device in Canada, manufacturers must meet the regulatory requirements as defined in the Medical Devices Regulations. The Quality System implemented by the manufacturer for design and manufacture of medical devices must satisfy the Quality System requirements of ISO 13485 and the manufacturer is required to have its Quality System registered by an approved CMDCAS Registrar. A CMDCAS approved Registrar audits the manufacturer’s Quality System to ISO 13485:1998 and ISO 9001:1994. MEDTOX Diagnostics, Inc. maintains a quality management system fulfilling the requirements of EN ISO 13485 and CMDCAS ISO 13485, Quality Systems – Medical Devices and ISO 9001:2000 — Quality Management Systems – Requirements. MEDTOX Diagnostics, Inc. has been issued the TUV Rheinland Product Safety GmbH quality system certificate to EN ISO 13485:2000 and the TUV Rheinland of North America Inc., quality system certificate to ISO 13485 under CMDCAS.

D. Centers for Medicare and Medicaid Services (CMS) formerly Health Care Financing Administration (HCFA). The Clinical Laboratory Improvement Act (CLIA) introduced in 1992 requires that all in vitro diagnostic products be categorized as to level of complexity. A request for CLIA categorization of any new clinical laboratory test system must be made simultaneously with FDA 510(k) submission. The EZ-SCREEN^®, PROFILE^®, PROFILE^®-II, VERDICT^®and VERDICT^®-II drugs-of-abuse tests currently marketed by MEDTOX Diagnostics, Inc. have been categorized as moderately complex. The complexity category to which a clinical laboratory test system is assigned may limit the number of laboratories qualified to use the test system thus impacting product sales. MEDTOX Laboratories, Inc. is a CLIA licensed high complexity laboratory and is accredited by the College of American Pathologists (CAP) Laboratory Accreditation Program.

E. Drug Enforcement Administration (DEA). The primary business of the Company involves either testing for drugs-of-abuse or developing test kits for the detection of drugs/drug metabolites in urine. MEDTOX Laboratories, Inc. is registered with the DEA to conduct chemical analyses with controlled substances. The MEDTOX Diagnostics, Inc. facility in Burlington, NC is registered by the DEA to manufacture and distribute controlled substances and to conduct research with controlled substances. Maintenance of these registrations requires that the Company comply with applicable DEA regulations.

F. Additional Laboratory Regulations. The laboratories of MEDTOX Laboratories, Inc. and certain of its laboratory personnel are licensed or otherwise regulated by certain federal agencies, states, and localities in which it conducts business. Federal, state and local laws and regulations require MEDTOX Laboratories, Inc., among other things, to meet standards governing the qualifications of laboratory owners and personnel, as well as the maintenance of proper records, facilities, equipment, test materials, and quality control programs. In addition, the laboratories are subject to a number of other federal, state, and local requirements that provide for inspection of laboratory facilities and participation in proficiency testing, as well as govern the transportation,

packaging, and labeling of specimens tested by either laboratory. The laboratories are also subject to laws and regulations prohibiting the unlawful rebate of fees and limiting the manner in which business may be solicited. As applicable federal and state regulations become final and effective it is the Company’s policy to be in compliance with these laws, such as the HIPAA Final Privacy Rule safeguarding the privacy and confidentiality of patient’s protected health information.

The laboratory receives and uses small quantities of hazardous chemicals and radioactive materials in its operations and is licensed to handle and dispose of such chemicals and materials. Any business handling or disposing of hazardous and radioactive waste is subject to potential liabilities under certain of these laws.

11. Product and Professional Liability.

Laboratory Services. The Company’s laboratory testing services are primarily diagnostic and expose the Company to the risk of liability claims. The Company’s laboratories have maintained continuous professional and general liability insurance since 1984. The insurance policy covers those amounts the Company is legally obligated to pay for damages resulting from a medical incident, which arises out of a failure to render professional services. To date, the Company has not paid any material amounts for claims of this type and no material professional service claims are currently pending.

Product Sales. Manufacturing and marketing of products by the Company entail a risk of product liability claims. Since 1993, the Company has maintained insurance coverage against the risk of product liability arising out of events after such date, but such insurance does not cover claims made after that date based on events that occurred prior to that date. The insurance policy covers damages that the Company is legally obligated to pay as a result from bodily injury and property damage. Consequently, for uncovered claims, the Company could be required to pay any and all costs associated with any product liability claims brought against it, the cost of defense whatever the outcome of the action, and possible settlement or damages if a court rendered a judgment in favor of any plaintiff asserting such a claim against the Company. Damages may include punitive damages, which may substantially exceed actual damages. The obligation to pay such damages could have a material adverse effect on the Company and exceed its ability to pay such damages. No product liability claims are pending.

12. Employees.

As of December 31, 2003, the Company had a total of 417 full-time employee equivalents as compared to 473 full-time employee equivalents at December 31, 2002. Of the 417 employees, 366 work for MEDTOX Laboratories, Inc., while the remaining 51 work for MEDTOX Diagnostics, Inc.

The Company’s employees are not covered by any collective bargaining agreements and the Company has not experienced any work stoppages. The Company believes that it maintains good relations with its employees.

ITEM 2. PROPERTIES.

The administrative offices and laboratory operations for the Laboratory Services segment of the Company’s business are located primarily in a 53,576 square foot facility in St. Paul, Minnesota. Until March 16, 2001, the Company leased this space. On March 16, 2001 the Company purchased the entire three building complex with a total of 129,039 square feet, which included the 53,576 square feet utilized by the Company’s Laboratory Services segment. The purchasing entity was New Brighton Business Center LLC, a wholly owned limited liability company, established by the Company for the sole purpose of purchasing the entire three building complex. The facility includes other commercial tenants that have individual leases that range from ten years to less than one year in duration. In 2003, the annual rent paid by such third-party tenants, excluding their pro-rata share of operating expenses, was approximately $245,000. In addition, effective September 1, 2001, the Laboratory Services segment entered into a seven-year lease for 30,000 square feet to be used in connection with its courier business and also as additional warehouse and shipping space. This building is a special purpose

facility and enables the Company to store its vehicles indoors, when appropriate, and to perform routine maintenance of the vehicles. The annual base rent on this second facility, exclusive of operating expenses is currently $141,000 per year.

The operations for the Product Sales segment of the Company’s business are located in Burlington, North Carolina where the Company maintains the offices, research and development laboratories, production operations, and warehouse for MEDTOX Diagnostics, Inc. In March 2001, the Company entered into a 10-year lease of the entire building (approximately 39,500 square feet) for an annual base rent of $197,000, exclusive of operating expenses. In addition, under the lease $600,000 of tenant improvements made to the building by the Company are being amortized over the life of the lease as additional rent. Effective February 1, 2003, the Company entered into a month-to-month lease for an additional 30,000 square feet of space located in an adjacent building. The additional space is used for warehousing and distribution for a monthly base rent of $9,400, exclusive of operating expenses. In November 2003, the Company amended and restated these leases. Under the terms of the new lease, the original leases have been combined and the term of the new lease has been extended to March 31, 2016, for an annual base rent of $385,279, exclusive of operating expenses, effective January 2004, including amortization of the $600,000 of improvements.

The Burlington facilities have always been owned and leased to the Company by Dr. Samuel C. Powell, a member of the Board of Directors of the Company. The Company believes it is renting these facilities in Burlington on terms similar to those available from third parties for equivalent premises.

The Company believes that its existing facilities are adequate for the purposes being used to accommodate its product development, and manufacturing and laboratory testing requirements.

ITEM 3. LEGAL PROCEEDINGS.

Not applicable.

ITEM 4. SUBMISSION OF MATTERS TO VOTE OF SECURITY HOLDERS.

No matter was submitted to a vote of the security holders during the fourth quarter of the fiscal year covered by this report.

PART II

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS.

Common Stock

Since September 27, 1993, the Company’s common stock has been listed on the American Stock Exchange and is currently trading under the symbol “TOX”. As of March 5, 2004, the number of holders of record of the Common Stock was 1,860. The following tables set forth, for the calendar quarters indicated, the high, low, and closing prices per share for the common stock, as reported by the American Stock Exchange. The quotations shown represent inter dealer prices without adjustment for retail markups, markdowns or commissions, do not necessarily reflect actual transactions, and have been adjusted for the 10% stock dividend paid on July 5, 2002.

2003:	High			Low			Close*
First Quarter	$	7	.58	$	4	.51	$	5	.12
Second Quarter		7	.32		4	.85		6	.37
Third Quarter		7	.45		5	.16		6	.25
Fourth Quarter		6	.37		5	.27		5	.95

2002:	High			Low			Close*
First Quarter	$	11	.36	$	8	.64	$	9	.45
Second Quarter		12	.10		9	.45		10	.31
Third Quarter		10	.45		6	.70		7	.25
Fourth Quarter		8	.40		5	.06		6	.61

*Closing price as of the last day of the calendar quarter

No cash dividends have been declared or paid by the Company since its inception and management of the Company has no plans to pay a cash dividend in the foreseeable future. The Company’s financial covenants under its debt instrument may effectively preclude the Company from paying cash dividends without approval.

In September 1998, the Company’s Board of Directors authorized and declared a dividend of one preferred share purchase right (Right) for each share of common stock then outstanding. Subsequent to that date the Company maintains a plan in which one Right exists for each common share of the Company. These Rights are exercisable only if a person or group acquires beneficial ownership of 20 percent or more of the Company’s outstanding common stock.

ITEM 6. SELECTED FINANCIAL DATA

The following selected financial data is derived from the consolidated financial statements of the Company and should be read in conjunction with the consolidated financial statements, related notes, and other financial information.

(In thousands, except share and per share data)	2003			2002		2001		2000			1999
STATEMENT OF OPERATIONS DATA:
Revenues	$	51,473		$	52,024	$	49,084	$	42,880		$	35,003
Cost of revenues		31,520			31,476		29,637		27,847			22,749
Selling, general, and administrative		16,722			16,317		14,436		15,480			9,348
Research and development		1,910			1,217		1,292		1,123			834
Restructuring costs		--			--		--		--			(164	)
Other expense, net		1,629			1,427		1,221		991			817
Income tax benefit		--			10,150		--		--			--

Net income (loss)	$	(308	)	$	11,737	$	2,498	$	(2,561	)	$	1,419

Basic earnings (loss) from operations per
common share	$	(0.06	)	$	2.45	$	0.57	$	(0.67	)	$	0.40

Diluted earnings (loss) from operations per
common share	$	(0.06	)	$	2.34	$	0.54	$	(0.67	)	$	0.39

Weighted average number of shares outstanding:
Basic		4,942,617			4,798,098		4,401,950		3,802,531			3,511,526
Diluted		4,942,617			5,011,330		4,614,152		3,802,531			3,611,980

BALANCE SHEET DATA:
Total assets	$	56,518		$	58,055	$	44,156	$	30,024		$	26,271
Long-term obligations		7,639			9,007		10,015		2,898			2,146
Total stockholders' equity		35,070			34,884		22,520		15,410			12,790

SEGMENT DATA:
Net revenues:
Laboratory Services	$	39,424		$	39,673	$	37,990	$	34,797		$	31,012
Product Sales		12,049			12,351		11,094		8,083			3,991

Total net revenues	$	51,473		$	52,024	$	49,084	$	42,880		$	35,003

Operating income (loss):
Laboratory Services	$	1,032		$	1,317	$	1,933	$	(2,457	)	$	2,192
Product Sales		289			1,697		1,786		887			44

Total operating income (loss)	$	1,321		$	3,014	$	3,719	$	(1,570	)	$	2,236

Assets:
Laboratory Services	$	39,893		$	42,186	$	39,358	$	26,498		$	24,269
Product Sales		7,290			6,532		4,798		3,526			2,002
Corporate (unallocated)		9,335			9,337		--		--			--

Total assets	$	56,518		$	58,055	$	44,156	$	30,024		$	26,271

All share and per share amounts have been restated for the 10% stock dividends paid on July 5, 2002 and November 9, 2001.

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

General

MEDTOX Scientific, Inc. (formerly EDITEK, Inc.), a Delaware corporation, was organized in September 1986. MEDTOX Scientific, Inc. and its wholly owned subsidiaries, MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and New Brighton Business Center, LLC are referred to herein as “the Company.” The Company is engaged primarily in two distinct, but very much related businesses. The business of forensic and clinical laboratory services is conducted by MEDTOX Laboratories, Inc. at its facility in St. Paul, Minnesota, and the business of manufacturing and distribution of diagnostic devices is executed by MEDTOX Diagnostics, Inc. from its facility in Burlington, North Carolina.

The Company has two reportable segments: “Laboratory Services” conducted by the Company’s wholly owned subsidiaries, MEDTOX Laboratories, Inc. and New Brighton Business Center, LLC and “Product Sales” conducted by the Company’s wholly owned subsidiary MEDTOX Diagnostics, Inc. Laboratory Services include forensic toxicology (primarily workplace drugs-of-abuse testing) and Specialty Laboratory Services, including clinical toxicology, clinical testing for the pharmaceutical industry (central laboratory services, bioanalytical and pharmacokinetic testing), and analysis of heavy and trace metals. In addition, the Laboratory Services segment provides logistical support, data management and overall program management services. Product Sales include sales of a variety of on-site screening products and contract manufacturing. For the years ended December 31, 2003, 2002, and 2001, Laboratory Services revenue accounted for 77%, 76% and 77% of the Company’s revenues, respectively. Revenue from Product Sales accounted for 23%, 24% and 23% of the total revenues of the Company for the years ended December 31, 2003, 2002, and 2001, respectively.

Critical Accounting Policies

The Company has identified the policies outlined below as critical to understanding its business and results of operations. The listing is not intended to be a comprehensive list of all accounting policies. In many cases, the accounting treatment of a particular transaction is specifically dictated by accounting principles generally accepted in the United States of America, with no need for management’s judgment in their application. The impact and any associated risks related to these policies on the Company’s business operations is discussed throughout Management’s Discussion and Analysis of Financial Condition and Results of Operations where such policies affect reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see Note 1 in the Notes to the Consolidated Financial Statements in Item 15 on Form 10-K, beginning on page 41. Note that the preparation of this Form 10-K requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of our financial statements, and the reported amounts of revenue and expenses during the reporting period. There can be no assurance that actual results will not differ from those estimates.

The Company’s critical accounting policies are as follows:

Accounts Receivable:
The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customers’ current credit worthiness, as determined by management’s review of their current credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon the Company’s historical experience and any specific customer collection issues that have been identified. While such credit losses have generally been within the Company’s historical expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that have occurred in the past. The Company’s consolidated trade accounts receivable balance as of December 31, 2003 was $7.9 million, net of allowance for doubtful accounts of $0.4 million.

Some of the Company’s Laboratory Services revenues for certain types of tests are billed to third-party payors including insurance companies, state Medicaid and Medicare agencies. These payors pay for such services at established amounts, which are typically lower than gross amounts billed by the Company. However, the tests are sometimes billed directly to patients or other parties and paid at the gross amount billed for these tests. In addition, billings for the tests are occasionally re-billed to alternative payors in situations where incorrect billing information was submitted to the Company by the customer. The Company estimates a discount on the billings for these tests, and recognizes revenue and related accounts receivable at a net amount, after discount, in order to state revenue and accounts receivable at the amount expected to be paid. While the Company believes that estimated discounts and the related net revenue and net accounts receivable from these testing services are materially correct, there can be differences in amounts ultimately paid compared to estimated amounts. These differences are recorded upon payment and may affect previously recorded amounts. The Company considers historical discounts when estimating future discounts on a monthly basis.

Off-Site Supplies Inventory:
Off-site supplies represents collection kits and forms located at collections sites throughout the United States used by Laboratory Services’ customers to submit specimens for testing services. At December 31, 2003, off-site inventory was $0.7 million. The process for valuing off-site inventory involves significant assumptions regarding the average time that a collection site uses the inventory, as well as the amount of inventory expected to be scrapped.

Goodwill and Other Intangible Assets:
The Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, “Goodwill and Other Intangible Assets” on January 1, 2002. SFAS No. 142 provides that goodwill and indefinite-lived intangible assets are no longer amortized, but are instead reviewed for impairment at least annually and between annual test dates in certain circumstances. The Company completed the necessary transition impairment review for goodwill and other intangible assets in 2002, and determined that there was no impairment. The Company performs its annual impairment test for goodwill and other intangible assets in the fourth quarter of each year. No impairments were indicated as a result of the annual impairment reviews for goodwill and other intangible assets in 2003 and 2002. In assessing the recoverability of goodwill and other intangible assets, projections regarding estimated future cash flows and other factors are made to determine the fair value of the respective assets. If these estimates or related projections change in the future, the Company may be required to record impairment charges for these assets in future periods.

Accounting for Income Taxes:
As part of the process of preparing the consolidated financial statements, the Company is required to estimate income taxes in each of the jurisdictions in which it operates. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities. The Company must then assess the likelihood that deferred tax assets will be recovered from future taxable income and tax planning strategies, and to the extent management believes that recovery is not likely, the Company must establish a valuation allowance. To the extent the Company increases or decreases the valuation allowance in a period, the Company must include an expense or benefit within the tax provision in the consolidated statement of operations.

Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded against net deferred tax assets. The Company’s deferred tax assets primarily consist of certain net operating losses (NOLs) carried forward. At December 31, 2003, the Company has a valuation allowance on deferred tax assets of $1.4 million, which represents the portion of its NOL carryforwards that will more likely than not expire unused in 2004 and future years. The valuation allowance is based on management’s estimate of taxable income, the period over which NOLs will be recoverable, and tax planning strategies. In the future, subsequent revisions to the estimated net realizable value of these deferred tax assets could cause the provision for income taxes to vary significantly from period to period, although the Company’s cash payments would remain unaffected until the benefit of the NOL is completely utilized or expires unused.

Results of Operations

Revenues declined slightly in 2003 and continued to be impacted by the softness in new business employment. Gross margin was also down, reflecting a reduced margin in the Product Sales segment, despite improvement in the Laboratory Services segment. Operating expenses were higher due to the continued investment in research and development and severance costs related to staffing reductions. Other expense was also higher than last year due to reduced rental income from the Company’s building rental activities. In 2002, the Company recorded a $10.2 million non-cash tax benefit as part of net income. The following table sets forth the percentages of total revenues represented by certain items reflected in the Company’s Consolidated Statements of Operations:

	2003			2002			2001

Revenues	100	.0	%	100	.0	%	100	.0	%
Cost of revenues	61	.2		60	.5		60	.4

Gross margin	38	.8		39	.5		39	.6
Operating expenses
Selling, general, and administrative	32	.5		31	.4		29	.4
Research and development	3	.7		2	.3		2	.6

	36	.2		33	.7		32	.0
Income from operations	2	.6		5	.8		7	.6
Other expense	(3	.2)		(2	.7)		(2	.5)

Income (loss) before income tax benefit	(0	.6)		3	.1		5	.1
Income tax benefit		--		19	.5			--

Net income (loss)	(0	.6)	%	22	.6	%	5	.1	%

Year Ended December 31, 2003 Compared to Year Ended December 31, 2002

Revenues

Revenues decreased 1.1% to $51.5 million in 2003, reflecting a $0.3 million, or 2.4% decline in Product Sales revenues and a $0.2 million, or 0.6% decline in Laboratory Services revenues.

Laboratory Services revenues were impacted by a decline in the average price per testing specimen for workplace drugs-of-abuse testing. The lower pricing was part of the Company’s strategy to attract new business to offset the impact of the reduced specimen volume experienced in the first half of 2003. For the full year, specimen volume from the Company’s occupational health and corporate clients increased 2.4%. This improvement reflects the Company’s continued success in acquiring new client relationships and gaining market share, despite the continued softness in new business employment. Revenues from the Company’s Specialty Laboratory Services remain strong, increasing 4.9% in 2003.

In the Product Sales segment, sales of substance abuse testing products, which incorporates the PROFILE^®-II, PROFILE-II ER^®, PROFILE^®-II A and VERDICT^®-II on-site test kits and other ancillary products for the detection of abused substances, declined 3.3% to $10.3 million in 2003. The decline is primarily attributable to lower sales within the VERDICT^®-II product line to government clients for probation, parole and rehabilitation. The economic uncertainty and budget constraints that the Company’s government clients are experiencing resulted in lower purchasing levels among these clients. The Company anticipates that the government sector will continue to be a challenging environment, and will continue to pursue new sales efforts that the Company believes will improve this portion of its business going forward. Principally, during the second quarter of 2003, the Company introduced a proprietary value added service called DARS^™(Drug Abuse Recognition System) that it believes will increase sales in the government marketplace. Sales of PROFILE^®-II devices to existing workplace and occupational clients were also down from last year and continue to be impacted by the reduction in nationwide hiring. Additionally, some customers are alternatively purchasing the PROFILE^®-II A device, which screens for the same five drugs-of-abuse, but also includes a patented lateral flow test strip to screen for the five most common adulterants. Sales of the PROFILE^®-II A increased 74.1% in 2003. The PROFILE-II ER^®product, targeted at hospital laboratories for emergency response screening in drugs-of-abuse overdose situations, continues to grow, increasing 44.5% in 2003.

Product sales from agricultural diagnostic products increased 23.0% to $0.3 million in 2003 primarily as a result of increased purchases from the U.S. Department of Agriculture (USDA) for the Company’s products. Sales of contract manufacturing services, microbiological and associated products of $1.4 million in 2003 were flat compared to 2002.

Gross profit

Consolidated gross margin declined to 38.8% in 2003 compared to 39.5% in 2002. Gross margin from Product Sales declined to 57.1% in 2003, compared to 62.1% in 2002. This decline was largely due to the costs associated with the expansion and improvement of the production facility on lower than projected sales volume, as well as increased spending in quality control. Laboratory Services gross margin was 33.1% in 2003, up from 32.5% in 2002. The margin improvement was driven by labor savings associated with staffing reductions and improved operating efficiencies resulting from LEAN project initiatives. The increase in margin was partially offset by a decline in the average price per testing specimen.

Selling, general and administrative expenses

Selling, general and administrative expenses were $16.7 million, or 32.5% of revenues, in 2003, compared to $16.3 million, or 31.4% of revenues, in 2002. The increase was primarily due to severance costs associated with staffing reductions and higher business insurance expenses. During the third and fourth quarters of 2003, selling, general and administrative expenses were 30.6% and 31.3% of sales, respectively. The improvement during the second half of 2003 reflects savings from steps taken earlier in the year to reduce expenses, including certain staffing reductions. In the second half of 2003, the Company also initiated three significant LEAN projects with the objective of further reducing expenses in the Laboratory Services segment in the first quarter of 2004. In the first quarter of 2004, the Company launched a LEAN initiative at the Product Sales segment to improve operating efficiencies and reduce expenses.

Research and development expenses

Research and development increased 56.9%, or $0.7 million in 2003. The increase was driven primarily by increased development activity associated with new product configurations and assays and other new product research in the Product Sales segment. The increase was also due to recruiting and hiring costs associated with the addition of a new Vice President of Technology, Research and Development at the Company’s Product Sales segment, as well as severance and other costs associated with the reorganization of the department.

Other expense

Other income and expense consists primarily of interest expense and the net expenses associated with the Company’s building rental activities. These expenses increased 14% to $1.6 million in 2003. The increase was primarily due to reduced rental income as a result of higher vacancy rates. While the Company is actively seeking additional tenants for the building, there can be no assurance it will be able to lower overall vacancy rates in 2004. This increase was partially offset by a reduction in interest expense due to lower average interest rates.

Income taxes

The Company did not record a tax provision or benefit for 2003. At December 31, 2003, the Company has a valuation allowance on deferred tax assets of $1.4 million, which represents the portion of its net operating loss (NOL) carryforwards that will more likely than not expire unused in 2004 and future years. Should operating results for 2004 fail to meet expectations, the valuation allowance against the Company’s NOL carryforwards and the related deferred tax asset may require adjustment in future periods.

Year Ended December 31, 2002 Compared to Year Ended December 31, 2001

Revenues

Revenues increased 6.0% to $52.0 million in 2002, driven by a $1.3 million, or 11.3% increase in Product Sales revenues and a $1.7 million, or 4.4% increase in Laboratory Services revenues.

The growth in Laboratory Services was primarily due to a 22.2% increase in the Company’s Specialty Laboratory Services revenues. This increase is due to the expansion of clinical testing for the pharmaceutical industry and the October 2001 acquisition of Leadtech Corporation (Leadtech), a pediatric lead-testing laboratory. Specimen volume from occupational health and corporate clients increased 1.4% in 2002. The slow economy and poor labor market caused volume from existing occupational health and corporate clients to be below expectations. However, this impact was largely mitigated by the Company’s continued success in acquiring new client relationships and gaining market share.

Sales of contract manufacturing services, microbiological and associated products increased $0.1 million, or 8.0% in 2002. Product sales from agricultural diagnostic products decreased 22.4% to $0.3 million primarily as a result of decreased purchases by the U.S. Department of Agriculture (USDA) for the Company’s products.

Gross profit

Consolidated gross margin declined fractionally to 39.5% in 2002 compared to 39.6% in 2001. Laboratory Services gross margin was 32.5% in 2002, up from 31.9% in 2001. This increase was primarily the result of the Company’s continued focus on higher-margin Specialty Laboratory testing services. Gross margin from Product Sales declined to 62.1% in 2002 compared to 66.1% in 2001, largely due to changing product mix.

Selling, general and administrative expenses

Selling, general and administrative expenses were $16.3 million, or 31.4% of revenues, in 2002, compared to $14.4 million, or 29.4% of revenues, in 2001. The increase primarily reflected the Company’s increased sales and marketing expenses related to acquiring new business and increased spending on client service support for clinical trials services. Selling, general and administrative expenses in 2001 included $0.9 million in goodwill amortization. No goodwill amortization expense was recorded in 2002 as a result of the adoption of SFAS No. 142 on January 1, 2002.

Other expense

Other expense consisted primarily of interest expense, which increased by $0.2 million or 18.6% in 2002, reflecting higher average debt levels that were partially offset by lower interest rates. Other expense also included a loss of $95,000 from the Company’s rental activities.

Income tax benefit

The Company recorded a $10.2 million non-cash tax benefit in 2002 and reduced its valuation allowance on deferred tax assets. The reduction in the valuation allowance was based on the available evidence, including the Company’s recent historical performance, tax planning strategies, and projected future results.

Liquidity and Capital Resources

The working capital requirements of the Company have been funded primarily by various combinations of profitable operations, cash received from debt financing, and the sale of equity securities. Cash and cash equivalents at December 31, 2003 were $0.7 million, compared to $0.4 million at December 31, 2002.

Net cash provided by operating activities was $3.2 million in 2003 compared to $4.2 million and $3.5 million in 2002 and 2001, respectively. The decrease in 2003 was primarily due to lower income before income taxes as well as a reduction in accounts payable and accrued expenses, partially offset by a reduction in accounts receivable and inventories.

Accounts payable and accrued expenses decreased $1.6 million in 2003 compared to an increase of $1.1 million in 2002. The significant reduction in the current year was primarily the result of the more timely payment of outstanding invoices.

Accounts receivable decreased $0.4 million in 2003 compared to an increase of $1.2 million in 2002. The significant increase in accounts receivable in 2002 was primarily the result of an increase in receivables due from third-party payors such as insurance companies, state Medicaid and Medicare agencies. Payment cycles from such payors can be lengthy, and in certain cases, were adversely affected in 2002 by incomplete or incorrect billing information provided to the Company by its customers. In 2003, the Company was able to shorten the payment cycle for such payors through a better understanding of the insurance claim filing requirements and by converting manual billings to an electronic format for certain Medicaid state agencies.

Inventories decreased $0.8 million in 2003 compared to an increase of $0.5 million in 2002. The decrease in 2003 reflects better management of required inventory levels within the Product Sales segment.

Net cash used in investing activities was $2.6 million in 2003 compared to $4.3 million and $10.9 million in 2002 and 2001, respectively. In 2003 and 2002, the Company’s investing activities consisted of capital expenditures. In 2001, the Company’s investing activities consisted of capital expenditures (primarily the building purchase discussed below) and cash paid for the acquisition of Leadtech.

In March 2001, the Company purchased the three building, 129,039 square foot complex in St. Paul, Minnesota, where the Company’s Laboratory Services segment formerly leased 53,576 square feet. The purchase price, exclusive of expenses and closing costs, was $6.35 million and was financed by a mortgage loan from Principal Life Insurance Company of Des Moines, Iowa in the amount of $6.2 million. The mortgage loan has a term of 10 years and is being repaid based on a 20-year amortization schedule with a balloon payment at the end of the ten-year term. The interest rate is fixed at an annual rate of 7.23% for the first five years at which time the rate will be renegotiated by the parties. The facility includes other commercial tenants who have individual leases that range from 10 years to less than 1 year in duration. In 2003, the annual rent paid by such third party tenants, excluding their pro-rata share of operating expenses, was $245,000.

In October 2001, the Company completed the acquisition of Leadtech, a private company operating as an independent clinical laboratory devoted primarily to the examination of blood lead concentrations in pediatric patients. The $6.1 million purchase price consisted of $2.5 million in cash, the issuance of $2.7 million of the Company’s common stock and $0.9 million of seller financing payable over 24 months. The initial cash payment of $2.5 million was funded primarily from proceeds received from private placement of subordinated debt in October 2001, net proceeds from the legal settlement with Morgan Capital LLC and operating cash flows.

The Company expects equipment and capital improvement expenditures to be between $3.0 million and $4.0 million in 2004. These expenditures are intended primarily to continue to improve efficiencies and reduce operating costs within the Laboratory Services and Product Sales businesses. Such expenditures are expected to be funded through borrowings under the Company’s credit facilities and cash provided by operating activities.

Net cash used in financing activities was $0.3 million in 2003, compared to net cash provided by financing activities of $0.5 million and $7.3 million in 2002 and 2001, respectively. The change in 2003 as compared to 2002 was primarily the result of a reduction in the use of the revolving credit facility. In 2001, the Company received proceeds from the mortgage loan discussed above and from the private placement of subordinated debt (discussed below).

The Company has a Credit Security Agreement (the Wells Fargo Credit Agreement) with Wells Fargo Business Credit, Inc. (Wells Fargo). The Wells Fargo Credit Agreement, as amended, consists of (i) a term loan of $3.185 million bearing interest at prime + 0.75% and (ii) a revolving line of credit, payable on demand, of not more than $8.0 million or 85% of the Company’s eligible trade accounts receivable bearing interest at prime + 1%; and (iii) a capex note of up to $3.5 million for the purchase of capital equipment bearing interest at prime + 0.75% to 1.25%. According to the terms of the agreement, the capex note may be amended, supplemented or restated from time to time and is generally done so on an annual basis. During the third quarter of 2003, an amendment to the capex note was required in order to allow further borrowing. The amendment was not completed in 2003 and no funding from the note was available during the second half of the year. In March 2004, the Company and Wells Fargo amended the Wells Fargo Credit Agreement to allow for borrowing under the capex note of up to $1.5 million for the purchase of capital equipment bearing interest at prime + 1.5%.

The Wells Fargo Credit Agreement requires the Company to comply with certain financial covenants, including a minimum quarterly debt service coverage ratio and a minimum quarterly pre-tax net income level. It also sets a maximum level for capital expenditures, as well as a limitation on the year-over-year increase in compensation of any director, shareholder or consultant. At December 31, 2003 the Company was not in compliance with the minimum debt service coverage and the minimum quarterly pre-tax income level covenants of the Wells Fargo Credit Agreement. The Company was also not in compliance with the covenant restricting the year-over-year increase in compensation. Wells Fargo has waived the aforementioned defaults of the Company.

In 2003, the Company entered into a Credit and Security Agreement with Wells Fargo Equipment Finance, Inc. for the acquisition of various pieces of equipment. In connection with the agreement, the Company signed notes payable for $2.0 million, payable in monthly installments over 3.5 years. Interest is payable at a variable rate of 1.25% over prime. The note is secured by the equipment purchased with the proceeds of the loan.

The Company received a total of $1.05 million from private placements of subordinated debt and warrants in October and November 2001. The notes require payment of the principal amounts on September 30, 2004. Interest at 10% per annum is paid semi-annually on June 30 and December 31. In connection with the issuance of the subordinated notes, the Company issued warrants to purchase 60,294 shares of common stock at $8.71 per share. The Company determined the value of the warrants at the dates of issuance was $281,000, based upon the Black-Scholes option pricing model. The value of the warrants was accounted for as additional paid-in capital and deducted from the principal of the subordinated notes as discount on debt issued. The discount is being amortized to interest expense over the term of the debt using the effective interest method. The effective interest rate of the subordinated debt, including the warrants, is 23.0%.

The Company is relying on expected positive cash flow from operations and its line of credit to fund its future working capital and asset purchases. The amount available on the revolving line of credit is based primarily on the receivables of the Company and, as such, varies with accounts receivable. As of December 31, 2003, the Company had total borrowing capacity of $5.4 million on its line of credit, of which $5.1 million was borrowed, leaving a net availability of $0.3 million and a cash balance of $0.7 million.

In the short term, the Company believes that the aforementioned capital will be sufficient to fund the Company’s planned operations through 2004. While there can be no assurance that the available capital will be sufficient to fund the future operations of the Company beyond 2004, the Company believes that future profitable operations, as well as access to additional capital through debt or equity financings, will be the primary means for funding the operations of the Company for the long term.

The Company continues to follow a plan which includes (i) aggressively monitoring and controlling costs, (ii) increasing revenue from sales of the Company’s existing products and services (iii) developing new products and services, as well as (iv) continuing to selectively pursue synergistic acquisitions to increase the Company’s critical mass. However, there can be no assurance that costs can be controlled, revenues can be increased, financing may be obtained, acquisitions successfully consummated, or that the Company will be profitable.

Disclosures about Contractual Obligations and Commercial Commitments

The following table aggregates all contractual commitments and commercial obligations that affect the Company’s financial condition and liquidity position as of December 31, 2003:

	Payments Due by Period
(In thousands)	Total		Less than 1 year		1-3 years		4-5 years		More than 5 years

Long-term debt	$	10,251	$	2,725	$	2,295	$	448	$	4,783

Capital lease obligations		186		73		91		22		--

Operating leases		5,613		784		1,158		875		2,796

Total contractual obligations	$	16,050	$	3,582	$	3,544	$	1,345	$	7,579

Off-Balance Sheet Transactions

The Company does not maintain any off-balance sheet transactions, arrangements, obligations or other relationships with unconsolidated entities or others that are reasonably likely to have a material current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Impact of Inflation and Changing Prices

The impact of inflation and changing prices on the Company has been primarily limited to salary, laboratory and operating supplies and rent increases and has historically not been material to the Company’s operations. In the future, the Company may not be able to increase the prices of laboratory testing by an amount sufficient to cover the cost of inflation, although the Company is responding to these concerns by refocusing the laboratory operations towards higher margin testing (including clinical and pharmaceutical trials) as well as emphasizing the marketing, sales and operations of the Product Sales business.

Impact of New Accounting Standards

In November 2002, the FASB issued FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Guarantees of Indebtedness of Others” (FIN 45). FIN 45 clarifies the requirements for a guarantor’s accounting for and disclosure of certain guarantees issued and outstanding. The initial recognition and initial measurement provisions of FIN 45 are applicable to guarantees issued or modified after December 31, 2002. The adoption of FIN 45 did not have a material impact on the Company’s results of operations or financial position.

In January 2003, the FASB issued Interpretation No. 46, “Consolidation of Variable Interest Entities,” as revised in December 2003 (FIN 46R). FIN 46R addresses consolidation by business enterprises of variable interest entities and significantly changes the consolidation application of consolidation policies to variable interest entities and, thus improves comparability between enterprises engaged in similar activities when those activities are conducted through variable interest entities. The consolidation requirements of FIN 46R will apply to variable interest entities as of March 31, 2004. The Company does not hold an interest in any variable interest entities.

In April 2003, the FASB issued SFAS No. 149, “Amendment of Statement 133 on Derivative Instruments and Hedging Activities.” SFAS No. 149 amends and clarifies certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. SFAS No. 149 was effective for certain contracts entered into or modified by the Company after June 30, 2003. The adoption of SFAS No. 149 did not have a material impact on the Company’s results of operations or financial position.

In May 2003, the FASB issued SFAS No. 150, “Accounting for Certain Financial Instruments with Characteristics of Both Liabilities and Equity.” SFAS No. 150 establishes standards on the classification and measurement of certain financial instruments with characteristics of both liabilities and equity. SFAS No. 150 was effective immediately for all financial instruments entered into or modified after May 31, 2003. For all other instruments, SFAS No. 150 was effective at the beginning of the third quarter of 2003. The adoption of SFAS No. 150 did not have a material impact on the Company’s results of operations or financial position.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Market risk is the risk that the Company will incur losses due to adverse changes in interest rates or currency exchange rates and prices. The Company’s primary market risk exposures are to changes in interest rates. During 2003, 2002, and 2001, the Company did not have sales denominated in foreign currencies nor did it have any subsidiaries located in foreign countries. As such, the Company is not exposed to market risk associated with currency exchange rates and prices.

At December 31, 2003, the Company had a $5.8 million mortgage loan payable to Principal Life Insurance Company at a fixed annual rate of 7.23% until March 1, 2006, at which time the rate will be renegotiated by the parties. At December 31, 2003, the Company had $0.9 million of subordinated notes outstanding at a fixed interest rate of 10%, and various vehicle loans totaling $0.1 million. The Company also had capital leases at various fixed rates. These fixed-rate financial instruments are subject to interest rate risk and will increase or decrease in value if market interest rates change.

The Company had approximately $8.5 million and $8.0 million outstanding on its line of credit and long-term debt issued under the Wells Fargo Credit Agreement as of December 31, 2003 and 2002. The debt under the Wells Fargo Credit Agreement is held at variable interest rates. The Company has cash flow exposure on its committed and uncommitted line of credit and long-term debt due to its variable prime rate pricing. At December 31, 2003, a 1% change in the prime rate would not materially increase or decrease interest expense or cash flows.

The Company does not enter into derivative or other financial instruments or hedging transactions for trading or speculative purposes.

ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

Reference is made to the financial statements, financial statement schedule, and notes thereto included later in this report under Item 15.

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A.

CONTROL AND PROCEDURES.

Evaluation of Disclosure Controls Procedures.

As of the end of the period covered by this report, the Company conducted an evaluation under the supervision and with the participation of the company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, regarding the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rules 13a-15(b) of the Securities Exchange Act of 1934 (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information that is required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the rules of the Securities Exchange Commission.

Changes in Internal Controls.

There were no changes in the Company’s internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART III

ITEM 10.

DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT.

The information required by this Item is incorporated by reference to the section labeled “Proposal 1- Election of Directors” that appears in the Definitive Proxy Statement to be used in connection with the 2004 Annual Meeting of Stockholders of MEDTOX Scientific, Inc.

The Company has adopted the MEDTOX Scientific, Inc. Code of Ethics for senior financial and executive officers (“Code of Ethics”). The Code of Ethics is available at no charge to anyone who sends a request for a paper copy to MEDTOX Scientific, Inc. 402 West County Road D, St. Paul, Minnesota, 55112. If the Company makes any substantive amendments to the Code of Ethics or grants any waiver, including any implicit waiver from a provision of the Code of Ethics to its directors or executive officers, the Company will disclose the nature of such amendments or waiver on its website or in a report on Form 8-K.

ITEM 11.

EXECUTIVE COMPENSATION.

The information required by this Item is incorporated by reference to the sections labeled “Executive Compensation” and “Summary Compensation Table” that appear in the Definitive Proxy Statement to be used in connection with the 2004 Annual Meeting of Stockholders of MEDTOX Scientific, Inc.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The information required by this Item is incorporated by reference to the sections labeled “Common Stock Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” that appear in the Definitive Proxy Statement to be used in connection with the 2004 Annual Meeting of Stockholders of MEDTOX Scientific, Inc.

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

The information required by this Item is incorporated by reference to the section labeled “Certain Relationships and Related Transactions” that appears in the Definitive Proxy Statement to be used in connection with the 2004 Annual Meeting of Stockholders of MEDTOX Scientific, Inc.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES.

The information required by this Item is incorporated by reference to the section labeled “Fees to Independent Auditors” that appears in the Definitive Proxy Statement to be used in connection with the 2004 Annual Meeting of Stockholders of MEDTOX Scientific, Inc.

PART IV

ITEM 15 — EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K.


a.	(i)	Financial Statements	Page

		Independent Auditors' Report	36

		Consolidated Balance Sheets at December 31, 2003 and 2002	37

		Consolidated Statements of Operations for the Years Ended
		December 31, 2003, 2002 and 2001	38

		Consolidated Statements of Stockholders' Equity for the Years
		Ended December 31, 2003, 2002 and 2001	39

		Consolidated Statements of Cash Flows for the Years Ended
		December 31, 2003, 2002 and 2001	40

		Notes to Consolidated Financial Statements	41

	(ii)	Consolidated Financial Statement Schedule

		Schedule II - Valuation and Qualifying Accounts	59

All other financial statement schedules normally required under Regulation S-X are omitted as the required information is inapplicable.

(iii)

Exhibits

The exhibits included in the Report are set forth on the exhibit index and follow the signature page of this Annual Report on Form 10-K.

3.1

Bylaws of the Registrant (incorporated by reference to Exhibit 4.2 filed with the Registrant's Report on Form 10-Q for the quarter ended December 31, 1986).

3.2

Restated Certificate of Incorporation of the Registrant filed with the Delaware Secretary of State on July 29, 1994 (incorporated by reference to Exhibit 3.8 filed with the Registrant's Form 10-K for fiscal year ended December 31, 1994).

3.3

Certificate of Amendment of Certificate of Incorporation of the Registrant, filed with the Delaware Secretary of State on November 27, 1995 (incorporated by reference to Appendix A filed with the Registrant's Proxy Statement on September 29, 1995).

3.4

Amended Certificate of Designations of Preferred Stock (Series A Convertible Preferred Stock) of the Registrant, filed with the Delaware Secretary of State on January 29, 1996 (incorporated by reference to Exhibit 3.1 filed with the Registrant's report on Form 8-K dated January 30, 1996).

3.5

Certificate of Amendment of Certificate of Incorporation of MEDTOX Scientific, Inc. filed with Delaware Secretary of State on September 17, 1998 (incorporated by reference to Exhibit 3.5 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 1998).

3.6

Certificate of Amendment of Certificate of Incorporation of MEDTOX Scientific, Inc. filed with Delaware Secretary of State on November 19, 1999 (incorporated by reference to Exhibit 3.6 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 1999).

4.1

Form of Warrant accompanying the Stock Purchase Agreement dated July 31, 2000. (Incorporated by reference to Exhibit 4.3 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).

4.2

Form of 10% Subordinated Notes issued by the Registrant in October and November 2001 to raise an aggregate amount of $1.5 million in subordinate debt, all with a maturity of September 30, 2004. (Incorporated by reference to Exhibit 4.4 filed with the Registrant's Report on Form 10-Q for the quarter ended September 30, 2001).

4.3

Form of Warrant accompanying the 10% Subordinated Notes issued in October and November 2001. (Incorporated by reference to Exhibit 4.5 filed with the Registrant's Report on Form 10-Q for the quarter ended September 30, 2001).

4.4

Rights Agreement dated September 18, 1998 between the Registrant and American Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 filed with the Registrant's Report on Form 8-K dated September 21, 1998).

10.1

Second Amendment dated December 31, 1986 to Exclusive License Agreement amending and restating exclusive license granted by the Registrant to Disease Detection International, Inc. (incorporated by reference to Exhibit 10.25 filed with the Registration Statement on Form S-1 dated August 26, 1987, Commission File No. 33-15543).

10.2

Stock Option Agreement dated May 4, 1990 between the Registrant and Samuel C. Powell amending and restating the Non-Qualified Stock Option Agreement between the Registrant and Samuel C. Powell dated as of May 23, 1988. (Incorporated by reference to Exhibit 10.34 filed with the Registrant's Form 10-K for the fiscal year ended December 31, 1990).**

10.3

Registrant's Amended and Restated Qualified Employee Stock Purchase Plan (incorporated by reference to Exhibit 4 filed with the Registrant's Registration Statement on Form S-8 dated November 11, 1993, Commission File No. 33-71596).

10.4

Agreement regarding rights to "MEDTOX" name dated as of January 30, 1996 between the Registrant and Harry G. McCoy. (Incorporated by reference to Exhibit 10.38 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 1995.)**

10.5

Employment Agreement dated January 1, 2000 between the Registrant and Harry G. McCoy. (Incorporated by reference to Exhibit 10.45 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 1999.)**

10.6

Registrant's Restated Equity Compensation Plan dated May 10, 2000. (Incorporated by reference to exhibit 10.46 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000.)**

10.7

Form of Severance Agreement between the Registrant and James B. Lockhart, James A. Schoonover, B. Mitchell Owens, and Kevin J. Wiersma. (Incorporated by reference to exhibit 10.47 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).**

10.8

Purchase and Sale Agreement dated July 27, 2000 by and between the Registrant and NMRO, Inc. (Incorporated by reference to exhibit 10.48 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).

10.9

Registration Rights Agreement dated July 31, 2000 among the Registrant, certain investors, and Miller, Johnson, & Kuehn, Inc. ("MJK"). (Incorporated by reference to exhibit 10.50 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).**

10.10

Stock Purchase Agreement dated July 31, 2000 between the Registrant and certain investors. (Incorporated by reference to exhibit 10.51 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).**

10.11

Purchase and Sale Agreement dated December 29, 2000 by and between MEDTOX Laboratories, Inc. and PHL-OPCO, LP. (Incorporated by reference to exhibit 10.52 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).

10.12

Mortgage and Security Agreement dated March 16, 2001 by and between New Brighton Business Center LLC and Principal Life Insurance Company. (Incorporated by reference to exhibit 10.53 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).

10.13

Secured Promissory Note dated March 16, 2001 by and between New Brighton Business Center LLC and Principal Life Insurance Company. (Incorporated by reference to exhibit 10.54 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2000).

10.14

Nova Building Lease dated March 28, 2001 by and between Samuel C. Powell and Karen G. Powell and MEDTOX Diagnostics, Inc. (Incorporated by reference to exhibit 10.55 filed with the Registrant's Report on Form 10-Q for the quarter ended September 30, 2001).

10.15

Amendment No. 1 to Nova Building Lease dated April 1, 2001 by and between Samuel C. Powell and Karen G. Powell and MEDTOX Diagnostics, Inc. (Incorporated by reference to exhibit 10.56 filed with the Registrant's Report on Form 10-Q for the quarter ended September 30, 2001).

10.16

Amended and Restated Credit and Security Agreement dated March 31, 2001 by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., Consolidated Medical Services, Inc. and Wells Fargo Business Credit, Inc. (Incorporated by reference to exhibit 10.57 filed with the Registrant's Report on Form 10-Q for the quarter ended September 30, 2001).

10.17

First Amendment dated October 24, 2001 to the Amended and Restated Credit and Security Agreement dated March 31, 2001 by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., Consolidated Medical Services, Inc. and Wells Fargo Business Credit, Inc. (Incorporated by reference to exhibit 10.58 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).

10.18

Employment Agreement dated January 1, 2003, between the Registrant and Richard J. Braun. (Incorporated by reference to exhibit 10.59 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).**

10.19

Second Amendment to Amended and Restated Credit and Security Agreement dated May 1, 2002, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., Consolidated Medical Services, Inc. and Wells Fargo Business Credit, Inc. (Incorporated by reference to exhibit 10.60 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).

10.20

Security Agreement dated December 10, 2002, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Wells Fargo Equipment Finance, Inc. (Incorporated by reference to exhibit 10.61 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).

10.21

Secured Promissory Note dated December 10, 2002, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Wells Fargo Equipment Finance, Inc. (Incorporated by reference to exhibit 10.62 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).

10.22

Intercreditor Agreement dated December 16, 2002, by and between MEDTOX Scientific, Inc. and Wells Fargo Equipment Finance, Inc. (Incorporated by reference to exhibit 10.63 filed with the Registrant's Report on Form 10-K for the fiscal year ended December 31, 2002).

10.23

Amended and Restated Nova Building Lease dated November 1, 2003 by and between Powell Enterprises and MEDTOX Diagnostics, Inc.*

10.24

Non-Qualified Stock Option Agreement between the Registrant and Robert C. Bohannon dated December 3, 2003.* & **

10.25

Restricted Stock Inducement Award Agreement between the Registrant and Robert C. Bohannon dated December 3, 2003.* & **

10.26

Purchase and Sale Agreement dated July 1, 2003 by and between MEDTOX Laboratories, Inc. and CoxHealth.*

10.27

Third Amendment to Amended and Restated Credit and Security Agreement dated August 15, 2003, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., Consolidated Medical Services, Inc. and Wells Fargo Business Credit, Inc. *

10.28

Secured Promissory Note dated January 22, 2003, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Wells Fargo Equipment Finance, Inc.*

10.29

Secured Promissory Note dated June 6, 2003, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Wells Fargo Equipment Finance, Inc.*

10.30

Fourth Amendment to Amended and Restated Credit and Security Agreement dated March 5, 2004, by and among MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., Consolidated Medical Services, Inc. and Wells Fargo Business Credit, Inc. *

21.1

Subsidiaries of Registrant*

31.1

Section 302 Certification of Chief Executive Officer pursuant to the Sarbanes-Oxley Act of 2002.*

31.2

Section 302 Certification of Chief Financial Officer pursuant to the Sarbanes-Oxley Act of 2002.*

32.1

Section 906 Certification of Chief Executive Officer pursuant to the Sarbanes-Oxley Act of 2002.*

32.2

Section 906 Certification of Chief Financial Officer pursuant to the Sarbanes-Oxley Act of 2002.*

Filed herewith

Denotes a management contract or compensatory plan or arrangement

b. Reports on Form 8-K

On December 4, 2003, the Company filed a Form 8-K dated December 4, 2003, announcing that U.S. Bancorp Piper Jaffray published a research report containing information about fourth quarter personnel reductions not previously disclosed by the Company.

On December 4, 2003, the Company filed a Form 8-K dated December 4, 2003 announcing that the Company had received ISO Certification and was granted a new patent for its “On-Site Drug Testing Method.” The Company also announced that Dr. Robert C. Bohannon had joined MEDTOX Diagnostics, Inc. as Vice President of Technology, Research and Development and as an inducement to accept the position was granted 20,000 non-qualified stock options and 5,500 restricted shares.

On November 4, 2003, the Company filed a Form 8-K dated November 4, 2003, announcing and furnishing results for the third quarter ended September 30, 2003.

On November 6, 2003, the Company filed a Form 8-K dated November 4, 2003, stating it held its quarterly conference call and announced results for the third quarter ended September 30, 2003.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 18th of March, 2004.


	MEDTOX Scientific, Inc.
	Registrant

	By: /s/ Richard J. Braun
	Richard J. Braun
	President, Chief Executive Officer and
	Chairman of the Board of Directors

Pursuant to the requirements of the Securities Act of 1934, this Registration Statement has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Richard J. Braun	President, Chief Executive Officer, and	March 18, 2004
Richard J. Braun	Chairman of the Board of Directors
	(Principal Executive Officer)

/s/ Kevin J. Wiersma	Vice President and Chief Financial Officer	March 18, 2004
Kevin J. Wiersma	(Principal Financial Officer)

/s/ Samuel C. Powell	Director	March 18, 2004
Samuel C. Powell, Ph.D

/s/ Brian P. Johnson	Director	March 18, 2004
Brian P. Johnson

/s/ Robert A. Rudell	Director	March 18, 2004
Robert A. Rudell

/s/ Robert J. Marzec	Director	March 18, 2004
Robert J. Marzec

This page left intentionally blank

INDEPENDENT AUDITORS’ REPORT

To the Stockholders and Board of Directors
MEDTOX Scientific, Inc.

We have audited the accompanying consolidated balance sheets of MEDTOX Scientific, Inc. (the Company) as of December 31, 2003 and 2002 and the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2003. Our audits also included the financial statement schedule listed in the index as Item 15.a. (ii). These consolidated financial statements and the financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of MEDTOX Scientific, Inc. as of December 31, 2003 and 2002 and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2003, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein.

DELOITTE & TOUCHE LLP

Minneapolis, Minnesota
March 15, 2004

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2003 AND 2002
(In thousands, except share and per share data)

	2003			2002
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	711		$	439
Accounts receivable:
Trade, less allowance for doubtful accounts ($372 in 2003 and $1,125 in 2002)		7,922			9,155
Other		145			243
Note receivable from related party		300			--

Total accounts receivable		8,367			9,398
Inventories		3,564			4,395
Deferred income taxes		1,258			849
Prepaid expenses and other		1,406			1,169

Total current assets		15,306			16,250
BUILDING, EQUIPMENT AND IMPROVEMENTS, net		15,092			14,769
GOODWILL, net		15,967			15,967
OTHER INTANGIBLE ASSETS, net		1,836			2,218
DEFERRED INCOME TAXES, net		8,077			8,488
OTHER ASSETS		240			363

TOTAL ASSETS	$	56,518		$	58,055

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Line of credit	$	5,126		$	4,345
Accounts payable		2,236			3,966
Accrued expenses		3,649			3,485
Current portion of long-term debt		2,725			2,285
Current portion of capital leases		73			83

Total current liabilities		13,809			14,164
LONG-TERM DEBT, net of current portion		7,526			8,822
LONG-TERM PORTION OF CAPITAL LEASES, net of current portion		113			185
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Preferred stock, $1.00 par value; authorized shares, 50,000; none issued and outstanding		--			--
Common stock, $0.15 par value; authorized shares, 14,400,000; issued and outstanding
shares, 4,977,221 in 2003 and 4,814,001 in 2002		746			722
Additional paid-in capital		81,666			80,699
Deferred stock-based compensation		(995	)		(498	)
Accumulated deficit		(46,171	)		(45,863	)
Treasury stock		(176	)		(176	)

Total stockholders' equity		35,070			34,884

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	56,518		$	58,055

See notes to consolidated financial statements.

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001
(In thousands, except share and per share data)

	2003			2002			2001
REVENUES:
Laboratory services	$	39,424		$	39,673		$	37,990
Product sales		12,049			12,351			11,094

		51,473			52,024			49,084

COST OF REVENUES:
Cost of services		26,357			26,792			25,878
Cost of sales		5,163			4,684			3,759

		31,520			31,476			29,637

GROSS PROFIT		19,953			20,548			19,447

OPERATING EXPENSES:
Selling, general and administrative		16,722			16,317			14,436
Research and development		1,910			1,217			1,292

		18,632			17,534			15,728

INCOME FROM OPERATIONS		1,321			3,014			3,719

OTHER INCOME (EXPENSE):
Interest expense, net		(1,147	)		(1,344	)		(1,123	)
Other expense, net		(482	)		(83	)		(98	)

		(1,629	)		(1,427	)		(1,221	)

INCOME (LOSS) BEFORE INCOME TAX BENEFIT		(308	)		1,587			2,498

INCOME TAX BENEFIT		--			10,150			--

NET INCOME (LOSS)	$	(308	)	$	11,737		$	2,498

BASIC EARNINGS (LOSS) PER COMMON SHARE (1)	$	(0.06	)	$	2.45		$	0.57

WEIGHTED AVERAGE NUMBER OF BASIC SHARES
OUTSTANDING (1)		4,942,617			4,798,098			4,401,950

DILUTED EARNINGS (LOSS) PER COMMON SHARE (1)	$	(0.06	)	$	2.34		$	0.54

WEIGHTED AVERAGE NUMBER OF DILUTED SHARES
OUTSTANDING (1)		4,942,617			5,011,330			4,614,152

(1) Share and per share amounts have been restated for the ten percent stock dividends paid on July 5, 2002 and November 9, 2001.

See notes to consolidated financial statements.

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share data)

						Additional Paid-in Capital			Deferred Stock-Based Compensation			Accumulated Deficit			Note Receivable from Related Party			Treasury Stock			Total

BALANCE AT DECEMBER 31, 2000	3,508,151		$	526		$	65,422		$	(472	)	$	(49,890	)	$	--		$	(176	)	$	15,410

Issuance of common stock under employee
stock plans	18,853			3			125															128
Stock issued in connection with acquisition	206,994			31			2,627															2,658
Settlement of lawsuit							628															628
Value of warrants issued							281															281
Note receivable from former director																(103	)					(103	)
Exercise of stock options	127,419			19			566															585
Deferred stock-based compensation	67,619			10			416			(174	)											252
Amortization of deferred compensation										183												183
Issuance of 10% stock dividend	386,175			58			5,134						(5,192	)								--
Net income													2,498									2,498

BALANCE AT DECEMBER 31, 2001	4,315,211			647			75,199			(463	)		(52,584	)		(103	)		(176	)		22,520

Issuance of common stock under employee
stock plans	13,525			2			97															99
Repayment of note receivable from former
director																103						103
Exercise of stock options	20,934			3			78															81
Deferred stock-based compensation	28,093			5			374			(379	)											--
Amortization of deferred compensation										344												344
Issuance of 10% stock dividend	436,238			65			4,951						(5,016	)								--
Net income													11,737									11,737

BALANCE AT DECEMBER 31, 2002	4,814,001			722			80,699			(498	)		(45,863	)		--			(176	)		34,884

Issuance of common stock under employee
stock plans	8,861			1			44															45
Exercise of stock options	1,222			--			7															7
Deferred stock-based compensation	165,840			25			992			(1,017	)											--
Traded shares for payment of taxes	(12,703	)		(2	)		(76	)														(78	)
Amortization of deferred compensation										520												520
Net loss													(308	)								(308	)

BALANCE AT DECEMBER 31, 2003	4,977,221		$	746		$	81,666		$	(995	)	$	(46,171	)	$	--		$	(176	)	$	35,070

See notes to consolidated financial statements.

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001
(In thousands)

	2003			2002			2001
CASH FLOWS PROVIDED BY (USED IN) OPERATING ACTIVITIES:
Net income (loss)	$	(308	)	$	11,737		$	2,498
Adjustments to reconcile net income (loss) to net cash provided by (used
in) operating activities:
Depreciation and amortization		2,850			2,541			2,595
Provision for losses on accounts receivable		635			445			242
Loss on sale of equipment		9			--			1
Deferred compensation		520			344			183
Deferred income taxes		2			(10,150	)		--
Changes in operating assets and liabilities:
Accounts receivable		396			(1,223	)		(280	)
Inventories		831			(498	)		(845	)
Prepaid expenses and other current assets		(237	)		(89	)		(87	)
Other assets		25			(18	)		(508	)
Accounts payable and accrued expenses		(1,566	)		1,131			(138	)
Restructuring accruals		--			--			(160	)

Net cash provided by operating activities		3,157			4,220			3,501

CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
Purchase of building, equipment and improvements		(2,563	)		(4,324	)		(8,459	)
Proceeds from sale of equipment		1			7			1
Payment for acquisition of business, net of cash acquired		--			--			(2,473	)

Net cash used in investing activities		(2,562	)		(4,317	)		(10,931	)

CASH FLOWS PROVIDED BY (USED IN) FINANCING ACTIVITIES:
Net proceeds from sale of common stock		52			180			595
Proceeds from note receivable from former director		--			103			--
Net proceeds from legal settlement		--			--			628
Net proceeds (payments) on revolving credit facility		781			1,431			(810	)
Proceeds from long-term debt		1,641			1,557			9,010
Principal payments on long-term debt		(2,637	)		(2,581	)		(1,930	)
Principal payments on capital leases		(82	)		(221	)		(225	)
Payment for traded shares for taxes		(78	)		--			--
Other		--			--			16

Net cash provided by (used in) financing activities:		(323	)		469			7,284

INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		272			372			(146	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR		439			67			213

CASH AND CASH EQUIVALENTS AT END OF YEAR	$	711		$	439		$	67

SUPPLEMENTAL NONCASH ACTIVITIES:
Additions to capital leases	$	--		$	--		$	75
Note receivable for exercise of stock options		--			--			103
Acquisitions:
Fair value of assets acquired		--			--			6,088
Cash paid		--			--			(2,473	)
Note payable		--			--			(957	)
Common stock issued		--			--			(2,658	)

	$	--		$	--		$	--

See notes to consolidated financial statements.

MEDTOX SCIENTIFIC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company — The consolidated financial statements include the accounts of MEDTOX Scientific, Inc. and its wholly owned subsidiaries, MEDTOX Laboratories, Inc. (MEDTOX Laboratories), MEDTOX Diagnostics, Inc. (MEDTOX Diagnostics), and New Brighton Business Center, LLC (NBBC) (collectively referred to as the Company).

MEDTOX Laboratories provides laboratory analyses, logistics management, data management, and program management services. Laboratory analyses include clinical testing services for the detection of substances of abuse and other toxins in biological fluids and tissues. Logistics, data, and program management services include courier services for medical specimen transportation, management programs for on-site drug testing, data collection and reporting services, coordination of specimen collection sites, and medical surveillance program management.

MEDTOX Diagnostics is engaged in the research, development, and sale of products based upon enzyme immunoassay technology for the detection of antibiotic residues, mycotoxins, drugs-of-abuse and other hazardous substances as well as distribution of agridiagnostic and food safety testing products.

NBBC conducts the Company’s building rental activities that are not related to the Company’s operations. The operations of NBBC are shown in the statements of operations as “other expense.”

All significant intercompany transactions and balances have been eliminated.

Use of Estimates — The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The more significant estimates include the valuation of accounts receivable, inventories, goodwill and other intangible assets, deferred income taxes, and the recorded amounts for certain accruals. Actual results could differ from those estimates.

Cash and Cash Equivalents — Cash equivalents include highly liquid investments maturing within three months of purchase.

Trade Accounts Receivable — Sales are made to local and national customers including corporations, clinical laboratories, government agencies, medical professionals, law enforcement agencies, and health care facilities. The Company extends credit based on an evaluation of the customer’s financial condition, and receivables are generally unsecured. The Company provides an allowance for doubtful accounts equal to the estimated losses expected to be incurred in the collection of accounts receivable. In addition, some of the Company’s Laboratory Services revenues for certain types of tests are billed to third-party payors including insurance companies, state Medicaid and Medicare agencies. These payors pay for such services at established amounts, which are typically lower than gross amounts billed by the Company. The Company estimates a discount on the billings for these tests, and recognizes revenue and related accounts receivable at a net amount after discount in order to state revenue and accounts receivable at the amount expected to be paid.

Inventories — Inventories are valued at the lower of cost (first-in, first-out method) or market.

Equipment and Improvements — Equipment and improvements are stated at cost. Provisions for depreciation have been computed using the straight-line method to amortize the cost of depreciable assets over their estimated useful lives. Leasehold improvements are amortized over the lesser of the lease term or the economic useful lives of the improvements.

Goodwill and Other Intangible Assets — The Company adopted Statement of Financial Accounting Standards (SFAS) No. 142, “Goodwill and Other Intangible Assets” on January 1, 2002. SFAS No. 142 provides that goodwill and indefinite-lived intangible assets are no longer amortized, but are instead reviewed for impairment at least annually and between annual test dates in certain circumstances. The Company completed the necessary transition impairment review for goodwill and other intangible assets in 2002, and determined that there was no impairment. The Company performs its annual impairment test for goodwill and other intangible assets in the fourth quarter of each year. No impairments were indicated as a result of the annual impairment reviews for goodwill and other intangible assets in 2003 or 2002. In assessing the recoverability of goodwill and other intangible assets, projections regarding estimated future cash flows and other factors are made to determine the fair value of the respective assets. If these estimates or related projections change in the future, the Company may be required to record impairment charges for these assets.

The effect of the adoption of SFAS No. 142 on the reported net income (loss) and earnings (loss) per share for all periods presented in the accompanying statements of operations is as follows:

(In thousands, except per share data)	2003			2002		2001

Reported net income (loss)	$	(308	)	$	11,737	$	2,498
Addback: goodwill amortization		--			--		878

Adjusted net income (loss)	$	(308	)	$	11,737	$	3,376

Reported earnings (loss) per share - basic	$	(0.06	)	$	2.45	$	0.57
Addback: goodwill amortization		--			--		0.20

Adjusted earnings (loss) per share - basic	$	(0.06	)	$	2.45	$	0.77

Reported earnings (loss) per share - diluted	$	(0.06	)	$	2.34	$	0.54
Addback: goodwill amortization		--			--		0.19

Adjusted earnings (loss) per share - diluted	$	(0.06	)	$	2.34	$	0.73

Goodwill and other intangible assets are allocated to the Company’s reporting units, which are either the operating segment or one reporting level below the operating segment. SFAS No. 142 requires the Company to compare the fair value of the reporting unit to its carrying amount on an annual basis to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill and other intangible assets within the reporting unit is less than their carrying value. If the carrying amount of the goodwill and other intangible asset exceeds its fair value, an impairment loss is recognized. Fair values for goodwill and other intangible assets are determined based on discounted cash flows.

Amortizable intangible assets are amortized on a straight-line or accelerated basis based upon estimated useful lives as follows as of December 31, 2003:

Customer lists: 5 – 20 years
Non-compete agreements: 2 — 5 years

Revenue Recognition — Revenues from Laboratory Services are recognized as earned at such time as the Company has completed services. The Company’s services are considered to be complete when it has performed the applicable laboratory testing services and the results have been sent to the Company’s customers or posted to the Company’s secure website. Revenues from Product Sales are recognized FOB shipping point net of an allowance for estimated returns. When shipment occurs, the sales price is fixed and determinable, and collection of the resulting receivable is reasonably assured.

Freight charges to customers are included in product sales and freight costs are included in cost of sales.

Research and Development — Research and development expenditures are charged to expense as incurred.

Income Taxes — The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance against deferred tax assets is established for the estimated amount of net operating losses that will more likely than not expire unused in future periods.

Earnings (Loss) per Common Share — Basic earnings (loss) per common share equals net earnings (loss) divided by the weighted average common shares outstanding during the period. Diluted earnings (loss) per common share equals net earnings (loss) divided by the sum of weighted average common shares outstanding during the period plus common stock equivalents. Common stock equivalents are shares assumed to be issued if outstanding stock options or warrants were exercised. Common stock equivalents that are anti-dilutive are excluded from net earnings per common share. Common stock equivalents are not considered in periods with a net loss as the effect would be anti-dilutive.

Fair Value of Financial Instruments — The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses are considered to be representative of their respective fair values due to their short-term nature. The carrying amount of the line of credit and long-term debt approximated fair value at December 31, 2003 and 2002. The fair value of the Company’s debt was estimated using interest rates that are representative of debt with similar terms and maturities.

Concentrations of Credit Risk – Concentrations of credit risk with respect to accounts receivable are limited due to the diversity of the Company’s clients as well as their dispersion across many different geographic regions. The Company had no customers that accounted for more than 10% of consolidated revenues in 2003, 2002, or 2001 or accounts receivable at December 31, 2003 or 2002.

Stock-Based Compensation — SFAS No. 123, “Accounting for Stock-Based Compensation,” requires companies to measure employee stock compensation plans and non-employee stock-based compensation based on the fair value method of accounting. However, for stock compensation granted to employees, SFAS No. 123 allows the alternative of continued use of Accounting Principles Board Opinion (APBO) No. 25, “Accounting for Stock Issued to Employees,” with pro forma disclosure of net income and earnings per share determined as if the fair value method had been applied in measuring compensation cost. The Company elected the continued use of APBO No. 25.

Had the Company determined compensation expense based on the fair value at the grant date for its stock options under SFAS No. 123 (as amended by SFAS No. 148), the Company’s net income (loss) and earnings (loss) per share would have been changed to the pro forma amounts indicated below:

(In thousands, except per share data)		2003			2002			2001

Net income (loss)	As reported	$	(308	)	$	11,737		$	2,498
Less: Total stock-based compensation
expense			(615	)		(586	)		(498	)

	Pro forma	$	(923	)	$	11,151		$	2,000


Basic earnings (loss) per share	As reported	$	(0.06	)	$	2.45		$	0.57
	Pro forma		(0.19	)		2.32			0.45

Diluted earnings (loss) per share	As reported	$	(0.06	)	$	2.34		$	0.54
	Pro forma		(0.19	)		2.23			0.43

The fair value of the options at the grant date was estimated using the Black-Scholes model with the following assumptions:

	2003			2002			2001

Expected life (years)		4	.0		4	.0		4	.0
Interest rate		2	.6%		2	.3%		4	.0%
Volatility		62	.4%		77	.2%		123	.6%
Dividend yield			0%			0%			0%

The weighted average fair value of options granted in 2003, 2002, and 2001, using the above assumptions, was $2.90, $5.74, and $5.30 and per share, respectively.

Comprehensive Income (Loss) — Comprehensive income (loss) is a measure of all nonowner changes in shareholders’ equity and includes such items as net income (loss), certain foreign currency translation items, minimum pension liability adjustments, and changes in the value of available-for-sale securities. In 2003, 2002, and 2001, comprehensive income (loss) for the Company was equal to net income (loss) as reported.

New Accounting Standards — In November 2002, the FASB issued FASB Interpretation No. 45, “Guarantor’s Accounting and Disclosure Requirements for Guarantees, Including Guarantees of Indebtedness of Others” (FIN 45). FIN 45 clarifies the requirements for a guarantor’s accounting for and disclosure of certain guarantees issued and outstanding. The initial recognition and initial measurement provisions of FIN 45 are applicable to guarantees issued or modified after December 31, 2002. The adoption of FIN 45 did not have a material impact on the Company’s results of operations or financial position.

Reclassifications — Certain reclassifications have been made to the 2002 and 2001 consolidated financial statements to conform with the 2003 presentation. These reclassifications had no effect on net income (loss) or total stockholders’ equity as previously reported.

SEGMENTS

The Company has two reportable segments: Laboratory Services and Product Sales. The Laboratory Services segment consists of MEDTOX Laboratories and NBBC. Services provided include forensic toxicology (primarily workplace drugs-of-abuse testing) and Specialty Laboratory Services, which include clinical toxicology, clinical testing for the pharmaceutical industry, pediatric lead testing, heavy metals analyses, courier delivery, and medical surveillance. The Product Sales segment, which includes POC (point of care) disposable diagnostics devices, consists of MEDTOX Diagnostics. Products manufactured include easy to use, inexpensive, on-site drug tests such as PROFILE^®-II, PROFILE-II ER^®, and VERDICT^®-II in addition to a variety of agricultural testing products. MEDTOX Diagnostics also provides contract manufacturing services in its FDA/GMP facility.

The Company’s reportable segments are strategic business units that offer different products and services. They are managed separately as each business requires different products, services and marketing strategies.

In evaluating financial performance, management focuses on income from operations as a segment’s measure of profit or loss. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 1).

(In thousands)

	2003		2002		2001
Laboratory Services:
Revenues	$	39,424	$	39,673	$	37,990
Depreciation and amortization		2,316		2,280		2,459
Income from operations		1,032		1,317		1,933
Segment assets		39,893		42,186		39,358
Capital expenditures for segment assets		1,113		2,666		8,108

(In thousands)

	2003			2002			2001
Product Sales:

Revenues	$	12,049		$	12,351		$	11,094
Depreciation and amortization		534			261			136
Income from operations		289			1,697			1,786
Segment assets		7,290			6,532			4,798
Capital expenditures for segment assets		1,450			1,658			351

Corporate (unallocated):

Other expense	$	(1,629	)	$	(1,427	)	$	(1,221	)
Deferred tax asset, net		9,335			9,337			--

Company:

Revenues	$	51,473		$	52,024		$	49,084
Depreciation and amortization		2,850			2,541			2,595
Income from operations		1,321			3,014			3,719
Other expense		(1,629	)		(1,427	)		(1,221	)
Income (loss) before income taxes		(308	)		1,587			2,498
Total assets		56,518			58,055			44,156
Capital expenditures for assets		2,563			4,324			8,459

The following is a summary of revenues from external customers for each group of services provided within the Laboratory Services segment:

(In thousands)

	2003		2002		2001

Workplace drugs-of-abuse testing	$	24,098	$	25,059	$	25,069
Other Specialty Laboratory Services		15,326		14,614		12,921

	$	39,424	$	39,673	$	37,990

The following is a summary of revenues from external customers for each group of products and services provided within the Product Sales segment:

(In thousands)

	2003		2002		2001

Substance abuse testing products	$	10,295	$	10,657	$	9,427
Contract manufacturing services		1,416		1,423		1,318
Other diagnostic products		338		271		349

	$	12,049	$	12,351	$	11,094

3.	ACQUISITIONS

In July 2003, the Company completed the acquisition of the forensic drug testing customer list from Cox Toxicology, a full-service, SAMHSA-certified drug testing laboratory and a division of CoxHealth. The purchase price of the transaction is based on varying percentages of the revenue realized from the transitioned business over the next three years. During this period, the Company estimates that revenue from these accounts will total approximately $1.2 million and that the sum of the payments for the acquisition should not exceed 25% of this total. Per the terms of the agreement, $50,000 was paid in 2003, which was recorded as a customer list asset and is being amortized on a straight-line basis over a five-year period. Pro forma results related to the Cox Toxicology customer list acquisition are not material to the financial condition or results of operations of the Company.

In October 2001, the Company completed the acquisition of Leadtech Corporation (Leadtech), a private company operating as an independent clinical laboratory devoted primarily to the examination of blood lead concentrations in pediatric patients. The purchase price of $6.1 million consisted of $2.5 million in cash, the issuance of 250,462 shares of the Company’s common stock valued at $2.7 million, and $0.9 million of seller financing payable over 24 months. The value of the 250,462 shares issued was determined based on the average market price of the Company’s common stock over the two-day period before and after the number of shares issuable became fixed and determinable.

The following table summarizes the fair value of the Leadtech assets acquired at the time of purchase and represents the final purchase price allocation:

(In thousands)


Goodwill	$	4,540
Deferred tax liability		(843	)
Customer list		2,141
Non-compete agreement		250

	$	6,088

In accordance with SFAS No. 142, the goodwill is assessed for impairment annually and is not amortized. The customer list is being amortized over a ten-year period on an accelerated basis based upon projected future cash flows, and the non-compete agreement was being amortized on a straight-line basis over its two-year term. Goodwill is not expected to be tax deductible.

The following unaudited pro forma information presents a summary of combined results of operations of the Company and Leadtech as if the acquisition had occurred on January 1, 2001, along with certain pro forma adjustments to give effect to amortization of intangible assets, interest expense on acquisition debt, and the stock issued to purchase Leadtech. The pro forma results were derived using Leadtech’s unaudited results. The pro forma information also does not attempt to show performance on a combined basis had the companies been combined throughout these periods. The following pro forma information, therefore, although helpful in illustrating the financial characteristics of the combined Company under one set of assumptions, does not attempt to predict or suggest future results:

(In thousands, except share and per share data)

	2001

Net sales	$	50,640
Net income		2,161
Earnings per share:
Basic	$	0.48
Diluted		0.45

Weighted average shares outstanding:
Basic		4,540,253
Diluted		4,794,539

4.	INVENTORIES

Inventories consisted of the following at December 31:

(In thousands)	2003		2002

Raw materials	$	1,082	$	1,616
Work in process		533		521
Finished goods		535		844
Supplies, including off-site inventory		1,414		1,414

	$	3,564	$	4,395

5.	GOODWILL AND OTHER INTANGIBLE ASSETS

Intangible assets, resulting primarily from acquisitions, include the value assigned to customer lists, non-compete agreements and goodwill. Amortizable intangible assets are amortized on a straight-line or accelerated basis based upon their estimated useful lives.

The components of goodwill and other intangible assets were as follows as of December 31:

(In thousands)	2003							2002
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount

Goodwill	$	21,100	$	(5,133	)	$	15,967	$	21,100	$	(5,133	)	$	15,967

Other intangible
assets:
Non-compete
agreements	$	521	$	(388	)	$	133	$	521	$	(231	)	$	290

Customer lists		2,467		(816	)		1,651		2,417		(494	)		1,923

Trademarks and
other		55		(3	)		52		5		--			5

	$	3,043	$	(1,207	)	$	1,836	$	2,943	$	(725	)	$	2,218

Goodwill amortization expense was $0.9 million for the year ended December 31, 2001.

Other intangible asset amortization expense was $0.5 million, $0.5 million, and $0.2 million during 2003, 2002, and 2001, respectively. Future amortization expense for other intangible assets is estimated to be as follows (in thousands):



Year ended December 31:	2004	$	362
	2005		375
	2006		313
	2007		233
	2008		180
	2009 and thereafter		373

		$	1,836

The entire amount of goodwill is included in the Laboratory Services segment, which is tested annually for impairment during the fourth quarter, after the Company’s annual forecasting process. No goodwill impairment was recognized in 2003 or 2002. There were no other changes in the carrying amount of goodwill for the years ended December 31, 2003 and 2002.

The changes in the carrying amount of other intangible assets for the year ended December 31, 2003 were as follows (in thousands):

	Laboratory Services			Product Sales			Total
Balance as of December 31, 2002	$	2,218		$	--		$	2,218
Add: customer list		50			--			50
Add: trademark and other		--			50			50
Less: amortization expense		(480	)		(2	)		(482	)

Balance as of December 31, 2003	$	1,788		$	48		$	1,836

6.	BUILDING, EQUIPMENT AND IMPROVEMENTS

Building, equipment and improvements consisted of the following at December 31:

(In thousands)	2003			2002

Furniture and equipment	$	17,268		$	16,923
Building		7,005			6,886
Leasehold improvements		3,608			2,627

		27,881			26,436
Less accumulated depreciation		(12,789	)		(11,667	)

	$	15,092		$	14,769

Depreciation expense was $2.2 million, $1.7 million and $1.5 million for the years ended December 31, 2003, 2002 and 2001, respectively.

DEBT

Long-term debt consisted of the following at December 31:

(In thousands)	2003			2002

Term loan, due March 2005, 4.75% at December 31, 2003	$	265		$	1,062
Capex note, due March 2005, 4.75% at December 31, 2003		1,477			2,209
Capex note, due June 2006, 5.25% at December 31, 2003		314			428
Capex note, due December 2006, 5.25% at December 31, 2003		1,360
Subordinated notes, due September 2004, 10.0% at December 31, 2003
(discount is based on imputed interest rate of 23.0%)		921			864
Non-interest bearing promissory notes issued in connection with
acquisition, paid November 2003		--			358
Mortgage loan, due April 2011, 7.23% at December 31, 2003		5,793			5,955
Various vehicle loans, due from January 2004 through April 2006,
0.0% to 10.3%		121			231

		10,251			11,107
Less current portion		(2,725	)		(2,285	)

	$	7,526		$	8,822

Long-term debt maturities at December 31, 2003 were as follows:


2004	$	2,725
2005		1,545
2006		750
2007		216
2008		232
2009 and thereafter		4,783

	$	10,251

Wells Fargo Credit Agreement – The Company has a Credit Security Agreement (the Wells Fargo Credit Agreement) with Wells Fargo Business Credit, Inc. (Wells Fargo). The Wells Fargo Credit Agreement, as amended, consists of (i) a term loan of $3.185 million bearing interest at prime + 0.75%; (ii) a revolving line of credit, payable on demand, of not more than $8.0 million or 85% of the Company’s eligible trade accounts receivable bearing interest at prime + 1%; and (iii) a capex note of up to $3.5 million for the purchase of capital equipment bearing interest at prime + 0.75% to 1.25%. According to the terms of the agreement, the capex note may be amended, supplemented or restated from time to time and is generally done so on an annual basis. During the third quarter of 2003, an amendment to the capex note was required in order to allow further borrowing. The amendment was not completed in 2003 and no funding from the note was available during the second half of the year. In March 2004, the Company and Wells Fargo amended the Wells Fargo Credit Agreement to allow for borrowing under the capex note of up to $1.5 million for the purchase of capital equipment bearing interest at prime + 1.5%.

At December 31, 2003, $5.1 million was outstanding under the revolving line of credit, and $0.3 million was available to be advanced under the borrowing base formula. The Wells Fargo Credit Agreement is secured by virtually all of the Company’s assets, including equipment, general intangibles, inventories, and receivables. The weighted average interest rate on borrowings outstanding under the revolving line of credit was 4.5%, 5.1% and 6.8% during 2003, 2002, and 2001, respectively.

Subordinated Debt – In October and November 2001, the Company received approximately $1.05 million from private placements of subordinated debt. The notes require payment of the principal amounts on September 30, 2004. Interest at 10% per annum is paid semi-annually on June 30 and December 31. In connection with the issuance of the subordinated notes, the Company issued warrants to purchase 60,294 shares of common stock at $8.71 per share. The Company determined the value of the warrants at the dates of issuance to be $281,000 based upon the Black-Scholes option-pricing model. The value of the warrants was accounted for as additional paid-in capital and deducted from the principal of the subordinated notes as discount on debt issued. The effective interest rate of the subordinated debt including the warrants is 23.0%. The discount is being amortized to interest expense over the term of the debt using the effective interest method.

Cash paid for interest for all outstanding debt was $1.1 million, $1.3 million and $1.2 million for the years ended December 31, 2003, 2002 and 2001, respectively.

8.	STOCKHOLDERS’ EQUITY

On April 19, 2002, the Board of Directors declared a 10% stock dividend on the Company’s common stock, which was paid on July 5, 2002 to stockholders of record on May 22, 2002. The dividend was charged to accumulated deficit in the amount $5.0 million, which was based on the fair value of the Company’s common stock. Accordingly, all stock option, warrant, share, and per share data included in the consolidated financial statements have been restated to reflect the 10% stock dividend.

On September 26, 2001, the Board of Directors declared a 10% stock dividend on the Company’s common stock, which was paid on November 9, 2001 to stockholders of record on October 26, 2001. The dividend was charged to accumulated deficit in the amount of $5.2 million, which was based on the fair value of the Company’s common stock. Accordingly, all stock option, warrant, share, and per share data included in the consolidated financial statements have been restated to reflect the 10% stock dividend.

At December 31, 2003, shares of common stock reserved for future issuance upon exercise of outstanding common stock warrants were as follows:

	Exercise Price Per Share			Period Exercisable		Number of Shares Reserved

					July 31, 2000 to
Private equity placement	$	10	.13		July 30, 2005		611,111

					August 31, 2000 to
Private equity placement	$	10	.13		August 30, 2005		135,803

					September 20, 2002 to
Subordinated notes 10%	$	8	.71		September 30, 2004		57,996

In addition, at December 31, 2003, 755,386 shares of common stock were reserved for future issuances under the stock option plans discussed in Note 9.

In September 1998, the Company’s Board of Directors declared a dividend of one preferred share purchase right for each common share then outstanding. The Rights were distributed pursuant to a Rights Agreement between the Company and American Stock Transfer & Trust Company. Each Right entitles the holder to purchase one one-hundredth of a share of a new series of junior participating preferred stock at an exercise price of $29.80, subject to adjustment. The Rights are exercisable only if a person or group acquires beneficial ownership of 20 percent or more of the Company’s outstanding common stock.

9.	STOCK OPTION AND PURCHASE PLANS

The Company has provided stock option plans to serve as incentives to eligible employees, officers, and directors in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted and unrestricted stock awards, performance shares, and other stock-based awards. The Compensation Committee of the Board of Directors determined the exercise price (not to be less than the fair market value of the underlying stock) of stock options at the date of grant. Options generally become exercisable in installments over a period of one to five years and expire ten years from the date of grant. Restricted stock awards are awarded with a fixed restriction period. At December 31, 2003, all of the Company’s stock option plans had expired, and no options are available for future grant.

The following table summarizes information about stock options outstanding at December 31, 2003:

	Plan Options Outstanding
	1983 ISO Plan		1993 Equity Compensation Plan		Non- employee Director Plan		Weighted Average Exercise Price

Balance at December 31, 2000	5,737		497,108		12,190		6	.58
Granted			124,362				6	.63
Exercised			(84,701	)			3	.97
Canceled	(2,458	)	(61,676	)			10	.38

Balance at December 31, 2001	3,279		475,093		12,190		6	.55
Granted			106,850				9	.91
Exercised			(18,011	)	(3,056	)	3	.87
Canceled	(3,279	)	(2,837	)	(306	)	52	.08

Balance at December 31, 2002	--		561,095		8,828		6	.76
Granted			218,924				5	.85
Exercised			(1,222	)			5	.93
Canceled			(32,239	)			8	.51

Balance at December 31, 2003	--		746,558		8,828		6	.42

	Plan Options Outstanding								Options Exercisable
Range of Exercise Prices	Number Outstanding		Weighted Average Exercise Price			Weighted Average Remaining Contractual Life			Number Exercisable		Weighted Average Exercise Price

$2.10-$2.25		155,836	$	2	.14		5	.2		155,836	$	2	.14
$5.55-$5.93		194,525		5	.62		9	.1		50,218		5	.84
$6.00-$6.95		176,584		6	.51		7	.9		120,888		6	.50
$7.75-$9.87		134,660		8	.55		5	.7		130,189		8	.57
$10.09-$52.20		93,781		11	.97		7	.7		65,237		12	.70

		755,386		6	.42		7	.2		522,368		6	.43

Nonqualified Stock Options — At December 31, 2003, 2002, and 2001, the Company had 142,224, 122,224 and 122,224, respectively, of nonqualified stock options outstanding to certain current and former officers and new employees of the Company. The weighted average exercise price of nonqualified stock options outstanding was $6.95, $7.16 and $7.16 per share, at December 31, 2003, 2002 and 2001, respectively. The shares of common stock covered by nonqualified options are restricted as to transfer under applicable securities laws.

Restricted Stock Awards- Restricted stock awards are issued to certain key employees and directors of the Company as an incentive for the performance of future services that will contribute materially to the successful operation of the Company. Owners of restricted stock awards have the rights of shareowners, including the right to vote. The Company awarded 165,653, 36,391, and 49,005 restricted shares in 2003, 2002, and 2001, respectively, to certain key employees and directors of the Company with restriction periods of three to five years. The market value of the awards on the date of the grant was recorded as deferred stock-based compensation and additional paid-in capital. Compensation is charged to operations on a straight-line basis over the restriction periods and amounted to $520,000, $344,000, and $183,000 in 2003, 2002, and 2001, respectively. Unvested restricted stock awards totaled 246,398 and 133,960 at December 31, 2003 and 2002, respectively, with a weighted average grant date fair value of $6.96 and $8.16 in 2003 and 2002, respectively.

Qualified Employee Stock Purchase Plan — The Company has a Qualified Employee Stock Purchase Plan (the Purchase Plan) under which all employees meeting certain criteria may subscribe to and purchase shares of common stock. The number of shares of common stock authorized to be issued under the Purchase Plan is 181,500. The subscription price of the shares is 85% of the fair market value of the common stock on the day the executed subscription form is received by the Company. The purchase price for the shares is the lesser of the subscription price or 85% of the fair market value of the shares on the day the right to purchase is exercised. Payment for common stock is made through a payroll deduction plan. Shares issued under the Purchase Plan were 8,861, 14,878, and 22,812 during 2003, 2002, and 2001, respectively. As of December 31, 2003, 97,950 shares of common stock were available for issuance under the Purchase Plan.

10.	EARNINGS (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted earnings (loss) per common share:

(In thousands, except share and per share data)	2003			2002		2001

Net income (loss) (A)	$	(308	)	$	11,737	$	2,498

Weighted average number of basic common
shares outstanding (B)		4,942,617			4,798,098		4,401,950
Dilutive effect of stock options and warrants
computed based on the treasury stock method
using average market price		--			213,232		212,202

Weighted average number of diluted common
shares outstanding (C)		4,942,617			5,011,330		4,614,152

Basic earnings (loss) per common share (A/B)	$	(0.06	)	$	2.45	$	0.57

Diluted earnings (loss) per common share (A/C)	$	(0.06	)	$	2.34	$	0.54

Options and warrants to purchase an aggregate 1,702,520 shares of common stock were outstanding during 2003 and were excluded from the computation of dilutive earnings per share as their inclusion would have been anti-dilutive due to a net loss. Options and warrants to purchase 928,065 and 828,160 shares of common stock were outstanding during 2002 and 2001, respectively, but were not included in the computation of diluted earnings per share as their exercise prices were greater than the average market price of the common shares.

11.	INCOME TAXES

Income tax benefit consisted of:

(In thousands)	2003			2002			2001

Current:
Federal	$	--		$	--		$	--
State and local		(2	)		--			--
Deferred		2			(10,150	)		--

	$	--		$	(10,150	)	$	--

Following is a reconciliation of federal income tax at the statutory rate of 34% to the actual income taxes provided for:

(In thousands)	2003			2002			2001

Computed expected federal income tax expense
(benefit)	$	(105	)	$	540		$	849
State tax, net of federal effect		10			62			101
Change in valuation allowance		--			(12,514	)		(1,536	)
Expired net operating loss carryforwards		986			651			680
Other, net		(891	)		1,111			(94	)

	$	--		$	(10,150	)	$	--

Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred assets (liabilities) were as follows:

(In thousands)	2003			2002

Current:
Accounts receivable allowances	$	426		$	795
Inventories		155			157
Accrued expenses		527			529
Other		150			18

	$	1,258		$	1,499
Non current:
Building, equipment and improvements		(270	)		(510	)
Goodwill and other intangible assets		(875	)		(468	)
Research and experimental credit carryforwards		221			221
Net operating loss carryforwards		10,421			10,015

		9,497			9,258

		10,755			10,757
Less: Valuation allowance		(1,420	)		(1,420	)

Net deferred tax assets	$	9,335		$	9,337

At December 31, 2003, the Company had federal net operating loss carryforwards (NOLs) of approximately $27.9 million which are available to offset taxable income in 2004 through 2023. In addition, at December 31, 2003, the Company had state NOLs of approximately $10.8 million, which are available to offset taxable income in 2004 through 2029. For financial reporting purposes, a valuation allowance has been recorded to offset deferred tax assets that, more likely than not, will not be realized based on the Company’s projected future taxable income, the timing of expiring NOLs, and the Company’s tax planning strategies. Section 382 of the Internal Revenue Code restricts the annual utilization of certain NOLs incurred prior to a change in ownership. However, such limitation is not expected to impair the realization of these NOLs.

12.	EMPLOYEE BENEFIT PLAN

The Company has a defined contribution benefit plan that covers substantially all employees who meet certain age and length of service requirements. Contributions to the plan are at the discretion of the Company’s Board of Directors. The 401(k) expense for 2003, 2002 and 2001 was $0.1, $0.2 and $0.2 million, respectively.

13.	COMMITMENTS AND CONTINGENCIES

Leases — The Company leases office and research facilities from a director under a fixed term operating lease. Rental payments to the director were approximately $347,000, $197,000, and $138,000 during 2003, 2002 and 2001, respectively.

The Company leases other offices and facilities and office equipment under certain operating leases, which expire on various dates through March 2016. Under the terms of the facility leases, a pro rata share of operating expenses and real estate taxes are charged as additional rent.

As of December 31, 2003, the Company is obligated for future minimum lease payments without regard to sublease payments under noncancelable leases as follows:

(In thousands)	Capital Leases		Operating Leases

2004	$	88	$	784
2005		81		614
2006		21		544
2007		15		489
2008		8		386
2009 and thereafter		--		2,796

		213	$	5,613

Amount representing interest		27

Present value of net minimum lease payments		186
Less current portion		73

Long-term capital lease obligations	$	113

Rent expense (including amounts for the facilities leased from the director) amounted to $1.7 million, $1.3 million and $1.4 million for the years ended December 31, 2003, 2002 and 2001, respectively.

Legal — The Company is party to various legal proceedings arising in the normal course of business activities, none of which, in the opinion of management, are expected to have a material adverse impact on the Company’s consolidated financial position or results of operations.

Legal Settlement – In 2001, the Company received a favorable judgment relating to the Company’s Section 16(b) claim against a former stockholder. The Company was paid $715,000 in cash, the net proceeds of which were recorded as additional paid in capital.

14.	RELATED PARTY TRANSACTIONS

In March 2001, the Company entered into a 10-year lease of the Burlington, North Carolina production facility for an annual base rent of $197,000, exclusive of operating expenses. In addition, under the lease $600,000 of tenant improvements made to the building by the Company are being amortized over the life of the lease as additional rent. The Company received $300,000 for reimbursement of tenant improvements completed in 2001. Effective February 1, 2003, the Company entered into a month-to-month lease of a warehousing and distribution facility in an adjacent building for a monthly rent of $9,400, exclusive of operating expenses. These facilities

have always been owned and leased to the Company by a director of the Company. In 2003, the Company completed additional tenant improvements to the premises of $300,000. In November 2003, the Company amended and restated these leases. Under the terms of the new lease, the original leases have been combined and the term of the new lease has been extended to March 31, 2016, for an annual base rent of $385,279, exclusive of operating expenses, effective January 2004, including amortization of the $600,000 of improvements. In January 2004, the director reimbursed the Company $300,000 for the tenant improvements completed in 2003. The Company believes it is renting these facilities on terms similar to those available from third parties for equivalent premises.

In October and November 2001, the Company received approximately $1.05 million from private placements of subordinated debt. Of this amount, $290,000 was received from an officer and two directors of the Company (see Note 7). In the first quarter of 2003, the Company repaid the $40,000 received from the officer prior to the scheduled maturity in September 2004.

In October 2000, Harry McCoy was replaced as Chairman and President of the Company but continued to receive payments as an employee under an employment agreement with the Company. At that time, the Company recorded $600,000 as the estimated amount payable to Mr. McCoy under the employment agreement. The Company and Mr. McCoy disputed the effect of the termination of his employment with the Company. In September 2001, the Company entered into an agreement with Mr. McCoy resolving these issues. The parties agreed to a mutual release of claims. Mr. McCoy resigned his position on the Board of Directors and agreed to serve as an ongoing consultant to the Company. In exchange, the Company agreed to provide Mr. McCoy with a lump sum payment of $250,000, and an additional amount of $250,000 in restricted common stock. In exchange for McCoy’s ongoing consulting relationship, he will receive $35,000 annually over the next five years. The Company also advanced Mr. McCoy $102,500 in cash, subject to a five-year promissory note, representing the amount necessary for Mr. McCoy to exercise his previously held options to 44,000 shares of the Company’s common stock. Mr. McCoy repaid the promissory note in full in 2002.

15.	QUARTERLY INFORMATION (UNAUDITED)

(In thousands, except per share amounts)

2003	First Quarter			Second Quarter			Third Quarter		Fourth Quarter

Revenues	$	12,471		$	13,157		$	13,568	$	12,277
Gross profit		4,740			5,065			5,460		4,688
Net income (loss)		(203	)		(250	)		383		(238	)
Basic earnings (loss) per share		(0.04	)		(0.05	)		0.08		(0.05	)
Diluted earnings (loss) per share		(0.04	)		(0.05	)		0.08		(0.05	)

2002	First Quarter		Second Quarter		Third Quarter		Fourth Quarter

Revenues	$	12,351	$	13,918	$	13,632	$	12,123
Gross profit		4,906		5,922		5,350		4,370
Net income (loss)		485		1,008		11,320		(1,076	)¹
Basic earnings (loss) per share ²		0.10		0.21		2.36		(0.22	)
Diluted earnings (loss) per share ²		0.10		0.20		2.27		(0.22	)

During the fourth quarter of 2002, the Company reported a net loss of $1.1 million as a result of income tax expense of $633,000 and decreased sample volume from existing drugs-of-abuse clients due to the slowing economy. The income tax expense was based on refinements in the Company’s tax strategy for utilizing future net operating loss carryforwards and related year-end computations of taxable income and deferred taxes. The fourth quarter adjustment reduced the total amount of income tax benefit recorded for the year to $10.2 million compared to the $10.8 million recorded in the third quarter of 2002. The net loss in the fourth quarter was reduced, however, due to lower compensation expenses resulting from a change in the Company’s vacation policy.

All per share amounts have been restated for the ten percent stock dividend paid on July 5, 2002.

SCHEDULE II-VALUATION & QUALIFYING ACCOUNTS

	Balance at Beginning of Period		Charged to Costs and Expenses		Deductions				Balance at the End of Period

Year ended December 31, 2003
Allowance for Doubtful Accounts	$	1,125,000	$	635,000	$	1,388,000	(1	)	$	372,000

Year ended December 31, 2002
Allowance for Doubtful Accounts	$	873,000	$	445,000	$	193,000	(1	)	$	1,125,000

Year ended December 31, 2001
Allowance for Doubtful Accounts	$	1,077,000	$	242,000	$	446,000	(1	)	$	873,000
Restructuring Accrual	$	160,000	$	--	$	160,000	(2	)	$	--

(1) Uncollectible accounts written off, net of recoveries.
(2) Represents payments of lease obligations.

EX-10 3 exhibit10-23.htm EXHIBIT 10.23 Exhibit 10.23

Exhibit 10.23

AMENDED AND RESTATED LEASE

THIS AMENDED AND RESTATED LEASE, is made effective as of the 1st day of November 2003, by and between Powell Enterprises, a sole proprietorship (the “Landlord”), and MEDTOX Diagnostics, Inc., a Delaware corporation (the “Tenant”).

RECITALS:

A. Landlord and Tenant are parties to that certain Lease dated March 28, 2001, as amended by that certain Amendment No. 1 to Nova Building Lease dated effective as of April 1, 2001 for the property commonly known as the “Nova Building” (the “Nova Lease”).

B. Landlord and Tenant are parties to that certain Lease Agreement dated on or about February 1, 2003 for the property commonly known as the “Nypro Building” (the “Nypro Lease”; the Nova Lease and the Nypro Lease are collectively referred to as the “Original Leases”).

C. Paragraph 4.03 of the Nova Lease provides that Tenant may elect to have Landlord pay up to $600,000 for improvements to the Premises (defined in the Nova Lease) and that to the extent that Landlord advances such sums, Tenant shall repay such advances by an increase in the monthly rent due under the Nova Lease in an amount sufficient to amortize the principal of each advance on a monthly basis over 10 years at an annual interest rate of 9.5%.

D. From time to time Landlord has advanced certain sums to Tenant under Paragraph 4.03 of the Nova Lease, and as of the effective date of this Lease, Tenant owes the aggregate amount of $245,364.47 which includes the principal amount advanced plus accrued but unpaid interest thereon to Landlord for sums advanced pursuant to Paragraph 4.03 of the Nova Lease (the “Initial Advance”).

E. Landlord and Tenant wish to amend and restate the Original Leases on the terms and conditions contained in this Lease to, among other things, combine the Original Leases, extend the term of the Original Leases and increase the monthly rent payable to the Landlord to take into account the Initial Advance.

AGREEMENT:

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, Landlord and Tenant agree as follows:

1. Lease Grant. Subject to the terms of this Lease, Landlord leases the Premises (defined below) to Tenant, and Tenant leases the Premises (defined below) from Landlord. The “Premises” shall mean:

(a) that certain building located at 1238 Anthony Road in the City of Burlington, Almance County, North Carolina, commonly known as the “Nova Building”, more particularly described on Exhibit A attached hereto (the “Nova Building”), together with all improvements including the storage barn located at 1620 Nova Lane as more particularly described on Exhibit A attached hereto, and all driveways, parking lots, walkways, landscaping and other appurtenances thereto (collectively, the “Nova Improvements”) and the land upon which the Nova Improvements are located (the “Nova Property”); and

(b) those certain buildings located at 1630 and 1640 Nova Lane in the City of Burlington, Almance County, North Carolina, commonly known as the “Nypro Buildings”, more particularly described on Exhibit B attached hereto (the “Nypro Buildings”; the Nova Building and the Nypro Buildings are collectively referred to as the “Buildings”) together with all improvements including the chase-way adjoining the Nypro Buildings as more particularly described on Exhibit B attached hereto, and all driveways, parking lots, walkways, landscaping and other appurtenances thereto (collectively, the “Nypro Improvements”; the Nova Improvements and the Nypro Improvements are collectively referred to as the “Improvements”) and the land upon which the Nypro Improvements are located (the “Nypro Property”).

The legal description of the Nova Property and the Nypro Property is as set forth on Exhibit C attached hereto and is zoned as set forth on Exhibit D attached hereto.

3. Use of Premises. Tenant shall have the right to use the Premises as a laboratory facility and for light manufacturing. Notwithstanding the foregoing, Tenant may use the Premises for any other purpose so long as such use is in compliance with all applicable governmental laws, ordinances rules and regulations.

4. Term.

(a) Initial Term. Tenant shall have and hold the Premises for an initial term of fifteen (15) years beginning at midnight on April 1, 2001 and ending at 11:59 p.m. on March 31, 2016, unless sooner terminated or extended as provided in this Lease (the “Initial Term”).

(b) Option to Extend. Tenant shall have one (1) option (the “Extension Option”) to extend the Term for a period of five (5) years beginning at midnight on April 1, 2016 and ending at 11:59 p.m. on March 31, 2021 (the “Extended Term”). Tenant shall exercise the Extension Option by giving written notice to Landlord in the manner provided in Section 24 at least one hundred twenty (120) days prior to the expiration of the Initial Term. The Monthly Rental (defined in Section 5) for the Extended Term shall be subject to a one-time adjustment at the beginning of the Extended Term and shall be calculated by multiplying the Monthly Rental (defined in Section 5) during the last year of the Initial Term by a fraction, the numerator of which shall be the CPI (defined below) for the month most recently published prior to exercise of the Extension Option and the denominator of which shall be the CPI (defined below) for the month of March 2001. The Monthly Rental shall not be subject to any additional increase during the Extended Term. For purposes of this Lease, “CPI” shall mean the Consumer Price Index published by the Bureau of Labor Statistics of the United States Department of Labor for All Urban Consumers (CPI-U) for the South Region for the Size Class which encompasses Greensboro, North Carolina (1982-84=100).

- 2 -

5. Rent.

(a) Monthly Rental. As gross monthly rent (the “Monthly Rental”) for the Premises, Tenant shall pay the following amounts in advance to Landlord on the first day of each month:

(i) the Allowance Amount (defined in Section 6(b)) plus $25,852.33, $16,452.33 of which is rent for the Nova Building and $9,400.00 of which is rent for the Nypro Building (the “First Monthly Rental”) from April 1, 2001, through and including March 31, 2006;

(ii) the Allowance Amount (defined in Section 6(b)) plus the First Monthly Rental times a fraction, the numerator of which shall be the CPI for month of March 2006 and the denominator of which shall be the CPI for the month of March 2001 (the “Second Monthly Rental”) from April 1, 2006, through and including March 31, 2011;

(iii) the Allowance Amount (defined in Section 6(b)) plus the Second Monthly Rental times a fraction, the numerator of which shall be the CPI for month of March 2011 and the denominator of which shall be the CPI for the month of March 2006 from April 1, 2011, through and including March 31, 2016.

(b) Tenant shall make all Monthly Rental payments to Landlord at the following address:

Samuel C. Powell, Ph.D.
Powell Enterprises
P.O. Box 2104
Burlington, NC 27216-2014

(c) Gross Rental. The Monthly Rental shall be gross to Landlord. During the term of this Lease, Tenant shall have no cost, obligation, responsibility or liability whatsoever for and Landlord shall be responsible for and shall pay directly, the cost of (i) all ad valorem taxes and fees (including sanitary taxes) and all other assessments and levies, general or special, ordinary or extraordinary, of every nature or kind whatsoever which may be fixed, charged, levied, assessed or otherwise imposed upon the Premises as it presently exists or as it may hereafter be improved, except that Tenant shall pay all license, privilege, ad valorem or other taxes or penalties levied, assessed or charged against it for Tenant’s operation of its businesses including all inventory, equipment or machinery owned by the businesses, (ii) all casualty insurance for the Premises, as set forth in Section 8, and (iii) all repairs and maintenance of or to the Premises, except as set forth in Section 11.

- 3 -

(d) Late Charge. If Tenant shall fail to pay the Monthly Rental when due and such default shall continue for a period of ten (10) calendar days after written notice by Landlord, then a late charge equal to five percent (5%) of the past due amount shall be immediately due and payable by Tenant to Landlord compensate Landlord for its costs and expenses incurred as a result of such late payment.

6. Repairs, Alterations, and Improvements.

(a) Alterations and Improvements. Tenant shall have the right, but not the obligation, to make alterations and improvements (collectively, the “Alterations”) to the Premises; provided, however, none of the Alterations shall reduce the value of the Improvements. Tenant shall submit written plans, specifications and drawings (collectively the “Plans”) for any proposed improvements which will materially adversely affect the mechanical, electrical or plumbing systems, the structure or value of the Improvements to Landlord and receive Landlord’s written consent before commencing any Alterations. Landlord shall not unreasonably withhold or condition its approval of the Plans and shall notify Tenant in writing of its approval or disapproval within five (5) business days after Tenant’s request or the Plans shall be deemed approved. All such Alterations shall be constructed in Tenant’s name, lien-free, in a good and workmanlike manner using good quality materials and at Tenant’s expense except as provided in Section 11(a).

(b) Allowance. Landlord has advanced the Initial Advance to Tenant. Landlord shall make available to Tenant up to an additional $300,000.00 to be used by Tenant for improvements to the Premises (the “Allowance Advance”). As of the effective date of this Lease the Tenant owes to Landlord the Initial Advance. The Initial Advance, together with the outstanding portion of the Allowance Advance, shall be amortized at an annual interest rate of 9.5% over the remaining term of the Lease in equal monthly installments to be calculated by Landlord and submitted to Tenant (the “Allowance Amount”). Within seven (7) days following the expiration or earlier termination of this Lease, Tenant shall pay to Landlord the entire unpaid balance of the Initial Advance and the Allowance Advance, together with all accrued and unpaid interest thereon.

7. Commercial General Liability Insurance. During the term of this Lease, Tenant shall maintain commercial general liability insurance insuring Tenant and Landlord that is written on an “occurrence” basis with combined single limits, for any one injury, including death of not less than $500,000 per occurrence for an accident affecting one person, not less than $1,000,000 per occurrence for an accident affecting more than one person, and not less than $50,000 per occurrence for property damage and issued by a reputable insurance company authorized to transact business in the State of North Carolina. Certification of such coverage from the insurer, providing 30 days notice Landlord prior to cancellation or termination shall be furnished to Landlord.

- 4 -

8. Casualty.

(a) Insurance. During the term of this Lease, Landlord shall maintain “all risks” fire and property insurance on the Improvements and all alterations or additions to the Improvements made by Tenant, in amounts at least equal to the full replacement value of the Improvements and issued by a reputable insurance company authorized to transact business in the State of North Carolina; provided, however, Tenant is responsible for and should insure Tenant Installed Equipment (defined in Section 11(b)) for any damage resulting from lightening strikes, power surges, extreme temperature, fire, and theft.

(b) Restoration. During the term of this Lease, including any period of time before the Closing (defined in Section 26(c)) of the Purchase Option (defined in Section 26) or the Right of First Refusal (defined in Section 25), after a casualty, Landlord shall promptly repair and restore all the Improvements to as good of a condition as that existing prior to said casualty, unless Tenant elects to terminate this Lease by written notice to Landlord within thirty (30) days following such casualty, in which case neither party shall have any further rights, duties or obligations under this Lease, except for those which specifically survive termination pursuant to the terms of this Lease. If Tenant does not elect to terminate this Lease, all insurance proceeds relating to the Improvements shall be made available to Landlord for restoration, Landlord shall promptly commence restoration and diligently pursue it to completion, and all Monthly Rental due under this Lease shall be equitably reduced or abated during such restoration period.

(c) Casualty Waiver. Landlord and Tenant waive any rights each may have against the other on account of any loss or damage occasioned to the other party, their respective property, the Premises, or the contents of the Premises arising from any risk covered by the insurance maintained pursuant to this Lease, provided that such waiver does not invalidate or prohibit recovery under such insurance policies. In addition, to the extent allowed by any applicable insurance policy, the parties shall cause their respective insurance companies insuring the property of either Landlord or Tenant against any such loss, to waive any right of subrogation that such insurers may have against the other party.

9. Condemnation.

(a) Notice to Tenant. Landlord shall promptly notify Tenant of any notice Landlord receives or knowledge by Landlord of the condemnation or the exercise of power of eminent domain or sale under threat of condemnation or eminent domain (each, a “Condemnation”).

(b) Total Taking. If at any time during term of this Lease, including any period of time before the Closing (defined in Section 26(c)) of the Purchase Option (defined in Section 26) or the Right of First Refusal (defined in Section 25), the entire Premises is acquired by Condemnation, this Lease shall terminate at the time possession of the entire Premises is surrendered and the parties shall be relieved of all obligations provided for in this Lease.

- 5 -

(c) Partial Taking. If at any time during the term of this Lease, including any period of time before the Closing (defined in Section 26(c)) of the Purchase Option (defined in Section 26) or the Right of First Refusal (defined in Section 25), a material portion of the Premises is acquired by a Condemnation, then Tenant shall have the right to either (i) terminate this Lease on the date possession of any portion of the Premises is surrendered by providing written notice to Landlord thirty days (30) or more prior to the date on which possession is surrendered, or (ii) cause Landlord, to the extent practicable, to restore any portion of the Improvements taken as a result of the Condemnation, during which time all Monthly Rental due under this Lease shall be equitably reduced or abated. If Tenant does not terminate this Lease, cause Landlord to restore the Improvements, or if less than a material portion of the Premises is surrendered as a result of the Condemnation, the Monthly Rental shall be equitably reduced proportionately to the percentage of the Premises or Improvements surrendered.

(d) Condemnation Awards. Any Condemnation award received by Landlord shall be the sole property of Landlord; provided, however, if Tenant does not terminate this Lease as provided in Sections 9(a) or 9(b), Landlord shall use such Condemnation award for the restoration of the Improvements to the extent practicable.

(e) Tenant’s Rights. Nothing in this Lease shall be deemed to prohibit Tenant from making a separate claim, against the condemner, to the extent permitted by law, for the value of Tenant’s estate under this Lease, its trade fixtures, machinery and moving expenses.

10. Indemnities.

(a) By Tenant. Tenant shall be responsible for and shall indemnify and hold Landlord harmless from and against all damages, claims or demands that may, during the term of this Lease, arise or be occasioned from or by the condition, use or occupancy of the Premises or by reason of any injury (including death) or damage to any person or property in or on the Premises, except as provided in Section 10(b).

(b) By Landlord. Landlord shall indemnify and hold Tenant harmless from and against any damages, claims or demands or causes of action for injury to persons or property resulting from or arising out of the negligence or willful misconduct of Landlord, its agents or employees or out of Landlord’s failure to repair the Improvements as required by Section 11(b), except as provided in Section 10(a).

11. Repair Obligations. The parties’ obligations with respect to maintenance, repair and replacement of all portions of the Premises are as set forth below and as more particularly described on Exhibit E attached hereto.

(a) By Landlord. Except as set forth in Section 11(b) or on Exhibit E attached hereto, at all times during the term of this Lease, at Landlord’s sole expense, Landlord shall:

- 6 -

(i) maintain in good condition and repair (x) the roof, exterior walls, foundation, and structural portions of the Improvements and all portions of the electrical (except ballasts and bulbs) and plumbing systems lying outside the Improvements but serving the Improvements, and (y) the portion of the Premises located outside the building, including, but not limited to, the parking lot and landscaped areas;

(ii) shall be responsible for the cost of all major (non-routine) repairs and/or replacement of any of the Buildings’ systems, including, without limitation, the heating, ventilating and air conditioning systems, the plumbing and sewage system, the elevator system, all windows and doors within the Buildings;

(iii) shall perform all repairs, alterations or modification to the Premises that are necessary for the Premises to remain in compliance with any existing or future laws, ordinances, orders, rules, regulations or requirements of all federal, state and municipal governments.

The foregoing shall not apply to repairs, alterations or modifications made necessary solely as a result of Tenant’s specific use of the Premises, which repairs, alterations or modifications shall be the responsibility of Tenant. If any of the Premises to which Landlord is responsible shall become defective during the term of this Lease, Landlord shall immediately repair and restore the defective part to working condition. In the event Landlord fails or refuses to commence repair of the defective condition, or make replacement as the case may be, after a period of three (3) days from receipt of notice from the Tenant, Tenant may cause the same to be remedied at Landlord’s expenses and deduct the cost from the next installment of Monthly Rental; provided, however, Landlord shall not be liable to Tenant for any damage Tenant may sustain to its business, merchandise or equipment as a result of such defective condition.

(b) Tenant’s Repair Obligations. Except as set forth in Section 11(a) or on Exhibit E attached hereto, at all times during the term of this Lease, at Tenant’s sole expense, Tenant shall:

(i) maintain the interior of the Building in a good, clean, safe and orderly condition, including, without limitation, the routine maintenance and repair (but not replacement) of the heating, ventilating and air conditioning systems, elevator system, lighting system and the security and fire alarm system of the Buildings;

(ii) be responsible for the routine maintenance of the parking lot (excluding restriping, resealing and repaving thereof) and landscaped areas of the Premises; and

(iii) replace or maintain all parts not set forth in 11(a) of the Premises including ceiling light bulbs and ballasts, doors, door framing, windows, window framing, ceiling tiles and supports and keep floor covering in as good repair as when the Premises were received by it;

(iv) be responsible for any mechanical systems and equipment that Tenant adds to the Premises including air compressors, lyophilizes, other specialized equipment, computers, and extra cooling systems (the “Tenant Installed Equipment”).

- 7 -

12. Surrender of the Premises. Tenant shall surrender to Landlord on the last day of the final term of this Lease possession of the Premises and the Improvements in good, clean and orderly condition, except for normal wear and tear and damage due to casualty, condemnation or Landlord’s negligence, willful misconduct or failure to repair as required by Section 11(a). At the time possession of the Premises is surrendered, Tenant shall remove all of Tenant’s personal property from the Premises, and, subject to applicable law, Landlord shall have the right to enter and be repossessed of the Premises.

13. Personalty. All of Tenant’s personal property in the Premises shall be and remain at Tenant’s sole risk. Landlord, its agents, employees and contractors, shall not be liable for, and Tenant releases Landlord from, any and all liability for theft thereof or any damage thereto occasioned by any act of God or by any acts, omissions or negligence of any persons, other than Landlord, its agents, employees or contractors.

14. Utilities. During the term of this Lease, Tenant shall pay for all charges for water, sanitation, sewer, light, heat, gas, electricity, power, fuel, janitorial and all other utilities and services rendered or delivered to the Buildings. Landlord shall be responsible for all utility costs attributable to buildings on the Premises other than the Building, and Tenant, during the term of the Lease, may elect to have separate utility meters or sub-meters installed at the Premises at Landlord’s expense.

15. Quiet Enjoyment. Landlord represents and warrants to Tenant that so long as Tenant performs all the obligations of Tenant under this Lease, Tenant shall have quiet and peaceful possession of the Premises during the entire term of this Lease and Landlord shall defend Tenant’s right to possession against the claims of all parties.

16. Trade Fixtures. Landlord recognizes that from time to time throughout the term of this Lease Tenant (or its sublessees or assigns) may place upon the Premises and within the Improvements located thereon certain machinery, equipment, fixtures and trade fixtures (collectively, the “Trade Fixtures”). Trade Fixtures shall be and remain personal property regardless of the manner in which said Trade Fixtures are attached or secured to the Premises, shall not at any time be deemed a part of the realty, and may be removed from the Premises by Tenant (or its sublessees or assigns) at any time at or prior to the termination or expiration of the term of this Lease; provided, however, that Tenant (or its sublessees or assigns) shall not have the right to remove any Trade Fixtures from the Premises if and Event of Default exists and is continuing and provided further that the party removing Trade Fixtures simultaneously with the removal of such Trade Fixtures repair at its expense any damage caused by such removal.

17. Default and Remedies.

(a) Event of Default. Each of the following shall be an “Event of Default”:

(i) Tenant shall fail to pay any payment of Monthly Rental when due and if any such default shall remain uncured for more than ten (10) calendar days after written notice from Landlord of such default;

- 8 -

(ii) Tenant shall fail to cure any default of Tenant of any obligation set forth in this Lease other than such nonpayment of Monthly Rental within thirty (30) calendar days after written notice from Landlord (but if such default is not susceptible to cure within such thirty (30) day period, Tenant shall not be in default if Tenant promptly commences such cure and diligently and continuously pursues the cure to completion);

(iii) Tenant is adjudicated bankrupt or a permanent receiver is appointed for Tenant’s property;

(iv) Tenant takes advantage of any debtor relief proceedings under any present or future law whereby any rental under this Lease is, or is proposed to be, reduced or payment thereof deferred;

(v) Tenant makes an assignment for the benefit of creditors; or

(vi) Tenant’s effects should be levied upon or attached under process against Tenant, not satisfied or dissolved or stayed by bond within ten (10) days after written notice from Landlord to Tenant to obtain satisfaction thereof.

(b) Remedies. Upon the occurrence and continuance of an Event of Default, Landlord shall have the right to terminate this Lease by written notice to Tenant, whereupon this Lease shall end and Landlord shall be entitled to pursue and recover all damages provided by North Carolina law. In the event Landlord does not elect to terminate this Lease, (i) Landlord may exercise its cure rights in Section 18, and (ii) Landlord shall have the right to collect the Monthly Rental from Tenant as it shall come due, provided that Landlord shall be under a good faith obligation to enter upon the Premises, as Tenant’s agent, and attempt to relet the Premises at the best price obtainable by reasonable effort and Tenant shall be liable to Landlord for, and shall pay to Landlord monthly, any deficiency between the amount of Monthly Rental payable by Tenant under this Lease and the rental price per month obtained by Landlord on reletting.

18. Cure Rights. If either party fails to perform any of its obligations hereunder after written notice from the other party, or to pay any amount due under this Lease within ten (10) days of the date such payment is due, the other party shall have the right to perform such obligations or to make any payment of overdue amounts of taxes, assessments, levies, utilities, bonding of liens, insurance premiums, maintenance of the Improvements, or any other amounts directly or indirectly provided to be paid by Landlord or Tenant under this Lease for such non-performing party’s account and, in the case of Landlord, to immediately add such total amount paid, with interest thereon at the rate of twelve percent (12%) per annum from the date of the disbursement by Landlord to date of reimbursement of Landlord, to the next installment of Monthly Rental due, in the case of Tenant, to off-set the cost to perform such obligations or the total amount paid, with interest at the rate of twelve percent (12%) per annum from the date of disbursement by Tenant to the date of reimbursement to Tenant, from the next installment of Monthly Rental due, or, in the case of Landlord or Tenant, to otherwise demand immediate reimbursement, with interest thereon at the rate of twelve percent (12%) per annum, from the non-performing party.

- 9 -

19. Subletting and Assignment. Tenant shall have the right to sublet the Premises or to assign this Lease without the prior written consent of Landlord to any reputable party who will use the Premises as permitted hereunder; provided, however, Tenant shall remain liable for all of the obligations of Tenant hereunder. The proceeds from any and all such subleases or assignments shall be due and payable directly to Tenant and Landlord shall have no right thereto or interest therein.

20. Signs. Signage on or off the Buildings requires a permit from the City of Burlington, North Carolina. Tenant (or its sublessees or assigns) shall have the right to install interior or exterior signs upon or within the Premises, provided such signs shall not violate any applicable law or order.

21. Landlord’s Warranties. Landlord represents and warrants to Tenant that:

(a) Landlord has the power and authority to execute and deliver this Lease to Tenant and to perform its obligations under this Lease.

(b) Landlord is the fee simple owner of the Premises and that the Premises are not currently encumbered by a mortgage, deed of trust or any other encumbrance which could adversely affect Tenant’s use and occupancy of the Premises or which limits or prohibits the execution of this Lease by Landlord;

(c) Landlord does not have knowledge of any pending Condemnation or similar proceeding affecting any part of the Premises;

(d) Landlord does not have knowledge of any uncured violations of federal, state or municipal laws, ordinances, orders, regulations or requirements affecting any portion of the Premises and the Premises and the current and intended use of the Premises are in compliance with all applicable laws, rules, ordinances and restrictive covenants affecting the Premises, including without limitation, the Americans With Disabilities Act of 1990 and all applicable zoning ordinances; and

(e) There is be water, electrical, sanitary sewer and gas utility service available at the Premises adequate for Tenant’s intended use of the Premises; and

22. Holding Over. If Tenant remains in possession of the Premises after expiration of the term of this Lease, with Landlord’s acquiescence and without any express agreement of Landlord and Tenant, Tenant shall then be a tenant at will of Landlord at one hundred twenty-five percent (125%) of the Monthly Rental in effect at the end of the term of this Lease and there shall be no extension or renewal of this Lease by operation of law.

23. Short Form Lease. Each of the parties shall, upon request of the other party, enter into a Short Form of this Lease setting out (a) the names of the parties to this Lease, (b) the description of the Premises, (c) the date and the term of this Lease, and (d) and Tenant’s rights to purchase the Premises, as set forth in Sections 25 and 26. Such short form lease shall be in writing, duly executed by Landlord and Tenant and shall be properly witnessed and acknowledged for recording under the laws of the State of North Carolina.

- 10 -

24. Notices. All notices required or permitted to be given to Landlord under this Lease shall be sent to Landlord at:

Samuel C. Powell, Ph.D.
Powell Enterprises
P.O. Box 2104
Burlington, NC 27216-2014

All notices required or permitted to be given to Tenant under this Lease shall be sent to Tenant at the Premises, Attention: Vice President, COO, with a copies to:

MEDTOX Scientific, Inc.
Attention: Chief Financial Officer
402 West County Road D
St. Paul, MN 55112

unless either party notifies the other in writing of a change of address. All notices given under this Lease may be given by certified mail, postage prepaid, hand delivery, nationally recognized overnight delivery service, facsimile or other electronic means and shall be deemed given when deposited for delivery or transmission by an approved method; provided, however, that the time period for any response to such notice shall begin to run only upon actual receipt or when delivery is refused or cannot be accomplished because the party has moved and has not provided the other party with notice of its new address by notice as provided in this Lease.

25. Right of First Refusal. If, at any time during the term of this Lease, Landlord receives a bona fide offer to purchase the Premises which Landlord is willing to accept, Landlord shall notify Tenant in writing of such offer and shall specify, in detail, the terms of such offer (the “Sale Notice”). Tenant shall have thirty (30) days from receipt of the Sale Notice to notify Landlord in writing whether or not Tenant elects to purchase the Premises (the “Right of First Refusal”). If Tenant notifies Landlord that it exercises the Right of First Refusal, Tenant shall purchase the Premises in accordance with the terms set forth in the Sale Notice. The closing of the sale of the Premises contemplated by Section 25 as set forth in Sections 26(c) and 26(d); provided, however, that Tenant shall not be obligated to close the purchase of the Premises any earlier than ninety (90) days following receipt of the Sale Notice.

26. Option to Purchase. Landlord grants to Tenant the exclusive option and right (the “Purchase Option”) to purchase the Premises from Landlord upon the terms and conditions of this Section:

(a) Exercise of Option. The Purchase Option shall be exercisable by Tenant at any time during the term of this Lease by giving written notice in accordance with Section 24 to Landlord (the “Option Notice”).

(b) Option Price. The purchase price (the “Purchase Price”) of the Premises in the event Tenant exercises the Purchase Option shall be equal to the then prevailing fair market value (the “Fair Market Value”) on the date of the Option Notice for the Premises calculated on a per square foot or per acre basis for improved property located in the area of Burlington, North Carolina comparable to the Premises (as adjusted for any variances between such property and the Premises and subject to the existence and terms of this Lease). The Fair Market Value shall be calculated as follows:

- 11 -

(i) Within thirty (30) days after the receipt of the Option Notice, Landlord shall notify Tenant in writing of Landlord’s reasonable determination of the Fair Market Value for the Premises (the “Landlord’s Valuation”). Tenant shall have thirty (30) days from receipt of Landlord’s notice to notify Landlord in writing whether Tenant accepts Landlord’s Valuation or elects to determine the Fair Market Value in the manner set forth in Section 26(b)(ii). If Tenant does not notify Landlord of its election within thirty (30) days of its receipt of Landlord’s notice, the Fair Market Value shall be determined in the manner set forth in Section 26(b)(ii).

(ii) Tenant shall notify Landlord in writing of Tenant’s selection of an appraiser. Within twenty (20) days after Landlord’s receipt of Tenant’s selection of a real estate appraiser, Landlord, by written notice to Tenant, shall designate an appraiser. Within twenty (20) days of the selection of Landlord’s appraiser, the two appraisers shall render a joint written determination of the Fair Market Value, which determination shall take into account the value of any improvements or alterations to the Premises which have been amortized by Landlord over the term of the Lease. If the two appraisers are unable to agree upon a joint written determination within said twenty (20) day period, they shall select a third appraiser within such twenty (20) day period. Within twenty (20) days after the appointment of the third appraiser, the third appraiser shall render a final written determination of the Fair Market Value by selecting, without change, the determination of one (1) of the original appraisers as to the Fair Market Value. All appraisers shall have at least ten (10) years prior experience in the commercial real estate market of area of Burlington, North Carolina, and shall be members of the American Institute of Real Estate Appraisers or similar professional organization. If either party fails or refuses to select an appraiser, the other appraiser shall alone determine the Fair Market Value. The parties shall bear the fee and expenses of its appraiser; and Landlord and Tenant shall share equally the fee and expenses of the third appraiser, if any.

(iii) In the event that Tenant is not, for any reason, satisfied with the determination of Fair Market Value made pursuant to Section 26(b)(ii), Tenant may, within ten (10) days following such determination, revoke its Option Notice by written notice to Landlord, and shall thereafter have no obligation to purchase the Premises; provided however, that such revocation shall not impair Tenant’s ability to again exercise its Purchase Option in the future in accordance with the terms of this Section 26.

(c) Closing. The closing or settlement (“Closing”) of the sale of the Premises contemplated by Section 26 shall be held at the offices of Landlord’s attorney, during regular business hours on or before the date which is sixty (60) calendar days following the giving of the Option Notice or thirty (30) days following the determination of Fair Market Value, whichever is later or at such time and place as the parties agree. The exact time and date of Closing shall be selected by Tenant by written notice given to Landlord at least five (5) days prior to the date so specified.

- 12 -

(d) Closing Deliveries. At Closing, Landlord shall convey fee simple title to the Premises to Tenant by limited warranty deed, which shall expressly be made subject to all matters of record except for past due monetary liens and any security deeds, mortgages, deeds of trust or other financing created by Landlord, which Landlord shall be obligated to pay off and discharge at Closing. Landlord shall execute and deliver reasonable evidence of authority and existence, evidence of non-foreign status required by the Internal Revenue Code (without which tax will be withheld as required by law), a closing statement, an owner’s affidavit of title (in substantially the form required by Lawyers Title Insurance Company, Chicago Title Insurance Company or another national title insurance company reasonably approved by Landlord (the “Title Company”), and other documents which are customarily required by the Title Company or that Tenant may reasonably request at the time of Closing to issue its extended coverage owner’s title insurance policy. Landlord shall pay all applicable transfer taxes payable in connection with conveyance of the Premises. All other costs of Closing shall be paid in the manner customary in North Carolina. Ad valorem taxes assessed against the Premises for the year in which the Closing occurs shall be prorated as of the day of Closing.

27. Environmental.

(a) Environmental Definitions. For purposes of this Lease:

(i) “Contamination” shall mean the uncontained or uncontrolled presence of or release of Hazardous Substances (defined below) into any environmental medium from, upon, within, below, into or on any portion of the Premises so as to require remediation, cleanup or investigation under any applicable Environmental Law (defined below).

(ii) “Environmental Laws” shall mean all federal, state, and local laws, regulations, orders, permits, ordinances or other requirements, which exist now or as may exist hereafter, concerning protection of human health, safety and the environment, all as may be amended from time to time.

(iii) “Hazardous Substances” shall mean any hazardous or toxic substance, material, chemical, pollutant, contaminant or waste as those terms are defied by any applicable Environmental Laws (including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. 9601 et seq. and the Resource Conservation and Recovery Act, 42 U.S.C. 6901 et seq. and any solid wastes, polychlorinated biphenyls, urea formaldehyde, asbestos, radioactive materials, radon, explosives, petroleum products and oil.

- 13 -

(b) Environmental Representations and Warranties. Landlord represents that it has delivered to Tenant copies of all existing environmental reports, Phase I reports, or other documentation concerning the environmental condition of the Premises (collectively, the “Environmental Reports”), that it has not treated, stored or disposed of Hazardous Substances upon or within the Premises, that to Landlord’s best knowledge except as revealed in the Environmental Reports, no Hazardous Substances are present on or under the Premises as of the date of this Lease, and that Landlord’s activities on the Premises prior to the date of this Lease have been conducted in compliance with Environmental Laws.

(c) Tenant’s Representations and Warranties. Tenant represents that all its activities on the Premises during the term of this Lease will be conducted in compliance with Environmental Laws.

(d) Indemnification. Landlord shall indemnify Tenant and hold and defend Tenant harmless from and against any and all expense, loss, and liability suffered by Tenant (except to the extent that such expenses, losses, and liabilities arise out of Tenant’s own negligence or willful act, for which Tenant shall indemnify Landlord), by reason of the storage, generation, handling, treatment, transportation, disposal, or arrangement for transportation or disposal, of any Hazardous Substances (whether accidental, internal, or negligent) by or for Landlord or any other party (other than Tenant), at any time either prior to, during or after the term of this Lease, or by reason of Landlord’s breach of any of the provisions of Section 27. Such expenses, losses and liabilities shall include, without limitation, (i) any and all expenses that Tenant incurs in the nature of consequential damages, including, without limitation, the loss of use of the Premises, lost profits and loss of business as a result of the foregoing, (ii) any and all expenses that Tenant incurs to comply with any Environmental Laws, (iii) any and all costs that Tenant incurs in studying or remedying any Contamination at or arising from the Premises, (iv) any and all costs that Tenant incurs in studying, removing, disposing or otherwise addressing any Hazardous Substances, (v) any and all fines, penalties or other sanctions assessed upon Tenant, and (vi) any and all reasonable legal and professional fees and costs Tenant incurs in connection with the foregoing. The indemnity contained in this Section shall survive the expiration or earlier termination of this Lease.

28. Brokerage. Landlord and Tenant warrant that they have had no dealings with any broker or agent to whom a commission is due in connection with the negotiation or execution of this Lease, and Landlord and Tenant agree to indemnify each other against all costs, expenses, attorneys’ fees or other liability for commissions or other compensation or charges claimed by any broker or agent claiming the same by, through or under Landlord or Tenant, as the case may be.

29. Future Expansion. Tenant may desire in the future to expand the size of the Premises and the Building to include certain property adjacent to the Premises, now owned by various third parties as more particularly shown on the plat attached hereto as Exhibit F (the “Expansion Property”). Upon Tenant’s request, Landlord agrees to use its best efforts to secure options to purchase the Expansion Property from the owners thereof on terms and conditions satisfactory to Tenant, to rent such Expansion Property to Tenant on terms and conditions satisfactory to Tenant and to cooperate with Tenant in connection with any necessary rezoning of the Expansion Property required in order to allow Tenant to conduct its operations thereon.

- 14 -

30. Miscellaneous.

(a) Inspection. Tenant shall allow Landlord or its agent to enter upon the Premises, or any part thereof, at any reasonable time to inspect the Premises and for making any repairs or improvements which are necessary or required to be made by Landlord.

(b) Dispute Resolution. If any dispute between the parties arises under this Lease, the parties shall submit to binding arbitration to settle the dispute.

(c) Entire Agreement. This Lease contains the entire agreement of the parties and supercedes all prior oral and written agreements of the parties with respect to the subject matter of this Lease.

(d) Amendments; Modifications. No modification of this Lease shall be binding unless in writing, duly executed by all the parties to this Lease.

(e) Severability. If any provision of this Lease shall be declared invalid as offending any applicable law, the remaining provisions of this Lease shall continue in full force and effect.

(f) Binding Effect. The terms, conditions and provisions of this Lease shall be binding upon Landlord and Tenant and their respective heirs, executors, administrators, legal representatives, successors and assigns.

(g) Governing Law. This Lease shall be interpreted in accordance with the substantive law of North Carolina.

(h) No Waiver. The failure of either party at any time to require performance by the other of any provision of this Lease will not affect that party’s right to enforce that provision, nor will the waiver by either party of any breach of any provision of this Lease constitute a waiver of any further breach of the same provision or any other provision.

(i) Counterparts. The parties may execute this Lease in any number of counterparts and transmit the counterparts via facsimile or other electronic communication, each of which will constitute an original and all of which when taken together will constitute a single agreement.

(The signature page follows.)

- 15 -

IN WITNESS WHEREOF, Landlord and Tenant executed this Lease as of the day and year first above written.


LANDLORD	Powell Enterprises


	By: /s/ Samuel C. Powell
	Its: President


TENANT	MEDTOX Diagnostics, Inc.


	By: /s/ Kevin Wiersma
	Its: CFO

- 16 -

EXHIBIT A

Description of the Nova Building

The “Nova Building” is a two-story light-manufacturing facility with a 3^rd floor penthouse utility area for air systems and a gas boiler that is located at 1238 Anthony Road, in the City of Burlington, County of Alamance in North Carolina. The Nova Building is zoned for light industrial use and contains 43,800 square feet of combined office and manufacturing space along with adjacent grounds and parking facilities. The Nova Building fronts on Anthony Road at the intersection with Nova Lane. The Nova Building was constructed in 1981, is rectangular in shape, and built on a concrete slab with a stand-up concrete panel exterior. In addition, the Nova Property contains a storage barn which is located at 1620 Nova Lane. The storage barn is a pole barn of approximately 1350 square feet built on a cement slab with vinyl walls and a metal roof. The barn is heated and has plumbing for a single bath and is completely enclosed with walk through and garage type doors.

- 17 -

EXHIBIT B

Description of the Nypro Buildings

The “Nypro Buildings” consist of a two-building complex used for light-manufacturing and warehouse use which buildings are joined by a chase-way that is 121 feet in length and contains 1,161.6 square feet. 1630 Nova Lane is a 13,789 square foot building which was built in 1986 of steel on a concrete slab with metal skin which is used for a warehouse and has a front office. 1640 Nova Lane is a 16,344 square foot building which was built in 1997 and is steel on a concrete slab with metal skin used for manufacturing and has a front office.

- 18 -

EXHIBIT C

Legal Description

Being all of Lot One(1), Map 2, Nova Corporate Center, as shown on plat recorded in the Alamance County, North Carolina Registry in Plat Book 34, Page 12, to which plat reference is made for a complete and accurate description.

See attached diagrams.

- 19 -

EXHIBIT D

Zoning of the Premises

Industrial- (“I-1”)

The Premises are located within the city limits of Burlington, North Carolina, and is zoned light industrial or “planned industrial” with the designation of “I-1” for use. This use limits the total area of the lot covered by buildings and accessory buildings to 33.3% of the total lot area, and the total floor area of all buildings and accessory buildings shall not exceed 66.7% of the total area of the lot. It also requires a front lot, side lot and rear lot having a width of a minimum of 50 feet be left undeveloped except for parking or road access.

Under the I-1 usage, there are restrictions on noxious or offensive odors, gas, fumes, smoke, dust, vibration or noise which substantially interferes with other uses of the property. Also, storage of materials and products before and after manufacturing shall be conducted within a completely enclosed building or within an opaque screen except for the on-site parking and loading incidental thereto.

- 20 -

EXHIBIT E

Ongoing Repair and Maintenance Responsibilities



Item	Repairs / Maintains / Replaces


Mowing the grass/seeding	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Landscaped area maintenance	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

External parking lot lights	MEDTOX-Replaces (bulbs only)
Powell maintains currently	POWELL-Repairs/Maintenance

Parking lot	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	(excludes re-striping, re-sealing and re-paving)
	POWELL-Replaces

External signage	MEDTOX-Repairs/Maintains/Replaces
Powell maintains currently

Window washing	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Roof (leaks, damage, etc.)	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

Exterior walls	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

Foundation	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

Structural portions	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External plumbing	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External electrical	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External natural gas	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

- 21 -



Item	Repairs / Maintains / Replaces


External water lines	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External sewer lines	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External HVAC gas packs (~9 each)	POWELL-Repairs/Replaces
Powell maintains currently	MEDTOX-Maintains

External HVAC electric heat pumps (2 each)	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External facility window (exclusive of washing)	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

External facility doors	POWELL-Repairs/Maintains/Replaces
Powell maintains currently

Trash container/pickup	MEDTOX-Maintains
Powell maintains currently

Cardboard container/pickup	MEDTOX-Maintains
MEDTOX maintains currently

Internal HVAC ductwork & coils	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Hot water boiler for heating system	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Heat exchanger/blower for boiler heating	MEDTOX-Routine Repairs/Maintenance
system (7 each)	POWELL-Replaces
Powell maintains currently

Internal plumbing	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Internal electrical	MEDTOX-Routine Repairs/Maintenance
MEDTOX maintains currently	POWELL-Replaces

- 22 -



Item	Repairs / Maintains / Replaces


Internal natural gas	MEDTOX Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Internal water lines	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Internal compressed air lines	MEDTOX-Routine Repairs/Maintenance
MEDTOX maintains currently	POWELL-Replaces

Air compressors (2 each)	MEDTOX-Repairs/Maintains/Replaces
(purchased by MEDTOX)
MEDTOX maintains currently

Refrigerated air dryers (2 each)	MEDTOX-Repairs/Maintains/Replaces
(purchased by MEDTOX)
MEDTOX maintains currently

Internal sewer lines	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Hot water heater	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Elevator system	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Dehumidification system	MEDTOX-Repairs/Maintains/Replaces
(purchased by MEDTOX)
MEDTOX maintains currently

Fire extinguishers	MEDTOX-Routine Repairs/Maintenance
(came with building)	POWELL-Replaces
MEDTOX maintains currently

Fire Alarm System	POWELL-Repairs/Maintains/Replaces
(Simplex and Wells Fargo)
MEDTOX maintains currently (Simplex
system came with building and MEDTOX
purchased Wells Fargo system)

External Security System (ADT)	MEDTOX-Repairs/Maintains/Replaces
(doors, windows, openings, etc.)
MEDTOX maintains currently (MEDTOX
purchased ADT system)

- 23 -



Item	Repairs / Maintains / Replaces


Internal Security System (ADT)	MEDTOX-Repairs/Maintains/Replaces
(equipment monitoring and notification)
MEDTOX maintains currently (MEDTOX
purchased ADT system)

Internal facility windows	MEDTOX-Routine Repairs/Maintenance
Powell maintains currently	POWELL-Replaces

Internal facility doors	MEDTOX-Repairs/Maintains/Replaces
MEDTOX maintains currently

Overhead shipping doors (2 each)	MEDTOX-Repairs/Maintains/Replaces
MEDTOX maintains currently

Emergency lighting system	MEDTOX-Routine Repairs/Maintenance
MEDTOX maintains currently	POWELL-Replaces

Internal flooring	MEDTOX-Routine Repairs/Maintenance
MEDTOX maintains currently (our area)	POWELL-Replaces (50% of total cost)
	MEDTOX-Replaces (50% of total costs)

Internal housekeeping	MEDTOX-Routine Repairs/Maintains
MEDTOX maintains currently (our areas)

Internal ceiling tiles	MEDTOX-Repairs/Maintains
Powell maintains currently	POWELL-Replaces (if water damaged from roof leaks)

Internal lighting	MEDTOX-Routine Repairs/Maintenance
MEDTOX maintains currently	POWELL-Replaces

- 24 -

EXHIBIT F

The Expansion Property

- 25 -

- 26 -

GRAPHIC 4 property.jpg GRAPHIC begin 644 property.jpg M_]C_X``02D9)1@`!`0$`R`#(``#_VP!#``,"`@,"`@,#`P,$`P,$!0@%!00$ M!0H'!P8(#`H,#`L*"PL-#A(0#0X1#@L+$!80$1,4%145#`\7&!84&!(4%13_ MP``+"`:B!5(!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+ M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$( M(T*QP152T?`D,V)R@@D*%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W M^/GZ_]H`"`$!```_`/U3J&IJ**AKA/\`A:=E_P`+7_X0+^RM4_M#^R_[1_M# M[$?[/QZ>?Z]L5@^-_P!HOPKX%^)?ASP)>Q7U_J^O$P0_V?;FX@@_Z[D'BO6: M*RM;\.Z?KFGS66IV4&HV$_\`KK:YA\X&DM_#NEZ;HZZ5;Z?9V^GPC]S;F`"` M?ATI=,\.Z5IND#3[*QLK>PQ_Q[P0CR?RZ4O_``B.A_\`0*L_^_`I-2M=*TW3 M#<3V<(M[,>?@0]/<56\%^+K'QMX:L-K%%5_]'^T?\?%6 M+>VJO15BJ]%6/^/:C[5[58HJO2?OZL_\L:**FJ&BBXZ"BWZ&BOSV^,/C+2/V MM/V@3\$]2TB'0+G0KZX:Q\4VNH?Z03!U@%N8/ZUY3'+C MR>EP;[!_])Z^FOV%?V:O'/[/-_XI/B\Z*MMJD,!A-A.9I_/'7.>U?8O$`]J* M****KU8^SCUHJO5BWZ&BBC[./6J]6*********KU8^SCUHHJ:H:**FHHHJ&X MZ"J]%6******FHJ&D_?>=VVTM'V<>M%35#7FOQV^-FA_`7X=7_BK6&5A"/(L M[$'!N)R.(1CZ5^:'@;P9\0?V]_B]J.K:K?\`V?1K>>#[=/GG2K>UOGZ5 M^GWPS^$WAKX.>%[/1/#&EQV%K!`%\YA^_FQSF:?&379U8HHHHHHJ:H:/LX]: M***FHJ&BC[0/2IJAJ:H:*FJ&L;2O#.E:%]F@AYGFXY/J: MV:****FHJ&IJ**AJ:BODK]O_`$R]O/A#=7=EXMN='-@8;G^QQ-#`M_@XQG'G MY]L^M>J?LP:WJ'B3]GSP!?ZJ9GU"?28/-^T-YQF.!^^S[]:];HHJ:H:FJ&IJ M*AJ:BH:**KT?:O:BK%5ZL44<0#VHHN.@HJ:H:*******/LX]:KT4?\O%5Z/^ M/FK'V7WHHHH^R^]5_P#EXJQ15>D_?U9_X^:*/LOO15BJ]6**+?H:****FJ&B MFS96']U%D^E?CQXI^%WQL\1?%CQQ\2+#P9JFB:OI.K?VA,+:"?'G_:/^7;_G MXKZJTC_@IYX-/A2>?4O#6MVOBF"RS_9ZPXMYKC'^H\_D0G..O]*][_9P^.,/ M[0WPU3Q5%HEQX?Q//;RP7$_GG([PSC`/:O7*L?:!Z44457H^R^]6******** M*****FJ&BBBBIJAJ:H:*FHHJ&BBBBIJAHHJ:BBBH:*****PO%7B[2/`6A7.K M:]?P:;IUO%\UQ<35^67COQYX_P#V]?C!8^'=$M_LWAZ"?=96!YM["W_Y^+C_ M`*;U^EWPK^$_AWX.>$;;PUX7L(;6PMP&+%;\*Y;X/_%)OBQX176W\*ZWX-?SO(.G^(;;[-6UO+J-K9P17#S&<88L>IX->W M?LXZ7I>G_`SP)#IEI;VT`T*PF$%O#Y`,QMQGC_/2O2OLOO5BBBJ]%6****+? MH:FHJ&IJAJ:BH:FHHJ&IJ***AHHJ:H:FHJ&BIJAHJ:H:**FHJ&BBBIJ*AJ*Y MNXK2"6::7R8(>IZ8K\H_VF_CYK_[8GQ&TSP7X&TB;4/#,%Z/[+"PDSSW./\` MCXN">8+?WK[<_95_97T?]F_P]$_VU?B;\;_`(_V&E_#GP]9S>#[:?-[#,,F:Q\[ M'VB6;!\@XS@8/T-?>=6***FJ&C[./6BIJ****AH_Y8T44F?^F-3U#1114U%0 MT5-1114-345#111117SY^W59377[,GC`0PQ7!@$$\ZMW@\\?Y_.M?]CS^SO^ M&:_`'V&9;B+^SE#'R/(/G<^=Q]=U>V4445-4-%%3445#4U0T57^U>U'_`!\T M4?:O:BK%%5Z**L4445-4-%%5Z/\`EWHHHMO]?15>K%%M_P`>U6*KT4458HJO M11;58JO]J]J/M7M15>K%%S5BBJ__`![458M^AJ:H:FJ&BOD/_@II=2V_[.,. MTRYN->MK?Y?I/7O_`,$?^2-_#[_L`:=_Z3P5WO\`RQHHH_Y8T444446_0U-1 M14-344444444444445#4U%0U-114-35#11114U%%%0T45-4-9^HZK8:!IT]Y MJ-S#8Z?;KF:>=A##$/7)K\QOVWOVJ+CXP^(_^$%\%WTUQX/LCFXN--F$_P#: ML_8?]OA_]H3]MJR/C>X^&7AKP:OCR"X8Z1JH2\G'VC/$\$'D9.<<9XKZ7^#' MP*\)?`CPU_9?A72SIPGF,]Q/=3^?<3_6:O2;FBVH_P"7BK%%%%%%34445#11 M15?[+[U8J:BH:**FHHHHHHK`\6^*]#\$:#<:MXAU.RT;2;/VYK?6Y_V=/%$NF7T%I90VY-_; M7%C]H%Q!@9&?^6/UQ6I^Q5%#;_LP>`!#-%?*M@0&@Z']_-S^I_(U[S14-344 M5#114U%%%0T?:!Z5G7'6K-%'V7WHHJQ5?_EXHMJL57_X]H*L5-4-35#15>BB MYHHHHH_X]JL57JQ11115>BBC_EWJQ15>X_T857JQ1115BJ]%%6****FJ&OAK M_@J+KJM\.?`NA+/]F6^UXRSCZ0$?^UZ^Q/"GAI?"GA72-#,\M^VGV-O;"XFZ MS>3@9/O6S115BJ]%6*/^6U5Z*L45P'@CXK>'?B3JGBJPT">XFNO#5^=/OC-9 MSP1"?'.">)NW2O1:***AHJ:BBBH:FHHHHHHJ&IJAHHHHJ:BH:*FHHHHHJ&BB MOR\_;O\`VO[[QYJNL?#CPG,+?PS8%H-5NMH!O9X3G'_7OTSZXKW/]AK]CR?X M/3CQSXHU"*?Q!?60@L8+4[;>WMYB&_[_`'8_7%?:%5OW%?(/[]7?V&_V5;?X0>&(O&.MP0W'C'5 MH/.A(@Q]@MR/^/M M%%%'V<>M%3445#4U%%%%%%%96MZ+8:_8?9]4L+>_MCU@N(!,/RJY;6L-O;"& M(`0CMFK-%0U-114->!?MI^&;CQ#\`/$TL.MWVC_8++W&?W$_'^I.> M?\Y9^PHOD?LN>!`?2Y_]*)Z^@*FHHHJ&BIJ*AJ:BBH:*KU8JO]E]Z#<_9Z*/ MLOO115BBBBWZ&IJPKGPYIMWJMAJU%5ZL57HHJO_P`M_P#44?\`+Q5BK%%5Z/L__'O1 M15BBBBC[./6BCB`>U%%%OT-35#7Y\_\`!1,V%M\=O@G/?"&XMQ<`7%O=?Z@V M_P!OMNM?H-11115>BC[5[4?:O:BBK%>>?'/XS:%\#_AQJ'BO69DVV_[F"WSS M<3G.(1]>:\X_8;$^)/#_P`&;C7/%OG?$!XKU:X\07,$YY4SX(%?153445# M14U%%0T5-14-34445#4U%0T45-1114-%%344445#Q`/:OS&_;8_;*U3Q9KM_ M\/\`P7>FUT""<6]QK5A<64(N?) M$^DZ-/;\V_\`T\7'_3Q7WY17SM^UQ^TQ9?L]^"5-JOG>*]6$\&E6P.>>\_X5 MX%^R5^QEJ^M^)+GXG_&*R^W:EJ'^D0:1K-MFXFG_`.?BX_7]QTK[TNKFWM8) MYYIOL\$'[^>OR@_:F_:-U;]J#XB:?X4\%F]NO"YN+>WL+#&/M]_DXG_#-?;' M[&G[,\_[//@6X_MK4/M'BG73]HO[=;C-O`?2"OHFVMO](JQ15BIJAJ:BBBBB MBBBH:***FJ&BBIJ*************AHKP#]L3QM9>%?@'XHL;_3[[4CJNGW%C M"]K9FX6`FW_UT_`\D#)Y/M^%3]@CR/\`AE;P9Y']^]_]*IZ^BJFHHJ&IJAJ: MBH:FJ&BBBBBBJ_V7WHMJ**L456_?U9HHHHHHKR#]J'X_V/[.?PUGUZ6'^T=7 MG_T?2M.[W%QV'ZUVOPRUO5?$?P^T#5=?T^+1]BK%5ZL5-4-%%%%%% M%%%?FA^V_<7'C;]LCP-X;GEFFT^"&PM_L]K!GR?/N,3DGZ`5^D]%%6*KW-'V M7WHMO]?11]E]Z\#_`&D_A)XY\:'P]XJ^&OB3^Q?&_AHS_9K:XG_T6]@FXQ./ MPS^=>6W'[8'Q5^$^I66F?%7X-ZCN:WP=2\*.;D38]`<@'_MO6CX@_;1^).LV M<,/@3X#>,VN+D?N;_6M/F%M^@S7!^.OV6/VEOC3;6]QXR\?Z+`;>\\^WT8SX M@AQTFS#;CGK7TE\)=+^.^CZC8:?\0-0\(>(M'/VC[3?Z;]HM[Z(9S`,'Y3GG M/>O;ZFJ&BBIJ*********AJ:BBBBBBH:FHJ&IJAHHHHJ:H:*^!OVS?VV=!A\ M,ZC\//AY?PZS?:O";&^O[<_N+>%B8&MX#G_7Y/3M_+:_8H_8NTKPAI&C?$+Q MHEIK6LWUG;7VDZ=/;?\`()SB?/\`UWYY/M7V_17+?$'5=7T/P9KNJ^'M)_MW M6K&QGGLK#SO^/B?!(A_$BOS^^#O[,_C+]H[XK:QX[^-UKXBT2TL+F"YLK:?_ M`$^(_B2XM[F>W\X0KX;MKCU]9S7Z MQ6Y%S!;SPTMS5BJ]%%S5BWZ&IJ*AJ:BBBBBBBH:**FJ&BBIJ****AHM^AJ:B MBH:**FHKRC]INUM[G]GKXEQW"QS0G0+^;!]H#7%?L!'S_P!E'P!_@]X M\7PIXMM];TW*Y_MKM/#7Q]^'_BO0K75M/\8:*=/N(083-?+!_, MUYGXB_X*$?!/PZ;Z%O$DVI75O_RPT^PG)E/MQ7E/AZQ^+O[7GCGP=XSUS1=+ M\,_"K2-575['3M2@^T7-S#]GP,XXFR:^ZJFHHHJ&BBBBJ]%6****K_9?>D@4 M0`B$9%6:*KU8H_Y8U7JQ;]#4U0T445-14-%35#7P!/XE'Q!_X*@Z+]@M\#P[ M;W&G7*N?^>-O]M5>YN?LW^O_T:WKYR\8_MR^!_"?Q6TSP'8:?J M?B:^GG@MKB^T0>?;P33]`"/]=3_C7XS_`&DM'\8SV/PY\%>'-;\+M;@PW]U/ M_I&?I]I@KU;6?BE!\._A/!XS^("KX<^SV4$^J00'S_(F(!,(]>3BK7PU^+GA M3XP^&UUSPEJL.KV!!SM_UT)[`PXR*[*C_EWH_P"7>BBIX8`HYI:*FHHJ&IJ* MA^T#TJ:BBBBBBBBBBBBBBBH:***FJ&BBBBBBOSU_;E_;*LKC2-8^&/@R:>XN M/-%MJNKPSB"%>.;>!LG)Z?EWJW^P9^QH+"&P^)OCFT@G>:$7&AZ-/;\VW_3Q M<9_Y;U]_T5Y=^T#\<]$_9\\!7'B/66,\Q_T>QL!PU[/V`KQG]C/]H_X@?M!Z MKXROO$^D66G^%[/R!87%M$1B<]8,_P#+;ZU]3U\+?MT?MDR>"QJOPS\(2E=9 MN+?R=5UB";:;`D?ZB`>O^-87["_['4(LX?B5\0=#AN#.(+C0M.OQEK?C_CXG M]Z^XU?3Q;S>?BWGN+@6XQVK]&/V%?&VN>/? MV;]#U;Q#JK:QK!N+F%KJ?_7']^1S_GL*^A*L?\L:KT?\N]6**FHHHHHHHHHH MJ&BBIJAHJ:BBBBBBBBBBBBH:FJ&O*/VJH)KC]G/XA"&;[/G1+@#VXK@_^">- MQ-\]6****.(![45\\?$KP1\!/@Q!X<\%3>&_$^OZA\2+>6;S_M'BC%Q-].1VKS/QE^P!\$ M_%UU-./"@T:

K0VRVZXBZ5/11111111114-344445#4U0T45\\_MD?M$:K^S MEX)TC5='TJSU&YO[\VW_`!,&*P0?N2>H_P`]:U/V5?VAK?\`:)^&8UR:Q_L[ M5M/F^P7\$,1\@7`_YX$]17O%0UXC^T'^TEX4_9V\._;=3E_M#7K@?Z#H]L?] M(G/OU\F'CJ?\:^?O!?QI^-/[8/PQ\3VOA>QMO`5Y8SP'3O$-A<3P07'K`._< M?I63IW_!.3Q9XNL?M_CSXG:A_P`)//-FX:W']H?Z/Z>?<T71?ACXDF\.:CH;03*5F\F>_MX(?^/?('?C-?//[/G[:WCCP=XGL/A]\8M# MUR;6=2OK=;/4;^W^SW,/G]#/!VA'K_\`6Q^A5%%%%?EO\#KCQ1J?_!1+6+W3 M[&\U!8-?U;^U=V/]'L(=8G_`'$-_J$` M@-C!S\L'!Q7T97.?$+P1H?Q0\%:EX:UR#[5HU_!]GGMZ^&OV0OV9/BI\&/VC M;C5M5TL:=X6,-_;3Z@+V!C<09_T?@<]H/R]J_0BBC[+[T?9?>BVJQ1114U%% M%0T5-1111111114-3444444444445#1117YT_M9?\%`?M'Q)::1\0?B!##/I%Q;?Z!X7N+?[OO<>OTK]'Z*\ M\^-/Q4TKX*?#;5_%FK[!;V$.8(#+Y)GG/^IMQ[FOA#P'X1\5_P#!17XIW/B3 MQ;]H\/?#[0?W$%O;`%F/>"WG&,^OGC\*_1KP]H.G^$O#ECI.EV,.G:38PB"W MMH.!#"!QC\J^?OVS/VC8?@7\-=1MM,O_`+/XXU:#[/I-O;G/D?\`3?Z5\K_L MC_L2?\+0BM_B#\05OH=&FO\`[19:-<0_\A7I^_N/^F!S7Z3'2X/[(^PK"/L_ MD^1]G@_<5\H_M4_LX_$'XQ:GX>\.>$9]&T?P/'8V\&H3W.?M(,$P/V^'VC^#M$8M8:?!M\^^OQ_Y,&OI^H:FHHJ&BIJAJ:BBBBBH:+CH**KW M-'VKVHHHJQ5>K%%%%%%%%%344444445#4U0T5-111111117Y0?\`!1OXJWWC M'XV_$5I4\]SHWAJ&!CIUO\`]!$G)_\`(!KU+_@D^?\`1/B0/L4I_P"/`_;F MQS_K_P!Q^']:_0VH:^(7_8/OO&_[4_BOQQXR>RG\'W%X=0MK%9/=?T^ZL](L?"NGW'^D"WNH((;!^ M%?17[3?QNN?V?/AC;^(V\-S^++P3P6\UO;L;>WASP9C-T@'O4/[/W[7/@O\` M:`MKZ#2TN=(UFQ)%QI&H\3R\$Y@/_+<<=?>O;+P!QQ7YX_ML?MN"Y%_\`#_X? M7EO/83P>3JOB&WG&03_RP@]_>N?_`&3OV`;[4M1TGQA\1[:*PTE1]IL/#EPI M\^X]KB#IY'_3O7Z845S7Q#\>Z'\+O!FH^)/$5R+#1["'=/<'L*_-*P@^(7_! M1?XM7'G7UQH'@;1YO/%KQ/!I9[>@GN/TK]'/A9\,="^$?@33_"V@6YM["QAP M"<>?.<+F:8[1F4XZG_\`5Y!^UY^UE8_L\^&S86/DZCXXU6$_8-/SQ!#T,\_H M!7QK^S?^SCXK_:S\7#QC\2;_`%NX\+FWR-0N;C_2;^?O;_\`7O\`\?%?J=;^ M1_J(/]'\BK-%%6**K_\`+Q1D6X\BBK%344444444445#114U%%%%%%%%%%%% M%0U-114->*?M;^"M/\;_``#\3Q7D$MW_`&9;G4;>%;PP9F@Y'-C_C MVHN:***O5#1111114U%%%%%%0U-4-%%34444445#4U>7:G\*/">D>(]8\?Z; MX4TL^.F@8C4A!FM?:E%0T445\P_M*:1X;_:N\#?\*]$>/?#(\06^JP79@^V MBY.8#G&%YSSZ5Z=^SY\&U^!GPIT'PBU_#?3V(E-Q++/PII5CXI(*_P!KV]B(9_WQP>?Y MYJ*#X0>`X/%G_"5_\(;H?_"1&;[3_;'V"#[5Y_\`UWZUWW_+O5/4=+LM3L9[ M&^@BN=/GA\B>WGAXGKYV\-_LH?#/X*_%K_A:%OK!O%%CJ7A2Y;2 M;"^@@N-/U&8'[0,">";]P>,\'\*]K\&^!]"^''AJPT'P]8PZ-HMB,06MOTKS MK]I[]HBS_9X^'T^M[;'4=>GE$%AI%S<^1]H/I_GUKX!_9R^$NK?MG_&WQ!XZ M\=^?<^&(;C[1?9_<":?_`)86,'/0=3S_`#K]2]$TJQT/3X+#3(8+#3K&#[/! M;6__`"[UIT6U'_+Q7FO@'X[^"OB=XI\3^&?#^I_:M9T&X\G4+8Q&'!SY/?W_ M`*5Z55BBBXZ"J]6+?H:FHHHHJ&C[0/2IJAJ:BH:FHHJ&BIJ**AJ:BBBBJ&F1 M7L%J1>317,WK%%Y0_4FK]%%%%%>.?M/>/O#G@'X.^(!XGN?L\&J6-Q8P_P"B M&?\`?-`V..]><_\`!.0;?V:;>+O!J]Z/_'O_`*]?4=35#14U%%%%%%%%%0U7 MHN:L44457HHM_(Q15BBBBBBIJAHHJ:H:FHJ&IJ*AHJ:H:FHHHHHHHHJK<00W M=N89AY\,W@W[-G[,NE?LZ:]XQET[6IKZ'7I$>#3S`(5MX8@:M9_$+]I3]G33I[.YNOA+XJU!!<_9VF8_N>1Y$Y_UPR"(_%]FN+^._A1^WSIUM?\`BO5=7T^ZU6WMX;:8_P"CBPN.MN(/Z_\` M3O7Z7T?9?>BOB/\`X*C^(9M*^&?@[0Q_Q[ZAJYN9SY.?]1`3_6O;/V(H?L_[ M+WP]'E=+`\?]O$_^->\4457^R^]6**FHHJ&BIJAJ:H:FHHHHJ&IJ**AJ:BBH M:FHJ&IJAJ:H:**_/W]MW]MFR72M0\`?#[4#<7$X^SZKK^G3C_1SW@@/=O>O/ M_P!C#]BX_$76Y?%'CNVO]%T_1+Z`V^D7-A]G%]C$_/\`TPY'%?J%117F?Q^^ M">G_`!Z^&]QX-O;^;2+>:>&X^T6T66'E,"!5GX-?![PY\"_A_8>%?#L!-O;@ M--]%QJ,PU'Q-<?<(P1R9[B">XA;G_CWX_<#Z5[[114UXM+Z;[1<6 MT]Q?3B6;U^E07/\`P3`\9W,S7$WQ'LKFYF_U\]Q!/D_K7V;^SQ\*+GX*_"+0 M?"-YJAUBYT]<2W9XR:])KY4_:X_8I'[1FJ:/KNE^(QHNLV$'V?\`T]?/MS!U M/%>Z_!CX=3_"GX9>'_"EQJ]QK]QI-L(/[0N>&F^M=M17YS_M'^&O%G[6G[4M MA\/Q8:MH'A70!W)QDW'8 MQA'H(!M'\A6W11]G'K4U%%%%%%%%%0T445-4-34445#4U%%%%%0T4445-4-? MG=^VK^VVTJS^!/ASJTUN;:>>VUS4?),)X&/(@)ZGKS4'["O[&L6MV6G?$?QS M87MN+>X^T:)H]Q#]G,O'%Q<#N37Z,44445Y)^T/^T)X=_9X\#3ZWK'_$POYO MW%AH]O*/M%]/_=%?E_\`#[X=^/\`]MOXT7]]?7^-S"?5=8G&?L,!_P"7?`_. M#\37ZK?!SX/^&?@EX-_X1[PM:"UA!%SM'V<>M M'V<>M'V<>M'V<>M(T(F&31#`%'-+1]G'K1]G'K1]G'K4U%%0W'057N+:"K%' M_+&BBD4B$"(?A2T5-14-%344444444444444445S7CW_`)$'Q'_V"[G_`-$F MOF7_`()C>?\`\*`U'S<>1_;T_D_3[/;U]?T45#4U%%%%0U-111114-%34445 M#111114U0U-1111111111111111114-34445#17Y4?L;#[-^W=3Q<:O! MQU_Y>*_5>BO'OVL/$S^$_P!G7XB7\-C-J+G29[7[-!U/GCR/ZU\/_P#!/3XZ M_#/X*Z%XQ7QEXCMM%U;4)X/*A-E<9%O!;\8GP<]_2OO7X??M#^`/BOI6K7OA MKQ)#J5OI47FWI2&:#R!C/.0/3MFN-_X;Z^!/_0\C_P`%%_\`_(]5_P#AX)\" MO^AT_P#*1?\`_P`CUU_PH_:5^'/QGU2ZTCP=XE76K^R@%Q/#]BN+<^2>!_KE M%>NU#114U0T5Y%^TK\&M6^-WPY?0]%\37?A;4!*L\5Q;\K<8S^XG`',)SS^' MX_)NC?LK?M9Z?H]]:P_%:RM[>^YFM[K6[BX8?]M_LV:^L/V;/AEXK^%'PTMM M,\8^+;KQCKAF:>>XNI3,+?C_`%$.>PKU^BIJ***********AHHJ:BBBBBBBH M:FHJ&BIJ*AHJ:BH:*_/?]NG]LF&>&W\"_#C7]PF\\:WK.GS_`/'M@8\CZG)K MA/V(OV-;+XL6UOXY\9V\5QX7@F)L='$Q/VZ?N9^#F'T'>OU#HHHHKS[XS_%O MP[\#/`^H>*/$$PAM(>8H(1^^N)O0>IK\;?$?C_7OVAOB5I]_X\\5PZ?X'6:?! MR>:]3HHJ(7<$ MM%%%%35#14U0U-111111111111111117$?%#4[#1OA]XBEOKZWT]?L%Q"+BX MG\@9\D]Z^=_^"8^H?:?@!J,/D[3#KLX_\E[>OK^H:FJ&IJ**********AHHJ M:BBBBBH:**Y'QMX0G\8Z9;V,.MZIX>$%Q!U== M61X:TJ^L=*CAU/4KC6;K&&O;B*&&0CZ0@#\JUZFHHHHHJ&IJ****AJ:BBBBB MBBBBBOD/]HC]GGXT?$WXH1ZWX0^)%OX5T>P@`TRU\^>`PD@"?/D=<\#FOGX_ M\$R?B?:ZQ=_PA"X_Y]_[0N?_`(_7 MJ7PT^"?@7X-07L/A'0+/1!?G=.+<8,Q]Z[ZBH:\5_:5M_B]._L??L-7WQ&U#_A(_B% M87^C>'["X@N(-.GM_(_M7C//_3O7Z8:)HFE^&=+M]*TNQ@TW3[&+$%O;P>1! M"/;TKPG]K?\`:JL?V;O#-B+2W@UGQ1JW%CI\[$0>3WGG/'`Q7R/;_MX?M%:Y MH%SKNE^&K&YT:PG^SW%SIVA7%Q;U[_\`LF_MY6OQIU__`(13Q;867AWQ#<'_ M`$"XM[C-O?#C@9Z3<=*^QZ\U^.?QET/X#_#R]\2ZW.D!7_1[*#&#/'KR*^K_"W[5WP MD\;V9GTSQYI1T$V#7R7\>O^"E>D>(-*UCPWX$L=G7^B:MJNH^,H/]1J-S/\`:+B# M_MXN/^7>OKK1/^"IVN>&=)@TG4_`UEXAU&Q@%O-K-KKP^SWL_'[X?Z/TX_6O MN?X)_&'2/CK\/-(\8Z,LMOIU^O\`Q[7(_?03>AKTBH:*FHHHHHHJ&C[./6IJ M*****AHHJ:BBBBBBBBBBBBBBBH:FJ&N1^)GAC2O%G@?5M+UJPLM2T\VYW6]_ M!YZ_B*^8O^"7\X/P0\01'_CY773YW[G'/V>WK[+J:BH:FJ&BIJ********AH MJ:H:FHHHJ&IJAJ:BH:@_M*#[=]B\V/[5Y/F^1GG&>M7:*************AJ: MBBBBBBBBBBBH:*****FHHJ&BIJ************AJ:BBBBBH:**FHHHHHHHHH MHHHHHHHJ&BOAK]O']L6Y\`"X^'W@N?C3S_%&E:I:^#[&#[>N;?R+>_/VC_CWK]<;:V^S0>15C_EC7Q7^W MG^R;??%BW'Q`\+[KKQ#I5B;:;3BIG^W6_/\`Q[\<3U\U?LG?M3ZI^R?K^H># MO'ND:I;^%YYC//!1Z'`_*O+?BCK/AS2OVFK_5/`L4#^'[;Q); MW%C#;C%N3]HM^;>OUZ^+'Q:T3X,^!-0\4>(KCR;>V``@W9:>;'$$/N2#7X^_ M%KXK^,OVL/BA:RWD%QP_&OUJ_9R_9Y\.?LX^!#H.B337 M<]Q-Y]]J%R?W]S.<-M/OK_P"'@B\*ZR8,0Z>!_P`2^8^X[5\!?%S]GKX@_`S51#XGT*XM MK:#_`$G^T;<>?;_]_P"KWP&^.$'P0UO6-4F\'VGC"YU:RFL+\WVH8@^SSD&X M'T.,'V)KTG]F;P1HOQ4_:.F\8S>#M-\-_";3YYIM0BU/$^D0_P"C@00FXG`& M?M'/`_"NY^*'[=OC?X8>)=1\/_#S2?!7A[POIE]-;V-OI!AO[>XMQTN,0?=^ MF!7TM^Q'^U9KG[1Z^*;7Q!H=GIVI:"+8'4-/.;>X$^[I_P!^:^K:*FHHHHJ& MIJAJ:BBBBBBBH:FJ&IJ****AJ:BBBBBBBH:***Y#XF:KXET7PA?WOA#0XO$7 MB`+F#3KB]^SAOQKY;_X)D_;1\._'9OSMN/\`A)#]H@\G&)_L]OFOM.C_`);4 M45-114-34444445#4U0T5-11114-%%%%%+;;Q8^DV1\26EN; MA"//6W/)ASZ'-=31111111111111111114-3445#4U%0T5-14-%3445#4U?& M7Q:_:(\?^$OVR_`W@>"XM[7P=?\`D*;&UM_M%Q>F8D'SR1^XP<\U]CU-114- M%344444444444444445#4U%%%%%%%%%%%%%%0T5\,_MT_MG7OP[N[CX?>!+P MVOB!H";_`%F#_ER_Z80?]-R*\-_8_P#V*KGXZ#_A+/&:WNG^#_/S;@G%QJ_X M_P#/"OU*T_3+?2[""RLH1:VT$(@B@@Z0C'_ZJFN:_$SQY\?/C+X=\9:CIVJ? M$'Q%I^KZ3?7%M<6MO?<03_:*]*^!G_!0GX@?#+7EM_&U_?\`C/P$?(^S3F` M7$'_`$\&X[CVKVKXE>!_A3^WM?ZAJGPV\3-8_$B"P@N)X-3AN(()H.,"XXY' M7F`_G5?X0?LN^%?V/$U'XG_&[5=*NKFQG@&AC3S<3>1<8/\`RP',UQG'(!KY M;^+7Q8\:?M8_%>=;*RU9K>^GQ8>'X)Y[BW@_Y=_M'%?IA^RM^R;H7[.OAH3S M&+6?&-RO^G:SC'I^X@R.(1Z?Y'T'4U0T450U/2;'7K&>ROK.&]L9N)K>>+(/ MX&OF'XR?\$Z_AA\1$EOO#\!\#:P(-L3Z1"!`/WG\B"YM_^?:OW&_9 MNMM!MO@QX7/AKPW>>%-&GM_/@T;4?^/BW![&O3ZFHJ&IJ*************AH MJ:BH:FHJ&BIJ******AHHHHHKX?_`."=.N6TVJ_&+3#--^XU\7HA'^I7//_"6" MX&!^Y_UO_LM?0E%%%0U-11114-34444445#4U%%%%%%%%%%%%%%%%%%0T5\8 M?MG_`+9EA\.M-U;P-X+U:>#X@02VXFN(8,P6(/K_`(5\K?LT_LB>+/VE_$EQ MXF\0BXT_PK]H^T7&LZA!_I&K7'_3O_\`)%?K/HFAZ?X:TFRTK3+:&UL+*$00 M6\/`BAQQC\A7F'QM_:;^'W[/GD?$/JC+?W$)G@TZP@\^YN`.XKR#P]_P4I^ M%/BG5+:PNTU[PV9AQJ&HVZ_9OS@G-?.G_!1+X,Z3I^L:1\5/"0TN?0O$?[B_ M&GS_`.OOB3.+G/X5XM^SW^SEXS_:G\57-S!>PMI]O/`=6UC4)_M%S!Q_SPZ3 M_C7W?\+/VZE M!;_ZC/\`R[P38SY`]*^E:******FJ&OFGXP_L%?##XN3B_@LIO!VK]3=>'C] MG$^?^>T.,&N:_9:_9W^*?P'^)&H:5J?BK^VOA?;64JZ?;F?F:X8J>(.D'6;H M2*^P:**************AJ:BH:FHJ&BIJ*AJ:BBBBBBBH:****R-;UW2_#FGM M?ZG?V^G6*CF>^N!!"/SKXX_8*\-7WASXB_&6PUO_`$?4OM-M=*N<;H)C<$3_ M`*5]R444445#14U%%%%%%%%%%0T5-1114-%%3445#4U%%%%%%%0T5-4-3444 M445#4U%%%%%%0T5-4-3445#4U0U\H_L]>*K+XG_M._W\.S:?J6@8T6+4A MJUQ,+J#S[@?\>_,`Y@'O7U=4U%%0U-1111111114-%35#4U%%%%%%%%%%%%% M%%%%0T5\=?ME_MJ67PHL)_"G@VXAU'QC-_H]Q.)^-*ZCG_IOSP*^6?V.?V4K M[X]>+?\`A*O%T%[;^"(9_M(N+D_\A6?[1_J#[5^JNAZ%I_AG0[#2M,MEM;"R M@$$,`./)AQ_]85K5^,W[>AU"W_:C\<_:/.S_`*/Y'G]/L_V>WKU;]H7]CCP5 MX=_9WT?XF^`[C5";>QL=0GM]0/\`KX)\?O\`_I@><\5R/[$J#XM6/C'X&^(5 MO3X0URW.KV]SI_72)X+CIG\!^5?77P_^"W@7]@?PKXN\8WGBK4]2L9X8()_M M<,`(`X@@''OC\:_/G]HK]I+Q3^TEXD,^I#[-X?LO/.EZ1;@9LS@#)]3@#\JZ M/]B_Q3X_L?B1!HGPYTK2I]?OY[>XO]1U&#_46$'%Q;?],(,_^V]?LU11116- MKFM6/AK1[W5=6N(+&PLH)KB>YGX\F$+:C^W1\#M+MYIAX[M[L#K%! M#/.?RQBNPA_:7^&%SX%G\9P^-]*?PY#'[77/#^HV^L:/>KF&YMVW0S#U'%;]0U-4-%34444 M4444444445#4U%%%%%%0T5-1111111114-%8WBOP?H?C?0;G1/$.E6>LZ1?&F?[/-Y/\`:$%NMT>JF">Y'D?K7W-4U%%% M%%%%%%%%%%%%%0T445-4-345Q/C/P!;>.'T)KO4=4T^+2;^'44CL;PPBU345#4U%%%%% M%%%%%0T45R_CCQUIOPZT,:GJ,=W-"9XK806$!GG\Z5L#C\:ZZBBBBBBBBBBB MH:FHJ&BBBOCG]MG]L.+X0Z1<>#/!M\I\;W`_?SV_/V"#G/?_`%W3`KY$_9)_ M96UC]H7QC#J^L6U[#X'MY_M%[?W)P-0/I;GM7ZR>#/".E>`_#&F^'="LAIVC MV$'D6]NO_+$>E>=_M#_M&>'/V=_!DVKZUMN-1G&-*T8<7%]/Z"ORE^*7[5'Q M/^*^JW&JZEXKU73+;S_W&G:+/<6]O!70:1X4\;_MC^'M0OVN%U?Q1X+LK>VG MU'4;_%Q?V+&XG'_;Q`3^M)OVLOC*(-(::ZT^:^_L_PYH^,#W/_`%WKH/BW\*/`_P"SE\+]1\)Z MIJD&L?&'7?L,]QY-OY\&A0G6O:_@=^RUK?[(&N3_%SQCXQTJ#PKI- ME<&>WT<3W'VV";D0X/H0,>^*^Y?@Y\5M(^-7@#3O%F@Q7EOIU[YODC4(=LXP M>N/\]*[NBBBN-^*7ARP\5_#3Q3H6I336VG7^E7%M<7%N<3P0F$[C]>M?A;XK M_LG^U[C_`(1Z>^N=._Y87.H_\?%?5/[/O[)6D_M$_L]S6^F_$""V\366JG4) M[#R/W%@WV<6X6<=\_9S^5?/_`,7?A-??";XE7'@4:M!XLUB#[/;S_P!C6]Q_ MQ\?\^]?3>C_M!>(_V5OV0/#OA4C5=.^(>NSW&H:?_:,)QI-A]H]+CCL/W'_3 MQ6Q^P+^U-XR\6_&:XT+QUXPGU+3]6LMUO_;$_P#R\Y_U%O7Z75#14U%%%%%% M%%0U-11114-%%345#4U%%%%%%%%%%%%%%%8/B2QU"_T._@TJ_.C7\UOM@OO( M^T>2?^N)Z_2ODO\`X)V6U[IO_"V[&_/GW$'B0_:+KRL>=/CDU]F45-111111 M1114-35#4U0T5-4-344445#14U0U-1111114-%%345#14U%0U-4-35#4U%%% M%%%%%%%%%%%%0U3UN:6'2KUH/^/A821]:^-O^"7//PH\43FXBN)I]<))7_K@ M*^VZ**AHJ:BBBBBBBH:FHHHHHHHHHHHHHHHHHJ&BBBBOF?\`;%_:FTKX&^$Y M]$LFN)_&VJV).G+;940#D><9L=J^!/V8OV:_$G[3WCR?5KZ^)\/PZ@)]=UF> M8FYG_P"G?CI/[U^OGAWPUI7A#P_8:'HUC!I^DV,'V>WMH#A88<=!6O7P;_P4 M8_9\\5^/8[#QWX>FN-9L-&L";[1A.2(!G_CX@A]>A/\`UPK\Y+FYO]2_LZW\ M_P#U'^CP?:)_^/>O8[?]FGXV?"WQ>+WPQH>MW%U8P>?;^(?!IGN+>X@G_P"? M>XK],?@W\1/$FA?`"Q\2_&"'_A%=7L+:47YOR("P@)'GD'I-,.<>_'O^)X)]/LM8MX-1FM](N/(,, MX[9_&O0?#FC^"_@5X!T_2;>XL?"/AFP'V>%;JX$$"^V9C_6NY:80C!IOGPVX MPV(?J*?17C?[4/QFOOV?/A/<^,=.T'_A(YH)H+O//V._`.F^*_&7B?XA>./L^H>$/!M MF-7U6WU.8F>>>3_&WXH:M\:_BCXA\9:IY]O<7\_P"XMS_R MPM_^7>WJQ\`?&O\`PKCXT>!O$D]]-IVG6.K6XO[BW_Y]_P#EXK]X+:ZANH/. MAF$T)[CFI*FHHHHHHHHHJ&IJ****AHHJ:BBBBBBBBBBBBBBBBH:**^0_V%[? M[+XN^.<`EA:"#QG<<"''>>OKRBIJ*****AJ:BBBBBBBBH:FHHHHHJ&IJ*\]^ M*WQ?\,?!;PL?$7BZ_P#[.T@3"WXA,IEE/3&/H?RKM;"YM]2LX+F!A-!,/.B- M7:***********AJ:H:FHHHHHHHHHHHHJ&IJ***AH_P"6U%>(_M+V/Q MZPG[.1^.VOL.BBBBBBBBH:FHJ&IJ*********************AKYI_;5_:DA M^`W@<6&C3PS^-M5S;V*Y!%ID?Z]AZ#-?`?[.?P"U_P#:I^)UU<:Q-JC:`)[B MXUSQ`3B!O`&A?#?0K?0_#NDV6C:-;\06UM#C%=)117PO^UQ^ MP#/\3_$]SXQ^'LUG;Z_>R@WVE:B?)MF]9_K7U!X6T_1_@'\%-,L=3OQ;Z3X2 MT>"WGOK@]5@@'-?E5^TU^TUXC_:D\5_V38Z?*/"]A-.-*T:UM_/GN,#_`%\X M[3^U>J?LNV/P_P#@+J7B&UU_7[&X^,]__P`2_0M/M[>XG;2;B>`$6WG_`&?_ M`%YGG.:\%L?@9XE3]I.P^&_BZ]-AXBOM5@@O[]9_M!/G_P"D?:*]P\<_LF>, M/BE\7?$'A#P9\.[3P)X+TF__`.1@FMCY%_QG[0?^>W_7"#`'>OTG^%?P_P!/ M^%'@/1O">E&;^S])MQ;P&XZXK\\?VFM1T#QY^W/IN@>.-7ETCP)IPL+6?^UA MBU!'[_`&>///'G]L5Z'_`,%4/B-<:=X0\+^#K*^DM_M\T^H7]N.L\,'^HY_Z M[[?RKRW]N'X1ZWH&E?#;X@KXL/\`9\UC8:-!]IGQ<6%QY!G^T?:/P-?J-:?\ M>D'T%6:R-9T/3_$&DW&DZE;P:A87L)@N+>XY$T6.0?SKP3_A@+X%_;OM/_"$ MMY>/]1_:EUY/_?/GUZQK'PI\+ZQ\-;KP+_95O8>%9[(V/]G6T(AAB3'8#&.U M>*W7["7@6U^`>K?#C1&FT^?4!;W%QKTQSVA/I#!C"C]:^3?CY^P1XY;X[:Q8_#WPJ+GP?JP% MS8W`GM[>WL,_\?%OBOTT\!V>IZ-X*T"PUJ>&XUNWLH(+V>WB\F%IQ"-Q`],_ MTKJZ****************AHHJ:BBBBBBBBBBBBH:FJ&IJAHK-UO1!K6EW%C-< M7%N)XO*^TV,IAG'T/:OBW_@GZ!IWQ@^.>DP^?_9]OJ'!N)LX/VBXK[DHJ:BB MBH:*FHHHHHHHHHJ&BIJ*******\X\*_#*6U\%PZ!XZU7_A8K>;YINM8LH/\` MT'I^/6O0>(![5-1111111114-35#4U%%%%%%%%%%%%%%%%%%%0T45\T_MR>. MOB+\//AA8ZK\.1<0W'V[%_-8V/VF:"W$)YQ]?Z5^9?BNYUWXV?\`"5?$F]_L M.VN-)@T_[?;:=!]GN+^XN/\`1_M'V>OU(_8,M(+?]E?P&\$'D"=;F8CZW,]? M1%%%%%%%%%%%%0T445-4-3444444444445#4U%%0U\T?M9?MCZ5^S]8MHNE( M-7\:W,)-O;];>SZ8:)-<,PT>XOC!JWB'/^H'_ M`#[V]?K%X$^'WAWX7>'(-#\,Z7!H^FP_=MK=1^\XKIZ***PO&GC'2?`'A2_\ M1Z_?#3]'L(?/N+@]A7Y8?M.?M:^(_P!I;Q,G@?PG;R6'A.]O;>U@L57%QJUP M;@>0)NN`2H.,]A7T/\'/V(=<^#GPHUKQ1H\H/QJU#1_L]C]I$!MM)N/^F'&* M^$?$/P+USPI\6-%^'WB"X@T_Q!J%];V\Y%Q]H\C[1<5[A\1?V#?BYXC^(^LM MH=A#XA\/X%O9:MJ>JP!I8(`(+<$=CB`?G7Z9_"KP7+\-?AOX8\-SZI-K-QI- MC!8G4;CK<8P,_P"?:NPK@_&OP+^'_P`1-6@U7Q1X/T7Q#?P0^0MUJ-BL\P'I MG%<1\_$&CZMXE@O1TJWU'7]6\[[-<7 M_$$&/6OD+]A?P[8_$7]HJZU>"]O_``)XBL/^)A_9NB6Y_L^_M_\`EXM_W_/_ M`#[U^K/$`]JFJ&IJ**AJ:BBBBH:FHJ&IJ**************AJ:H:FKY2_:T_ M;*TSX!Z>="T98==\;W,'RP`D6]@O(\^X_P#C/4U\2?L]?LT^,OVL/&5UXEUN M_O!X?GO2=6\0W)Q<7$X_Y]Z_5[P'\/\`0?AAX4MO#OAC3X=-T>V&(+:W[5U5 M0T45S/COQMH?PW\(7_B37[T:?HU@//GN.9<"OS#_`&E?V@O$G[87CS3_``/X M%TG5/[!,V+*PP!]OG&2)[C_GW`R:^L?V5_V(+#X!ZQ;>+-2UV;6/%XL6MC;P MG%C#YW7:N.:^L:_.7]KK]C7XB?%#]HO4M<\/:78W&C:O#"WV^XO_`"88?(MX M(3YX')Z'`'I7V3^S[\&+/X%?#>P\'V&J7FIV]L3+YU\Y/[T[2?)&.(O;_&O4 M:FJ&BBBBBIJ**********************AHHHJ:BH:FHHHHHHHHHHJ&IJAHH MKY5^"]M_9O[;WQT_W\X>MQGK7VW111111114-%345#4U%%%%%%%%%%%%%%%% M0U-17S+^U5^V7I/[.A_L.#2[C6O%]S8FXL;8Y\CT_?$'BOAGX%?LY>./VP?' M<_BGQ#?WH\/?;O\`B:^(+B?_`$B<#_EWM_;I7ZQ^'_#NG^%-(M=(T6S@TW3[ M.#R;>UMXL0PCVK7J:H:+?H:R=:UO3_#.E3ZIJE_!I]A;K^_N+F?R((0/>OR: M_:=_:2UO]IWQ[!H?A:WU4^&#.+72M`@^]J$XSB_[)O[*NE?LZ^&F M,[0:AXOOOWU]J`B_U.)="L]!UFYTG3I[^PMKD7!@G^ MSV_[G/ZU]FU-111111111111111111111111114-35#14U%%%%%%%%%0U-11 M11111111111111111114-?G]^U)^R-\3/V@?VD+B]B;3[/P<+&WMK+6;EL_9 MX<9-OY'?]_S7AWQ"\:_M*_!FW\+>!M:US6M'N81.-*_L^;[1]?#OP!^`7C/]KSXE7.O:W//OUJ\&>!]"^'/AJRT'P]I<.CZ-8C$%K;C@5O5-4-%4-3U6#1K*>_OYXK6P MMXC/-/.?]37Y2_M"_M;^*OVGM7M_!OAW3YM.\/W$_P!F@T>W'VBXOY_2X]J^ MO/V0/V.K'X'V-CXH\0P33_$&>WF@N#]I^T6]CSR(!^'ZU]6T4444445-1111 M11114-3444444444444444445#14U%%%%%%%%%%%%%%%%0U-117RU\'_`/D^ M;XZ?OO/_`.)?H_'I_H]?4M0U-4-3444444445#4U0T45-114-3444445#4U% M%%%0U-4-35#4U%%%%%%%%%%%%%%%%%%%%%%%%%0U\<>(O^"C?@_PKXD\;:3= M>&M;^T>&;G[!"`T.+Z?S_L^/^F//KVKYUF^(TW[:/[7OP[USPCI,^C7&C"WN M+BWU>]ZV]O>;'0=*_/3X`_L]>*_P!JGXA: MC<&XGTW3IY[BXU;Q%Y'VC_2/_DBOUU^'7PWT/X9^%;+0O#NG6.G:?;Q`E+:W M$/FS8&93CN>3^-=91116/X@\2Z3X(T>XU?6K^#2=*MUS/?L:P?!:"U\ M2^+;*&;X@0>?;PW,-X9X(+<]`,U]:T44444445-4-3444444444444444444 M44444445#4U%%%%%%%%%%%%%%%0U-11117R5\&C`/V[_`(ZP?\][#3__`$GM MZ^KZFJ&BBBIJ**AJ:H:FJ&BBBBIJ*A^SCUJ:BBBBBBO'AHFIW'[2?]MS^!;$ M:=#H9MH?&(O_`-_DS9-MY&.G?/\`^JO8:********AHJ:BBBBBBBBBBBBBBB MBBBBBBBH:*.(![5^0_[97P>O_!?Q1UGQW"MEK'P]U[5_M'VC1[__`)>/^??_ M`*[_`/'Q6Q^PM\6?AOX+_:#UK5;S3I?"T&O?\2_0;6$W%^(//N/^/?[1_P"` M]?K!4U%%%%%%%%%%%%%%%%9.IZ=_:6G7%FL\MMYT'D_:+P]J]0HHHHHHJ&IJAJ:ODK]K']M;1O@9!K/ MAO1K:74/'>%$%O-`?(@\V$E9R?0>GN:_/OX.?`3QQ^T]XSU%K1A.!/\`:=6U MK4C_`,][C/\`X$5^NWPB^$7A[X*>#[+PYX:L_(MH<&>)_%U]XJU"^G^T%;F;_1[$'CR(/;_``KT M[QKXPTKX?^&]7\1:W.+#1]+@-Q<7'H._]/SK\DOCI^TKXY_:Y\6Z?I6B:3JM MO8'_`$:#PMI\XG-Q/VN/PK[>_8Q_8[A^`>G'Q)X@`N?'5];_`&>807/G6]E# MZ0<=*^K******\?_`&D_VA-$_9R\"C7=3BFO]0G/V?2].`YN9^P]J^9/'O[3 M_P`=9/V;;CXD-H.B^#X5U6"*WW6Y-Q-;'(^T>3<=/WY@&*YO]EC]OWQQXP^+ M6B^$_%_V+6+;7;GR(+A8/L\]E]1WKZ>^*G[!OVBKC4;#PJU]:WVEP0W%Q;ZC;F`B$G@UV?Q"^-O@7X40 M&Y\6>*-/T8E01#<7/[]OI#U_'%;G@[Q]H/Q`T2WU;PSJMGK6FS=+BVFR*WJF MHHHHJ&IJ*******************AJ:BBBBBBBBBBBBBBH:**FK#UVWO-2T*^ MM[*].EWTL,L-M?"(3>2V"!+C\CBOD;]F/1=4\/?MC_%_3-;U:?Q%K`TFP:?6 M;F#[/]H^6#_EAVZ]:^U:*********AHHHHJ:H:*FHJ&IJ*************** M**********************AJ:H:FHJ&N:^(G@ZQ^(_@?6?#.I^>-.U6SEMYS M!*89L$8X(Z?6OR!^,?ASP/\`!3-A\*_BM+XR\^_N+?5=%GLLVY'Y?9Y^]6?@ MAIEC\#[?]Q<_P!G:?;CR(+BPYQV_P"/C[/Y]?LU4U%%%%%% M0U-11111111117GOQ4U/X@Z=;:0W@#2M(U.>2[`O_P"UYS`L-OZC')->A444 M4445#17S5^V)^UE;_L\^&+>PTH17_C+58<6-O<8VV7'_`!\3^W/MTK\VO@E\ M%/&?[4/Q#N;&SN/M%Q_Q\:OK6I?:/]'_`/NBOU\^$GPFT;X*^`M(\)Z&/^)? M80J#<2#]_/-CF>8]SQ7?4?:!Z5^;O[8O[4T_QFU33_A5\+)KR_BOKAK#4+FV M/D"^G)\@V^37O/[(?['MC\$-!77O%=GIFI?$"XG^T&=81-_9?[D#R+<]0!ST MZYKZ3\5^*-+\$Z%?:YK5Y#I^CV,)GN+F?HH]:_'_`/:@_:9US]J+Q1:Z=I=C M>Z?X7MY@-*T=1B>>X_Y[SCM,.P[5VNB_L)?M$?#?6+>]\+O;VNI?9\_VAH^K M_9C`/^>'TKT+6/%G[;/@9-/M[VPO]9$&9_M%O86-\9_^G>?[/T^M0V__``44 M^-VB:3_Q,_AA#/<6_$]Q<:3?VXKK_AY_P5'TK<+'QWX.O]%N`,>?H_\`I'_D M#K7I/AS_`(*1_"/4--\W4[G5/#UQY_V?R+FQ-P0?^V&:[KPO^V;\'?$,VH06 MWCNQA>QA^T3_`-HPSV&!_P!O`%>E6_Q.\'7%Q!;V_BS19YYO]3!#?P,3],&N M@M[D3C]Q.+BO@K_@J=X2US4=(\':W;F>ZT6V^T6\]O;PY\B<]+BL3]J;XM># M/%?[&_PVE/A7Q%;Z=J$MN+"W$W]GM8F"`GFXG@N`1T`XS/SSS7Q;IWD?\+#\ M*_\`"MO[5MM1\_3[BP_M'[/]HM]0K0\/>+?"FMZAXY\2_$*QO=:\0W\%Q<:5 M;6X^SV]Q?W%Q_P`?%Q7N7_!.SXYP^`OC=<>&I=*L;;1_$D$Y_M'_`)\?L]O] MHQY__/O7AGQ]\;0_$CXW^.?%FFW$USI%_JW[BYGX'D?\N]?9_P#P25\@V_Q* MF\V!IV_L\'_GO_R\=:^F/VM]:^)&C_!NXG^&-E/=>()[B"WE.G1&>X@@.M_ M#?X_V/@"Q\#GQ';-!!<7G]GSB?4%S^_N<0#'$$'/7J:]+_9Y_:Y\&?M&7^LV M.@Q7FGWVE#SO(U`8,\!(`G'M7O=%%%%%%%%%%%%%%%%%%%%0U-1111111111 M111111111163K'V_^RKG^S?(_M+R3]G\_P#U/F]O?K7R5^S.FO0_M??&!?$D MUC:?[/;U]ET44445#11114U0T5-111114-3444445D:S MK5AH&DW-]JDT.GV-G#Y\]S/@0P@=R:-%US3_`!-I-GJVEW,-_87L(GM[B#D3 M0D<$?F*UZ*******************************AHJ:H:KZA80:G8365W$) M[>>,Q3#U!'_UZ_)?]L']CN#X3?:?%?P^F_MGP-_Q[S_O_M%QI$_;G_GA70_L M7ZYI_P`1_P!L^PU9M!@T]8-!_*_4^IJ******* MAJ:BBBBBBBBO)-7\._$>[^-6@:OI7BBR@^&XMIEU309[+_2'F/3#?C_/K7K= M%%%%%%0U-7@?[6'[3EC^S5X+M[[[)'K.OW[>39:<;D0YZYE/7@5^76D:-\0? MVN/B]=,9[C6O$&JS_P"D:C<6Y,%A;_3_`)805^N'P$^".A?`7X?67AK1(5<8Y.>WK6A^SA^PMX2^`6M7&MSW\WBKQ#G%I>W=N(?L([K!VKWGQ[X]T/ MX7^$M0\2^(KX:?HVGPYGN#VK\E_VDOVD_%?[4OC]-`TSSCX8&K?\2+1P,?:+ MD_N(/M'ID]O^GBOMW]DS]A_P]\%-*T[7?$]C!K'C\#[1]HG/GPZ6>?EM\]/K M7U?117"^)O@I\/?%!O#^L33<33W-A"Q/U)&:YO_ADKX-?9_(_X5QX= MQY/D?\>`Z>E'P7\;-<\.Z?<'[1<6UK#/;^=/Z MGR+@5Q"_!;]LSP$/M&E^++C6?W&.==^W_P#I15Z'2OVV/#N;S58+?QE81#%Q MHU^;":"X'U'->;']ICQW\%?%7_"2?\,Z^'?!>H:A/<>?=7&@W]A?_`*^/M%O_`*^NK_9_^)W[ M,OPQL;F_U?3?&$WBB?SH!/J`\\V,`@\@B`P"#@CCIGK@BOGC3KG[-JWB'PUX M7\63Z=X5U;_1_M.HS_V?;W]O;_\`'O\`:*^L_@):^'/AQ\"_'WA+1/C)X5L/ MBCXMN(/L6HZ=?3P6]MZ0?:/(_P"OCL:]B^`-SXM\!_!#QMI6L_%O1?$?CG5; M>Y_X1NQ@U^"_GMY_LY^SCS^YR!VQ7QW^SYK<_P`+?V@]`@\7_#F?7O%,^JV\ M!?6?/^T6T\]Q_P`?'V<_\MZ_0SQC\-OA/^S'>^.?C5>:9)/K.H;C*//RS3S8 M!@MQV\]B!WKQW_@F7\(KS15\3?$34],73K'5H18:&GGY(MO/8SDCMRL'/L:^ M_P"BH:FHJ&IJ***********AJ:BH:*FHHHHHHHHHHHHKGO[3U'_A(OLG]E'^ MS/L7G?;_`+1_RVSCR?)Z].OKZBBBBBH:***FHHJ&BIJ******AJ:H:FHJG=6<-W!+!/%'/#,.89AP:2T ML[?3;:*WM88H+>(8BAA&!BKM>/\`[/\`X*^(W@V#Q'%\0?&$'BLW-]YVEF%< M>1;^G/UKV"BBBBBBBBH:FHHHHHHHJ&IJ**********AJ:H:*Q/$FA67BSPWJ M>B:B)%T^^@FMYO(E\HB$Y!P>W'&:_.CXW?LN>/\`]FWQU:7GP,O/$$^DZQ.) MO[&TZ&>;[$8,_P"O&?(G@_?GBXKJ_P!A#1]=\??M+?%KQ]XH@^S:W9YTZ>VM MFQ!;S_:.8!]/(K]!ZFJ&IJ***********************AKYY_:N_:FL?V`=`NM<\07T&FZ;;0^=/ M<3\8%?D3\@P_>:X`ZD]Z^]OV2/V/=$^!7A MC3=6UO3XM2\?SP^=<:A,`?L61_J(/0"OIZBBBBBBBBBBOQ,_:WT7QCX3^-WB M&P\9:]-K5^+@W]O<"?@6\_%N/^G?I7W?\"OCM>3_`+"-_P"*FOQX@\5>'-*U M`2_VB?/S+H/&O@[PQ+>^M]0M]*@ASYX M[]?SZUX[\=?VA/V;[CXDWXTSX.67C5AGS]:-]/8?:;C_`*8<#_P(KU'P;^QG M^SO^T9X`&M?#^XUO1CY^)\3?O[(]X)X)R>6W_!-GXVV^KZ=?6_C30[>XL)LV]R-6N/M$`^OV>NVUKX$_MD7_A#5 MM#U/QAH7B/2K@%)K"_D@N?MP],SVW`Z4OAWXU?M9_">SM?"M]\+_`/A(VL#! M`+BWTH_ZC&/]?;_Z/3?`_P#P4H\5Z/+/;?$'X;3JB@@2Z+;SP3&?S\8(N.U= MSX8_X*B_#_4==-EK'AS7/#T.W!N&_?&(]LP@9%=[;?\`!17X'7!AB_X26]MR M>DUSI5QC\\9KT#P=^U3\*/'6KV^EZ-XWTN[U&\E,-O;!C&TY]L]:];HJ:BBB MBBBBBBBBBBBBH:FHHHHHHHHHHHHJ&IJ**AJ:BLG7-=L/#NDW&JZK/#8:?9PF M>>XG/$(]37R9^SIXTLOB+^V7\4=;T6Y^TZ!-H]N(#Y!AYQ;_`)U]DT44445# M14U%%%%0T5-1111111111117E7QO^.UC\$/#=OJ^HZ#KNM).2(H-&LC/@X'^ MN./W0YZFM[X6?$BR^+7@'2?%5CI]]IMM?KD6^I0^1/#]16_/KFG6&HVVF7%] M!;WUV#Y%O+,!-+CK@5L44444444444444444444444444444445#17A/[6OQ M,^(/PP^&L6J?#S0H]:OEG47S>09S9V^/O>2.O_UJ^%/C)^W_`/$?Q7!X7_X1 MZ^OO`>H6,$_]K6UO;C]_..@_?]O\:]K_`."7?B.^\2R_%._OC`+B^O[?4;@G M_7^?.;@G/Y5]^4444444444445#4U%%%%%0U-111117SI^UI^U59?LY>%+8V MBV&H^*[^4?8=)GN,$P\YG^@XK\T/!?P_^(W[7_Q.U":W4:QJTH\_5=8OQ]GM MK<>@`K]6?V<_V>/#W[/'@RWTK3((;C5YX1_:NLX_?WT_.]5AQ<3J,_8(,?\>\'H*^I*FJ&BIJ*AJ:BBH:*_)7 M]L2W\7:+^T/XEU[QCX$M]9\,&46\-Q?Z>1;3P8_T?]_!SY];_P"S7\&_$GAC M]GGX_P"L>(/#5[IT&I>&FT^QM]2LI[>XG`%Q_P"0.14/P#@UO6/V(OC%I?A/ M39K3Q!;WWGWU_!#@:A8$@3V__?C[0/QKE_V3_B?\&_`'@WQAX<^+GA6#49[Z MX^T0SW.D^?<7'_3#I7 M?_2/U%<-IW@[XJ_LP?L]ZAK5CX>O?#NI^*[\V%_JXB^SZCI&GVX'V?C_`)=_ MM$YG_,5[Q_P3A^-?CGQ;?:MX4\1Q:WXAT#R?M%KK]T9[@69'[G[-YY[_`"Y] ML5^@535#7-ZC\//">N:G_:=]X;T;4-2`YN;JPAFF_P"^B*XC6?V3/@[XBO+B M]O?A_HANI_\`7216WD[OP7%0>'?V1_A#X4UZPUO2_`VE6NI6$YN;>X`Y@F]1 M7M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?)'PN?RO\`@H3\68O[ MV@6Q_P#2>OK>H:FHHHJ&IJ*****AJ:BBBBBBBBBBBBBBO*_#WP2T+PI\7O$/ MC^VO]:N-:UVW^SSV]S?&:UB7`^[#V_U(_7\)M4^"G@O7OBQI/Q(O;":Y\7:3 M;?9[:Z\^;;$,'I#G'_+8_F*].HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKX MM_;?_;$UCX#>(]&\,^#X+`ZS-8M?WUQ?0&7R8,XA,('#$[9^H[5X#XS\;?!; M]I[X/:QXY\9S+X%^*.D0#[>;%R#JT_D?N.W86XQ_SP[^M>^_\$LK:V/P'UZ< MVL4-S_;\\$]PO_+?%O;\U]IT444444444444444444444445#7DG[1'[0?AS M]GKP-<:MJ5S!_:]Q#/\`V7II.#>S@9`'X_SK\F-.TWXD_M4_%+S_`/3O%?B& M_P#L_GW/D?Z/86__`+;V]?K!^SS^S/X3_9\\.00:9907'B":W$%_KY'^D7QZ MY)_STKV*BN&U?XV_#_P]?"RU3QSX=T^^,G_'O<:K`K?J^@S_'+ MQ%XZ\6ZM_P`)5I6H:I*QH?A^:8>"+&?$%M;>?_Q-1_SVG@P. M!VKZ5_8V_83'@F[T?Q_X[,P\56\QN+'1H)SY%ATYG&.9^>M?<]35#1114U0T M5-11156YM8;J#R9H1-">QYJ2JPMH+6V\B+%O![5XM\4?V.?AA\8-=M].D_'->G^`O`'ASX;>&;;0O#&E0:-H\'^HM[;@5YO^UEX M<\8>*_@UK&B>"]'TOQ!J-]+#!<6&H_=FM\C.??C^=:'[,'@O6_`/PBT[0_$. M@:)X6U*WFF_XEWAZ7-L!GJ/?_`5[#111111111111111111111114-35#4U% M%%%%%%%%%%%%%0U-152Z:>&WF:&,33#_`%0-?%WP(N_$VH?MS^,+CQMI\.C^ M(O\`A$1YMM97!GM_]?;_`.HSS_6OMRBBH:FHJ&IJ*****AJ:BBBBBBBBBBBB MH:FJO/;+QCTJ/3M0MM3MQ<6D\5Q`W26$Y%7******AJ:BBBBBBBBBBB MBBBBBBBBBBBBH:FHKX`_;=_9B^(7BSXR:/\`$OP/I<&M"QLH6FL3[J^OH/LT& MKZY/J%CS_KK?R((`?SMS7V%14-35#4U%%%%%%%%%0U-111114-%35YM\*]3D@/V&`_9[*>X$'VR?!Q",]S7XW>-/$OC']I3XO7.H&QFU?Q- MKDWV>#3[?@6P'_+O7ZK?LI_LRZ7^SY\/[6">"QN?%\]O_P`3;5H`/F/!$(X_ MU(QP*]^HIOVD>=Y/_+;&:_.'X/?\$^/%OB'XHW_B7XM16D>GG4/M]Q;6LXG_ M`+5G]3Y)'D#Z5^D%?G!^W[^US_:=UJ/PJ\)SYL+?_1_$>H$?ZW_IW%6O^">' M[*\UU<0?$_Q=I8\@8N/#=M<=1G_EXK]%:FJ&IJAHKSGXW?&?0_@-X)/B/Q`+ MN>R\Z&W@@L%W3S,?;C-_$_B+Q?\`LRZAK/PS>\DUK5[&"YTZXM_W%Q#; MS;9R?8B$XQ7YZ?LU?'SX@:?\=O`NDQ>,M5U+3K[5K>PGT[4=5^TV\\$_<5]T M_M4_M8:O^S3?:!M\&CQ)I.JPSC[?/?\`V8"<=(,>2?\`.*]^$:S_P`)'X:T MK53#]F-]9PW'V;S?-\K(SC/?KU]JZ"H:*FJ&IJAJ:BBBBBBBBBBH:FHHHHHH MHHHHHHHHHJ&IJ***************AHJ:BOD_P5,+G_@HE\0L=(/"EO#^MN:^ ML*****************************Q_$7A[3O%>@W^E:I;+?:??0&">`G(E MB/;]:POAI$?"GP=\-C0_!NBP:)I/G>?]FMAQDUVM%%%%%%%%%%%%%%%0U-1 M1111111111111117P7^TY^V%\7O@#\9KFQ@\*65SX'AYL3=6\^;[_1_^>_3_ M`%_%>`?M%>*O@?\`&;P&GC?PE#/X9^)$TT%O?^&88?L[7!G/[\$8YX[^W2OT M+_8]\.7_`(3_`&;?`.DZI93:=J%OIZK/;3_>!Y_Q%>T44444444444444444 M445C>(=;M_#.B7VIW`FF@L83-*EM%YLY`]!WK"^%7Q&C^*/@JP\10Z)JGAV* MY'_'AK-O]GG'X9KMJAKAOC)\6M%^"?P^U'Q7X@,_]GV*Y\FWYFF/H!7Y*^,? M'OQ/_;3^)]M80PSZC/-/<7%CH\!S;V%OZDU^C'[(W[)ND_L\>%?M%Q%;ZAXP MOH<7VH>2,0]/]'@XX@'/'^1]%T5X#^T[^U-H?[..BVK20C6/$]]_QXZ.)Q#D M?\]ICV&1Z5\>?LV^'OBA^T7^T33[8XQ6S14U%%%>&?M;?`F;X\_"*^T32YI%UBTE%]8VPN/(@G MN!T$_J.37._"SX4^-=-_8[G^'WB;[#;^+)]*U#1X=DN;>'/GBW.?8%?T]*^7 M_@I^R7^T%\%_B=I(TRQ\._V)<303ZAJ*W$$\'V?O;CS[?[1^5>T?MX_#3Q]\ MP&*ZZH:*FHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHJ&IJ**AJ:LO6=5M]$TJYOKTX@LX3/*?H/_K&OBGX#_$72?BS^WEXG\5> M'Y[UM'OO"8\C[3;^1_S[U]U4444444444444444444444444444444444444 M44444445#4U%%%%%%%%%%0U-4-%3445#7YR_MP^`_C%X"\6^)_B1X:\2WMQX M-OH(;:XTZVF,_P!AA$!#&XMS^X\C.?\`)KX\^&_BSP>WQST#Q'XDT2WL_")O M8+B]TBP&;:V@[''>OW$\.^(+#Q9H-AK>CW,-_I]_!%<6]S!SYT)YS^IK?HHH MHHHHHJ&BIJ*****KQW$5P/W9!/M5BBH:**XOXK?%CPW$?!]WXC\3WXT_3K? M(XP9IC@<0C/)YK\EOC9\:/%_[8GQ.TFQL=""+DV6B:1`<9/?V:?&'[5OCD?$#XD7U[<>%)BLT]_/ M@7&JB`X%O_U[U^FGASPUI7A#PQ8:'I5LNGZ38V_V>"W!QY,./_K5^='[;?[; M=UK5YJ_PW\$WPMM*!-MJNLYN(+B>?)$\%O\`],=N,_C7A'@?P1X4^&&G:?XY M^,6AW]_;ZA;_`&CPUX7'^CG5?>?C]Q!74?MK_'+0_CE>!<0'CKQ;_I7MG_!+/6M5;Q%\0M(A%Q<^%H8+><&>XP;:X-Q<9(@ M[?:!G_P'K]':*AJ:H:********FHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHJ&IJ****AHJ:BOD;P]H4&G?\%&?$$\/_+QX-%U^Y^MO!_[;U]< MT4444445#4U%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%0 MT45-117.^*Y=4A\.:K+HL<$NKBRG:Q$Y_N-=_ MX275;;6;C[1Y]QY_^D47'BV?Q)X9_LF?28-2\0SZM;W$'B+_`)B,_P#R[_9Z M_=KP9H5EX8\*Z/I5C9C3["RLX88+4#_4@#&/Y5T%%%%%%%0U-11111116+XD MT2W\3:'>Z7>"4V-Y!+!.893$0#P<'\^:Y'X-_`OP=\!M`N=#\(6#:?9W,_VB M83RF9ICZY)_I7I%%0T5YU\;OC5X:^`_@RY\2>);@"WX@M[>#F>]GYQ"ON?\` M/O\`DW\1/BC\0OVQ/BEI\!@GU'4)Y_\`B4^'K?\`X][#_/\`S\5^E7[.'[*' M@[]GC1;`QVEMK'B[R=M[X@N(!]H)QR(/^>$.<\"O?Z*^9/VL?VP;#]G'3K#3 MM,ALM:\87,P_XET]SC[/;_\`/Q/CI76?!7Q)#^TK$_#_BGQEX+L;:[FFF>" MQU&R$WE'.!/#YXR,^H%>UA8;6`QC]S#"/PQ7YA?MX?MF1^/)V\"^!M7E_P"$ M?@)_M74+3.+^;)Q;\_\`+#U->(>`[31_V>]7\/>*_''A6R\4W^H6T&H:3X56 M^M_(@@N!Q<7'[B?'./L\':OH'QMX%O?^"B?A.V^*'A^"#P7XBT*8^'[[3M9O MLZ?]G'^D?://^SY/_'QVKQWX%?LO:%\4/VF_$7PWO-OT-^%FB?!W]D;1G\#0>+-(T:_N!_:%[-K6J06]S<>LYR17KN@?$?PKX MO6WFT3Q+I6LB?_4_V=?03Y^F#73U-4-%%%%%35#7S9^UU^U/JO[-5MHHTSPI M_;?]J^=F_N;CR+>W(YY/Y5\MP?\`!5+QT9[<3>#/#@M_^6Q$\^9>.U?;4/[2 MW@@?"31_B1J>JC1O#VJ6_GP?V@-MP3U\CR<_Z[M@5Y+X4_X*5_"/7]7AT^\; M7-`@F&4U#4;$^1GZPDU]3:+KFG^)M)L]6TNYAO["]A$]O<0.?".E6^L^ M"//@,%IJ5O\`;X()\X\BX'7[/7C_`,+/A/KB>*_A+K$4,TZZ[KMN88#!@`6] MQ;U^W53444445#4U%%%%%%%%0T4445YM\;?CGX6^`7A+^W?$UU\I8006\`S/ M<3>@K\I/'7Q'^(W[:'Q'T^Q@L1K%\!<'2M(L#]GMX+<#J2?8=37Z/?LG_LK: M)^S]X+L9[RQ@N/'%S;XU74`?.(SC,$!QQ".P_P`CZ&HKYZ_:5_:Y\,?L\:%- M;L8-9\8SP9L=%!/`Q_KKCG]Q![G_`/5\F?LG_LP7W[2WB>_^+GQ.$USH]_?? M:8+8\#59O7_KWK](L6'AK288?W.G6$$/DX'$$(]*_-7]N/\`;1D\?7&H?#_P M'>#_`(1>W/D:MJ-N/^/X\_N/^N')YIO['/["J>.Q8>.OB%8^1X7'^D6&B3]; M\]?/N/\`ICCM2_\`!2OX*_\`".>.H/B";^SM[#5H8-/L=.@@_P!(_<0?RKS7 M]DKX7^/OC0/%/@+2-=O/#G@75+RZUK=_B";4+F#R2L'400CL,CUK:^)W[(WPJ^*GBF?Q)XF\+M>ZQ/! M]GGN;:XGMS,/?R2*\>"%X)_<0`@@5%_P@O[:WAVWGU&+QGI6L>1#QI[RP3>>?QMJZO\`9[^+ MG[3.N>/;'2_'_@#'AZX4F?4YK;[";?\`#O\`2OL2OG3X@_MW?"_X8>*K_P`. M:M_;@U.PG\B<6VF%@#]>,C\*9X,_;T^"_BZ6VC/C$:''M1\9_![Q M?H.BWT.G:SJ.ESV]C<33^2!.0<<_45^.OQC_`&?/''P.N(+?QGI8L+>].VRN M+6X^T6\Q]#6!X\^)%_XVL/#UAY']G:-H-A;Z?!IUM/\`Z/\`:/\`EXN/L_\` MS\7%8UOJ4%S;V\'V"#]Q/^_N;;_CXGK]NOV;?[%'P)\$?\(Y97NGZ)_9<'V: MWOQB=5P/O?K7J%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%0U-111 M11116/JL-]=Z?.EC-#!J!AS!/-%YL*R^N,@]:^-/@%X?\<>'?VT]0A^)6KV7 MB'Q0?!@G&HZ=`5@\C[3C^=?<=%%%%%%0U-1111111114-34444444445R6C: MKKMSXFUBSO\`0O[.TB%8?L6JF_#_`&TGJ/(`S#@\>]=;1111111111111111 M111111111114-3445#4U%0W'05\^>*_C18^$_P!I_P``?"[3H;VV-UI-S=3: M?9""*VY_X]^,C_GWN.*^@ZFHHHHHHHJ&IJ*******AHHK"\:^-=)\`^$]0\2 M:W>K8:-80?:)[@]A7X]?%+QYXR_;+^.UN+'2?](GSI^DZ?;_`/+C!W-Q7Z%_ ML@?LCV7[/?A:WU+5[&QN/']PI%]J$(,OD0_\\(#V''ZU]+T5X#^U=^TUIG[- M_AJWD-C+J/B+5[:X&EV^TF`F`+GSCG@?OA]?PKXD_90_9A\2_M+>/+CXD?$+ MSKGPN9_M,]Q<_P#'QKL_>#_KWK]2=-TRVT6QM[>VBAM;*"$0Q6\`Q#$!_G%? ME[^VO^V//\5CK'P_\,M97G@@&'SM3-O.+F::$YQ]!.`/PK7_`&$?V0+/QWQG\BQTC4M/^6^`@4&?]_\`\L2"<#OBOT[^SCUKPG]I_P#9DL?V MEM"T>QO=/F!Q[5J_LW_LS^'/V:O#=_8:+>W>H7-_ M-]IO=0NSEIVKV>BBBH:FHHKS_P`>?`OP!\3M2MM0\6^%-+\0ZA;Q>3#/?P!B M!Z5P>K_L3_!._E%Q)\/;&W;R/(QI\T]MQ](6'YU9\&_L9?"CX>^*=*\1>'_# MDECJ^E@BWG6]GX^N20:]*\=Z->^)?!VL:5IVK3:'J%]9300:C#C_`$=B.)OP MR#^-?'D'[*W[1_PY'V/P7\:X;K3_`#OM'_$Q0D^?Z?Z0+BO'?V@_V7_VE_B% MKFG0^+!_PL2VA@/D7&GS0+;P'Z'[/7">*?@_^TK\8-0T?2/$^B>)]8-AF"Q& MHP"WMX.F3]H_[8#\ZP/C]^R+XY^"IT^>72M4U+1Q86]Q?ZC;0?:+>WN/^7BW M_P"O>O)=9UN_U+^SX+VPL=.N+"#[/_H]A;V]Q%\G=VP#7UQ>W]OIUO/<7$\4%O`#+-+, MW$0Q7/Z+\3O!WB:[^Q:/XLT74;H#_CWT[4()C^A-=/\`:8?^>P_.G5-11111 M111111111111111111111111111111111111111117R=X6@O;7_@H?XB\V^$ M_G^"_/48X$'VFW`'YU]8T45#4U%%%%%%%%%%%%%%%0T5-111111111111111 M14-344444444444444444445#4U%%%%<9#X@\/:EX_U#2H;59_$VE00^=^,'AOX+^#[GQ'XFOOLU MA`O^IA&9YS@<0C(R:_)?XZ?'OQE^US\0]/M[?29_L\!\C2O#VG_Z1D__`"17 MZ"?L??L?:1\!]`L=8('[A3GIS7U)17@_[1W[6?A/ M]FVVT^#6X;W4]6U`_N=-TX[KCR.AG^@(JS=?#SX9_M2>$O"/C'Q#X:@UNVFL M1/8&XGY@6=1F',)YZX[UZAI.F:1X(\.V]E906^CZ-I<&(8(!B&&$?TX-?EO^ MV/\`MJW_`,8=4O\`PIX2OS;?#^"8`W%LQAN-6_/_`)=_>I?V>_V3-?M_`NI_ M%/Q#X*'BB&WL?-\-^#IR/^)HQ`(GN,_\L<$$"OM'X"?&/XL>.?$G]E^)_@V? M`F@00<7YU`#RCV'D8KZ1HHJ&BIJ**********AJ:H&A$PR:S[KP[I5W;7%O- MIMI+;W"^5/$8!B4>AK&C^&_A2'4K'4H?#.E0:E8C%G<064*SP`CG#8_E6OKF MC67B70]0TK5;=;FPO8);>>W//FQ'@_H?UKYMNO\`@F[\$Y[:XB@T[5H)\<3# M5I\Q?3FN.T?_`()S7?@+5S??#[XN^(_"B36_D7+&`>=-]?LYMZ^R-.M9K33X M+>68W]Q%#@W$PYF/K7REXEU?]L32IK<6>A>`]9MO^H9`^1-%-0OH-T MVCZC_P`?$!]#7C'_``\)^"::W<:5)XBO(7@/DFY;2[@6V?KBNX\"_M8_"7X@ M171TGQWI0:W_`-<;YC8X_"<+7IFB^)-*\0+*-,U*SU#RC\QMK@38^N*UZ*** M*************************************^'/AY\5M"\;?M\'5+6#5-/M M]0\)'3XK;6-/GMY_M$%QSUK[CHHJ&IJ*******************AJ:BBBBBBB MBBBBBBBBBBBBBBBBBBBBBBBBBH:FHHHHHHKQ;X??M,Z'\0_C'XG^'UGH>N:= MJ6@0">YN=0MC#`//'^A?#CPU<:YXBU6# M1M-@'-S<]*_'_P#:4_:,\2?M._$&W$%O>_V1#<>1H?AZUM_/N&/<_P#7Q7WQ M^Q5^Q];_``'T3SSB&Y@O\7-M;XS;V\'I^_YK[8\/ M>&M$^'WA*PTK2[>'2-'TFW\BW7/$$(]/2OS._;(_;=OOB?JQ\*?#W59K7P?# M!FYU"U/D3WY_^1ZZC]B;]A.76IK+QU\2+."YT"6#S]*T6?DSD_\`+>X]Z_29 M;<06_E0C'UJQ1114-3444444444445#4U%%%%%%%%%%>MT5#4U%%%%%%%%%%%%%%%%0U- M14-344444444444444445\>:G=SZW_P4-\+FYLKW218>&[BW@M[\08N.;C]_ M;XS^-?8=%%0U-114-34444444444444444444444444444444444445#114U M%%%%%%%%%%%%%%%%%>4>#/V=_!'P\\>:YXVT;2Y;?Q%K7GB_N#>33!_/G\^; MC/&6P1CT`KU>BBBBBBBBBBBBBBBBH:X_XG?%?PI\'_#DVN>,-5@T?30?)WW) M_P!:?05^1OQ]_:,\8_M8^--'L9;?[-IYN/L^E>'K?DFX_P#C]??_`.Q[^QW: M?L]V+:[K_P!GUCX@7RGS[J`'R+&'_GWM_;_/U^B]*UW3M;BF-G>V5_!#+Y$W MD2^?MFXX-?GC_P`%5[:^MO%?P]U>"XF@@N+&XMS`)L9(X_\`:]?$/@/Q;?\` M@GQ;HWB72_(_M'2)_M$'VF"ONW]C7Q[^T!\>_BQ;^*M3\1WH\"PW$_V\3V__ M`!+[CH/(M_IQ7Z#:GJ5AH%A<7U_=PV-A`/-FN+B<0PQ#W/3\Z_+G]M/]M:_^ M*&H:CX&$W_V;P-`,7&H6QS/JW_W/7K/[!O['>EP:5X>^*OBP_VAJ-P/M.E: M/<0CR+;TN,?\]SS^5??U%344444444444445#4U%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%0T5-11111111111111117RKXRL!=?\`!0SP#_RR%OX- MN)L#_KO/7U51111111111111111111111111111111111111111111114-34 M44444444444444445SWBGQ`OACPWJVJK"9Q86,]R(/[PA!.*\P_97^/A_:/^ M&3>)KC2X='O8;Z>PGM8)_/"D'U]^/RKVJBBIJ******AHJ:BBBH:\N^/OQUT M/]GKX?7/B768FNAD0V]A;C]_Q\/ M:?Y]Q;P>_P#]T5^BW[*/[&>A_`/P^-1UF*RU[QQ-AIM2,`F%F>?E@R,@=/>O M9_BM<6^G_"[QA//,+>`:5N6WQJG\6?!#Q4?BYXDU3QF=7N/L_AO3O]'^T6.H6_\`Q\7'VC_E MA!^_%=+^QE^QK<_');;QEKLT$'@FRO\``MP`;C5/(_Y8D9'D`>U?JIH^BZ5X M3T2UT_2K.VTW3K$>3#;6X\F&$>F*_-7]MG]MA?B+'J/PY\%6\NG:/;W!M]4U M"=<"]\@DF#_K@<\FNH_8D_89>9=%^)'Q`@V$XN=*T"ZM\B9?)'D7%QSG."?W M'0=Z_1FVMA;P"+/%+114U%%%%%%%%%%%%%%%%0U-11111111114-34444444 M44444444444444444444444444444444445\F:E/JI_X*"Z`-0^PPY$7/V8 M1$D&#[3W_P"FW]*^LZ****************************************** M************AHJ:BBBBBBBOGK]L2VM=(^"'C3Q5]FENM0T_0[BPC#7TUO`( MKC$,V<<9Q_(5SG_!/+25TK]F?1IC+:,=0O+BY!M>W.W]][_N?Y5]145-4-34 M44444445#4U0UPOQ<^+6B?!WP)?^(]?FAM[:"'$4!;F>;!Q"/QQ7X[?$3Q_\ M0/VL?B@;C[#>ZQ?SSYL=&T[_`$C[!;_].]??'P:_95E_9E^$]QXOT_3]$U+X MO"R'VB?6;QH+""+<#-"".@$`/)';\_9KS5[WXW_LZ:]:Z5JFA:EXCU?1;FP, M_AZ_%Q8"^-N?W(G';+#GT)K\\_V6?&NDZ9XE\=?"KXJZI?0:!XDMSHPTVX\^ MX)U?[1]GQ^XJ]%UN?M'V<-@S^?QZ']Q M_.NZ^"?[`?A'XB>)O#_CK1_%@\5?"V;%R;;4;*>WU">>$D"#G'^C\5^C6EZ7 M9Z)I4%A8P0Z?8V$$,$(P(1[?G7YW?\`!0']L*+6;>Y^&'@R_%Q;=/$=_;=9 MA_S[P'N?\^Y^=/A]^Q9\7?B;X+7Q)H_ARW73KDXMK?4KC[/<7!_Y[_\`7"O5 M+?0?VR_A>XTNR7QA>WU"WKT#PM^V3\>_A/I.G0?$/X7ZMK.FV\WV: M^UB_L)[:XG]P?]178'_@J+H=O?'[?\.M=L-.(QYS3#SORQ_6NET7_@J!\+M2 MM\:KI7B31KC_`)]_L'GG]*[CPQ^WO\$_$MO<3R^+CH9@ZQ:Q;S6[?J*[3P_^ MU3$_%6MP:5I7Q`T2[U*X_U%LMP`37I5OK5C>6_G0WD%P/\`IC,"/YU$Y`(Q_C^E>5>*O^"E_P]\.>)]8TJ+2M M4U*VL9Q;Q:C;^28+@@YFP<\8_7VKZ%^#OQM\)_'3PQ-XA\)7K7-A%,;>;[3` M8)H3CH16DWQC\#12B(^,O#WG>;Y.TZK!G/IU_2NNM[J&Y@$\4H,/J.E6:*** MAJ:BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBOE;Q<8K;_ M`(*'>"!$(1/-X,G$N>I'GS_US7U311111111114-34444444444444444444 M44444444444445#4U%%%%%%%%%0U-114-34445\=_MY?'+PG<_`OQSX/TSQ5 M9'Q7#-!;SZ1!/BY&9UXQ[X_2O1OV&Y_M'[*OP\/K!\5-111111111 M11117G7Q=^,7ACX&>$9_$7BS4%L;$?+!!NS//,1Q#".,DX_6ORD^*/Q6\9?M MJ?&;3K:WL)S;SSBWTK1[?_2#8P8Q<7)K],_V<_V:_"?[.?AN6PT6$WVKW(_T M_6+H#[1<=./:(=A7H/C_`,)V7C[PEJ_AO4Q*=/U6RGMI_)]#Q^=?E7^SM\9/ M%/[&_P`;;_P?XEBF@\-W-\(-5L+^X!%B.#_:`/H:7]MOX7_#_P`)^-+;QG\/ MO'-EJ-SJU]/%/".D^`_#-AH&@6,&D:-80>1;VUN.(!7 MP7^WG^V/87.G'P#\.?$N^[\^>V\1W%O#D"``CR!/V)R1QVKCOV(_V&6\=QZ? MXZ\=6]Q;>'H)S]A\/W$'-]_UWX.8?05^H%M!#:KY,0Q[4ZBL;Q'X2T3Q=IXL M=;TRSUBQ_P!;]GOX!./J`W%O88_="_LA/.OXP[>*9K'[-7[6GAOPU!#I M7Q)&LVT-OY/V&VUVX\\CUS<6]3^'O#G[;WABWOX(;C^TA<0_Z_4;^PG\@X_Y M8#_&JWBW]I_]JOX<^)-.T75_A_8WM^3D'3M+N+H7_P!/(Z?A6CH'_!0[Q_HT MS:?XT^#&JK(/-]/,@_QKT.W_X* M+_`ZYF\C_A)+RW/_`$\Z7]\=1_`R_TSX?: M;=ZIK>KW"V,ZZ=`)YX;+!:<@=R0##_VWSVK\AM:T35O"7VC2=4T*?1=1_P!' M_P"0C;W%O<6]?=O[$?Q=_M/]G7XB>#K3P[I>D3>&]"GN)M6:^%NM[<3_`&@Y MGXS`>.]?!/\`PB6K7/AFXU:"""YTZW_T>?\`T^W^T?\`@/7L7B']I[7;7]GO MPMX.\,067@V#S]0MM=_L;_1_[5'^C_OQ_P!_Z]*TW_@G+?ZG\/[GQ39>/_#N MLF"R\\6^CP"_S/C/D"XST[5T/[#_`.U-?_#OX>_$BR\3W%]K/A_PQI-OJ%AI MW2Y@&1!]GMR/^7?@?]<.E:_PH_X*&^*O!W@"ZU7XCZ5>^*&U;5OL^CW5M;"P MMA`/]>?//H>:Z']FO_@H/KGQ(^-G]A>,ELM/TG70+?2+?3HS,8;@=BW6OT&H MHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHKX4USQ?XCU MG_@H1X.AN/\`A&+H6MO?V$']FWQN&@MQ]H/^D`W'V?CCMQVK]#_V>?!5Q\.O@IX(\/S6L%AW_UZ_*[4=;\OT_P#V9_V4 M_#'[..A3Q6,@UG79Y2;C6;F%?/*\?NL^G^->Z45^=O\`P4Y\'>!XKC2/$@U8 M0>/I_(M_[)W9-_8[B#-CVQC->'_L;_LC#]H35=1O]CV.@Z79Z9I<$-K8V4(AA@7_`)8@#@5^?_[:7[<0,`\&_#/7+=VG M@G@U748()X+BP(X\GIP<5Y!^Q9^R'_PN+58/%OBX0Z?X%T^?_1[:XZZO_P#< M]?K=;_ZBEHHJ:H:*FHHHJ&BO(]6^`7P=T?PY.=5\&^%;71X9//GN=0L(!SZF M4]/SKS77?@]^RKXTMKBVA7P'87-\OV<76DW]K;7$)_Z88Z'Z"LG6_P#@F3\( M]1TT16,>N:;<]YX-0^T$?]_\UP>K?\$I]#\N^;0OB!J=HQ`,-M-90,,X_P"6 MQP,_E7`WW_!.+XO^#-7T_5O"'C/2[C4+?I=6\\]A<0CU%;7AW1OVTK#2+G5; M'7WU$FYGA_L^_-N+G,,^`09[?_4$9Y'-<7\59/V@_$>G0ZI\3?A#I?BB"&?[ M/!=3Z%_I(_Z8?Z!<>?Y%;.H?MW7UK\/;GP;XA^`D6G:-<67V#[-!<7%A;?9\ M8Q_Q[\#Z5\=?V;X:N?%NG03_`-JZ+X>\_P#?W%Q_I%Q;V_\`Y+U]:7]Q^R)J M7P8_X0VSU>]TWQ!`LX@\4:AX:N/[0%SW^T&WM^?_`*U>/?\`#/&NW/\`Q(O" M'Q)\#^*]&N)_[0_L[3O$OV?_`+>+BWN*^R?V*_V/]*^&FD^(;[QK/H?B'Q!K MUA_9UQI%O/#<6UO8Y'G#CJ"3S_\`7KL?VR?AX-%_9X.A_#_X9:)JT$UP87TW M3])_?V'GC!N+:"`#]\/6N*_X)\_"&;3?!UY+XS^%%CHFIZ=>K=6>N:Q89U*> M7)Y`G&ZW,`6$#Z<'(+']OGX7?$]I:^'+BX^U3WURD7V?^UAS/<<_\MS_( MU]QT444444444444444444445#4U%%%%%%%%%%%0T5-11111111111111111 M111114-345#7YR_M_P#P@\;_`!2^*UF/"WPOFE:"`0GQ/I[*?[2!`P+C'.(, M$\YZGM@#YN^'_P`'[[QW^T%#X/\`BQ<^*-$\0:K,6-TT/GSSS^Y["OV>T[2X M-%T^WL;,""W@A\B$>E:=%%%%%%%%%0T45XA^T3^U7X3_`&?/#=_]MOX+GQ>+ M'[38^'L_Z1WN:_4#X%? ML\^%/V?/"W]E>'H-UQ/C[=JUP!]HO3ZDUA_M@:_K.@_LW>/[G1IY5U2.QR/L MN#/'!YP\\C_M@6K\@=)^)WCG2+R'Q%:>,M;AOK*?[-#.VK3F%M/E-Q<7&GP$F?\`T'N9R#^_SQQTR*]\U?\` M9K^''[<&M6/Q]MQ8#3Q#]GSY!/;MTKZQ\&^"-"\!:%!I/A[2;+ M1M-A&(;6P@$"C\*^)_VT/V\&$7&H>`/AQ<$:U!/]GU;6.GV`M?-7PS\=^*OV@O MV(_B!<>.-2T@7-S!?VT6I:@?LUN``^(?[.VM_"BUM+JXO\`0KWPK8SZ MKH&KR^=J`N#_`*\SSG,\)`(YY&0?I7Z)6_\`J*GHJ&BN5\7_``M\&_$&*WB\ M2^%-&\0BW.81J=A#<>3]`PX_"O-_%7[%7P5\71YE^'NE:=IFN^,-(NO/ MS]JMK^W$W^IQU^SUFR_\$Z=9MK<_V3\/VM/A M38WT.@?$?0M1BGFW`:E?3W)7_O\`V];.HZ'^VSX;G\^'7?"GB.W@_??9[?[/ MFX]O^/>WK/UK]J7]I[PG/;SZK\$,P?O\P:=!<7!..G_'O]HKE-2_X*5_$CPW M?P6_B#X4Q:9<$>?/;7'GP7`@]1GO78>&O^"J'A6]CN!XF\'ZMH;#_4_V9.+\ M-](8#;+_`-_LXKO[?]L/X,7'W?B/ MH7_@17J?]LV'_/[!_P!_JL+,+B(-%@Q>M/J:BBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBBH:FHKXK_:CU&VB_;(^`T\-XIEBN/(F@'_`"S!F')_E^%? M:E%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%0T5-11114-344444445# M4U%%0T5-14-?EM^WWX\^*W@S]H&VOC?7N@:+9K_Q2MUI\V+9N/\`2,C_`)^* M/V:_VKOB?\9_VD?AMIOB+7K.XM3]HM[C;ID*F?\`T>X[CD5^I-3444444444 M5#17Q=^UG^WII'PM_M+P=X(FBU7QB8;B">_MSFWTJ;&`,'_73^P_J17RK^S+ M^S9XD_;`\9:AXM\7:Y?'P_!/!]NU&YXGON,^1`>P]Z_43X8?"3PK\&O"<7A[ MPII<&G6()GEVKS/,1S-*>Y.!_D5V%SJ5O;"'SIXH&F_U7FG&37XZ?MD27ME^ MV#XRAN]8O='MK^X@M3J,YSBPG@MP1_UP!R*F\5_LL>#_`(/?&+PSHGCCXF:' M<^&K[R9Y9K.&X6&='\%:/;:)X>TNWTC2+%<6]E;0"""$?@*^ M!_VVOVY9A<:C\/OA[?"V^SFXL-=UDV_(.,>1;GU]Z\,_8P^`=E^T)\5S/XFU M:QN=(TG]_?:=<39N-6)[GVKW'X?_`+:6F:'\5KKX7O\`#GP[HW@.^UR?1@VD M'[.#`/W'V@C&)\]\#^0JQ^UC^Q+]BU/P;R444444 M44445PWQ7^&FD?&#X>ZQX4UEL:=JD&TS08S$<$B4'UKP/X;?L*Z1X9^&GC;X M>^(M?F\0>'=?O8+^!88?LUQ`8",?RA_*LSX9_P#!-GX;^`]<.L:Q>W_BN:WN M/M%A;7`^SPVX\W=R(<>:>G7^M.T']@M%^.\OQ(\7^,I/%]N;Z>_&G7]F,3?\ M^PF]?([<=NU?8%%345#4U%%%%%%%0_9QZU@>*_`WAWQII%QIWB#1++6=.N.) MK>^MA.)1]#7F/B/]BWX+^)DMS-\.](M&@Z#3E-A_Z(VUR&H_\$[/@KJ.EW-O M#H-[I]Q,/^0A;:I<"YB/LLS3?^ M"?/C+P!+/J'@3XVZMHMS!Q96TUL6MQ#Z<3UG-\'_`-LKP=XB$VF_$&+Q%;Q0 M;3//?P>1*&['6"1YHN;2R@F@^F16S/^U? M^T=\-_"=M>>+_@E]K@$_D3ZA`QA8>_D0?:#4=[_P4YL]%>:UU[X9ZWH=P.L% MU>D$_P#?Z!:^I_@9\9-*^/7PYT_Q9ID4MM#<9AFMIQ\T,PQD?K^M>DT44444 M444444444444444444444444445#4U%%%%?GO^TAXYT3PU^VC\.-3T73/LVH M66HPV&MWM_I<\)G#&"#(N",3X@N>!ST'6OT(HHHHHHHHJ&IJ************ M***********AJ:BBBBBBBBBBBBBBBBH:FHHHHHHJ&BBBOPL\<_$_Q7\5]"TO_!WPYFBOO$1M_W^OPD&"PZ$$/Y5^%O#6D_:+>VN8/ M^/\`N/\`EWM_^O>O8/\`@FZ?!NF?&6YU#Q#K?V'Q2/\`0-"TT?ZB?SQFXQZG M.*S_`(9_LI^-]2_:6MQ=^!M4?PC!XCN'FNM6@\FV:V\^X.1CK7ZU6_0T5-4- M34444444444445#14U%0U-1111111111111114-4-;\/Z9KEKY&IV%OJ-M_S MRN8/.'ZYJS:6T&G6X@MX8H((AQ#".GX5R6U]XDO?[/T^`1&7SI_2NXHHHHHHKX"_;3U. M+1/VF/@W?/KD^H06VKP3W&CX\_[%_I%O\V.V:^_:*******************A MJ:BBBBBBBBBBBBBBBH:FHJ&IJ***AJ:BBBBBBBBBBBBBBBH:R/%/BC2/!6AW M.M:U?6^G:39+NGN;CI"/K7Y*_M'>&OAA\3]5N/$GP/-]=ZC;SW']K>'[>PGR M;?\`Z"$'_3"OMS_@G+_8EQ^S)I`TNR%O/#>SB]F,_G_:+G/,^??(_*OJNH:F MHHHHHHHK(U+4[+0[":]O;F"QM(%S-/<3^3#%]2>*_+?]M']MR?XPQ:CX'$_ MZ-X',P6XU`$^?JH]A_S[_P#UJ[+]B[]A";6YH?%?Q6T3&CS6\%QI6CW$_P#K MN/\`EXMZ_28KY"XB'X5/4->1_M/?#)?BI\"_&&A6^G#4-1GLFGL8,];B'YH/ MUK\X/V9?V&?$WQ+\?LWCO0-5\*^%M/\`L]S%H;X3SZA<3@3W MP'8?\^_4TO[('[$1^/FD?$7XFO;[1_!_G&"WMK?(GO\8[XX@YK`^*NB7$_[ M77Q;T&R\2W'A^"_@O[:XU*XGG^S_`&?^S_M'V>X_Z=_^7>O,OV:_ACJ'Q6^, MGAC1+!;Z%EO8+F:_TZ#'V&#_`)[U^YM%%35#4U%%%%%%%%%%%%%%?"?[?/A3 MXO#7AXQ\/>+3X>\#Z3I^3#;:V=/G-Q]>E?"/A?XY?$?PMXLMO$FF^,M;;Q!. M1!_:%U/]H\^`'(@N/QK]0_VPOB]XC^#G[/@U>QU*TT?QG>306Z_9\3#SC_KQ M;B;@@(YP,?;]1@_?_`)6_%?H)^RM\?P_;::OB&;4 M8)]<^PX^T&?[1;_9_/QV^O-?H[1114-34444444444444444444444445RGA MKQWX<\5:IK6FZ'KFFZO>Z1,+:^M[6<336TV.DP!R/QKJZ*********AJ:H:F MHHJ&IJ*************AKRC]J?PGK'C;X`^.="\/6']HZQJ&GFWAMO\`GL>. M*_+O]C"_U?PO^U?X0TT6;)W.FWT-_/]G(_P"?@C_Y'KW;]A74;B[_`&R/ MBH+$F?1S_:'G&XG\C!_M#_GWK]):FJ&IJ*****Y+XB?$?0_AAX2U'Q'X@O8; M73;&'SV8]<>U?DU^TG^U-XL_:=\5?V3HT-]#X9,_V>R\/V__`"\'_IX])_;M M7TW^R#^P3I6CV.C^,?B-9B_UF>$7$'A^Y@'V>#!_<3SCO<8S7WC111165XBU MZQ\.:1&9Y[;X?P@;A M/"8)[ZX_Z;_].]=3^QA^PT/B8+?QGX\M[BV\/03YM]&N+?R+B_\`^OC_`*8> MU?I_::=#IEI#;6\,=O;PQ>5%!$,`#T'Y5\#_`+2O[%WC'Q[^TA!XL\/Z18ZA MX6U.:W.H+->F#@?\?!G`ZCTQ7U[\)O@1X'^!NGW-OX-T*#2!/S/.,RSS_4UZ M)4U%%%%%%%%%%%%%%%%%%?%_[:_Q!^&?Q`O]/^#WB;QG?>%M6,T.H?;;:W^T M6$)!X@OCG&#Z>XYK\_/CE\,?#GPRUNVLO#/C_3/B#I]Q`;CS[#&;?_KXP37U MU^TSXGTC]H#]FKX8S:CX@TSPAXWN1;:G_8VL3C3DN&,+0-<`9SY.3F$XYR.O M./FWXQ?L@^/_`('>";/Q1XG&C"QNYQ;M;V%VTT\&?0D8/X9K[M_X)S_%:]\> M?!&;1M4,TUQX9N?LW]HW$N3<1'$H;]<5]?44444444444444444444444444 M444444444444444444444444444445\!?MR^%/\`A'/B_P##7Q'#I6BV[7VO M6['4H+#D`_G7RK\,_@%XD^.G@/Q3XET6X^T>*? M#6K6_P!ON=1O_L]O]G^S_P#'Q]H_Z=_L]?2'_!+[1G\1^./B'XZU&_FN-:AM MX+:=KDX$YN)_/GN/S@%?I/4-35#14U%0UY+\?_VC/"GP!\+7.JZU>0W%_C%C MH\!_TBXG]`*_*;XF?$?QC^UQ\7[>_P#["FO]7GS!8Z-IW[\6]OW-?H-^R=^Q M/I'[/J_VWK<]GK_C&XMX,3O;?+IAQ^_6#ZD_Z[@G'IU^LZ**AHK.UK7-/\-: M3>:KJ%S#:V-E"9Y[B;@10@9)_0U^7_[;/[;MO\8;";P-X+4?\(CM$]QJ74W_ M`/T[>1U-'[%W[$B_%:8^+/B'I=[;^#K.E7J*FJ&BIJ***************AJ:OD+]I?]@O2O MC1XFOO%.BZT?#_B"XAVSP20[K:]F[%L\_P`Z\%\`?\$N_%=]K)C\:ZWIEAX= M'4:+.)KF?_OJW`KU+]NG]C6_^*!M_&/@R$W6LV-E#I\WA^#@7%OD\?A_2OF, M?L[_`+1OCVQT+P%J6D>(?^$?L1_H<.KS>1808]<=:_0W]DC]GT_L]_#+^P[V M:SGUZ[F-S?W-B,!F/3K^/YU[I111111111111114-3444444444444444444 M44444444444445YUXW\3KI'C/P+I[ZS#I0U74YX!8SQISP3Z[;VT.G9S#;\P_Z1!_TW]/QK[H MJ:BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBH:*FHHHHHHHHHH MHHHHKQ[]H;X+>#OCMX'.B^+)HM/6`_:+'4!<"">RG[,#FOSOL/A=\8_V4M;\ M8:'IGAVY\4>#-=T2>WOM1T6`RZ?<0""X_?F?_EA/!^M>[_\`!)ZU@/@3QS-Y M,HN/M]O`;@]\05]Z4445-14-?$_[3O\`P4'L?AU=WGAKX?"RU_5Y;$_\3VWF M6XMK&?H,]?/_``KX\^&7P!^*W[8'BN;6Y9IYUX6^\4^(%_T8?]>^/]>*_4?] MG_\`9Z\-?L_>"[?1=%AAN+['^FZN;=8;B_/]Z?&CZ?`/WMS?SB"!??)XK\K?VOOVWM7^,6J:MX4\*7TNG>`0OV8E1^_U M8]\>U6?V,/V,]0^+'B*#Q+XSTF^T[P/;_P"D6XN!Y']K?],,=[>OUA_Y8T5- M114-344444444444444454@NX)YYX8B"83B48[T_F>7L8<58HHHHHHHHHHHH MHHHHHHHHJAJ%Q-:6,UQ%`UU/%$2((O\`EJ?05X#^Q_\`&[Q3\>M%\4:_K^AV M&BZ7!>BTT_["/W/YFOHVBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBL M?5_#FE:^;9M1L;>_-E.+BW\^/=Y,O9A^=;%%%%%%%?`/[>FEWZ?$#X>S7'CM M[JWGU^W\CP_#!!G2N.;GTG^D_'I7WI;@P01"6;SC_>]:M444444444444444 M44444445#4U%%%%%%%%%%%%%%%%%%%0T45-1111111111114-35^9'_!3OP9 MXZA\5Z?KVJ7D^K?#^X_T>RM;>#-OI-S@9^T'OY_3/M7R9X-\1_$'PGX:\0ZO MX1U76].\/6WV?3]5_LZ?_1Q]H_Y^*_1K_@EOI]Q;?`?69I3+Y$^O3F$'T^SV M]?9535#14U_BT[1K(9GN&[5^7/[3W[=7BKXP7$^B M>$IIO"WA`?:+>8V\W^D7O&,3>@XKN_V6/^">^J:U?V_B3XGPKIVCV[>?#X=S M_P`?WMCV,/D6]A;0^3!"H]!VK?HHHHK` M\9>-=%^'_AS4-?\`$-_!I6CV,)GN+FX.`HK\G/VQ/VK[C]HSQ7;:'H%O+<^" MK*8?V7`L'^D7]Q_SW'MZ5U'A'_@F-\0->\)ZA?:YK>F^'=8\GSK'1POVCSSC M/[^?K#^&:N2_L$_M%>'X/L^E>*[2XMX/^/>WL/$5S;?S%=/H/PK_`&U?#0MC M:>)I6MH(`OV>XU6WN?\`5'`_U_K7(7_[2_[76@23&[L/$,"03?OC/X2XQ[?Z M/747_P#P4S^(/A#9I_B#X<:;IVKJ,;;JXN+'/U@.3^M=SX2_X*G^'-3D(\2^ M#;_18##F"?1[G^T`WL=#\1O#L0_??\?%^(.A]Z]*TWQ=HNM6%OJ%CJEG?!/!.,2CU%:TEQ%;C]X0#[TZBBBIJ*******^2OVKOVW+#X"ZK;^&_#U MC!XB\6G#7MO,2L%E!CJ2,5QOC_\`X*9:-X1N+&PT_P`$WNIZA]BAN-3MKV\:9J5AK>GPWVG3PW-M./W- MQ!R"*NT5-111111111111111116?J6J6^D6$]]?316EK;Q&::>8\1#U/MUKY MZ_8Q^%GA/X<>#O$5[X1\5Q>,M.UW5IKC^T+;'D0>4=H@!]N:^E:********* M*****************************_.K]N:RL-(^*OAR\_X5];Z*LVNZ?-?> M,KBX@/\`:P'_`"[>0>3]:_16BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB MBBBBBBBH:**FHHHHHHHHJ&IJ*****PO%7A/2O&F@ZAH6N6,.HZ1?P>1<6TXR M)AZ&OR3_`&D_V2/&?[/MOXJU6&]A7X?WU\+>$6U\?/G@_P"7>WG@QS^%??\` M^P]X3A$?LQ>`CY-O;3:A;?VC<>1TF,_3'U'D_E7T)4U0U-7S5^T;^VAX.^` MD,EC$/\`A*/%+0S"'3=/F!,,P'2X/_+`9]>>M?G7K.I?%S]MKX@W%]!8RZ_? MV$/[C3K?_1[:P@)_F2:^^/@%_P`$_P#P'\')8=7UJ)?&?B@?\O6HP_Z-;_\` M7"#M7U74U%%%0UPGQ4^,/A?X*^'EUWQ9JRZ=II86\.093++Z#'>OR0^-WQK\ M<_M=?$F"Q@@O=0MO/N#H7A[3X/\`4?7_`*>*^V_V*?V(H/A0D'C+QU%;W_C& M;!LKX-Q;:/\`$.W\0:1B!OLVM7%Q;^?. M._\`R\4ZW_9X_;#\`Z#!8Z+XT6ZM[<8AM].U[_Y(MZ33?BG^V5\.;Z:RU/PK M>^+`?N^?I7V@0_\`;Q;]:0_\%!_C-X!$X\:_#&,`3X^T7-C<6/DCWSFK/A[_ M`(*N7!U2`:U\/X+;3S_KO[/U47%P*]4T?_@J#$[R#_3K'Q'IT__`#[BP,Y_ M,5UG@O\`;_\`@KXTU461\1S:1<&7[/$=9M&MAGVEZ?K7IGA?]H/X<>--:M=' MT+QEI6I:E>PRSP007')4$9_K7I'VF'RO]:,>N:=117)_$OQ#)X'^'GBC6X#^ M_P!*TNZU&']T9?\`4P%NG?D5^(?B_P".OB?XUO\`^V=0\-Z3<:OF MY_TB<7'_`"\7%O\`]L,?^!-?.OQ$^P>/_%OCKQ9I>NP?9Y]6N-0@T[6?]'U& MXM[BX_\``>O>?V4/"3?&+X,_&#PW8^&O#W_"4P:5`+'61I(\_P#T@'_1S<0? M]>_;^5?+FH^"?$NB7%Q87NA:KIUQ!_K[:YL+C_EWKZ*_8P_:=G^!TWB$ZUJT MP\$:=8&Y3P^1FXFN;B>`9MQ^)KS[XU?M=?$+XT:WJ][/K]_I'AZ88@\/V%_] MG@AM_4_\_%?9GQ`_;3UOX3ZO\-OA_P"%M`;QSXAGTJPN-5&HS!;F">#J+@>]?:E%%% M%%%%%%%%%%%%%?._[=O]O?\`#,OB?^R/(\C]S_:OVCI_9^?W_P"./ZUYW_P3 M+TVSM_@GJU];W%[<7%[JI>=;B+$$1'&(/;G^5?9E%%%%%%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%?G5^W=H?P]'QD\%P6%E3]I@T6W#>1T^Z.GZ5ZM4- M4M2U2QT.QN+^\GAL;:'F:XGX`_&OA;]I?_@HU8Z;8:OX:^&,$UUK"_Z/-XAN M%'V:W/K;_P#/P?\`&O!/V=_V(_&/[0KVWB+Q%<3Z+X.OY_M-QJ-P/^)A?_\` M7#_Y(K]0OAE\)_"?P>\-P:'X1TJWT;3ACY8!_K3ZFNOHHHJ:BO&_C_\`M%>$ MO@-X3U.^U/5;%]=BLFFL=&:8?:+V;I"!]2*_)'XI?%;QQ^U+\2+>:[MY]0OY M_P#1])T;3H/]1_TP@KW?]B3XF?!WX#SZ_KGCG5]5TSQR/]!-O<:5/]GL8!CS MQ;^0IX]^HP*_4C3M4@UK3[>^LR)[>>'SX3ZU=HJ:H:FHJ&BBIJ*AK!\;:[H? MASPQ?ZKXFGL[71[*'SY[F_QY"CU.?\\U^+?CSXM:[J7Q:\0ZMHFK?VU;W%_< M6]A_Q*;>XM[BW^T?Z/;_`&>XM_\`KWK[#^+WA3X)_!W]F_P?XB\:?"'2KGQ3 MKNGV\']GZ?\`\2^X%P;?SYQY_P#RPZ&OE7X>?$UXV^(=O\`8O@'?:UX>O[_ M`.SP:=IVK7_^C_\`;Q7NO[3G[+7P!^%6H`S>/-3$7FH6\YL-'AB_M>"">`9 M/&#/[=:Y+P+^PU8?&KX<#Q#\-OBA#K1L9C"+?6=)GT^W@N![=>]5OA[J/QZN M_B/K/PQ\*?&J#4=9`#$-JL]S!-CFX^SW$]OU'M7J?A?Q5^VO\-_])O\`09?% M>G10S_Z/J7V>?)[?\>_^D58O/V_OC)\.]/'_``F?P9N=/_?8^U7<5S8V^/J; M>K_@O_@J?HL]H1XH\%ZA8W7G8!TF87'[CU_?8KP;P/\`$;X-V_[26M>)+LZY MHG@;7K>XMO['^P@6X^T6_P#I,%QY$Y_(KF_T#XU2>$])_ MX^!IM_9Y'_;`W`'\J^R/@Q\!/`'@KX<^*]'^%7BB<7_B73U(US^T!<7$)\@^ M1/\`AYX/XU\QW'[#/[2\&CZQ9?\`"P["YMM7'DWUO_PDM_\`OQZ_\>]<9XS_ M`.":GQ4T.'3ET5])\1GR/].%M?\`V?\`TC./^7C_`*8<5X+XA^''Q"M_L^A: MIX,URW_LG[1;V]O_`&#YT74 MX<"PF\CYC^`S7CW[&_A.'XQ?MF^(O&=G%JEKH&DWVH:Q`W3_`(^+C_1X)_\` MR8-?J=11111111111111117E?[1'ASQ[XL^%&K:3\/M5M]%\4W`B%O=3=`-W M[T?E6%^RSX6^)'@SX='2?B.=*-_;SXL3IN<_9\'_`%W;->XT444444444444 M44444444444444444444444445\;?\%'+BWTWPS\--0E,)GL?%=M<#,.:^PZ MFHHHHHHHHHHHHHHHHHHJ&IJ********Y[5O#S:EK.G:JNI:G;?8P2+&WN/*@ MG/\`TV7'-=#111111111111111111111111111111117Q'_P5$\<66B_!G2O M#)(^T:W?B8@38_39>;YWD#R>!GO@& MNSKQ;XY?M:?#[]GRXAL?$=Y<3:Q-"9UT[3H?/N"/7%?F=\4_B/XZ_;*^)%L+ M+PY/<@?ZCP_H_P#I'D?]/'_W17UY^S#_`,$]])\%&U\1_$Z"RUKQ%"?/M](5 M=UM8>W'^O^IXK[(11=J=114U%0UX!^TI^V'X5_9TTHQ3?\`$_\`%%P, M6^CVLPSG`YG/_+`=>HK\K_%NO^(?VE_C'X@UH06ZW^K&XU$FYG`M[*QA@Y)N M!@>1!"<^Y-?7'[`7BSX.>#-$U2739I=9^)_]D3ZA?&XL?(,,$&X^T:!?#-N3`83CZ5VM0T5-1111114-%>4?M+?"*;XV_!SQ#X.L[ MF"PU"^%O-;3W`S"LT,ZSC/?JO^<5\'6__!,KXNZ;?VU]I?B;PW;7,'D7-O/] MHN(#!<#K@?9Z]G_:;_9B^)/Q'^!/@&R:_B\5>-O#9N#>^3<"`7XG')'G])N. M_?/M7SK\&_V??VC?AA\0+*QTW3/$'A73%U:PN-1^SZ@/[.F_TCG/_/?@UX=\ M8]'\1V/Q7\41>)K*];7[G59S,T\&1&"6_N?]=<$`#SC]>3^=7M1T M^WU6QFLKV"&YMIX<303<@CWKD]3^"'P]UO2+C2KSP+X?N=/N!B:V.G0X/UXK MC[_]C/X*7B9_X5KH2-_TPM_)_E7@'[47['WPE^''P:\>^,=#T!=.U*"S@^R` MW$_D6\OGPX(Y]0OZURO_``38_9ZMS&?BW<7TT$\J^,[&]B/G:CITY'V;V(%O/G_Z]>,>(/\`@I#\ M-]8T.[T+Q9\/O$,ZW,'D7VBSVT$\&[O`>>?RK0^#O[=WP&\.:=?V&E^&Y?AI M89,YA@TG$$TQZX^S@@FOICX8?&;P?\:-#N=5\'ZY'K>GVTWV>9T@:$PGW$H! MKT6BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO MA'_@HAX<\.6OBCX8:U>K):WU[JXM[^Y6#S\V,/+9'X@_C7W14U%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?G#_`,%5 M-=L;S6_A]H9G_P")A;Q74\]MY&?]'G:`?^V]Q7V[XB\5>$O@Y\.&U6[FM]&\ M,:59`Q;<<0XXAAZ$]`/R_#X0^-G_``4[OM:CO],^'&B?V?930FW&MZQQ<03< MXG@M^^,UY;\#?V,/'W[06I+XBU:XN-&T"YN!//K.KJ6N+[.>8,?ZX<'D\5^E MWP+^`?A;]GWPP=$\,6\A:8^?>7]Q\T]XWJ37IU%%%%351U#48--LYKFXN(K> MWA'[V:;H!7Y[_M*?\%(I[6?4?#?PK6W\@P?9SXJG)_(%TO5[ M&_U`7)GN#_HQZ_\`/`=./:OE+]EBXN-._:$^&TT%E/J'D:[`/(MNU?IE^V#^ MRQJW[2&E>%[#1=+=#MM:T^"<7,,%ST$W/-<#X(_8^^%'PZ\8-XHT'PO\`9]6BF\Z%S/,5 MMCCGR1G_`!KVVBBBOCG_`(*9^.)O#GP)L=!L2,Z[J]O!<*L6<6\'[\_J(*\F M_8._:Z\+>`M!M?AMXD8:9`+BXN(=9NIK>"VA'IU_6OT!\)>.?#WC[3?M_AG7 M++6K#_GXL+@3C],T[0/$L'B2">:""^MVAFEAVWME-`>#[@<=.?Y5N5Q^N_"? MP9XMEGFUGPGHFLSW``FN-1TZ"COO\`A#/#=EH:W_E&6?M`:/XS\4?#C4 M-+^&NN6^C>,)C#+!:#'U M'(KJ[W]LKX^?#Y3-XU^`MPVG?\_.G>>/Y>?69IW_``4RU>RLO-\2_"G5;,_\ M_.G7#8_*:`5]G_#3QW:_%+P-I'BJSL+W3K748!/#:ZE!Y-Q$#V([5U]%%0?: M(?-QGYO6IZ****A^SCUJ/[(/^>TW_?RJ!NOL]X?M8$/[C_7YK9HHHHHHHHHH MHHHHHHHHHHJ&IJ***************^/O^"ADYN)X(IXI9[VF M\Y:_*;_@HY\2?#GC?XZ6L&C+]ONM"L/[/OY_^7>;_EXQ7FEEI'Q6_;*^)!NH MH)_$6H#_`$?[0!Y&GZ3;^P_Y85^@G[._[`'@;X0"WU?Q%!#XN\3B&`[M2@$\ M%C,.IMP1P,U]7T444445POQ*^+?A3X1Z+/JOB;6K/3K:&W\_R?/'VB;`_P"6 M,!.3^%?D_P#M"_M<^.?V@]VDWF=%\.DY_L73V)\__KO_`,]Q[4:+^QIXYNO@ MEK7Q.UHP>';#1[>>YAT768/](OK>#./^O?I6O^T?\<-)^,7[./PG2RTO2_#N MH:5>WVFW^FZ?!]G%OB"#_2+>W_YX+]+T[7?[.\.G2KBVU M8_;I\"XG!\@F#_EN!/;DYK[-_8S_`&)_^%(WEUXF\8RV6I>+QFVLA92F6"Q@ M&/[P_P!=[U]C445#4U5OM<'G>3YL7VCT[U9HHJK<3FW$0$,LY/=1T^M25^;/ M[7/C[XY_"G75\#6/C'7/$6G7T%OJ*ZS8:/\`9KD?Z1C[/Y\'2O%/!_[77QT^ M"VJXO]=U6Y%Q_P`P[Q5!<7'_`*4?Z17ZL_!CXM:5\:?AQH_C'1H)K?3]07(@ MN,!HL=<_I6YXS\:Z3X`\-W^O>(+V#3M&L(//N+FX/`%?._@S_@H5\,O'WCS0 M/#6EV7B`W^L7W]GV\\^GE8,_7/\`2OJJH:FJ&BIJAHHKX,_X*M7`_P"$1^'L M`G_T@W]Q_H__`&[U^>W_``A/B6YTBWU:#0M5N=.N/]1J-O87'V>OIS_@F3J- M[;_M%W-C'<3"UFT*X,]NW28C[/@U^L%%%34445A3^&=+U#5;#5;BTAFU&P$Q MM+EE_>P";[V/3(K=HJK=VD%S;-#-")H2/]5BK5%%%?!7Q;_84^(&H^/=9\<^ M"_B,;+5[B_FOU@N3-;B'/83@FLG5O`/[;.C3?8[?Q7_;-O%_R\Z?>V`)_P#` MBWK,\/\`Q0_;(^'+2_VKX4N_%<-E,1*;BQ\\W`]OL_\`2OM3X%>+?&'C;P+! MJWCOPO\`\(=KWGS`Z9NSMAS\I_E^5>E45P/Q+^-O@CX.PVTWB_Q%;:(MZ<0& MY/7Z5H?#OXI>%OBOI`U;PGK=MK6G_P!^V.0*ZC[./6F6UK#;VPAB`$([9JS1 M1111111111111111111111111117DWQJ\4?$'PWJ'@T>#/#EMK5ALTV<_A7V M#4U%%%%?&7_!0[1=8\2P?";2=-O?LHU#Q(L`'G8VSX_T>;WP<_G7V%;`VT$, M$/)\@^_3.:Z"BBBBBBBBBBBBBBBBBH:^8?VC/VUO!GP MCT;5-+TO4XM>\6[1"-+L+C!M\@_OFFQVX_+\_@/6_P!I?XV?&NYN/#NC:KK= MQI]Z(!_8^C6_^D@=_P#CWM_8?E7N/[/?_!-.Z\1Z):ZW\3;R^\/Y&8?#^GG$ MP'_3P<=?:OO?X??"SPG\*-".D>$]$LM%L&_UJV\('FG'64XSW[UV5%%OT-%% M%%?+7[3'[<_A;X'/,_$$_)N3_Q[6__`,CU^@?[('[#EA\*8/[=^(&EZ7K'C`7'VBR('GP6'3D9 M'^N]Q^%>\?M$^!+'Q[\&?%VGWL$'VAM+N!#(%GL-2TGQ+_H^HZ><3BW^S6_[@GL*_2+P+\-O#7PYT#7H-%%%0U\[_M$?%2]E^#GB'_`(51XATK6/&D*?N8-&O(+FZBP<3> M3%W('\Z_)OXA>/?%?CW71?>+=5U76=8M_P#1@-0_X^+>OU(_8N\6>&O`/['? MA/5]4UHZ=I,`N1-=ZQ^XQ-]IFSG_`#VKX0_:_P#VI[[]HOQE]FL3/;^#=)YL M+?M/_P!/$_H*XC]F_P`.7'C7X\>!=)@G@M_/U:WN/M%Q!]H_X]_](K]RJFHJ MM.\5O#^^EP/4U5L-:L-5DF%I>07/D]1#-G'UQ6G114-?FC_P51\0S3?$/P?H M8G_<66DSW+0>IGG`S_Y+"L+]E3]K_P`*>!/A=J_PX^(]A)_8`AGMX+G2K>M?6O[&_P@^%7A+PC/XL^&][/X@BUS+?VA?L3<0#'^H`ZP_3_ M`.M7TM114U0U-111111114-3444445Y!\=?V:/!W[0UE8#Q"+ZVO[#FVU'3I M_(N(/QK)^`G[)GA/]G?4-4OM`U/6KJYU2(13C4;PO;<="(>`#7NM%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%?.?[=]]"X^RCF*#SQEJH M_L!:;I=K^S=H-[9Z*-)GN9YS?28P;Z?SS_I'XU]-44445@ZMI=]'+K1-:MEO\`3KU<3P'I**;=^%M,NGA\^RAN!;"+R+>89BAQ MP,#_`#VKH************************************AJ:BBBBBBBBBBBB MBBBBBBBBOF/XL_MV_#+X6W&IZ?%?S^(O$%@)E6RTZ+=";@?\L#/C`.?2OBWQ MU^W?\9?C$USI?A:`^'8+@>?]F\.PFXU#[/\`]=^E=?\``W_@FGKOBF`7WQ"O M9_"NG'R#!I^GD3SS`=S_`,^]?>WPL^"O@?X):0UCX1T.ST<;?W]R%'VB;_$SXY>!_@Y8+/XN\16.CF8?N+=F_TB;UQ#UK\\?C'_ M`,%&_'/CVW&D^"K$^#=/$\_GW4'^D7-Q;C_TGI?V>/\`@G9KOQ/\-Z-XC\47 MS>%-&GFR=&%O_I$]O_[0K]#_`(0?!7PI\#?#<^B>$-+_`+-TZ>?[1,K3&;)_ M&O1JRM;T2UU_2;W3KZ$7%K>0^3-#V((KS3]GC]F_P[^S5H.J:5H%]J5]#?W' MVF>?4I]QSCM7L%%%%%%%0U-1114%P!/F'UZU^0/CO]EWXO\`[.'Q2T[5O".D MZKK7V"_N+C0M9T:P_M#_`,"+>N-^(?AKXZ_%GQ*-=\7>$_&.LZA_Q[6__$AN M+?\`]MZ^\8/V.-1\1_L>^%/A;K>LG3M>TBZ.JFZM_P!_;_:/.N&\GZ?Z01]: M^,OB#^P;\4_AUX9UW7;VSTJ_TC30;'V$_?Z5^S7@_3-4T/PAHUCK>J?VWJMO;0P7&H;!^_F MP`9OQZUU%?)?_!1#XHZ_\.?A%I,?A_4K[1M1U?55M3>Z;<>1.D/.<'\1^5?- MW[6$7CK7?V5O@[XIUOQ'<:SI\UA]GU:W,_\`HUS#IM`L;; M2?$MOIXOX,_\O$Y\FX^SSC_GW//O7V14U%?E3_P4"\)3:W^UQHNE#IK%AI\$ M'V;_`(^.;CR*Z'XJ?\$P+[PAX9O]5\*>);WQ1=V-O^XT46.9YS]?M%>@_P#! M/_X&_%;X;R-JVMS'P]X.U7SS<>'=1@/V^>;_`)87'_3#CM7VA_PEVAS>)IO# M8U2R/B"*#[0=/6;]^(/7'6L7QS\:O`GPOU*PT_Q1XJTS1;^^XM[:ZG`FG^@K MM?M4/G^1YP\['3O5FBBH:*FHHHHHHHHHHHHKPSXL?M<_#GX)>,+?PWXNO[ZQ MU.>Q^W;HK&>>#;]0*Z'X+?M#>!_CYI]_<>$M0FN#8G;/;W$!@FASZBO4J*** M***************************\^^,GA[_A*OA5XHTHZ(/$9N+"98M(^T&W M^T'L/.[="_A'X8T,:'+X<%M8A3H\]R;DVY_N^=W_P#KUZ311111 M7R+_`,%"O#D&N>%OAP?(GN;AO%EM806MO_RW-QP1^E?75%%%%%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%%0U-4-%%3444444445#14U%%8/B7Q7H_A+2I]3U MO4[/2=.@YFN;J;R0OXFOEGXN_P#!2/X?>#8#!X.@G\>:CTQ:MY%M$/>6#4/ MB1KIG`'_`"!](&`/K/UK[>\$_#+PG\-[">Q\+^'M,\/VTY\V:#3H!`&/KQ77 MT44445#5.[U"#3K8SW$T4%O",&>);&VUG5I_P#2-9\0S_Z/_P!O M%Q7Z2_LG_"?X$_#"Q?5=$\8Z#XI\003S6\NM7&H0$P#^*W@](/3_`#CZ[ANX M)Q^YEB;Z4^IJAHHHJ:BBBBH:*FHHJ&IJAHIKVXFMS$>E<[X9\`>&_`<$\'AS M0M,\/0SS&:>#3+.*W$Y]PO%=517D_P`>_@#X:_:%\'-H?B'-M<0'S[+4+<`7 M%DWJ*\O?]ASP[/\`!.7X=:MXG\0:OIXOX[^QNKJ?/]GS#/-O%T`/G3<>_M6) M\/O^";7PY\$>*]/UZ]U35/%5O8#_`$?3]1\DVX_#%2K^Q]XIUG]J2Q^*'B3Q M38ZOH]A?M<:?IT-K]GGA@S_H\!([0=??-?7%%%?E-^U-I_C+Q5^W4-)\/Q+; M^(5FT\:&T_[\6^/WYN/:O;;(?MQ>&O/A/_"/>*\?\O$_V'^GV>N=\9_M>X_L_Q#J'G_9[>?_EX_P"N_P#H]Q7"^(?%E_XU\2W&N^(9Y]:U"_G_`-/N M+B>O:OC'\?\`2S^TI;_$KXL06]Q!J'V;6#<0>0,_O[?_KAC'_UZ_2SP M=^UA\*_&-O8&'QAI=E?SV]O/]EO[@0-"9^D))QSQ_*NUO_BSX-TR#SKWQ9H5 MO;^=]G%Q/J<"CSO3KC/^<5UEK?P75N9X)HIX>S0G-2T44445-111111117Q3 M^W1^R9XJ^.WB#0/%'@R>&;4[:$:=)-# M^/'CG3YX9K6PL=*^S:K;'_EA![:#[!;V%_8>)H=:M_^/B$@W`/D M>IXK[U@_X]X?^6W^U5FBBBBBBBBH:FHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ& MIJ***AHJ:BBBBBBH:Y/QG\4?"GPZBGG\2^(--T>."#S2+F<"4#UQUKXR^.G_ M``4OMM"U0Z;\+["WUEC_`,?&M:N)Q;G_`*X0]3_GBOE[P_X=^.G[6_B&PAOI MO$GB.TEF^T_VA?J8-/MP/0#]P?H*^QOA'_P30\*^#-<;5?&FJ_\`"8?N-&T]@T_3_`);^G$_/7G)_SZUQUQ_P2 MV^$D]O+Y6H^)X+D\0S_;8)C"?;,%<3HG_!+_`%7PGX@&J^'?B_<:+Y MMM(_?P?C]HK+M?V;C^SM(L-0X_[86]3>'_V_OC-\,-'G'Q"^'%UK`MSY!U'4+*X MT?/X_9_(KLO#W_!5CPWUG_`.6(T^_M[G/Y^17<>#?^"E_PD\0Q M7`UG^V?"S#H=1L#-YP_[89KM=)_;T^!^L:I9V5MXS6*YN?W,`N;"YAMV/H)C M#@?G7K]O\4_!EU]E-OXKT2?[;_Q[^3J$+>?].:WM/U&RU2#S[*XAN+8_\MH) MLC]*TJ*AHJ:H:FHJ&BBIJ******AHHHHK\;;KXY7VB_M8:U\1_&EB;_6-)OM M0%OHT_&+B#[1;V]N*^NOAY_P4]\$:UI1/C71+WP_K'G$?9K`?;H?([3[AT'X M5]3Z_HVB?&GX9ZAIQF%QH'B;2F@$\!ZVT\/7\C7S;^SO^PG#\-])\3Z)X^U+ M3?'?AZ_N+>>QT:6W_P!'@FA&/M!_Z;&M;_AVM\%P+\FQUR87'^HSJA_T?_KA M_=_&N,NO^"9GA6Y^)L&L+J8@\$@X'AN"!A/_`*C'_'SY_P#2NB\2?\$S/A/J M&GS?V7-K?A^Y_P"65PM\;DK^$X-<%K'_``2AT(C_`(DOQ!OK8_\`41L+>XKF M=%_X)O\`Q.\$P?;O#'Q(LM,UB#_2(+?3Q/;_`.D>1C_7]:L:-\,/VSOAD98] M'UR768)CY\IDU2WOB"?3[37,^(?CW^U[\-M0_P"*@L-SOO/_P!1FS?\%2_A@H_=>'?%;?\`;O;_`/R1706O_!27X(W' MD_\`$TUJV)Z_:-(G_=?7BO3_``[^U9$/$MO<"R^).B?Z/\`ZXW%Q]FQ_P!_ M\5W&@^/_``OXMFE@T7Q'I6LS1?O673KZ&X('X$_Y[UT=3444445^8_[:/[3G MQ3^'7[0/B?PQX?\`%,VD:);65O#;VT5O`V&G@SGGGK6_^PO^U'XP\:_%34/" M?C"^G\1'5;#)'3]_.><"OT9HHHHHHHHHHHHHHHHHHHJ M&IJ*****************^.?V]O!N@-8^!/%&STZ"&&$64$40`@&/W0]/YU?HHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHHHHJ&IJ*AJ:H:*FHHHHJ&OGCXG?MO?![X8"YA?Q,?$&I MP+M^P>'Q]I./KD0_K7R9\4O^"F/C'Q'<3V7@;0H/#]C/#Y,%S<_O[_/KCI7) M>#?V._C-^T-<:-XS\1:A!]GU:#S_`.V=9O\`[1>^UD_$UJ!$/D'6;<&"#'I!T_.OJFTM(+:V6&&$0P@?ZK%6J**AJ:BBH:X M7XK?&#PE$/#AUSQ9JT&G6V"(1P9ISCI",\GFOS?^+7_``41^)/Q&OCI/@6$ M^#]/N&\BWM[`"XU&;_/_`$[\UXMX%^'.E3^)]7M_B3K=QX5U"$^?!HUQ!/\` MVAJMQC_4'_GW^T?]/'K6?H_@DZ)\2O#UA\2-!U3PIX?O[ZW\^VN8/L_^C_:/ M^7?[17[D:<8#:VYBE%Q`1^YFZU;HHJ:H:J7%K!=VL\$\(N(".8)A7)W/P.^' MUU;?9Y_`GAN>V_YX?V3!_A7+7O[(?P;U.3SI_AOX=W^L-@(/Y5YU.?M!_L`?"CX5?"O7_%-O?\`C!KFR&^WM[?R M+[SICT_X^T6_VC_1_^ M/>OL33?V:?VK/"UEJ`'Q1MM'L%_U'VCQ+.?.N#/_`->]=3;:#^VQI_AVWDTS MQEHNM06T'6"2QGGG_'[-BN,D^/W[6?PZEMKW4M._X2O3OM`YT_2H-1@)%OG[ M.38ZKX>N+C]R)]8LC;V\1]#,>*] MHM_C[\,;NX\B'X@^%IY_3^U[?/\`.KFB_&'P+X@AGEL/&6@7,$,I@)@U&%@# MZ=:[/_EC114U%%%%%0T5-4-%)I_C)^QG\2/@M?P6\U@?$6G7MS]EL=1T>V,_\`X$9_ MU%?K5$/AOI7P=^'ND>$]'\T:=I<&U3-UKL**FHHJ&BBOG3]O/['/^R]XPGG MGFMQ$(&BN;>#SR#YX'2OR&T[3;_4K^WL-+@^TZC<3_9["V_Y^+BOKWXJ_%CX M)_"_Q;HWAJR^#?A;Q5J-N8+?Q+J*VX^SP3_Z/]H%O7EGQ2^+/P:UK5;>#PE\ M&KX(/^/FXU:>WN)Z^I/#W_!/[X0?'+PAH'C/P7J'B'PMI.JVXN8;:?-QU M]I\FJGB3_@E1:(EN?#WCRYA/_+9;ZR'/_?G%<3I?[!/[1/@+5)SX1\9V-G;D M9,]AKT]L9OK_`*/7:ZU+^VM\-=+BU2:^M/&%I'>)OA"_]H#N[W-DW_?E MKXT+Q5!. M>QM[?_Y(KU30OVTO@IJJ;1\0;"`&'S_^)C#/:X'K^_`KS;XM:!^S;^U$&U6Z M\E6J******^7?V^+N?3OA;X-GL[X::\/C/3S]J'_++B?FO MJ*BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBH:FHHHHHJ&BIJAHJ:H:FKS/X MA?'OP%\);)9?$WBJRTUQ+Y(@+?:)\^GDPY;]*^8/B-_P5'\-:/,(/!7A2^\0 MD?\`+UJ$XL+?]:^4?$?QB^./[7&K:OH6EC4]7TZ:?SIO#NC<6]O;GM/^G_'Q M7M7PI_X)AZ]KVC0W_COQ$?#[3+G^SM/@\Z>#VW'BOLOXX@'M4U%%0T4445D^(?$>E>$=)N-4UJ^ M@T_3K>+,UQ<2X"BOA3XW_P#!3/2K/3?[/^%=O-J-_<#;_;&HPF&"`8Q^YA/+ M?C^M?)VG?![XH?'YO$/Q`U2&]^P06]QJ.K>(=1@_T?\`X]_M'^C_`/W/57]G MSXT:K^SKXB/C&'P9I?B('_B7&YU#_EA_U[W'_+O5#]H[Q%I_C/XW^,?$=A// M<:;JL_\`:%N/(_Y[V]O7UW\)?V-(?VC/V<_AQ<:UJWB'PKJ&D"X@`N!Y_G0> M>>88+C_CW''I7WKX5\-V'@OPSI.@Z%`+72M-@AM[>$^++[PQ M\%/#NDW&KZOJUQ!J%P(,`#!/D0?CUKI_&&E7G[)'[!-UH%Y/$/$4T$VG!K8\ M13W\YZ>WS&N7_8@^+?@_]GKX!Z;!XYURW\/S^*]=N;G2[6Y/_+#B`3_]>?_M;^&]#\ M$_'SQ1H6@:5H<%ABW^PP:+-Y_D?AVN*^H_A]_P`$YO`GQ.^$'AK7!-XC\&>( M=4T^WN9[>Y\B<0?]L,8I^G?\$HM)N="MY[WQU,M/B4--;06\"PXQ_RPG@YS]:N-^VM\<]&L#>Z MK\`KZWTZ#F>X,%_!_P"V]0>%?^"FXMKV&W\>^`=1\/V]R.-0TZX$N/I!,`:[ MNW_X*9_"*XDXB\2>1_SV^P+M_/SJWO"W_!0SX->(M4-A+JU]X>&.)]:L3;P? MGFNHN/VTO@E;WOV<_$73!<>F)O\`"O2_`WQ&\*_$K0HM5\+Z[8ZWIQ'%Q8S9 M6NFHHHHK`\<>([;P5X1U?7+V>&VM["VFG,T_1<)-6\-W_`/:VB7]] MHNH_]!'3I_L]>D_#/]I;XKVWQ8T[7(/&=]J/B"_OK>VGMM0O\6]]_P!.]Q_R M[V]?MG_RQH_Y;45-11117!?&3X;+\5_AKK7@Z75[C1EU:W^S?;[4_OQ]*^+M M8_8$^*WAK3[[PUX&^)[)X/N;>;.G7%[;&:X/B?QQO` MAQ9_V+"+;;/ZUV!_X)<>"%\*ZA8-XIUFYU:>;[3#K4\4!:W/L,"=)\`>$[#PYH%DNGZ/80>1;VX["N MCHHHHKDM6^'/A/Q+.+C4?"FBZC/_`,][S3X)_P"8S7"ZC^R)\&]8OIKV^^'V MB/=3?>8IUKE=8_8'^"NHZ2;"+PE_8_I=:;?3B?\`F:\XUO\`X):?#>>P_P") M5XB\26&H_P#/Q//;S_SMZWOV7OV$H/V>O'7_``EDWBHZSJ/V>:W^S6]B+>WY M_&OKJBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO/OC-X:'BSX::[I?]@Q^*6N+< MB'3K@0X/U\_Y?SKN_P#EC4U%%%%%?)G_``4C?[/^SI#/_P`\M>MV_2:OI+PI M'Y/AK21Y]Y.LW'7U]R:Z&H:FHHHJ&BIJ*AJ:H:*FHHHHH MHHHHHHHHHHHHHHJ&IJAJ:BBBBH:*FJ&N*^(OQB\&_":QMKCQ=XCL=%M[C_4_ M:3_KOI7R3\1/^"I7AS3H#!X+\*WVM3_\_&L?Z-;UX5XI_;P^-GQA:#2O"UO_ M`&+=0\FW\*V-Q<7,]8OPM_8D^*OQZ^T^*]4N+?PY!?7T]Q/?^(?/_M&XN"<3 MW'V?W/%?7OPJ_P"";7PX\&SP7WB>>^\=:@(=IM]1_>_%CXU^#?@CH']K>+M:@TR$K M^YM\YN)R.T,/4FOB'XR_\%/9]2T6XL_A[X;GT2XGA,']L:N,3P'U@M^YKYT\ M'>%?BY^V3XDO[>+5YO%,^DP"::XUJ_Q;0'L!7V_X$_X)D?#G0]+L?^$IO-4\ M1:J!F9A<&"`GZ`5[S\>_ADOQ)^"7B;PA8K!;7=]IYM[`O_J5FB.8!^8'Y5^) MVG:)!]@U&_GOX+;[/_J+;_EXN*^]/V#?V0+;6M#N/&/Q!\-:7J>CZM!;W&AV M]^NZX7`!\\^F0?UK]#+6WAM(!!%%Y$$70#I5JBH:*FJ&BBBIJJ76GP74`BFA MBN!Z3#-)I^GP:=;_`&>W@AMX!TBA&!0;"W,XN#!%Y\8P)<,8%>._&C_@G]X-^,/C*Y\51:MJOA34;X_:+W^SC"8;B;U.1G-:_PQ_8E\*? M"/PGXI@\/WM[?^)]=TNYT[^V-1.6A\Z'&^*]+X@'M4U%%%9MUIECJ8A^V6<-P?^F\`/\`.N$\4?LX_"_QKJO]J:WX M%T34]2'_`"\7%D":X/6/V$/@IJDT\_\`PA<-J9OO&"^G@_D:^?/VO_V/?A=\ M'_@-K'B7P]I5[;ZU!/;P07%Q?7$^/W_UKEOV6/V1OB3/X$L/B3X+^)$/@N_U MVWG)@M[`7`GM_P#EW_+%>76'[3_QLU7QG!X9B^,H@GN9_P"SH-0N;?R+8W'_ M`(#UZW?_`!:_:?\`@9>K#K_COP;K=_<3?OM&UC5M/^T0#V_X]ZK:;_P4)^-F MEZCJ:?\`\%+_`(-7%K;S2G7+(=8U:Q-O;VUK93G.?PKPS_@G7X=\#:U?>.1XZF\.W M-A>.O#]_X9U32=/T^V/VB?P_IOV>9 M;_\`?9R?09X[U]G4445-11111111111111117F'[0OQ'O_A1\%_%?BO3H+>X MU+2K`W%N+C_4&;WKY!\"_P#!4Z6V6UMO&?@SS5`(GU#0[@K_`.2\_P#\?K[X MT37+;7]*L]2LI?/MKV`30GU&,_UK5HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH MHHHHHHHKY$_X*6>?_P`,Z0>5CR/[>M_-^F)L_K7T[X,_Y%;2#Y$MM_H4'^C3 M=8OEZ'W_`,!6]1117D/QV_:0\*_L]Z)IU]XG%Y/)J$WV>RMM.@,[3FO*M(_X M*0?!^\,Z7ESKVD$=[O2V;_T22:["W_;E^!US;I,_CN"'SHL^1-87(X_[\UZ) MX8^-OP_\9V-O<:'XPT;4H)^862^7YOS-=+_PEVA_]!6S_P"_XJ_:W<-S!YL$ ML4\&.##S_6I:***FHHHHHHHHHHHHHJ&BIJ*AHHHJ:BBH:*CN+^"T'[Z>*'ZF MO._B!^T-\.?A9<6UMXG\8Z7HT\_^HAD;D_E7@/BO_@IO\*]&!&C1:WXA_=9_ MT:Q-O^^]/W^/Z_C7S[XS_P""GWQ'U+4=WA[2M%\/:?YVW%S$;B<_ATKRS6/V MI?CS\:KJYT2W\0ZUJ#7$&3H_AS3^3!_V[UT/PU_8)^+GQ.L].UR_AAT2WGF, M-P?$4UQ;WX`]8.@KZV^%W_!-'X?^$;@WWB:_O?&5SC_47(\FW_(5]/\`@/P1 MX;\`:!!I'A/2K'1]&@'[FVT\8%=+14U0U-14/V@>E%%%>5_%;]IGX=?!>]%G MXK\1P6&H^3Y_]GPQF6X(]0!7Q#^T/_P4@U;Q*E]HWPYM&\/:1(3;RZS?L5OY MP?\`G@`<0_CG\*\?^%O[,/Q>_:>U6WU>Y-\--GM^?$7BJ>XX_P"O?_GO77?M M??L;Z'^SG\.O#.MZ;K>IZQJ%]>K87HN'S#@VY_U`[=*]7_X).Z--CXAZJ2!; MXL((/W../](K]#:/LX]:^:O#_P"P!\&M#\0+J9T*XOVBF^T"VOKPM;`_]<>G MYU](6MO!:VZP0Q"&&(8$0'%6Z*AHHJ:BH:*FJ&BBIJAHHJ:BH:FHHJ&IJ**A MKY-_X*3^([?1?V=&LYC_`*1J^JV]K!^!-Q_[0KVGX%^"H?AM\&/"'ANT"W"Z M?I5N`V/(\^;:"?U_I7YP>%_V:M6]_K<$_B+4=6O_`-_^_P#](O[BXK]0_A=XS^`? M[-(\6^$_"6J"UO=/MI]9UBPD>>XN28.H,Q&/.Z?N,Y]A7C_PS_;>\?>(O"'Q MB\8ZCX9&KZ'I$%O;Z5HEM8?Z/!//G`GN/^6V"HZ=XEUVWM[^VN-(M_^6]Q_R[_\^]?>?[5O['GPD\/?!'QAXFT7PI8^ M'=5TK3S<03V\T\$`(/>$''X8KQ7]DG]AKPY\?/AL/&/B76]4@X M^TM]@W=>+?-QR.3^_P"E?:.C75S=Z593WEK]@N)8V,T$'U.:3PU^WK$_%?BG2-!TS5M3NM2U:YBL+9 M?[)GP9R3@'CC_/6OH#4=3LM$@:XOKB&QMQ_RWGFQ_.L+3_BAX.U<7`L/%>BW M1MY?(F\C4(3Y!].M=+!=PWEJ)H9A/$W_`"UB.:MT44444444445YE\?_``WX M<\6?"#Q-I/B[5O\`A'_#]Q;XN=1\['D>]?FY<_L`_$>X\-6VJ^&;CP[XYL+_ M``+>XTB^Q^X/_+<&XX)^E?IQ\*_#]WX8^&?A71+V&W@O=/TNWM9[>V_U`80X M(^F17<444444444444444444444444444444444444445\G_`/!2C_DV]_\` ML*6W]:^B/`J2VW@KP$KV;4)OL,!-Q`9%S<3PW$7_?.VO+M9_X)8:YMG-GXYTR MX)_U*W&G^29CZ'&:YG_AUK\2?/G\G7?!P@/_`"W,]QG_`-)ZT-'_`&3_`-J# MX1VW]E>"]>_XEV?/QHNN^1;_`/D>FW/@O]L?PBMIJ!U#Q!<"U,\ZFWO[>XP? M]1]<5L:;_`,%1OB`MY;S7?A3P]/I__+:&W-Q"P_$YKM=-_P"" MK;6\`:A!;F;&XWPS_*O7+#_@HM\%+_ M`.T>9KU]8>1U^UZ5./Y"KT'[>WP,N);>$^-#"TPX$VEW*^3_`.0*[:#]I[X4 MW'BJ#P]!\0=%FU":#,(@FW0$8ZB<9A/TS72S?%GP/87\-A/XLT2UN9HO.%N; M^`9'KUJO<_&OX?PV5O=GQIX<^S3S_9X;@ZI!@S'MUQFM3_A8?A/_`*&;1/\` MP80?XUT5M=0W%L)HB#">^*?3(+J&ZMA-"PFB/0CFGT444444<0#VJFVI65K; M^;-<0P00_P`7G<"N>N/BQX/MASXNT'_P:0?XURGC/]I[X4^`8[5=;\>:5;F^ M_P!0;>?[1G_OQFN%O/\`@HE\"X+CR5\675P?6#1M0/\`[0KFO%O_``4J^$/A M_0KB71;[5/$U[C]Q8P6,]NS'WFG`'XUXOJO_``5@U22QG^Q_#>TM;@?\>]Q- MK)F'Z6]<;XI_X*??$_6[`'3-+T;P\1_R\V\)G_2?BO-O&/CO]HGXTZ5`VLKX MV\0Z.W^DPFUTB>WMS_X#V]5_"_[)_P`9?B<9YHO!NJ@P_P"NG\1?\2\G_P`" M*]/\$_\`!,/XA>(+:_N?$&I:;X/\F?,%LN+\S#U/DD?XU['X#_X)=>&]-6VN MO&'BG5=8F\S?<6VGP_9[>?VS_KOUKT36?V<_V;O@)X82_P#%>AZ3#IQO@8+K M63Y\YG/_`"P'7/TKWOP-:^%+O0=/U3PA!I9T6>#_`$*YT:&%8/([8(_I7`?M M4?M'?\,W^!=/UP:&?$%S?WWV"&U$_D/M'V?_GO]HK]6*******PM?\6:3X2TXW6LWMEH]BHQ]HOIQ;P_KQ7S?\ M5?\`@HE\*?`5IJ4.C7TOBO5X!M@M].A)MVG]#/TKX;^,W[>/Q/\`BU]HL?MW M_"*:-/!]GGT_1O\`EO\`]O%<+?\`P?USP[X;\+^,O&A&C>%O$A\^RN+;_2+B M^.,_U'_'Q7WA^PWX$^"WBG2M0\2>$/"FH?VOI-P;&74O$ZBXN.%_UT/)AASR M?E&>/S^VZ^)/^"J&IBW^$_@^Q'_+;7A-_P"2]Q_C7L7[$WA!?!7[,7@>`S_: M/[1MQJ^[_KX_?_UKWFIJAHJ:BBH:*FJ&IJ*AHJ:BBBBBBBH:XG5?BIHF@^/= M(\$W,6J'5]3MS<0O#9SS6X`ZYG`P.G_ZJ[RH:FHHHHK\^/\`@JKJ_P!ETWX? MZ()P+:XFOKZ>V[\>1C]#/7W1X.G^T>%=(F,7D[K*`X\S./EZ5JW-O%=02PSQ M":`]5/.:Y3P_\+O!OA:]FOM%\*:+I%],.;K3M/@@8_E7F7Q#_8K^$_Q-O/$6 MJ:GX<6UUC6@?M&H6$VV?S^UP/28>O-!_@]XQU+PWJ-O> MM?\`VF^NC";\S'YA/-``3^'7'TKC/V7O^"?4'P^UZ#Q9\09[/6M6L)S/9:/! M^^MK><<_:#GK/[UW7_!136K[0_V9M2M[=80M_?6]A/G_`)X$G-4?^":*^1^S M2/\`L/7_`/,5]8T4445S'B#X<^%?&$UO/KWAK2M:N(/]3

&?BYKNA0][7[,P'YPSBOL[P;H-[X8\,:5I=YJLVO7-G!Y,^HW7^OG M([G_`#VKEOC7KGCKPYX%N+SX?Z'8^(O$$,H/]GW\^T-#SGGUZ5\HVG[47[3D M/B33M+NO@U%<37JD06YL[FW4C&#NGSB'\"WLIKC"XL9K=9SQ7$'9H3FKE% M%?,G[>7P<\2?%_X.&V\,3[KC2Y_[0FT@#_C^`_A_G^M?GG\$O'WQ)\`_&'P+ M;G5M<\.6UQJVGZ=]FU'[1]GN+?[1;V_V?[/7VO\`$/X^>.-#_;J\,?#_`$^[ MMY?#,YMX9].\CYB)H2TL^?:OM"BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBN&^) M;>.D\.@^`(]"FUXR@8\1^>+;RN_^HYS7/?!SXTK\6)O%%A<:)?>']8\-7QTG M4(+C_CW:?'_+"8?>_P#U5ZU111117R?_`,%)O._X9KN=N-O]J6WG8_&OI#P8 M8I_!OA[RI!-#]B@`;/4>2*Z"BBBBH:**FJ&BBLC7/"&B>(9K:?4M*LM1N;;/ MD2WMN)_*/X_XUQOBOX!?#_QI?:?-K'A31;HV9)$#Z?!^^KD/%7[&'PD\1W.C MW$/@O2=&_L^_AU!AIEC!#]M`S^XGPO,/3Y?R]]/_`(8Y^"5S#_R3;0L?]>]< M+XC_`.">/P;\13WMQ#I-[HT]S#@C3[TK!#]`:XV#_@EG\-@/WWBOQBW_`&\6 M_P#\CUA:I_P2M\+7=T#8>.=9M+'R,&VOK."ZG'XD#^5_\$M/%,*7S67BS1)_*M\Z>OV&>`W$ M^,YGP3Y'X9ZU4M_^">7QUM8/L\'B31+:W@_X]_\`B>W'_P`CU7N/^">?Q\-Q M;_\`%2Z5B:UX;_;4\-W%Q8_;_ M`!CJ/_3SIU_;W%73\./VT;G11JIUOQ'NE&9M/.MP?:`/^N'2HO%7[,_[6_BW M2/[)UO5K[6M.N/\`7V]QXEKB_#?[+'[4'PZL?[5\.6.N:-<7X\B>WT[5H/M! M'_3P?M%:.H?LH?M+^)5OXM3BU.Y76/LWVXW&O\7&>GVC_KWJ:;_@F9\7(-4\ MF"?P]<:=YV[[>;PAL?3K791?\$I=>6&<2^/M,B_YXE=*F^7ZY-:7_#IS5!_J M/B39_P#@F/\`\D5I:3_P2CV7D#:G\2#=6X_UXMM(^S_^W%>DZ#_P3'^%6GVN M=0O/$6LGTFU#R/\`T0!6C8?\$^_@+HNO"WETB>XN9X?W&GW6JSGC\Z]8\)_L MS?"KP4UHVB^`/#UM/`/W-R-/$T__`'_/->%_'3_@HKX7^%&O_P#".>$])_X2 M_4+"X^SWP%P(((1C_EAQ^_\`P_.LCX>?\%1_"6IVV/&WAN^\.W)FQ"VG?Z?" M?Q&,5]L:;>6^HV$-S:7$,]O.`T4\!XE%?EUX[_;T^*WP_P#CUXJC%]8:AHVD MZMVU;1 M[F?-U8S_`&\&B:8W^E7QOS!<]1!/R/PX/ MYU]6_$WX=Z5\6O`>M>%-9\X:=JMO]GF,!Q-%GWK\GOVE_P!C/Q)^SC!!KLU] M#K/A::_^S0:C`"+B#_GW^T>M?3?_``2Y^%^EVWAOQ!\0?MTT^K7%Q<:,;`_\ M>]O;G[//Q[YQ7WM1114=Q<0VEO+-.1#".I->)?$W]LSX4?"BZN++5/$D.H:Q M".=-T>(W%P/P'%?&WQ1_X*=^*_$$%M!X$TJ'P=;C_77&I`7\\H]`!_\`KKRC M3O`'Q[_:RU;1O[4@\1:SIUQ]HN+#4?$4%Q;Z=!7T3X,_X)86;^'\^,O&%]%J M7>V\/>3]GM_^_P"IKY>_:[^&_P#P@'Q:U_"?_``CG@V#[/I^DW%O_`,>] M_P#Z/_Q\?:/^?BO0OVF?&NA6W[+GP,\*67A2QTZYN-)_MB"XM_/_`-`_Z]_^ MOBO8/^"V?\`7YZ5^@_$`]J_ M*_\`X*CW\LWQW\/V,LP$$/ANWN8;<#'DG[1<#)_*O6O#W[;GA7]F?X5>!?!E M]H>LZEKMCX:T^Y98%@@@/VBV\_KGC\J]I^`/[:G@7]H3Q';^WGYMO^N%?27[+EG\5['P%<6OQ=:.Y\ M10W;""?S8#*;?W\CC->V5-4-%%35#4U%%%0U-6#XD$Z3XMTZ:PUK3++5M/F M&)K:^@$X/M@US_@3X+>!/AOJ=UJ'AGPII?AZ_N1Y,\^GVP@\X?A74:WI::SI M%]8RRRP13P^29[=G_A8-]]G]/[)MZ]\_9F_9@T_]FC3M M8ALO$>JZT=4\EI;>Y.+6W(!'[B$?=Z_YZ5ZIXS_MV/PGJ?\`PB\%G<1VKSC]G[4/C+J9\2#XI:3H>D?9[@)I?\`9+L?.4=3_P!1.1^8KCM'^-OA7XO\`_!0?P?XG MT:W-WX?`@L()[Z#R#]H^SW!\\5^FU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%> M6_M`^'O%_BOX5ZQ8>!=4ET;Q4Q@^Q70F\G:?.'4]N*YKX&_#'Q7X"^(/Q(UG M7I--G@\17%E?K+I\TPS<"#;_Y-BU#_5?\A;3^ MO_7P/\_G7O\`X`F%QX!\.3QP^1Y^F6Q$)[?N00*Z>BBBH:*FHHJ&BBIJAJ:H M:FHJ&BIJ****AHHKXQ_:3_;WMO@[\6K#PMI>E#4[33)Q_;D^,7&.OV>`>I)@ MY]Z^K_!?C&Q\?^%-)\1Z//Y^G:I9BXMSZ@_YQ7BG[67[5_XD1\0W MVNBX-O;B<0"+R/(X_P#(XK:_9V_:9$_M%:#;RZ9-#IWB""#-]H%Q/FYMSCJ M.GG0\GD5X]\*/^"AFE>,_C<_@34_#S:-I]U?3Z=I6H"X\\37`FQB4?PU[5^T M_P#M`V/[.7PV/B.>Q.LZC/.+&PT[SL?:)SV_2OCJY_X*O^)#!^Y^'NE?:/\` ML+7'_P`CUV7[/G[?WBWXX_&KPSX-?P9IEA8WWGF]FM;B::Y@VP9$PXP!V_&N M^_X*&_%?QQ\)_`GA>^\&:K-HSSZM]GU#4((_U'_CXN+BW^T?9[C_R7K]>/B_K5]8_!KQAJNBWKZ3JL&AW%_97)AR;< MB#(X]01_G%?D?^R-\`M*_:&^,!T+6=5GT^PM[#^T)Q;\7%Q7H/[=7[,&@_L] MZ[X>U;PN9[?P]JWVC-M<3^?]GN/_`(QTKZ"_X)@_&+6O%?AOQ#X%U23[58>' M8;:>PN9P,P03\BW/TQ7S+_P4$^&$'PY_:&UF>RL8+>PUV#^V(.?_``(_\CU\ MU_9I[:WM_P!Q/;>?!7T[_P`$^O'T'@']HW1K>]N)[:WUZ#^Q_P#1_P#EXN/^ M7?[17[`5X5^V!\'=4^-/P+UGPUH'_"^JV6V&VO_`-P9;GS\\V_;@S_F/6OO^BN9\<_$?PK\ M+]*^W^*-?LM$M!_RWU";`KXE^,?_``4\L-,7[-\,="_M)<`?VQK),$'3_EA" M>37R;XX^/?Q>_:,U.?3I;_7=2M=5GP/#NCPDP?\`7N8#R:X[3OA=?_\`"R[C MP9K?D>'-1L/M'V__`)>/L_V>W^T7'_'O6A^SOXDG\.?%+P]Y&A:5XB^WW]OI MT^G:S8?VA_Q\7%?NB`((1$/3%)_".KZ5!?3Z//?6,]NMW;_\L,CK M^M?&.@?\$M=*TW6["XU'QS/J=C;WOVF;36L2!QA,]QWM[#^SH(#/_I)M_P#2/_DBOHOXT?'OPK^SU\4/ M".D0?#KP]XZU'0_#5A;S>(]0`^TR_P"C=N/^??GG/6N;^"G_`!E-^V'8^._" MFAV?@8:28-9U""O'K7ZIU-1117QI_P4UG6V^">CPR MV-E/;W.N6\!O[@#S['/\4''7BO4?`W[,GPCN_"7A^>3PWH7C,+HFG6L&M:C8 MP7!OH((1]GGQCT/^>M>._&A-/G^/.@_#WX5_#'PD?$\"P:CJ_B+4="@G@T^W MY@M\8Y[_`*"O=-?_`&3OA1XL+SZW\/?#MSJ$Y$\\\%B(/.G]>/ZUAG]B3X*^ M1?P_\*]L=MUT_P!=^[X_Y8_-^XY]*Q[S]A[P=%9:CI^C^)/&_AS1KF#OA9?\`@[P[\2?$]O5I%BLV/][!Q6"?AO\`M/\`@[4O M^)!\3_#GC/3/3Q98_9[C_P`E[>I-8_:)^,7@;7X],\0?`RZU>V:W\^74?"%^ MU[!GTP;<'-4_"_[6GQ*F0GQ%^SQXQM3ZZ0!<#^E6=+_;P\-36]S_`&IX%\?Z M/;\LFN^J&IJ*AJ:H:FJ&BO//CG\3;;X-_"?Q#XRN+(:C_`&7;F>"U M'6>;@0C/UQ7XK_$SXHZ[\4?'FH^+/$-_/<:C//\`:/\`KW_Y][>WKG=&UN_T M37K?5K*_GT[6?^/C^T;:?[/'_&%B%MX-4MEG^S]X)N?.&? MKG_)KT*H:*_.O_@JWK@;5?AYI(@S]G@U#4/_`$GJU\;OVM=2_9^^$/PN\'^# M(K&?Q#?^#+&>XU`\?8K?[.!;F`=#]V?&>P%>3>(OVL_VG/A];:%X@\0:A>V^ MC:H?.LQ>Z7;B"]@(!QD6^0<$'\17WQ^RS^T-!^T;\-!XC%D=-U>VF-AJ&G9) MB@G'I7M=)]IA]12T5E:WXETGPZ@_M/5+*P![W%P(/ZU-IFN6&M6QETZ^L[]1 MSNMYQ,/T-7Z*FHHHHHHHHJ&IJ**^2/VM/V.+GXYS^%[WP=)HOAK4M))@E%W9 M+Y#6_7`_T+1_P#@H;I&B:%+!8:?8ZWY`7[%]FMS<06W^D"W@'_3 MQWK]8********************AJ:BBBBBBBBBBBBBBBBBOEW_@H%X=EU/]G7 MQ'?"^FMX;"6U)L#_`*FX'VF#&?U_6O3/V8K^]U']G_P!/>F:6[?28/.:?KG' M6O5J****AHJ:H:******FHHJ&BBBIJ***AJIJ-RFG6=QSSV\\PQ.+<>@[5]/?\$N?BA/;>.O$'@6^U6^.FWU MC]JTK3KG_CW^T#_CXQ7<_P#!5C0[RYT/X?:Q;[?L$$U_ITY'_/:?R,?^B#7P M3\*_BAKOP>\::?XD\/7T^G:A!_Q\"W_Y>+?_`)]ZZ+X1:W/J7[1_@W5O^/:X MG\66]Q_HW_3QJ%?M1\0_AOX;^*/AF?0O%.DP:UH\_6VN*_)[]NCX(:?\&OB] MY7ARPL=%\.W]E#-8VUOY_4$@]/<5^E/[+?AOPMIWP.\$7_A^RA*3Z);@7XL1 M;W$XVCKQGKFO*_\`@H[\.G\;?L^W.KV+6_VGPW?C59A<=#;@&&XQ^!_2OS2^ M%7AOXD^+)]9T+X>P:Y<6U_!;_P!K6^C?\^__`$\5C?$WX;Z[\)?%NH^&O$,' MV;6;#[/Y_P"_^T?\N_VBOW.U?1['XB>`[C2S+,-.UW2S;"X@Z_9YX,9_+^=? MC5X6\5^,OV3?C/XT^W`MS_H^?^6'VC[15CX> M?\$O9M#\9:+J/B#QA9:GHMC?_:9].M;*6W\]?^>/7I7Z$U6_<6T'GX^SBO.O MBC^T)X!^#.CP7OBSQ)#I\,LHMX5B)N)F;_KE""<5\X?%W_@IMX,\-W.LZ5X+ MTJ]\1ZE!!_H6I!?^)>9^PS7RWXQ_;X^,OCVPN-!@OK+3_M\/D#_A'[$FY!_& ML3P1^RE\:OCQ_P`35M#OO(QD7_BF>X@8_03\FOL[X6?\$T_`_A.X@OO%M[>> M,=0\C,^GG]SIYF]0!7T)KFE:3\&/A'XAG\+>%X(+72=,GN8-&T>`0>?MAS@? MEC\*_(;X%>/?'/A3QWY_@NW@UOQ3JUP()[BYL/[0\^"?_CX_[=Z^J?\`AW!X MZ\;?$"ZU[QIXH\/V5A?3?:9QX<@`_P"_$)MP!^)K[P^&7@*+X8^!-&\,IJE] MK0TRW^SB_P!1EW3S>Y-=51117PU^UQ\#_C!\?/BCI?AS2_)T_P"&,'D7#7/F MP>3YP)\^:<8SYPR0`./SKY"^-?PYT+X8_M8+X5\,37UIH]CJNGP03FX%Q.?V^OA1X" MU?6-$O[[5+C6M)OO[/N+:VTF';B>3&[ M6;,V]OG_`*[=/QS7L?@_XU^!OB/>O;>&?%FBZW-C_4V-Z#-^0YKNJ^0/VK;+ M3_CW\6O`OP5N+=K>>#[/XIN-1FO3#FP_TBVN(`!G]_W^E>H_&KXW:%\'M$B\ M->'YM$N/&UPUM8Z/X5;48;%BT[>3!UZ#/3_]58/['_[-\WP&\'7]]X@:'4/' MFN3FYU74#_I$Y/:#S^X%?1E%%%%%%%%>%?M;?&*P^"_PMN-4\B"X\07_`/H. ME6UQ8F]AN+@]("!Z\_E5?X5?!;2/'OP>\'M\5O`_AW4_%$5MY\]O<:7`1;M- MG(`Q@?\`UJH_$GX*_#'X'_#KQ/X\\+^`/#FF>(=!TNYN;"X6W$'DS>0<<_E5 MG]AS4](KVXU*XG\]K>ZN9Y9[B:'SV`,Q/\7&/I^-?1%0U-14-% M35#7EOQY_:%T#]GKP_IVJ^(;>]N(+^^%C"MA#N()]:^6/#'[5=E^V+\1=7^# M>K>'(;7P/KD5Q#!?V]T1?-Y&9X)R/^V&?KBOCVT_9ZU;Q-^T;?\`PHTNHMX/^7BO?9_^"5?Q#/^I\4^%E^OG_\`R/7KW[3/P/\`B%>?!;X8 M?"3P)HHUO0[+[-#JFH&>!2LL`'4'W!_R*^I_@SX!'PO^%WACPJ+B*Y_LJQ@M MCU=S4U0U^:/_``52'VCXB^!X("?M!TJX/^C_`/'Q_K^U=+^W3^SK MXA\7>#?`?BKPMX*@LCX;T'[-JVGZ<UG;:=7M_P#GW$'_ M`"W^M?:G[-/[8/B/XS?&OQ3X'\3^%K/PO]AMI[BV@\_=<0&WN/(GAG'3.>:^ MMZ_-#]OK]G@6OQ!UCX@:G\0M%MQJMN!8:-J<%Q]I/V]OY%?.?[+,WB*Q M^/G@:U\*:H-(U;4+[[,9V&0;?_EXK[2_;E\2?M`^&/$=SJ'@N6;1OASI=B+I M]2L+F"'D?\?'GYYP.U?(VC_MJ_&W1OM'E?$'5+K'3[3;V]Q7Z[_#>YUJ^^'7 MA>Y\4P+:^()]*MI=4@]+GR0)A_WU78T5S^MZI?V4M@+/2Y;\3SBWN/\`2!$( M(>_;WKH**********_'GX!>1J/[;^CW%[C,_BRXN/W'3[1_I%?L-11111 M1111111111111111111111111111111117S?^WS<06W[+?BPS]/M%A_Z505V MG[*MA/IW[.7P^M[N$6]PNDVX8?AFO7*****AX@'M3;:YAN!F(YIU%%%%%%%% M%%%%344445#17C_[67B&]\*?LY_$#5]-G^S7=MI19;CRL^V?U_6OS$_9B_90 MOOVG;GQ,(==A\.V^B0VZ_:1!]H\^XG!//Y5!\0?V:?B3^SW\4+:'2[#7-9N+ M">WN+'6?#MC/^_/I7US_`,%*(M?USX!>$+M]#,$%K?V^H:N;>;[0+"?R&&,X MQP9F'GCI^-?,_P"SC^S!8?M&_!7QT;.">V\#M+D\*WMAXH&KV$]C;W\&;>&] MZ+=V%B+ M!K74?^/C]SP"?R_2NA_:'\&7_P`2/@AXP\-Z7#!=:OJ%@8+>">;CS_1Y'3&!S7VCX!T2]\->#-`TJ]OO[2NK*R@@FU M!A_K\#%8OQ"^#/@SXKP"'Q=X;TSQ`JC]Q//;#SH?I/U% MHVZ^?-IYG_?_`)5\]>*/^"H'PUTV(+H&D:YXCN.X,/V']37BL_\`P5<\=7`G M\GP9X<@@'?_ M`.Z*Z'P)_P`$VOBMXD_?ZI#I7A6W_?\`_(0G_P!(YZ?\>]?;V]]X MAT6#_7V\'_/O&/^$OU6XUKQ%<6XO[BYN9O/G_?< MCG\?YUZW17/^'/`_AOPU/=W&C:-9:1<7V#//8VP@\X_A705-4-%%%%?D,/#= MQ\7OV^M0L;,PP^;XRN+@W5O/R;>WN/\`[GKZ*_;(_81OOB-XM'C#X;PV5OJ- M]QJVD$_9Q+[V>XU[P;X=UJYF'[^;4M)@N)V^I()KAO'/[&GPB\?BW:X\%6 M.G7$'2;1?^)>?_(&*9\)OV-?A=\'_%0\1Z)HUP^KIQ;W&HWAN/LX_P"F.>E> MZ5^5?[1OPR\&^&?VCKZRU/6OB'9ZA?YUBVO[6R-_<":>YXM[?(!$./\`EMY_ M!M\>]>K-_P`$[?&/ASQ-I/C'P)\5K@^(`?/.H^(K;-P>/:DFUO\`;(T6WO[_ M`$K7=#\:VUA?7%A-#;P0&X_<^D/V>WK8^&?QI_:LL+76)O$GPJ'BBVCA\ZWM MY<6%PO\`L_\`3>N3_P"'HGBSPE^X\7?"?[-<_P#7_<:?_P"E%O7HMA_P4]^' M%SK4UI+HOB.VTL?ZG43!"6/TASD?K7L7P1_:R\"?M`:GJ&E>&+B^MM5LH!<& MQU.S,#>23@3`>G/K70>,OVB_AS\.]>M]$\2>,-*TC5;CGR+BZ`\D8X,W:'\< M5I^%_C3\/_&^K?V7X?\`&>AZUJ&//-MIM_#.#K"QMXK6WM]*ML00#@?N!7944445-14-?/W[:?PPE^+'P&UNPTK21K/B&R MG@O]/MD_UWVA2`?Q\EFK\]O@G^Q[\5O'D.H:[X?@G\%ZUH4\'V"?6;>XL#\]>E?\$[?!4W_#37B*]N;@>?H=A<"X\CI//Y_V<_IFOU`HJ:BH:*_,_P#X M*26JZE^TCX!LI;C[/;W.EV\!_P#`Z>O+?C%\>?BK\;OC=J7AK2?$=[I=M<:O M_8&E:-IU]]GMR?M'V&?1[ZXN+8^ MH_TC_KWK],OBK\))/VC?V=K?0]:Q:ZW?Z?;W\$X_Y87_`)'7\,G\Z^'G_P"" M?/QZU?P7:Z1?:[IL&G:5/FP\/3:FS6WY@5U7P0_X)X^,/"?B+_A*?&MOHVM' M2+*XO[#P[;W;8N-0_P"7?[0<8KJOV!_@3XL?X@^(OBMX[TRYM-2F,T5C_:]O MY%T9YSFXG_'!%??W$`]J_-+X]?M$_`GX\?$RUT[QGIOB>V\/:!#/;V_B&QG: M(^=W'V$P9)]_TKY8\<'PYX!^*ZW'PK\1WNH:183V]QI6H3PYG%S]>]??G[=7 MB+P7\4$\*_"B\\96_A3Q.;ZWU@-J4.;"("WN`(+D_P#+'(YKX=_:&^`=_P#L MT>.].T*]UV#6;F>PM]0@U#3H/L^/](N/_D>OUH_9H\5ZMXV^`G@;7M:8W6L7 M^EV[7%P"/WYP/WWX]:]2J:BBBBBBBBBBBOR!^!5O-XC_`&W]'-F8%7_A+-0U M$G/GX'^D5^OU%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%?.W[=]O]I_ M93\9C]UULCST_P"/J"O2_@3=?:O@K\/9_P#GMH-A_P"DZFN^HHHHKP/]KC]G MZ\_:%^&B:'IVM'1[ZSN!?6]O-C[-?38.(9Q_=^GK7P*/V(?CWX2`N-+T/[+Y M$`_Y!^O6XZ_\?%:5Q;_M;_!."WG!\8FWONH_Y#'_`,D?9ZK7/[67[4/A(?VY MK0UP:=!/B?\`M#PU]GM__2>NVB_X*K^+(+OSKSP1HJ6.,",7TT##\P175:-_ MP58L393'5/`%Q]I$VV$Z=JH,#?CBI_A!_P`%*]#L?"\&G_$"QUN?4(<[M9M8 M89C<_O\``_<@\?7FO7XO^"CWP2VP^;KFIPD]FTFX']*GA_X**?!,W%O"-?OB M9^DQTJ?:?TKU+1?V@OAAJ^C0:I:>//#HL)^C/J$,0_4UI_\`"ZOA_P#]#WX< M_P#!M;_XUJZ/XTT'Q(/^)7KNF:B<>;_Q+KZ&?^7\ZZ"BBIJ***AHHJG=V]OJ MEM-;W<,,]N1^^@F&17'Z+\/G\)^*8KW0)[+1O#PLC#-X?T[28(!<3YR)S,,' MIVKO*JW-K;W,)@E`G@/_`"PQ533/#VG:.C#3;&WL/.Z_9H/)K3EMH<(O$VE>$M/%SK6K66GV__`#WO[@0?SKG_`/A< M?P^_Z'KPY_X-K>N;\5?M3_"#PC(+;5/B'HD$^//_`-'N/M'_`*(S7#>(?^"@ M?P3\-BV$/B:XUOS_`/H#6$]QY/UXKSN^_P""I'@6SO\`4(+'PKKNI0038AN2 M8(!2>._P#@H7\7O'R;;+58 M/"EKY_GXT:#/'_7Q7/\`@+0_C=^U5KNH#2M=U7Q%<:?_`*^XU'7?L_V>NNUO M]@'XNZ99:MKGB(Z);V]G";^]N;C53<7&0"?Z59_8_P#V6?!?QQ\.7'B/Q?XJ MN=&\C5#I$&GB:"`7UP+<QKY&N#!;B$3S=YL>^#^=>V5\4_MQ_LI>-_CY\0/#.K^%_[+_L^U ML/L%Q/?SF$P?O\\8Y/7M6A\)/^";O@;PG8^=XSN)?&.HD?O(6_&+R88/;%7:*****R?%7BS2/!&@W&M:]>PZ;IUN,S7$_` M%G:A?>$9Y[BWL9_L\_VB`PG->C57N.EQ7XZ_L7>(]+\`_M"W M.NZS;RFWT+2K^X(L+?C$$'/Z9KV#4?\`@JMXD:[673/`.F1:>HQY%W?SSW'_ M`'_``_2OH_\`8;^*WC_XO^"M>\1^,O$6D:Q;3WVRPM=-@Q<6`])Z^HZ****\ M5^';Z/XS^)WCF]OO"FMV>K^&K\V]EJ_B&W`5H&Z_8./]03!^9KVJF16L-LO[ MJ(1?04^LS4-#TO7!B^L8+\_]-X,_S%<3XB_9Z^&7BQKE]6^'WAS4)IQ^^N)] M(@-R?K-C/ZTGP]_9T^&WPIU?^U/"W@S2]%U#;Y/VNW7]\1Z9K`^+G[(GPO\` MC3KDVN>(M"_XG4\'V?\`M&UF,%QCZUX5-_P2Y\*6]\LVC_$#Q'HCD9^3R6F_ M[ZQ7#VG_``3N^+VC:J+C3/BO!:?&/XX_$SQU\/OAX)_$7P_A^S MCR-'AMS!V?C#17M[X?N#]O7YOUKLK/4K+4[:"XM)HI[>?\` MU,\!R*NU-4-%%%5+NY@TY?.GGAMX/^FQQ7B7[3GQ=E^'?P3U[7?#267B*>R" M17PCOS";>&`19XI:***^ M3?C]^P+X5^,_BZX\5:;JL_@_5[@?Z:UO9K/#2+F?J+D$?\ML=S7CO@+_`()O_$;7O%5M8^,[B#1=`L5\D7T-\;YO MLW_/O`#R/QK]+_!WA6P\!^$])\-:-`+?3M+MXK:"'^[$./Z'\JZ&BBBBBBBB MBBBN8\9ZI-I?@[6+ZT@FN+J"RFFAMX/]>3C/%?EQ_P`$\]%_X2+]IG2-0G^W MW-QI^GW&H_:%GR?^??\`?_\`@17ZW4444444444444445#4U%%%%%%%%%%%% M%%%%0U-1117@7[<5O]I_9<\>#_IA;_\`I3!6Y^RCJTFL_L[_``\N9Q#O71X+ M4?9^G[@>1_[+7L-0U-1114-%?E!^T-^WAXC^)_A/Q7X&&DV6FZ?#4;> MX_TB>W^T>E>:?LH?%BQ^&/Q!\[Q##I=_X.\B>YU:#4+#[1_X#_\`3>O2/@-X M`F_:U_:@O/%%QX>LF\'V]\+[5;"0CR(H`/\`1[?R/7BON/Q5^R]\`_!/AO4- M=U3X>Z%;:?8P?:)[C[/VK\J_B9K?PVN?%@G\">&]O MK+P[^QO\&OB3\$3\1-)\2>*/!NG+;3W37&LM!<-;"#/GG&/8]^U8'PV_89^' M'QR\.3WW@+XJWVISV,T%O/]$L/$?B:_AMH)IQ;P7.GZX1<07!]#W_"N'_X:'^*/_10O%7_ M`(-KBOUO_9:^,>D_&SX2:+J=I?2ZC?V5O;V.K-/#@B_6!?/'OR37M5%0_P#' MO!]**FJ&BBBBBBBBO*/B]^T9\/O@M`?^$I\2P6]_CC3K;]_.N_%C5H+'P5!/X4T>'[1;P7(GQJ%Q_\CUX'X?\`#OCGXP:I!%:66M^*K^:? MR"2;B<"?_KXKUGPQ^P#\7/$&GZA<3Z%I?AW[#,8)O^$@O3#G'_+QQ_RP]JX# MX=_"70O%OQ$M_">J?$+0]%^T3_9X-1MX+BXM[BX^T?\`'O\`\N]8OCKPGX;\ M%?%&?0X?$=QXI\/6,_V>_P!0T^#[.9_^?C[/7Z=>%_\`@G%\&]"U6'5C8:IK M-N.FGZQ?%K?\J^'_`(YZ=\/_``I^U\NAV=CI7A[P/H6JVYO[?^SS-D_\O'!_ MU]7_`-M?XY:)\:?$GA^#P;%!!\/M*B)@N;>Q^S^?/G]^/RQ7L?\`P2T\+Z1+ MK?CG7IX+&ZUFP-O!;S>;NN8;><9P/^F'%?9_[0WPPNOC'$/$'@ZRU5M&GU& M':+@8(_ZXU^?W@W_`()F_$74=0@GUO4-+$XO?))MYC/.!_S\0'H#[5]'WW_ M``3%^%6H:GYZ:QXHT^&89-C:WMNJ_EY!KZWT_3(-%L+>QM\06\$0@A'I5RBB MBBBBIJAK'\:>+M*\`^&M2\0ZW/OCQ_84\\] MOI^K:#K&GSW%M_RPM[BWKW'3OV1]$^`7PH^('Q`UKQMI?C.W/ANXTZQM]/A` MMQ/./(MS[\X%>C_\$OO#M_IOPU\7WMY8W]O#?ZONMYYR1;SX@'-OCJ.?]?WK M[IH^SCUHHHKE_#_@?0_#FO:_J^EV(MK_`%R:&XOK@2?Z\]`?RS74444445-1 M4->7?'_X3:A\:?AKJ'A.R\23^%Q?8%Q% M?"\XN;`9N!<7,_GW%Q,<9G/Y5ZA69_PC&E?]`RS_`/`./V3OA1\0+R"]U_P`&6=Y07_`/P2V^%,P\VTU?Q18/YNX[9[>8'\#!7F5K_P M2QUBV\0ZPUGX]L]-TGSA]AE^P"XN9X/2X)P#71?##]C;X]_""[EM/!?Q4TS0 M]`NIOWR_9Q_!VJ6\'B;X4E&\CBR72+Z`S'U&0:[.W_`."E MI.DPW%]$_$EO<&',W[X?9U_2NM\=?\`!0[P?X`D\/6M_P"%O$3:CJNE6VHS MPM;^0;,S@8A;S\#-;O M]$_MF"RGGMK?5])N+>_MK?\`Y;V_V>OT0_X)3:6/^%;>.=8Z-/KOV40?]<(! M_P#'Q7W91114U0U^5'PQ@@N_^"C5L;/5(9[<^)-0N8)[?_43_P"CW''%?47Q M#_X)Q_"OQG=37VFC5/"UY//-/%O^"77A/0?$NGWUSX MRU74+"PGANOLHL8(3<3#OYXY/;\Z^[**AHHHJ:H:FHHJ&IJ*******AKR_XR M_M#^#/@*ND?$;?7%M_:L^VW^SP&;)J7X@Z_I'C[X">+]1T76K:YTF^T.Z\C M4H)@8<&`\@U\-_\`!+GPI>W'Q1\4^)#"!I]AI/V#[0>\\]QD_P#I/7Z:T444 M4444444444444445#4U%%%%%%%%%K>)-$U M;^SK?2<_;X=:_P!!-L#])G,^JZSJ, M'^C06_G_`/+O_P`]Y_\`GW^STOQ%TZW^.GQ:N(/@W\/I[;3H/]&@T[1H/^/B MW_Y^+C_GWK]2?V:?@%HGP!^'MMI5A!G4;C_2-5U"X_U]Q<>IK,_;*U_0O#/[ M.GC`Z];RSVM[9-I\$%N,DSG)@'MS@_A7XNW-M_H]?8?QJ^+'BCQ'^PW\+[>7 MPX-'TF]N#I]Q/IUP/(EM['$%N/QZ_P#;O5']EG]L+7?A3;>%O`?A[P-I<]O? MW_\`I]R)Y_M-_<3_`/+QS7M_[:_@KP-\<[*W\=0_$S3;71_!Q_LG5X-/@74, M>?./]1@_\?'TSTKYG_8DU+X?^"?VCY]=\3ZJ-&T728-0N-#U'4C]G_?_`/3Q M_P!L/M%?.M:&JZS;3SV]M/XAU"W M_P!&^T?]?%6/`W@(>/%@TO0(;?Q#XHOI_(.CW5Q]G`'_`$[_`//Q7V=X/^.G MQE_9K\-:3;:G\!M+T3PQ/-@G1(!`5S[0OZ!-'UJQU.WM_(OK>X_/C#XH_'[QEKTNK:7H'AZ M_P!6;4+>X4?:+@P3<$>1T!SZUZ/KG_!,7X<:A8Z/!8ZUK>GS6-O]GO;DF"8W M_P#O`CB;WKZ7^&GP/\"_!G3IX/!GARQT?[0/W\\"8FG^LQYKT*BBBBBBBBBI MJ*AKQSXX?'KX9?"D6NA?$+6H-+_MVWGQ;S6,]Q]H@&<_Z@&N-^"'[2O[/L>F M3^'/`VLZ+X7L+8>>;>YM_P"R8/\`R,!_*O7[+XH^#+G5I["'Q9HESJ'D?:/L MZWT&?(_#M766^HP78_1N^P_NOM'3/GBOS MN_98\!_\)7\/?CUJL&GQ75Q9>%+BVL"H_P!(%Q."?W'M_H_\JX;]GKXL:]\* M-3UO5+?P[<>,?!QM_LVNZ1/C^SQ]H[SYXK]C/A'XDT+Q9\-/#&K^%K+^S_#U M]807%C:^1Y'D08'&*[>BBBBBBBBBBBBIJAKY\_;/^'OQ#^(OPA?2_AS<_P"E M&8?VAIWVC[/-?P#K`)^W6OR.UGPEKOPNU:WG^WV.G:S;W_[C^QM6M[BXM[C_ M`+=Z^@C_`,%!OB;;_!K3?"T$[7'B*:XN+>;Q5: MH?#S]O#XS?":0VNM3_\`"0VOG>?]F\56\_V@?]O%+BWG%?IQ\8OVL?AW^SYJ]AX<\3WNJ#4+BR-S!]DL M?M&81QD_E7I_@3Q_H7Q0\):=XE\/7T.HZ-?P>?;W`]*Z.BBBBN'\3?!SP+XW MU4:KX@\&Z+K6H"'R/M.I6$$YQ[YKYV^./[#?PS;POJNN>&/`D]SKQMX8+/3] M(U":W@!SQ-@'L/Y5^;?Q:\&7O@WXD>(/#LNE?V--I4X@FM_/^T9'_7Q7K'BO MX9_#'Q'^S(/B;X1M]8T37M*O(-(U73[E_M%B;D'G]]<#IR.<]^E>F_LP?LK_ M`!/\2_##3O%/@7XNS^#+;5O/,^GV_GXS`3;_`*8KVKX)?"[]JSP3XWTVY\1> M,=,UOPK<3YU6VU'53>L+?_IW_P!'!%9WQ`\>_M=_#BY&NWNA:+XCT@7T$T^F M^%[]=+17Y.?LT:W\.?#G[5GB37?&-\?#L- MC?W\^DW$Y^S6'G_:;C/GGUQG'O7Z9^%_BQX,\?6\\WA[Q9HNMPP?Z[^S;^&< M#ZXKK+>[AO(?.AFCF@/<=*DHHHHHHHHHKSSXV?&30_@7X`NO%.OM,]K#B&&W M@&9YYCD`#\J^:O"O_!0F^UKX.>./'5]X"&GQ:%-8V]C;17TYAU":?TN/LX`P M2.QI?`__``5%\#ZI'90>*/#FL^'KQEQ<2P)]HMX#]:^O=:\:Z#X<\/C7-5UF MRT_20,F^N9Q##^9.*T=-U"VU2QAO;*>*YMIU\V*:`\2C'6I[6ZAN0?*F$WXU M8HHHHKY+_:G_`&+/^%\ZI?\`B/3/$U_8^(!;FW@L-0F,^GG'/`_Y8_A7RYIO M@+XI_LY_LV_&.'Q!83>'XKX6.FV[3WWVFWF\^Y%O="W@[?N)Q^_]O:O8O^"5 M.G_\49XZN_/F`.J0P&W$6(!BW'0?C_G-?>M%%%%%%%%%%%%%%0_9QZU-1111 M4-34444444451U*PMM6LIK.\ABN;6=?*FAFZ,/2IH56W`AB'2K%%%%%%>"_M ML3QC]F/QQ$9A`6@@$7/^M_TB#_'%._8I\W_AF'X?^=Y6[[`<^G^OF_\`K?K7 MN5%%35#7A?QT_:H\!?!F#5M(UKQ&EOXH%A/<0:?;0F:X[^2<8K\J;CXV>+/$ MG@/Q#H7BCQGKFM6]Q]GN+"VU&?[1_I'VC_GX_P"7?_1ZT?AWXVOKGP7;^!)_ M#6AW'@VXUVWU#5M1U&>XM[?[1_T\7%O_`-.]>H^(?$/BS]IAK#X4_!70KBW^ M&OAN#$%O]O\`]>/^?BXN+C_TGK]`OV;?V>])_9[^'RZ59!;G6+UOM.JZB?\` MEXGQVXXBZX%>S5S?Q"^&_ASXI>&KC0?%.DV^LZ1/]ZVN!Q7SMX5_X)S_``@T M;4[F_O-/U7Q%%//]H@M-2OL00'V\G%>]:C$?!>L^#8/"EYX6T:Y\,V8`M]) MN+(?9X<>@/'?TJAX1^!GP_\`A_9ZS!X7\*:9HEOJBF*_.GP8EG[8)KS[X4_L M1_#+X7Z%XBT*'3IO$6FZ[]F^W6_B!Q<[O(_U';M61\0_^"?OPA\;G3OL^A3> M%A`>3X>/V?SQC_EOQS7JWQ.^"^C?$[X5WO@*[$NGZ5-;PVT!MSS`(2##C\0/ MRK\B/BWX;^&_@I=8$Z--XBU#Q7I.NW%N=9G@MX+:>#_`)]_(KC_`(0^/_\` MA5WQ2\*^+/(GN?[(O[>XGMK?_EX_Y^*_=W1M3MMOC'3[?Q7\ M"XUB^_\`:\]=WJ&BV'[./Q8U#0M3\-Z)\3=9TFW_`-.M]1M[C^S[>X^S_P"D M?]?%?9/QAUWP!\\'D\8G@Y!&. MOH,5\K?LD^"Y_$7[5/A>X\,0:KJ/A[2-6_M"?4?L^?(@_P"GC_GA7[)5SGQ$ M\`Z1\4/!FL^&?$$`N-'U:W^SW`]J\?\`@5^Q!\.O@9KKZ[8K>^(M:'-MJ&L/ M]H-E[0<<5H_$W]C'X6?$?0+C2D\*:?X7N9YO/_M#P_96]M<9^H%>&S_\$P+# MPWJZWO@3XDZYX=N8!G[3<0#[1_W_`+*U6>`-I M[WOGC'?_`(^.U?7/P&U7XCZWX'6;XGZ38:-XG\\_N-.E#+)$.A/IUKTVC[./ M6BJRW$&3##U@[59HJ:H:****R?$?B;2_"FD7^KZS>PZ?IUC#Y\]Q<'B`>IKP MCX0_MI>#OC7\0V\*^&M$\17*B`%=8%@1;#C!W'/[G\:^;?\`@JOJ=O\`\))\ M/[%80;_[%$H-%T^&'SYKF?5KB"W M@^O[_BOSEU?X;V7QQ^+<^E?!+P=>0:!,MO;V<$RF<0'O%8OB$" MY@OH;^>X@7V."1^5=W\`=:^-OP>^#WBGXD?#VQTK_A%IKCR-6N+B&">Y_(8/!7@7P=VU/X737']EVT`/_"/3""VA^O_`#PKUV'_`(*'* M_P!I03V'_I0!7I47QB\#W4T,$/C/P[/<3#B`:K`2?R.:R_C/\:]"^"'A5==U M]-2N+5I1;H-)LC<-YQSQC\_UKLM+U+^UM+M+TV\ULLT/F_9[F/RIXO8CL:TJ M********^2_B[^VQX)T7XG:W\*M5MM3T8M;S:=<>*L?Z-83S0$C\LU^.8/$D]Q8+K-A]HM["WGMX,W'_@1!^E'/!?Q!\<^,?'=M9MHO@72O/;SX1/]FO_ M`+1_HY@_Z;_Z/<=.>?Q'S[XQ\>ZK\1?%>L:YK,PU"_OI_/GGG'`K](O^"8'B MS3;SX1Z[X>MKJ^#S^7O7VW111117,_$?Q[I/PQ\ M%ZOXJUN:6#3=)@-Q<^2,\5^-?[0WQT_X7Y\0O^$K_L*#PI<3V']G3_9Y_M'G M_P#7Q74?'SP(/A3^SQ\'=)M[[[2/$D.H>)[XYSFXGM[?R/\`R!D?A7ZN?!_1 M++P[\)O!FG6-O]FMK?2;:&"#Z0#_`.O7;45Y[J'[0/@#2/B!:^"+SQ380^+; MB01+II8[R>N/\FO0JFK#\5^)M+\&^'-0US6K@6FG6$)N+B=N?*7UK\W_`-DC M]E;PI^TM;_$'Q+XHFU4VW]K_`&:Q^S3_`&?`_P"/C_VXKU&]_P""4O@R[EW6 MGCG6T_Z^8(+C^8%>9W/_``3[^-?A&]SX2\9V:V%O/-]B2VU6XL2L!Z`XS6-H M_P`.OVLO@OXYM],T>XU/49[X>?F"_P#MVGS>3CC_`$CD=17I?ASXN_ME^&M? MB.M?#]O$5@1@Z>;."`#_`+;P<"NB\4?MQ?%WX?2"7Q!^SWJNG:FR@)\*>*OM)_UUO\`9[?C_P`F*Z/P]_P4C^#VH67FWESK M>COYNWR;C2S-C_OQNKJ+?]OOX&3V\)_X3/R<]!/I%^/_`&WKTFU^/?PXU&:V M@MOB#XH-/K MXM_X*D6\Q^#OA:X6#/DZ]G[3_P`\/]'N.:XVWNM)N?\`@EA;#4Y[>W_T?[/# M<7,/VC$_]H5^=U?:W[:7Q8GUO]F/X&:3>Z7]@N=6L8-8GM^X\BW\C'_DQ7GO MCGQ?X_\`!VD?#SX"Z%XM6'P[JNE6"SD?N//N;\^>1_S\>1F?%<[?W7Q=_8V^ M+RZ'9:X3X@."+:QF-_;W_G_].QZ5[5XB_;@^,1^+.M7UEIUC:^'?#4%Q!?Z- M/!_Q+Q0/)^S MV\XX_P"VXKZ3HHHKY"_X*5WOV7]G^"SWP'[=K=LN)YL3]?\`EA[_`.-9'_!+ MNWDM_@KXAF>.^59M=+1"Y/\`H^/LUO\`ZCVK[4HHHHHHHHHHHHHHHHHHHHHH MHHHHHHHHHHHHHHHHKYC_`&]_"?AG6OV>M8U76;:">_TD&?2;BY_Y87$QQFMK M]ABZ@N?V7/`HA`)"W,,OU%Q/7T%4-%35#7Y0?ME^$Y_'W[:^H>&[*>RMM1U8 M:?;P7&HS^1;_`/'O7;Z-^R;X;_90F_X3KXM:CHGBGP^+&?3X-&@T[S_M%_.> M1SZ\BO+?"W@/QU^VEXK2W\,Z%HO@WP=H1"_V?;*8-/L3<>N!^_N*_2CX!?L^ M^&OV=_!HT/0(?/GF^:^U&X_U]]-CJ3^=>I45-4-%%%%%?&/BK_@FKX-\7^,] M:UV[\8:Y;OJM_P#;VM;?R0`?.SUQTZ?YXK\^?CY\,?\`A4'Q>\4>%8)H9[>Q MO@8%@GP1;_\`'Q;YK[S_`."9?Q,\0^+?!WBGPWJ)KZ?6=8_X]X+:V M@_U'_3O;V]?17[*/[!.N?$?5M(\5>.M+&F^"!FX_L[SC#<7QQWQ_RPY''>N- M_;-T#0OA7^T5INF>$='LM,T_PU8V$\%M;C&;@'S\S_\`3&;JS^)N MN0>(K!@!8^&)LWUA8X.1/F<']]R?S-?2'AKP=H?AGS_[&T;3=(,W^N^P6(MM MWY`5O_\`+:BBBBBBBBBO@GQ5_P`$N(-2\3ZC?:5\1K^""^G^T'[?8BYN!_V\ M9IVF?`+]K7P5NTOP[\3[&XT>"?\`T*XN+[G[/[^?;W%?5'P`T7XA:%\.8+#X MEZI8ZSXIAN9B;JU'!@W?N?QQ7IE%>7^.?VC_`(=?#/Q5IOASQ)XKL=.U>_Z0 M,_W1CK-Q^Y'UQ74Z1\1?"?B5?*TWQ9HNHGTM-0AG_D:Z6&YBN1\N/QJG=WL& MF6.I_(U^='Q)\9^*?V]?BG_PK[P;A_`3P-!X;T$37%N,SSWUPV9[B;U-?GA^ MW!K6E6G[:UM-JNGK?Z-H\%A/?6LW2>VS]HG_`$Q5YO#_`,1_^"AWCJXUR$Q> M#O`^E>38`7-Q<&`]2?W'_+>?MSQT%?:7@_P/X`_8[^$NHW`N!;6EA"9[_4KD M1"XOY_)&>,CG@XA[=O?Y-U?XW_%?]N#Q$_@WX=V-UX(\&VYW:KJ!G!(M\8Q. M>,_]<(#WY-O!WA[P/XF\*ZYIFD:O!/K%_K.H@?Z1//G_408_P"/?]QY M'U'USY+\-/@7J'[5OQ5\07WP_P!"C^'W@X3SBXN?.^T061_YX'?@%X,_P"$=TP3:A-.,WM_<];@^]8GQZ^*OPP^!]E9WOBBSTZ?6&\^ M;2=/%D)[B:?'\/\`G^5?(W@S]E#Q5^TE\5H?B%XW\#V'@#P?=V\,XT:RE^SW M$^.S0\_Z_N?W!^IZ_4-S_P`$_?@;<3>7Q3U/X6Z!/8^)[?[1> MW$&H3^%=0N)X+:Q\[K<#_IX%>J7/[%OQZ\%^)1KO@KXVG4]1N?\`7SZU-<6_ M;//_`!\>?^->;>._'G[6?PW^(DWA7_A*;SQ%K-O8_P!I"#1]/MYS/`<_]._7 M]P?SKI_!G[0/[76@Z7+#>_#VX\4X'FK?ZAI9$V/3;;\5;UC]OGXV^&[:XTG6 M/@S]F\000;OM(M[_`)_[=_\`[HJ[:?\`!4XV-N+;Q#\,K_3-7[BVOR/R\Z`5 MZ'H__!3?X27<`^W6?B+3Y_*S]F^P&8X^H-:^@?\`!1'X*^)=-OI;S6;[PV;? MK'J%C/NE^GD@U[-HGQH\#:WH]AJMCXST.?3K^#SX+E]0@B!'YULV?Q'\*W][ M!8V7B72KF]G&8K:WO868_0"MZVN8+D?N9_M%?%'[6O[!+?%G7KOQEX'O8=.\ M17HS?Z??RG[-??\`3;/_`"Q/N*^<(/\`@FQ\=9[:WLIY]$M[8<_9AJV;>#_R M7KQ/QY^S-\2?`'B;4=)O?!FN:C]@G^S_`-HZ=I-Q<6]Q_P!>]Q]GKWSX:?M' M?M)?![PU_8-G\/;ZYT:WL/L\%M<>$[BW^P?]/'^CU\DW'GZE<>?/_P`?$_\` MI'VC_GO7VRO_``3'UN[^$NDZS#KAM?')+E_%C MP'K/A/6@QT[58#;3^2>8_I7Y??%S_@G?\3?!,\'_``C]D/'6GRC+3V!%N5^M MO3_VN=#\5ZE\4?A'\-O$]_\`:=0L-"TC3Y[FV_Y^+C]Q<7'_`)+U^K>G:6NG M6%O8P_\`'O!#Y(_*KE%?"/\`P4;^`/\`;&CV_P`3M%LIKK6;`P6^J_9N,6V? M]?\`ATJ7]B']LB]\?W$_@7X@ZS9/K,$,`TJ_GQ;SW^>#`02,SC,'YU]WU@^- M/#.E^-O"VJZ%K40GTF^@,%PA[J?\BN4^#GP5\-_`KPI_PCOA>">'3_.-Q-/< MSF:>:8XR2?PKTFBBH:*J?V;9>=]H^S0_:,?Z_P`FN`\1_LX_##Q;K%QJVL^` M?#^I7]R/W]U/8*9I?QQFN'\=_L+?!SQII!LH/"MOX6N/^6.H:`?LUP/Q`KS# M5/\`@EI\-I[7R;'Q'XK@N/\`GXN+BWG_`)V]<3XL_P""4\`T[/A;QPS:CYV[ M&L6($'_D#%9EC^P=\<_"^C3:7HGQ5BM-%L;8-8Z?I]]?VXFGQG/DYQ!^!-.\ M,?"W]M#P3J!M=-\1S7,./.W:AJL&H0_3]_S6?XX\>?M5VVB3OXY^&NG^-/"Y ME%M/I]_H5OJ%N9NUQ]GM_P!_CG]:L>*OVM[GQ9\/;7P-XG_9JU&YT<>3;_V; M!//!;'R3G]Q_HW;M7B]O\1_V==$\;3W'_"H-;UK1)^MMJ.N\V'_/Q]G@_P#N MBNI^-WQ0_9[_`&E]5\/3S7'B/X9'0;#^S^="^T6]Q8?\^_\`H]Q6=\9/#GP_ M^.WB;P__`,*^^)]O/K-AI5OHTW_"90_V1;FVM_\`EXM[C[-78?LQ_LPQ67QH MT3Q+\1O'W@_5C8W0G@MK7Q,+^XOK\G]P>?2OIG]MS1O&WCWX66W@_P"&?A:W M\0Q:W>A=4N8+B!1;B(B<#G@DE?K^?/;?LD_`F;]GWX/VWAS4KB*YUB\NY;^_ M%M*?(^TM@$0@]L1`U[C4U%%?GK_P58N;?S?AI;B'-^/[0G'_`)+U](?L4Z"N MA_LN_#^,SS7'VC3UN29YO:I;:/Q<6&G,<3_\`?C_EWK[R^'?PW\.?"WPO;Z%X8TJ#1M-@'%M; M#@5TE344445#117+R?$3PH+RVA/B72C<7A\F"W^W0DS_`$&>:\H_:[_:"L/V M?_AC=3K+-_;^K17&GZ*EN`?W^/\`7>P@X/\`^NOS<_9Z^"WB3]I_XLW'V[[; ML?:,7,)G&<#\J_87PKX0T+P#H5OI/A[2H-'TZ`8AMK:'`%;M%3 M45#6/XC\4Z3X1TJ?4];O[32-.AY-Q=3^2H_.OB[XP_\`!3GPGX72>R^'FES^ M)+\2!?[1U+-OI^1W'/G3_@*^'/B5\>?B/\>M0^P^)]5GUJ#SA/!H]O!F`SCI MY$'>O7/@G^P?KOC.^T^'QMXDTKP&+_F#P]<7`_MF>W_Z]Z_2'X>?L\_#;X3W M"W'A?P?I>F:A!!Y']H"W'VDCWG/->GU\K_'/]@KP=\=/B%<>,;S6]:T>_O;> M*WN(--,`6;!P)CQZ?R->R?!KX->'?@=X&L?#7A^(BWA'GSW5Q_Q\7L_>><]2 M>*]$HHHHHHHHJ:BH:*****\M^+'[-?P\^-"SGQ-X;@N+\CC4+93!U*[2 M3[>3BOK3_A"[34?!B^'M:ED\26TMD;&\.HKDWHQ@^=]?ZFL;X8_!OPK\&=!7 M2_"&E1:=;F4SSD@S3SGWE//YUZ%7XZ^-IO`NK_MM^+Y?B5<3P>#EUR_%^;*1IGANRN8+FQT\8GM03R8(+?W@/_'QUR:_2_P`%^"-# M^&_AG3]!\/V,&G:-80_9[>W'85^P\C'7\IZ[3X3_L[&V,7BKXJPZ?XS^)9OCJ`OR#/ M#8X_U,%L)^8<9'3OWKZ'KXS^,?[86N^+]@KZ$KRSXQZ M'XR\86S^#O#T_P#PCVCZM83K?>*;>?\`TJQ.`!Y$'<\]?>M[X0_#F#X3?#O1 MO"L.H7VM+I-O]G&HZC_Q\3^]=K7E'C;XX:7X=\0R>';>VU.?7IO(@AEATJXG ML5N)_P#4":>$'`./4<5Y!\._V+5\5^(M8\ M$`)S^-4OVH/AK\#/@!\,+CQ)/\*O"VI:A]H@@L=.(%O]HN.PKY&_9*_9"N_V MB=8OM<\1P3Z-X&A_Y>--_P!'^W3]X8/0#UK[$U'_`()C?!BYN//M['6]./\` MT[W]+/%2_4V_P#\CURNI?\`!-GQ;X2UW_@/6/!K7[;?@N8ZY?0:KK5M# M!_Q[>183_P#DO;U?@_;4_:2\`RP3>-/A1<:AIYFQN&DSV!'YUF?$O_@I!>^/ M?`'B'PM#\.+C1KG5K"?3_P"T#KDW^CF<8S_Q[9[T?L/_`!@^'6I^!+;X)>*_ M#EYF M^(=5YO\`4+:#%Q+[>S\30ZC<^$["XU'5X+&W MF)MH8/\`7GT)'M7YUWW[2^A>,_VU]$^)^J,;#P=I\WV;-U!S!;_9^M?J%\._ MBAX;^*/A&W\1^&=4@U'1KCI<\PBNKMW$JYCG$PI]-GMENH/*EYSZ5^=7[0?_ M``3&_A,WVF'PF+$$+!_S[6YKU[]B/]KE_C!IEQX/\67$/ M_"8:5_JKC/\`Q_0<8)Y_UW7(_P#KU/\`\%(-9U'2_P!G5;>*406NH:Y;P7I$ MN/,MP)I]OYP0UWO[&-OXAM_V;_!DWB&_FU&^G@GG-SOP6\5WWGKX$T:Z:W@)_ZY9Q^ ME<'_`,.K/A=_T,?BO_4X_P"/BW_^1ZQ?#_\`P3)O?#-O/!I?Q@UW1K8W'V@6 M^F6Q@_E<5G0?`/\`:[\`P3Q:!\0K;68)N06U;SR/_`BWK/N?!O[<&F6X,7B8 M3_OL_N+BPGX_\!ZWO$O[0W[5OPSLM.E\2?#*PU:W>WS+=Z7837!^L_D7!$%< M_-_P4@^(VE@3ZI\'V@TX',Q=KF$B#\;>NN\*_P#!4[P!#I_"<-ZUAI-EGT4444444444444444444 M44444444445S?C/5-5T3PGK-]HVG?VSJ]O9S3V=B6`^T3`$K%^)P*@\":UJV MO^"=$U76](;P_J]Y90S7&E.XS;3$9,.?8\5U=%%%%%?/_P"VOK=UIO[.?BL6 M>E3ZFM];_9YS;G)MX"3F?\.*M?L6?\FN^!/^O>X_]*9Z]PHHK"\9^-=#^'_A MO4-=\07T&G:;8P>?/<3G`45^=7C3QM\5?V\/%&I:9X&@.C?#VPX,.H2F&`Y@ M_P"7@#GJ3Q[U]2_L\?L6^#?@;#!?3P_\)#XG$($VHWW,,/J(01Q_GI7T;]G' MK14U%%%%%%0U\\_M>ZS9:M\-]0^']IXXTGPEXJ\1PL+&WU.]%N;F#I/"#],_ MG7Y1?$/X3>+/A-JUO8^)_#=]X=U"?_4?]-_^O>NY^-OQS\5_'P^!_#>IB>XU M'0X/L!_Y^+_4)^/Z5^G7[)?P#7]GWX2VVAWAMVU^YE^TZKXN)^!#"!R3^1KX'^.?_!3PZ;JYLOACI=E MK.GPX-QJ^KPW&)S_`-.\``)_&OC3XE?&GX@?'O5K?_A)M^"_[&/A7X.?$BU\9Z5KFJ7-U!!/!#;7/D8`G//2 ML+]H[]N2R^%7BY/`WA+PTWB[QS*8!]D!_<0SS$XMR1_RW(YQ[\U^>?[2]I\3 M[3XA";XJB8>*+ZP_M`6PZ6]O]HN/^?>O%O#WAV?X>V=Q8: M38V]AQJ)^T>1`,=/L_H*Y_XV_MJZM^T)XMT?0KRXO_`?PU-]B<:>?M&H3V__ M`#\7'_R/7U[^S)\2?V*=*TQM6FY75V\G4+BX_P"FY(%?0'BG MXH>%/"/@R?Q7JFNV-OHH'_'T9_\`1S7ROX>^(_QD_;.\-K<>']!TKP)\-KZX M^SSW-SJUQ!J-];X/-O<6_3O7U1\._A[X=^$OAFU\/>&]+@TO2;3&$@(S)QS- M,>/3K3/B)\8O!?PHM[>;Q;KMOHRW'[Z'[2<5S/BKP)X[\4_$G0-7T_XCS:-X M&M5BN;CP_IMC`T]],#QFXZ^21CCVKUVN<\:^.-)^&_A/5_$>MSBVT?2H/M%Q M<'TKRO6(_B-\6M'LO$7PW^(VC>'O"]];_;=/-QX9GFN9U/:9I[@8'_;#/Z5U MWP?^#^D?!?P[>?),YZ_AP/RKR?]K/]L33/V?M/@TK1XX= M;\;Z@3]GT\7&!8CG]_/]./W/4U\O?!O]D;QE^TE\0A\1OC%JC:?;ZJMOJ/V; M$,&H7X&/(_<8/D0>W4U^E>C:)8Z%I5KINEVD%A800>3!;6$\B$?2N=\&?&+ MP;X]\5^(?#>@:Y;ZAK/ALB#5+:&,_N#Z5T^F:?-;?:O-O9[P3SF<";'[D''[ MH>U2ZGJ=EIMOYUY>P6L./O7$_DBN1\;>&?$6N:UX>O='\57'A^VL+@SZA8?8 MH)_[4@P?\$UO@EH MEA\/1\1IC;:AK^H3&"#)_P"/&`8P#Q_KNN?PK[HM^AHKE_%?Q0$^"M5T[3- M?\1:?H^HZAG[%;WUP(#.?8FNHHHHHKSGX]_VI:?!7QQ/H>H7FGZU;:3W%? M*GQ5MM)\-_%+XAZ3I=A!_8UOJVH6]A_T[_Z17W]X5^$-G\+O^"E>*M$U'4Q%YWV;3]0AGFQZX!-=74U%% M%0T45-4-344445#4U0TR:W6X3RIAYPZ\C%87_"">&O\`H6]*Z>5_QY0]/R_2 MOR5_:W\!:%X5_:IUCPWX>TJWT;1Q]@MH-.TV#R.9[>W!K]>=%T/3_#6D6^DZ M;;P:?864(@M[>#@0Q`<`?E6O1111111111111111111111111111116#XCL; M_5-`U&UTB^_LC5)X9H;:]^SB7R)B"!+CO@]C4?@^QU;2?#6FV>M:H-:U:*WQ M<:GY'V?SY>Y\D=*Z*BBBBH:^=?V[-:U[3OV?=:LM$\.3ZV-5'V:^N+8_\>$' M>X_#BH?V`Q_QBIX-/D16_P"_O^!_U\W%?2%%>6_&?X_^#O@;HLU[X@U2WAOO M)-Q9:3#/BXO?8#O7P-I/AGXF?M^?$2VUS5WFT3X?V-\8>;C_`$>Q`QF&#_GO M/TR>G(K]$?AE\)/"?P@TDZ7X3T2RT>V;'G2V\`\Z8XZS'&3_`)Z5W5%34444 M4445#7@'[3'[)'@SX_:8;S4?^)/XGMK?R+;71@$#`P)AQYPXZ&OC341XY_9` M^$'B;P]XLETRYU?6]0A'A.=;@7$\)Y%S/!_S[X@^S_B*/^"=_P`&+SQY\4#\ M0-0N0-&\-S$\SS_:)[^< M(==L=M]/C;]@MYLC(Y_UQZ@5\5?LV?LM>(_VBO$>8?M&C>%H.+[Q%<6__D"# M_GO/[U^E+_!/PW^S7\)?$&H_#3PEI]SXFLK`SPW&I8\^ZG@!_?7$YZ\<_A7Q MWXO_`&N-'^,_[,3:3\3?#-]J&L0Z];VYU#1?]''3S_M'_7?B?_1Z\=_9P_9? MU7]H[Q;J%A#<3:)IUC!]H_M&YL/M'_7O7Z;?LV_LNZ#^SGH%S86=Q'K6K3RG M=J\VGP07'V?C]P"!GR1C@#UKW2BBBBCB`>U%>5_M&?#K4_BO\$_%/A319H+? M4]1AV0-<28ASYV>?P'\JR?V4O@.?@)\*-/\`#E]*+C6)I3?7[6_^I\\]=\"/B0/7PYJ'_I,:_/7_`()^?LXV M/Q:\5W'CGQ`WGZ1X;OO]'T[/,]_W,_TK]13=00+//-^X$/\`%,:^&OC]^V5J MOC[5[+X?_`::[U'6+ZX-O?:UIT)/R_\`3`G_`-']!7J'P)_8I\->`+#^V/&T M-CX[^($]]_:-QK5S!CR+C_IAZ5\,?MW:EKOB3]KSQ#803SW-Q83Z?I^D_9O^ M6'^CV]Q_Z47%?2/[-7_!/6'3+JX\5_&.`>(/$,]Q-G1VF^T6QR?]?/S^_/\` MB*]B\0_L$_!+Q'+-=GP$5FM]('^D""WOM/N+/#XD\96U\1 M87UO?Z@9_L^#G_CWG_Y;^U?8F@_\%(_@Y>Z%93ZGJ.J:#J#`>?82Z?/<-![' MR`177^&_VY/@KXDN[^WM/&0A-A82ZA/-J%G/;!8!U(,X'^1VKIWDT[XBZ_H& MNZ/\1+FUL4L8IY?#L$ML;?4+>;H9Q-`9\$>X^@S7J5S?V^EV<]Q/-]GMH!YT MT\_0"OSL_:>_;^'C.(^!O@W]NN+B_N/[/FUFU@Q<7'_3"P]3[UYQ\"O"/@7X M*?&#Q5/\3]>@U#XF>"X+C4+#1KC_`$?3Y[C[/]H_X^/^7BXKY1UKQ;JVM^)K MC7;V>?\`MF>?[1]I\_\`TBO>O!W[9/Q5\/?"[1_AOX9O9X-1@OL0:A`?M%_< M?].^.E?I?^S1\*[GX<^`+&;7[?2CXZOX`-5UFPL1;SW//[GS^^0/\]:\L_:< M_;XTOX&Z[#H7AG3K/Q?K-LQ&J6YN?(AL0#_J,_\`/<^G_P"JG'P5XD_;2>UO M?'>@S^#?AQ9P?:+'2&FQJ%Q?Y_X^"0,>1@\#O^=?5?[C1[#_`)8VMM;P?]^: MK:;XNT/4I_L]EJME<7(_Y803BMNN%^,VN6_AOX3>,-2N[Z32(8-+N&-_##YQ MMQY/7&.>:\)_X)L_\FP6W'D?\3>_X_&OK"BO,?&_[/'@CXB_$31O&/B#2_[1 MUG2H!!9?:)28`/.\[_4]"U>J5#11117B5W\#/AQ\%X/%7Q&T#PSI^E^) M+*PO[YM0"_6=L\],@5\:_L&_!_0OVA/$OQ)\2?$+0K#Q%;L;>?-R,_Z1<7%Q M<7'ZXK[=^._P,M_C1\+O^$%@U:;P]I_G6Y:>U@$W[B`_ZC!-=!\(_A9I7PA\ M!Z1X4T4.;"PA`\]@"9IB!F8_6NZHJ:BO@C]JS]D/5_"_B#3_`(F?!NQEL=:L MYX?/T31[?[TV?]?`/7D`U[#^R=^U2?CSX?U.'Q"-,T7Q=87A@;1[0-"WD\8P M)N3WZ>E?2U?#/_!43QMJ6C_#_P`+>'+&X>&RUV]G-ZR]9TA`_(;;2K&GGCCL*^UH#YT$+>V:=4U%>& M_M4?'FX_9P^&0\26&EP:S>3WL%A#:W$_D6\1/?-X?6W%O;K_TP&09_TK[^^#7[5.A?$;X!ZC\2-5@731H<-Q_; M>GVY\\P&#)8#\.:\$^(O_!46PL-=\CP9X4.LZ1Y&#J6KW'V8^?Z>1UKW/]FG M]L7PI^T4MU8PV\WA_7X1@Z?=3#]]QUA.>17T)4U%%%0U-1117X__`+5>N6<' M[;6JZ@FJ"_B@US3BTX_Y=S!]GS;U^P%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%0T5\Y?MSZSXBTS]GOQ%!HFA+K.GW$)M]4N;BY,'V"WP,SX/^N^@K M\\_^$D^*^I?LYZ<=$GFTWX;>&I[C[?PYK]`_`FD>&]!\,V-AX2MK*VT6V'D6]OIV/(A^E=-11<= M!4U%%%%%%0_:!Z5\\_M@?M*C]G3P+87%E80:CKVKW'V:PMKC_CW/0S&8@],9 MKXTN/VC+?]M74/"_PX^)H_X12"YU87%AK'AZ$X^T>1'M!G-M-!E>':+_P42^,FF>)=0U:75;' M6+:`;J"W<8^U:+?^<1_P!L)L']:]7_`.'G'P:\_P#U M/B/'_/Q_9)_QJUI__!3'X)7$_D37^N:>?^GG2;@5V'A+]N#X*>(UN!%\0[&W M,'7^TH)[#_T>!7J.@?%CP-XEL!?:5XST34+<_P#+Q!?P$?SKK([F&YA/E2"; MZ>45-114-345#1111117C?[6DME;_LX_$"?@CXYUS6[B'3=._MW/VBXGX_P"/<5YSK/C[XE_\%!?&EQH7A!6\ M-_#W2[@)>A+PPC[//TGN,?ZZ;&?]'Z?G7V)\$OV?OA_^R?X0N+V&\A%UTU#Q M-JY$#39FS@]A_P#J]:\)^,'[0_Q`_:7UW6OAS\%]"FG\*K,;#5_&D%QP/7[/ M7R#XA^$L'@K]K/3OA[JFNSZS;P>)=/T^XU`_Z/WEOHFG3W-W/ M#8V$$&9IYSCR?_K5\9_'/]J'Q;\2OB+I_P`-O@'>2S:C"W_$U\06$(N;>WR< M#/;R?^FXXSTS7M?P!_9-\,_`PG5C--XC\,QI_PH(N-.\1ZC:VWD7=S/QF"# MSQT\D\GIS7MWP3^#NA_`SP#;>%?#YO#IT,T\_G7)S-DGU[UI^*/A+X,\?P>1 MX@\*:+K0\[S\:E807'\Z_/\`^)GP!U;]H/XA:E8_#'X.:)X,\*V-S]G'BNZ@ MGT_S\_\`'P!;_P#W/7IVC?\`!+3P5_8]@=;\1Z];:UY,(OO[-GMVM_M`[V_G M6YQ7COQL_8(\._`+2;3Q'%\6X=%NC/BS.KP^1/*<9_T?R,$S_A7F_P`/&_:) M_:%\&:CX:\/ZOXBUGPM@PS_:;C[/;\=8/M'_`+;UT7PYT;XV_L9^++B_'PO. MM6Y'D3W!T_SS/_U[SP5Y;\=M:O\`XC^)=8\5ZK\+]=\*ZS?S_:+BY,\_V?\` M\F+>N%\!VO@P_P!LS^*+_5;:XM[?_B4Z=IUC]H^WW'_3Q_S[P?\`'O6=X4\6 MZMX)GU&?2Y_[.U&>#^S_`+3;?\L+>X_X^*^@_P!FGQ-JWA*Q\0_$?5/BM!X> M.E6%QI]CHMUJQN)[^_\`('D?N,?ZCG_7]Z^=+FYU;3=6\^>>>VUFWG_?W'_+ MQ]HK[3_9R^-7C#]D?X5:CJGC3PMXBUC1/$<]LWANVFN!Y(!R)R1_R[C_`%/6 MH/VZ/VMS\5-`T#P7X>BO](T^Y@MM1UZ"Y'/[\">WMSZGBOF7X9^+;?X7?%+P MKKME?S_9["_M[B_N;?\`T?\`Z^*^D?VD?^"C6O\`Q#FM['X976J^#M*AYN;J MX,-O?W'T!)Q7IW[0?QNMO&O[$&@W,OC6SM/&%[8Z=/?:-8:A;^??F=1Y\$H[ M<,9STZ5[Q^PGI=A8_LP>#9M,LI-/^VP7%Q.+@&'YKC58(A/Y M.,XMQ_B*^YJ***FHKXZ\<_M!>-[/]N3PQ\+]*N+*W\+7$,0GAN(?FF/D&JQ7L]_J&FO\`Z0++(YG@4^QGX/K7T%^R M=^U;I7[1NB7%O<01:3XNTH@7VGCF&8?\]X#W'^?IVOQ]^`?AW]HCP8-#U]9; M:>!OM%CJ-N?](L9\=17R/X;_`.":&KW?PTU72O$_B:U&OQ7@?0KJP\^:"VMS M_P`?`()S^_[^E.M,\2V,^I>*?#\-A:S_:=MLMQ/GZ0'`_6N]_:P M^!?Q>_:)^+>GZ5;Z-I^F^"]/$UO8:O-<9P#Q-/.H]>P`YK[LT^*6"Q@AFEW3 MB+!/O5VH:*Q_$GAG2_&&CW&DZUIEGJ^GW`_?6-_`)X3^!&*_(;]I_7/'3:Y? M^&]9\#:5X6\.Z3JMQ]@.G>&OL^?^O>XKZ%_X)KZ+X4\:_"SXJ>%-4L9KC4+^ MX']K9_Y>-/N+?_1__;BO,/B'\3?V>?AS>7_A;PE\)8/':VT_V>?7M7O1@\?\ ML">3^&*RO^"=7A^:^_:4T:Y-D-0MK"QG$]RT&!`3!@#\\5^N%%3445#4U%9. ML^(M+T-!_:&HVE@#WN;@0_SK0K\9O!_@*W^(O[8#>'+_`/T;3;[Q9<&XM_/_ M`.7?[1#5=1N+B"WU#^QM.G_`-'G\C_GX_\``BOJ'P)^Q+XK\)_LV^,M M7FTJ7_A9VN6T$%G8V]Q_I%O!]H!GM\_0FO4_V+_V/H?A)H1\9>.].A/C'F:" MWN1#/_9,.`1R!_K^O/:L?X\?MO\`P^^)/[.WC^Q\,W<[:S?`Z1!8:C#Y%Q+# M/Q]H'_3`@GGVKB/^">7C_P"'WP=\,^*=5\3^,]$T74-8GM[:#3Y[CD6]OW_\ MF*^__`WQ$\,_$K2?[4\,:Y8ZYIQ/DBYL)L@&NFHJ:BBH:*FJ&J.M:O;:%IEY M?7TWV:QLX3--/Z`=?Y5^,FH?M#>)!KWB&W\0^)+[QYX5UW[0+[3O/_\``>XM M_P#GWN*\TT71/^*9N/$OV^QN?L$]OI\&G?\`+Q_I'VC_`$C_`,EZ^I?^"<7P MP/Q&^-VH^.]2O23X:/G\?\M[BX^T<_\`I17ZGT445DZWK.G^'-/GU#5+V#3K M"W'[ZYN9_(A'XFOQJ_:5^*U[^T%\;]1O5FL9]-L3+/@1IU]X#\5P:-XJ\)_:+B_T[Q#_H]QKMQN//N?/_`.GBO2O^$`_X:B^.%OI/PV\) MP:+X5@^SZ?/J.G6'_+O_`-!"X_Z>*_0'PG_P3Y^"OAVUL!>>&?[;OX+;R9I] M0O)_WY'68P[L9S7R;^U+^SE\)/"OB>V\-?#C5-;U'X@W_DB'PMI_^G09!X\^ M;G[..O.:?:_\$O\`XD7>DZ=/_;WARVOS!_IL%Q<3XA^G^CUX)\3?V>-6\`>) MK;PU8Z[I7C3Q#//_`,@;PK]HU"X@_P#)>N-T7X;^+-;\2W'AK2_#6JZCXA@_ MU^G6\'VBXMZV/%/P,^(/@N"WG\0^!=;T:VGX-Q<6%Q4&C?%'QWX2TC[!HGBS MQ'HNG?\`'Q_9VG7]Q;V];'AW]H_XL>$I[B?2_B%XCM_M$'_+S?\`VC_THKNK M?]NCXZ6]];S'X@S7(@GQ]F^P6_\`I'_DO7LG_#TSQUY.?^$,\._G<5TWA_\` MX*L7#M;PZY\.6(\G,\^G:J"!^E>@^%/^"HOP_P!2DG&N>'M<\/PC_CW9E%QY M_P!,8KI+'_@I-\&;F]-O+?:WIXQQ-=:3.!_*NRM_VWO@G<0>OTK>^T#THHHHHHHKY<_X**Z MR--_9>UJ&*>&!KZ^M[80'_EMF<9'Z9KXP_99_90UW]I7P7.+WQ6?#W@:QU8_ M9[:UQ/\`:-0_Y>/]'/\`Q[_N,#\:^\O'?Q/^&'['/P_T^Q,-EIZF#R+#1=/@ M'VB^^G_UZ^=_"OP[^*O[=ND#Q#XT\2GP-\-KV=9['PYIT.6F$)P"QUW M4+_[/<7/GVXOX/M'V>W!_P"N]?2OA7Q+\3_V_P#2+:<:G#\.O`MDT]MJ]OH> MJ?:+B_/_`#P./YU]5_`OX`^&?@)X,MM"T&`3W)A`O=7NH1]HOSSS.?6L?X]_ MM-^&/@]H#M/N_C9>7G MAS1II?/_`.$$T3_1P,<":>X_U_KQD8_&OJ#3M.TKPSI5O8V,%OIVFV,&(;=? MW$$$/\A7A'[07[3US\.WT;PW\.]*'C+X@:K(#96!@GFMS#_$3..!V[UU>A_! MN?QM=^"_&/Q%(/CW08!F#0;^XBTZ*8CM#G^=>R5\Z_%K]KG2O!?C*?X?>$=$ MOO&GQ%*_N-'ME(MP<]*\Z\/?L6^)/C#JVC^,?CGXKE\0:U`89QX=L; M>!=.@AZ_9\8Y'7FOK+0/#6D^$=-&GZ/I=EI-B.?L]C;BW@_2MVJUQ;_:K>XA MFY!KB?%_P)^'WCZPGMO$7@_1=3MYAR&L1_2OC?\`:L\,?!:\TS4?AQX3^'0O M_B38^1;V%IX>T?[.+`3^3BXGN,>0(3\O7(X[=:VU_P""5O@UO#<%N?%?B+^V M/(S-=#R#;&?'7R,5QNH_\$R/%GA)S>^`_B/#;ZP!F!KB">P'_?\`M^:JZ;^S MO^V'X3T0KI?C0W'GS_:?L!UPW$T'XW'%?-WQ5\`?&?QMKUQ?^+_`GB/4=9@G M_L^?6K;0;C]__P"`_P#Q\5L^#/&_PV\-GP]8^+_@%_Q+O(M[?5M9N+^_^T?] M?%>1_%3_`(1/_A.]0_X5[]N_X1;S_P#0/[1_X^*Y[]Q;6_\`T\5^V?[+5GI^ MD?`+X=Z1%J4-U.-)MSGSP9SD>=_6O2?'$_B*W\/7)\,0:=-KI_U"ZK*P@_3F MM73?/^PP_;?)^T^3^^\GIGVK2HHHHHHKYV_;RURWT7]E_P`9I.?FO1;0PX]3 M<05F?L!^"[?PI^SGXN&?4+AB>6!G;R!_WXVU]+445-14-HQ7HGP^_P""EG@6\\"6,_C"#5+#Q/#^XGM=/L3/Y_'^ MO@]17UE\._'&D_$GP;I'BK1)_M&D:K;BYMS['_)KJJ*AHHHKXB_;@TSXYZ)X MKT_Q'\/=4\1#PO!8$7%MX>.3#..`?([\8_.OGOQS^T[\<_BO\+[GX?ZGX+O[ M@W%O]FO]0M]#N//OOH.@K-\>?`OQ]^S#^S[IVMG5-4T?4_&-_P#8=W_`.GC_IXK M]$OV3?VV/#GQ5\1:;\/HO!4GA&Z6`_V3!8D3V'V>&'/$`@QT`QZ5]CT4444 M445\!?MW^/?@5XMURV\*^+;G7+GQ/H@W?:/#MO!<&`G_`)87&3Q]*]C^$'[2 MO@#XP?"OQ'H7AV^U2YF\.:%Y-Q#K,'V>YG@^S@>?CZ=Z^*?^";OAR^UG]HFP MU>&"*YM](L+BYGGF^]#Y_P"XP/RK]<****************************** M*******AHK\I_P#@H9\1?&6H?%'4/!OB#[%!X7L)K:_TFP@ZG'_+P?UKPW1? M!/COXQSZCXLGT+5?$=O<07'GZU;6_P!HM_M%O;_\_%;'PL^*'Q`MO`<_P^^' MUO>FXU75_P"TIKG1K>?^T9O^/?\`T?\`Z]Z_1CX&:%GK6/\``+]N"R^.GQ8\0^&UT*#1O#]M;FXL+^YN M,7%R?M'V?_45\@?ML?LO0_!3QD/$>@006_@C7)\0V]N,?8;C_GA^->E?LL_L M->#/C3\']-\9:UJNJV]SJ$%Q;_9[>>#_`$>>WN/L_P!HZ?\`3O7VI\"_VAW5AX8MI_/O?FO;J[F,T\Y]S7J=%%%34445#2-")ADU^6'[;'[(>K_#C MQE_PDG@S0;BY\'WQ\_[/I\'VC[#?]G_L[_EX^T5^S'[)_P`'8/@S\&/#NER:7#IWB&>VAGUO!S*UQCOC_/6O M;****_*__@H'^T]_PLSQ9<^!/#S%O#NA7&;^YMYP/MUQC_VWZ_C7HGP1_88U M6U_9J\=3:W!#_P`)UXMTK%A;>?\`\>$'_'Q;V_\`X$5\/^%?AOXL\;07$_A[ MPWKGB.WL/]?_`&=87%QY%?K5^R1$-#\/_#;PKXJU+P/8^&_B%-I0@U"Y%B+ M>Y/J#^E?05%%%8OBW5)?#V@:GJD-O]J:RLY[@6WG>5YI`SC/;H>?>OP]^'WA M6;XX_&[2-+=IEF\2:KFY:`XGMQ/WR&N M+@KF>]FQS/,>YKQ7X^ZG\5?CCXCUCX=?#BWOO!ECI6$U?Q%J`\F"_MYX#Q;] MS@D_K78?LN?LF^'/V:-&U`V(=0\"?`6/2M=U&TAVZKXGNK@"VTEB)@![GY>/J:Z7X#_`++'@;]F#0KG MQ)`)IO$-OI1&KZSU?2;VXT>>QGN)_[/ MM[BXG\^>X^T?9[>OTK-W"EB)YY!!;^5YTWG=A[U\7?$W]O;2=>O/^$:^#W@[ M4/'7BJX^T00SK9G[/`VGFQUGXY^E?0GC3]D[X4^(Y[_5_^%<:'J6LM#/_``^1Y\Y^G\Z\XL_^ M">?PPURY_M74]'N=&N)]/$$NCZ1J33065QWG@G($^?Q_"LW4_P#@EM\+YK0Q M66N^*M/N.UQY]O.?UMZQO^'57@__`*'GQ#_WY@_PKSSQK_P2X\1VBW-SX8\9 MV6HD3;H+34+;R&_[_CFO+M:_X)Y_&[3;WR8-!TO41_S\6VJP9_\`)BN5UO\` M8J^-FAQ3WMQ\/[VX:'H+>XM[@G_P'KS:XTWQGX;U?R/L&N:=J-A_H_V;R+BW MN+>NYT;]JGXS>')L0_$CQ$9_349_M'_I15CP[^VK\;?#ES;F'QS>W)\_S_L^ MI"WN/M`KU7_AYU\7_P#H$^%?_`"X_P#DBNQM_P#@J_XE\C_DFVE?^#:X_P#D M>NWT?_@JYX5N+?\`XG'@?7--/K83P7/]:ZC0_P#@I]\*K_3[B74[+Q'HT\/^ MI@-B;@S_`$\C->@^!OVZ/@[X_P#$\&A:9XI$-]<6_GP?VA$;>W(_Z['C]:\$ M_P""GGQ(\.:E\+/!VA:9J=C?W%_JW]HP7%O,)_)AMX#D\'O]H%>:>!?VI?"G MP%_9NT_PIX`TF:Z^*.N0&XO;BV_Y87Y&(+@_:/\`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`$?3 MX!Y^M>(K[]_/[SG\:9\(OC)H?QETK4;_`,/QZ@]A87C6'VB^L3;BXQC]_!D\ MPGL<=J]+HK.U?5++0M/GO]2OH+&T@7]]<7$_D0Q?B3BOA+XZ_MT:MX\US3O! MWP*A_MFYO9SI]QJ=SI5QB"?_`*8?A79?LX_\$\_"OA/PEY_Q.TFQ\5^*;[F> M"X&;:Q]K>OE']J3X&^&](_:PT7X?^$8+'PII^KFPM_\`1Y3+]GN)S_Q\8/-> M_P!Q_P`$H="M;6X.C?$'5;;4O^6%Q/80&N:TW]DC]I[P'=W5IX2^(,0L+;%O M!NUNY`N(.V(.D!^E5[KXC?MG>`[-6OM(U*ZL=*'[X_V3;W!N![?9ZVKK_@I% M\1_!>G0#Q?\`!EK6)M5L-.3Q3)82WZX@^WV5Q!N_[:D8_6O9_#/C?P M[XNMS/HNMZ;J\,7\5A?+<8_(UTU0U-7PW_P5$\8W%C\/?"/AJ&^%L=5U">>X MMO\`GO!``?ZU[K^Q[?RZW^S+\/[B>::>X.DK"6GZD^_Y"O;Z\>^,'[3'P^^` MLUA;>+]7>VO[T>=;Z?;V\MQ._N,?_6K/^&/[7/PQ^+7B2_T+P_XB%QJ5E!]I M87$/D^;#ZC/_`-:O3(?&VA3@>5KVF'S?]3MO83GZ?Y-=+4-%35!-;+<+B7I7 MYP_MP?L5'PXNH?$'X?60;1Q^_P!6\/VT(_K/_!-OXZP:9+<_##6[ M^4"^G^TZ%NZ_M_P#2?WYGO_M'TZW'_/>M']C;PM?:O!\8KZ>>XT;P^W@V M_M9O$(_T>W@N/]'_`-'_`"R?PKUG_@E3H\TWCSQQJS#-O!I4%N/K/.3_`.V] M?I=11111111111114-3444444444444444444445#117QY\=OV3=7^,'[57@ M_P`63V-E=>![>PMX-6%SRT+5?`? MPTTB^_Y`UOY_]G_\?'_DQ7M/_!/;]H3P9\.M$N?`FMB]@\1:[XE#:>((3,,S MP6\`Y^HKJO\`@IM\']'[>XN+>Q_LZ?_B83ZA;V_VC[/\`].__`"[_`.D5]=?L^^,/ M%G[:-WJ7A7XD:%8ZE\/+#2@8;F"Q^S_9[_(\@V]QVG`YK[=^&G@#2/A/H%OH M/ABP&GZ+#_R[?\\*[NWZ&BIJAHJ:BBH:**\[^.7Q.MO@U\+?$'BJ1K?S[&S; M['!<2[?/N<'R(?Q/\Z_.+]@[X4S_`!?^-]QXEULP:CI^A'[???VC`)_M%Q_7VR?PK]8:***^6_V[/VC9_@;\/[?2_#UPMOXRUW(LKC;_`,>,&GY5]:5#1117F'[2>L7NB?`/Q_J&E_\A&WT2X:#_ODBOR$_ M9X\6Z[\-_BUHWBSP]I,^M:AI-O<7']C6W_+_`/\`+O\`^W%?;.G^$OC9^U]X MAU'_`(3&;5/A9\,)K>`3^'H3BXOX<9_E?7^FVVA?!WX:I$;N:V\ M/>';'_CXN)?.86\`[GZ#%?(,'QA\%O@IX2MO#GA:P&G6$`X'6:8^I/6OG#]N7X ML'4_"6L?"3P[I/B'4/%&HV\%R?[-TB>YMY+?[0!/"2/8?K[5SW[//@SP=^QK M\"K'X@?$;21H_C>^N)P3<0^?J`,Y_<6W'.<05/=^$OB=^W'X;T^Y\0WO_"MO MAY->D3:`UK_Q,;@0'B>'Q<6\-O]@T4P6\$&/;%8>H?\$OOA==>3Y&N^*K?' MI<6__P`CUQGCC_@E;H=V)I_"7C&^T[(Y@U>'[2H_'_ZU>)^*O^":?Q6T2U#V M,_A[Q&V,_9[:\-O/^=P,5YOJ/[&'QNTV#SYOA[JO_;O<6]Q7FFH_#?Q9IM_J M%A/X:URVN+#_`$>>V^P7'[BN6N;;^S;BX@G@^S7'_+>WK[5_X)V_LXP>/M4M M_BA/JMQIT_AO5OLQT\67G6U\/L_7/_;QVK]+?$6MP>&]'U#5;W_CVL(///D> ME?GQ?_ML?$W]H+5W\&_#;P7<>'[;6)[>WAUB":!]HZ>1!P.]>MV_[ M&O@#X+V?B'XC^-+_`%3X@ZQ86-]J$]YK!R6/4SXQ_K\=_>OAS]E#]I>']FG5 M/%>N#1#X@N=0@M[?[`M^+B M^'@1WZ05\^^./VP=>^)V MMV_@W]GC2CXLUKBYO_$5Q!]GL+&#SL'/G@9/6MGX#?LK^*K2]U7Q#\:]<7QU MJLZ_9[;1)Y_M^GVX&,3@7`_UW;/:OJ;_`(]JL5POQ2^$7AWXT^&6\/\`B>WN M+C26E$Y$%[-`V1TZ?6NPT[38--MQ;V<`MX/:DBN8;B4PK*&8#]Z*MT5YY\;; MCXD6_@LGX8P:)<>(3.,C7Y2+?R>YX_"O*/%?[%'@_P")/QC_`.%B^,EFUFYG ML1!?:%6,\>M=)XW^('AC]GWPYIW@?P1IVEW?BHV_P#Q(O!H MO18M>YFP0"1@<^<>_3WK@;K_`()\>%/&^K+KWCGQ3XJ\2ZP6$^;G4/\`4#_G MB/:O2OC7\1M$_94^"-QJNC:/8V]KI2_9]+T>`_9X,^G'XUC?L;>/_B'\2/A7 M-K?Q'M_LVH7%Z?L1GLOL_FV_8X_.O4/BG\2=,^%/@75O$VLS06UK8P&<>?M>HU^;OQ+\)67BK_`(*; MV%EJ@LEL8)K&[Q?3^49S!IY/'K7Z1445!?:=;ZG`8KR&&YA[K-'D?K7#>.O@ M?X&^)'AF;0]<\.6%QIQ'"B#R?*]Q7C/CO_@GA\(O%NFP1:9IU[X3N!UFT:X^ M:7Z^=G->8'_@E?I-K^_TKXC:O!J,'_'O<7%B/W/ZU6OOV1_VC/A-K?V[X<_% M:?68IQ\PO[XPS@^@@N!<6YK'O/B%^V7\,_$-\^I:3?\`BNUB`,WD:1!/!C_I M@(.?SK8_X>6^+=$E:;Q%\'+FPT^#_7W)N)[;'_?ZW%>"?MD?M+:%^T;?>#K[ M18+W3A86-Q;WUM<#'V>>>ONW]C?XM>'/$7[.?A"`ZGIEC?:38#3[ZV$X@\@P M<$8].A_$U]$6UU#=0>=#,)H3W'-?!7_!2[PWX&TS2]'\1W%C.WCJ]8Z=`;:X M$`\C.3/.?09V_P#;>OE:YMM$^$WP*\/:K97UYIWQ0\6B>Y]X-!_TBW_\F./\ MBK_[$_P%T/X\_%#4=+UJ^FTZVTBP_M&$V#8GFG\^WY)K]DZY7XE^-;?X;_#[ MQ!XKE@EN8-(L9KYK=?\`EM@9Q_GUKSO]FC]HB3]HWPIJ^NKX=F\-VMC?&PB! MG^T&<#OGR1@?GUKW2H:88A<*8IHABOEO5_V`?!DOQ=T[QSX?U2]\+K97]OJ! MT;3K>#[-YT'3R,C]QGVKZGK(\2^)M*\'Z1/JNL:G9Z/8P#FXO[@00#ZDFL_P M7\2/#7C^VGE\/>(-,UY8/]?_`&;<"<#\C73T444444G$4OL:GHHHHHHKGO%N ML_\`",^&M5U6.SFU`V=G-/\`9+>%O!?@ZX\&_V3/IUQ MJJF_%P+WS[@\BX]3Y%>U?\$L;#3;?X8>,+J.(?VWZC!:M, MRW%_.9[B8M,9>3WZG]*ZZBBBL+Q!XAT_PGI%QJ^JWT&GZ?`OG7%U=3?N(!]: M^-_@[^U-\3_VB_CY;6WA"P@T;X>Z1_R%OM`^T">W]I^T]=W^WGXTU72OV>=9 MF\+ZK8^1]H@L-=@Q]H_T>X/D5^5NB^))_"6O:=KNES_9M1L)_M$%Q_S[W%?> MNM?M/1>$_P!G^V^'_P`7KG5-1\;>)-!G-]/;009L(;C(M_M'.//QCBN7^'?_ M``3)\277BZ$>--6TL>%[:?\`TC^SY3]HO[?V_P">'X5^A?@GP%H?PX\):?X; M\/6(T_1K"'$%LO:NB`AG`FZ^].J:BBBBBBBBH:_.#_@IY\6M"US5/#W@>R\B MXU#0[C^T;^X_YX>D'XC%>K_\$WOA#+X*^%]SXPU2$V^I>(]IA6YAQ/#;PY4` M_C_*OLBBBJMS<"UA,\W$$-?B[X]\7>,?VQ_CU80PSV0OM4F^P:5;W&88(+?^ M9KM/#O[7GBO]GC5_^$,\%6]C_P`(;H-_<>?;7,'VBXO_`/2/](_TBNOLOV)I M?V@O'ESXK\":[I<'PNUV^%S!?K-_I-A_S\6_V?\`Y[^]?IGX=T:#PSX$ M?#>H:YJ4WV?3K"":>3# MJ^G_`(GFX`Y/_+`B?OBOMWP'X'T_X<>#=(\-:-#Y&GZ5;BW@'M725\H_M._M MMZ'\"]1UGPK9:5>7_C&WL8+B'S[?_0(O..!EOZ?Y/9?"/X+OXG\`--\5-0'C MS4/$+6^L7.G7S"YT^QN-H.+'/2#D$?AZU[Y111116?J>JV&CQ":]NX+%9I/* M#7$WD@GV/K6A7,^+?B!X;\`Z=]O\1:S8Z!8S3>3]HU"<0`GV)KHK:ZANH/.A MF$T)[CFI********_"3]HC_2?CA\0YYH)[?_`(J74/\`1[G_`)8?Z17V%^RQ M^TCX$_9I_9;MI=*KV]OY[7P];6^+I>;IOA_18(?)@@.(`*_,W]IW]MWQI\3YO%.A>#2(?AQ`)]/N;JVMS.+^#'-Q M/.8#]F'M7S7HWA.R'P9\0>))A-_:\&NV&CP'R/W'D3V\]Q<*[WQ5=0VUQ.=(U"X\^#'UG^IKJO#O[+W[07[2OBM1\09] M< M]R>?SKT2L7Q%/J%AH>H3Z/8C4]0B@)AT\S_9_/F[#SCTKSG]GZ?XN7^GZS=_ M%;3]$TZ!]6\:^,;@`K86 M\$T$`@]?M&,5?\1?M#ZI\-OV;KCXA>//#-OX5\0_9C]G\/7%[YQFN#GR8`1W M/%?"/[&?Q5\1>)_VN["\U7Q)>Z8OB6^GN;[3_.G-M>7`M[C$//'!Y_"OT+^- MW[4?@#X!FVA\6WTXU&>'SX=/L8/M%P1Z@5WG@'QOI7Q(\)Z/XIT6;[1INJVX MN+<^HKI**XNP^%'@_1?$4VNV_A[3$UJ:XFN3J)MA]I,TQ^8^=UYZ?E4GQ6US MQ'X;^'NLZAX2T0>(/$-O!FQT[(PTWO\`G7SU\#/V1X+NRUGQ)\8M-M_$'BC7 MK\ZO<:-6_A7P%H=GXR^($\/VF#P\U_!; M&"WY_?G/:N&T?]F'5?CE?:=XK^/HLM0UFQN3/8>'=%F_XE]C!_S[S_\`/Q]: M^B_#OAS2O"FDV^F:+86FFZ=;CR8+:U@\D1#T%;%%?G?\'=$N?C%_P4-\9^*X MO)U#2/"=]6W]W["(`/R%>0_$O_`()[_#+QKX9M]+T" MT;P5-;W'V@W.G_Z09^/^6XFSFO+]&_X)J>*M-TA+#_A<]]IT$72UT^QG$'Y& MXKG?&_\`P3+\9ZK:9M/B?!X@-O!BRMM:M[C`/U,\^:Y#XJ_LH?M(>+=/\/P: MWI7ASQ6-/@^SV-SH_P!GMKBWM_L__'O_`,N]8OPFTKXY_L?ZY<:I#$3J%O< M0?O[D6/VC]Q_U\6_^H^E>J0?\%2=>@/D3_"F'S_.QMM]6GQ_Z34WQQ_P41$ M_%;X'>*?#5[H>J^'?%&JZ3<6ZBW'GVPGQC`G%7?V'/VG_A9\,?@O'X:US7+; MP[K,%Q6'CC0=6D/V'7=-N2)O)_T>]A;_`#]*Z"BO)?VA_P!H_P`-_LY>&;'5 M-?@O-0N;ZX^SV6GZ>,SSM["OSE_:`_;9F_:`MK?2;WX?Z,VD0SBXLC=75T9X M+@>D\)@Q7$_!SQY>_LL?%&XUR_T_^TO%,%C/!;Z+;W'^C_O^GVBL_P"*GQ]^ M*_CZ^QXN\2>([;S_`/F'#[1I]M_X#U]`?!/_`(*&R_"_X37-CXM_M3QSXI@U M#R;*VG46_DV/D`Y^T?A6C^R;^U/XKO/VBKK0O%VM3PZ1KTUQ;6VBZA.,V%Q_ MR[XS^_["WY]*_2FL_7=?L/#FDWNJZI>0V&GV<)FGN)SQ"/4U\/\`C?\`X*(W MWB+4[;0_@SX+O/%6I;?FGU&QN"%SS!B&#G'^%<+\!?VM]8\`?$[Q1+\;?B#> M_:K=IM//A:&R-P8)P1U-O^X@_K7WY\-?B7X;^,/@ZV\2>&+]=1TBX^[/Y77\ M*ZZDW#S?*[8S5*YU2QTV>&">\B@N9_\`4P3S8S]*U****X#XW_$[_A3WPO\` M$/C'^RKC6O[*@+C3[?[TW3I7ROX5_P""EWPUO].%_K_A34])UPS8,&GQ0WH' MN)SY-.M=^&_A2#P\+C7+"WN,:1]FGGN/M-OH_\ M$R]`ETGX`ZA?/]W5M;N;N']]G@8M_P#VA7V'111111111111111111111111 M11111114-0V>H6^I6XGM)XKB!O\`EK"V:N5#7PO^T9^WIJWPE^*MQX2\/>&X M+^'29X/MUU?3X\\F#)@&>F3_`,MSQVKT3X+_`+<7A/XP_P!LV_\`95[H@TC2 M!J]_<7_D"#:/]>,Y^M8/P]_:@\*?MG:]K'POE\&ZH/"U]I/VB?4;F?K[5XU\ M?/B3X6_97\-M\-?@A-]E\0:K<"?5=1M[X7%Q8G_4>1U/[_\`PKY3U"W\6?"_ MQWXA\-ZU?_V+K%Q_H^N_:/\`B8?]/'^D?\_%5_`GA+Q9]GM_%GA>W_M'4;"_ M^SP6^G?Z1J,%Q_U[_P#/O7V=^SE_P3\U?4M;_K MYGK]#:***FJ&IJ*****AHK\5?VP=2AU/]I3XE?8YOM!_M7[.1_V[U^O'PGT6 M3PY\+O"ND333W%Q9:5;0%KB7,^1"!R?7_/:NRHHKXZ_X*%?M"V_@/X>3^!M% MU-?^$GUS_C[@ZF#3\8N#^5X,XQ7SU_P3T\5:%\,O@;\3_&6JB2(`1]?]>:]YMO# MLG[:7PNMKWQ#>:MX8\'WUZ+FQL-$F%M<7]OCI?"XM_4?\L#WZ\5]$Z5HD&B: M1;Z98K]GM[2$00^PQ7-^%/[<\-^$_P#BM=$;>:XTZXL;"&W4:L.T\%SS@5VVM?LD?#3Q9>: M-?\`B+0I?$.KZ=:06S:MJ-[.UU=^.:]OHHHHHM^AKF?'GC>P^&_ M@O6/%6J'_B7Z59&YG$/H/2OS\^%GP\\4_MV?%V?Q[XS6>V^%^EZJ3;:)?RFX M'`_X]X#T'I/FNC_;^^)'B/QU\0M!^"G@QKT3W$&[4(()_LUO?">O3?V-KC4)_V9OA^ MU[9P6J_V>(8!_P!.X_U'Z8KW.BIJ**AHHK\+?VD/])_:`^)?D?Z3_P`5+J'_ M`*45]J?L7?L+_P#".V]OXY^)%G97NHW$/GV/A^XM_/@MSU^T3Y&#/7T'\>OV ME=%^"]C/IUE;S>(O&]S;W%QIGA_38C,;CT\['3\Z\!\,?LO?$#]I;Q)8^,OC M=J=S8^%U!O\`2/":S?Z1!!.`?LT^;<#VS_K\\$@UW_\`P4%&D_#G]E34=#T: MPATZWU:_M]/%OI^+?'6?_P!MZ_.W3?C!]E_9\NOAC/X5LS;7.JB_@\07/^OM M[@>1S^O_`)'%>U?#[]I[X5?LU>$])'PP\.S^*O&UR,:YK.OP?9F$'>#/YSV-QI\$XG"D'U_P`]*[#QS\3O#?@/2-2F MO] M)?%=E\0O#6B:9X7.I>'-0AN&U77EO!`;#'^I`&,DGFK'@_PAH7PI\)P:3IKS MV&DV`EF,U]!]+\136W@^Q^T06,ZP">W8P< M7$_./8N>&-"@U(6/\`:&C6-MJ,_P#J/](_X^/_`"7K ML-+\.VO@'06^-?QHAM_%?BKQ%^^T+PI?D?Z:<`_;[CT@P1^=>Q_#3_@I]?6V MMZ?;>,_"FE6WAZ<8^T>'[C=<6/UMSS7Z&VUU#=00S0S>?;S]#ZUY-\/_`-J# MX??%'XB:MX.\,ZLVIZSI\'V@XAQ;3@_\\)^AJ_\`$3]HOP=\,/B#X6\'>(9Y M[;4?$N?L4P@S!Z?OCD8_STKU2BLG_A&M)_X2#^V_[-LO[6\CR/[1\@>?Y/\` M=\[KCOC-:U+?!6H:3X:\23>%=8N5Q;ZO!!YYA/T/%:/A/2[[1_# M=A9:MJ?]L:C!"(9[]H?),Y]<#I^%'BN>>Q\,ZK<66#?PV<[0^<>,@9_F!7Y_ M_P#!+/4;C7/&?Q1U:\:6:XOHK:YN;EN\\]Q<$_RK]&*FHHJ&IJ*AHJ:BBBBB MH:;]FA_YXC\JX?Q'\%/A_P"-=4_M#Q!X'\.:SJ(A\DW.I:5!/.1]2#7'>(/V M./@SXEBG:?X>Z7;>=][[`AM<_P#?G%<9XH_X)V_!WQ%9B*TTB^\/3B3)N--O MB6)_[>!/_*N`O?\`@E;X&>?S],\8^(],/_3QY%Q_,"K'A3]AKQ]X$T[48?"_ MQUUS1A-"1!;V]M_HX(X@_P"7CZUQ_P#PI;]LO3II[*R\=_:+8]+AM5@!_(V] M>=?&'X>?M1Z^='TOQSX:_P"%A:=IA%Q!/;V,$XS_`-=X/WX->8>*M%'A2^%Q MXG_9TGT86-O;\VUQ?V]M_P!O%5M7\1_!*>^MM=\/P^./AYXB_P"/C[/IPM[C M3["X_P"F'_+?R*W_`(?Z)\%?B!<:?KGQ3^,WBC4=0@F/^@76DW!Q!;]+>XG_ M`-(R/Q%6O%WP=^&-OXQMK_X6?'/2=+NYY_[0L;76(;BQ%A![7/\`]85];?LO M?LI_"OP@UIXTL_%$7Q#U\#[1;ZFE["\-O/CG[.%P<]OWQ-?8?V@>E?D7^U3\ M5O$'Q6_:"U#PIXCOYO#WA33-6_LDV(N/(MXH(+C_`(^<]Z\X^"G[0?CG]GWQ M)IVJZ,)SHHA%U/HMP?\`1YX)SD?R_P"/BJ'Q$TW0O&WQ$_XMY?\`B/QI<:]/ M<:A/;:CI/_$Q^T?^W%>M:7^TKXB^&WP-@^$?@SPU"Y[_Q7XCO0;^^U#Q$?]&L9 MSC_1X!WZ5RO[/'QF\?>*_P!JWP+K-[K=[X@UV]O?[-F6;Y<6T_\`Q\8MQTM_ M^7BO??\`@HW;P6_QV^$E]I=Q-!XJ'$##_EC^_'V<_P#@17Z'5-114-%-%OX<^;B:PA89_*OB__@H_<:5X"^%W@_P-H$%CH&G7U]/?RZ7I M]D(('$`!S@``=Y'WK[_CWZ?\?4]?2%%%%%%%%%%% M%%%%%%%%%%%%%%%%%%%%%0T45\X_ML_&;Q%\&/@VVL>&EBM]0O[[^S?M[]+` M$3?O\?A7YN>._P!I#7?B/X9U#2-:T'PY<:Q?SV_V_P`56UA]GU"?[/\`\_%< M;\.]$\2^-M>M_"?AW_2;C7I_L\]O_P`N_P#V\?\`3O7V'^SU^T'\#/V:_)T" MT@U'6]5N"+?5?&-O:YM_/[^1SY_D9K:_:/\`^"?MS/JS>+/A8!/<3W!U&^T; M4+@D7$_K!QQ7QGX=T3_A9'CS6?\`A(?$MCX MQ@^SP6X["MRBIJAHHHHKX*_X*L:W-;>$OA_I($/V>YU"XNCF;'^HM\?^UZY3 M_@F7\._&,^O7_C*+53I_@6`W&G_V>`#]MN,0I MVQT:"XA_LR"?%E<^?]OOY\_ZDGIY&.M>I_#WP#H?PP\+VOAOPS8C3=(@ M\WR8%Z0\]JW--U"PU$&:SGBN1#^Y)AYQ[5=KY4^.W_!0/P5\&_%5]X5ATC5O M$.L6,P@OA`/L]O;_`%G/>NZ^!/[7?@7]H2_N-)\/37EMKUO!Y\^G:A!M*C_/ MTKW&BBO&OVLOA[J/Q,^`7BOP]H\5O-J+0">""YCR)VA(E"_B0!]:\$_8"^*O MB.'0+7X7Z[X`UO2[32#<3PZT;"XMX.9S-^^,_(/S=?P[UZ/\,_V.['PI\??% M/Q0U[5QXAU&^U"XO])MR/^/`3GFL+XU_LQ^/_P!H7XISQ>+/%<6G?"2Q/GV& MFZ1Q1/!<_P#$VN/])_[>*^_?$/[3OQ`^('BW3OA_^SAHZW&@ M:']GL+GQ"+#_`$8G_P!H0<#GVKW/X`_L?^&_A=<_\)+XBA@\4_$>YOI]2O?$ M=R#D7$_+>1GH.E'QU_;5\$_`OQ/8>&[PS:_J]Q-_IMMIXR;&'U-?"/[9^L?$ M[Q!HVC7OQ-G_`+%G_M:_M])\+&')-OC_`(^"?]03B<6^37?_`+._[*7AK]H; M]DAG@NY=-\86NM7[65]YI\@7!,&#Y/3'RP?E7R=\2_`/B3X3ZJ/"GB?0H-&U M"QGN"+GR/^/C_MX_Y>*_1[X46.M_LU_L[_#^Q\`_#V;QYK^N@:EKMNU$+BV MN9X,[KC/H0(/P%7/#?[#MCX^\=ZE\0?B^TVL:WJD\LZ^'S/Y]M86^<0VWG?\ MML`=Z^E9[_PW\,_"!R++P_H&DVIN/(@A\A8+>+GB''3BH/AC\4_#7QD$V_B M+PK>RZCH\\IB6?R9H,D=<9_#GWKM*XCXM_#X?%GX>:OX4;5)M&@U6#R)[FV_ MUXA[XKSOP5^SEIOP"^%'B"Q^&%A;_P#"8W&DSK%K&H?Z^]N,'R#.>_.!^%?+ M'['/[#FN'QP_BOXI^'K>VL-/.+'1Y^3-<<9G_P"N.#P*]T_;B_9;E^/GAN#Q M'HMQ*/%&@V5P+'3MP-O?1'G:??D?G7S'^RQ/\/\`Q5X[\)^#_%_P0N=-\0:5 M-D:SI]O,!)<`=;^#'X\YK[\_:(U[Q)X;^"/BC5?",XMO$-C8&XMR8?/Y],?G M^5?BCJ.FZMIMO;^?I-]IWD3_`/(1N(+BWKZR^`VA^-_VOOC?X5\=ZL1;:-X* MM]/@N-0N")_MTUN0"W/_`"WGSS7WSX<^*ME\3?$GQ!\,>&YQ!/X:$%L=8M9H M9X/M$\!;@>L/&1WKO_#EK>Z?I%E!J=]_:6H0PA9[_P`CR1,?7':MBOE.?XB? M$+]H>#3M/\&:'=^"O!\][<:?XDU+7(!;ZE`J_P#/"`]?/SU]_>OH;P-X/M_` M/A33]"M[V]OX;&$0Q7.H3>?.0/4XYKIJX_XG:G!HWPU\5:A<3>1#!I=S,6\S M'2$U\<_\$JM$-MX-\;ZL(>+F_@M?/\X\F"W'_+'M_KZ^]J**AHHHHJ:BBBBB MBBBBBBBH:FHJ&LK4O#>DZH,WFF65SY70SP`XK@]>_9=^$?BG5+C5-5^'OA^\ MU*?_`%UR]BN6_*O,_'G_``3N^$/C.\^TV>E7OA2?;_S`)_LUOGWA'%>=ZM_P M2R$*HN=!\7^(;#4.\]U%!<$?]\B"H+C]BCXN^"+K^V_`'QFO;CQ#<>3]ONM M8GN(5G`_O'%QYWXUYO\`%3]B_P#:'^).HZ,OB&[$^*[FP@^S?VR;C[/,O%6B^%Y;+[=]IU"YMX!!!C//GV_'X_P!:\>^*EWX4^$>I^#M# M_9]UWPY;'5K+BX_P!1!7?_`++OP\\$:Q\2[7QEX_\`C'IG MC[Q!8SFWT.RN-6G(2<>UPP0_P#;85;HHJ:BOS)_X*B> M+I[OXH>%O#OV>(6^E:3_`&CYS?\`+;S[C&/_`"6K[8_98MIK7]F_X90SGSR/ M#]C_`.B!7J$VJ64%P(9KR&*"/$%QXZD6?5['Q'?VL+"#'^C@_*, M?B:Z?X]?%;_A3/PGUGQ5!I%SK5Q8*##86_\`%]?^F/%?,OP!_:.TO]K#P_XG M\%_&"PT2WM;46]_Y_G^1;W`\_CJ?I7Q%\;M$GT3XI:CH4%AH=M;03_9["V\. MS_:+>>W_`.7?_KXN*^[OV4/V:9_@3\*->^('B'2=0/CO4-*N,Z=:C_2-/M\$ M_9X/2?C\Z\-_8)_9X\)_&,^(=6\0^?O`@]#G-/7]CWPE\0?!L/Q!\:07'A M3QGJND_VAJ]OIT_^C07'_/Q]GJ'_`()>>?\`\*]\9>?U_M:W_P#2>ON&BBBB MIJAJ:H:***SM;UW3_#.D7NJZI>PV%A91&>XN)^!#"!R3^5?+'@H?LV?'+XOW M'C'1]1LM;\8^5Y\T.H>?##<#R/L^3;S@"?CCO7R[^VA^RUJO@OQ!XK^(UE?: M9_PA%[-;?8K>!3Y]O_R[_9_(Q@P?2NT_X)7Z*+CQUX[OOL]N3#806PG/_'Q# M^_N.*_2RBH:^4O\`@HCXP@\/_LVZG9"XMX9M6OK>V\FXFQY\()G8?I7@W_!+ M?PE9:EX[\8^))8)OM.DV-O;P9]+C_P#AZ_2:BBIJAHHHKBOBII'BWQ'X.GL? M`OB2W\+^(#)$1J-S9?:A"O?]R>.>.M?$7_!2;PUJ>E^`/A+-J^IPZO?6+7-E M?:A_J!<7#0P'(@]_(S^->\?\$[;46W[*/A2X,N[[1X.JB"W,Q//''[GJ(.]=6^-7A# M4=>^.B:E<:IK5Z=0LO#)OY_(T#'3R!QY,W)[_P`Z^MJ\_P#CMI?BG4?A%XHM MO!*@^*9[$PV/[[R,-]>W>O&?^"??P9\4_!;X8^(=-\6:6-&NKS5OM46GBX\_ M:IMX1G/U!_*OH_Q%K5MX:T#5=5GEQ;6,$T\WX#/]*_%OPS\1KGQ/\"/A=IOCF?PKIGPDN-SVVHV^HC_1YX+BF7&J6.FR"*:]AA;TGFP?UJY]H'I7QQ\7OVH_$&F_M3 M>#_AKX$GM[[-[#;Z]8SV7*[N3ANW[CG\!7U-K'B_0O#=YIUAJ6K6>G7.J3?9 M[*WN;@0F_#WX:?#[]G/P3J2Z-867AO1X+?[1?W4_'G>0,?:)SZU1 M^)GBSQOXK\`Z9??!>'1M3?7(28-:U&]\JVL(#_R\>1C]_P#3BO,?@%^PUX<\ M-^&KNX^*NCZ5XU\8ZI?'4)[BZ@\_R3V`->"_\%89X5\6_#^"(Y,.E7!'T^T6 M^*YSQC^R!X_UWX-?#W6O#OD6VGZ1X:_M&^T:X^T0:@=0_P!>?W'_`#\3G[.# M_P!>]9_AW1OVN_&7@4B"'Q1?^'R/L)MM:-N+G'K_`*1_I%?;W[(/P!@^!?PN MT^WU30M*T[QC/;C^UM0L!FXN".?W\_4FO8;WQSX;L/%6G^&I];L;?Q#>P>?! MI\\H\^>$=2!UZUYG\>/V9_"7[0FO^#;_`,2F]=?#ES-<"UMSBWOP2,PS^H_< MBO5O#'A+0_!.D#3]!TJQT>P7G[/8P+!#^0&*\V_:$_:6\.?`KPY?F>YL]1\5 M+;^?8^'O/`N+G\*['X5>)M<\:?#W0-<\0Z$?#FM7MN)[C2#-GR">W\OSKL*\ MA^%GQ-\5^/=4N5UCX9:KX+TN'S0+_5[Z#,TW_7`<^O->F^(-=T_PQI%]JNIW ML.GV%E$9[BYG&!#$.I/Y&F^'M9L?$VAZ?JNDW"W%A>P13P7(_P"6L1Y!_(_K M6G6=JNCV&OV$]AJ5E!?V%P/W]O<0B:&4'V->2?$SP/\`$Z>[T#2_A9KWA[P+ MX5@'E7Z_V<3=`=OLZX\G]*]6T311I-C#N$#7XBQ//;P"'SC_`$K6K/\`$?AN MQ\6Z'?Z3JD(N-/OH3!/`>A4TSPWH%EX4T*RTJQ\W[#9Q""$S2&0D#ID]ZV:* M^:_V_P#7)='_`&7?%1@^_?RVUACR]W!G'^%8_P#P3M\&R^$_V<;&\FB:WN== MOI]08-V7(@AS^$`_,5]6445XK^T;\,M7\>^'[76_#=QJEOXN\-9U#2K6PU#[ M-!>S@?ZB?U'^-?GEXO\`VK/VE_ACXH72O$GB:]T^]AF^6WO])M\7`[8_T>OK M/]A?]I3X@?'V]\51>+["R.FZ>(!#J^GP^0IG)Y@([UL_&+]M,_#+X[Z)\.;3 MP=<:B;FXMX+B_N)_LX/G]/LX/^O/T[U]2U-1111111111114-344444445#1 M<=!15*_T:QU5/)O+*WN8/2:$&JOB#PUI?BC1+G2M5L8;[3;R'R)K>>+(8>]> M37'[%'P3N/.S\.-(.?13S^M>4^(_^":?PXUK7+B:Q%[I&E&P^SV]O;SF::"X MS_Q\9GSS5#4_^"6/PTFFG-IXD\26JG_EB3;3@?G!7(VO_!.3QCX!U^^OO`7Q M6G\/EA]GM]D4T$YAY^6>X@()Z0]OX34OB+]G+]JWP?+87WA[XKWOBZ5IOW]M M]N\@1#_MOUK/N-4_;?T:R%Q/!-<0V0\_#0:1.;CVQ!6;K7[8/[3W@ZP#:U\- MVMP/('VF;P[<@<]>AK2T;_@IYXBT6""#Q?\`#7_23!F>YM;^>VQ_VPGM\U\Q M?M6_'JP_:#^*'_"5Z7I4^C:?!8P6!-S/BXY.:_6KX#?8Q\#_``+]CLI--MO[ M$M=ML>L'[@5^7WQ9UK_A+?VXYIM,O//N/^$KT^VL9M2$]O\`9_(GM^/^>_\` MQ\5^Q%%%%5;FUANH/)FA$T)['FG6MK#;`^5"(?PJQ11111111111111117FG MQJ^&,/QB\`:AX4N-8?.F`S^XY&/\]:^5=8_P"";M_X;C@U M7X#C1KJ:`&<_\`;"M`?ME_'33_`"(+ MW]GV_:_,.<6\%^1_Z3U]C^'KV?6M!L+R[L9M*N;F"*::QGQF`D#,1]P-H/.T3QEHFI#SNMO?C%>)_P#!/(?9OA=XPA-O!!CQ;J'- MO_RVX@YKP/\`;"_;.\277C3QE\./#MP-%\/0?\2^?4E_Y"!N(+C_`$C[/7P_ MJ-S/H6-]!!<:? M/!]GGMKC_CWQ7Q]_P2W6$^#/''[G%]]OM\SXZ_Z/7W)120J(!@TM%%35#111 M17C'[4_A#Q!X\^`OC+0?#7F7.KW$*K!#;S[3<`S?OX#]8//`&N^" M=7_LGQ1H5]HNH^1]H^S:C!]G_P!'JQJ/C[7=;\%^'O"=[?7USHV@SW%Q86]Q M/_J/M'^?_)BOTV_X)U_!B;X<_"*Y\1:G`L.H>*YX;^'$VXK8X!MA^1_6OK:B MBOR^_P""GGB(W'QJT+0XKP3V^E:']I^SC_EC<3SSC)_*W_2OJ[]@SP)JW@#] MGO1QJ=Q971U63\3/BA_PBD6E MP0V/@N>XM_M7G>=<3S9@,XQ["#%?6?[)?Q.\+:#\&/#WA'P6=8^(7]DW$%OJ M=UI]B8(+'[0OGD_O\8@Y/0_E7UQ]G'K11]H'I7@O[3'[4V@_LSP^'CJ>E7FL MW.K7&#;VHY@MP?W\Y^F:]NTZ^74+&"]BBD`GA$P'X=*\D_:A\'>,/B#\&=9T M+P'/T@S]#7FW[0WQ7^)'[4WBNY^$/A_X??V=HT^K&"#4M:L9_ M^6!S]H_Z=ZY71_V8OB=^QWK]Q\1;C2O!_BO0-#'VBXGN+@Y%OZV_G])_>O2? M^":O@OQ#_;_CCXCL%L/!^O7%Q#;VS#-Q-.+CJ:X']IWQ[\&/B)XZ'Q!U2#7/ M$=Q/8_V./!ES;SZ/<6__`$__`&BO>OC#^SB=.^"6@ZMX+\=>+_!>C>"]#N+F MWT_3#_I%P/\`7\^_!KB_V"?@)XM/BNX^+?BW79[JYNK?[-98U'[>UZN#\T\^ M.>U>K>,M3^(WBK]JK0-(L_!&E:I\/_#B07,^L:S8*&@GG',]M.0/WXS_`,L? M7FNC_:P_:=L_V;?#.G3Q:8=7U_56FAL+19@",#/FGVZ5Y1^SW\:7XV?\%"V\!_%#6/!OAKPWIE^=*F M%O?ZMK.H"WME/U%=G^R;^V3%^T7JNHZ)=>&?[!UJQLUOCY-QY\$R=#SC]S@& M$X/K7U14-%%%?./[>?B*]\-_LP>+[C39I;>[N1!9&X@Y(AGG"DC\#BOR9^&? MAN_\6_$3P]I.EZ3!K6HSS_N-.N9_L_V_[/\`Z1]GK]#M!_9U\1; MVT'2`>@K6K\PO^"I7^C?&'P;/^__`.0%VG_Z>*^T?#GPE_X3#Q'\/OB9XU>: MW\?Z1I'V>:WL+D_8!-.!G,)/)YKV"ZO(--L9IY*M`$YTV_7,)NH/(G_`"KIOLL'G>=Y,/VCU[U)L?#KX-6`_M$6\%Q_PG7VP?V?;C.9AWY'3BNE^#W[(FD?#?QI M;>.-8US4_&'Q`$%PLNLZ@>OG]1C\*V/VB/B_XR\#Z9#I_P`./"4GC+Q!<-]G MS;1&:"Q]Y\'(%X`\+B:W%@(3]TR^2,$]?I7 MTS7R7\0]#^+G[1/Q0;0[:VU3X9?#70[@PSZ@LX%SK)_ZX?\`/#ZU]8;HK>`& M3$*Q>_`KXW^*O[;;>(+E?!WP2M;GQ=XROKC[`-6,.ZUM>/\`7YP,\\@D>3[\ MXKZA^'.FZ_I?@#P[8>*;Y-1\2V^GVXU*_``$\^!YV/;(/YBNQKQW]ICXUR_` MKX?_`-N6=MI>H:E),(+>PU+5!8"8G/0DW_9YAMY3F>]U:W6#ZUWG[ M%.E2:#^R]\/HYH(H&EL?/95ES_KIBW]:]]J#SAO\K'-3UR'Q*^)7AWX3^%;K MQ%XFOXM.TV`9+,?]8>P]Z_,&U^"FA_M1>._'/B7P_P#%?[0T'VC4#;>*8/(U M`?\`/O\`]N]5OV`_C%XJ\`?O"FFV(UG1?$EQY%_!;_P#+O_T\5SO[5^NV MWQ+_`&N/%#6S3V%HVJV^CS-<'R!`(/L]O<'-?L+I%DNGZ?;V4V_X1O]I?Q-`=+TRPM[!;;R+"QM\0&W^S=2,#FOU]\.W/\`:GAO M2;CR?LQE@@G\C^[D`U^7GQU_8<^)VC?$OQ#JWA?0_P"V=&O]6GN+`6%]BYM\ MGSQP?>OTL^%^FZWI'PV\,:=XJG%WX@M]+MH=4G:7SO.N1"/.Y_W@379T4444 M444444444445#4U%%0T45-4-%%9.MZ)8^)M'OM*UFRBO["XA\B>VN1^XG![5 MYA_PQU\&/W__`!;;0N?^G>O//&?_``3J^%'BS7CJT-A?:,!_S#]-G\BW_*J? M[$OPE^'_`(4B\7ZYX,O-0,P3G(@XZ5Y7\=?^">'VNY^( M'BOP]JESJ-Q/\`7M.T�I]1UG2(+C M3_LVG6'^D3_9_P#GX_Y^*^S=/^)?[0?PHT'POX,\)?!JST_3FTBWN(/]"N)\ M?Z/_`*1Y^/\`EX_Z8=:MZ/\`MY?%CPY?>=XV^%]Q_8T'^ON;:QN+?_T?7K_P M,_;HT+XS^,K+PL/"FM:+J%PI,-RW[ZW/'KVKZ\0W\.G M:-8P?O[@]J^+?^":6M:5X<\+^.OMNKV.FB>_MS#;W,UO!D?9_P#7U]Z6UU#< MP>?#-]H'K5FBJ=YJ$&EVOVB[FA@MU'[Z:/\`4'Q$+?\`]N*_)/X_W-Q\1_VE M?&0TLP7-S?Z[_9U@;?\`X]_^?>WK]@OA7X,M_AG\.O#7A:$Y72+""Q'X#%=? M117XB_M8^/M=\??'#QE?:UY'VBPO[C3H+>W_`.6%O;U^SGA72UT3PUI%E#"+ M>WM[&"$6\/1>,5O4444445YY\;-#\>>(?`TMA\.==L/#GB;0_#JSW\QU&YL[3,T\,7^NP.WY5^#GQ$U+2=2\6ZS?\`AZPG MT[1I[^XN+"VN?^/BWMZ_0[X%_M=_LX_!+P;8:+H5Q>V%S/;V\^J30:5<3"XN M/LXR2<&OH;X>?M9?"GXG6K-HGB^RM[H#BWU(?8;C\I\9KU/1O$FDZVN+'4K* M_P#^O:X$_P#*M6OSA_;KT/5/B=^UU\/_``/!*)K>YL;>&&WN!_HY\^>X%P3[ MXMA^5?HI;""U@\F'_1X(.*M445G:GIMAK]A<6-_:0WUA./*FM[B`30RCW'3\ MZ;X=T'2_"VCP:7H]A::5IUN,0VUC;B&&(>P'%<_XM^$/@SQUJEIJWB+PKI.M M7]B,076H62SS+],UTFIZ9;ZW8SV5]!#?V$\.V>WFBR)OK4&AZ!I_AO2H-/T6 MRM].L;8?N;6VA\B$?@*UJ^>,'X[?LR_#WXR_%'PAXMN_$<.@ZO,8)[BW6?G5H!_J! MS7"?ML?!WX*>"]`\3>,]?@DL_'&NP3_V4OVVX/GW^/\`7"`'J#C\*Z__`()S M?#F#P5\&[C7)](O].U[7+TM.;^Q\C]Q_RP$`_P">&#Q^/H*^OJAHHHKYE_X* M-?\`)K7B#_K]L?\`TH%?#/\`P3H\*6/BO]IO2+B]A\\:#I]QJ,)_Z;_ZC_VX MK]@***_(_P#;K\_Q_P#M@W&A?9X1<'^S]'@!ZS_Y^T5^KU@T%KBP@FA-Q!#C M[..U:5%>2_&S]HKPE\#5T^'6C>:CK&HS8L=%TR#[3J%SV_<0=374>#8?%=[; MZLOC,:#%?!NO:SKVBZ)9:?K&MS>??WT$`\ZY/N>M5OB7XNO_``/X M4N=7TOPMJOC&_3_5Z=I(A^T'Z$G'\ZZ^W/G0\PF#/:DGNXK2WFFF/DP0]6[5 M\1>(_BGXR_:8_:!/PV\"^+8;'X:640;5]8\*7L'GS0G&<3]0,_N?W!/)/-?3 M/P2^"7AWX!^"X?#GA>*86XE,\\USS/.?4UZ=7$_$SQ_'\,?"<^NS:1KFMI`. M;#P]8F]N9O3`Q_6L_P`/?#NQU#1=.E\2RS^+I;:]_M2QGUZWA\^QE[8P!@CV MKT"BN8^(E_XLTSPI_MV_M/>&_C5IFF^'/!E[?ZA8V5]S<009L-5_T< MG$![XR:_1OX=>%-,\#>!=`T+1X!8:986,$%O;C^$8KK:\K\4_`VP\4?&?PS\ M19]:U."YT*SFMH=/MYL6[;NI(KU2N&^*?PNT'XN^#+_PWXALAGUV@$,\Y'J>IK7KQ_\`:7^$OAGXL?#CR?%&KWVBZ?I4PU<:CI_6#&?\ M:^!OV2?V3]"_:,7Q4VM:KJNGC2)X+>&YMX0/.&*^\_V>/V?SY_2XKZR\1?`+X<_!;]F'4O%6E?#[3=8U^WT$:AGQ5;BXG!G(/^D9 MZ^0#C\#T-?#EMXC\)^-M"UJQ\4:5H?A36(+"XU"PUG1K?[/]ON/^@?<6_P#J M/_2>OMO]@;]I2'4?AKJ/A;QEKFE:) M]/\`MVC:G9ZM8'I/8W`G!_$9K6HHHK\Y_P!O/]IWQOX4^)-MX3\,7^I^#[?2 M(?M%Q=6XS]O,QXS_`-,!C]*\@\0?M'#]I?1_#OAGQWX3@U'4-!L+BXM_$5MJ MWV>X_<6_^D?:/^OC[/7&?L6>$]6\6?M&^#CID%E*_#/CC6=/7P?HT^CZ?>SVHA%Q/] MHF_?XR)^GZ5]2_LH_M4V7[2NAZTUQIO]BZ[I4R_:-.)\[$$V3`<^X_E7T+11 M14U0T45\8_&+_@FEX-\>^,H]:T#5F\&65R/]/TZPL5\@^\&.+?\`"OGS3OV` M(/'MWK,7P[^)%OJHTB__`+/O_P"V]"N+#[-/C/[@])_Y>]6_$/\`P2T^(6G6 M%Q/IGB3P[K-S_P`L+8_:+>O/=1_86^.O@">VU;2_#?\`Q,?^?GP[?_Z1!7/# M3OV@_`6JZA#;P?$;3]0,]N9S;07%Q7*)\8/B?+\4%\<2:IJE_P".-'&)K^>W MP+_^D6]>Y^'_`/@I'\7=&G@^W0:+K-O#"(#;SV1MC_U\?&._^)EUXG\?R;7QU M"S8\_P#TJQN(?YP"O1?"OQU^'WC?_D7_`!CHNI_N?/\`]'OAT]?I796&LV&J MK_H=[!<_]<9LU<^T#THHKPSXC?LPZ#\2/C/X6^)%]JM_;ZMX<^SBWMQY/DSB M"X\\>_7\JM?&G]EWP+\WZS30C,YV^A_P!' M-?,O_!+_`$^>?X_:C/#!,((-!N!-<$]3]HMZ_33Q_?>(].\)W\WA+2K+6?$` M7%O8ZA/Y$,Q[Y;M6II4D[V,1OH8K>_\`)_?6\4OFX_QJ_7XOZUJ6K?$C]N'S M_/GU&XN/'?V>#[/!_P`N]O';OQ5,HGL+_Q M-YLT&GZ?/CIYZCD_2N@^"W['WA/X9K8:UK=N_BCQE#!"!J&L7!O_`+%.!@FW M:;E>3UZ\5:^-OQFU-]/_`.$7^$FJ>'M:^)=S<"*#3KF_A!@MQS/.1[>E-T/X M%^(?$7QHMOB!\2-3TK5;G1(=OARTT83V_P!@R/W^[_GOGCK7O]>3?"+Q]XV\ M=:GXG/B?P4?!VD65\UMI+7,V9[Y1+_KS%_".A^M>LUA^(]9&@:#>ZL;6XO%L MH)IS;6$/GW$W&?W([FO,_"7Q>\5?%.X\-WNC>!KK1O">H&>#5O\`A+U-A?P8 MZ>1!@^:#ZG%>LZ7X?T[2(R-.L;:Q!ZBV@$/\A5^O&?C/XR^)VD_$3P!H/@7P MU%J.BZK*='\*>'+6S\3>+;V6&> M?11?"">&Q).;CD=!BO5:RM9URRT&PN+_`%*>&QT^"+SIYYS@*/>J_AWQ+I/B M_P`-V&N:+>PZAI%]`+BWN8!E9H<=J_-#]OS1(?\`A<_A7X>^"]!L=-M_L)N+ M?3M&L?L_^GS_`/7#_KWMZ_3K2+=K/2[6"7!GAAP:TJ****AHJ:BBBBBBBBBB MBBBBBBBBBBBBBBBBBBBBBBH:*FK\7_`]N?&G[8]A#K0-T;[QG<&<"?R/^7C_ M`)[V]?J]\;?$&M>#OA-XJUOPY8G4=?L=/FN+&%8#.6G`X_==Z_.7_AY3\7\^ M1_Q3F?\`KP_^Z*_1GX(_$9/B]\+/#WBH6ZVMQ?6R_:+;'^HGZ3#\\UZ'1111 M11111111114-%%3445#14U%0T4445F:CJ%OH=E/<7EQ#;VT`\Z>>?H*^+_V: M_P!O=?'?C+4-`^(,^EZ*)_\`D$W,!,$!_P"GZ.\PXO]/.V>'\>:^./^"<6FWOAS6/C)H-Q-!_H&JP6 MYS-F?S_](SFON2BXZ"J]?FU\`=1M_@'^W=XRT+Q%!-;SZ]/<:?8?9X./](N+ M>XMZ^@_^"@GCZP\$_`#4=)FLIKJX\2S_`-G0D#_4G_7Y_2O)/V(_VY_45]W?LX?LJ^&OV:K+5X-`U74M1GU4VYGN-1.3^X MX'\S7@,?["OQ>:PGMS_X$?Z15[PE^U1^T;X0N+X^*_@QJ?BFU/GW`^R6 M$^G^3^_X'_+QD8K[%\#^/8O%OPXL/%=[I][X:MKBR%Q-I^I0^1<6?'(([5^? M'[6_[2GP2_:#\"ZE!8V6JVWB^P`&D:O<:1_KSSF#/4P'/Z5\A^(O!.N^&_#7 MA[Q+K=A]FT[7OM'V"YN9_P#7_9Z^SO\`@E^?"UKK'CF_U*>QM_$`$%O8SW$_ M^DF#_EO_`.V_Z5^CEM+/BKJEEL]_<7'^CVX_P#`>M=? M&GP.^-5CXFFUOP./`OC>=?M^EG2-5_T#4+G_`)X9'%O_`*1VQW_"OIS_`()S M?`KQC\,]/\4^(?%%C;Z-8>)(K5K&V_Y>%P9SSZ?Z^OM^BBBWZ&IJAHHHHH_Y M8T57_P"/:"O./#WPO^&.J_V_K>CZ'X?O3XE@F@U:^TZ&$_;H)N2)R/O9%;_B MCX7^#/&]G!#XA\*:+K4%N?.A&I6$$ZPGVS_2N(OOV0_@QJ-L8)_AQX=A\[O; MV`M_Y5PLO_!.+X(M+D:)J<7NFK7'^->=:[_P2M$/97)T;QAK5I>D<'48H+B M'\00,5S0_P""4(M[>X(^)6;@]_["_P#NBN$\>?\`!+[QUH>D"?1M>TKQ5 MGZ3K?C/Q';^(;C_2(+:WU;^T/M'_`&[UYYXS\:_&;0]=N+[Q=JWCC3=0G[:C M/<6];/@7]K+XO>`K[S],\=:K?_`,"*^IM/_P""LU_YMN+S MX7P`_P#+KZ/\:OA_KD-L;'QIH=Q]H@^T0_Z?!T_.N@TWQ9H6MSFWLM M4LM0N(>L-M<"+(M5&G:-8P_V;/IT'2_)Z9_Z]^GXU^G%%%?B]X? M^+-AX"_;)U+X@ZK;S'3K'Q)J%Q<6T`S/A;_@I%\'M:L_,O=0U3P]< MF7:8=1TQIB/^_&:7XK?&WX:?%[3O#UI9?&_2="\-7I\K7-&`'VG5K&=<>1SB M>W)R1GC@UZW\+-$^&'PH\,OI/@R?P]IVGC_29_LM[!F;C_7S'^M7[GQ;K]]X MK\/0>&;+2_$7AB;SAJVIVVJ@36.`/(*KSYV>15KX=_"#PE\*&U'_`(1K1;?3 MKC5)Y;BZF7_7SL3Z_E7=T445-4-%%%%%>5_'[X7^(OB[X,M]#\,>.KWP(WGA MKB_TZW$YG@Y!AZUT7PT^'&E?#/PIH^A6<]QJ`T^W\A=0U`F>Y8>\V*/B?\6? M#?P?$7'B/Q9>_V=I$$PA-QY9EZ_3Z&OF>#P'\3?VJ-3@U;QI":' MP9_R\:A``2+AK@#SES_SPX'Z5]"-\1?!?@3Q;X6^&3WHM-?O+$MI.DPP2\VT M"GGZ`0G\O?GX/^).F6_BS_@IS;6%[;^?IYU;3SCW@T^OT\HHHHHHHHHJ&IJ* M***AJ:BBBBBBBBBBBBBBBBBBBBBBBBO#?#?Q]GUS]H[7_AC/X4O=.BL+`7,. MLS_=G^[T_P"_U>D^.9I8/`7B&59OL)&F7#17$0Y@_'6 MOVGO#_VP0W7D6-]/#Y\7G$3F``G/L,FOU9\5^+M.\#^%M6US5)!;V&E65Q?S MD=H8`2WZ5^67BG]M^QUKQ+J5]9_!OP#!]HO_`+3]IU+21<7$_P#U\8_Y;U^D M'P'^):?%_P"#_ACQ=)9C3KC4(,SV\1SY$X/E$5Z=11111111111111111111 M4-%35#111117S7^W1JUAH?[./B"&XO[W3C>F"W@&F@?Z0?\`G@>/]3CK]:_- M'P9;>!/$F@_V%XAGOO#FLW$]Q<0>(O\`CXT[[/\`\^]Q;_\`@1_I%>L_LF:% MXC_:+_:$T;7/$NIS:@/#4,&HW$]_;^?^XA/[B#\R37ZPVU6****Y[Q3]C3PW MJ)O=5.C:<+?,VH"X^S^0/^>WG]NU?&?_``3MMK'3?''QET_2M5&I6$%]`+:= MO]?

?<_OS7W;15>XMJ^1_VQOV2]:^-FN:;XS$:M#I_BC2K'[,MO-^X%P/ M.#96X'^HFYQFO&=%_:=^)]KX._X0?XD?!'5OB(8/]'N+C4(+CS[C\/L]1>.O MB]\:_P!I#2-/^'7A3X5:OX&TB<"WN&:WG\BY@QCR+B>:V_<0_0>U?8O[*OP# MM_V>?A9;:&?(N/$$_P#I.K75O_RWN/6O9J***H:E-;VMM/+?-%#8K#F8SD>3 M^M?DI\8OV-O&5[\1GO/!,%CXS\,^(]6G^Q:QHP/V:PS/G]_Y'^H%OZ^Q]#7F M_P"T/IL_A/QI;>!;VX@N1X+L+?1_M-M!_P!O%Q_Y,7%?:/PO_P""=/@OQ5$ MO#U]XTM]3T;Q1/88OX;#4<+N)VB;/KY.!^-?0O[/?[-&A_LZ:=J=MHVK:SK" MWWDC_B8W&Y81C&(>./I7C?B_]FOX]2_%#Q?XH\&_%:VT:WUF]\_^S;FXFQ!` M,B!<>0>G.:;J-K^V+\.=*M]7.J>%?'D%M_K]&T^W_P!(G_\`)>WKQ/\`;,^/ MGQ/U+P8/A_\`$GP)H?ARXU80:A;_`-FZO]HN/W%Q7L/['?[.>G>+_P!C'4]" MUJY_T?QQ/<7[?N/W]N3B#^4`_.OF+XM?\$__`(G_``ZN)Y]*TK_A,](,PA\_ M1O\`CYQ_U[U^C'@KQ-I_P&^`?@4_$;5[+P]/I^DV&G7,]S-@?:1!CR,XZC%/ MTW]K3X0ZUJP7(NK>&>*;[0OK!T-6J*FJ&BBBB MBBOFK]O7Q7JOA']G+6)M$O8M-GOI8+&>X\_[/-Y!//D'U_Q-97_!-_P7-X4_ M9Q@O9C;_`/$\U"XU"'[/VZ0?^T*^JJ****KU8K\L/!WB2]\2?\%-S?:J8%F_ MX234-.)\CSL"WM[BWM_I_P`>]=E_P5(UOPUJ>K>%[+BX\56$)_P")-!_Q M[P6\_P#R\7%9G[)?[!]GXA\+S^-/B.(;?3[BR`TG3A+N\C]P/W]QS_Y`Z"N5 M_P""?WP=\*_%C5?B#H?BWPK8>(;"WL;?[/K)_P!?9'T@/;_[G[]*^RKG_@GY M\$KB#R3X4FME_P"G>_G_`,:Y+6/^":?PINK#R+*]\1:?/]H^T&X^W^<UY_\`!.3XT^!?A1-XIL?%VN?V-J.J^0;>XN/^/#[/ M`".#V/-?=6D_M=_!_6];T_2;'X@Z)=:A?#]PBSCGVKUY9A,,"JEU=PZ;;S3S MRQ6\$/6>?M7Y5_L+:)X<^+/[1GC'_A,](T36X-7LI[C[-<6(GM_/^TC/V?\` MY]^*_0O_`(9<^#?_`$2[PI_X*K?_``KB+_\`8'^"FH:DLX\&&*W`_P!1%?W` MA/X"?^E>$^!/V$/@[\3M4\8V%G9^/-`ET/5/[/FGU<6XAGQU-OF#D<_J*NZ- M_P`$R9O#GVC^ROBQJFC?:/\`7_V=8_9_/P?W'_+QVJKKO['W[1/A*]N[[P9\ M9+G7$\W,/]HZI<07)'IC_4?I61-X!_;8\-6T^J+XDEU`6W[X6OVZWG\_VQ6? MXI_:Y_:NT2XGAO?A\=.QT^S^'+BXK?T/_@H-\5=+TN!M;^#-U=7$(_T^_@BN M81^1MZV/#G_!5?PY<7\$&J>"M0T^P(_TBY@O5N/(^N!7H=E_P4K^#%W(5FO= MYTL@5U7@[]N7X)^,9;B"+QW!I[P=?[9@GT__P!'@5Z1X>^./P]\53F# M1/&>@:E,)?(\BVU&$G/IC.:[?[3!GRO-BSZ9I]>%?M6_M'V7[.?P^^W0I8ZA MXGO218:-Y//V?[0!_G->C?LE?MPP^/O#FMZ;XMTEM);PIH?]H?VE;F>X@DMH``?. M)Z3\9(^M-N?^"@$_Q;-AX;^"_A/4]2\9:A./^0Q;XM[&W_Y^#SR*]9\,_LP0 MWFGZ:_Q9UZ;XMZOI=_<:CIE_K-L((++(&/W`./3UZ5G>)OVN[:/XYZ1\,/`W MAT^,M6EE_P")O=6]\((-/&.<]'_L__/2\OEMQ_P"1B#79ZYXST'P_86VHZIK5CIUE M-Q!<7-Z((9C]3Q6AINIV6N6$-[97,%]:3KF&>WG\Z&7Z$<5HU-11114-3444 M4444444444444444444445#7YTC_`(*D:[H>K>(+#6O`MCJ7V>^^S6)TZ_\` ML_\`W_\`^/C'X5U_A/\`;KT_XT_!GXHV/B#0K?1_$&G^'+FZ^S03_:+>]@-N M>1^9KQW_`()AZ:MW\=-;NV@%S]CT$J)S/GR?W\''Y9K[$_;P\47OAW]E[QE) M91`M.(+"X&.D%Q<"`G_QX?G7Y@>'O&GA73O@IXH\.7NB_:/&^K:K!/#JWV?_ M`%,$&,09]L'\Z_67]D6RT44444444444444444445 M#11111115>YKR#]ICQOX2\%?"#Q!/XT^T7.BW\!T\P6N/M%P9^,0?Y[5^/>M M:W/<_9[I[G1M(^T?8+>Y_Z^*_0_\`X)H^'+&T^$^OZO#!*+^_U8VT]PT. M/W,'3^M?9E6/M7M1116/XGR/#FH9TF;61Y!_XEW[G_2/^F'^?SKXZ_8+T^V; MXV_'*_M]+N/#MI%?6]M!I$_[C[`//N?W'D#I]:^Y:******FHHJ&L+QAX1TG MQ[X9U'0/$%BNHZ/?0?9[BUG'^N%?"GB+]E'QQ^S!XH;QO\'/$GVG1[>&>XU; M3=9G\B#[/`,B`X_UW?KZ5\N?!?2]3_:*_::T274[=9IM5UT:OJH'`%O_`*^< M5^T=6**2>$&$CTK\B?\`@H/XCM_&O[3NH6&EW$%S]@L+?1O]'_Y^/^??_P`F M*^KM=_;T\!?!8V?@R[L]9U76-$MX=.OSIEO"8(+B``3P9R,8Q_\`JKF?@_\` MM+>.?CG^V#=VOA?7_MOPJ@MO/-A/;"WQ;_9\9Y_?^?Y]?8OCGX;>&?BCI2Z= MXKT2QUW3XIA<0V^H0Y\J8=#^M?/E[_P3>^$,OV?[.NMZ>!<_:&^SZACSA_SQ M/M7T7X#\$Z7\.O"6E>&]%A,&CZ7`+>V$TIE('IDUY;^UKJ'B31_A.-0\,>.M M)^'5Q#?0-/K&L?N5$&3F`'U.:^=(/!W[9-A;:3J7A[XD:'XRT^Y'G&YM+B": M#'L9[?/Y5:U'X^_MA:#;S7=[\)]/FMX/]*]&N?.VEQ!<+"?QFMQBOK7X:>.X?B1X&TGQ)#IU]HMOJ%N)Q8:E"8;B'V( MKC_%/[4_PH\$:MJ&DZUXYTK3M0L#Y-Q;LW,!]ZF\)?M(?#+Q]9VMQHWC;1+G MSX//\B;4!#<8_P"N!YKN[#Q3H>O2>5IVKV6I'TM+F&7^1-;'V@>E%?G-_P`% M3M?MY_$7@#PM!?8N(8+B_N+7_KNT,%N?_(%Q7W7\*?!-C\,/AYH'A6QAAM[? M2;&"V"P#CCBNNHHHN.@HHHK\X/VK_`%]^SE^T7H_QRT72KC7=&FOOMVH0'BW MLKC`M\\?6L'PO^S=\+_VG?&OC/QE!\7I[?3[V^.H?V=/`(-0L//_`.?CSZC@ M^(GPX_9&\/\`BCPY\*]5E^)VO^*C!;WL]P,V\$'[_!_)K<:=K_B,0;M.(.;>&#&WS_P#IORM M8/B/P1H7BVW@AUO1K+5UAZ?VA;B?'YUX?X[_`&&_AIX[^(6F^);[3A8VEA9? M9O[`T^"""QG]RH6I+;]@CX&VUO#`?!"W`'_40N?_`(_7FVJ?\$MOAM-#.+'Q M%XDT_/H;:X_G!6>/^"7FB6P7R?B?XBMH(/\`4@0P<5R7[0W[*/Q(\)?L^ZRH M^,NJ^(O"OANW%R-`U&Q%N&@@[?:,YS@>E>"_LD?"_P"-?B+3_%&L?"35K#1< M,-.OKFYG\BX!/[\?SKZ=\&ZY^V7X*U73XM4TG2_%5O<0?9X+?49H!!!C_EXN M)[?FKTW[9_Q=\$^-1I7C7X*:@ZP6_P"^_P"$>,]SCW!_U'ZUMZS_`,%&M"\- MS?\`$U^&WC?1K#SX;<7.HZ?Y`YK/\.?\%0/A_J`G_MGP]KFC8GQ;^0HN//\` MRQ7L?P]_;%^$7Q&!@TSQG;Z=.!_J-9S8,?PGKN?!WQK\"_$35)])\,>*=*US M488?/:"UN/.('K77_:H?.\CS^?2K/$X]JX?7_@I\/_%4$*ZWX*\.:D!_S\Z7 M"W]*\\U_]B3X)^)M3_M";P'8V_[C[.+;3P;:`CZ0XK`_X=U?!2`?\@/5)O\` M>U6<_P!:X+6?^"7'PZU*]GGLO$?B#3H3TMBT$X@_2N27_@E:MO>BYL?B7-;S MPS_:;(?V&_C;X:=7\"?&Z^N1(_#T]A<6^O M:=Y%Q]GN-/\`^GC[/_Q[UT'[,'[1]Q^S1XZU'Q)!HXTC2=+AUWPKX.A.=6MM&OL:A??2?_GASUKJOV8/VC/V;_@&M M^;+1?%0U0`@Z]K.G6]QE_$Z?X,C28+C_BGQ M8"_O]5N!T_?_`.H\BL3_`()K"QN_BKXS\8^(?$D5MJ[6\%M%!?7,`:]GN)SR M,O-_C;\'-#^.G@"Y\+Z^)K>VN,30W%N<3P3H M:AK?C/2O['L+?^S_``7X>MAY^H&W_P">'_3O]G_Y^*[;]BCQ5XI^&/[.'Q>\ MM]6A\6:KIVH>?]H_M M'[?+WL&MK+5H;B!EU&_SR;< M9Q/Y&3]1!S47[`_CWXA?$_X?:]XD\N&.13/AE\2-#^*_@^V\2>'III](N1^Y: M>$PGCVKL**************************K7&/)G\_'DXK\-M6^$YU[XO:OX M-\%ZII>ODS3FQF:X%A!-['S^*Y_P9X3U6Y\)^*?&5E!;_P!CZ3;_`-GWPN?^ MG_[1;V]?;_\`P2G\-VQ@^('B-H)O[19K?3A.>\`Y'\L_A7WWK.B6'B32KK2= M5LX=0L+R'R9[:>+,,P/8BO#]7_81^".N.,>!H-./K87$\'\C7M?AWPUI/A'0 MK#0M&LH-/TZP@%O;VT!P(8?0?E6[1111111111111111111117+>,M+U;6O" MFK66B:O_`&)K%Q93P6.H&`3?9YB"!-CV/:O#OV>O@'\4?AGXONM4\7?%2Y\5 M:;<08_LZX>>;]]Z@S'C^=?2E%%%5Z*_/3_@IU]AN=>\"^?KL%M<>1>`=C_K_ZU]14 M4?::L4?:O:L;Q/X?L?%&@W^D733+;7UO-;3K;S&&8";KCT-?#/[`FF:5HO[1 M/Q6L=,U@S:?80W%O8VL_,]Q;_;S^_/\`/_MO7Z#T445-4-34445#17S)^WC\ M81\,/@=J&EV5Q!;ZSXDSIUO;S19!M_\`EY_\@9KPG_@F=$//O=8^(\U_-;P MP`Z1;VMM'_`!E?>'+W1?#V MDP7%Q]HUF">W\_S[?R/]'S7ZH45POQC^,.A_!/P3J'B3Q#*?LT`S%;VY_?3' MT`K\EOVA?BS\1_CX8/&/B"QO=.\'_;_L&E6W']GP9_Y8&?\`Y>+CBOH/X:?` MS0_%G["VB>(_$OC#Q3X6TC0[?5]0:#3K^"WMYY_M%Q_I'3^M>"?!OX#:W\3_ M`(1>./'\.H:Y<-X<$$%MHNG?\?&H8KZC_9H_;)UKXSW\7PI'A^]T8MH@L;+Q M#ITXU"XLC]G&+BXSWZ?C7B_BCXG?M/\`A+XHWWPH7QC-XB\4@?:%MK86\_G# M[/\`:/\`GWXKZ*_9N\%>'/VH/#_B#7OBK\&]+TSQ7!PFM_P"T/W`_ M?\^O2NS\7_\`!.SX->)T/D:3?>'FFZ_V/>E!^M?(.O?##]E'1]:U?1(?B-XR MTK4K$`W&K0V(N()CZ0$6Y'Y5T6G^'?$WP#T'P1\1_!'Q!U;XJ?#;3]6X\/Z> M+B`06_KAKYD\ M1?`/]I_Q)X]\/>-_$-AX=\9ZSH(@@@M[B:`#_MX@KLM/_;3_`&@O!>I;O%_P M9N;BPMX/^/:VTNYMQ_W_`/\`2*]'^`W[>\_QU\?V/ANW^&VK6$$Y\F?4+>X^ MT6]OQTG_`'`Q^=?47COQQHGPW$:AXE\07HT_1K"'S[BY\KH/6O.O!O[67PI M\>VAFTKQWI5N?]3Y&I3?8;@'Z3XS7:0?%GP-<#3R/%NAXO\`_CR_T^#_`$CZ M5U5AJ5GJ2YM[F"?_`*X39_E5NBLC6=$T_P`2:5=:3JEG#J%A>0>1<6UQ#F"< M>AKPN]_8$^!NH7JWK>!H(6Q_Q[V][.(#^M=M\/?V9OAC\,YK.X\/>"='M-0L ME_*38N]N+YH+&X9;?S]L,\P6?C_=)KS/_@E=IT]M\'O%-[-!BWN-=_<7.?\` M7C[/;\U]MT5%/;075OMGB$T74B:N<\1?#KPIXNT^XLM:\-:5K5C/Q-;7=C#, M#^8KC-9_9:^$&M:?/93?#GP[;_:!TM=.@AF_,"O*[C_@G/\`#*WUBWU70[[Q M-X7N;;(A.FZE@!O^>W>O/X/^"4WA<>'_`"!XUU8ZUMS]I^PV_P!ESZ?9^O\` MY'JM/^QS\8_@%I5M/\%_B3?7P_?"^T>\(MK71]"\0B'_`)>-0FM_M!_\F*3QE^T9^U/X(NO#UK=_")KBX@&+YM.A M_M&"_P#?,'^HIOAS]O3XGVWBRYM_$7P+UZ'3[D>?#;V$-P;B`?\`@/\`O_PQ M75Z/_P`%'=",'VC6OAMXXT73O/\`L\^H_8//MX#]16W_`,/)_@EYV/[0UWZ_ MV3/6A_P\5^"?_0?O_P#P4S_X5/J7[1'[._Q\\/P^&];\1:'J>G:K]W3=7/D% MOSQ_.N\\3_`#X<>/OAIIW@J]T*RG\/6,`_LNWM9#_H?;,$W44_0O@EX.\!?! MJX\`VFA#4/"T-M,)M,N!G[9W.3[_`.%>!_#;]C;X>_$[4-%\;W_@W5?"6@0V M^!\-=9L!;VT-SWGG&?WYIO[6OQ'^!_PZN%\+ZU\,K#Q7XPNH;=K+3#H_D?:! MYV`!<>00.>:\O^"7_!-W5/$FNW^K?%N&QT_3KFWW6^C^'9S;S03^N>G2MK]K M']B'X8?"7X$^*/%7AC3[ZWUFQ6W,#7%_/./^/@=L^]>!?LH_L6V_[2OA3Q/K MD^K7NC7%C<&WL;GR1/;S3#J>>W3\Z]MTC_@FE\0_`VMV^H>$OBI%I5ST^WPP M307/Z$UHM\$/VT=#NR]E\1+?4T]1JV?_`$?;UHW%S^VQ\/;.W_<:1XRAB@Y^ MS_9YR?\`TGJM/^TA^UIX;\,B^U/X46]U;V?,]Q_95P;@_P#;O;W%8>G?\%0_ M%>F6UO;ZU\*H[G40,2F#4)X3+[B`VY-:EA_P5CMVN(/MWPW:VM_^6]Q;:OYX M'Y6]>1_`_P"(GP2\'?&M_BKJ?C;5M*N7FN9_^$8FT*>X:UN+CN+B`'[1!_I% MQ7GO[9_Q&\*_&'XVCQ7X,U@ZG87UC!;SFYL9[#R)[<\?Z\"OI3P-XR^/.H?L MYZAX7LM4\*W/C.VU8V,-O?WNG_:#I/V;&?\`G@3Y_%?,=W=ZY?>&#X(U#X"V M$WB]08++6M/TF>WOP/4P6_\`KZ^V?V5/V3K#4/V=(?#OQ;\*B6\FU676;>QO M)29K'=!``!_SQ/RGCW%?6OA/P=H?P_\`#EAH>@64&D:/9#$%M;C"@5NU@>,? M`NA>/-*&E^(=*LM:L/-$IMK^#SU_(UJZ=9VVEVL-G9PPP6T`$44,`&(ACI6A M114-%344444444444444444445#7C/[6FGZUKG[.OCJQT>=8+^XL=H,T_D?Z M/YP^T<_]<-U?CUX=^&_B3Q_H/B&_T329]:M]!@M[B_MK:"O0?!OA[6]#_9=^ M*6IWVES6UCK&JZ!86\]R>;B>W\_)_4?G7V]_P2ZTJU@^!GB"YCAVW\NOSPSG MZ6]O74_M@?MC']FRXT[1-+T,ZQX@U:$SV\US-BW@YQS7YP>,OVD/B3\2-6^W M:UXSU6YN/^7?[//]GM[?_MWMZ_5S]D36K_Q'^SGX'O\`4]4O=9U"XL`9[K4? M^/@GI_A7LU344444444444444444445#6!XQ\2V'@KPQJVOZG/\`9M.TNWFN M)YC_``CK7S?_P#)W06Q MMH";CZ'-9,__``4PTH00>1\-_$=S/_RV`GZ50_X>A_:?M/\`Q:Z^_8W'V*W/_"H-4N!<#_G^_P!'_P#2>L/XB?"KQ%^WC=^#?&^EZ7_PAEC; MV]QI%^NL\D`YY@_Y[C@_E7RGHOP5UP_':V^&\T']HW\&K>1?G3O](\C_`)^* M]*\!^+=>_8/_`&C-8TK5;>XUC1\?9[[[/_HYOH/^7>XK]/?!OQ)\->/]#_M7 MPOKMEK6G>MO/7QY_P4*_:,_L/2H/`'AC78;;4K@8U[[.3Y\%O_SP\[L@_;QY'[@?]?!G\@?C75^'_P#@IQ\0 M=/U^XN-4\-Z7K6GSC%OHUL?L]Q!_VWK])O[;@MM!_M:^_P");;^1]HG^T_\` M+"N5;XB^%OB3\/O$6H>%_%*ZIIT$$]O-J'A^X\^Y@(@/^H(S^_Y!%?%G[`!T MO3OVF?B#I6FS:I/8_8)_L,]_!Y,X@^T?\O'_`$WK]'J*****FHHJ&BBOS!_X M*7_%>P\5_%+1O!EE!`3X9M_M%Q3 M"()]6@&L3K[S\_X5]`445\M?\%&=5FTW]F/48XIIK=[[4+*VF:WEP0"V2/T' MY"OCS]@S]GNQ^.=]\0O[9GF@TC^R?['\^WN,7,$\YY/_`)`KQ3QW\'+_`,-_ M'#4?AMI?GZEJ$&K?V?8?:(/L_P!H_P"?>OU^_9N\+^,?!7PBT#0O'-];:CXB ML8?L\]Q!-YV81D0\]^/Y5ZK4U?.O[5O[+D_[2>G^%[:W\2_\(ZFD7%Q<2@6_ MG^<)@!C]#4OQ%_9!\&>._@OH/PTAN;[P_H^A7`N;*?3SB>.7#<_^1C7`?&S] ME/Q)IOP$T?X6_!Z"QMM(GO//U:XO[CR)YAWP<=3Q^0KW'X`_!:P^`GPSL/"F MES"Z$$LUQ/<>5@SS,>3^GZ5O>"_A9X4^'$VL2^&=%L]'.KWOV^_-L,?:+CU/ MO7QI^S=\&_%GQ"_:B\7?%KXBZ/JGA^^TO4,V6GSP>1Y\Y!@R)_\`EY@@@``] MS7WU7.>._$"^"O!GB#7?W9_LJPN=1_?=,0PD_P!*_%7P-\!_B-\8(KCQ'X9\ M'RZQI!O2TZP'%OYXQF#Z#(_,5[]^U1X+M_AA^RG\+?"EOXW_M&*?]S;ZC?6]AHUS]?6OM3]L3]ISQ)^S7HGA8Z/I6BW6K MZ[]H\Z>Z\[;!Y`@]/]['/I^?F7[,O[7'B3]H+Q[>?#GXC:%HVLZ3JMK<'6_$>G6WD?OX!<6^,?^`]=)^S]^Q%X.^"_Q'@\<>&_%-]J[06\]L;:?R".? M>$#-?5U?+_[5GB;]H#PW?V__``J32+:YT""Q\Z^N/(AN+DS^=P((#RW'K7B? MA;]KK]IK11<#6O@U?^(A_P`L/^)%/8>1^==UX6_X**Q?:/(\6_##Q3X)) MM0@TOQAHMW<6$_V>X5;Y?W,_]TY-=+HOB/2==4C3-3L[_P`KK]FN!/C\C6K1 M114U%0T445\6?\%2;^:V^#/A>T^T"""YUW$]O_SW'V>XXKT#]@[P#-X!_9V\ M-2WH4W6L9UDYFR=L_P#Q[X_[8;:^DZ*******FHJ&HKFTANH9X9P)X9A@PGN M*XO0/@_X&\-VWV?3/!FB:=!^]R%L(/7Z5PGCK]BOX.^/[VWO[[P7;:;<0=#H MO^@>;]?(QFO+?%?_``3#^%^M(6T34]=\.9_UN)_M.?\`O]FN4N?^"<7B/PUX MCT[5_!7Q=U?3KF"W^PSW]P,7-O;?\$/)QC\:HVW[+G[5?@[7[>XT#XMV^HP M0',%SJ6JSG_7',^8)[>XZ'D4[Q5HW[<^DWT]M8ZOI^KVQAP+C3O[/&3_`-O% MO7GNI^/_`-L2U$3>(KZ'59[>QO_`.SIK:X\-V\]R>_GBW^S_P#'OQ_Q\5?? M]O[X]^%9S?\`BCX;PVNCD8G-SH6H6&/I.>*P_P!H;]NBP^.7PDO_``Q>>`;G M3#JT$-S9W\]\`([B"X'GF'CD@"<`U[S_`,$L-3L!\#?$-C#Y7]H0Z]<33[?> MWMZ^V:*AHHKX7_;6O?@W\$/"=SI,/PH\-W'B?Q'!/]AN5T2W@@A..9VGQQC( MZ?I7YQ?VW!_PC/\`9,^A:5OVC/V??#7P/^#'PWOI="GM_& M/BJ'SK_[1JMQ]GL#_H^?W'XX_`UY/\"?A=X;^)'B748/$^NS^%/#VD:3<:A? MZS;V'VCR*SM9\6W^FZOJ/_"/>+/$=SIT'^CV%QOJ/X;?LW?M M'V.DZ-XK^'WC2Y_L_5["#4;>XGU0P$^>,_Z1;SU1\<_$C]H+X&:Y-#K_`,9M M*&L03?:)M&_M6WO[C'_7O]GKL/AW^V7^TOK>@7/B.R\-6/C71;*#R+B>"QS_ M`*1_VPKI/^'H7BOPV?L7BCX3"VU+_GW^W7&G_P#I1;U?_P"'KD`\[S?A?.H' M;^W?_N>NW\._\%/OAOJ-A!_;.D^(-&U$C_2+:"U^T&`^Y'^%=I_P\(^"'V?[ M1_PE=YN_YX?V/?\`_P`CUZ=X4^//P^\<6$-[I/C+1+K=!Y_D"_@\Z$8],\5U M6E>+-$UV]>VTS6K.^G@_UT%M.)B/R-;-%%34444444444444444445Y9\>O@ MGIGQZ^&^H>$M4O9K"WG>&XAN+8\V\T)R#7R%XG_X)L^*_#VF6TO@3XD3SZC! M>_:?L^HM/86^?)Q]HQ;\^?GOBN1_;(TSXD?#_P#9R^'WAKX@^(1X@U>?5[BY MG-L,6Y@@@S!;W'_/?FOIO_@GCX>T_1_V9]&U6WAMX;G7+J>^N)[V_$#X1>#?BO96]OXN\.:;XAMK(O#\_D?\29M^!/V>/!^@^(;#^R-7M8") M+3S=WD_ONGZU[C1114-344444444444445#116=J^B6.O:7=:;JEI#?V-Q#Y M,]M<1`PS#W!KS*;]ESX07-[YY^'/ATF']QDV`S3+7]E'X26TL$\7PZ\.DPP^ M0#-;"?`].!_#EC MK$^LVVBZ;!J\X\F:_6Q'G-Z M?)_U]6L6]M!Y$'D?9X!_Q[UR?Q*\;V_PV\%:MXCDT^]UI+`?\@[38//N)Y^V M!7Q)^R_^T7\&[?XC^)_%6M6NH>`_&6N"X^TW.HWXGT]_WY'[@@<>O[_'2OJ? MX[_LY>#?VA=$MEUE#;ZC;@&QUG3^)[?KT/\`SPKX9UC]BKXK_#CQ,+WX;Z[! MXANK'-O/?^'K\:?-=+^'WA+5O M$>LSF#3M*@-QU@_+Q%=65Y_9EAXBN;(F^L+?_`%`-O/Y'^D0>XQ_* MOTQHJ:BH:*****JZC80:C93VUY#%=^!_A"/`WCCQ!KM MIKM^VE:K;VUK;^&"<:?I0AAP/L$'&<`X%7/B!\"O!?Q1UW0=6\5Z%!K%_H> M6LOM'^I4GVKX\^(?_!.WQEHOC[6OB#\//&^:\W^"/[#'Q0\._$_1 M[CQ;X%\/:CX?-[]IOKC4-5P;?_KW$']:G_:O^"GQC^,W[1GB99]+OKCP]I<' MGZ/+/VM/VI?$/PPA\61Z#X.T$_O[83$P&"$_Z1/C_EO/SW MZ#KTK-_9EUG2O@+^U-?>'/"_CB;Q3X`&E3W.J:A%8_Z.I@M_/[=3B`_O^_2O M`?B)\?O&?Q9U[4-=\0^+-5MM0_YA-MIW^CV\'^D5]?:W^US\9/@K\!OAKXC\ M1:#I6LW.O6]Q]HU'4)_L]QYYN/W'[C_KWJ5?VS_C_P"%]#F\>^(?A3I__"O_ M`+/!=K,;GR&-O/\`Z@_:#S_$/^7?O7K8_;L^&NF?";P]XD\3S3VFH:]!N_X1 M_3?]/N8/F\@CC_/->D_LX_%CP-\8O!9U7P+!#I^GP3%;VP%E]G,-QWXX&:], MUK2;?7-*N-,O8M]O>PF&;'H1TKXY\:?\$P?AA.RW&F:WJOAVSA_Y83^1"WX_U`X].]=3\&Q^U;I_B;2;'QF?"VJ^'8IR;_`%.>8"ZF M@(ZVX@'7ZBO5_P!HGQEXW\`?#.YU/P!X5?Q9XA^T06XT](S,1!DYF$*D=,=/ M:OG/2_V^_'6AVP?QW\#_`!+IQMX?)EU'3K*YV_:/0B:`>2/KFNN\._\`!2WX M<7*%?$6E^(_"=P?]0=0L/M'G_3R,UZ_\*/VG/AQ\:-:N=($^(#J>H6\'VF> M"XL;BW/D_P#;8"O6+B[AM()9YY!!!%]YI>@]ZH6OB32[N;R(+^SF/I#.#_*M M2BOS@_X*JK"OBKP+N\_/V&X_Y>,P8]X.]?8/[(FH0ZA^S5\-KB"'R+O44GD#SL]J6BIJ*****\5U#X8^.6^/%CXT@^(U[!X'\HB?PE+`/( M_P!21G\^:]DJ:BBBH:*JW%K#=6_D3P>?!W\^N.\1_!;P/XNT*QT36O!FB:AI M.G#%C:W&G0E;?C_EW_YX\^F*N_#SX3>%/A-H\^E>$=$M]%L+B?SYK>WX!-== M4U%0T5YW\:M%O];\":E_8GA[1/%.KV]O/<6%AK4`GMS.M9\:?%3PS?6-SI]Q;W-EINH0>1!//U^T8]8.@^M>3?&O\`9T^.7Q;^ M/?B% M?I[X&_;R\`>)=!\47"VGB*S'AG2AJ-\=0T_R&G&X0$=?]<9^*_-GXY^--+^) M_P`7?$_BO1]+GTBQU:^%P8;@8N"?7%?HK_P3<\&7?A[X(W5Y>6&I6,>JWIOX M1<^0;>;(_P!?!CH#_2OKRYL(+H?OH1-]:XGQ%\%/`'BW5!JNM^!O#NL:FHYN M-1TF"XG/XD5FZQ^S1\*M>L#;7_PY\+O#Z0:1!#C\A7'V_P"PW\#;;IX!@_\` M`^Y_^/UQGBO_`()O_!G6F@>RT[5=%(/*:=?Y,WU\[-<)>?\`!+O1;;6FO_#G MCS6=#*#]RUQ;"YN(C[3*8#4^H?L'?$\Z3(KFY$&(+:X^T?9_\`THKS M'3_V1OVI/!VN6]YHWBP75Q$/M'FP^)+B>`S_`$N*ZJY7]MCP)8:E?3'_`(2( MGD[383G_`+80"M^#]J+]I?1=/@M]3^!ESJ-UY.9[J"RN&\X^WDY`K)M?^"C? MC3PCJTUCX\^%5SIY'6WM_/M[B+Z^>*ZC2?\`@I]X%O+X0:IX5US3+'R<_:08 M9Q^0-=3:_P#!2+X/SV,$TQUVWF(YMSI9)AKT/PW^V+\'/$<]A;V?Q`TH3WW_ M`![6\[^23^8KT#1?BGX0\2WGV/3/%NAZC??\^VG:G!.WZ&NIHHJ:BBBBBBBB MBBBOSD_X*H>(YAJ_P_T,00_9XH;C43<'\OZ5]6?L;W`NOV8_AMGMI*P_K_\` M6KX8_:O^)_[0/PP^+VL3ZGXEU7P]HMQ/_P`2DZ///_9Y@]_>O/M-_;6_:#U$ MF&Q\9:I<&&#)^S:1;W&?_)>OTE_9.\9^*O'OP+\/:KXWBEC\12B4-//!Y!G` M/$V.V>:]RHHHHJ&IJ************AHJ:L36[>]N=&O8-+N!87\T$OD7)B\X M0S=CCOSVKX_UK]G;]J#Q:]N^I?&NS@\CMIP^RG_R#;BLJ#]DS]HR>?\`??'N MX;V%_?U5L?V(?C?//;SWGQRU"'':UO[[^IJSW_P#2BJ'_``ZR@_TCSOB3 M/_TP_P")3_\`=%>O_LM?LB7_`.SE?ZQ>3>-+C6(+^#R/[.MH/L]OU_X^,?\` M/L+5_V!?BQX#M;8^`_B1<3^ M1_R[&XGL/L__`%[XK.M_&O[8OPQ\27'VZPUSQ6"/^/?[!!?V_P#Y+UH^%O\` M@H;XM\):M_87QC\"X/G_`+^YM[?[/<6__;O<5VL7[4_[-/QCC:;QGX=LM-NK M&8V\#>(="^T?N?;R,X_I4-W^S3^S-\:+NWO_``QXDAT>YOH!/!I_AW5H("?? M[/.*Y_QM_P`$M;":XU"X$^,KFW'D?N-/UBWSC_MO7R#\0_`/CKX7ZOH^D>. M]#OK>WT__1K&VN/^/>>W^T?\N]Q7O?\`P3TO]/?]J*Y&FZ?/HVFSZ%/!!IIG MGN/(Q]G/_'P:_1OXF>/K'X6>!-8\5WMC>ZC:Z3;_`&B>VTZ#S[B8>U?E#^T7 M\7]!^/'Q='BGPMI.N&(_&W@*V MOO&NA0>%?%/G3"XT:"?/D8KT^IJ*AHHHHKSS]H"QFU3X(_$"QMHI+BXN="OD M@BAA\TL?LY``'U[>]?DA^ROJ-CX<_:-^'M]JEQ!;6_\`:W_'S<5^V5%%%?C; M^VQX_'C;]HKQ1<`0+;Z5/_9$%Q;S>>M%%345#111111117Q!_P4:^-7B7X=:?X/T+PGK6I^ M'=0OVGN);K3KCR2P`&(#^M?8WA3SO^$;TGSO-^T?8H?-^T?Z[..<_CFMFBJE MII\&GIY,%O#;6_I",5;KY"_:1_8'L_CS\2CXKLO$4?A@SVYAGMQ8"?SY\\3\ MGK7I/PI_9,\&_!GX;Z[X6T7SY[C7+>>&_P!7N#_I,^01S^=0_`+]D+P;\%_! MEKI-Y9V?BG48+XZA_;&H6*_:#.?XOPI/VI_V88/VEM-\,64VMG1ETF^^TS2B M`3F>#^[S_GFN`_;B$^,/^%"Z?X+^'?A2\UC2I'M[:YATX>?-;VT`!A@$)ZC MA?RKX^N/AEJG[*/Q?\,:MXP\`W?BW0-/L+>>X(@W6PN<`\SB#R/]'G(/XU]S M_LR_M0V'QSU>_P!,\/?#_5/#FD6\/GSZB?(^S^>>HX[U]*5^<_\`P4\U=Y_' MW@#P[J.J2Z;X8NH1<73`>?!"1/C[08.^.E:GP:^*WP7_`&4?@EXE\3>!]8UG MQ"=5OC:V>G:S&89I[Z"#L,#R(/WPZ@8SQFO"?^&]OB[IOQ('B.^OISHHG^T# MPJ8/(@\C'^HR>_O70_M*?MD_$&Q^,OB&U\$_$*XT_P`*V_V?[!;V$,!)_P!' M_P!(R3;DG]_7I&E?M\^*/AC\)?"`\6V-CXI\9:C_`*3FWO@2-(/^IGG\G($Y M_P`3U->D_M8?MLZO\$/&.@>%O#6@66K:A?V<-[-+J,^`!*Y`@_$`'\JZWX27 M/BSX^WUU!\8?@9HNBZ/!9C[#<:B;?4?/Z>N<5[5X1^%'@KP!>W%[X9\*:-X> MNIQY4UQI=C#;D_\`?(_2K7Q$\!:3\4O!FK^%=;AEN-'U:`V]QY,V#BOCCQ/_ M`,$KM#@EFN/!?CC5-$N6_P"?^(7('X\5GZ'^P3\7?AY(U_X,^+PM;_'S!H9X M/.]CS7M7[,/P\^/'AS6=0U#XK>.+;6-.GA\JWT:!?/VG^]Y]?)?_``5$\63Z MU\:]$\-?9MMOI.D_:?/_`.>WVCM_Y+UZ7X4_;M^)_AO0M(L=5^`>KD0P^1/< M6\-Q!@^UO]GXKN?!/_!0BWEO;BV\7_#'QEX>[6_V?3Y[_P`[Z8%?4GC+QII7 M@/PE?^)-?G_L_2;"#[1<3E#+Y([GBO*O!?[9?P=\::P=(T[QM9M="'.=0@GL M("/3]^!7K6D>,]`UV#S-.UW3-1A_U>;.]BF&?J#U]JZ&BBH:*FHJ&IJ***** M*AJ:H:**FJ&O+Y_B)<6WQ[LO!$U]HRZ9<:'_`&C#:@7']HM/Y^,\#RO)Q^.1 MZ5ZA4U0T50T_1;#3;BXN+2R@M[BX(,\T,('F_E65K'@+PYK?A[4?#M[I-E)H MVJB47M@8<"XSU.!7S'/_`,$U_A3<^+(=7BDURWTP3_:9='6XS;,/^>&?]W@X6&(=`/RK9HHHHHHHHHJ`V_GC]Z,^ MU7\/DW'J,9XK(F^'?[:/@[4!I5CKU[K<,PS_: M%O?6\\`_"XY%+K7BK]M/1=#@AGL-5/D#[>9[>QL+B>X_Z=\6_'>NNM_VQOVB M;6W@$WP#OIYH8,SS#3[['\J3P_\`\%,KG31/!XT^&6K::W_+DVGCEA[^=CFN MALO^"G7@-[V"VO?"GB33@W!N&AA(@_6O1=)_;Y^"FHV$-Q)XR6QS_P`NMW97 M`G_D:Z;P_P#MD'^D7%?&M+U;23=?\)Y?`?9SIUK!Y]M(8X+?5(9IYF@@G\X0B:XU'4 M;"XT^X_\"/\`CWKU/X>_\%*O`WB.]N8/$VD7O@R#_EWN"?M_VC_P'KO]+_:Z M^`OQ%U,:?/XLTN[N8/\`4MK5C/;P9_[;@"M"_P#@5\"?C-IDRV6A>%M1\X33 M?:/#Q@AN/3K!R?J:\.\9?\$O-#N?M\_ACQE?:;#1=?OK M?[//HVH8G\__`*][C_EO7@?['W@:V^&G[;WC'PE:WD]S;6%C?6,$]U_RW@!M MB/U%==^V]\5_B[\$OB#I^J>'_$4UKX/O8,06QLK=X#."?.@)/).!GFO%_P!H M_P`3>.?VA]#\+>,/"'A6]M_`XMQ`=,T:'[0;>_.?M'_'O](/RKS7X1_L\_%C MQ%\0M/A\,>&M=\*:A;C/]LZA;W%@8/\`MO7[(:#:7.G:-86]_??VG?0V\,,] MSY('G38`\[\3S6U14U%%0T47'05^&GQM\%3_``G^,'C'PW`)[;^R=6N/L&9_ M^7?_`)=__)>OVA^%^N0>*/AMX6U>WN!?)?:7;3^>).I,(Y_,FNJHHK\-?B[Y M&F_'_P`93ZI!]IM[?Q+<7$]O_P!._P!HK]OM.\E;&V^S@00&'$4'3`JY114U M%%%%%0T5-4-%?//CWX>?!OXJ_M`:)?ZIK4&H?$/0HE6#1DU`$#R3Y^9[?VR# MR*^AJ**********S-&T'2M`AFBTVPM]/@GF,S)!#Y(:4]3CWQ6S7/^)?!6A^ M+[=8-:T;3M7@CZ+?VZSX_,5P'BK]EKX4^+DTUM3\`Z,W]E_\>XMK<6VW_OSB MN0^+7[(FA_&3XL:=XYUG7-3@N["P_L^"PMO)V0$&X\F<''4>>>/;\OG'Q%_P M2EO?MT!\/>.X!:C^+4;#_2*[;Q-_P3#\*ZKX#2_%6JZ?KUC8PVW]I3CS[ M>7'K;DYY]I_\:^9OCQ^RA\7+3Q[K,\.B>*/&>CV&+>#6;FY^T7,]O!!@?F:^ M^?V-?"$_P]_9Z\/V5[IFMZ+?S`SSZ=K$^3;G&<`<^3#QP*^AJAHHHK\COV^2 M-<_:]O8-*EAFU#;IUO;J9\8N/2OTWTWXT^!M0\07'AV#QEHD^OVT`GGT^"_A M9H1^?\Z[JLGQ)X9TOQ=H5]H>MV4.H:1?0_9Y[>X'$X]#7@>K?\$]O@EJ8&[P MS/;?O=W^CW\X_K7EDG_!*WP[!?3WVC_$'6M,?S_M%F%LH"+8^W`S7JWP(_98 MU[X,>+Y]=O\`XK>(O%UN8)8/[.U/(MP">#_KCR,=Q^5=_P#'9?B%+\.[B#X9 MW%A;^*)YX(/M&I$XA@/WB/67D8__`%5\GZMKG[:W@N"!91;^(6N9RQFT^WL) MC!_TPQ_6O2OA]^U5\9O$OBS2=*U;]G_6-,T^YF\F;5&FGA6W]R)X!D?C7UY1 M14-34444444445#4U%9>HZ[8Z;+##=WEI;>;P%GF`)^F:J_VSHDNK1P"^LVU M#!@`\X>?]`.M;%%3444444444444444444444445#4U5[FVAN!B49KB?&WP4 M\#?$:]MK_P`3^%-%\1:A!#Y,-SJ-BLY4?CVKD+?]C+X)033%?AMH7/K;UY?X MD_X)J?"O6([C[%)K>CM-+F'[/?F<0?03Y_*N/O\`_@E1X->SG_LKQCK5M?8S M#<74,$\0_P"`XJYX=_8/^(_@O0/L/A[X^ZWH^.?LUK;W$%O_`.E%-OOV:7,UKJ"X('M-2NG MW\L!'YBVMZDU[7_VQO"L]IX@OM(\.ZUIUC;SS3Z+I8@Q<``X!Q^_\[KQ!P:K M7_[<'QUTRWN+B]_9\OK>W@M_M&3!?_\`R/7Q?\=OBSJW[1_Q2_MV]TG^SM1O MX+?3H-.T[_2*_9GPYX?MM/\`!VG:"L`_LZ&QAL/)_P"F(@"X_I7QWJ__``2N M\*7=Y<'3/'&K:;8_\L+6>W@N/L_XD"N0\4_\$JK^W`_X1CQU!<'TUF#R/_2> MOKW]F_X07/P+^$VC^%+O5O[:N;*[G]L^YG M\4_;/^$A^P7_`/:OVK_7Y[?KBOT^N=.@N;?R9X?M`]Z^5/VH/VN]6_9K\8Z- MH6F>!H-2T>XL/M`NI[@08/\`SP'O7S9\+?VL-/\`"O[3GCKQE/<>)-9\*ZM8 MSW5A;ZA?X\C$'VG[/]G_`/)>WJI=_P#!0_Q]#\8;CQ+9S3_\(/YV/^$7GA@# M?9L^O7SZ_4>UN%NH8)X/]1,/.S5NBIJAHHHK\^?^"HO@#0M,TWPKXS@L8H/$ M-_?G3Y[J'K/;^0>/PKUG_@G7\0K?Q5^SOINDM=2SW^A7T^G3"X'S=?/@_P#( M!6OJVBBORI_X*4:*-/\`VA_M`AG/V_0K>XX_[>+>OOW]G3QW-\2?@5X,\2WO MD_:KJR43_9_^?@'R:]9M^AHHJ:BBBBH:FHHJ&DN9_LT.:_/?]@/PX?BC\9_' M_P`7]4T^V@7[7/\`8O)./L]Q/_K\?]L=M?H?114-'_+:BBBBBIJ*****AHHJ M:BBH:**_$;]IFVU;Q)^TM\0[?[!]IU'^UKC_`$>W_P!(_P`_Z/7E>G:;?W-A MY]E83W-O!_I'VFW@_P"/>OTP_86_:[\9_&'Q)=^#?%%B=2^Q6`G@\0V\1Y]I M^>#7V[4U%%>:?%_X%^'?C/\`V!_;\VIK%HE]_:%O#I]V8!+,!QN]>_<5Z714 M-34444444444445#4U%?E_\`\%,O@[=:9\0H?']SJMA/IVJPP6$.G3KB>`PG M)/\`UP.TZWT2#_`(G-Q/;V]A]F_P!'N/M'_+O7Z[?M$_M) M']FGX1Z7<:C=6^H>/KVQM[>RTV8X-Q<`8GF^G)/Y5^=/A?\`:M^+?@SQ9JWC MFTU*5I];N1!>W%UIX.G3$="/2OTP_98_:5L_VE_"=_J@T2;1=2TJ*_.+XN_`SQO^ MQ]\4SXQ^&QU-O"XPWV^WQ)+_3_[&U"_ ML1<3:?'[+Q/-`/$-Q,;^PO\`Q&3-S]<>0/RKQ7X.?M?^*='_`&G-0TB? MQ'>^//`FO:[_`&;8"X'^H$]Q_H\]O[>U?IA14U0T5-4-?,G_``4#^'5CXX_9 MZUF_FN#;S^&O^)Q!CI*1VKY]_P""5_B/[/XK\=:%//AIX+?4+:#SLX/2X/\` MZ3U^CO\`RQHHKXJ_X*;?#";Q#\.-(\;07'_(LS"&:U_Y[BXN+<8_3]:S_P#@ MEQXS74?`?BOPM-,%DTJ^%];P^=DBWN,X_P#1!_,U]RT45-1111111117S[^V MWX[@\"?LZ^)Y);(WW]JQ?V1%M(_=&<%?./L.OU`KB/\`@FE8"S_9[GN3_P`O MVMW1_E7US14-35#4U%%%%%%%%%%%%0T5-114-<-\9=9O/#_PE\8ZMIMY!I^H M6.EW%Q!<7`XMR(20?S%?D_\`L-ZC]J_:Z\#3WQ^T7%Q/J'-Q!_R\?9[BO:?V MOOVN+_PAXV\5_#'P9H>B0>$(8)]/U>VNK'B^GG_X^`/SKWO]@?1/AMJGP^G\ M8^!?#\_A_5[G_0-5MKB^FN,$<]S_`)Q7UW1111111111111111111114-35\ M$_MC?'GX.>,?&4'PV\=:5XG/]DWQ-QK&G9MQ8L8,YSSYX]J^"OBC;^#M%\<7 MQ\`:Y>:QX9-L+FRO[^'R9[<]P#@9_(5ZU^VQXB\>>(?%7@Z;Q59SQ6\'A2Q- MA<:]\2YS_P`>WD:?_P"W%?HS1111111111111111 M11111114-3444444445SOC+Q#;>%?#.LZW.)#!I]E/?3&'J1"NX_R_2ORC_8 MFT.^^*7[5.D7VK7UZ;^`7'B&XU"#I<3^_P#X$5^O%3444444444444444444 M4444444444444445#1111117(_%+XA6'PG\":QXLU."]N=/TFW^T3V^G0>?< M$>PK\_\`]C3Q'H7BS]M;Q#KGAC2CX>T:_P!!GG@T8CR/(_X]ZW_'7@3Q_P## MC]OK3_$WAG0[ZXTWQ'?"Y;[#_P`>\T&!!^* MP\+>(_"=A<:SK%B?L,^GPD?ZAB3YWX?X5ZGHG[.7A7XC^`_`]]\3?#=KKGC& MQT6WM[VYOQ_I`G\@!L^^=U=)X<_9?^$_A;4;74=)\`Z';7]A-]IM[D6X,T,_ MKFO6******FKF/''ARR\7>#=9T.^LXKFTOK*>":`]&!&,?G7XV_`/Q7?_!_X M^^%]4GL2+BQU7^SIX)SR/^7>XK]L[?H:**YCXD^![#XG^!-:\-:E"+C3M6LS M`X]<_P"17Y"_L_\`B[_AGG]HW1K_`,6P?9[?2;ZXT_5?^F'_`"[_`/DO7[,6 M]T+F"">'I/S5FBIJ*********\N^.WP*\._'SP7_`,(]K\EY;PPW`O8+FP?$ M\$PS@C@^M=9X$\`Z'\,?">G>&O#UE#IVC6$/D6]NO0"NEHJ&DF80#(I:FHHH MHHHHHHHHHHHHHHHKPC]LKQK_`,(!^S+X[OK<2F>>P.G18Z@W'[@?S-?G/^Q] M\`_^%^6/Q)TFQU:;PYX@@TJW%CJ-N?\`IX_Y;^O_`![UY)\0?A1XJ^&7BO6/ M#NOZ',VKV,^9KJU@N+@7`_Z=Z_5;]A'X<2_#S]G'P\E_;S6U_JC3:G<0YF.# M.<]#^'YU]'45-4-344445#4U%%%%%%%%%%0T5S7C'XD>&O`5A-=>(=._&3]F+X8?M7:?9:V9\W,T&;?Q%X?FA$TP_WL'-(CJMU]N\8G'[BP\2"WN;9?P\@5O?M=?LIV_P"TKH&GW%EJO]D>*=($QL9Y M!FWGS_RPG'I_]>OCZP_X):_$D:I`;S7/"T$'G9GGMIY\G\[>OO?]F_\`9ZT+ M]G+P*WA_1KB:_N+B;[1?7]P?FN)_6O7J**************************** M*****X3XS+]H^$?CJ'UT&_'_`)+G_&OS=_X)H?Z-^T9^XA\_S]"G\\_\\/\` MCWK]5Z*FHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ&IJAHKA/C!\,]/\` MBS\/M9\,:IO%MJ2?P('Y5^<7[#H;X#/!.MV&AZ]XETO2-8OQ_HUM?7`@,_T)XKKZ M^?/#W[9?@[Q+\;+CX8"UU.VU2&_N-/AOVAS;SSP?>`-?0=%%%%%35#17X_?M MZ>"9_!7[2GB&?R(;?3M6^SZQ!Y'6?_-Q]HK]%/V4/C(_QJ^"VC:Y?><-5BA% MC?&6#[-!/<`<^3ZCI7MM%%?E1_P4>^'5OX5^.,&NV/D?9O$EC]HN+?\`Z>(! MY%??G[+_`(I_X3/X!^`M8DU)=3NVTJWAN+GN;@`>?^HKV&H:FHHHHJ&IJ*** M^$_CWX^UWQK^W)\-O`WAJ_U:P&AW$#7XMYO(MYQ_Q\7`]_\`1Z^[****AJ:B MBBBBBBBBBBBBBBBBBBOD;_@I7=-"OGZO8C!_P"6_-?`_P"S#^T_ MYKZS_`&6?VF/#GQ.^$VGC5/%5OJ/B?0=*M[CQ%-?#[.8N M"3. MBZU?P0^=-;:9?PW!`]\$_G78T5-111114-34444444445#3)[J&UMC-,PAB' M4GBOR9_X*-Z;W_`,_\O%;_`/P2\U<0 M?&C7M+^V7D/F:&;H:?;C]S-^^@'VF;WYQ]":^E/^"C7Q'_X0KX(V^E66L2Z5 MK.JZA#Y$-O\`>FMX2&G'TQC\A7QE\*/VO/CSJ/BCPSXIVO[5WQ-F_;8'ALZJ+GPNOBS^Q_P"P+#F#R//^S9SZX_TB MOIG]L7]J'_AG;PIIT>F06USXJUSSUL3,?W$$`_Y;DCT)AX]Z\T_9%_;1U#QO MX7\=3_%+5=+M;?PW!!?_`-HH!;&:!OM&8O(/<"W/US7M_P`-?VQOA5\6O%%O MX<\-^(Y9]9F&8;>>RG@\[Z9`_6N=_97_`&OH/VC]?\4Z3_8D7A\:4L,UDGVX M7$US`>Y'^>M?3=%%%%%%%%%%%%%%%%%%%%%%%0U-114-1SW<5I;S33'R8(>K M=J^=/A]^W)\/OB7\3[;P1H4.II@?M,7,%I^S[ M\2Y9KV'3E_L"_P#](N.@_P!'-?$O_!+SPE?W7CKQ?XC&FPRZ?!9C3_[1GFS< MPS@Y(_$`U^E]0T5-111111111111111111111111114-34444444445#17YX M>&K&\\9_\%+;FY\5:3;Z+?:5Y\P$$_%P88,6TY_[8$5[G\!?VI;WXH?%[QC\ M/?$>AP^']9TBXN/L/D";_28()\9.?Z5XM_P5)\"R&3P?XO4_:856?2;BV]CF MC7]E>PZA:SV4!ANX3Q,,=1_GUK\]?^"A/P]O_AY\6]!^ M*&BS3VHU4_OKFVY\B_M^_I_J,_A;S^M?>'P;^)%G\6OAMH/BNSABMUU6W%S+ M;"X\[R3SQG_/6NYHHHHHHHKXB_X*7?#'2=<^'NG^.A<36^KZ3<0:>#G]Q/!. M>17+?\$N?'DUV?&'@R<2^3`?[7M]TV?('^H(_3]*_0:BBOG#]M_X0V/Q*^`N MLW$\+MJ'AV";5K#R81R0#^Y_$8_*OD[_`()M?&?5O#WQ,7X<2_9Y]!USS[BW M;'-O/!`"1^.*_2+Q+XVT'P9:BXUO6K'2+<][^X$'\Z;X2\?^'/&OG_V!KFF: MUY!Q+]@O1<;?RKIJ***AHJ:BBO'?!WQ:U[6OC3XP$7^AZ78:/I$`N+?4;;7 M(;BXGZ`^?;CF"OE?]D>ZOOBO^VO\2_'4P%SI]C!<6XG\_P#U)^T>1;_^2]O7 MZ%4445#_`,MJFHJ'[0/2BL[6=%: M1^W=\%O$&N0Z78>,]]W<2^1!]HL;F"W8^@F,&!^=?0U34444444445#4U%?! M7_!5_P`2VEOX`\#Z$2#>7VJ37X(Z^3;P'=_Z/%?`7PT^'%A\3YK?2H?$NE:+ MXIOK[[/8:=K/VB"WN/\`MXK9^,O[./CKX%P:?/XHL8/[/OQF#4-.N/M%O]H_ MY]_M%?='[!'P+_MC]G[Q3;>.=+N[GPYXCO\`$>BZC#]G@GA@QMF'_+;)ZM;$__``2W^'Q^T>3XI\2+_P`^^3;?N/\`R!7"^(?^"5E_ID]M/X3^((#? M\MQJ%EY&?IY%>W?LI_LL^*_@)K>K7^N>.&\06]_`(1I\'F^0&_Y[L[PQ_P4-\9 MF2&VU_X-ZL#<7FU;BR^T1*(.Q(-OS^=?57QN^.N@_`3P8/$GB&"^N-.\X08T MZ#SV_&O$(/\`@IK\([J\MK?RO$,,,XYN#IW$/UYKW/X:?'/P-\8K>X_X1+Q+ M8ZQ/;C_2+8-^_@^L/6NPUG6;#PWI\VH:G>P6&GVXS-'\P<5O4444445#4U%%>2?M$?!>7X[_#FX$_P#" M27OAVWGF$]Q/:P"RL=:^#WC":[\7W$_V:_P!0N!!8^18=Q!Q@4O[1G[-GQ_\`BUX5\$:/ MJ=_I?BFZTBQG-_/#Y%MFX-QV!_Z=Q!^(-(O$5G8:+I M.E3_`-HS3VU_]H)_Z=\5K_"+]E[XJ>&_VP=1\:C2H=/\+6_B74+DW^H30%I[ M>XGG/[@=0>1^=<'^UYX`^-7Q4^)_BK6KWPKK`\'Z`UQ_9@F^SBV@LH?F-QCW M\C/XU\GV^B7]S!<3P6$]S;V_^ON;:W_X]ZT/LU_;:#Y\&A3Z=<6_^OUK_2*^ MJ/\`@FCHGAVZ^+EQ>W6N3:=XKLH9UL-(-N#]L@_Y;MY_?!Q7ZF5-11111111 M11111111111111111117#_&3QRWPQ^%OBGQ9%8G4)=(L)KI;0?\`+4CM7YK^ M+_V[-*FD?Q-X8^%GA_PO\2#-.LWB9X+:YG7'H<9.>^2:O?$K]M>?XT?`?QAX M(\'9=4MM1OB)_)NHA_R\0<=<_^W%?3GQN^$>D_';X> M:EX/UJXO;.TO3%+Y]B<3PD'@Y_`UTW@/P/I7PX\':1X;T:$0:=I4`M[=?05R MGQZ^"FD_'#X>W_AW4MMM/S/8ZACYK*X&<3CFOB#]@_QI-\%OCIXI^&/B$>1< M7L_V`$3;K?[?!UQ]17Z44444445\F?ME?MBZI^S]J?A_0?#NE66I:Q?P&^N# MJ!(@@@''4?2OSH\=_'7XA?%&?Q#?>(==OM1TZ_G_`'^G>?\`Z/;_`//O_H]6 M/V'O$GGS_`-G6]Q]GOL_Z/Y]O/7[@IY6/W>,^U+15+4=,@U.P MGLKB(7%M-#Y$T'MBOQ9^(6B_\,L?M,SPZ-*=8_X135;>YL5NNL__`"\8KUK] MM'PYK?Q@U[1?C5X7TJ76O`&KZ1!!#J%J//N(/6"XMOJ:H?L\_LS_`!!\-^+/ M"_BNS\9>%O`>H>?;W!MKG5?(U#[/_P`^]Q;_`/3Q7ZT5-111114-35X/\;_" M7A3X3^!_B5\3]$\-Z;;>,9M#N//U%8/](N..AKP[_@E=X<@M?AYXRU\_ZZ^U M6#3S_P!N]N/_`)(-?=-0U-114-35^3/Q5_9J^.?Q(^*?B'7?$]D-/M_/G_XJ M'6+^W@T^WMX/^/:I?^"?'QRO?`/Q>@\#W]_`/#WB.?R/L]Q_RPO_`/E@+?V- M;'_!2;XB^,)_B=_PAMW<7T/@6*&"YLH/(-O;W%SY!R/M!_U_)/':OF?Q5X;\ M-:)X*\&ZMHGB6#6M9U:"X_M;1?\`EXL+BOU5_86UW5-:_9A\&RZVJ_NO/M;$ MG_GW@G,$'Z**^C***********Y'XI_$;2_A-X`UGQ;K?F_V;I,!N)_('.*^* M?A=_P5)L]4UVX@^(/AZ'1-''^HU#1A/<`_7C^5>.?\%$_CIX.^-5[\/9O">J MC6?[/LKFXFQ$8!O$D\][_PE'B75K^W!MH/ M]'@@@_R*T?@1^T/XS^$MA<>&M$L+'Q7HT_\`I'_".ZU8?:+?[1_S\6]?LSX# MU?\`M_P5X=U8V9L/M]E!7^+/V._@[XON8+B[^'FDVLD'3^SP;' M_P!$8KI/A;\`O`/P:24^%/#=EHUQ.,W%R$,D[>QF/-0?M`_!6P_:!\!MX5U+ M4[[2+,W<-Q]HL#AFV]!^M?)5[_P3A\6^%[V*'P3\6=2L-&FEW7@'G6US&?\` MGL/((\\_7'7ZU]AZUH_BG0?@S<:3X:O8M2\7V6E?9K'4=1Z3W(A`$Q_$FOBW MP[<_MK>'M8N+K[#>:U#9S?O[#4/L`@N!]>N/^O>M.Z_;E^.G@H6]AXG^#.-2 MGZ'R)X/.^F:^S?A%XLUWQK\.]'USQ1X=/A76[Z`3W&D&X\\P>V17"_';]KOX M?_L]ZWIVD>+9M46^OH3-`-.L3<<=*K?!C]LGX>_'#Q7_`,(YX=GU0:B+?[0/ M[1L3;B4>U=[\0OC'X*^%!T\^+O$MCX>^VMBW^U38\[Z5S_AW]J+X4^+=7@TK M1O'.DW6HS_=MA<+=#UR4PZ;JUE?S#M;W`FQ^(-:]345#7FG[0GQGT_ MX#?"_5_%=U$MU/`ODV5KWN)S]V$?7!K\XKG_`(*2_%ZZL/$(/]B6XOX/L]C< M6T'_`""KC&/W'_/Q7-?#_P#;G^-&@:A#`=:F\5-<^=;PV%]!!,QN)CE>1SP> MWU]:^P/V&/VE_'?QBOO%/A7QX8+C6-(_?PW'D_9K@`\>1<0=B*^O]1TRWU.Q MFL;V&*[MKB'R9H)QQ-QTKGO`GPN\&_#FWN8/"WAO2O#T-[_KUT^Q%OYQ]\5' M\2OA1X7^+OAT:'XMT.WU?3MWG[7Y\J8=Q7+_``B_9=^'/P.O[B_\)Z*+35YH M?(;4+B4SW!'IDUZW4U%%%%%%%%%%%%%%%%%%%%%%%%%%%>5_M'>$-"\??!SQ M1HGB#6Y_#ND2V_G7NK6QP;982)\_^.YK\JM"_9RN/'&M^)F^'WC#P]XHL/#E MO_:-Q?W7GV!7CH8)[?[3/DU]-5#4U%%%%%%%% M%%%%%%%%%%%%5K?GWQC/OFON^BBBOS>_;V^&<_PQ^,.@?% M;2[B\M[?5+^V$YM7\FYAG@`Y@_[86Y_*O2O'/_!1>Q\(ZH!:?#_5-3T"X@MK MFQUOSS;V]QY\.1U@/^?RKVCX#_M9^!?CW-]@T6>;3O$`@^T3Z+J`Q<**]OHH MHHKP3]J/]E[2OV@?"LY6"WT[Q=8P?\2K5^F.I\B?`YA)ZC_)_/?XP_L6ZY\$ M/A7?>+O%OB/31?->V]A8:-8*9O/]C.<$'\*\&\1?\(U_Q)O^$>GOO^/"W^W_ M`-H_\_'_`"\?9_\`IWK]7?\`@GMX\U[X@?L_6\^MW%[J5S8ZI<6(O]3O/M$\ M\*D8)/Y5]/T4?\L:^!_^"GGP?BN?#V@_$#3=/"WUC/\`8=3N+<_-]G_Y89'L M?YU/_P`$_?BI/XY^!?B/X8:=<_V-XMT2VG72[]F^T#]^3_I&,<^1<'!^@KXF M^)GP!^(7PX\2ZC!XH\-ZK&\P7&I!?/U.^MXL?:9^[?Y]*]:HHHJ&IJJW,Z6L1G MFE$$$76OD/\`;"^!.H?M72^'K7P9XX\/_9])$[7.DW5R64D\>>/))/I7YZ?# M2>?X&?M&^'YI[B'41H6NV]M<7.FG[?;S_P"D?Z1]GKZ2_P""H?CZ?4O'?ACP MK_8?S]GK[ZHHHHHHHH MHHKD/B1IGAO6/!FK6/C-;(^&9X-M\=0F\F#;[D_XU^6W[4OP#\*VOB[33\$K M'5/&D-[;XNH/#H_M:VL2.I`@)Q/^-?/GQ;^&.J?!_P`5_P#"*:R0VL0007%_ M;@_ZBXGM_/KVM?VE?#7@?X->$/AE#X$TCQKH[6`O]=.L37`N?MT_:`_\L.3! M^?Y]]^Q_^TK\%O@+I>HSW'AOQ#IWB2^_<37['[<&@'(R<08'X5^F/A7Q#9>* M_#FGZWI+^=IU_!%/;DQ&+$)Y'!]L\5T-%%%%%%%%%0U-1116'K7AO2M=D@.I MZ99W_D?Z@W-OY^/S%8/A+X.^!_!6NS:WH/A71=&U>:`0&[T^R6W8PY^[Q7!? MM%_LI>&_VDY=`FUN^U/3IM(%Q]FN+`Q`_O@`W45X5K/_``2N\(7.FW`TOQAK M5O>8_J^)(;VWBMYM/L+:&':9X#_ M`,MKC_:]J^MM_@TZX%A?3P'R9SR(I<=?Y5\!W5Q^VOX!\701&=/%D M"]3;V^GW&GS?^D]Q_P`MOTKZH_9S\0?&/Q%H>H3_`!9\-Z1X=NE.;(:?<%C* M,?\`+8=CTK`_:G_:@O?V<[/09;#P?-XI_M0W`,RW`@@M_(&>6`0$#/7G_G@3^=?'GV7WKU'X%Z=\0-$^(= MQXB^'%E_PD.L^'(+B<7%M9>?`>/(XM_I.:^S/^"?_P`#O%EKX^\8?$[QWHD^ MEZG?_N;$:C;_`&>X,\^)[B?R.@R2/UK[K@UJPGN/(BO8&N)?%N@W&K>%]"U7Q';P3_`-GS_P!C6%QYGMX+?\`Y]_^V]?J3^P9I@T_]E?P M(?\`GL+F8_C<3U]$5#14U%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%97]IV7V_ M[!Y\7]H>3YWV;S?W^/IUQ6K11114-%?('C3PQ8:3_P`%"_A]>6EA90+J&@W$ M]P"!$#/_`*1^_P"G,W;Z5]?T445\E?\`!2331>_LYK>&64'3]WGT_[#]H.9_](@X^E>60_M3^ M&OA!\?-9\5?#?P+HEMX6G@!R(/L]S/`.;C_KW_\`N>OU"\%^(K?Q=X7TC6K+ MFUO[*"XBSZ'G^M;U%%%%?G!^WA??&3Q!XBU#PK=^')]<^'L\]O/I7]CZ3YY! M]#/V-?(6C_`SX@ZSI.L7T/@W6Q;Z5!Y\W^@W'-?1O_!,CXG#PI\6=8\*3B"W MT_Q)!FW_`'^?](M__K9K]3[?H:**YGXA^%++QMX*UW0KV$7%M?V,]NT'KD?X MXK\>_P!E_P`?7'P"_:%\+7VM0SZ9;^?_`&=JUOX_P"?C_TH_P"W M>OM/XX?\%!=.^%7Q8U7P--X+GUBPT\#[1J/VCR?W^WS\>2>2/>OBSX:?&+0K MG]IRW^)/C6>^T:WN-6_MB<:-_I'D7'_R/7[.Z-JEMKFE6-];@&">$31?3_)K M3HHHHKA?BU\6_#GP6\*GQ%XFFGM[!9!"&MH#-*2<]!^%='H6KP:[I5GJ4!E\ MB[A$\(GB\I@".,CM7Q_>_$7XR?'OQ];2_"QKSP)HOAG5KC3M;76!#Y%_B;_7 M@&`DG`/3_$G[7HHHHJ&BN6^)?@>V^(?P^\0^&YK@VT6KV%Q8-<#K&)AC^HK\ MQ[G_`()M_&73-4G;2QHOV:'_`(][BVU0VY_+%=M\#/\`@G;X^\,?$OPMXD\3 MZMHNCV&D:A;7_P!FMI3<3W!@;SNN,=:^S/VA_P!F;PE^T9H,%CXA\ZUO[$YL M=2L#_I%O]*^)M'_X)N"?X@7_`(<@^)^B7)LOL]Q>VMO!_P`3""#M^XZ<_P!1 M7W-^SW\#-*_9Z\!+XO6*AJ:BBBBBBBBOCK_@I# MX+\<>-_A1H\'ABSGU/2;*_\`M&JZ;IZ^=K>-OB)<:[K<\%SK.K:#H^HW%QIW_/Q_9]O7 MWI\0OV"]/U+5X?B5X+O['3M3MM'MKN#P[]B']G3W\,!Q<8]R((/Y5H_#7X`?# M[X0WM]>^$?"MAX?N+B`0SW-LO[\CZ\UV?B*PN-5T'4+*UO9M&N;B":&&]AP3 M;D@XE^H.#7P-)_P3,\9:3J9UG3?B?:6VL#_2/[06UN8;K[1_UW%P36CJ/[,/ M[5WA-0V@?%8ZP9^9P=5G)'_?^K$]G^VOX;T:&*&_LM75?W+-$MA-./?FJ/\` MPTO^U=X!O=/T#6OAK_;6H=#<#2;B?S_^WBW_`-'K[TTV2>YLK>6^ABMM0\D" M>"&;(A]A6M7!_$_XK^%?A%X?@UGQ;J_]B:=-,+<3_9YI_P!Z>@(A!/;TKSCP MU^V[\%O$&ISZ?!X\L8=HXNM2AGT^`^WGS@"O2K?XR>`9[@00^-_#D\YD\F.` M:K`3N]``?%WQ[H^E0?##Q5:>'`C'[=#=MY7V@?7R6/\OI7R/;?LK_M1_#G0SHG MA_Q;86UCJM]<330Z-JOV?K!CS\_9_4#CZ5YY^U[X>\?>%_#/PF\._$758-;U MFQL;_+6TQGW?OQ@CUGQCG_IWK]"OV-/#LOAK]FCX?6,\WVAIM.&H;O:X)N,? M^1Z]OHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHJ&N"T[X5Z#8?%S4?'+`2Z] M?Z9#81":+_4P1$G@^Y;/:O0Z**AJ:H:*^(;OQ1KFJ?\`!1[1UU#0[[3=/M]+ MN+&P\^'_`(^(1#<'SX#]>OXU]O45Q7Q5^)^D?!WP'J'BO7Q>_P!FV`_?_P!G M0?:)_P`J\(F_X*(_"&UT#3M6-QJA-_/-;FV%@?/MR/\`GN,\5[+<7/@S]H[X M::AI]AJEOXA\*ZY!/;3W.GS\8]J_.7]B?PYXHHHHHK@/CA\3K+X._"_7_%>IV$ M^L6MA;Y-A;PY,Q]*_%+POX]U7P'XZ@\5:!,-/O[&?SX1;](!_P`^]?LW^SM\ M;;'X\_##2?%=I!_9\\X\F]L#UMY^X_SZUZC117YC_P#!2WX#3>'O&\'Q&TN$ M'2M4`@U`>?@_;SG!QVS`#^5>'6_PW\6?M(07'Q"GUW0[;[!_H^O:CK5_]G^S M_9[?_CXN/^OBO8;G1/V/?#G@K2!>^)-3\9:EI$'V>4Z=]HAN-0G]QQ7W/\"O MV@/AI\7-*M['P)JEOFQA$1T:X_T>X@A'3]Q7L-35#4U%036RW"XEZ4M34444 M5#4U0T4445SFD^"M!T3Q'J6M6.C65KJ^J[1>WUO`!-<<<><>]=3111111111 M1117S%^UQ^RK-^TMJ?@B/^W(=%M]'N+@7N822UO/C)M_2?\`"X^SV]?N3]FA^S>3@>3CIFO._`OP`^ M&_PQU[4-<\+^$]+T35[C_CXN;:#!KT:BIJ***AJ:H:FHHHHHHHHHHHHHHHHH MHHHHJ&IJ*AKDOB'\,_#7Q8T(Z'XLTJ#6=.\X3_9KD<<5\WZ[_P`$TOA7J,H. MG7GB'1SY./LT&H>>/K^_!KYY_:=_8-T#X'_#>_\`&-AXJO\`4?L/E6_]GW-B M/W_G-M/[_.:XC]FC]EKQS\8/"U]XI\"^,[+PX89C83P>?<6\_!$_6W^HKTK3 MOV;OVNO`6I"3P]XHEN68&#SSKWVC(XS_`,?'_7$?G71WUM^W!X9%O?2SC6/W M_P#QZVPL)^*V+G]K?]I#X76'V?QK\'AJ,Q_U-_;6\^#]1;_:*9??\%.]5\/I M`/$'PBO],.[R9C<:@;;!_P"VT`KM?#O_``4_^%VI08U2QUS19?3[/Y]=%;_\ M%'?@Q]A3]GTC2H+6'/'_`/0)-'S96_\`Q+./]"_<+^Y_X#TKJ*AN.@I(&$\`S4]%%%%%%%%%%%%% M%%%%%%0U-111111111111114-%%#=9\1_8;C4O[+LIKG^S[8? MOILGPY_:6@_:$_;0^%NN:GI4/A[[!!/(N/M'GW'V>XXK])JY/X MF6NNZE\//$5OX7O?[.\0SV,_V"Y/_+">OSK_`&./B/XT\2^(_BEH7BWQ)K>M MP6_A2^N)]&UJOI7X)_%G7OV,?C! M*[:R^(.NP^(M8L;#R+?4#?07_^C_\`7>"O MT_\`V!=8\1ZW^SEX;_X2'S0UC/<06%S<`;KC3Q_Q[GZ8./\`MC7TK]G'K114 MU0_9QZT5\H_MN?M0WWP#\,Z?I6BZ;!?:YKD$XANKD_Z/;PXYX_Y;'GI7YD_$ MKXKZ[\3O['_MJQTNW_LF$P0?V/8P6'^C_P#;"OJ[_@G3^T;;^%->M_A?K?\` MHVGZO?&?2;G_`*>#_P`N]?IM117FGQX^&EO\6OA+XF\*RV=O)(-*TSP;K8GFY)N;&XM[8?\`;Q7UY^RU^PY\2/AE\;O"OBWQ3;Z)IVG: M29II_L]]]HN,F#`_6OT?J:BBBBN1^)GCVP^%_@36?%6IPS7&GZ5;&XG6W&9L M#V_&N%_9H^/LW[0G@R_\0_\`".W'ARVAO3;0"XG$_G@=^/P_.O:****AJ:H: MFJ&BIJ*AJ:BBBBBBBBH:FK!\6>+=$\$:/-JNOZK9Z-I\`PUS?W`@A'XDU\JG MX-^%OCM^T+8_$?PI\:9]1M](OK?4+S0=/U%9EC:`\+UR(2?;'-?"_C33YO&G M[:^M66C$:A/-XZS"2>!_Q,*_;"BH:FHHHHHHJ&IJ**************AJ:BBB MBBBBBBH:FKX1_P""I7B:>Q\#>"M$@GEM[:_U":>:$?ZAA;J",_F:]G_8;\%: M5X1_9O\`"L]C9""YU:W&H7\W_/>-[;BX_GFL*_P#A!X%U&;S[WP9X=N+G;Y7GSZ5`Q(_$5YQXM_8A^#7BK2#9 M'P;;:9^^^T>?I'^CSY^M<9/_`,$T_@SY1\FWUVVF[7`U0YKR\_\`!*.Q7)B^ M),PF]?[#_P#NBN"U_P#X)K?$CPJ8+_PCXJTN_F\B?S7)GL)X\]",&O-]9\6? M&SX!Z_HOAVQ^*]C`O^"GOBGPAX6TG1=3\&6>M75G`(#J)U$P" MXQ[?9\"NRT;_`(*QE9"-8^&_V:#L;'5RW_M"O0_#?_!4#X7ZC99UO2]<\/7' MG8^SFW^T']*]!\"_M\_!OQM<7$/_``D>?[29_P!Q M^)K\NOV#KV^\0_%#XA:I?,=0^W>%-6NK\S_\O'G&V/\`2ODNWMO]'KLO%?\` M;OBWPEHWB6]O_P"VM.TBWM_#W^O_`./#_GWMZ3X5^)+'1/BCX>UWQ!Y]QH_V M_P#XFV?^/B>W_P"7BCXE^$])\%_$+Q!I7A[58-8\/03W!L=0M_\`EO;U^IW[ M#'B3XC:W\*;>W\>Z)!I]C86]O;Z%?G]S/?6^#R1VX$(]Z^GJ*****^8?VROV M4KW]I73_``_<:+K%GI.KZ0;@9OU+03P3\$'`]J^'8-$^!?P*M]0L/&D%[\5O M'=A?W%O<6^C"XL-.@_Y=_L]Q<7%>!>'O%DW@OQG;ZYX8GGTZ?2;[[18W%S_I M%Q!7[=?!'XK6'QM^%^@>,--A6W^W0`SVW4P3\>?`?H0:]#HHK\CO^"AGPF@\ M`_&^YU73-#FT_0-=@\\W(_X]Y[C_`)>/TQ7=_!+X/?$[]J?X9P:Q#\?;ZUMO M^/#4/#V+C]Q_TP/^D5]%_`_]D'Q[\*?$^D7NH_&;7=9\/Z6I`\/?OQ;S<>\Y M_D:^JZ**FHHKQJ?QGKWA3QMXRF^(M]X6T?X<$6\.@ZE-?"&XE)!\^&?<<=:] M8TWR/L4/V'ROL'E#R?)Z8]JNT4445#4U%%0U-7D?CG]I'X=?#+QAI_A77_$< M6G^(;TPB"T>&:8DS'`Z#H<5YG\>/V\O`GP3\0W/AO[%?>(M?LYQ!?6MB/)6# M]SNYF/X5UG[-7[4.A_M(:!J=_86,VB:AI,WV>^T^Y&>I_<_ONG/]:^?_`-KC M]N_6_AQ\0O\`A%?AX;(W&E38U:YN;,D&?M!_]>OM/PKK*W_@K1];O1]@%Q90 MW,XN/W/DYA!.?3!-?!?QC_X*;:MIOCJYL/AQ8Z)J7AZ#G^T=1@G_`--]AC%> MO>.?V\M#\%?`SP=XLBTY=9\3>([)?LVBP?NO+G`'GDYZ0AN_L/PM_L8_%[XU M_$6]UF+XDZ`;?1X%\R#4KFR.GW(FSS`8/;KFOJC^T;;[9]C\^+[1C/DYYQ5R MBH:*_.__`(*OV'B%K/P1>AD/A*V\\L%ZB_/W<_A_6OE/PAX[M_V?OB]X?\5? M#'59O$7VBQM[D:?J($%R#.]Q7[,U-4-%344444444444444444444445SOB[6Y_#WAK5-6@TN M\UFYLH#.NGV`!N+@\GRE]ZLZ)J/]NZ%87TMI-8&>&*?[+<#]]"3SAO'_!4+41KFK_"_PYI[0F^G:YGQYV.9S!;P'\\U];^'+_P-^SSX M'\,^%+_Q+I?A^VL;(6UN-:OX+>>8#ZG^5>HK,)X21WI:*FHHHJ&OB#_@HM\= M?%GPPM/#'ASPS>MHD&O17,]QJ,/_`!\'''D#Z^?FOS)_Z85[Y^VG\4?#?QD^ M)6C>)?#$XN-/_P"$:@M_LUQ!Y%Q!/_I'^CUY9XR^$WBOP#I/A_5O$-B-.T_7 M;'^T+'_2.E?HI^PM\$?">C?LV0:QXWT+3+I]5GN=08^(+"W_`-&@XXST$/[D M$`U\&?M#_#C_`(0'QG<7%EXD\*^(3J_VBY@'A7_CWL+?[17Z7V'[&WP@^(WP MUTC4+[P=;:=?:M96U]/J.G#[/^"_P"V1X5EOVL?B'87@F/!O[[[ M5C_O_;UF>(]5_;7\#-JSS^5XCMK:W,XFTZSL9E.>H@7_`%Y_$5G_``5+@L6-MX@^&5_IMY!-BXB-^08/ MKYT"UU>@?\%1_AUJ<_DZGHGB#1(>USB&?!O4%G\GXD>'LP]?.NO)`_.OS'\%^/A\3_`-LGP[XKM]/FMAJW MBRWU`6O^ON/L_P!HK]F:FHJK<3PVEN9ICY$,/.37E_P9_:,\'?'*^\0VWA*> M]NDT.<6L]Q/;&&"8XZPDGD5ZU14-34444444444444444444444445#4U%%0 MU-4-%%%%?FS^U+\*/"<7'_`'X^M>!_`O\` M9@O_`(K^+?B#X,^VG3_%/ANQN!`;:?\`T::XM[C[/Y!KNOV5_BQJWPZU#X@_ M"CQY%K;PWK$'_``CVH'_47%O_`,N]O_Y,5U?_``2M!_X65XSQ?X/]D6__ M`!+O/_U_^D?\?'^?^?BO--1TSPI\'?VE?BGH7B'PG_PE6CP?;[?2?#O7S_M' M^D6]=_\`LI_&+X)W/B34/`VO_"[2O#NC^)#;_P"D:CJ!U>WGG^T?N(/WX/D0 M8[5YQ^UUX*MV_:S\0^&]#L8-.MKB?3]/M[>V@_U'^CV]>T_M#_\`!.2_\-"P MO_A9;S:OIPMS!?Z/1_P`L/H++CX$?$+Q7JF@WWARX\- M3V]Q;_VU8?9_M]O_`*1]H_\`;>NO_87_`&DYO@CXZ_X1^_@GU+PYXFGM[8BW MF!%E/WG.>U?KE117BW[4WP;A^-7P>UG2;/2;+4/$,$!GT@7)\GR;CL<]J^`? MV"_BS>Z(_UY`QG]*ZZBH:FJ&IJ*AKXH^.7BW]I:^^)WB>Z\%^1X*\ M#^';;'VG43;^1?=S/F>`_H>U>=_L`^+/B/\`$KQ_XA\6Z_\`$F\N/#.A6^=2 MTW4;T7/G&-O#GC[2/[5\-:O9:WI_P#J1=:?/YRCVR*_ M+_X9:)/^V%^V=J$_BBX.GVUM-<:A]G@/_+O;W%O]G@)KH/V\/!FA>*/B;KWB M_P`/>.O!]M]BT>V@U;1H+PKJ-Q<>?Z0:Y?]FG]F#7?VC?@YJ5C8 M^*SX>T?3_$G[_39X/M%O<_Z/;_OQ7":)^RSXD\2?M`^(/AEX?U6&?4-!6X;^ MV+FWN((![<9\C\*^XOC9H?QXL?V;]%\'V;P>,_&&JW(T_6]7T>#&++!!_P"/ MCU!_UY],XKY$^*7["WCWX=>#?"VJ6&B:IXBUJ^M[@ZKIVGP>?]AGX^SP#[/U M'(YKUG6_^";OC2?5-%UKP_XMTRUU*&PT_P`XZBIMY[*>"!1D&W&.L2_Y%?6G M[+_PJ\??"OP[?6?CSQQ/XRN+F?SK>"4&4V7^SYQY-:&K_LX>$]4^.UA\6#<: MG9>)[>'[,WV>XQ!*"OD@$8],5[+1117YX?MS?MDVVF:IXG^$5OX4@UG3?(\C M5+C4+C[/^_QYX\CUXKY?_9O\)?"_6QXAU;Q=JU]_PD.@Z3J&H0:+`DV]?J#^P)J\VL_LN># MY+N6:X>$7%N6N!R<3G'\Z^BZFHJ&BBBN9\=_#7PW\3=(&D^*-%L];T_S1-]F MN1D9]:X:X_94^$%UHD&AS>`-$.FV_P"_@3[.,`^M>>>,_P#@G3\'/%FNP7\& MGWGAVV_Y;:?HUQ]GM[CZBKOQ9_81\`?&+QGI&O7]QJFGK8V-O82Z?87.(+BW M@)\@$>U`/&WBO4=7;6]:TVVOSC^SK8P_9X/W..F/\_K7F_BS_@E M-9#3X#X7\;W!U#SLS#68,0-!Z8@Q7V]\.O#M]X-\!:%H=[??VQJ&GV4-O-=F M'R?.(&,X[=ZZFBIJAHHJJ=-@FF^T36\)G`_UX%8'B'X8>#O&$D$VM>%-%UBX M@_U+ZC80SD?3(KS[5OV,O@KK,T]Q+\/])6>?J8$,)/Y&O*_CK^Q5\%=#^&?B MK78M$E\*RV-C<7PU#3I;BHC2/A[XHU#,8\C3+F?]]TXA/7\J^*O^"6VH:FVB M^.;"00'1?M%O<6__`%WP<_IY%??U%%%%%%%%%%%%%%%%%%%%%%%%0U-14-35 M#4U%0U-114-'V@>E?C]^T_\`#_0O$?[3=QX:\""_&L:[JUQ;7W]M0^1;_;Y[ MC_E@?^>%=A^QG\;K;]F/Q_K_`((\?Z(/#]IJ,_D3:G-#F>QG@_Y[D?\`+OCO M7'_M&ZUH=K^V/XXOFN(+K2)[:?-SCS[(+B6>8W/_ M``C<^;8P8X^T6])\7+;_`(1/_@I%IU]K<,!T^?5M/U"`W$__`"P^S_Y_\!ZZ MK]H?X%?!/XD7%SXL^'WQ)\&^%)[<#[?;BX@_L_/>X_T?_EO7@7QC\6Z)KG[3 M=KKV@>))M8TF"?1_)\0J$-0MIO$M__ M`&<+[[1/J.GP>1Y'_3O^X_Y85Y+J/A*_MO"6G>+/^/G1K^_N-/\`^WBW_P#X MBOU=_8D^.&E_%GX.Z3I37X;Q/XPU2W/)'`$$WT('\Z^EJ**_+C_@H]\' M/^$(^+%MXRT70YX-'U:W%Q?ZE;]3J'VCK_Z3U]A?L8_M#Q_'/X46PU*^6X\7 M:0OV?5AG!+?\]OH:^A:FJ&BBBOSQO/#?_"VO^"FMU/`+RYT_PU-;SSSP](#! M;\`_]O%?;'P_\*^)/#5QXAG\0>,;CQ2M_?&XLH)K:*#[#`0,0#;U^M=Y1114 M-%%%>*_M4?!_Q7\9_A1<^&/"^OP:-<7$P,XN%S#<0=X#C\*\IN/V'9[7]E5O MAUHVK6FG>)K^:#4=5U`*3;WTXZP$8SY';'M7MW[.GP+T_P#9_P#AM:^%[.\. MH7/G&>]OVX-Q.<9./PK2^&WP,\#_``BU/6;_`,):#;Z1Z'>7-U?3_:9[)K^?[,9_7&:]H\#?#CPW\-M"M]#\+Z39:- MIT'2WMH0!6IIN@:5I=YD37$\,0'G'W-:]%%%%%%%%?E_\`M"?L MLGXF_M">+[WPKXST;6KK/]K:MH$$V=9LL`GR8+<<3`X[X].XKYUTCX"_$!?A MOXG\?PZ5/X<\+V5N;<3ZC/Y'VBWGN/L_V>W_`,]Q7U7_`,$HO!L"MXX\5?:) M1J,`@T?R/)_<"#_7C$V.>M?HS14U%%%%%%0U-4-345Q?B;Q;KFC:[H-E8>%[ MW6;&_F,-YJ$$$^P#'5@3S7:445#4U0T5-1111111111111114-?DQXB^).E M:;_P44U#Q9XU$%MH^D>)+BWGN#!_Q[_9[?[/;W'_`*3TG[1O@GX8^+?VCO!W M_")ZK>VVC>.S;ZA?7-M#FW@$]Q]G^TP<5^G7PK^&NA_";P78>%?#MO-!HUB, M6XN)O./YUVE%%0T45^<_Q<_X*;:]8^+[^P\`Z%I5QH$&((=0U:*X%Q,?:`8. M*T?@?_P4LU?Q1XZTC0_B!H>E:7I5_-]F_M+3O/\`W,_H<@\5[_\`&S]M?X?_ M``)\2_\`"-:V-5U#6?(^T?9M.L2>*X'P/_P4L^'_`(O\3:;H5[I6M>'A?3&W M.H:B(!!`].J:BBBJE_ M&KCR,_\`7Q;U^JE%%>1?M:?\FU_$G_L"7'_H-?*W_!+4S^7\01_986`G3\:C MQ_T\?N.?3K_VWK]!J************************AHHHJ:H:YIO^$B_X3FW MV?V5_P`(U]A/G8W?;?/W<8[>5C\&M M4TZV\&7&?M-P/^0O;_:/](^SUU_Q!TOPG_P4(^%9U7P3;0:+\0-`S!Y&L#K! MU-N9Q_RP)R>*XSQ1_P`$Y_B!XFU?P?//KNF7_G6$%OKVHW4Q%Q;S@XS_`-/' M[@6]O5/]B'X<3_#C]M'QCX;FOYR-"L-0MP1_R\?Z1;U4_;Y\(P>*_P!L#PMH M,\WV6WU>RTG3_M'_`#P^T7)MZ\-_:'_9GUW]G#Q9_95$]1T:X_X\-9\C[/; MS_\`W17FOAW3;_Q)KVG:39?Z-J-_/;V\'_7Q7[WZ+;C2])L+.4_OH(((#]1Q M_2M6BBIJ*AHHIEQ;BY!BE&82*\YT_P#9Z^&VB>&]7T*Q\#Z+;Z/JV9K_`$\6 MXQ<'WKC/CQ^SKX:\1?L[:QX+\/:5;Z+;6$/V_2K>PAQY%Q!R,>OI7YY?L:_M M"S?`/XEB"^'V?PMKIMX-5^T_\N__`$\5^Q-%%:_X4O2;>VU M:R-L9@.8J_)WX-^([_\`98_:AM[#4M6^S:?I.J_V/KES8#_1IX.W%?L787D% MY;PW$$L,]O,,Q30]"*GHHHHKY%_98^#7B'PY\<_BUXU\7VVFV&IZK>F"UT_3 M[F*8"W\XSDF,=#@P<]:^P*****AHJ:BBBBBBBBBBH:FHHHHJ"X_U%?AK:_$; MX@Z%\9O$'CGP[!?>'?&-O/?ZQ?6T%CG[!_I'^D?:(/\`GA_I%?3?[3O[2^H? M&K]CCPCJL4=O87&KZ\-/URUQRLUN//Q`>_(@.?>O7?\`@EO8_9/@?XBG\B6V M$WB6X,1,./.'V>WYK[3HHJ:BBBBBBBH:*FJOY\.[R<_A5BH:FJ&IJ**AHJ:B MBBBBBBBBBBBH:QO%VM1>&?#>JZI+'*8+*SFG;R1R0!GCWXK\3=%M]/\`%GA/ MXA>.?%$&J>(M2-]86X&G7'V?]_?W%Q"]5G\0P03_\3"UN?^/>WN/M'_'O7._`3X'>(_CQXX@T71K`W.F@?:;^XG!@ M@@M_:<I:MIT_A#2=5T73OL%OY]MJ,_VC_2/^7BOU?\`V$/&VJ^+?V:?#$^M6TD) ML5.GP3N?^/B"#@3_`$/]*^C**FHHJ&IJ****PM;\7:)X=6W_`+3U6RTYKCB# M[=<"#S3^->.?M>>+0O[*WCO5M$EL+ZWGL/LC7)D$T#0SSB"?D=0`6_R*^7/^ M"5QL+CQ;\0IYX(?[1-C8?9[@=[?S[C_[GK]':FHKY_\`VV-1ET_]ESQVT(D+ MSP>0,=LSBO&O^"7>HX^&_C>S\GBWU?SO/\[.?VMY_^>%?/?PC^,/B3X*^++?Q)X1OOL]QUGMO^7>>W_P"?>XK]?OV?_P!H M?PY\?_!L%_IE]`-8MX/^)KHX/^D6,_O7R-XLM!\)_P#@I-I%Y#XC_L^V\330 M3WX?]SG[1_R[GU_X][>M'_@IMX7FLKGX?^.]/N#87^GW']G;K8CS[<@F>"?\ M"*]]U'X<+^UA^R;X7L?$5Q!;:QJ^DVU_!J4$/_'O<^1Q/^O\J_)3Q%HD_@GQ M;K.D_;X/[1TB_N+?[3;S_P#/O7[F?"N>6[^'OA:YN3+]IFTBRFG\[L3`,_K7 M8445-114-35#117Y;_\`!0/]FNW^'7B8^.?#T-O;Z!KLP@N+8'_47YZ'\<&O MIO\`X)_?%F?XG_!*+2M3OSJ'B#PU%9?$&I:__`,([I@UG5[86%]?BR'G7 M%O\`\\9CU(Y[U\6?\%,_#6B>"/A-X%TC0-+L]'T^?6YI_L]C`+>#/V<\D#CT MZ5ZA^Q1\5O!%A^S=X0L)==\/:-?P+/!/;M?V\$Q_T@CSL9]\U]-Z'KNEZWI\ M5[I6I0:A;R_=N+>?SP?QK5HHHJ:BBBBBBN/^*'Q&TGX4>`]:\6ZUYYTW2K?S MYQ;Q;IL>PK\G_#'[1E_8_%WQ?\8]4NKF+49;:_MM!TB$_:3WO].UF#[1;_Z/7V)_P3U^-'P^AO8?`EEX:O-&\4ZL)]1EOVG^ MT6T[`Y$$'_;#%?H?14U0T5-4-?E+XG_X)O?%R*\N7L3HNL6OG9@\J]*X'XXK M0^%7P2_:<\`_$:#P]I3ZGX?TN:Y@GO[I;BW;3O)!P1QW\@8QZ\4__@IO;^*Q M\4M'O;V*>'P>L'V;2O\`GW^T?\O&:\#^$O[-'Q)^-,L#>'_#5Q_9LPS_`&SJ M`,%O_P!_QUK]E_AGX)M_AK\/O#?AR$PD:58PV.Z&$0B3:`.!V].?&,]N+?1]1^SZ?!DX M,\]OU/Z_K7Z&445\R?\`!0#6M-TC]F;Q)'+.MO=WUQ;VUBP_Y^#.#_(35Y]_ MP2\^S_\`"JO&.-OVO^WCYF[_`)X_9H,?UK[VMO]'M_M'^;BOW'^$-N+7X4>#(/WO[C0;#Z_\>XKM:*+CH*2V\['[W'X M4M3445#117!_%?X2>&_C+X'OO#OB:Q6_MIL30X&6@F`XFA/4$$Y__77Y$?`W MXKS_`+.?QM@\1^3/J%O8SW&GWT'GB#SH.QY]*_8+X;_$;1?B?X0T_P`1Z!/] MJTF]@$X;C]UP/W./SKMZAK%U[0+'Q+H6HZ/?`7%CJ%M/;7`_Z8S9!K\3O&7A M/5OV>?C>-*O?L.HZAX:U:WN>F+>?_EXK]AO@K\:?#7QX\"6WB;P[.#;S?N+B MUN/]?;3CK!,/7FO1:**^,O\`@I[\0/['^"VC>';>_P#L\^L:J#/;]Y[>#)Q_ MX$&VKZ+^`_AJX\%_!7P-H,^W[38:):P3^3_SV$"Y_P`_2O2************* M*AJ:BBBBBBBBBBORY_X*F^(-3F^*_AWPW)./[&LM(&HPP#^*XGGG&?RMA57X M)?\`!-Z;XL?"+P]XQF\9'1M0U:`7$-@+(7%L(#T!YS5,?\$SOB_;S"X@O_"O MVB"?-O<6^K7'_P`CUB:_^QK^TAH]K/J,T-]J(LA.1]@UWS[GGI]G!H\.^+OV ML_#D<%W8GXB>3!;^3"MQI,]Q!]2+BWJO=?MN_M$^"S!8ZYKMQI]P1YY&M:%! M;SX^GV?%>D>&/^"IOC'1]-L;;6O!FEZO<0P?O]1%^(/./J`>*[SP/_P53TJ[ MOC!XM\'3Z;!VN-(F^TC\J]2A_P""DGP28K>!OVC/AQX_T MM+W1?%VF%3!YS6\]P(;B$>\!YKTFVNH;J#SH9A-">XYJU117B7[5WPWO/BQ\ M`O%?AW1V?^V&A%Q;6ZS?[,G[),O[0.D>*;#Q'<:WX4N= M!GS8W%S"!B:?K#]G/8>171_#+_@FW\5O^$MM+C6MFXN/\` MMAZ?C77^$/@Q\0OB]^VE<^.];\&7_@C0=/OA?_:+^#!8P8%O_P!=_P#4"OTA MHHK/U+6K#0;"XU&]O8+*Q@7,UQ/,!##CW.*QH?'WAN?P[/KT7B;2SH4`Q-J* MW\/V6'US-G`_&G:#\1_"OBV8P:-XFTG69QUM]-OH)_Y&NG^T#THHHJ:H:FHH MHHHHHHJ&OD+_`(*2?$2?PG\$[?P]#"/,\37OV=IP>D$&+@_R%?*GP9\`_!3P ME:?#/Q)\0O$>J6_B?5YO[1@T>WA^T:?Y'VBXM[?[0,?UJO\`L&6FK>%/VN=. MT&^THVNHV\-_!?6]Q#BXL#Y%?KA4U%%0T45\D_M-?MOW'[.OQ!MO"T?@W_A) M'FL8K[[3-?\`V;'./^>!]/\`]72K/P;_`&[?"GQ(\`^*-_`'XZ^&OVJ/!NHW\.A?9EL;@V%QIVH>1<8->V_+;1>D, M0KS;7/VC_ASX9\66/A?4_%VF6^MWN<6WVD9AX_Y;_P#/#_@6*],HHJ:BBBBB MBBO-;CXA_#OQ7?ZMX-E\0:3=:EDZ5?:1+>`3AB#^Y(SG/)_.ORP_:.T3X'>$ MK34O#?PXL?$(\36&MSV]]/K&?($-O]IS;VY[C[1CMZU]C_\`!+F")?@OXGV6 MTL&=>.;AO^6_^C6_-?:5%%?#G_!4;Q*+;X:>#]`\G)O]7-SY_IY$!_\`C];7 M_!-?Q#I5]\%+K1[.$VNK6-[+/?DVAVS"8DPGS^D_'?\`PK[#J:BBBBBH:FHH MHHHHHHHHHHHHHHHHHHHHHHJ&IJAHHJO<>1BOR._;ZTWPE;?'37_[$_MW_A() MY_M&J_:O(_L_'V?CR,\Y^M?,=?37[''[*/B3XG>-/"_BK4]*_P"*`MYQ<3W& MH3Y^W>1T@@'I]H!_(UZ-_P`%(+J?Q+\?_`OAO_CXM_[)@_T;_KOU_\ M%'O"=@W[-^FO!Q_8>JVWD`]O^7>O`?C9^S#I.N?LN^#_`(NZ7?&VU+3O"FD6 MU_IY_P"/>XX$'V@?]-^:^=/B9XUL?'T'A;[%H5CX=U'2="M]'O\`^SK?[/\` M;_L__+Q7[4_#83I\._"T5Q##%/\`V7;&86X_<@^2.GM755-4-%3444445#17 MY;_\%#?V=)?`7C__`(3_`$6RF_L#7N;X6\`^SV-_ZX_Z>.E?2/\`P3?\;6^M M?``:5_H-KJ&A7UQ;7$%LV">_G3^Y_I7UO4U0U^^,'_+O]H_?W'_DO;_K7Z%VUH+>W@A!S MY0JS1111114-34444444444445#4U%0UXQ^TA^TSH7[-.E:-?ZUI6J:R-5N/ MLT*Z<,X-?FU^V[\3+'XN_&73];T6QOK>WN-$L8+>WU&$P7/+$_Z@_P#7Q7ZU M?#[P_;^%_`GAS1[:#[/!8V,%OY([;80"*Z*IJAJK<:=!=C]]!!E03$_4L*Y[Q+^S#\*?%5K;Q:E\/=`80S><% MMK`6^#Z_N<:?;P^=YVG6M_.+>?/J,UYOKG_!*7 MP=>30?V=XRUJT@'_`"[7\,%R/S(%<=XM_P"":?CNRML^$?B,;V""W^SP6FIF M:`_H35;0?V<_VNO!-[/<:=XRN"##P/\`A(C$=(M[?Q!\+KC6+CSMHU"?2KBV$X]ATK M?7_@IKXET&V\_P`0_!N_T^W'^MN&O9[<+_W_`+85M^"O^"I7@?4+Z>W\1>%] M6\/VX_U%S!.-0S^5=]I7_!1GX*:K)]GGUK5M%/\`SWU#2)\'_OR#7H?_``U; M\'Q]A_XN-H'_`!,?]3_IW7C'/_/'\:['0/BKX%\737$&C>,M$UEX1YLT%I?P M3X'X&NBTO6;'7+"&_P!,O(+^VN!^ZN+>;SH3^(-8OC+Q!/X2\/7]S96*ZCJ* M0$65B9=IGN/^6,`],FOQF^*7QJ^*'C.]\0:/XFUW50-5OO/G\.#_`)=Y_M'_ M`![_`&>M'QGXL\*^$OV>]/\`AM9:5K=MXX_M4:QXD&HC[/;V]S]GYM\_E7/? M!+PY\4-1O=2U?X8'51K&GSV^GW!T;_CX_?\`_MO_`*/26.J_$?QU\3]`T6ZU M_6[_`,;VNJFPLFNM0GGGT^?[1U-?L;\/?C9X'\>ML:5#_`*=! M:3Y(]S7Y-ZC^V7\9+GQ)_:G_``L#5+:?SO.^RVX_T;'I]GK]>_A'X@UOQG\, MO#&N>)=*&BZ_?V$-Q?:/] M(L<6.J"'OF>86W_7#,Y'X5=_8,^"_P`0/@[8>+HO&EA!80S7,!L"+B&YN)P. M&Q.O6''D8'UK["HJ:BH:CGN5MH9IISY,*CJ:\Y^''QW\"?%S4]:L_".N+K-Q MHIB^V?9X9QC(X^;'[WTXS^-?F-^W-\6-%^,/QJEOO#8DGL])T_\`L=[B7[L[ M07%QG'MG-U[6[""YU'XB?Z1I-Q_SX:?;_`&>X_P#`BXK[ MR_X)O?#^_P#"?P*EUC4[."UN?$5^;F`&+$Q@QQG\3/6U^WG\)_$4!M[>VMY0)X;<_P"ON/P'%?EAX#MO^)];SP6$%S;Z1_Q,9[>XG^S_ M`&BWM_\`2*]2\<_MA_%[XBWUM?7GC.?PYY'^HM]&N/L%N:]:^,_[;?QDT;3- M%\.F?2]%:^T*WN/[:T4^>+_S_P#EX@G_`.6'XU]`?\$^#\7G\-:O?>.I+O4/ M"^J16]_H>H:EJOVFY((Y`](<$&OLZBBBBBBBOQ__`&S[;P!HGQF\07_@W7?$ M/_":?V]]HO[>>#_1H)^WV>?M^_Q7BOC#QYJGC+3=-37]/MY]76>>>;Q"+?&H M7P_Z>)_^7BOUY_8^\*+X1_9O\"PQ"\47-@+\0:@?FA^T'S\'Z%OUKVNBBO@O M_@JD/^)7\-CYLPS/?_N1_%_Q[U[#_P`$\?\`DV#PO^_\_P#?7WS?]O!KZ9HJ M&IJ***************************Y+4_"+WOC'1]<&LZC;PV$,T#:1#+_H MUR9D,-?E%^W%::%XB\56OCG1=0LB==&+ MCP\=)^P:C!_T\7'_`"\5\Y^'?#?]M_VC!Y_V;[/I-QJ'^H_U_P!GK]3/^"=_ MB$:U^S%H]B+?']DZA<6!]_W_`)__`+<5X%^U5IUMX]_;U\#:'I5[C4!_9$%P M`/\`4?Z1]H_])Z]^_P""B&G3ZE^S'K(@@Y@O]/ND?LPVL-Q^S3\-(9 M88;BW_L*V'M_J*_-3]K_`.$^E?#G]I+4-"T6`6^D:M]GGAM[48$!GX-?K1X5 M\-6WA7P_I&B07$MQ!86T%C#-<',S"#@$\<]*Z*IJ*AJ:BBH:FHJ&BN$^+OPQ MTGXO?#G6/!FL>9#I^K0&W,]L<&'G]T1^-?D1X.\:>*_V3OC1J,UG/G4-!O[C M3[^V_P"7>_M_M'_'O7[)^!_%-AX^\(Z1KVEW$-UIM_;PW$$\!X.>:WZ*\6_: MQ\"Z1\2O@#XNL=2@#+9V,^H6[9_U,\`)!KY(_P""9/QIUH>)[_X97`@GT'R) M]7MV`Y@!(X^E?I!117SQX9_99ET7]IK5_B[-XH:[DOC*?[)^R`*!Y`@ZYSQU M]Z^AH5$`P:GHHHHHHHHHHHHHHHHHHHHHHHJ&J-_IEAJEMY%Y:0W$'^N\B>'/ MX_6ORC_:)\0V^K_M]"^T28+

)M(L3/<=KF`V\!_4U^M5345#114U%%%%%% M)/LO_/#R;7'_`*(K MBK__`()U_%#X+?$.DW!N+>YG-N>G^H_ MY]Z\1^*7P+^.7Q#\8W/B+Q#\*KZWUC4ABX.D:7F"<8[F#G\37IGP<^./CK]D M;P4=)A_9\N+:?[/]HO\`Q#J$%Q;W%][W'^C]:SO@=^T;\#/!OQ7UCQUK'@?7 M-+U*_,]S!;^?!J%O!<3G_2!;\BET7Q;^S#IUMXX@T75O&VB77B72;C3VU#4; M""XMK#[1Z06]>*?#3P5X;N/$GA^_\3_$C0_#VCB^^TS@03W%R?L__3O]GK]> MK#]J#X2ZC<" ^&F;R?/XU6#I^==YHOB32==L/MNEZG9W]MC_CXMK@3C]* MU:2;#`1#O7E/P"_9O\,_LY:!J&D^%Y[^XMK^X^T3?VC/YYS7J]35#14U%%0U M^4W[>4,_CW]KW^P].(U"_%O8:/!`2,&>?_EAGW%QFOU.T^W@TZVM[>#_`%,` M\@`U;HHHHHJGJ-K;:I8SV<\`N;:;]Q-#[5P/PN^`7@+X-3ZA/X1T&/1[F^YN M#%--/G_OHUX)X._X)N_#_P`->-(]=U35=2\1:?$?/.BZE%!]GZ9_?<<_I7I_ M[0&@_!WPW\/]+O?B/HFF)X=T2;&GV`ML[3C_`%,$$/7MQ7C_`,-_^"DG@?Q- MXK.A:WHMSX-\/9\BPUB>?S_/QVG@$`^S_B:Y?XI3_!/]KC]I2Q\)W%SXJ@\4 M6'VG2!]U#Q%;ZC\.-4L[73IQ!!/INL2,38@=[>;&?PKZU_9K^$-W\#_A'H?A"]U? M^V;G33+;:QUD:1?_ M`-GP:=<0?9[?R(+C_CWK/^.GQIOOCEXDT_5;W0K+P[]@TJ"P@T[3SFW^SDYK M]A/@1IHT/X)_#W3_`#O/\G0;"#/KBW'^?PKT6BBOSJ_X*F>))SXB\"Z(;>(6 M$,%QJ)N&[$JZ??1:G>6]O9^=Y]E`T7D3DC_`):Y M&>.O!_*N@HHJ&BBBXZ"OSY_;8\.?#WQ-\:?A]X4@TJ#3O%&K:]`NNZA;6/D7 M$]O.8!_Q\5]`:O\`LO>$=+^"FK^#O!VBV9OI]#GTJVNM08^>V9C.!/IYK#_8;^#'C#X)_#W6-!\7PV-M<7&JFZ@AMKC[0`!;BWZ_]L*^:?V:?B)J M'Q:_;\U#Q5=0P(;^&_@-O;#_`%%O;P>1!^?/YU](_P#!0^Z%O^S'J7G=9K_3 MQ_Y,5Z5^S!<9_9P^&G_8"MO_`$17YV_'>V@U+]N_68-4_P"0-!KMO<7_`/V# M[>WM[BX_\E_M%?37@7_@IQX(\1>*X-*U/1+[POI$X^75[NX$ZY_`?XU[7\,/ MVF=)^)WQ8\8^!;+2+VVN/#6U44445-1114-%%?!_\` MP4L^"5KKGAVU^)MG);P:II8AL+T?\][>:X`A_(G]:I?\$N?B/?W6F^*O`DT' MVG3[#_B>(O&<_BBPU M?5?M.DVUQ_S#K?'_`![BM;PK_P`)I_PD_B$>(AHT>@B1TS_I%Q7ZOP?$CPG/!!/#XDT:YMY9O(%PM]#@S>G7&:ZFIJ*AJ:BB MBBBBBBBH:FHJ'_EM14U0TR>VANH?)F'G#N#7-W_PS\(ZG!Y5[X3T6Y'_`$WT M^$_TKE-?_9H^%_BNP@@U7P%X>N8(3YRB*P6``_A7DVK_`/!-GX-:RL_EV.MZ M>9Y_M!-KJA'->2^./^"8_P`-_!6G:AKM_P#$C5/#>DP#/GW\-N;>W_E7S7I_ M[.'@OQIXS.A_##XOZ7K6LS\V&G:AI%Q8?:/^V]>N>'?@%^UM\##Y'A"^^TV\ MQ_YA^JP7%O\`^`]Q69XR\:_ME>']:72;V7Q5I]+_X*M>-(Y<:GX'T6]@_ MO6E]-`?U!KJ=(_X*L3G48&U/X;PVU@1B:XT_5S<3#\/L]>QZ;_P4<^#<^G03 MS:AJMC<^3F:W.E7$WD?7`KTRR_:S^$&I6$$T/Q%\.Q`]KB_$'\Z]`\'>/?#? MC[2#?^'-:L=;L,^4+BPN!.,_45T%%%?E/#KOU8HHHHJ:BH:**^,_\`@INNKW'P1T>>S\W^QK?5H+C51;38 M/7_1_P#R/BOSH^'FFZ3K?BS1O^$ATG7+GP=8?:+C5O\`A'8/M%Q]G_S]GKZ4 M_8=TV^\?_MD:CXST33YH/#T%Q?ZA/<'_`)86]Q]H^SV]?J?1114U%%0U-14- M35^4/[9'P,\*P?$/6[_X8WTOB+6/[0N/^$C\/6K?:;BQGN.]O;X%>&_$SPW? MZ;XTT;PW/87W_"0P:3I^GW^G7'^D7%O'PW`Q^OVBXK](/`W_(D>'/ MG\__`$"W_>^O[D<_Y]:WZ*FJ&IJ***AJ:BBBBBBBBBBBBBBBBBBBBBBBBBBH M?LX]:**^'/VP/$OB:Y^-OPKTG5-)L-/\+V'BRPN+'4;:X^T:A<'_`*]Z^VZJ MZG!-/87'V(XN/(_<5^:?_!,_PG_:/QH\5:]>SS_:=)L/L^>T_GW%>W?\%.OL M'_"C_#WGS_9KC^WK?R/_``'N*][_`&>O#DWA+X#>!=)N/(^T6^AVWG_9_P#K MA7P-I_A.#XH?MW_$O29]5GT71KC^U_[6U"VG^S_Z/]G^SUS?QC_9A\"^%/`* MW_@7XJ^'O%&M6)N-0OUNM6MX#/;_`/3"W&1Y]>D_\$N_#U\GCWQ;KIL91HQT MLZ=]J/\`Q[BX\Z`^0/?_`.O7Z4T?\L:**FJ&IJ**AHHKPK]LWPQ?^(?V9?'- MGIQ`NX[?^T&]XH)Q<']%KXL_X)@ZO;V/QW\0:5_%>Z$2OU@G@']:_4BBBOR/ M_P""@OPGL?AS\<#?:9YUM8>)(/[8(!_Y>/M'^D?I7Z4?`KX@7'Q7^$'A'Q8T M4&G3ZC8BXFMH#YP';`/^>M>D445-14-344444444444444444444445S/C?6 M9_#7@W7=5@A^T75E9SSQ0#O@$_TK\GOV'?#A\:_M"W%^(+VX_LG2K_4(/(_Y M^/(^S_\`MQ7SYX=\)3ZE?ZCI,\']G7%AI-QJ%Q;7$'_/O;_:*_6W_@GY\3M4 M^*WP!M;G7IYM0U31-0N-&?4)^MQY&,,?PEQ^'M7T[114-344444444444445 M#1114U0U\4_\%!_COX?\,^`)_AE<:)+K>J^(+<7(=9_(M[,>?@3[L?-,)\8@ M[U\Y?LN?"6'X4VEE\?\`XBW?]A>$M*4W&D6`P;G5+@@X;'U%>?\`BKXV?$[] MHKXRZC8>$-=\0I'K>J_\2G1?[6^S"V`KZI\4>,_CC^Q[^S'!JOB?6[/Q5XIO M=;@MH1J/GWZ:7;M`I'\7&>:S/V1?VQ/B?\:OC1IWAOQ#KGA:WT?[/ M///;^1Y%S]>Q?'#]L'X8?"?1[B;1-+TOQUK!N;C3[FVTTP$P3P#I.>U> M`?!'XF_!3]HGXEV_A'Q)\%?#'@^ZO[?%A=Z9<`P3S][?]P(,G\.:^JKC]AGX M(SSM.?A[#Y\O4_;KC_X_7G7BS_@F7\-]8@G_`+%U76_#MP9OM"@7/G0PGT`/ M^-OVM?AUH-O;>'_B1_;=M!-DVVGZK^_Q];BWQ6-< MM^VA\.K"_O\`[3J>N6\/D3#]Q;ZAGU'V?_CX[?I7C?PWE^-OPJ^*]UXXB^&V MO:SX@N9[C[1]O\.7,QG^T7'^D!=4^SG_7W,%];D05Z=H/_!0?X-:]IWFS^(+_`$2<_>MM1TF< MW!_"$&NZ^'_[4WPI^)DEO9:#XRL;C4K^3$&G3$V]S,?:&?!KUB#4K*Z'[BY@ MG^DV:MT5EZYKMCH6E3ZKJDT.GZ?90^?/<7'_`"P]S7Y-_M'_`+9_BWQM\4=0 MO_`GC36]%\+V_P#H]C;6T_V?[1_T\5YY\4_CU\5?%5EX(N=?\1:I:&SL?M6E MW5K-/;_:3Y\X^TG_`*>,`#\*L^%/VLOC;:Z'IWA71/%>J7+>?B`_9_[0N;@? M]O%?3?[!_P"U5\1OB/\`%C_A#O$E]_PD>CS6'GBX^PV]M]A\CC'[CCGCK79? MML?'6^_9@T[1O"GPOTFQ\*:AKN;Z?4=.L8/W&#C_`(]_PKP+X)?M^_$;1?BE MHQ\=^(_^$A\+W\ZVU_`+&W!@$QR)X#;]NOYFOUBHHHJ:BBBBBBOS1_:^_9W\ M)+W2? MLUQ?^);>XGT;[1]G_P"7C_CWK]NJ*FJ&ORH_;STV?Q)^UC/I$$,$%S/;Z?IT M!]?/K]0/"VC0^&O#.E:3#TL;>&#\@!6O14U%%%%%%%%%%%%%%%%%%%%%%%%% M%%%%%%%%0U-4-QT%?GC^UM\,K'P;^TMX%^(7VW0[;^UO$FG&>`?N)X?(_P"7 MB<]Z_0ZJ]S<_9J_.+_@F,,_$SXDP>EC;_P#I14__``5(\>6T]_X/\*VU\/M- MG!<:EJ%@/^6/`%N?R$]?>7A33X-%\):+;1>=Y-C8P0`>P@__`%5^/6G?VM\6 MO%OQ-/^T6_VBWKS31O"6K:WI.LZM96$]SIVD0? M:)[C_GWK]2O^"<7C;7/%OP/%AJM@(+?09_[/T^__`.?B`XMQ7[1445\9_\%+_A0OB/X7Z;XYMUQJ'AN?R)SV^SS\?^C_L]1?\`!,[Q M58:I\$=8\-PWLUUJ&DZO-/+;W'_+O#.21Y/MD3?C7VC7QQ^WO\>O%'PY_P"$ M-\+>"-5ETCQ#KETWG75M!DK#DB'GZYKZO\/VU[:Z%I]OJLXN;^&"$3W/3SIL M<_K_`#K8J:BBBBBBBBBBBBBBBBBBBBBBBBO,?VA/$4'A/X#_`!!U:8P@6VB7 M1_?]#^X/7\Z_-3]A#XK1?!C5/B5XKU*RU/4/#VGZ&#<&P7=^_P#M/[@?B,C/ MO7T[#^T'\(OVF?AM\3R(;+X=ZQ-I?]D7/B+Q##!;?\?`(M_]([C)Z?X5[%^Q M_P#"'2O@W\&-/L=%UZ#Q1::K.=8.I6Y_T:;S^

V/YU[U111111111114-3 M444445#11;]#14U<1\0OA!X-^+4-A%XP\.6'B)+&;[1;"_A!\D^U9?Q.^`W@ MWXK_``_'@[6M+A@TB%<6?V$"!K(XX,.!@&O$_!O_``3A^'W@'Q;HWB32?$GB MJWU'29_M%NWVBW(!_P#`>O*-5_9"_:1D\1:M%IGQ7AFTC4)OM)O]2U>%/"/A6;6?#M_/Y']HFQT^?[?;_P#+O_U[UZY^ MR/\`L4^*O#WQ'TCXA?$*QL]-MK`&YLM*7`GCFSB!C##\O')P?3I7Z-5#114U M0T55_LZW\ZXQ"#]H_P!=[UQ/BGX%_#[QU/;W'B'P9HFM7$$/DPW%U8PM@>W^ M%>=Q?L)?!017`'@J'%QZ7L_^CSUWQ'I,1'_'J MLUO-;G\#!7&:]_P2Z/AVW-_\/O']_:ZP!F#^T/W&/^V\&#^E9$/[%O[26A7? M]L:7\3H9M1@_U"MK]\3_`.1X"*BGT7]N+30)_M^JW`/:WGTB>O*_%/Q@_:*U M#P7XA\&>--'UO6=/UZWQ/_;.@W'VBW_Z]_L]?/?B+P3KNB6'V_5/#6N:+;_\ M_&HV%Q;V]8US_P`>%O\`OY[GR(/^7C_EW_TBO0?#OB3P=IOP*\0:%>Z2/^%@ M7^JP7%CJ/V#F"PX\_P#TC\ZT?@G\<-<_9]\,^(-5\,G1!K&JFWL/W\)GU&P@ M'_+Q;X_T?_EX^G^CU]R?#71/!_[7'PZT_2_C'J'A?7?&^AS8$GAV]'V@0C)X M..,\Y\CCIT[_`#9^S;\'=?'[8D4&D^%IH](\-:Y<7$T.I+G[-!V/G]YZ_6JB MBBBBBIJ**AJ*X;[/;']^(UQ8:UJWVG1I_%GV>>XN/_2?_`-MZ M_6>BBBIJ*AJ:H:FHHHHHHHHHHHHHHHHHHHHHHKRG7?BS?:)\>O#O@)K#3C8: MKI4^H?;YM3$5P##C($&,D<]?\*]6HHHHHJ&XZ"OSO_;+\5>%=0_:,^'FE:-I M4'_"8V.JV_\`:L]Q!/!Y_P#J/L\!./\`4'//^<_HA7@O[7'QTL_@K$-7N+E M1<:SJHGL-*T_/-PV,?RKP3_@F1\.I],\&>*?&<]E`IOY[?3["Y/^O^SP<3@_ MC_*N5^&VH7_Q8_X*+^(;S4=+TJ\MM(GO[5;>9]?8/[3EU< M6W[/7Q'GL9IK:X@T.X\BX@ZC@]*_)KX-_'SQ)\`[[6;[PC]AM]0U:`03W.HP M?:/L]=C\??VGY_VC=!\'6&M:5#X>N-)-P;ZX@.;>?_MWK]._V9_#UMX1^!7@ MC2;+5H-:@MM/'D:A:P>1!./7'^>E>KT4445-1114-%%%QT%?E1_P4-T0^`/V MG8-=LXWK]%_@?XWG^)OPF\(>*I[>*UN-7TNWN)K M>$\0DC/%>@5POQ*^+7A7X.>&O[<\5ZI_9NG"86_GM#-.!-Z<9KC?^$N^'/[7 M'PF\7Z3HVK#6=%GB.G7TZP&'R9L>DX&#T]?KS7Y]_P#!/+Q]/X*_:-T[2KB< M?9O$L%QI]QD9_P!(_P"/BWK]I?!+XT?M!6'AS63)J7Q!\+,#; MZ=<"X@A'D_O^G^HGQUYZ+#!%N::XL!]/]*@_P`*^*_@'\*/%7QZ_92\8^%? M"6K6-MJ-OXLM[^?3[B;R//M_L_\`R\?I_P"`]>>?$']FKXO?!<7'AN70K_4= M/U[[/Z1<3#_D(6FJ3BXA/MDUY[<_\`!*;P)K-S^ MVO\`M!_#'5O[*\:_"&"XN/L_VC-K!NRTO_@J3\/IH/\`3?"WB6"?TMQ;7`_2>N^\+?M_?!OQ.UO; MW'B6?1IIUQY&HV4\'E'WFQBO1O#_`.U'\*?%6H?8-*\?:)=W_P#SP6Y&?UKH M?^%L^"?*\[_A-=!QZ_VI!_C76PW*W"YBZ4M%<5\7?%O_``K[X:>)_$?V*?4? ML%A<3_9X.K<5^:W_``3?$0:W^T-]NFN.=)TFXN/L_\`SW_Y=_\`VXK]7J** M*_(;0;BPN_V\X9K%HK[3[GQT1;LO^HF_TCM7Z\U-14-34444444444444444 M444444444445P>L^`_"&J>/]&\6:E86]QXGL89;?2I[B4;E!P6$(S_G-=Y11 M1114-?'O_!0S[1IVG_"S4-+,%OK,'BRW^SW%Q_Q[#_KO[5];XF*P">;]_P!_ M(Z5X9\?_`-DW0?VB-7\/7VM:[JFG0:0,_9=./^CSUUOQ3U2U^%?P0\1W^E7% MOH%KH6AW'V#R(?\`CW(@Q!Q[$5\E?\$P?`<%P?&'CF>^G%^W_$F,!''43^?] M3FOH?]M+Q+;^$OV:?',]Y-,OV^P.G0"WZ^?/7Y%?VE/IL%O!Y%C<_P#+Q_I, M%=%HOV_XD?V-X+TO0M#MM9O]6^T0:C;_`/$O^T?:/^7>OV)^`'PME^#WP@\+ M^#YYH;NXTNV"SW`/!F]?UKT&K%'V<>M'_+#]S7DW[/>A_%;1/#E__P`+6US2 M]9UJ:XW6_P#9L.T0P^A]:]?J&IJ*AHHHK\^O^"J'@R0V7@?Q3;6(\BV-QI]S MJ`]3S;V_ZW%5?V5OVK$^$O[(]QK'BU9=8M]"UC^P=+MM.4?:6./.\@_AQ7T9 M\)/VPO"?Q<^&7B_QG#:WNCZ=X9RU]!,/!ES+Y&H: MJ8-1T_\`Z;F`8N#^1@_.O+?VN_!6I_LY_M*W?BK1;B:PMKZX_M_2Y_/S_I&/ M](!_[;FOU*^#O^"?UQ#\6_P!H/XF?$#4U ME;4"#/`K?\L1<3]/_)>OT._Y8UBW'A;2+O6K+6I]/@N-7LX3!!?M#F>('KCV MKH*************************^._\`@I;X[G\,_!2P\.0PQ&'Q-?"WN;D] M(((,3Y_\=%>)_LQ_!3Q7\:?V-/$WA[1M6;PY-?>(S/!. MS"OO.IJ*****************AHHJ:BLW4=4@T6PGOKR46]O;P^=.?3_.*_/7 MQ]_P50GAU:XM_!?@Z*XT[R,P:AJ]SMN"?^N`YKT+]GO_`(*/:7\4?$FC^%?$ MOAJ?1_$6JWQT^WET\^?;$]N>U>I_$W]N'X4_"GQ"="U36YK_`%*$?OUTB#[1 MY'UQ6]\$?VH?`'Q[O;ZR\*:M-<:E9*)GMKZW\B<0G'./3-=UX-^)'AOXBP7\ MWAC6+/6+?3[@V5P;8Y\F<=C^=;5QK-C;WT.GW%[!!X_X);_``^.G^1!XI\2V]SYV?/!ML_^B*X+Q5_P2G*W0?PUXQM_ ML_D9_P`.M:5U M\%OVR]#TFYGB\2ZK/C_EW@\2^?<5BB?]M#PEX?FF$WB[^S8!YTPN!;ZA<8]! M_P`O%8OQ%_;'^-6N?#"_\'^*?#']GPWMB;"]U*YTFX@N)B1@X]/_`-=='_P3 M(\+:I??&'Q#XEB,`T>QTG^SYQW/GW&;?_P!)Z_3^WZ&BBJ>H:G!I>ESWUR?( MMX83/*?08_\`K5^3'[%GPOM_C%\>'\_4[O2%TFW_`.$@BGLCB?SOM'[C/MC- M?KG;]#4U%0_\MJFHHHHHHHJ&IJ******************Q]0T/3]4O;*XN[*" MXN;(F:SGEB_U!Z<'L:V******AKX^_X*/3_9/!'P\GAN(;>Y_P"$LM_(NKG_ M`(]X/]'N*^M]-_X\8/WWG_N>OK3JR_%7AG2O%V@:AH>M64.H:/?P>1/;-_RW M'I7-_"_X3>%?@]X870_"FDKIMCQ.P'^OG..?.)'/6OB#_@I[XTU"?Q'X.\)Q M&,6\\^?LX'X#SQ_VWKV+1OV!?A)XM\&^%;F^TK4A??V3`+B_MIC M8&X_<8S<0?3MBO+='_8M\2:=^U3H]_IW@VVT7X<:%>V]S;3PW_G^?Y'2X(ZB M>OT/HHHHJ:H:*FJ&IJ**AKQ3]K7X2K\8?@/X@T);>[N=0@A.H65O:']_-_8K_8E\8_";XF6WC/QG<6-A<6-OW_ M`-:J/_!5NPE+_#;4Q"#"OV^`S@\C/V>F?`']H.;3_P#@G]XQ,.J#3]9\)V\^ MCV-R8.GG_P#'MQ^->H_\$TO"J:)\!YM4_?M)JVK3SD3_X2CS_P#A%?M]O]O_`+._X^/L]=!H_C6W^'/Q M9M_%?A*>(/&4.D MPZ)H]Q/_`&C??V?;YGGN)R.?J/M=\>^+-0\2:U?3:AK$\_V@7`_Y M=Z_:;]GOX@6WQ/\`@WX2UVTN_/,]A;P3"7KY\/RS_CD&O3JFJ&IJ******** M***AJ:H:FHHHHJ&BIJAJ:BH:*^!_`_[<0\-?';XD6_Q&\13:=X8TZYN-/TC2 M(-*^T$>1/C.8`WG@ MN,BX7/&V-N/\`EVM\$Y_3'_;"OOZB MBN0^+TYMOA5XSFBYF@T*^Q]?()_PK\Z/^"8WD?\`"_M1_P"Q:N/(_?Y_Y>+> MOU&J:BBBBBH:FHHHHHHHHHHHHHHHHHHHHHHHHHJ&IJ***AKXT_X*;7,-M\'O M"Y,.3_;H\B<38P?LUQ7USHW_`"!]/_Z][>K5S7Y0?&7]M_XH>(_B'J$^BZ[/ MX4T:PGGMX-/M_P#VXKZ^_9%_:^@^-'@O6/\`A+IK+1_$/AN#S[^X$_\`HTUO M_P`_'TKVF^$_#WXKMH^K7>GZ)XR.E'=9:@P@N?(/L>@KT"C[./6BWZ&BBBB MIJAHJ:BBBH:*J7]M#;B;Z5^,_BGP5-^S%^UOIUCY\-K;:'KMOJ% MCOACQ3^W/\;/&D4$0\5#38++J=%M_LY->2Z=XD\9ZWKW^A:MK MFH^(9_\`1X/L\]Q<7$]?J%^UO$]8\;_`+'UA]ON);GQ3X9L;?6)_//,]Q;V M_P#I&?P\^OEC]A:#P=\3_P"W_A#XTTF"YMM6/]L64_G>1#C[/[?N,?AFO MT<\$>%O!OP/^&PTK1+B#3?#&A">X+379F\@>?%'P?I8G_XEUOH9F@@];B>YQ_.W@K[F_9T\.?\`")_`#X>Z48!; M?9M$M1-!_P!L!7J%%%%%%%%%%%%%%%%%%%%%%%%0U\1_ML_`35K#X>^/?%>B M:[XO\1W^N7%N)_#JW/VBWMX//_Y=[?M7YW>&-8UWX0>.;#5#H1MM8LAYYT[Q M!I1!_P"_$_2OK?P)_P`%'?B#XCUC3_"VC?#;PYOC' MQ%;:M;:]J/\`;=O/IVL^?^_MKBP^S_9[C_KWK0\!^&]6U+5K>_LO">J^*].L M)[>XO[;18+BOK>%M/L;*"Y_X1ZY'_+_`.1P/P%Q MC\*\.UGX7>-/#=A]OU3P9XCT73O^?G4=)N+>WK[A_P""8OQJTW3X;[X7ZE-?$/A.RU:?4;>PG_L^>Y_X]_M%Q;_\`W17W9_P2RL+ZRT'X@ZA/#+:Z M?//806]P?]1<3_Z1G'X3P5]_T45X7^V7XEE\)?LX^-[RSN)K"Y^SPQ+X^*/BG7!9?Z#8Z3]@%]QF*>>XY'_DO7Z;45#4U%%% M%%%%0U-11111114-34444444444445#4U%%0T5\D?\%#[:"Z\(_#."X_X]_^ M$SM__2>XKZOR+<>17S'^U?\`M3Z[^SAKOA

$X=7\/:@3]OU&>?'/\`SP@] M3]:\A_:CUKX.>/OA7H/_``C^D:7=>,?%GV>;PHT-D8"US/.+>#&U&P\%V,WBO5X)S;_:+C-O8`GN#G]_\`A7Y\?'7XUWWQS\=#Q7J>DV.B MZA/;_9I_[/.3<5^H'[&'CZ#XK_LIZ/#XAAAG6PAG\/WPOA^XN((..?;R,5\) M_M<_M'Z5X^'_``@GP]TJR\/?#W2/]'^SV]A]G^W^1_[;UQG[-/Q[T?\`9]U2 MZ\1/X#M_%VOL,65_=7WD"Q'I!_H]?J/\`_C#I_[4_P`%SK-_H(T^"\FN-)O= M(NC]H@R!SU&)AC'YFOS`^&T_\+V%QL:Z_9J^(^E>+?$'AIO!U[/K.E07$]]]G@Q;F#_`)[_`&BOH/\`8X\% M^.O@7^UM#HEWH)NS>Z28-5N+4_:+>""?[/<>?]H^M?J314U%%%%%%%%%%%%% M%%%%%%%%%0U^5'_!1_49I_VG+:WEFF%M;Z3I_3I_Q\7%?JM!CR!Y7ZTM3444 M44444444444445#14U%0U-4-%1SVT%RO,,4WUQ65;>%-#T_4;B_M]+LX+^7] MZT\,`$Q/KG&:I>,OA]X<\?6`L/$.B:9K5OYOG?9]0MQ.,^N*=X,\#Z#X`T.# M1/#&E66BZ=`.+73X/(`KX]L=$^"O[6?[5VLSB'Q'<>(O#5O_`*1!?[/G_GN>?H*^OOB-X"L/BAX$UGPOJAF@T[5K;[/.T!Q-@^_X5\@?L]_\$]M M;^%/QEL_%6M>)+*YT_2)_.L!86Y6XN?^NY_PK[GHHJ:BBH:FHHJ&IJ****AH MJ:BBBBBBBBBH:**_"SQ5\1_$EK\;]9\V]MY%Q_P`M MLW`R/T%)"?_`"7MZ^T******AJ:BBBBBBBBBBBBBBBB MBBBBBBBBBBBBBBH:K7%Q;VN)YL`8_P!?7YU_M7_M0>#/CW$[6;1/M%M_8/C M.V&-2ASY]O\`9[C_`$CR#R8*]P_;A^+NN_#3X%Z1?^"YY]-N-4O[>V&KV`YM MK?R&GS^.*^*OA_\`M4GQ)H&M>!_C1JNJ>(_"&K6__(9)\_4-*N,'$\!P>.:H M+>>)/V/->L!J=AX6\:>=#_:^A?:@;^WL/^H@/^>$_P"XK])O&/QMOO!G[-MQ M\1[[0AIVLC0[?4?[&N9O]5<3@?N,^Q-?G#\/?VU?B3X3^)/_``E6M:[JOBJV M_P!(QHUQ??9]/%?6D7_!2SP=I^EZ(=9\.:V-8FL3,P6/'0&X^S^?7V M1I.IP:II]O>V_-M/")HOI_DUIT5#14U%%%%%%%0T7'05^8^J_P#!.^;2?C!J M-SK'B/3?#GPK\^>X@U!KR!;GG_EWYQ7S]\;_`()V'@#QKXJ@T3Q+X5U'1K?[ M1J%A;:=JWVBX_L_[1_Q[_P#7Q7T+_P`$SO&W]I6_CKX;:IJOV?3[^P_M"PMO M_)>X_P#;>O3_``?_`,$M?A_HFN&XUGQ'JWB'3X`?L^GD>1C_`+;CDUZ3J7P* M^`'[,^@S>,[WPGI-A_9*_N+J_P#].N,_],/M!_UY]J\5^"O_``4*\2>/_C1H M_@[_`(0_2TTC5=4-M;M;D^?;V_J1TKYZ_;7^&NM?!']H?4]>T^ZO&M]4N?[? MTK40P/V>X\\$=/\`GWG(/T(KT+]N#QQKOQC\#_##Q_X>FU6X\'7NE7$$_D0S MP6\,YG^SW!N/;J.?[M4/V'OA;\7(?$?@[QSX:@G_`.$%^WBWU6V-_P#9_P!Q MD>?^X_Y;\U^K%OT-344445#4U%%%%%%%%%%%%%%%%%%?CA\?+;4?C]^V?J_A MJTN)M]_KH\/0^?T@@M_3_P`F*]['_!/CXR>"K#3K#PA\8?LVG;=T]N9[C3_L M\_K;_9Z-9^%W[:/A.^O1IGC*;Q%;0096>"]MQYY^EQ6,/CY^UW$[$V_B#PG M-K1N)\P:A?Z5Y_7_`)8?Z/\`SKH=+_X*1_$'0;^YG\;?"*YL-'@AW9MX)[>X M_P#(]=3I_P#P50\&W,/^F>#=;M;@_P"JM[:>"*KW[#:^/+&*Y\GS\:C!-8^@MSS`WH:[6BH:_,[XO?M_?%3X=_%SQ%H M_P#96F6^FZ5?3V\&D7]F0US;CH=PYKZV_9._:._B=%^WGX<\*0:GJ?_"OI[;[1-;P MZ=_HX/V><_Z_Z@?E7U#I?A/0M$OK^^TW2K.QO[_][<3VT`BFF/N<9K;HHHHJ M:BBH:FHHHHHHJ&IJ*************AHKY0_:MT;X-?!WP/K6L^)OAT-2@\5W MXAU"?1K4"XGFYG\^>?J.5ZG/^'YZ_'?P3X3\`:3X%_X1"?5;BVU[0?\`A(9_ M[9@M_M$'_/O_`,>__7O<5^L?[-O@*T^'/P1\$:'9@*(M+@GE?_GK//\`OY_S M))^AKU:BBOA+_@J?K(3PU\/](\G)N=0N+K[1Z>1;_P#V^NI_X)E>&=4L/@OK M&J7^#I^L:J9['Z0?Z.?_`$G%?95%%%%%%%%%%%%%%%%%%%0U-11111111111 M11114-%?/W[9/Q;MOA5\$M:,]M#J-QKL%QHUO;F;&3/`17P3XJ^%\_@K]A_1 MM=U30O[.UG5O%OVB"X_Y>)[?[/'=(US0X+_1K_2;< MSZ=\%0W.J_#V:X\5:-_ MRWTZY_Y"$'_R16;^RO\`LP>*_CI\1+;QEXVL?^*7L;[[1.-9@YO_`/IA^M?J MO`H@@&:6IJAHJ:BBBBH:FHJ&BOB__@HS\,O&GQ1\'>$+;PEI5[K6GV-]/=7^ MG:?^_.<#R)\>W[[\Z^-?`G[$7Q5^(_@TZWI?AP:WL-E:W&A:M]FO[?4+C_`$>W_P"7>XK]*/VL_P!M32OV>[B# M0=&L8?$/C"X@^T"VG.(((/4D5^8WQ;^.7C+XTZ\=6\6ZK-J'DG,-N/\`CWL3 M_P!.]O7U9_P3DNOA5H>E:_KGB:]T73O&-A?YL;K5[@6_V>WG@'_'OGUYKT7_ M`(*EZ4-2^'WP^U^"?]Q!JL]L?LW_`"W\^W_^T5>_X)I?%.RU#X/Z_P"$M2OA M]I\.7QOU@,'_`"XSC(_\F!M\P3 MX'_+Q]G_`-?Y'X"O6_@GX[U3XG?"_P`/^)]:T*?P[J>H1;I],N.L)\W&/R%> MA45-114-%345#4U%%%%%%%%%%%%%0U^/WP+M/[;_`&[-''BL_#?PIXDTNXTS5?#.E MZC83C$UM/90D'ZC%<%/^QS\$[F;YOAMH1/M;UR'B#_@GM\%/$E_/.?#]_IWG M#YK;3[^>W@_(5YIJG_!++P+-9[=,\8>([>Y(X%Q%;7$!_`V]<7J7_!-'Q1X) M?3]>^'_C^/\`X2FP;SC-/:FS(/\`TPG7.*OS_LT?M>P6\Y'Q8@N0>EO_`&[< M?_(]48+W]MOPM>PV_P!G7Q!!"""9_L$L,WE>XP03^>16[)^V7^T)X#OM1_X3 M3X*&_P!/L0?/N--@N+<0'U^T?Z1!^M$7_!2W7M/FLO[9^#>JZ98-+MFNC>SD M+_Y+\UW'AS_@IM\*[][FWUJS\1>'G@[W%@9__1&:Z!/^"BWP0>#S9?$=Y:K_ M`,\;C1;@-_Z#796?[9GP4FMUF/Q&T.V$T/GC[1(8>/4YKTO3O'_AO6;<3Z9X MDTS4(O6WO86'Z&M*WUNPNQ!Y-Y!.)_\`4^3+G=^57JFHHJK#;P6LA,46TR\D MBK5%>3_M`6GB2?X1ZTGA'Q+8>"]9^SCR-8U$F&W@X[L?]3]:_,^#]C[XJ_$W MQC%O%5_//]HO\`4;?Q)!J!_P"OBX'6ONKX0^,OCD_QJ\0Z+XF^']MH MWPTCS!8:A!?GVQCZU\2?MFZ5\6Y?B=?:IXWTK7+KP7;ZK/ M_9%ONW:>;;_CWR3!S!G_`$?D]:H?!']GOQCX<\*:C\1]:\2_\*BM[>QN+?0M M1U"?[!<7UQ/SS_TPY%)-+T_P`12V(^W?9B5^T7'_3"#O7Q1\7?^"F>N>);K7]$ M\):7%HWA^6&YL+?61M7U MQJUS;Z("/M&HZC!!@9_[_9%9/P$_;7^*WQI_:,TC2XM*LAX5N//^T:/;09-A M!VN)Y_Z5^AU3444444444445#14U%%%%%%%%%%%%0UB>*[>^NO#.K0:7Z\&ZAX6OO%6J:EI%]/Y]]!J(^T''I_I'TKG M_B7\4-=^)]]IU]K7V'_B4Z3;Z/!;Z=!Y%O;V\%?N/X%T]=/\&^'+2+B&"PMX M0/80#_ZU=+5*TU2#4A.()HK@PS>3-Y/.#Z?K5W[0/2OSJ_X*HZU?_P!O?#[2 MO.`T\P7%R;<=[C_]5?1?[!>G2V'[+W@T31S;IA<3$3Q8(S<3_P#UJ^BJFHHH MHHHHHHHHHHHHHHHHHHHHHHHHHHHK,N+64WUO.+Z585'_`![C!\VM.H:FJ&BL MGQ)KD7AS0+_5)H9;B&R@\\P0#,Y_#-?G#X;TSXC?MX?$;1O$?B*S@MOAMI%] M]GGT^&9Z3_`(**?$:^\$_`N'2K2>:WD\2WW]GW M!MNOV;R#Y]>2?L'?LY>`=1^'MK\6/$LL&I7]M/F&VU$>1;Z5/;SG]^.1@YQR M>*Y?P+^U#XJ\:?MK:<=&US5+GPKJNN_V?!HUQ-_H_P!GQV_]**_3>BIJ*AHH MJ:BBBBBBH:*R?$.KV&AZ/>ZK?W`M;&S@\^>WVS-<$8_N?TKS;Q7_P2DM$C!\,>/;B&[[KJUD"/S@Q7SK\7?V(/B#\'3J-]JAT. MY\/V_P#J-9^WV]OY_P#X$?\`+>OL/PMX*T+Q9^P!/X3AN-*^(FHZ'H4X']BD M:AY.H8)M_L]?,W_!/#Q];^'?B9X@\*3G%QXLTG^S[#_KXMZ\C\/?L]?%=?%> MGZ'#X-\1:;X@`\B"ZN8+BW'_`($5^K?[*_A_Q_X2^#^G:7\2;G^T?$%M,@K\L_V%=1@ M\6_M@W.NS66W[=!?ZC!!_P`^XGZU^I]3445#14U%%%%0T7'05Y[XZ^!/P_\` MB/-//XF\':+K-Q*O_'Q<6H\__O\`=:X[QQ^Q1\&_&VE-83>#;+2<\BXT@"VG M'X@5YMK'_!,GX4W-C/\`V9-XAT[4/)VPW*ZCG!_*O./^'2]A]O\`^2A3_9_^ MP3_]T5B6'_!.GXN^`[V"]\)_$#2[>>QG\^Q6":X@\BM:P^%7[9_@S4IVTWQD M=<`'E":ZU."XA^NVX&<_A6E/XM_;7\,16\4VAZ3K!(FF^T&"WG^@Q;_6N8/[ M77[4'@F]-MXA^'O]HW$-O]H_TC0KC_VWKHH?^"ENN>'8[*U\;?"O4='N&AW3 M7,-T8/-/M!/;@_K6C_P]=\-$?N?A]JQ_[?[>O1=$_P""C?P/CSX5:U\/[ M?PIXP\47MM="X.H6\'AT^?/YT$)_UX_YX8G&:^._V=M>'[*<+?%3Q3#.-0U" MP^SZ%X5P(+C5[>?[/]HG\\_Z@6]>/L^OZ@?WTI[@6 M\X'D?C^E>M?LW^'-<_:K^$>I2_&:\T+QWI,T]M-I<-A)`+BPFP?/\\V_^IG! M/0'C)J^/V5O@M^REX)UKQSJ<']J7.GD7-C=^*#]I^SW&OI_L]M//_`,?`\C&3^XR>2>IK M9TWX'?!*Y^`7@'Q=\4=5U7X=ZBEA/;SV%K;BWO\`5O(N/]?Y'D>>3QGCL16M MX[^"ND?M>:#X0UCX%7NF:-X?\.60T>X\+:LK6-Q8GSO/Z#./]=_DFNX\'?L; M?&'P6UKJNE?$/PWX.U^RL)].\CP[I/\`HVH9&1">Q=9DGG"_\M@?)]^@]37T3114-344444445#14U%%% M%%%%%%%%0U-7CW[2WQQ@_9Y^%UQXKN+`:Q.?PZ5^:/Q;_ M`&G]"^)WP\\0VX^']GX=^(.O36POO$.CP9^WV_\`Q\9SU_Y=Z\4^)G@F?X;^ M+=1T*>?[3<006]Q]IM_^7C[1;V]Q_P"W%?K=\>_BGXC^%7[.6GZUX2TS^UO$ M)BL;"W./.^S^=#CS_?!X]Z^%-%\0_M/_`![\6C2K'5/&%K,?AC\;/V(M6M]=@U;^Q=/O[[[/!J&CWWGV]_/\`]/%N:^^_V,_VC+K] MH7X?WEUKJV5KXATBY%K/%;G_`%V85Q/^)$WY5\C_`/!3_4)T^-_AZPGO\P0: M#]HA@Q_J3//<<_\`DO7WM^SCX-F\`?`_P3H5U;P6U]:Z3`+B""7CSL`FO4:* MFHHHJ&IJ************************YRZ\6Z58^)+#09[RZ&:>WL?X MIH8C@D?3(/YUT=0U-4-%%QT%,].MO#UQ-_PCV@07'V?[0/]?@ZO\7K'2IO$<%A!/K$-S]M^W^Y^SU7 MM/BM\)OVY_`FL>!9IY]&U*X`GAL-2_T>Y@QTN(/U_.OF+_AA#X]^&UU/PWI= M]9_$[KG_(0_L[5#;Z?.;CQ#=65]#`+8V]O\`9\3$#^HKZ?\`^":'C.#7?V>3H1@^S7&@ZM/; MSY_Y;&?_`$C/_DQ^E?65?)O_``4>$WWB/\`9WGOK(0"WT/5K?4)_M(Y\C_4 M?N/_``(KP+_@ESXETJU\9>.O#5VL)NM7L;>?,^,S>1_RPY]/M%?.GC+1;[X% M_M*W$,T$&B_V%XE^TV]MTMX+?[1]HM_^/?\`Z=Z]*_X*':YKVI_M&3P7TQ71 MCI-OX_T>>W_`.?BOI/_`()Z?M0ZI\1[`?#C78)KG4-`L1<6^LF;/GP= MO/\`?FON6IJAJ:BBH:FJ&IJ**************Y/XAZU+X3\"^(-=L[$:GJ.E M6%QJ,%GG'GRQ0D@?H!7YV?\`!,/PSJ=[\8?$7B+["&TNQT=H9;RX8!HKB:XY MQ_WXG_.OTYJ:BBBBBBBH:FJ&BIJ***AHHHJ*\T^WOE`FMXI_:5+:_\`\$PO MAAK-U<3VVJ>(]$CG'_'K;SV\]O#[@3P&O&)_^">?P^\2:KXAL?!GQ>$]UH5Q M_IUK<0V]Q]@_Y^/M%?&/C/1/">B7]Q!X>\2S^([?_EA<_P!D_P!GV\__`),5 MV/P1^&'CKQ'9:QXQ\%7^EZ<=)!L+_P#M&^@MQ;V\]OZW'_+#FXKCM.^&^K:E M8>?I<]CJ/_3M;7]O]H_\!_\`CXKTKPWX<^,WPY\$^(?#EA\-_%.C6NKSVYGU M*VTF_M[@^15CXE_M=>,OB=\%O#WPUUFVMQ;6&3?ZS<3_`&BXO_(YMZ\U^'FM MV/\`PFGA[_A(?$FN:+H]A/\`Z/J.C?Z1<6'_`%[UT7QW^.OB3XZ^+?M_B&_@ MU&WL/M%O8?Z!]G_T>OJK_@G;\1?A[\,O#/B#5/%_B+2?#VL7%QY$!NKX&>>` M$8_7G_MO7WEX6^,7@3QG8"]T/QGHNHVY[V]_`U;6G>+="N[W[#9ZI93W0_Y= MX)P3^E;E35#14U%%%0U-114-%%344445#4U%07/G8_=8_&EJ:H:FKY\_;7\. M^$M9^!=^OC/7+WPYHL%[;W']H:=!Y]PLP)VX'^>E?G)X>_9#\2_&(7-Q\+[^ MQ\1^'?/N+?[3J,_]GW$'_7Q;TGBKPHOB7]M#_A%;VR&W_A)-/T>>#43Q<6UO M]GM__)C[/7ZB_'CXN#X#_"#6?%UKI@U-=.,%O#IX;RA6]AW^']GXC'B* MVL()[>?3[4F_:?'_`!\`^O4U\%?$RY^'WC_7?^+8>!/%6BW,_P#S#O/^T6W_ M`(#U]V?L+K\;=/L=0TGX@V&J6_ABWYL+CQ$?^)CY^1F#'_/#CBOL6BBBBBIJ MAHHJ:H:FHJ&BCB`>U%?G=_P5-U'Q($\)6/ERP^#R09[@`>1-?>A_[8[J^)?& M=M8>";C4=)$>._^$K\/:O!;_;[G3H+C3[>X_P"OBWN*^E/^"8WQ8F\.?%S4 M/!L]Z(/#^NV%Q/;VY[7\&,_^2X_2NJ\4_P#!4KQ+<:M?_P#",>%=$;1P,6%S MJ7VC[0:\K^(?[2GQL_:AT0Z)8Z1/_8$$'^GP>'K"X-O/[7%;'[*'[)?Q5D^* MWA?Q7<:3>>%],TJ^@FN)]3_T>)8"8.G[BX@@M[?R./7K7,:C^V+?6WP\\"Z%_P`(9X6\5Z?8:%_8\]QXKL?M M%Q]HM_\`-O5[X+?M*?$_X(:GHVJ-80ZEX<\2W$YM_#HLC;&<@Y'V1Y!'_+O]W_/-?9W[*]U\9#H>KGXK7VF M:Q;CR?[*U+3IH)A..^?(]\5]!T5-114-3444444445#4U%%%0T45QWQ8AU^? MX<>)AX4F6#Q.=,N!IA,7W9]O!_/%?-7[!GP0\1?#'P[XH\5>,]%ET[Q'KEU@ MV]Q%_I`@P#@CU\XY_6OFS0/V6O$?[5'Q9\3W\'AN#X1>%K*__?6T^D>1\B>]UFUL;B>X%]!./(!Q^/YU\IZ= M\"O&?AO5M.O_`!1\-O&-SHT%_P#O[>VL+BW\_P#\EZ^R_P!L7]I.QUCX>:?X M5$^*I?`7B6W@M]0U;2+B">"ZAM_LX_T`\#D^>,_05^?6BZ)/K?B73M)@@GN M;B_GM[?[-IT'VBXN/^O>OTE_:N^"OA;X2_LHZ?\`V7!HD.K>'1;PP:EK.DV] MQ?WI&!@_9J_9R\`_$W]G_PSJOC3X9^'+;6-1L%\VXAT\03S0<^1 M.,G6 M6/\`D'?N9E@_$BLD?\$KO#>EP&?1_'.JVNHP'[1;7$UO`WD3^O2NC@_8J^+Z MV\\'_#27B0Y]!1[PSVV,_ MC6G87/[:'@+7IK>X@T/XAP7/2XS`L$'_`*3FNB;]H[]I'[7`(OV=_E/^O)U8 M*[:]@7Q1\#/$NG6^,37.GFXN"/^V'V?/ZUI:G_P4V\%:--< M6]]X%\8Z==6W^N@NK>W@(_\`)BM30?\`@I7\)+][A;^+7](Q]VXGTXS>=_WX M)KI=%_X*"_!76YO(/BJ733Y_V?&H:7<0<_E7H>@?M,_"CQ1JMOIFE>/]#O-2 MG'[FV6^&6KO+7Q-I5X/W.IV4W_7&<'^1K3HJ:H:FJ&IJ********AJ:BL'Q5 MX7TCQKH\^E:[I5GK%A./FMK^W$\!^H(KY`TW]A_Q)\(?CI:>-_A=XDL=(T>Y MG%M?Z1?6Q"PV&,^0,$^=STR:^3?V3]&F^(W[8/AZ_P!5N)KBX_M>?6)[G_GX MN(/M$XK[V_;[U.+3_P!E_P`4F>VAG\^:W@B^T19%NWV@?OZ_/CX`_#G]H'[% M<>(_A'#K=M87_P#H\^H:?<6]O;S^1Q_R\5[=,]*N!\5O"<.C00P_N-0&8+B<^]OVKXJ_:0TV_N?^"@U MQ8V7^DW$^O:/Y%M_V[V]?J]1114U%%%%%%%%%%%%%%%%%%%%%%%%%%%%?,W_ M``4!M](N_P!GG4(M2OK>PG^W6_V!YXLC[1GG_P`@?:*[[]FKP_;>%/@+X'T^ MW\DP?V3;SDV\'DK*9ANSC\?Y5ZW4-%%5_P#IA7Y2?'O]N'XBWOQ)\0V_A#Q% M>^%?#]A<&PL=/M[>W))AZ]:Y_P".O[4NJ?&GX;^'89O$6J6VHS6_V;7/#Y@@ M-A/Y!R;^WN/^>_3_`"*]D_9>\3?#[]D7X>Z1XJ\=WL(\0^.H/M%C!I]AY]Q8 MV'7]_4WCGX8?LJ?&H71\%^,=+\"ZUY)N2+=A;V_3.)K>X`SSQ^XQ63^S)J_Q MG^!WBRU\&:+X8L_''@R]U`,=:TS%Q;0V\_\`RW@N(!T_Z^.:_2^BBBBBBIJ* MAHJ:BBH:FJ&O,_`7P6L?`6L7&I6?B7Q-J`N;V?4);?4=4,\!:;K\I[=,5Z97 MPM^TKX<\$?LMW,'Q`FTOQ)XVUK5K^Z%OH^KZIY^D">>`B-=/\9^"?A!H?A7^P?^)A?V^FP?VA;_\`;Q_R[V]<)IWBV#1/B';^);+2 M?LUO8:M_:$&G>?\`ZBW^T?:/L_VBOV`?]G+X4?$^'PCXM/@^RL?LW_$PL4MK M$6`D\\=)X,`GMUKV'3=-M]-MH(+*"#3[;_GWMX/(JW7R%_P4E^&8\6?`Z/Q% M;V*W>I>&[X3D@<__`"0*_2Q]*L;L6_G64,_D?ZCSX!^XK3HHJ:BH:FJ&IJ*AJ:H: MFJ&IJ********^._^"F>HWEA\`K"*"<6\%[KUO:S`RX,@(F.W]`?_P!5?GW< M>$K_`$W]E.W\2^?_`,2[7O%GV?[-Y_\`S[V]Q_Q\5SVG>-?$GB32=&\"P>+) M].\+6'VBXL;>XG^SV\'_`!\7%Q7WY_P35^*'CGQIIWBG0_$-_?:QH.DP0#3[ MFX&?(./]1YW?@?I7W;11111111111111111114-%35#11]G'K17GOB_]G_X; M_$#6/[5\1^"]%UC4-OE?:KFR!FQ]:YKQA^S3X;N?A]J'AWP)96/PZU:+KKQQJ5A;_9H+6Z@S`/?]Z37U[!;K;P[ M8OUIU345#4U%%0-")ADU'>Z?!?P>5/#%XL5,TQ]2>N:YFY_8Q^"ES97$`^'^DVYG',]NI$Y_&O,[W_@F5 M\(KH`>;XDBM_^>*7X`_]$5Q&L?\`!*30B+G^QO'5]:D#-C;ZC807`M_Q[UL7 M'[*'[1<$-O-9?M`W-S-`.(;CSX`?RK&TGX8_MI>&);BSL_'.F:E;^=_Q\SWD M%RVS6AX@\0?MH^$K'[;+I^B>(+<38^RZ9!!-<8^E<]?#F'&DW\'X?%#_P(?X5V4/_``4$^"##GQ=J%O\`]P2Z_P#C%>@> M%?VG/A3XNTZXN]-\=:,;:&;R"]_=?9L'_MM@UWNB>+-$\16L$^FZK9:C!/S" M]O.)@WY5KT5-4-%345#117)_$K7Y?!OP]\4:Y;I#/( M8O#&GWYAQJ`OA;$3YXY)%8W[//@KX??`7X?+HGA[QE9:OI\\QOO[0NM3@)G) M]P>G'_UZ]THK\M=(M%^+'_!1:YFTW6+V!8M>\]KY;<03_P"@P^'GB'R83G,WOC'05U%M;0VT/DQ8`':G444<0#VKS'X[?&32O@7\/=0\6 M:G#-="#]Q!I]O_RWG[5^2FLZ)X3N?!6L_$+[!JO[_7KC3X-%N;^W^SP?:+?[ M17D=?<_BS]FN]^.?[(WPS\<^'S-J'C+0M!^S_P!G6$_T^W^T<6__;#G\J^. M?!OA.^\:^+-'\.64&-0U:^M]/@MS7ZH_L\?L1^'_`-GSQU_PE>F>)M4UFX-C M]E-K=0""WSWF^M?4=OT-%%345#114U%0U-4-35#11117SW^VS\%]<^.OPA&A M>&/).M65]!?P6\\_D+-M/0FO&(/V"%\#_L]>,-+T:_&H?$77]*MK6>ZN9SY& M8;A9YK>W';)AQ7QQ^T?^SSJWP"N/!VDZH#<:CJND_:)[FW_X]S9Q]HF!AYQ!UZ<_E7X__`+*_CX_#CX[>#M=F\ZX@\^WT^OVRM[FK'V@>E'_+&BBIJ*AHHJ:BBBBBBBBH:*FHJ&BO@C_@JIKDD'A?X M?Z6DT(M[C4;F=H#U)6#;_P"UZ\,\&_'KPW\./V.]&\'^(?"MGXSU#7=4OYX- M-U!O($%OG_CX\_\`Z^._O5+PKX_^`>I?#SQ3XEO?A1!IOBFP_P!'L?#O]NW' MV>_^T?\`+Q7V=_P3[O/!E_\`!J:X$:%>Z%/]M\C58KBXFG,]P(5S-S_`'N/ MR^E?5-%3444444444444444445#4U%%%0T4445-11111111111114-35#117 M#>(O@M\/O%84:UX-\/ZAY,WGC[3IT!P?7I_.N%\8?L6_!KQ=8>1-X"TW1SWG MT0?V?./H8,9KS&'_`()B_"GS3YNK>*;B''`:XM__`)'KDI?^"5^@P7PGTSX@ MZKIO[T-`RV$!F@^A[UGWO_!/GXD>'[6XU'0/C+=?\)!FXG_?KY-Q`?UMZZ_PG_P`%//AI?:0LVO:3KFB:@HP+:V@^W@?]MAQ7=:7_`,%" M_@IJ,FUO$=YIO_80TNX7^AKT3P=^T7\,_&^F0WND^.M$FM[A>/M-\+>;/M#- MAA75?\+#\)_]#-HG_@P@_P`:V;;4[?5((9[.:*YMIO\`EO!-Q^%>(_MLW_V# M]EOXAM&LQ::R\@?9QR/WP'^-?'G_``2S_P"2X^*?^Q:_]N+>OM_]ICX`:1^T M?\/CX;O;Z;3;J"?[18ZC;]8)Z_,OXZ_LX_#_`."FE7/D_%W2_$/B@?Z-;Z/I M^DCFX_Z;W'VC_1Z\=T[6]=N9[>PLK[5;G_EW@M[:XN*_8?\`9SB\4^#OV?M& M/Q/OE;6;"":XU&YNIL^1;@DCS_<0X-?GC^Q7K&J7?[7OA^_CW:U->W%^]Q<3 M3>23YT%P?/Q@YZ5^O=345#114U%0U-11111111114-34444444445#4U0-,( M1@TM%%%%>7_'3P-I'C7X<:U'JOAJQ\5R65O/?6.GZA-P9Q`NW. M@V_AJ">^N=.GO_M$&G6__+>X_P"/?_P(KL?CK\*+WX+>,[;PIJ3!K^#2;>XG M(@X^T7'^?_)>NY^!?[5'Q8^$]M80:5<7WB#P?I4V)](GMQY`_P"G?[0?^/>H M=&T6W_:&^.'AZX^'NA0>%/$-_/<:C/IVHWWVBW^T6]Q]H^T6]Q7[,6_0T444 M445-4-34445#4U%%0T4445\8?\%*O"LVN?!'2-;@TV:[N-'U;SIM0MSS8V\W M!/Y_9Q^%"?LP_` M/Q9^UE\0]0\6:IXDOK>#2;_[1?:SYY_M#[1_TP]*Q_C_`.`1^SA^T[P?M.G6 M^K6_B""WMO\`1_\`1_M'VC[/7Z]>#_$-CXR\.Z?KUC/]HT_5+>&]@/L0#_A6 M_11114U%0T5-4-%%%344444445#17YA?\%4O^2P^#?WV/^)$?_2BN"^+-SX' M^*'@3X2ZIX3\::)X6\9:#H5AI%]I&M6XMA^X)_?_`//#B?SZ]K\1?LF_!SXU MVUCXE\._$_PYX5UJ_/\`IEMI\]O/IWVC_EX\B#]Q^=?9OP0^$FE_!?X;:/X4 MTP0'[%!BXN(+<0?;)\#,QQZUZ11111111111114-3444445#4U%%?FS\7O\` M@I=XMT'Q]J]AX&L-"U+PS83_`&>+4M0@G/V@]^?/&?R%>J?LO?\`!0"P^-/B MO3O!?B;0SHOBB^$WV>>WYMI\>E?3OQ(^*?A/X3Z`-;\6:O;:-IOGB`7%QT\X M]/Y5XUH'_!0;X+Z[JD]C/XDGTUEF^SKZ7;7'_3@AM3_P"0 M,5POB#_@G'\'-;FGF@L-3T=YH/L\1T^]*"#Z=:\PG_X)1>&_._=>.M4\CR,8 MGL8#52P_X)W>.?`XMI_"?QEN-,O[+SQ;F"">`0P'MQ<5Y;^U/\!OC;\,?A[< MZKXH^*%QXS\+B807%L;ZX[_],.A_"NH_X)9>%M43QCXR\2,T]IX>:P@TX?\` M/"XN//SQ[X!/_;>O:_V__B?\0O`'@+3M*\%66JV]KJPG&J^(=.@)_L^WQ_>/ M^I^M?E?_`,>U?4O[/7[9OASX&6%M8V'PBTH7($%O?:S;WW_$PN#[_P"CU^@G MB7X@Z#\7?V:?%/BGPS>>?HM_X>OVMKF?]SG]Q/%D^G(-?GW_`,$X8/M'[3FG M7'[[]QI5^.?K7ZT5-4-%%%%345#4U%%%%%%%%%%%%%%%%%%%0U-4-/X])&IF\)TN_@U&W^SWLT'[^$G;G!Y'7ZUU=%%%?&__!0CXM>*O`_AWPMX M8\(WEYIVI^)9[@2WFFS8NB(0N;>'W)F'Y"O(?`G_``4(_%NO_`!"UFW^TV_A.'%CG MM/7DG[5'Q\L/VCOB%;^)-+TF^T[3H+&"W@M[FO;/^";.J>*M!^).L:7'H=]/ MX4UVQQ/0_M,^&9/&GP%^(&DP8GN9])F,-M%# MYWFSQ9G48]RH&*_/W_@G%\1+'P9\$+'0M)U76K;^U)OMMMIT$UP-OV?[17K/[:&NK\:OAO\+OC18Z9#81:I;SZ3J%L9OM'V>>$G%OP,=KG\J^O M_P#@GWXMC\0_LR^'HFOQJ%WI,UQI\YS_`,>X%P?L\'_@.;?\Z^FZ****FJ&X MZ"BBBBIJAHHHJ:BBBBBBH:_+#_@J/K<&I_&[1;*#R?\`0=!S/GM^_N*^BO"O M[`'PH\;^$_#FNZG8:G;:C?Z587%R+"_(@\_[/`,@?A4/B/\`X)??##49K`Z7 MJNN:-;C_`%]O]H\_[1]:^P-/MUT^WM[>#_40#R<5HT4444444445#4U%%%%% M%%%0U-67K&IV6E:7<7]_-#;Z=#%YTT\W0#U-?BYXJUOX>^`/$WBFP\!V'_"Q M?[6@_L^PUGQ%8?\`'A_I'_+O;_\`+Q_U\5[1^PS^RK\0[;XMZ!XZ\0:#/X4\ M/Z4/.`U&+;<7Y-OC_4=NO6K/_!4_6%G^*?A"RMM36;['I>ZXT]?^67[\+&VT^&"#Q#XPO<>1HP MG_U,'_/Q/Z"OD/6O^"CNK>)(((+WX4>"-1MS_K[>X/VC%>X_LX?&GX0_M*^, M+C3]>^&'AW1O'2VQG'VNRM[C[?Q_I'D'K7M7[2\FD?#C]EOQY;Z;;PZ3IL.B M3V-O;V4/D"#SQY`P.W,X/ZU\K?\`!*W_`)'+XB?]>&G_`/I1<5^CE35#4U%0 MT45-1111111111111111114-%%%%35R/CGX@:%\.;2PNM?O(-.M[Z_ATVWGG M.,W$Q(`KIO._U/\`M4ZBO/OC+\3M*^#?PXUCQ7J#//@^1#^)K\ MR#^VMXDUSXA>%O%?CSPUX<\17&A3_:(,6_V>XM_^O>XK#_;%\.>"--^.EQ;_ M``ZF.H-?$SSV]N0;>&_G.!!;X'<8/XU]Z?!G6?@S^R]X4L/`I\=Z%;>(/^/B M^%Q?P?:+BX]Z^/OV\O`/PQ\)^)?#^H>!I["VU#4()[F]TS11Y\$P\\?OSR?( M.;@]/_KGV/\`X)U^,_B?;PVOA76_#E\GPV^PSW&DZWF80\=(01\HKT.BBBB MH:**FHJ&BBBN#^+WQ'MOA-\.?$'BJ\MA/!I5BUP+?H9IO^6,(_'`_&OQ7L/B M-JL'Q1/C**^'A[6+G5O[0.H6]O\`\>/VBXK]TM.G_P!!M\S_`&K]QG[1_P`] MJ\Q\=?&+X0Q7L_A7Q?XN\+3W)&9M&UF>";]#_6N?US]E?X%^-+_3IQX*\.M< MP'[1!_9N+?SO?]Q7E7_!0+P#:Z-^RY8V'AO2X+'1]`U>WG;3]/\`W%O;P8G@ M_P#1]P*X/_@F]K1\7>`_$_@:#6=2T'4-/U>WU@7%AY'[^`\>0.#_`,\"#[&O MT)JQ11111111114U%0U-1114-%345#7XJ_M/W%_\4/VJO&%OID_]LW-_KO\` M8UCSY'_3O]GS7[">`]/FTCP9X>TJ$-]86,%M(O#?AK5QHVK7L!PV5Q..]N?3SNE?E MWK'[+WQN^%^JW&H0>"]!_CUJWC&:QFNM&U6:WO MX-1%MY]M!C_EWN!_V[UXKX[\:W'QT\6Z-_9?@70_#NL^1]G_`+.\*V'_`!_W M'_/Q]GK]9OV2/A+K'P?^!^C^%_$4\%UJ\!FN)X(#\L`F.[R/PKVVBBBIJAJ: MBBBBBBBBH:**FHHHJ&IJ****AHHHHHK\ZO\`@JAK=_\`VY\/-(QC3A!<7X'_ M`$WKZ*_89\%CP5^S+X.BEL$L;[5[)_P#OQY%?GS\?3;P?MD>* M#\09Y_[%/B3_`$[[/_T#_P#^'K]*_"OPE^#7B/P7HW]E>#/"NI>'H(/]`S86 M\^!7Y=_'WPYH?PY_:,U?2OAO>SS06-];FQ6W_P"7>X_Y][>OO#_@H/XCU/PY M^RX+#[>#=7]_86%[<&#_`%__`"W)'_?C]:\E_P""4FA@W_Q"U4S_`/'O!I^G M_9__``(K]%***FJ&BXZ"BIJ******************AHKF-8\>^&=`O/L.I>) M=*T[4&'_`![W=_!#/^1-4C\8O`P_UOC3PX/KJT!_K1O]GWPGQ^5=/7EWQXO/`NG>$[!O'ND) MKFD_VG;P6]L;'[<&N#]W]S@^A]:]1X@'M15>OD/]O/XFZ#X;TSPKX.\7:'/< M>#?$DY%_J]K/B>P\G!S`/7_$U\$_M#?#?P;$O$=OH?AC7+[Q5]HL8-0_M"Y M@%O;_9Y[?_1_L_\`S\5[S_P3P_9YLO'NL:CX\U_3#?Z/H]R(-)M[@`VYGR,S M#/>#I^->._M2_"$?!GXZ:QI=X;RYT>_N#?PW"MFXG@G.",^Q!'X5XK;>1_U[ M5^J__!.OP]K>F_`33]8U/Q'+JEAJ89=)T['[G28()YX=J_7^E?6U%%%%%%35 M#7B/[0?[4WA7]G(Z/#K4%[J$^K>;]GM[#RL\?4C_`#UKT7X8_$32OBMX"T;Q M7HQF&FZK;_:+<3C;+CZ5\O\`Q&_;GG^&/[25UX$UOP[#:^$;&XMK>?5#+-]I M`GAR)NG0=/7WSS7V34U%0T5-4-%%5[FBODG_`(*5>*9=+_9ZBL;?41%_:NL0 M6T\`'^N@!,Q'YB&OSB^*GP=USX37'A\:U8WUO;Z[I-OJ$'VB#I_S\6]?JI^R M)\0%^+'[-GAZ?^W;W4-2AM_L%_<_\O$%P/\`(KYP\8_\$MH((-2GLOB.=O[^ MX#:S8@AL_P#/>XKX8\9>'/\`A`?%EQI4&NZ5K7V'_1_[1\.S^?;_`/;O<5]3 M?L1Z9XK^,PP2WS0P^:+>V_UTWH!7S%X>_;Y\'7O MQ'M_`WB#P[XA\':R;C["IUB"$"&?MR#^OZ5]6U\]?%W]J'X+>$_$5KX5\7:S M8:A)+7X7_#F_/C+5+?PMX>OV'GG6;JWM[> M>;_MX[UB?"C]JGX;_&?Q'<^'/">O3ZEJ-O;_`&@V]S8SV_G#V\\"O4]<\1:5 MX9T6?5-9U"STZP@'[ZZN9_)@'XFOD/Q#_P`%./`VG>)+6PT?PYKFMV`G^SW& MHVPX)_Z=_P#GXKV7X_?M3>%/V=+72#KT-[J%YJI_T>PL1$9_*]<$C(KUGP]X MFL?%NA:?JVESB_TZ^A$\%Q!T(K5HJ:BBBH:FHJ&IJAJ:H:FHHHHHJ&IJ*AJ: MBBH:\M^)'[1_P\^$.NZ?HGBWQ+!HFH7T)N(%N8)L&$<9R.^:Z_P5XWT/XD:! M;:[X:U6WUG1YQ^XN;8\5^;?_``5`\6SZE\9]&T*:"$V^DZ2;B#/_`"W^T?\` M\/7W3^R=;7&G?LV?#R"]_P"/@:3`#^YQ7@W[:'PG^#?Q/O\`[1>^/_#W@WX@ M6,.,7-_!;F^/DGR(+C)Z=,>U?%?AG]E#QEXPU,V?A_7?!.I"VM^=1M/$<#00 M?@.:^OOV.?V*9_AOXQ'C/QKK&B:OK-C#,+#3].G\^W@R1^_KM/\`@I/J/V7] MGFW@'^OOM>M[8?\`D>N;_P""7'AL6WPN\8:\3_I%_JXML>=G_40#_P"/U]NT M445-14-344444444444444444445#7P1^W!^QMXD\;^)=9^)WAF>'4+H007% M]H^#YY%O#@?9SZ]*_/*XMOLW[B>#[-<56K]$/^"=?[/,VAKI_P`7KC5L#4-/ MN=/AT>W@Q@?:/_N>OOVN`^)ECXSO++0#X-OK*VN(=6M[B_74?^6]@"?M$(]^ MGY"NWKX:_:P_;+U:W\7#X8?"J8W'B*:#C$$\YZXK=^-WP;T+XY?#34/#FIS?9H+ MC_2(-0M^L$_.)Q7Y2?$'X/\`CKP]XRT3X-BWTO6=8,T]S8?8)B#/]H_Z;GI_ MQ[U^M/PH\$V'PX^'^@>&K.RM["WL+$0?9K>7SL3_`/+<9[\_SKRO]M+X*Z#\ M5?A!/G_`#W^$_!WP@\'[*_-P-&_L^#%_C[/_`*1]H_YX?]>]?H1^Q=Y/_#,/P_\`)OYM07[` M,&XZC_IAS7O-%%%%%%%<+\9/BSI7P<^'>K^*M8V_9[*',4`;F>;!Q"/ONS_`()J?%;0KGX83^!Y M=5_XJ&QOKB:'3KB8'-OGCR/8<_G7RI^WW_R='X[_`.N-C_Z005^MOA[_`)`] ME_J?^/>#_4=*VZAHJ:BBH:*+CH**^5/VR?V8K[]IN;PK8V'BNR\/3Z3%?Y_D#^F*\O_`."D'@+^Q?@1\/)X?.N3H5];Z?/@]1]G_P#N>LW_`()7 M^(97T+X@:"P!MOM$&H6]P9_8_P!/(JK^W3\2?BKXP\>77PR\*Z)KC>%KF"WM MC]FTO(U8S'!'GYP(!T/TK)^"/_!,6XU*W%_\3]5FT8?\L-&T:X_TC_MXN*_0 MO1/#5AX;TG3]*TNQ@T_3K&#[/;V]O_R[U^,_C/4M6^`7[5FLZ]]AGM[C0?$M MQJ-O;W'_`"\6_P!H_P#D>O>?VG_B?\5O@O\`M+GQA8ZCJ]UX<^SP2Z2;B(_8 M/L\_!M\_ZC/OUKC_`-G+]L'XGO\`'7PK:^(?%D^LZ+JU];Z?>V^H3C[.IGZ$ M5^N-%%%%%%%35#114U%0U-14-%%%5KBX%M;F>;_EC7XK_!KX7?\`#0_QXN=" ML?$G]B_;_P"T-0@U'R*^FK']AO\`:`^&]VT'@7XH0P:);S^?8J-4N83_`.`P M'D5T6B>$?VT?!E[<6$&MV.M6O^N_M#4[V">WQZ8/^D5U`\9?MD6&MI/>>!?" MFI:?;R_O8-/N/(,X]1FXK!U']O'XP:)<>1JGP$O[;_P/_P#D:J7AO_@J?IJ6 MQM]:\":A%J?_`#PLKT?^U@*],T;_`(*3?!R_TRPGN[_5+&ZG&9K=M*N)O)/N M0*[?2?VV?@I?R_9X_B'8QMZW4,]M^LRBO3[?XF>$KH?N?%NBW'_<1A_QJ_IW MB[1-;F-O8ZK9WUP!_J8)P?Y5KT45D:_XETGPCIQU#6-4LM)LEX^T7UPMO"/S M.*X7XI?M%^!OA%X-T[Q5KFIF;1]5F$%E<:=#Y_GD^F.O>D^&?[1_PW^,-Y<6 M/A/Q38ZGJ,,7S6H/E3@?C_2O4JFHHHHHHJ&BBOE']L3X3_&SXH:AI'_"MO$1 MTS0(8";BPM[XV,[3]OF^E>#_`+/_`.RC\:OA?\>=(\5:IHFA:E"M^/[0O]0O M_M!%N?\`7W$`[7%>L?M2#]IHWGC&+P:-'_X0-HE-N;*8#48(?('G]>^1-C\* M^*?A=^Q=\5?B8MANL7\_DP?9\9\\`3;V__`#[_`*5]1_L@_LH>*OAKIVH?%?Q1X>U) M/$.DPSSZ%X6AG^SSW&8,8N/<]/K^5>3?&N_^/7QY\,^*?$?BW2;[1?!WAJ>" MY_L6ZL?(,%QGR/\`1\V_^D=:XWP?\)O%.G_":X^-.G0:G!J.B>(X/L%I!8?> M'^O-QCT^T$?G7,:-<^#/&WVC5OB'X[\1VVLW%_\`O_[.L/[0^T6]?IA^SA^U M5\)/%K>%OAMX)GU.VG@L/L]AIVHV/V<_9[>#_"OIJBIJ**AHJ:BBBH:FHHHJ M&BIJ**AJ:H:FJ&BBODG]LOXV?"?P'=Z/HOQ!\#'QI=77^D0DP0XMX1P;CSCT M%?.D?_!1*+X6-<>'?AE\.M$L?!\$TXL1<3SB:'R># M^']*_*WXV_L%>/\`X2F_O=,A@\4>&+(^>+^QXN88,9_?V_?CTKYE^S?Z1^_K M[:_X)Y_!8#XE-XOTSQ_H;VUE8SVU_HNFM<+TA^S_;YKBYF M'_/:X\\@G_R#7TI4U%%%%%%%%%%%%%%%%%0U-14-35#14U0T5\H_M2_L@?#_ M`,=>&M?\:`2^'?$%C8W-_,S97T&J M:;X4MX+C[1K6GP8_TC_GWKW%_P!@;XQ_"'7VU;X9>,;%Y85Q#-!(;"YN`>Q7 M'D?A3M&_;Q^+WP>G&A_%#PI_:5_Y_P"_N-0@_L^X^S^O_/#_`/77T9=BW$PMR0#],U]":EK6E M_LC?LSV*:M?RW*Z#I/\`9]N`/](N;W&,0_CN_*OFS_@G)\-;[Q!XE\4_%3Q# M964YN+B>"'4+@`W!O_\`EYG@R.AZ5C>-/#/[0/[)7Q!U#QIINIWWC3P]?W_V MF^S]HN()H,?\MX/^7?KU%X_LZW/VBXGO M_P#Y'KZ"^-?P>\0_"7]C^+P'I`\-:CHEA97%QK5SK$]Q!<^=YXN/]`]\Y_2O M:OV'?M\W[,W@XAAN!F"X\X=Z^+?B)_P`$ZO&?@'X>ZQXDFU72 M]:N-*M_M/]GZ=;W%Q<3_`/7O6]_P3_\`V:=<\1?$"W^(.N"^T;3?#<_^A6]Q M9!?MLW?SY'V?R/Q^SYK]./ M`UO/9>"_#UK=P_9[B"Q@@GAZX*PC(_.NFJ&BBIJAHHHJOXT<7%QP(+?[/]G_`/2BF7/[4NN?'76OB3\./&M_I5SH M&JV%Q;Z2=/\`W%O!?P?\>XM[C_EN/M`!_?\`I7DW[&WQ7OOAC\=O#PB\C^SM M>N+?1[ZWN/\`GA/TK]9?B?\`%+PW\)_#-SXB\3ZK_9VG0@\D9GF_ZX#-?G)\ M2/\`@I-\2O$-X%\)6=GX/T^W_B:W%_#5K#_EAS]GZ<#\ MJ\"\<_`7XG?`TZ=JOB?2_P"Q;#2+ZV@L=8,]O/`)S_I`R/\`EOT/Y5^Q'@#5 MY/$7A71]3DN+&ZGO+&"2>?UK\U?^":OA2?4/CT=7@G@ MMK?2-)G\^WN?]?.9^\'M7ZM4445R.K_"_P`&ZTDXO_"6B:A]H&)O/L(&\_\` M$BN(!;S:A\//#L[0=-NG0Q#\<"N-U[]A#X)>)0`/!W]E'UTVXFM M\_K7EUQ_P2O^&I^T>3XC\2+.8<6Y)MOW/T_<5R^G?\$O]6\$WHU?PQ\5FTS6 MH/\`43V^D>01^5Q6SX@_97_:1T:"WG\._'2XUFY@ZV^I7MQ;?_)%5M.@_;8\ M$33Z?Y.C^-%SYPU"XN+?'T_Y=ZR-1_:7_:P\-ZA)+ M#Q!X#UB^M[BWTK5["_-_;Z3_`*/_`,NY_P"/@7'7L?PK0_9A_:,L?@;\?K^S MG\?WFM_#&]GN()=2U*"X_?G_`)=[CR,<>E?I)!^T_P#"*XZ?$OPJ?^XM!_C7 MH5KK=E>P?:(KVSGMS_RVAG!'Z?XU=HHHHHHHKXK_`&O?VF/C/\"M2O\`^S?" MFAZ?X1GQ;Z7XB^T?:+C./^?>M;]E']J[X@_'73?$VH^(?`\=IHVD6YF@U#3! M/_I,^/\`CW@AQF?IUR*\F\.?\%4+BU,T'B[X.Z?\`\%,?@U<0CS?^ M$BTZ?O;G2>:^G/!GB_2?'WAK3O$>BW"W^CW\/VBWN!W%7=.T73],O+Z]MK:* M">]82SSKUEXZFKEQ;PW=O+#.!-">H-<\?AYX3GBQ_P`(SHF/^P?#_A4VG>"] M"TA[7[%HMA;"R_X]_L]N(?)%=+14-3444445#4U%0T5-4-34444445#14U%0 MU\4_ML_LW^*?C)\0_#WB/PYKGA[3ET^P^S+!K%X8)C/Y^<@CM7Q%\2_V1?B] M\.;BW&I^%)M2-]/]G@N-%_XF!GKG_A%\-_\`A-OC3X>\":UY^G?;]6_L^_'_ M`"\05^TWC+Q=HGPP\%ZAKVISS6^C:1;_`&BX,`,_[CZ5^;OQ+_X*8^._%EAY M'A'2K+P8?^?D_P#$PN*^8[C4K_XM>-//\0Z[I6G:C?\`^OUK4?\`1[?_`,E[ M>ONW]@[]G;2O!OQ#U#Q5!\1_#GBS4;>RFL/[/\/7'V@6_GD'_2/_``'_`$KF M/^"I-Q`/'G@:`P_Z0;&XQ<>G[_I7U5^P[X6G\.?LP^!([X_Z1/!/?G_MO<-/ M_P"S5[W4U%%%%%%%%%%%%%%%0T45-1114-%%OT-%%%QT%96E:+8>'K""RTNR MM]/L!P+>VA\@"M6N,^(GPN\*?%'PW<:%XHTJ#4=-GZBXKX:_:<_8(\&>#/#- M_P"*_#^O3>'X+<0;M'U`>=;`SXM_]>3D=:^;?@7\,O&/QZ^,.FV#M-XIM]*N M;=;ZYU*X\^W@L(+CI7Z;?M,?&*']G_X/WM_HMI9C6)@+'0].6#AK@YP/)[X_ MPKPO]@;]G+4O"_\`:'Q/\8"2'7]=A\FQM[KFX\B8Y^T3^\Y`-<-^W-XRU#XX M_&#PQ\&?"4$.H_8;F"XGN(`)\7$_?C_GA!D^O-9/[3'C_P")/[(VN>#O!G@2 M]/AOP;8:3!/!]FL;?[/?W'_+Q]H,] MWMQ!/;W%N+BWYM_^NX_(5].?L>Z9>?$7Q7KWC;Q?\(]+\%>(K8#^S]8L+*>Q M:Y$QG^T=>3VY]_6O4_VN/!.A>+/V?_&=QJNG6^HMI6GW&H6+W`X@G$!Q-^&3 M6-^P;>W\1&#[1_I'^D?:*KZC^R'_P`*E^*,$'Q;OQHWPUM[ M[C6<\:O_`-.]O;V_^D5Y)\3=$@^$OQIU&#PO/_H^DW]OJ&DW/_3O_P`?%O7U M]^W;XP'Q;_9=^%OC&Q@OOL%]?"Y(N(/^/<&W/_'Q^1KS7]AOXU_"#X*6_B&_ M\:P7UOXIO_\`1X-1^P^?;_9_^?>WJ;]NK]I_PI\=+'POI?@O.HPV4\]Q1./^G<5R_B']FKQ%X<_8WL/&.IPS6]U;:]_:$%M<7'_'O87`\C'V?_`*[_ M`&>L_P#96_:JG_9QT'QUY-B=1U#5O[/^P:=<'%O]H_Y>*ZCXJ_MWW/QU\$W/ MA;Q?\.=,N;7SO/@ET[5I[>>W.>O3.?QK[@_8=^).A>/_`(!Z+;Z+I_\`8RZ" M#I$^G_:/M!MR/^F_>OHFK%%%%%%%%%35#1114U%%%%>'_MC:Y;Z)^S-\199I MOL_GZ4;8M_U\?N!_Z%7R;_P2M_Y'+XB?]>&G_P#I1<5^D50T4445-14-%%%? M$'[3G[+?Q#\4_M-:!\0/A_<6]L/L]O\`:;Z>^\@P7$)QT'/,%<+^T'^Q+\5? M^%J>(/%OP\U&WUK3M=G$]Q;7%[BXSCI<+(=._ZX:CC^E>:G_@E)8?Z1CXA3G] MSB'_`(E/3_R8JI9_L%?&[P[/8'1OC&R6UOTW7]]!Y/TP35>?]FW]KJQFL?L7 MQ&M[FVTS_CR#:WC=QCG-M7IGA_6_VR?#@%OJ&A>#/%6_CS[J?[/Y/X05QNG? MM9?M+>$8;F7Q/\$9M8L(#Y1GM8+BV)]_^7BJUW_P4M\6^$H;"+Q9\&Y],N[@ MP$Y_Z8">W&?SK9\,_\%3_",NJ&W\0>$]5T73_^?JWF%_\`RQ74S?\` M!37X0K_RS\2_^"]?_C]>L>$OVL?A)XVT@7MGX_T2VA/[DPZCV_M" M_!1?B[^SZ?A_\/M0TO1+>`V_V*&$D6P@@_Y=_P!R>!TX%?&>B?\`!.SXO>"O M%>GZQ!;^"?$8T^X^T?V=J-Z?L]Q_U\#[/7H'[3W[8'PV\4^'M:^%/B>R\1F> MQN((-0U'P[;V_D07,!'_`![^?QQ.`.G;K7PE_9L%SKUO_P`(O_:NM?\`/#[3 M8?Z1/_V[_P"D5^WOP8MO$FG_``M\,P^,XK*#Q5#8P"_%A]W(X_S^-=_14%W< MP6%M/<3R>1;Q#S6F)X`[UR?PJ^+7A;XP^$H?$7A*]&H:0TIA%QY1BY'L?J*[ M.IJ***AHHJ:BBBBBBH:**FHHHHHJ&IJAHK\;_C;H>N_&O]JOQCH$VKP'61JU M_;:3;ZD?(_X]_P#CWM[>N-\*Z)\2?$GQ#\/>&O\`BH[;6=!G_X^WZ[<:AFX_[>+BOV#UO3+'7M)N+#4[*# M4;">']_;SP>?!,/IWKYC\0_\$X/@YK>H"^@MM:T9?.^TM0(M\_3']:X3Q M/_P2L\+70N#H'C'6],GQ^XM]0A@N8/RQ78_LG_L1I^SCXUO_`!3J?B9=%>,\?]L!^=?-G_!2771JOQVT_2IK+R/[(TJ`?:?/_`-?YYZ5^ M@W[.6GWVE?`KX>V6I0"VOH-!L86MQ_RP(MP/_K5Z34U%%%%%%%%0U-111114 M-%34444445#111115>O!_P!MS6[C1/V;/&%]93P6]QB"#-Q!YX_X^!VKR7_@ MF/HHTSX3>*=6_?>1?ZO]G&?^F%O7E7Q@?7/V@?V^]'T333]FT[PE?V]O_P`? M'D>1!`?M%Q./Y"OL_P#:3^,%A\%_A+K'B2XF6#4"#;:6K09\^^(_T8/^G>OV"^R^]>&?MD>)+_`,.?L_>*S8Z#>ZU:WVGW%O<-;7'D M?88/(.9L^U4?V#;86O[+G@QOW69[B_GX][F>OHFBBBBBBBBBBBBIJAHHHJ:H M:**XCXQ>`/\`A;'PO\1^$_MLNF#6+(VXN1%_J?>N8_9V^`>D_L\_#VW\-Z9/ M]ON)Y_M%]J!_Y>)_6N)_;"\5_"+PWX,TB#XMZ5_;6GW%^/L%C!!NG,_DG,V, M]0,C/TZXK\X/VMQHFH_%9?$GAJXL+KPAJVGV_P#91TS@0006_P!G-O/_`--_ M]'K[@_8<\:^$_C;^S6/A]JEE;Z@=!@_L[5=/N1S/;]8)_P`<5Y9\3/\`@G7\ M/O#=W<-!\7H/"W&?LWB`VY\BN&\+^"/V5_A-JD%]XG^(=]\3=2@'&GZ;8?\` M$O'^?^OBOM;P_P#$?P+^V'\+O&>A^';VX@_<3U^5OP[\ M):3;?''3O"?CR">YT[^UO[&O_P"SI_\`47'_`![_`.C_`/;Q6C\;O"7PO\)^ M)+BQ\">,]5\56\$_V>>XU&Q_T?\`[=[C_EXK[]_X)U^`_"GAOX::EK6A^+(? M%&IZP+<:G%`/(%@8`?\`1\>WG]\5]BVU6********+?H:FHJ&IJ****AJ:OE MK_@H#XOTOP]^SAK=E>+;SS:]/!I]G!/#D%L^=_):\0_X)Q:GHGPV^&OQ`^)/ MB;6H-'T:XOX-')N3@+]G'_W17WOX=\0Z3XNTF#5=%OX-7T^Y'[FYM9_/A/OD M5KT5-1114-%%%35#14U%0T5-14-%5+C3;.['[^W@G_Z[0@_SK%_X5UX2_P"A M3T7_`,%T'^%>5:O^Q!\%M=7$W@2RM")O/S933P9/O@UR]Q_P3B^"=Q/;SG2- M5A\B+`VZM.,?K6>W_!-#X0^7?`0:UY]Q_J;@W_,'TKRZ?_@E4;:>W_L;XH36 MMOG]_P#\2G/_`+<5REO_`,$_OCWX)@U"^\/?$.QMKFX/GSV^G:M?V_GFN>\* M?`3]J_3?[8^Q?:/M%C?_`/,1GL+BXGN/^?BWN+BNB\&_&S]JCX=:MB"?_G^>YM?/_P"_]N*T M/#__``50L6L;>'6O`%R-2_Y;'3KX?9Q],BO0]'_X*7_"G4=-MI]3AUS2+J8? MOK8V/G^0?*X@;I+"._B9\2?AO^TAXA\4ZA$X?$^H6 M^H3P:%J4N@S_`&C[/GR()_/@!^T9M\C\:VH/^"C5]XXTGQ#H-Q\/V@U^?2;B M"WGTZX^T<^1.1^XZ]OUKR;_@G%X9OT&/TKV;3?VEK[XG?L@^*?B3HEM_PCGB"PL+_% MO_Q\_9[BW!X`_P"6W05Y?_P3I^,OQ*^(]]XQ@\4:K<>)/#U@1_Q,=0GS<6]Q M_P`^]?//[7]_-??MG:@NI3V^HVUO?V$'V?\`YX0'[/F#\>M?KC114U%%0U-1 M1111111114-%3444445#1111111<=!7YY?\`!3[XI&ZF\+^!;*XA_<'^V+X0 M38([6_\`C^->T7%WJ7[,_P"P_P"=_J=?T?1,_P"DS0#[/+BX_[=Z^__``)X,L?A[X-T?PUIHQI^DV,-C;B;G('' M^%=!;5Q7A[X-^"_"GB/4/$NB>%=*T?Q!?C]_J-O8CSVKO:\I_:=/D?LX?$L_ M]0.Z'_D"N,_8*TW^SOV7O!C2P30&87$Q%QU&;B>OHFBBBIJ*AHHHHHHHHHHH MHHHHKR3Q#^T?X`\-_$BW^'M]XAA@\4SS06XTYH9]V9SQ^_Z?CGT_#=^+_A7Q M)XU^'NKZ3X0\1'P=K,\.(-2$&=IK\I/CZOQ[L_#%MH_Q.M];U#1-/OO/M]0U M"W\\"?\`Z^*S_$7P"U;P3^RIIWQ!UN""VN=6UVW^P6__`"\?9_L]Q7<_\$X+ MB:Z^*/C+08M5FT^XU;PW/;V_D0>__'Q6Q@Z_P"+/BYXYL_#NC6/ M/]HZ?;_;[B?ZYKY*_L2?6_$W]D^'H)]1\^?[/8?]/%?K7\"?V:[W]G+3M&L/ M"USIFL_VA?F?Q+J6L#_29X!!BWM[?\:_-_\`:[MO^,EOB'^__P"8M1X4_9F\ M=:E\0]&$ZIX3US3K>_O[>WGN?L'^CP6]Q_R\?:*^Q?V&?V:_'WP6^,/BJ_\ M0:(NGZ,-)GTZ"Y%S]H\__2!_\8'YU]ZT458HHHHHHHHJ:BH:*****^!_^"J. MN7,'A#P!I;6#+!<:E6] MOXZU6YU>Q73X/M'D'B`7&;?I_P#7K1^#_P`5_@G^Q]\0?$.GV_CSQ5XR$Y$! MM[6QQI\'MG_EO<5][?#SXC:%\4/!6G^)_#EP;G1[YN2UOX+?#_`,2:?"]#N;>X_UP-A!S]>*X^X_8Z^"=RLW_`!;?0AZ^3;\UR?B+]@#X,ZW.9QH4 M^G'_`$?$&FWA@'[CI_\`7KE=9_X)I_">ZT74;?2CKFBW\]OB&Y-Z9_(^D/0U MYOIW_!+_`,2:+;YTKXL'3Y_6UL+B#^5Q5?QG_P`$]OB];61'A[XH-XB\_P#U M]OJ-[<:>#^/^D5G^%?V8/VKO`.GV]OX=\6P:?;6_^HMAKOVG_P!*+>M;PC=? MMG^`_%,_FV`\96L`FN)[749X%@F]!!/U'TIT7[V*_.?6?BQJNH_"C1_AQ/I.EV MVGZ%?3W\%Q;PG[1^_P#;\:ZCP[^T]KOA+]G[6?A'9:7%_9VK37$_]K_:/W\% MOM?6/_``2D\X>$OB%"9^E_;_Z/_P!N]?+/[1WB2'QK^U5XQOHKB;3X M/[=^SFYN!CR#;_Z/_P"V]?M#11114U0U-1111111114-%%34445#114U0U-4 M-%%%?CI^TEXNLM3_`&M?$VO1I#J]C8ZY;92W;R?.-N+?C/?ZU]*_\%'?B+-K MGAWP+X`T86]W=>)+@WTL)FP0./('XF?^5>L>-M1O?V8?V,XK.\U=+7Q%I6A+ MI5OBBK%>._M2:C!9?L\_$-+BXMX>.Y@@-Q-CSIC`<"F_LBX_X9G^&OE=/[ M(M\U[)114U%<1\5/BAH?P<\$W_BSQ)--;Z/8+F9K:`S3?E7PUK7_``4U\9:W MK\]CX*^'UE=6PG_T877GW-Q/!Z^1!SFN_P#V:_V_A\8?B+;^$/%&A0>'M1OL M&QGL9]PFN!_RPF'8XK[7KR[XS_M&>"_@'IMM<>+M5-M-/_J-/MHC/<3_`$`K MROX'_M[>#/C)XIT?PI_8NJZ-X@U228"W*_:+?COYXP/R`KO?C9^UE\/?@%); MVOB'4Y9]6G^[INGK]HN/RKY*@_X*NZ@=4Q-\/[(:?_SP&K#[37U'\0?VO/"' M@+X+Z3\0)&^;6['[=I6C7!\BYO3@''Y$'\:^6M`_X*HZL^LVZZWX-L;?P_YW M[]M/FG-S!!ZU^A.BZY:ZYI=C?6-P+BVO8?M$,^/^6/!S^HJKK?C?0_"CVL&M M:U9:=<7$ODV_VZX$'G'VS70?:!Z45\U_'/\`;=\*?`'X@#PIK&E:KJ%S]@_M M"6XL!"0![@FO(_V5/VV=<^,WQMN-`\:2Z1HNG7]ENTG3X(,[;G.1#Y_<^2)S M7W17YU_"O3K?Q]_P4B\97\1L;C3K#[?/_J//_P!1]GMZ_0366O+71KYK"&&> M^^SS&"W)QYTV./\`/O7X5_$KQ[XK^(OBO4-4\6WLT^KS3XF%QQ;6]:'AW4-< MUOX3^,=*G\27O]CZ0+#4+?1KF?\`T?S_`+1]G_\`:]>Z_P#!,:V@'[0UQYU] M]GN?["G\BV_Y[_\`'O7._MM?'[Q5\4OBAX@\-W=Q?:?X4T*_\BWT:X/D9G@_ MY>+BO%/!FB>,[:_^W^%[#Q'_`&C;_P"HN=%L+C[1!_V\6]?>_P"P9X)^,L&N MW/B/QMKOB*W\+"">P@T7Q'<7`N9I_7[/<5\I_MNZ;/IO[2WQ#@G@_P"/B?[1 M;_\`;Q;V]?KMX+N1J/A+2+@#'GV-OY)\_P`^NBM^M6;:BBK%%9FH:W8:7-!! M>7L%OYW03SXS4UWJ-OHUC-^O9HK?3X(?.GN)N@'J:_,;XM_P#!1WQW<^.=7_X0:^L-/\+^ M?Y%C]HL"W`A@/O>_P!DS4?CYX[\1^'_`!3X@^(NE:WX(\@W5]H@O;>XN/)G@S;Y\BW`Z\]1 MWK[FM^AHHHHHHI//'DY[U^8/_!4?Q]_:7Q#\'^&X)H9[?2M*_M'SX)Q_Q\3W M&/\`VWKS[]H_P5XDT[X+_`2PF\-WI.G^&[@7%Q;0?:,?:+C_`$>WKR3PKX2G MN?AIXZUV?0OM-O!_9]O!J-S!_J+C[1_R[W%?I/\`\$S_``KJGA_]GNYO;V%8 M+;7-7N-0LE!Y$/$`_P#1`/XU]=4444445#4U%%%%%%0U-114-3445#114U0U M-14-%%34445#13;JUAN0/-A$WX5Y[??`CX;:E=7,E[X&\.7$\\PGF-QI4!.> M/;_IB*\^US]A?X*^)-3FU&;P@+.6>7SY[>PGFMX7;U\D''Y"N5\5_P#!.#X0 MZXUL^GVVM^'S`?NZ=?DF;V/G9KD?%O\`P2W\&ZK/Y^@>*M5T0][?4+>"_'Z@ M5YGXS_X)B>*O#5O8W_@7QC%J&LVTV1]HMQ8F(>HG&2:BMOV/OVH-.@Q!XZ:V M/_8U7-:EGJO[9O@2[N-)6RO/$44/D$SW$%O/`?7R)_\`&H=/_:W_`&H/!6HP MR>)/ASJ&K07`Q;V4_AN>%A^,.?UKK+__`(*$_%#PSI\\VL_!*XM?L_\`Q\7- MS<7$$$'U)MZU?#'_``5'\#W6DK-K_AW6],O<8-M8"&YA/_`LUV/AO_@I'$] M7CQ-<:WI+_\`3UI33C_R!FN[T?\`;4^#>NBX\GQW9+]GA\^;SH)H,#UY%=5I M_P"T'\,=1L(+BV^(/AL03P^>"VK01/--^W^'=;L=8T_M<6%P M)Q^E;U%%%35#1117F/[3$'VC]GKXECU\-ZA_Z3G_``KXX_X)7Z-.->^(6J!I MOL)M]/@Q_P`L#.//S_/]:_16L+4_"FDZG9S6\^EV4]M/#]GG@GA&#!SQ7SC\ M=_`'[.WP4$0:YXL^'&E&"XOA!;P:1I`,\]Q]!BO2/V<-0^&'B7P+%K?PQTJ MST;1=0FQ/#;V(MI_/A/2?W&._KUK\R?AIHH\:_MDZ/8W%C!<"?QG<7-QI_I] MGN/M%?LS11114U%0U-4-344444445#14U%%%%%%0T44445YE^T/\4%^#OPF\ M0^)Q87NI?8+?_CWMA7QM^Q3^S7:ZK\+];\5>,]%DU*#7+G3UTL:=<9N1#!.# MYY_[;G/_`&PI?#OG?&;_`(*0ZEJ']E03Z9X8N+B"Y+0]/(M_(@.?^OBL7]O' MQCKGQ-_:'\+_``AL9I]-L(KBW@/V@8MY[B?@3_@)\5]1_$WXX>#?V/\`P%X7 MT.]L[ZZS8SV^DVUM;_+-Y"@_OCC]R.>O^&*\6^&G_!3_`$JY;4&^(.A_V);D MYLO['S<\?]-^>*^XM$U:WUW2[&]M_P#47L(GA_+/]:T[?H:*\4_:QN-)3X"> M-_[1EL+>XQY'_3?KTK'_85UI=<_9E\&`^3_P`2^&>P/V?I M^XG(KZ#HHHHKYQ_;>\7>!_#WP0N;+QU;W]]IFK74-M%:Z1/Y-RUP"9A@YX^[ MG\:_+OQ%HFD^$K^WO_!7Q)GN?/L/M'VG[!<:?J-O_P!.]>D?L<:+KOC7]HO1 M_$8N3/#HX_P!'KJ?C]_PK M?XH:YK'CK1OBS?76MZM/]H/A[Q#I%P/L'_3O]H_Z=ZZC_@GKXMGM?CI;^$[W M[%J/AW5H+C-OJ$/GXG@_?VYM_I70?\%(OBUX6\;>*_"_AO0;_P"TZAX3;4+# M5/W'[BWG/V?@_P#@/7QG_P`>UQ_IL$_V>W_U]O\`\>]?K_\`$K]H7PG^R3\' MO!]@UM>:C.=)@M=%TW'D7%Q#;VXQY^1B#_'BORQ^+GQ8USXT^.M8\5>(!B_O MA@6W_/O;_P#/O7TBW[>>M^`_@'X&\&^&IQ=>,38YU;6-0S.++,^(/)&<-QZB MNQ_8*_:`^*'CGXQ:AH6LZ]/XIT:^LI;^]_M";/D'<`)[?@X!Z>1VSFM/_@IG MX+O]<\5>#9]%\"7^HW,T)$^LZ?8W%P>O%O\`N/:NY_9/_80TGP%%X/\`'_BB M75/^$O@A%\='9L6UC<'J!7T]\7O&X^''PJ\4>);>W^TW.DZ7/?Q0>N`37QE_ MP2W\,AHO'^O$PY4V]@`/IY_]:_06O+/%/[-?PO\`&6K7.J:SX&T2\U&]$OVB MY>R'GS9]^M>=_%G]E;P7!\"/''AGP5X:L?#]WJ%CYY%J"K3SV_[^WA\X\XR/ MUK\]/V)=1FT7]IOP//%-Y`U"8VUP#-Y&?]']*_5WQI\%?`GQ`U6WU;Q%X4T3 MQ!J,`\B"YU&P%QBH?BMX2\6>)/`>HV'@/78/"GB&?_4:CY%;_A/3K[1/#6D6 M.M:@-:UF"`03ZCY/D?:)_P"E?F9_P4?^',_ASX\'Q)Y`_L_Q)8V\YN!VN+?] MQGW/[0O[$>A^&_P"T;WPFIL#HOV[3L9:"#%OG_MN`?\BOHWX= M>$[CP1X#T#PY-?W&MW&DV,%@=0GQF<@`>?77T45\]_M??M&W_P"SEX+T[4-' MT'^W-0OKC[./M(F^S00?WI\?6OF3]AO]I+XJ?%+XUW.EZUJYOS/ M;XM])P21Y'XDP?C7CW[=FA:Y-^T9XYO9=/UO4--MA;@:A/8?Z-;_`.C_`//Q M3/&/QW3X]77P^\#ZQXPU/PWX'L;""WU;4M1`G^T7!M\W-Q<0?7]Q;_6L_P#9 MS\42_"K]IRVMO`VN?VGX=^T7$$]S]@_X_M(_X^+@B#L?]'K](?@;^U5X2_:, M.L6?AS3]6-S8V7GW']H6)M[<9_Y8"?I_DU^1VHZ)/<_$34;"?PGJMMNH'P7\5>`?A_8>./%W@Z]/AB;518&UN+B>PN;<'.#^ MA_(UW/[#^HP6_P"UQX7_`+$6]T_1YY[B`6MS/FX\@6]QC[17ZQ>(?B)X5\)6 M/GZSXFTK3("?)-Q=WT,/ZDUPGQ"_:S^%7PQ2WBUOQI8M=S]+;3\WLY_"#.*\ MUUS_`(*,_!FQ(2"_US5C_P!.FED?^C\5P'_#T`:G>_9]%^%]_K/^[J!'_MO1 M/^UQ^T3XKO;:V\+_``*N-/&//G.IPW!/Z_9ZVO$5M^VIKE]YMG<>$/#MO_S[ MZ=Y`_6?[16;=?!7]KWQE)G6?B?I>@6^.%TVX^SF'_OQ;UCWG_!,?5O$6JW5_ MXA^+^J:U\\B>U#>3Y&;>"XG@A&/HHKZ#HJ&IJ*****AJ:BBBBH:FH MHHHHHJ&BBBBBIJ********AJ:H:FJ&BBBBBHYK2&XMC#<*)X3U\[G-&=*N#!S#Y]C"V/IQ7*^(?V9?A5XRU."_P!:\`Z'?7,,/D`O8`8' MIP*\T^(G_!/[X1>-XB+#29O!MSMR)_#LQMA_WYZ5P]Q_P2O^'S?\>_C#Q9!] M#;?_`!BJ%O\`\$M/#=KY_P!C^(7B.VN3_P`O`@@JCJ?[(WQZ\#7,-]\/?C+J M&KSB::[GM]Z/BL7`A'G"UM[VP\\^W_ M`![XK/\`"?QZ_:T^&^@W7]M>`M3\5V[?ZFXUG2)_M$/U^SUKQ?MZ?&7PK:>; MXH^"5QC.?M)@O[']Q^-N:Z*W_P""I/A6UL(/[2\#:W;:B8BW/_`#PGT_S\?]^,UV&C_MW_``4U*:>W'C2&U^SCFYN+ M*>"#]179Z1^TQ\+O$FE6]_9>/-#:WFZ-/?B#^==QX=\8:)XLL3=:+JEGJ]L) M?)\ZQN!.`?^4NMPA<^AMQG^0KZW^(/Q5\*?"C2A?^+=>&G.9Z^* M_P!@W[1XD_:X\/ZK>G%R?[0U"*_7FBBBBBIJ********** MAHJ:BBBBBH:FHJ&BBBBJES:P:C;&&XA%Q!..8)Q6=<:%8G1_[*6(6^GF'R/L M\'[C\J^)_P!FDZOJZ?I]QYX^TW$$_P!G_<7'^CFN-^&GAV'X MH_\`!1GQS<>);;^TO[)N+^XM[:Y_?VX$!^SV_P"0KK?V[_B+;&Y7PCXE^'.H MZCX3VV\T'C"";'V&XG/6#(\G/&.37F_A[]@#3_B=\)_"_BOX?>,QJ-QJN//_ M`+8@\B#[.>+CR!]:_2/PEHP\->&M)TN+]]]ALH+?GV&/Z5O45X1^U['H-Y^S M[XP;6-)DULPZ?<36:_8IK@VUP+>?R)^/]1@G'G^Y]JYW_@GO<1']F?0/)QYO MVV^\[Z_:#G^E?3-%35#17,_$+X:^'/BAX4N?#GB?2X=2T>?@VS#@U\T:I_P3 M2^%-U>2SQWWBJP@(YAM+X`?EY!KWOP)\#_`OPQ\+3^'O#_ANQL-.GA\F\4VP M/VWY2,S\#SR!?@+XEU+7?#AOKB_OH!;@ZA<^?Y$`YQ#QQV MKLO%?P(^'WCW4_[0\1>"M`UF]`_X^+FQ7SOSQFG:C\#?`NI_#L^!9?"MA_PB MO_0'MX/)M_R%?-FI?\$M/AM<#,'B/Q78>PGMY_YV]>G?`G]C+P#\`]2.JZ-! M>ZMX@$0MQJ.K7&XPC_IB,,W^SVQ@^S^1`?3'O7SW\?/^":E[80:=/\` M"D7&LY_X_K;6KV#_`,"(..#[5\^?$+]F+XG?`VSL/$7B'PI!_9`GM[C:9X+^ M#S_^>%Q[>]=E\!/'WBG3OB?I]Q\&/A/;Z=?3?N=7-U!<7XG\_G/VC_EWM^*^ ML/VF+7]I+3?BXGB'X<_Z3X,T^R"KIZ7,!@N&ZS^?"W)/H:?^RC^T%\:_C'XQ MNM-\7>#;&UT"QEN+>]U@P7%C<6]P.D`4_A^E?1_Q7^%6E?&#X>:SX/U>>>WT M_55VS2VQQ-_*N>^`/[./AS]G#PU?Z3X?N+V_@OY_M$\^H3[CFO6**SM1M;>Y ML9X)X/M%O/\`Z^OQ6U'[!\$_VEKCSX)[;1O#7BS_`(]K;_GWM[C_`.1Z_:'3 M[F#4K>WG@_TBWN/](JS]FHKX2_X*D>$+=="\#>+/-F6YAGGT@P#O!_Q\'_TG MJM_P2Q\1:I=Z+XZT&XGEN=&L+BVN;:V;I`9S<&?]<5][58MJ*/M7M7P?_P`% M&;[Q5XLN/"_@[PM>QW&CW\)GU73X[F"`^?\`:+86_GYY`/G#^=>#?L\W?C+] MGG6+F:]^(_@_P;X?FGW:[;?;K#4-0N/I!!]HGS7SY<:WJUM;ZCI,/C/[3IVK M?\?_`._N/L]Q_P!?%>J:/XW_`&>_">E6^E3?#75/B)<00?O_`!#J&K7&D>?< M?]>\%>U_"G]H:Q^'_P!GU;X;?LL3V_VB#[/_`&C;3SW%Q/\`]O'V>NH^'_Q& M_:"T_%A\/_V=-"\%Z?<7'VB:W^P_V?;SG_IO6_+\/?VR?$T_VZ3Q;X6T>><3 M&W($!N+$'I`#]GYK(O\`]B_]H+XC:$;?QG\7@,GR#IPGGGM[B#WK8T7_`()6 M>%K;3(/[4\<:W<7F/W[:=#!;P$_3']:[#P7_`,$U?A-X;O;BYU4:KXJS%M6V MU*XQY/\`WXQ7I5M^Q=\%-,7$7P\TMSN\[,WG3\_B:Z+2?V9_A3I%K#!;?#?P MNN/^?G2+>;^8KJ?#'P]\,^`Q/_PC7AO3/#OGG,_]EV4-OYY_#'ZUU%%%%?C] M_P`%#/$5QXA_::U^VOHH8;?2+>WTZ!H.IM_L_P!H_P#;BM#X^_$7X?>//#7@ M[0O%'AS5O#OQ*TG2K""_\0V%C;W-O/\`Z/\`\>_D?:/]('^HKT>'6OV5OB=\ M-/!D/B75[W0/$NEV&GZ/'==\::58:N9?)FMI;D?N#CCS^T.?>NZTKQ] MX;UF"!M+U_2]1$W^J%M>PMGZ`&NAHHKA+7Q)XSD^*5[I5QX6MX/`ZVHG@U\7 MX\^:X[P^1C/K7H-%%%0T5-114-35#111114U0T445-4-%%`?#6L7GVW4 MM!TNZU*4?\?%U8PFX/\`P(CFN7UW]F7X4^(Y_/U7X?\`AZ\N/[S6`_I7+:W^ MQ5\&=:7W_!+[X474DQ@U;Q38D]TN+?'_`*3U MCZ?_`,$O_#6EC-G\0?%6G#_IT$$/\A7SQ^V-^RC/\!]`TC7K'Q7?>(M%OK@: M<(-9YGBG(G.0>XY_2OK#_@FUX;M]$_9Q_M:&';/J^JW$]Q]8,6X_])Z]'^/_ M`.S/X;_:,M=`AU_4-2L+?2+B>XA_L]L";SQSDU\I?$?_`();W-WJHF\#^*H$ MLO(P;7Q!DSVY]C`!FN8\0?\`!+;QWITT)T7Q'X>U`3']_P#:?/@\D>HQ7TEX MK^&0^`/[#_C#PE#J$NLM9:%<^=<7)SF>8<_2#)_(?E\5_L!PS3?M2>%3%#-. M((;\3F`X\@F"X`%Q7[`T445-111111111111114-OT-344445#111111<=!5 M>C[5[5\)_MU_M0_$#X8>+/\`A#?"_P#Q)M.GL(+@ZS;PYN.O(MZ\J_9?_;:\ M96NJVO@KQ+?_`-OVVJB=;?6-0G_T^PF$'3SND_[_`(JC_P`$Z9]5UW]H;6?% M>JWWVG[/H4]S?ZCJ,_\`SW^SFM[XI?MG_$?XP^.-8\$?#;0[.ZTKS[BW@M_L M4.H3ZM;P=;C!/'2N]_9._;$URT\=Z!\*?&WA2Q\.9_XE]C]@LO[/%OW\B$?9ZLT44457HK\AO^"A MNAW&F_M-^*)[B"&W@O["WU"#R.MQ;_9_L_\`[;U^KWA.X^T>&]'_`-'^RYL; M<_9_^>/'^?RIMSXHTG2]7T_2+W4[.VU>^'[BPN)QY\_]?TK5KXN_X*EVL_\` MPJ7P=_]M[BOC?]F;]J'5OV;[_Q#_9>@P>([?5K>W\^WN9_L_V?[/\` M:/\`Y(KZ,_X;Y^,VN:L-"T7X40V^HS_9_(M[B"XG\BJVF>(_VTO'SW6NZ5C3 MK*>:>V-O;0:?;F">WN#;SY^T?]>Y_6NJL/@+^UMXUTD7^M_%&#P](-;\0:WJ!_P!=Q7/_"'0:A-CBWU">>X@'OY!.*]E;X8^$C-!/\`$GHHG@_ MU)_L^`$?2NBL+2WTZQ@MX0(+>$8A&>U/HJQ1111111117X[_`+9=M_:7[97B MFW@M_M%Q/?Z?;_9KC_EO_H]O7Z?>*?V>?ACXVGANM?\``^AZIT#3O">A6&BZ7; M+:V%E"(((`<>5$.`/TK8J&IJ*AJ:H:***FHHHHHHJ&IJAHHHKQG]J;P-XO\` MB3\$?$'AWP=?K9Z]>B(PC[1Y'GC/[Z'/;*@G\?:ORCM_"7A3X;GQ38?$^"]N M/$-O!]GTK1?#U]_J)_\`GXN+C_GA7L/_``3+M=3/[0=Q/I\X_LR#2IOMV8,< MY&/UQ75?MA?L5Z3\.(?%/Q(L?%<.G:-<3_:1H]Q;_OS//L9]%T&PL[N^GU6YMH(8)K^?`, MY`YF^NO$>F?'8 MZ#X0\5ZWHUMH=C!!";+6_BAXIUV\`.HZ#8VWV'/I<&XS^E?IM1114U% M%%%%%%%%%%%%0T5-1111114-%35#115?_EWKXG_;L^(7AW0_$?AC0_&_PSG\ M5>'RIG768+R:":!O^7B&`#!/[CW%?&WQE$?\);XEN/$OP]\-:K_`,*LM[#_ M`$"Y^P?ZBWM_^/C[1_V\?:*^@O\`@FSX+-6_8H^-%S?>*/"EQJ&LV%A<6\%O<3_`&?_`+>/^O>O5_V:?#WC M+]HO]J'3OB?K.A7T'A];Z:__`+1MX?(MP((,6T$'_DO^1K]2J**\L_:6U/3] M,^`WCI=1U"QTTS:#?00SW\V!YQMVQ7E'_!..Y^T?LWVQ_P">&L7P_6OJJBBI MJAHHHHJ:H:**/^6U%%%%%%%%%%)-`&'%0?9?>ORF_P""ES7I_:'87MF(8!H= MO;65P.LT'^D$`_\`;)-(\1 MW^CV5UK.DB;[#J4\'[ZRSUQ73U\3_P#!0[P9KC_!W4=6GUW[1H,6NV%U#HWV M*&`6/[@P']^?]?RW3MG':O*O^"6MO,/B+XYSY'VU>"?$G]M?X4_"_5#I5[XA_M;489X+>>UT>'[0;Y@U7Q7;SC3R/M'[C[1_\CV] M?LE14U%%%%0U-4-%%344444445#114U0T5\]_MM_$+Q!\-?@'J^N>&+Y=/U$ M7$$$M^PYMX)6P3^>*_';[3!]O\^]@_M']_\`:)[?S_\`7U^E_P"PY^TOH?CS M7[OX?Z+\.K+P';65B+^!=(/G@=OW^._-<+_P5&^)NJC4?#_@"&`0:0;?^V)K MG`!FF_TBW`KZ6_8X^$_AKX;_``5\/W_A^WO8+_Q+8VVH7\^HS9N+B?R!R:^@ MJ*FHHHHHHHJ&IJAJ:BBH:**FHHJ&BBBBBIJ****AHN.@K\_?^"KG_'O\-/\` MGW_XF'_MO7U-^RV+Z']G/X>#4OL_VL:);9\GICCR?TKRG]I?XY?&WX=>.H;' MX>_#YO$?AV*P^T'4/[)N;_SY_P#MWZ5\\^(/^"C/Q=T(6^D:GX,TS1M9L9L7 MYU*RN8#./^N'6OFW_A)+[XV?'"VU;6M)_M'4->U:W^WZ=IW_`"WK[_\`^"E' MB6#PW\!;'08)(`-6U6V@\GU@@_?X_0?G3?\`@F/H5KIOP2UO4CDW-]KLV?I# M!`!_*OLVBBBIJ*********AJ:BBBBBBH:*FJ&BIJ*AHHHJO7SM\;OBU\$O%M M[K'PB\=^);.&YG7]_:W!GM_)_P"WCIFOE_1?#'PJ^'?[,7QGU_P-XKO/&)U2 M&WTBX%_#]A\@^<1;C.!Z]:K_``;\?ZM^SW^QU!\1O"7AS2=0U?5_$<\&JZA? MPD-Y'/D=.W2N8\1?M\_$+QKI-]]L\&^#Y@L%Q;_;Q83W%Q8C'^O_`./C^7I7 MJG[`7[5/B7Q+KL'PN\3_`/$ZMS!<#2=1$&/L_D?\N]Q7Z"6U6**\0_:U_P"$ MD_X41XI_X1[^RL?V?/\`VI_;'GY_L_R&\_R,?\ML=,_SKS;_`()F>=_PSWJ7 M3R/[=G\CZ?9[>OKBBBIJAHJ:H:FJ&BBBBBBBBC_EC161XDUJW\,Z%?ZM>&46 M-E!-/-Y74@<_GUKRK]EOX^2?M&>!];\1W&BC1H;?59K"&W,PG)A^SV\X8D=2 M?/Q^%>V45R/Q(^(^A?"CPA?^)?$U]_9VC6'^ON/*,O\`*O!_"7_!1'X.>(%N M5O=8O?"UQ"?O:U8G,WT\G-?#7[<_Q?\`"OQH^)^G:YX2U@ZYH_\`94,&3!/; M_OR2?^6X'^?7K7ZB_`W4H-<^#?@6^LY_M%M/HEKS_P!L!7?5F:CJ5AH^G3W- M[<0:?:P#_CXGQ`(17S!_P4?33]0_9L\^6^%M.KBQT^XM[F"?[/<>1]HN//^SUSGB']H3XY>"]2U#P MOK7C+Q#I^IP7OGSQ7$_^DP3=<9]*^KOV%OVP]=\6Z[;_``_\=WLVMZC?L7L_@_2 MH+>VM=/N?]1]HGYX_+/_`&WK]"*******R_%/_(#U+_KRN/Y5^4G_!-_PY!X MC_:5TZ<3_9_[(TFXU#_KX_Y=_P#VXK];Z*FHHHJ&IJAHHHJ:BBBBBH:**FJ& MBIJAJK<6L%U!Y,T,,]OZ&N!\5?`3X:^-)UN-;\#>'M1N(83`+BXT^`^2/Z5I M?#WX;>&OAOI<]CX9T'2_#]L3^^&G6P@$I]:Y+XM_LP>!?C3XJT77?%VGRZA/ MI0,'V?S_`-Q<0]<3COW[UZQ;006]L((?W$$(\@"K=%%><^&-/^(]K\3?$]YK MNKZ7=>!YE!TJP@@(O8..YZ&O3*AJ:BBBBH:*FHJ&BIJAHJ:BH:FJ&BBIJ*AJ M:H:***_-'_@I^DTWQ?\`!L`G!)TG,,`&/)/VCK7VQX-\$WGPG\&^#O#GAUM, M_P"$?T2TFMK^:^,QN,X_Y8?6;&<]L8YQ7R'^SU^W/XW^('QR72_$\^ECPA-! M!7SS$?BMX,U']MO6?!6A?#/P?I_P!@^T6]EXCT^W']H'R(.G3\*\__ M`."I&IS?$[X'TD>1]@M]*N+B+ZW$X_I;BOIW]@WPK!X9_9H\+'$['5OM&H3 M"XZDSSFOI&WZ&BBBIJ*******Y'Q]XBF\'^%+_6[;2Y=8>RC,\MC;WTK7\-Z];^)-#LM4LO--O>0B>$3Q&)L'ID=JUZ*******AHJ:BH M:******KU^&OB+X7>)=-\2^(?[:TF^\.?8/M%Q/>#_1YQ]IN,_GBOC_]H3]AKQ7\,O$T$_@+3]=\5>'KZ#`^SV_VBXL? M^F$_MS7VK^QY^S78?!WXZ@L(N+B')_U'VCKQ7T9;58^ MSCUHKR+]J/3]7U7X&^,XM-U7^Q7@TJYFN)OL?V@36P@;SH<>X_I7DW_!-33Q M;?L^7LW.9M?N#_K<_P`,-?6U%%3445#14U%%%0T4444445XY^U1X!\2?$WX* M:_X9\'K#/J^HB&`B>\,`\G.3D_G]:=^RY$G^!OP?T;PW-WMM2\^"Y@^U?ZF4Q'./;_ZU?E!K7[-_P`4 M=-U;4;"?X>^(_M%A_K_L]A<7%O\`^!'_`"\5ROB+P!XE$06\_B'PUKFBV]Q M_J/[1L+BW^T5^N?[$OB5?$?[,?@8>1/;M86(T\BXAYF\CC->\UYQ\?O@KI7Q M_P#A]_PBFJ7][IUJ9X;C[1I_!R#_`"KSS]H+X7V&A?LCZ]X3TO15U>WT/0\6 M%K)Q7UW5BJ]6***^'_`-OO]EWQ'\6=6TCQIX-M%U*_L+,Z;>V(XG\C M=YWG6Y]<\5W'A7X5Z_\`M)?LU6'A[XT0WVC^(8;\S+/:MY%P2`?(FE'K^^.0 M/3ZUS>E?\$Q_A?;W<5Q]B MUV^T'3]"L8-(6PME\U5MH/NB`DGR#VR/RKVWX1_";0O@MX-T[PKXA4444445Y;^TGJ7]C?`#XA7'^D'[/H=T?^)?/Y%Q_J#T/; M_"ORN_99\.?%RX\2:QKWPE*VU_I-D!?;O^7B#/%O^=N*^E=*_:5_:N\$1WU[ MX@^&]SKEJ!P;K1#!Y'U,!Y_&F:7_`,%._$F@ZH;3Q=\.8;:YA_X^;:VO9K>X MA_[83C-=GX2_X*B^$K[5#;Z_X4U71=/\G=]IMYA?\_ABO2K;]O\`^"ES#;&? MQ1>6_G]?M&D7(\C_`,@5ZY;_`!S^'5U#YT'CSPW<+Z_VK!_C76VVIV5X/W-Y M!-_UQG!_D:MT4445-1111114-345#1117E_[0_B'^P_A-X@,/C*Q\":BUOBR MUJ_G`$$_;/\`GO7P=^R5\5?CGX_^,4&EZ5XYOO$GA;3[[S];OK^`3P-!V49( MGR>@K]'/B'X]TCX7^$]7\3>(+P6VCZ?`9YR>PK\_]8_X*IZO:ZW]MLO`%G!H M_P#SQN;\?:9Z]_\`VG_VV]"^`<,&D6%C#K_BZX@BG.F^=B"R@)^].1T[UY_^ MS%^V5\5?C]\0/[-_X0;29_"T7D+?:C83SP?8_G% MS-"UM!;PG!)F!]_PYKT7X:_M/_#[XP^,=0\->$-;_M/4K&#SV*Q'R,?6O6J* MFHJ&IJ*AKR/XZ?'"X^#.G:>;/P/XD\::AJ`F\FWT.Q,XAP,YFYX%=QX#UJ]\ M2^#=&U75=)F\/:A?6<,]QITV,VS$WTN MXGFU&WP)[?$)_?CW`'Z5^+OPB\?V'@'7M9OKV"?]_H6H:?!]F@M[C_2)[?\` MT?\`X^*]+_82^,?A/X)_%/Q#KOBZ_P#[-TZ?0OL\'[BXN/\`2/M%O6A^Q=K> MK>)?VR-'U6`^?&X=8^)WAG3_&7POAU7^SK^'^S_L_D7`Z>1/_1]?+7B+6_'?@F#1O#5[?ZKHOV"#[1!I MUM/<6_\`Q\?Z16CIVB>)?$GPT\5>.Y_$M]_9V@W]OI_V:XO[BX\^XN*_4C]A MWQEJOC3]FWPGJ>MW\VI:DQN+8W%QU_<3F#^E?05%%>4_M+>$M*\4_`OQO!JM MK!<_8M+N=1@:Y'$4\,#%9A]*\:_X)H?\D*U?_5?\AVXZ?Z__`(][?K7UW14U M%%%0U-4-34445#114U0T45XI\6?VHO#?PA^(7A;P=J>GW]_J.O8^S?V?!YWE M?OQ!D_B37M=%%%?.GQ%^+%A\\%?$_3_@1X0U?X@^([+Q"=(UBXTZ'^S[TWV8)_P#GXN.\_O7U M/_P3>UJ?4OV;+>";_2#8:K<6T!\_K7UC17G?QWL+W4O@QX[MM+/^E3Z#?P0? MC;__`%J_-K]@73-3USXH>*=)TC5)M'O[_P`*7UO;W$`S]G.;;'ZXKQVYMOBQ MHEQXRTF>P\1_:+^#_BI;>Y@N+CS_`/KX_P#)>OT/_P"":.HWD_P#O[._$HM[ M#7I[:PA,./W'V>WG`_\`'C7UY5BBBBBBBBBBBBIJAHHHKY\_;J\20>&?V7_& M(FY_M$06$1_VI[A17S__`,$I+>=?^%E9_P"/<_V>!_Y,5^@=5/[.MYIO/\B' M[3C_`%YAYKF_%/PJ\&>-T,/B#PGHNM"7K_:6GP3Y_,5YEKO[$7P;UK3]2@?P M=;6[7TQG%Q8?N)X#_P!,2.ENK MJW@+XG:OX>N2OD^?]G`N?^_\S<_L;?&31=/OSHO[06NW6H^3B"VG%Q#;R MGWQ<5GPZ+^VAX,&G3G5]"\9V\0P-/!MP3_UW/V>W_2G:C\6_VP[;_FF^A?N8 M//\`]'AZGT_X^*YRW_;M^-GA.^MAXO\`@Q/]FG,\`^SZ??:?YUP.PXN*V=,_ MX*?:?:7US;>)_A[JFB)!_!;7PGG_`/)C[/7H&C?\%(_@W/9V$]YJ&JV-W/#N MFMC83S>1]2!_2O0_!?[77PJ\>Z=<7EAXSL+4P3>1Y.I?Z!.#])\9KTJW^(?A M:Y'[GQ/I-Q]+Z'_&N@J:BBBBBBBH:*^0_P!HW]A[4/V@OB=!XDO/']Q;Z,L& M!IMQ8BX-E[V]8WA3_@FY!X4AU>"P^*_BG3[348/L\\.G,+<7(QUGQUKT/Q%^ MRC/J7[,ES\)H?%M[=:C/.+G_`(2#6?\`2&FG^T?:,D5XC\.?^":P\*:_::YX M@\8G48=)N;>_L[33[$9D,$V[#>?GV_.N!_:2_9[^/?Q%^)>LZL?#=CXJT7SC M#I.I6]O86\XMY_\`CWR?]?\`Z/7>?`W]D3XA?!_X&_$V>"*QMOB-KNE?V?I0 MMKW/DP8_??\`;;KSZ@5YEJ/_``3B^(/_``J:X\23W_VCQUGS_P#A'C^__A_:;F]:XEU[^SP9Q8PXS;BE6_P!E MKQW??"KXO&7P)X,USQ5_:$']GSV^H@07-O!]H_TBY_<5^@7P?_:`D^-7C+Q" M/#VA-=?#>P`MX/%0G\GS]0',\'V8_OA_KAR1VKWVBH:FHHHJ&BBBBIJ*AJ:B MH:FJ&BBIJAHJ:H:**_+?Q]^W)\58?'_CQ]-U6"PT.RN+FWLM$U.Q@@N(,_N+ MV^.7Q'T^\T_6HOB!XBNM6N)O/*F^GP1]HZ5W?AR_URX_ M;>T:75%%MK__``F=N+Y;8<>?]H_TBOUZUFQL-4TFZM]2A@GTZ>$PSP7',$T) M_P#K&OSX\0>(OV)AK$]O_P`([>M-;S8/]GVU_P"03Z_Y%>*>*/!7[,!U6_\` M['^)'B_3(#-^YMAH?VFVMS^5?8G[&_[+7@'P!J$'Q'\)^,Y_&=O>V4UO87!@ M\BW@R?WY_/C\*^;/^"AFH7OB']IO3]!$$.+&QL+""Y/_`$\$G_2*_4/1-.&F M:18V7DQ0^1!Y(6W'[@?A^%:M%%%%3444444444444445#4U%%%0T4444457K MP?\`;%^-.J_`WX,7.NZ-/96^OW%[!;6*W/W3G_\`5^M?%'Q.^*/PX_:&T_X; M?\)/JVM^!+K_`$BWO=-\/:3Y^G07'VC_`(^*U_VR/`,/B3XO_!WX;^&D@TOP M_?Z5!;Z3:B#R;>`3W.)S^(P<5W?QPU7]F_X_?%73_#FI^*;[3M3L+#^Q[?7] M/.-/_P"O;/3->67'_!/_`.,NBS:UH6B7^EW'A:^GM[DS_;O(@OO(_P"/?BOT M6^"/PQM?@Y\,O#W@ZWG6Y-A;@/<$\SS\^.K`1?Z M_0K^$?C`<5X!_P`$SO(_X9XU#_L/7'_I/;U];T445-14-%%35#4U%%0T5-4- M%%?!=AXFTGQ]_P`%-K9O(FMO[!MY]/A/DX$\\%O<9Y_[>+BOO2BBL?Q!ILVL MZ+?V%I>'3[FX@F@ANH!S`>F?K7XJS_L\_%#PYJOBF&W\-ZX;C0OM%O?7-M!< M?Z1;_P#'O_H__/Q70ZCX3\2>$OV1,:IH6JZ+I\_C.WN<7$'V?S_^)?\`\^]? M;'_!,W18+7]GJ>]_Y>-0UVX\^OL'_EWKQKX#>*_B?XK3Q-#\2/"=MX3N+'52 MMA]GF^T"XM^WU_Z[=\^U)\>/BYX7T7X9?$BW_MW3;B_TK29OMMA!=YN+$8S/[8].?=W[%W[7H^/<%SX<\0V]OI MWC*Q'G_9]/AQ;W$':<5]5U8HHHHHHHHHH_Y;4444445\^U^%)O;$%Q-_P"RUJ_\$V/#JZ)^SHMX;<6YU?5;FZ%Q_P`_&"+?_P!H M5]94444444445R>K_##P=XCOS>ZIX4T35M0D&)I]0T^">8CW)%9>H?`+X8ZG M_P`?OP^\+7/UTBW']*\D\3_\$]?@WXFNOM$&DWNCM_U![TH/US7G?BG_`()8 M>`=0MV;0?$.MZ),!Q]N,-U"?PP*R=0_X)@7%O8W']B_%35Q<>3B`W,`X_6JE ME^S7^U=X'D%GH'Q4.KV4W)EN]6F9D_[_`$!_2D\/Z/\`MJ:;937QU2WN@1Q8 M:A)8&?\`='UQCFMRS^+'[8=O>0P7/PPTN_6$?Z0?*@7S_P`?M/%5S_P4:\9: M*DZ>(?@EJUM-;_\`'P/M$\/D_7-N:O>%O^"HWA6YU*WMO$/@_5?#]C.,?:HI MA()H8M+\:>'=1FF[6^J0,3^1YKK+?6;&]'[F\@G/_3& M8'^M7*****S[:V^S3W%:'V<>M5ZG\@>3CO1]FA]!26MK#;`^5"(?PJQ114-% M35#11111;]#4U%%0U-1114-%345#111<=!17Y[?&>?\`9.^)GC_6=!OYKO0/ M%4VJ"VFU_28F^S_:?=^8#^6:T_#/[./[-^A_M0GPH;^\U;Q!]E^TP^%]1;[1 MIZG\1C_MA^E?/G@);?Q9_P`%`[:;2@/$-M/XSN-0MY[:?@6_VBXN/M%?<_[= MOBZ;PC^S'XODL[X:?&=(AMI[=C-DP3W!G+`? M4"O)OVR;JWNOVWQ"+G^SQ#/H\$]U_P`\/^/>OU?HHHHHJ:BBBBBBBBBBBBBH M:FHHHJ&BBBBBBBJ]S7#_`!7^#G@_XT:/;:5XNTN#6;6VG\^$&4Q&'WXK\O\` MXE_LF_$'X3_$NW^P^$Y_$6CSW_VBQN-&@N+BW%O]H_Y>/^?>O4?C'8WGBW_@ MI/H]F8A,OA=XTT?6-)^,FK0:/I4I(TMK8@FW_`.?]A#>Y@(S_`"KYS_X)C?\`)O%S_P!AVX_] M)[>OK>BBIJ***AJ:BBBBBBH:***HZQJEGHEAX^T7'\K>OO2BBJ>I7$UM8W!MX?/N!# MF*W'>OS3\$O'7AN;28/`GC."?[/8W,'G_N3]H'VB#_`*^.*\#\ M<_M7>./BM\)[?P-XMF@UCR+T7UOK-Q_KP!G'V@?B:^Z/^"9&LKJ/P2UG2IYQ M.^E:[./(\G!A\[D#]37V)7*^/?AQH?Q-T:WTOQ%9#4;""Y@OUA\TQ?Z1">.G M;I7"_&'X8^'&^''Q5U&Q\/:7!K^O>&[];Z_\@>?.PMR(///4_P#UJ_-']ASQ M&NB_M-^#=WG?9;[[18?N.D_GV^?&?]@&"?5O^$U^$5]-X-\76\L+06%I M.8-/_P"F^`/]1D9Z>GO2_L6_LD>,?@7\1-8\5>*+BRMBVG_V?!IVGSF?SQQG MZ?Z@5]NT4457_P"7BBC[/SY]6*****FHJ&BBBO@#_@JAXU$.F>!?!\*P!IYK MC5Y\CD>1^X@Y_P"WB?\`*O=_V"K@7/[+'@LP_P!VY_\`2F>OHBBIJ**AHHJ: MH:FHJ&IJ****AKE/%OPM\&_$"2WE\2^%=&\0M;G,)U.PAN/(^FX&N&\1?LA_ M![Q)9>5;N\.7AS_P!12X']:XZ^ M_P""6_PGNG!BU;Q3;GS=QVW%O_\`(]88_P""8GAS0[`ZAX1\;^*M"\3VX_T# M4FFB!@/TA45-IW[%7QETR"WM[']HS7+>"`>1C%Q_\D5B:A$?VR?!-B;?1/B M';^(K:!?*@/GV_GX]X./7 M$%QFH=,_X*)?$F/3+>67X)W.H_\`/>Z@:XA@'XFW-;,'_!4'2M.$$'B'X<:Y MIVI'_76]O,/EK8L/^"G_`,/KF^MX)?#GB2U@_P"6]R88"+?\,UZGIW[;_P`% M-<@,Y\=6]G_TQOX9X#^HKNO!OQ]^'WC[3OMNB>*M+NK?SO(!^T>3S^-=CI_B M;2M4%R++4K.Z^SR^1/Y$X_&"X^S3D<3XK\D?AK^S!KOBH?%/X?7'AJXN?%.DP"?2?$0M MB=/GN(#C[/\`:)_^?BE^%?[/7Q!M?C3J%_XVT+5-._X1/2;C6)[FY@^T6]Q] MGM_]'M_M'_@/_P"`]2_\$V])%[^TGITQGA_XE^AWUU^_Z\$0?^UZ^W_VL-#\ M#?%C1M-^%OB#QO9>%-=O[V#4+"#(\^:X_?X`'Y_E7R9J'_!+7X@M,(8/$OAR MYS;SG[1_I&?M!KR/QU^R=\9?AA<0:#-X;U76M/G_`.)@?^$=M[B_T_\`_B*^ MY?\`@GY^SYKOP:\#ZSJOB%9].U#Q*+?_`(D]U%B>PA@,^!]3]H_SFOESX5:W MJOQZ_;UT[7-3L;<`:M///;D_ZBW@M^*_6"BBBBBBIJ***************AJ: MBH:*****KUX'^V1\:]<^!OPH;4M`C@.L7UZ+""ZNND&8#^__``Q^M>.W/[5? MCWX._LU>!?%GB[1K#Q%K6NS_`&:WN3?>1YUM]G$]O//GI.<=!7UA\,_&$OQ` M^&_A[Q&8/LMSJ^EV]^+?_GCYXS_GZ5\7>*6E$_\%+=/U#^Q;RXM-4,%N64\ M3>=8?9S/^&,&OO\`HJQ114UO[D\5\S?\$Q3]H^ M`&H_O_\`F.W'^C_]N]O7V!114U%0T5-11111114-%%%?[1?:B(/(^ MT3^N*]?HHHKX]_;!_8?_`.%^ZZOBOP[JL.C>*(+?[//;W,&;>^^M?"WQ;_8^ M^('P-\&'Q'XG_LNVT\7HL(+?3[TSW&#G_"OLC_@EKI\UM\,/&%X81Y-SKI-O M/Z@6X_Q'YU]MUR'Q-^*7ASX0^%I_$?BB^_L[2()A`9_),Q'Y?C5?4=0L?BG\ M);G4-`F&H6.O:'.+''[G[0)X./\`/:OR$_9?N)]&_:5^&HN!]GG@UVWMK@5^ MV5M115BBJ_VKVH^S?Z15BN*UGXQ^#/#GB[3O"NJ>)=+T_P`0WP_T?39[@>>U M=K7RM/\`\%'_`(,V\]Q`U_KD[0=0-*.*]!^"G[57@/X]:MJ&D^&+B^%_8PBX MGM]1L3`1`3C^M>T45-4-%%OT-%%QT%?EU_P5"UN>X^-/A[2?(_T>PT'[1_X$ M7%Q_\CU]??L+:)+X<_9?\$0W;0F2Y@GO0OI#-.6'\Z^AZ************FHH MHHHHHHHHJ&BBC[./6N)\:_"3P9\0"/\`A*/"^E^(;@0>1Y^H6`N./3D5RU_^ MR7\(=0B@$_PY\.OY$/D09MQP/2N.U3]@_P"#/B*"#S_"@TV>W'D9TZ;[/YU< M7XJ_X)D_#?7)?M&EZGKNAM_=AN/M'_H_-N/L]9^M?$?]LOX4K!-K6DS^(KM^'KG_EE!"/MY;\L5W=K^W_\`!*Z^ M_P"+KBW_`.N^E7(_]H5Z#X#_`&C_`(<>/K9)]&\8:7<-CFWFN1#<#_M@>:[6 MS\8Z)=_ZK6=-F_ZX7`_H:V+:ZANH/.AF$T)[CFI********FHHHJ&BBBBBBB MN6\?Z1JGB+P7K&EZ%J?]@ZQ=64T%EJ*\FWG/0_F*^(M&_9=_:?\`A/\`;F\& M?$:RN(;C_2)K8WN3-WXKS7Q%\"?VB/AAX,^)&N>(O%'[VPN+K5!; MZK]H-]<3\9'YX_&MO_@E]X3GU+XE^,?$A@@%O8Z5_9P]_/N/_N>LO]NWX7^( M/@]\<+#XI:'?2FVU6^%_#>_9_M']GW\'3CTKZE^#?[=WPY\;>$+"Y\3:]8^$ MO$!7%]87+G@_]=NE>5_M`?\`!1FST?&D?"IX=;OA*%FU>Y@W0BBBBBBIJ**********AJ:BBH:**FHHJ&BBOS%_:\^,_C MGXL_'&Z$^`H-<,/@^:?R(-&$WVF>>W_`-?/D=1R8/Q->^?LE?MA:=\4=*@\ M)^++^'1_'%CF"$7+8^W\#$PX_P!>>)M)\6_L8_`V73+G)L)Q83C'2>"W_TC^1K[L_9F_P"3>?AI_P`N M_P#Q(=/_`/2>O5*L445-117FOQP\&ZAXY^&FK:5IFNZMX7N##YPN]&Q]H.`? MW0^M?,G_``2[M1!\-O%\YX\_5L^1YQX_<#_ECV_K^%?;]%3445#114U%0T5- M4-%%%%%%%%QT%%QT%%OT-%5Z^4_^"D6DV\O[--W.,$V&L6-S#[$GR?ZUYI_P M2SU2Q3POXZTK^TP^HB_M[@:*2!]G@[3\^O3_`+85][_\>U9/B;PCH7C;1SI6 MO:39:S8'G[/?VXG@/YUHV6FV^GV\%O#;PP6]N`(881Q%7XU?&/7;WP9^V!XH MUBV(@O['Q7/<@BX\C(^T5^R-AE?CU_PG^K7/CS3O%FMW\^M:S!?V^H3W M-S/_`*1X'_`#[FWKSS]@3XC0?"?X_7&A>(-)GM]2UW_B3B>Y@Q M/8W'VC_CV-?K!1111111<=!7Y+_\%#=;/C;]IRYTG38)KG4;"QL-'X@_Y;Y^ MT#]+BOO;Q;\,?&%K\`=%$_#;Q&/`VMZ18VUO!<3C[00(8,"#Z%[FYGESYUQI-N9C_P`"Q6?<_LL_"&?3YK=_AIX5$)[6ND00_P!*\FUK M_@G1\'=1L888+76M.`N)K@36]^2Q!/\`J?WV>/3Z'FL;4?\`@EK\+KD?Z#KO MBJP/^S<6_P#\CUBZ-_P3N\8^&M)@T_1?CKKFB6%OS;VFG03P00_0?:*I:S^S M7^TYX&TZUM_!?Q?"W6_"NCE=O]H0? M:+@>?Z?Z1;V]=9I__!2CX070_?\`_"1ZE?#;XY>"/BAI:7WAKQ'8ZC#CE0_E3@_]<2,UVUKJ-E=K_H< M\%Q[0S`_RJW1111111111117SM^W7XA_X1G]F3Q7CSO/OS;Z>/L_4>?.!_C7 MAG_!*V<&Q^)4)Z^?83_ZG'_/Q7V_XA\/:/XNT.YT?6K&WU+2;U?(N+6YAS#. M*^1/VAO^"?&A^(M#L?\`A5FAZ3X>U?[)/$-^/%'B"WB\^WMV@_XE]G`O$?FD>0-+N<^=_ MUQ-?FM_P31\)V^M?&_4-6-]]GGTG2OM)M_(XF\_]QG]*_4^BBWZ&BIJAHJ:B MBBBBBBBBBBBBBH:**FHJ&BBBO@7X7^$]<\$?\%"O%-Q>>%M4ETW7/MPL=:@A M!MH///V@S$^_3\:^)_%?AN?6_'GCK[%8?V=]@GU#4?[.MH/^/>WM[BOO[X0_ M$>']H7]BKQ5H.M7TUQK^DZ1<:???\M[C/D?N+C\?Z&OCO^VY_$G[%OV#[//_ M`,4SXT_Y=O\`GWN+>X_]N*_2#]D[7?\`A+?V7O`DVES^1L_#+Q-X>LOLL,]]BZL(S"+$0'CS\GO_6OL:BK M%%35#7"?%M_%B^`]7C\&0:5<>(6AVP#5I3#;D9_?$D>W\Z^3?^"6VJRW/AWX M@:.9YC#!?072@_\`3?SP?_1%?=M35#114U0\0#VJ:H:FHHHJ&IJ*AHHHHHHH MHHKY?_X*,6_VG]EW6L0Y^SW]A<8_[>!_G\:\P_X)O8_G7W/117XF_M8B9?VA?B4)IY[@#7;@`#M7['_``^S_P`* MZ\*^;U_LJV_]$5T=M5BBBBJ]S7RK^U!^Q!_PT)XSMO%5EXMF\/W8M_L\]K<0 M">`CZ5\$?'[]E[7?@7\0]&\*37\&M_V]Q87(@^SU^IG[/'[/'AG]G#PGM?"OB/P?^TA^SE\7M0\8P:??>*YKZXGQ<6OVC5K> M?SS_`,^__+OTK9_90_9Q^)7C3X[:?\4?'6GWVCPV]_<:A//J/^CW%Q]? MI=11111<=!52ZN8+:W,\TP@@A'^O)JMINMV&L6IGTV^M[]1WMI_/%?DY^T?J M4&N?M[7'DV_VBW_X271[?%O_`,M_^/>OJ'_@I=\6+[P;\,-.\+Z9>P6S^))K MA;X_\M_L\&"`O"_P`5M,\5_P!C:AJW^C7&FP#_`$B# M[1_I'V?_`,EZ_0_]D_XR7WQL^#&D>(M46`ZQY\^GW_V?I]HA.#7M-%);_P"H MI:*FHJ&IJ*AJ:H:*FHHHHHHJ&IJAHHHHHHHHHJ:H:**FJ&BBBBBBJ.JZ-8ZS M8_9]3L8+^W/6&YA$X_6N.\1?`[X>^);>W@U7P+X>U"WA/G`7&G0'!_*O);__ M`()Y_!349Q,V@7U@?^>-IJLX'Y9KSSQ[_P`$O_!NLWHN/#WB+4/#]OWMY[<7 M_P#,USMI_P`$R=0\.W7RX;?49H)A./4F MX_?_`/DQ4FO_`!2_;$\$_9[W4_`VE:W;CK;:?8_:#_Y`N*ET[]MKXSZ;9VT. MM_L_Z]?I7COP[]S/^XQ/_Q\>0#W MG[\_E7Q9^Q9XBG\!>&_VA(;(P_\`$NT+[3;VUP?^>`N!_P`?%)^RO\*)_B?^ MR;\8](AOX+;[1?V_V>XN/^/?_1[<3_UKV[_@F+N/(^T_ M\L/]'MZ[[X-_LJS?![X^>,O','B+^T=.UV"?%K&I?L'Q!U]O^/>:YM]/'U@_?\`_MS7WY11+=&\2^'IY[;[//\`:)[?_CWM[^W_`.?>NQ^! M7D?%K]K+PM<:F/L\&K>)?[1GMO/_`.WBOTO_`&H_V?\`2OVC/!-MH4VJPZ/X MALK@7%E=;1-Y)[PGZ\5\5:UX"^,OC3P!H_P<\4:KX(TVV\-7VZ&XU#Q'!]IN M./3KG]_7WM^S#\*KSX._!/PYX7U2X6XU&W^T7%R8.\T\YG_]FKV*BBBBBBBB MIJAJ:H:FHHHHHHJ&IJAHHHHHHHHHJ:BBH:**FHJ&BBIJ**AHHHJ:BH:**X+_ M`(47\/?^B?\`AC_P3V_^%M+4=&_;@TZRS#KVDZBWG?\`+#[`#C_P'K&U M/]J?]J?PMJMU!JGPH-SY0Q]GMM"N+D?]_P""XQ7B'[57[3?BWXR:;HWA_P`4 M>"6\#"PN/[0'VL3"XF'H/.`K[@_8$T:^T+]F3PP=1@$$ES/<7UN/^F$\Y(_G M7TI117@W[;A\C]EKX@&*;R"+.#!]/](@KR7_`()@:=]G^$OBF]$Y\BXUTX@\ M[.#]GMZ^TZ****FHHHHHHHHHHHHHHJ&BIJAHHHHHHHKFO'GAFX\7>#M7T.RU M>?P[<7MO]G@U'3_^/BW]Q_GO7EW[-_[/5Q\`K#68+WQE?^*_M_D?\A'_`)85 MZ1;>!O#EK%K9LM%TN#^US]HOA#;@?;>/^6W'/XT'P/I(\-:CH=E9P:1I]];S MV_\`H$'D8\_J1CO7F/P(_9JT[X#_``\UKPQHWB+5+FXU6ZGG_MAX!]H@;`AX M]QU_"O'?V4?BOX_\0_M1_$OP[XMUR;6+#28IX!;X_P!&@:"XQF#\Z^UJL444 M45C^(M(7Q#H5YI<5]=Z2)X?*%SI\WDW%OZ%3VKY5_8WTP6_Q^_:-O\9']O?9 M^?\`7_\`'Q<=:^R**AJ:H:FHHHHHHHHHHJ&BN8\9^'5\8>#/$&A13?9FU:QN M=/$__/#SH,9_4&O,?V2/@A=?L^?"K_A&]5GLKG5I]0GOKB?3U(@!;`'7VAKW M6BBBBOSI_:8_;<^(/PE^/FHZ/HMC9GP[H1,']G7,)S?_`+C/6L?XZ_MT>#/C MG^S_`.(?#0\-ZKIVOW_V?[/:W$_^CC_2/^/C[175_P#!*R<'PY\0HBC[5[58HHH^T#TJO?%Z\9S^=?*7QL^'7PP_:(^(2W'A+Q M_I=I;^!-(^SW'A2VL?(\Z"#[1<8M_P#/:OGW]AG3?[2_:E\"SP3P6WD?:+C_ M`,E[BO,Y_'WBO2_B3J'BL:K>Z;XP$]P)]0'_`!\6]Q/_`,?%+K7@F#PWX*\" MZM!_R$=>@U"XGMO^O>X^SU^TOP!N-=N/@MX(/B4S?V]_9,'V_P"T_P"O\[`S MG]:]&HM^AHHHHHHHHHHHJ:BBBBBH:***^./VG?V]5^"_C:?PCX9T*#6M:LAF M^N-0N/L]M;_ZG^C5R/P0_P""FUMXK\6P:3X[T*R\.Z="O&OQ M1.DW7G>'_"D\!MX+_48,&XOO.Z`_\\?)PV\\WGW$'AO3\GU/V'V?_`$C^E/\`^"8G_)!M9_[&6X_])[>OL"BBBBIJ***************A MJ:H:FHHJ&BBBOGK]L7X:^.OB+\-X8?A[JL]MJ-A.+\Z?:OY$U]CL)^W6O!_V M7OVV]4_X2?3_`(;_`!6'V?4B180:S<_N+C[1_P`^]P.QK[U^U>U>4S?M!>"/ M^%RP_"_[PGMNAMSC]Q^GZFO9?#OP<\"^"OB9K/C+2[?%&O#_2+CSS_I'_ M`&PKTVBK%%%%8/BVVUR]T"X@\/7%GIVKX_<7%_"9H!^5?*7[''V"M!\%>'_# M^MWNF:KJ][<7$_\`9UQY%Q+;P`9`/I^_'Y5]3?#6WUVT\"^'8/$)?-MUU&&`P:6MPY/^H'YU\-R M?MFZ3^T%\/+GP+\0?`UGXB\9$>?H1MSY%O?W_P#R[C/_`"[S\FOF'XF?"[Q9 MX!O_`+?XG\)_$7;:M_I%AIW^?\`2*^S_P#@E(\RV7Q*4PS>29[#$^?W!_X^ M*_02BN.T,>-3XVUA=6M]$'A$*O\`9<]I-/\`;R<=)\\5^0_[1'C:#XD?M'^* MM=\C[3;SZM]G@M[G_EO;V_\`H]?L]IP46,,,,'V:WQ^Y^SGH*TZKU8HHHK\Z M?BQ^U-XZ\=_M5Z-X3^'NJWNG:/I.KV]A]GTT>?\`;_\`2,7%Q?C;$? MV5/#FKZG??VAJ'BRXN#;ZS?_`+^XL+`V\'D9]9^;BOE(?'WXDW&K?VK-\0O$ M8UCT^WW%?:G_``LCXF_'C]B+3+WP5K<\_CK2[]H==;3IP+^:"`SY'U.8#^=? M$?\`9OQ"^$NK:=KL]AXC\*:C!_J-1N;"XM_](K]=/AY\?M!U+X$^%_B#XNU6 MQ\/V%_;0&>XN9N//],U^8GQC_:H\<^._BB-'XG^']+D- MQ<'[/K8!_<8&!!<'\:^,_A5J6N^$M>_X271/#4^M?8(-0MY_W%Q]GM_]'_TC M_P!**^GO^"6GA*PU+XI>*M6G_P!)N-(TG[/!_P!O%Q_]SUUOQ=_:-\92ZU*_V8[/4-.L[R<*^KV,]R)QV(G^SD=_3TJM\%_C]\.?BK\:?!_A/4O@9HGA^ MXT^8V^ESZ>?/.F3X-QCR/LX`Y\_FOT9MJL44444444444445-111114-%QT% M%?EK^U9\6/"W@#]J;6?%7@^P'B+Q7;F$3W,UR?[/L+[R#;C]Q_R\'&,^]<_^ MSK\#/&O[7?Q=?QEX^AN[CPW!*3J>H7<'V<7Y_P"?>#';.*\>^.OC;5_BC\;_ M`!3JUQ!JES=3ZM<6]CIUQQ<06_\`R[V])H.I^#O&OQ/L8/'&D#P)X9^SG3[T M>%H?LP@/:X)G!Q^5?M_I]E!IEC;V5OA;>&$0Q?E_]:KM%%%3445#114U%0U- M114-%%%345#4U%0U-4-%%%%%%%?D;^WQXKL?&G[26L0:;#.3I4,&D3_]-[B` MYQ^'VC%?J[H$`MM'L(A!]GVP0#[-_P`\>*U:*+CH*_/'_@J+XBBFU3P+H,1_ M?V_GZA-/]H^Z,#CR._UKZC_9-T6RT+]G3P"+.TAL1UT4445-111111111111111111114-%%%%<%\;/B!/\`"CX5^*/%D&GG M6+C2+#[1]F_Y[XK\D?CY\8?#?QRO?^$C@\*'PKXI^T'[=_9\XGM[X?\`/?C_ M`);U][_L!_&"+X@_!RU\.3W%Y<:]X9'V><7(R?(_Y=S^7'_;`U\V?'SP[!\% MOV[/#FL3:A+J>GZQJMOK,\"_Z^#[1$;3X:_MU>.-*\,Z=/K= MIH5CJS6]M!+!^_.01!@C@@X@]L5I?$S3]>/[?7PU\2WWAR>!M=&GW%CI\T^+ MB`X\BX\_R/\`GWK]%_M-6*L4445Q_P`3O`"_$OP1?^'#K>I^'TO5\F34-'F^ MSW"]C@XKY5_8DTP:;^T1\>X(;>]MK>WN+>W'VGU^T7%?;5%%34445#4U%%%% M%0T445\!_M"W%C\;/V[OA[X,%A!K-AX;YO[8]O\`EXN/_;>OO2VJQ15>JMSJ M4&FP&:]GAMK?UN)ZX7XB?#;P9\<]!TZQ\3Z5;^(=-MY_M$`\_I/7Y@ZS\#]! M\1_M76_@'X>Z3KEOIN@ZIY.KZC?7Q;/V>X_TBX%P.8*Y?]L+XGP?%GX_>*=6 M@M[>VM["?^QX+@3^?]HMX/\`EXK]+_V-/!%U\.OV;_!EEJ21P:O<1&^N#Y7> M<^=CZB'`^M>]T5S7Q.\:6/PX\!Z_XEO>+?2;&>Y:OQA^%GAW5?C5\;_#^E&W MAU+4-5U;[3?^>,V__'Q]HN/M%?N';58HHHX@'M5>YK'\9+JA\-ZG_P`(_/;6 M^M&";[#+-9\9>-&M[7Q%-#-I]E;VY\_`S_ M`,?%=C^RE\`OB/\`!?7O%-WXV\8P:YIVI9EATZVN+BXVW!GSY_[^O+?VG_V6 M?BM\:_CU;74]Q#J/P[\ZWM[>XMIX(+G2;?\`Y>,=S7U-XO\`@3X2\>?":U^' M-[I\H\,6UO!;PV]O-Y!@$&/(Q^0_*O!;;_@EM\-+>_,\VO\`BFXMO^??[1;_ M`/R/7%67[`WQ2^$&JSWGPF^)HTR._MQ![?'3]EO2_BM\%=&^'NG7X\+Z=H36_V M!U@$_P!G$,6%'Y?RKP>[_P""6_ARX;PX%\87\0AAQJ[+8CS[W_KAS_H_X9J7 MXQ?\$^+S2_$FG^*_@SJD/AS5M*%N(-.N1Y`)@_Y;>?US^%:7P]_8*U"X\?:) M\0?B=X_OO$7BB">VU">&&$`?:(.WG]?(]L5]=>-O!.E>/_#.H>'/$%D-0T;5 M8/L]Q;GH17A_QR\+Z%\!/V3?'-AX,TNPT6PAT^>W`7H3./()![S^@@'G MS?CC-;M%'_+&BWZ&BBBBBBBBBBIJ**AJ:BBH:**_*[QS_P`$^/C&_CW4)]*U M"QUNW,_VBW\0W%]]GN2/6?UGYZUZU^S;\#_VF?`WQ.L#XF\5SP>#X)2;VVU' M5S?"XX_Y80]OK7D_[4WP$^*'PG^.VH?$KPA#JFIV]_?3ZC!J7AR">XN+'_IA M<5P?@;X!?%?]HCXMP7'BS3==MUO+W_B:Z_JVD?9S!@=`*_8NBBBBBBIJAHJ: MBBH:3C_7>U3T45#114U0T5-114-'_+:BBBBBBBORG)B^(O\`P48/G?Z#"/&7 M`Z;C8?\`\/7ZH58HHK\M_P#@I;""&"RA@Z+#@`?I6Q114U%%%%%%%%%%0U-11111114-345 M#4U0T57KR']I#XM>!?A/X*_XKRRGU+1]=/\`9_\`9UO!]H\^ORB6Y^&X^-%Q M]HL=4/PUGOOL\!$_V?4(+>X_^1Z_4[]F?]F?PU^SQI.H?V+?WVLW&KG[1/J- MSWKRK]JO]F#Q9\8/C?X&\6^'YK(:=I\%O;W_`-HG\CR/(N/M%3>#OV5/$GAW M]K_Q#\2)MOS<3K]AF,-P#/T@/Y9KA_V\OB?XQ^#7Q*^'USX.UR;1=V ME7$!,X%QG_2+?_GO7J3?\%`?A?IGCO\`X1/4O[;TZY@OI].GU&ZL/(MX)QVS M7P7]E$"+>_MOL_G0>L'//:O:JL6_0T45B^+=.T3 M4_#>HP>((;*XT2:'%ZM]CR##SG.>*^+_`-@L3Z?\=_C9;WT\YN/M`_Y"/_'Q M_P`?%Q7W5114U%0U-111114-%%%%%?G9^PW;7_C?]JOXE^,Y_P#B8VUA]HM_ MM&HS_P"D0>?BG5O]&L#HT_V?[/?_:/\V]?7W[4 M_P`4[_X*_LM^%_AMK=_<:UXZ\2Z5]FO]0N>UO_R\?:/_`$1^-?.7["OP:N/B MG\;;"]ETNSO_``OX:!GU9K^W'D#_`)]X!GC_`/AZ_7FV_P!&MZL45\O?\%#_ M`!&/#G[,VLP?;?LUSJM[;Z=GO/GM^E?+/_!,?3IKGXX:QJILIY]/AT*XMA<> M1_H\%Q]HMZ_1:;P)I\WC;3_%LU]?M?V-B;""W-Q_HW/.?(_Y[5W-5ZL44446 M_0T4444444457K$\5^)=*\%>&M1UW4YQ;Z=86_VB<^D%?GG^V!^T_P"#/VA? M@=Y'AF?4X&L-=@'D:A;8\\?9[C]_7T-_P3HFENOV8](,XF)AU6_$6>X^T'_$ MU]0U8JO5BBBBBBBBBN#\*?%OPIXUN?%-OHNNP7/_``C=Q_9VJX_Y=[CWJ?P; M\6O"7C[5-1TGPSXETK6=1TG`O[?3[CSS!^5=K1114U0USGAO0]2TF\UJ>]UR M?5H;^]-Q;P3PX%E"0/W`QV^M='111111111111114U0T5-1111111111114- M%35#4U0T4444444V:YBMA\V/PK\@?V1KC5?$O[77A;53;S:W?W%]<:A?W!_[ M>/\`2/\`R8K]@*+CH***_'_]N6YL=2_:D\5?8K_^T;?_`$>WG_Z87'V?_CWK M]=K6#R((/:'%6J***FHHHHHHHHHHHHHHHHHHJ&BIJ**AHJO7)?$KPAX;\?\` M@K4-$\7007/AZ<8G%P?(\D=J_.7]K#]A^X^$T%OXD\"6]]K/A;R/]/\`M%Q] MHN+#T_[85]"_\$]_CY!X^^&\'@:]_P!'\0>&K*\P_X*EZ>/[*^&NMP7$&1/<0&X_\``>N5/['5_P#' M/Q)O"& MO:9I,&M>';#53Y_B+1KV"YT_[/\`\O'[\=?I7ZLVU6*FJ&N.^*OASPGXK\"Z MKI7CF"QN/"\Z_P"G#49O(@Q[G_Z]?)G[$NZ#]I+XZ65O!9+8B>W-O/8'_1O( M\^X^SB#_`+85]R4445-14-%34445#11117(_$_XCV/PH\`ZSXKU*&:YT_2K? M[1/!;C,^/I7EO['7BWP/X]^'VI:[X%\+#PJMQJL_]JZ=C!^T=R?TKZ`HJO\` M:O:O.M%_:`^'OB[QE<>#M&\8Z7J'B(09^RV\^2/RK\8?%?BW7?#?Q$UF_LO$ MM]M77PE@^!FJ^%OB#\2;_2]9.KV'_"06'A M:VMY_M-]?I^F*\U^#G[0GC*P^$VF_"CX<6 M`T;QC/JQN/[8MYQ]HO\`_IW_`-(_Y>/]1_WXK]4M-UVY\)_#^VU;Q?/;:;/8 MZ5;W&JW/_+O#-C_2/UJUX$^(/AOXD:1_:OA?6[+6M/\`.\C[3I_3/I76T447 M'044444445-4-%%!M=U72X8+C4+&RGG@@N)O(@8@$\G\*_,#P= M_P`%'?BQX,-'N)L"">W%N;;_MO!Q7EOQV\:_#;QKI'@Z?X>^#8/ M!EQ!!?D MFO>**L57JQ2>>/.QVI:****\H_:B\17W@O\`9[\=ZMIDTUMJ%MI5P8+FW'^H M..M?D)_PEW]B?#2V\-:7!/IW_"2_Z1KNHW'_`"W\BXN/L]O_`->__MQ7OW[- M_P`1?@-\%?BO!?WD_B%]7T^#[!_PD_FBYL+FX`\B<6T$$'G^3GG)X_G7MOA_ M]I7QEI7[<6L>#-?BN!X>O;C^R+"P`\F"$9S!>:Y_P"> M0QG_`!_*OS._X)I>&IM4^.L^K1#R+;2-#F\\>\Y&*_5"BBBOQ_@TZQ\1_MSW M-CJ8S!/X[N//'_<0K]>*L4445-111111111111111114-35#4U%%0T45Y;\? M/@S8_'/X;7W@V^O9K"*#;[Q)?>--.S M.+;^T81^YMS_`,N]=)\,?A+X.^$NE'2O".AV.BVI_P!<+8?ZZO$_^"A'AR7Q M)^SEJ]Q#YP.DW]OJ`%O!]H-Q_P`L/_:_Z5^=GQ+\5:I\1OA/X'U?4YIM0U+0 M[C4/#]SJ0'^I@Q;SZ?`?P$_Y5]4?'?PY_P`+C_8)^'OBO1?(N?\`A$K>WN)_ MM/\`S[P6_P!GN*^:+;]GK7?&WP9T?XC^'A/XBN?/_L_5M/M_](N+'R/^/?\` M[8?9_P"=>D_L+6_Q5UGQW;:5X3\2?V+X6TF>WU?5=.U#_47%N>PK]6;:K%%% M8_B?0]*\2Z%>V&MV=GJ.DSP_O[:_A$\!'N#UKY<_9H7[#^US\>K)Y+<0#^SV MMQ`>D&,0?H37UW111111114U%%0T455NKF"U@\^:;[/;P]:\%\??MO?"3X>? M:+>7Q=#K-["O_'OHT)GY_P"N_P#J/UKYO^)7_!17P9\1O"6M>%-5\"ZZ?#VL M?:-/N+FWOX+>X^S_`//Q7?\`P5_;"_9V^%_AS3?"OAN^U/P]I&9Y_M&IV,XQ M/GGSSC.?\!TKZ8^&?QB\&_&*PO[CPAKMGK=O;3?9Y_LQ_P!3]:[6BORP^./@ MC0_V._VN?`WB/28MOABXG_MCR+@9^S'[1]GN+>W_`.W>NZ^/UM^RS\-_'FKZ MZ;";Q7XR\_\`M`^'=.G_`.)=<7'_`!\?O_\`EWKYA\0:SXZ_:Z^+]M-+_P`3 M'6-6G^S6]O;\V]A;_P#QBOU'_9J_9QT+]G/P4UAI9FN=8O\`R9]5U*4Y-Q<8 MYQQQ#G->V4?\O%%E?C?\`!OP%KG[1 MOQWMK&XN+>?4+^X&L:MN3_H\\%OCS_P!__P`]^O\`X#U]5_!S]L&?P0%^%_[06GWNG:E;0BWGUG4H MC,+X=#]HQ[?\M^G\Z^TO`O@?PW\/](&E>&-#LM&T^:4S^1IUOY$'Y5TM6*** M***********R];TJWUW0[ZQG/D07L/D?F#7YX^!OV!?B-X'^)&G00:KX=U#X M?7-[;-JR7,(N#<6T`R+>>">#'8]_^6YKS#]O+X&>#/@7XR\.V'A*QGT]M6M[ MC4+BW\XS`G[1V!KH_@E^V_XR_9Z^&?A;0?$7@2?4O#IM_P#B4ZCP^T6__ M`$[_`.CUZW_P]4T,>1YWP^U7_4?\_P!;_P"O]*]+T7_@HM\&M1MA/-JVJZ0> M\%UI-P/Z5W'@K]L7X1?$";[/I_CJQM;C_I_B-A_Z/`KT+2?B=X2\2WGV+2/% MNBZE`]>\*:@TL&GZO8SV$\ M]N>85/I_GM7R9H/_``3S\)>(_#>M^*I]1M)9Q06:V\VD3YP_.?W_G M8M\Y_P"?<"N4T#_@EO/::KI\]Y\2"T$$\%R/LVGFWGX]2)^*]I\1_LKZIXB_ M;!L?BK<:U!!X>L8+?R;0#-QY\,.,FOJ6BBBBBIJAHHHHHHHHH_Y8T4444444 M5-114-%%3445#111114U0U-14-%%%^%WB'QE]@.HG2;8W'V$ M38\ZOAZW_:<^)OQ"LM4^(VD?`_P;<:5X=S-)J%W9>?=1$#)N+:?OQ_*J'B+] MO;7/C'\$OBGHFI>%++3+G^POL\-QIMQ]HW>?/!;7`_\`)BL?_@E_J%];_&GQ M!!"!_9\VA9G/D=/](_T?],U^H]%%%?E!^SUX"G\>_MO74,\-O/;Z1KNH:S.3 M/P/L]Q_R[_\`;Q]GK]7Z***FHHHHHHHHHHHHHHHJ&IJ*AJ:BBBBH:+CH**XC MXG?$_P`.?"7PG/XC\3WO]GZ-!^X8B'SOY5F?"/XU^%/CIX=&K>$M0-P(9<7% MK'M7H5#%?F)^SA\' MK?XG_`#XV:%<&8:OI-Q;ZA86]N?^7F"WN,5I?LJZ;XD^-GP(^)?PHTOQ98Z= M;_\`(0M[>Y^T?:/^7?\`\E_]'_\`)BN5_9&_:IM_V7Y_&5AK>A3ZC;7_`/I' MV:W_`-'N(+B#_EWKZ"\=_ME^!?C5X/TVSL_&>J?"/6K?5;>_FNKG3Y[AIO(Z MVY-O]!_KZ^U/`7C_`,-_$CPS;:[X8U6#6='G_P!1<6QKHJL57JCXBT#3_%6A MWVDZI;PZAIU]`;>>WGX$P]#7RG^SAHUAX=_;.^.FEV,%O;VL%OIY@M[>#_4# M%?85OT-%%35#1111;]#4U%%0T5X%^T?^UIX4_9VL8;>^2XU?Q#<6YELM(@XS M[SS'(@'7D^E?G'XJ\??%?]LSXA?V3!]M\0@3W%Q8:-;?Z/;6'^?^GBO8/`/_ M``2Z\5:LA;Q;XJTW1;8?\NVD(;T_KBO4O&?_``3!\&ZCJ6E/X8\2:GX=TX,U\Q_&3 M]E_XA?LSZM;:M/;_`&C3X+[-AXAT;J/_`)'KZ!_9L_X*)M;6UUI7Q@O\M#;^ M?8^(;>S,T\XS_J)X+<'!'->RZ_\`\%'?@YI=A/-9ZOJNN7\`_%?V>=`U#2O#WVVX MN;^?[1?ZAJ/_`!\7%>K58HHKX0_X*1?'V;PWH\'PNL+*V9==LH-0OKJ8_P"H M@^T?N/([9W6YJ'_@GG\)=#\%^$?^%D>(+C^S?$.O?:+>P.H7%O;XL,C]_;UZ MUXQUK]G[XV\86,'_$JU`\8Z_N)^.8#Z?Y/SI\`/VL]=_9YUW_`(5?\:;>?3K? M22-/L=1,&/(_^2(/^GBOT`TO4[+6]/M[^RGAU"PN(,PSP'/G"KE)^_JS1_RQ MHHHHHHHHHHK)U_[1_9%__96/M_D3_9_^NV./UK\4_$/QK^+VA>--0OM:\9^( M]-\4V\_[^V%_<6_^D?\`7O\`\>]8VL_%C7?B?XT\*ZK\0M5F\16UA]GM[BXN M/^??[17[:Z?X.T&UT*PTJPTNR71[*'R++3Q;Y@@HO?`'AK48((KWPWI=U;P\ MP6\]C"1!]/\`ZU>-:K^PM\%=;U274+CP=!;33#YK:QFGMX#[^0#@52O_`/@G MS\%+GR-WAR\M_3[-JMQ_C7$^*_\`@F5X`U'5K"_\/:WK?A40(_^"BT'A,6XUKX4>,M#\_\`Z#-O]GIND?\`!3?X;WB?\\=L$$WVC\C74Z)_P`%%/@WK&O6VDK?ZIIXGF^S_:-2L#;P0GZU MZ7'_BEX+\4VT%QI7BS1-2$_^H^S7T#>?^%= M7:W<%U!YT,L-Q[V]6J*K_:O:K%%%%35#1111115>K%5Z*L444G;]SBEHHJ:B MBBH:********FJ&BBBBBBBN!^+OAK1/'OPTUCPWK>H?V1I^JVYMS<";!AK\Q M?'>H?%?]GGP9J'P3O;^QM]'U:^\^"YMM6M_^/?\`]M[>X_Z>*3QU\%A\%/V9 M8-3^W:)K6M>,[ZV@OS;WL$XL+>#-Q;V]N>G:W_3UKZ8_X)C?#^YT#X6^(O%4 MJSBW\27ZP6\+1!0T$!.)@?7,\P_[8BON&BBO-/V@?$*^$_@IXYU87KZ<]OI< M[6UU!U@N<8@/U\XBOSZ_X)MZ')=?M!W4J^;;I9:#<3$0]#FXM^*_5"BBBIJA MJ:BBBBBBBBBBBBBBBBH:**FHHJ&BJ]>9_M`:WX`T3X>ZBOQ&N;&#PU?`P&"Y M(_?G!P(1U\[GC%?F1XW\4^&?@1\3M(\8?`KQT=:TVY%P#I\\-P#!;_\`/"_6OT`_9M_:V\*?M#P7-A%'_PCWBFW/[_`$:YF&2/^>\![CFO>Z^"?V%K M33]%_:/^-.AZ9!!;:?;7-P;;_GX\B"_(Y_.O)_"O_&-_[=&G_P!EP0#P]J]_ M]GM[>V^T?\@^XN/L_P#Y+URGQS\!>&KO]MW7_"NIW%QX>\.ZQKMO!]IT\>?Y M%Q<6_P#\D5C_`!U_9$\5_L]Z,-8\3ZMH9M;F^_L^PM].GN/M%Q7U)_P3`\?Z M2OA/Q!X.GULMK7V_[?;Z-/VMS`/^/?VK[]HHHKY"^"ER)_V]/CCY`$T0L+#S M)O?;!Q^6:^O:***FJ&BBBIJ*AHKYK_:V_:SL?V>]-ATO2H!J?C>^@,]O8'_4 M6\&<&>?T`Q_GO^9_PF^%7BK]HKX@7.B:;?PW&KSP3ZA?ZCK,Q)_Z^+@"OUZ^ M#7P6\)?`KPU#I7AC3((=T,`O-0X%Q?$#!GG/KU_6O0OLOO5BBJ>H:;!J5O/; MSP0W%O./WT$_0BOBSXX_\$VM$\>^)!K7@;5[+P>9@!<:0;$&Q/'6$`#!/MQ4 M=C_P2U\"I-`;[Q7XCNU6/LOO115?_CVKPW]HO]J_PI^SYI/DRRC4?$]Q!_H/ MA^W/7@8\_P#YX#GK[5^<_A?^T/VL_C=J6O?$#5)M/\/V]O<:CKNL9Q;:386_ M_+O7IO[83']H77/`UM\*-*_X2KP9H6ASF$:+!Q`>D]O_`-._^HMZ\Z_9J_9[ MU;]J?6[FRO?%G]G:?H,%O;3"Y_?W!L/](P+>OUYT[3+?3+&WL8/^/>"#[/!7 MF7QW_9E\&_'W2I_[9L1;Z_!`;>QUFW_X^;?Z5\6>`/B_\0?V$O'5O\/O'5C_ M`&GX-GG,\$]MY]P(K?\`Y[V'!X_Z=Z_1W1==L/$VD6.K:7<0:A87T'GP7-OT MG@Q_]>M2BC_CVJ?M^YQ2T44444445\0_\%,/BMX@\%^#_"OAO1+R738?$?VD MWMQ;@9FMX#!F#\?M!K\R-1MI[:?R)_\`CX@_T>NJ^'?D7/Q3\*P64$_V?^UM M/_T>XG_Z>+>OWCJQ5>BK%%%%%%5KBV@N1^^'VBN;U'X<^%->O8;Z\\-:5J5S MVN+FP@FKA-1_8Z^#.I78N9?AQH?VGU@MO)_E7&:A_P`$]?@GJ%K<0Q>&[RP\ M^7/^BW\X\H^W-V_L>\\0>'KFW^]/#=>>9O^_X-?"#1[FY\*^+EUP7UQ]HN+>UU#[1#]I_\`:D\!Z%"GB+X3RZV?XK_[!.?S%O5G4_\`@H#\2M&L M+F^U3X"ZOINFP?\`+>YGOH!_Z35M:;_P4W\&)I\']I>%/$=MJ/\`RWMX8(#_ M`%K3_P"'H?PN_P!(_P")3XJ_Z8?Z!;__`"17:Z)_P4!^"NH:0;V?Q+-HTX_U MVGZC8SBY'X8KTKP7\?\`X?\`CZZEM_#WB[1=2N(8()VAM[D<";H3]?ZUVEGX MKTG41^YU2RG_`.N,X-7?M,'_`$PJQ11115>BBK%%%%%%%%%35#1111111111 M111111117YL_\%2;?Q%J7B?PQYNDWO\`PB]A8W!BU`?\>_VG`Z_ABODKQ%XV M_P"%D>)?%7BSQ1/?7-Q<0?N/W_\`R\?\N_\`G_IWKGOM-_;>&OL$\$]MIU_/ M_:$'VG_EO_Q\6]?KU^PE]C_X9=\#?8MN?)G\W_KM]HGS_7]*^@J**\$_;3UR MVT+]F?QO)-9_;[>XMX8=OJ)K@#^HKP#_`()?>"K8Z5XN\5&>2,=>M??5%%%%%%3444444444444445#1114U%0T47'057KS7XVZI\/H M/`EQ9?$R]TJU\+ZA_HY&HS@"?]\UPTYGL?^?C[ M/[_YS7Z'6UM]GM[?,WVFX_Y^#7P#_P`$]M!,FK?'*:RO;>'5]XL++4+>#_1[ M?'V@@_@<&OF7XW?%#Q)\1_"?PD\6>+O])UF#^T+?^VK>#[/<3V]O<5]!?\%( M](N+'5/A;X[T9=A$)7_A(/)SY\X,$]L?Q'V@UR_CGX7?M!_&O0/^%@3>5XT\ M*Z[I-O?_`-C07YN/(X_Y=X/^6%Q[V]+?$=CX3\-ZKKEZ/]!TRSGOICZ"`;C_(U^,'BGQ'XR_:@^*5SJUO MI][K.LZO<9@MK:W^T?8+?_EW_P"V%?J+^R?^S[!^SW\-X='G_L^YUZYF\_5= M0L1C[0CPW\*M4L;ZY MQ_I_B`P_:+>W_P"N&.+@_2OG'X%_LZ>./VI]8U#QEJUR)]'-\3JVHW-Q_I%_ M..L%O[5CKXJ^)'Q]TO2/A3X6T&QT6PTJ">X/A73O]`M[C_KX^T?Z^>NK_82T M3^Q/VN]&L)IX+FYL(-0M_M.G7'^C_P#'O_Y,5^GG@3X2>#/AQ/J$_A?PU8^' M;B__`-?_`&?;_9_/KLZ*X;XJ_"GPK\9O#%]>T]=2^'.JZH9ENF@_P!=!WG@Q_RW\@#-O[5# MXB_X*@^.KH:Q;V>@Z'!;S^?;V%S!Y_VB`CO7AFG_`+3/Q?\`"?B6WG@\=^(_ MM$'^H_MJ?[1_Y+W%?H_^R-^U1??M&:??V^I^%I]-U'28<7VHP\Z?//W`_+-? M2=M14]O_`*BEM^AHHHHHHKP7]H_]ES2/VD_^$:AUG5[[1H-#N+A\6$7^O\\` M?TKY(_;Y^%/PB^%/@S2K#PSH-CHOC'5=0$XMK92+C[/B<\'_`)8CGK_A7S=^ MR_X3@\:_'[X>Z5/Y_P!FGU:WN?\`1_\`IW_TBOVZJQ11111111111;]#1111 M11116=_8MO\`://\B#[17$>(_@%\-O&E_/>:_P"!?#VM:E.,37%SI\!G/U/_ M`->N+U;]C+X*^)76;_A!K*UDA'D9LA-8X]OE(KG]7_8`^">NZ/N:N_P#@F!8:5;B_\,?$ M#5;;68#]HL;FXA'^CS^O[C%5F_8T_:/T6>8Z/\9?M,$\'D3"YU6_A/UXK`UK MX1?ME^`;+RM,\8WOB.P'`.GZK]HN?_)BNAL/&O[9?PXEA@U7PW!XRM2#<$^1 M!-_V[YM_YU/%^W=\8/"NJ75AXL^"=_/=0=#IT-S`/T@GJ"Z_X*7Z]IVGW%]/ M\&K^VL!_R]7%]/\`9_\`TFKO+?\`X*9?"?I]A\1C_IW^P6__`,D5TFD_\%`? M@MJMO#)+XGOM)F/2*_TNHZ-X\\-> M(P1IOB72M1\K_GTOH)_Y5N#4;>X'[B:"?Z3U:HH^T#TH^T#THHHHHHHHHHHH MHHHHHHN.@JO]E]ZL4457KY3_`&M#^T%/KEO8?"^QAN/"UQ8XF\BWMY[C[1_T MW^T=OI7@=UXT^.GA?.DZC^SQX6O[$RV]O/`OAS-O-.>^(./^6_IZ^]<+_P`% M"9KA/C;I^D?9(;+3M)\.6,%OI\'_`"[Y)./H.GX5^DGP(L/[,^#/@6"$6XQH M-A_Q[0>1!_Q[CH!_GI7HU%%?'/\`P4J\0V^D_`_2='%X+6?5M8@/V`?\O,$) MR?U,%5/^"8VG7%K\'?$-_-_Q[W^N_N/W^?\`EWMZ^T:*****FHJ&IJ****** M*******AHHJ:BH:**KU^:W[1?A*7XY?MY6'P]U;5+VWT40PV\`M>/L,/V`W! M_7->Z?M-?%:;X+_!#Q#XEL MQG6;>'[/8F>'_EXF/%?-/_!,KP]JVE^!/''BN>`7-KJUQ;V]GF?_`$B>:W!Z M_P#?^O!/VN/$NJ^)?AI\-;CQII4VC>.?^)A%9;":?Q!W`N#GZ3U]0?L<:,-%_9D\`QM+> MW0N+`7`74.?(\[D0XQ_J0>GT%>W58JQ]H'I17/\`BRZU:TT+4)]!MX+K6HH< M6-O?3>1;SS=@37Q7^Q7J%_J'[67QCGU/2K+3=0F@_P!/MM.YMX)_M%?>E%%% M35#1114U0T5\A?\`!2[Q!=Z-\"M.CL;\6,6J:M#:WT/>:W,$Y(_0?E7GW_!* M_P`$V]OHGB_QE/YOVF>X.D6^?]1]G_U_'YU]_444444?\L:**K_\>U5;F[@M M8/.GGA@@_P"GB?BOF;XS?M\_#CX;:9OD?N-/TX_N`?^F\_05\#^ M+_VE/C)\>+M_#\GB#4[Y+V8P1:!I$/V83"?_`)8$P?Z^OI[X`?\`!-*WMC;Z MM\3Y_M-P#Y\/A[3YR+?I_P`M^.:^V_!?@G0?AOX;T_0O#VE0:-HUO_J+:WKX MY^/_`.Q)XJ^)OQ^N/%/A[4[+1/#^NP06VJS)-Y-P!_RWZ?Z_(]:]X_9__9,\ M#?L\_P"D:!!+J&L3C[.=8U'FX$'_`#PS7N%%%%<)\7OA)H'QC\%WGA[7K2"> MVG&8+B:`>?93X.)X#C_7#.01C^A_)C]H7]FC5OV>_&8L=4M[[4/"\\_^@^(+ M>#F:#T_Z^*]R^+?Q6\+?#;X9?#_3/#/@G1/B?H9TG$WB?Q5IXGG`^T#_`$?U M@/[\_G6W\.O^"CW@SP3H-O8:9\*(/#_.9[?P]/;V]N*^H_V;/VJM+_:.MM7^ MP:!JFC3:?U-R,P3>F)P.:]R^U>U%6**+?H:*****^6/VB_V7OAYXF\6S_%_Q M&;Z<:)9?;M2TZ!(9H-0@MP3@@^P-?,W_``3;\$Z5XE^-_B'Q5*#;W&AV/GV. MGCL+CJ:_4"BBJ]%6******KU8HHHHHHHHJO5BBJ]6**KT58JO534--M];MY[ M*]A@N;:]Q#Q7+7'P4^'Q&9O`GAP_728*X[4?V0_@S=6\Y_X5MH7X0>16 M5KW[#'P:\1I;#_A#8=',$N0VD7$UO_*N7O\`_@FS\&[J68PVVM6Q/7[/J!'] M*X/4_P#@F7I-AJEOJW@3QWKGA2ZM_P#4&X@%QY/N`#!53Q5^QS^T)H@MCX7^ M-U]K7_/?^T;^XT__`.2*JC]F?]K:WLK?R/B]!D#_`(]_[ M']5MC_;MCJ0($'VB`6`M_P`C;UCZQ\6?VQ/"6MB>\T*^U.U@G_?V]MI-O<?V]_BS;F;SOV?\`5QC[V!??NOK_`*-_+%9%Q_P4N\9Z&+>?4_A"=-T^ MX_U!N;BX@_G;UZ3I'_!2[X7ZE86!O(-;TZYG_P!,AI1AZPZO;SVY_45T=C^UG\(-2@G\CXC^'3Y/7S[\6^/SKN+7QQH&H6 M\$\&NZ9<07$7GPD7D.##QS]*WK>Y%Q;^?"?M%6?M`]****+?H:**+?H:**** M*****KU^2_\`P4%2]OOVG-9ME$\X-C8006P]3!DU^JGAG3AH7A_2+&$>3!;V MT$`7\*W***^!/^"I6H#R?AM9?N"/A7/>V,/AHSM>W.G\B].`+CSO3[/\`UKD_!OA/Q)^V=KW_ M``L+POXE@\%_%/09[>WO_P#GWGM_L_\`H]Q;UW^D_P#!.+7O&6K:SKGQ'^($ M]SK4\V1,]0TC5O['N-1/_'O/]GN/M%Q;_P#MO74ZAK4'[7G[ M<&CZ5>S6]MX/L;_^S[&V$'_'Q86_VBX_\F*]8^,7[:C^*?@UXSL?`C7W@;Q/ MX;U>"P^SP]9;#[3]G\\Z_L)^/-5\?\`P'M]6\0>*IO%>L_;[B"X MN+D?OX#Q^X_#%?15%%M6?K=S=6NE7LMC!]KOXH3Y%OYWD">;'3/Y5\8_LPZK MKM]^V9\6KFY\.3://=6%M_:E@MQ`18S_`%'^O^M?O2/^":.HV]S^SF((9@;B#5;D7%OYV?(Z5]9 MT?:!Z4444457KA?BK\8O"OP<\,OK?BW5!I]@`,+S+/-](#7RG_Q?3]L35C!Y^M^,[;S_(/_`"[Z=;_^ MV]);>"OA[\#_`!O]A^*L.H>,=9LE_?>'_#LV+"V_Z=[B<]_^N%?9_P`=?%NA M_`O]E[1O%OPP%O<6UB//^SW$'VCZYKFOA1^W]K>NQ_#?P7:^% M;SQWXDGMX+?7K\S"WF\[',\(Z$=37WS111115BJ]ORA_:?_9%G_9QUZWOO/OM9^'U]/;V_V^W_`./D?].]$'['7_"U M]/T[5O@MXD@\5Z?/!_I&G>()X+'4+#_2/^7B"ONB[_:$^#/[./@,Z1!JVDVM MQI4WV:X\+>')X)[G[1_RW_<9^M5?"'_!0KX;^-O&.C^&].T_Q.;O5I_L%M<- MI^`6KZKHHHHHHHHKQC]KOQ&/"O[-?Q!U"-9K@SZ2=.`@Z_OSY`_]'YKYS_X) M<2>7X1\'%];_P#$Q./(F_K%5ZL4444444 M444444?:!Z444457KG/B'\2?#?PG\,W'B/Q3JL&C:/`.;BXKSCP!^V)\(_B) MK?\`8FD>,X&U/&8;;4()['SOIYX&:]?U#7+#1/(^VWL-MYW3[1/C\JS[?Q;H M=U/]G@U:QGN?^?>"^S6W5BBBBBBBBBJ]Q;07,%6*/LX]:IZAI]OJEF;:\@AN M+>;K!<#BO/M0_9Q^%^IPVXO?A[X6N?L_^HSI$`KC-2_8@^">J333R^!+&V)[ MP3SP?UKFM=_X)X_!G68\VVC:KH;C_EK8ZC-D?]_LUP%Q_P`$K?!GD0?8O%>M MVUQ_RVN+F""X)K(U+_@GGX[\-0_9_`GQ>O[;3?\`GPN;B>W'_DO69IG[+/[4 M_@*2_;PQ\2+*X,_5;G5IR9C_`-M[#/VT[:#[./%OARW^S\?:+C[.?/ M_P#)>D\+^/\`]LWPX+BWU3X?Z5XI/:YN)[>W_P#1%Q6=X@_;&_:!\!6\'_"3 M?!)8!<'[/!6XL`%A^O[_`#7=Z+^W1\%M=GA@B\:06EQV%]93P?S% M=I9?M+_"B[F@@@^)/A:X,W3_`(F\'^-=?IWBOP_J :[IUQYH\X?9[F$Y_Q M^M:T-S!YQ_?PD^U6:******KU^5'CSQ+JOBO_@H);DD3SV_BRWT^QM[GI_H] MQ7ZKU8HHK\V/^"I_B$3>-O!&AB'(LM+N-1^T>GGS@8_\EJ^Z?@U#-;_"3P-! M+^YN(-"L`?.]?L^*[:K%%%%%35#114U%%%%%%%%%0U-4-%%%345#17R!^T9^ MT'\3_@#\4;'59=%L=1^$)GMXKBYMXMUR,Y\__MMUP*]'^"GP<\`^&]:U?XD^ M%?MET_C2WM]0:ZOY_/!@G_TC(';\_P`Z^-OCY\,-5_8\^.^B_$[P9#+#X0FO M@3;6Q_U`S^_L/^O_M=?'^R^`WPPG\B&>? MQ#K<$^GZ5;*VO2O@9\,?%?[0=MJ_@7QOI5[X+GN(?[?O\`Q7;Z%]FN-6_TCBWN M/J<3U]^_!GX-^'O@CX)L/#?AV`PVT&#/<%1Y][/WGG/<\9KT&K%%9.LZ;_:F MD7-C#>3:>9H/(%S;_P"OA]Q7Q!^QS'JME^V%\6K#Q%JLVMZU;6)MY]1;_EOY M$\`_K7WK;]#111111114U0T5\4_\%1?"YI/M(@'[[%N*_$SQ'XN\?\`[4OQ6@LFU";6-6U2^N#I5A=W/^C6X'_+"`G_ M`(]Z^W_A%_P3L\.>#/!=[<^+8;'QEXON(,PVUVI^P03X/_?[GU]"*^.O$?C[ MXV?L_?$>YL-5\2:IH^K65]_:%Q:P3_\`$NN9S_[;UY;X[TV>VU[^UI_^8]!_ M;/\`J/\`GXK[V^!7[+*_M!_!#X;W'Q#OO$6G6V@?:+>+1I_W%O?6_GYM\CZ` M5]>?#/X)^!_@Y8&S\(^'K+1C,/WTZJ?/G^LW4UZ%1]G'K15>C_EXJQ115?[+ M[UA^+/"&D^-_#NH:)X@L(-9TB^&)["Y[BOSB^,7P%\6?L1^-8/B1\-[V]N?" MW^HOC/DSP#)Q!<''^HX_U_;\C7QY<:)JVI?:=6\B^N;?_CXGU'_CX_\``BXK M]#_^":'AZ:TT3Q!-JO@@:9=8@N;#Q344457HMJL4444444444447'04444445\-?\%"_@Y\0?BA MJOA:X\/+!/X8L;>P@M[CM.?/]*_/'XB:)X3T35_[)\/:M?>(_(@^ MSW]S<0?9[>>X_P"G?_IWKWG]LBX\<:)X:^$OA7X@:L-1\0V.E7,]Q;^=Y_2Y M_P!'N/\`KX\C/_@/7S[\.]$@UOQIX>L?[=@\*?:+^WM_[9N/^7"OWD\/03V> MBV$%Q?C4;B*`"6].!YYP/WWI_P#KK8HHHHHHHHHHI//'G8[4M%%%%%5ZL445 M0U'2K?6=/N+*^ABO[6>$PSP3Q<3?7VK@/^&;/A3;_P#-,O"`^F@VW^%<[KO[ M'?P;\22PSR?#S0[9Q_T#A]@_]$8KDO$W_!/'X/>)-.6"RT6]\.SCK=:3>_,? M^_\`Y^/RK@KK_@E7\-KB;,'BKQ7;^P^S_P#R/7-6?_!,.?1]>&I^%_B/&X!_/%:TO[-_[46B:?-=6/QB%_J(A.+<3`^<8>8/]?;G M'/6I=,M?VTO#6D?9Q-H6L>3_`,O%S-;SW!KG=:^-?[7?PQN)Y_$/@VWUO3X! M^^-MI7VB#'UMZMG_`(*"?%&W$$^J?`N_M;<_Z\BWO^/_`"7K?N?^"H'A33H? ML]]X&\1Z=JX_U^FW'D`V_P".>:V]&_X*8_"BZL?].L?$>FS_`//M]@\\UU'_ M``\.^"DXX\27L/\`O:5<#^E=3IO[6?PC\2:%?W%G\0M*MC`.?M%Q]@G'_@1B MOSX_82\-GQM^TYX>GEN)P=)M[C6`;F?-Q/\`Y^T5^N]%%%?EE^WM<_\`"6_M M::=H7D?\>]OI^G?^!%Q_]T5^H&G:9!I6GP65G$+>V@A\F&#T%7:******FJ& MBIJ********AJ:H:*FHJ&BBBJ]>;_'[X4VWQJ^%7B#PG.RFXG@,]DQX\BX&? M(/YU^;G@W]JSQQ\)?@;K'@&QF_L3Q%I%^8+&>XMQ]HA@^T3BX@/N)QC/I7Z# M?#K3+?XZ?LX>%K?XD6]CXB_M;2;>XO\`_GWG->E>'?#6E>"?#VG:%HUO!I^D M6%OY$%L/^6$%?)_[=?[5EQ\*-/@\&>$;W[+XPO\`]_/J$`_X\+?)Y_Z[FJW[ M)/P)L?@'X/U+XK^.]5L8=1U:P\^XF/2QM_\`CXY_Z;\UXWX8\/2_MU_M4ZSK MU[>07/P[\-7-OFVG\\>?IY/[B#[. MF6'A[P;#<6'V?P__P""EWBSPW-8V%OX-\.IX7LO M]'@L!Y_VD0>O->Y?L(Z/'X]\1>+_`(JCQ%K<]]>3W&FRZ)?S>?;VO[_S^+@? MZ_@U]FU8HJQ61XCU*?3-(OK^RLIM7NH(/.@L+>;!N/0"O@K]AJZU2]_:R^+5 MQK6E#3]7N;>XN+['2QG_`+0_X]Z_0RBBBBBBBBBIJAKSOXY?#6U^+?PO\3^$ M[ET4ZC`1;3%L>3..8#^$PS7XS6&H>*O@A\1S>V@ETCQ?XOV M,^"OQV\-?''P7!K_`(>OQ<8!@N(#Q/!./6'MZUZC111117PA_P`%%?VA]3\( MV?\`PK+3+>`P:]I7VJ^U$S?Z0(?/P8!Z9%4/^"8?PQM[30?$'Q!OK>X&H3S_ M`-DV+7$.`+<8/[@U][5\(_%3]AOXH_%O6_$&H:U\58[G3C?3W.E:;<"U%%%%5ZIZQIEOJ=A/8WL,-W;7$/D36]Q_RWK\POB=\"OB!^Q+\0 MF\?^!`=:\&^?/;G@S_9[?_GWOS_SP^E>J:W^WOXM\3>+-(M_A#X'N?&7A^QL M(+C58!83_:1<'_EWQT@_'-?;^B7\^I:587\^GSZ=//!YYM;D#SX>G[FI-2UR MPT,0?;;VRT_S^UQ/]GS6E;W-6******^+O\`@J%<3CX+>'8()\6\_B6W$_\` MX#W%>C?L/^&;7P[^S9X6N+,7D)U6V^WW"W-Q]HQ,>OD>W'Z5]%T57JQ2=OW. M*@JQ1111111111111111117YF_\`!074?BQXW\;7'AT^%=>/P^T0P-#/864] MS;WISS-<$<<=/PKY^_9Q^+'@WX*^,]/OO$WP_@\074$_[_4KF?-Q8?\`7O;_ M`//>O7/VVOB/<:U^T-HT'C;P+_Q2VA7'D07'D7$%QJUA_P`O%>:_M8_$CX;_ M`!(\6:-?_##PV/#NGP6'V>>V%A;Z?Y]Q]H_Y]Z_5CX!:)J?A[X&^!=*UF`6V MKV.B6UO<0`_ZAA"!C],5Z31111111114U0U-14-%%%%%OT-35#111111111; M]#17-ZOX(T#Q))YVIZ#I>HS_`//QJ5C!.:IS_"CP;=13K-X3T*X\\>3-_P`2 MN#D>_%C[+[U^4_QW^&__#07[;NL^&_"%O#8>=-]GO[BX@S!!<6_ M_'Q<5^FGAS0=(^'WA*PTJQ4:=H^E0>1#]HF_U,%?)O[3O[;T&C`>!?A&L/BC MQCJV+<7^G?OX(//_`.>&#BXG]JK?LX_LD3?"C5M:^)_QHU'3-0UR>'[1.-0` MG@LL8S<3W#=9_?WZUX-^VS\?]0_:`\__ M`%PK&U?]L,Z%\&8O`WPV\+M\/)VN)[?55@Q?B]M_L_:XG'^O^N:\-\&>-M=\ M)0:CI.B3_P"CZO;_`-GSZ=Y'^O\`^G?_`)^*Z'1=2G\6Z#_PB?A#P)!_:-_/ M;_:-1MH+C4+C_1__`$GMZ_8;X(?#<_"7X6^'_"GVC^T9])M_L\]Q_P`]Z[RB MVJQ16/K4]]9Z5H7/[8OQA;4[*'3M1N+ M>:XOX'F\\P3_`&CG[//Q^X_K7WK;]#1111114U0T5-4-%?,O[5'[&6D?'PCQ M%8W\VC>,;>P-O!<=()_^NXK\W-"\3_$W]E+XAS;$U/POK*W(:]TZ[4'[=".A M'_/>"OT2^&W_``4,^%?C6VMAJ.H3^%-2,'GW$&I'%N)_^>'GXP37NGA+XR>! M_&NK?V5X?\5:5K6I>3Y_V>POA<''X5V]%5_M7M7S9^TQ^V]X3^!UI]BTU[?Q M3XIERJZ?!./(@]YR#P*^!_@)\%O$O[7/Q>U&_P!3GF-AY_V_Q'K!@P">PM^# M^_\`PK]?M%T.UT/2[:QL(5M;"S@\B"W`_P!5BM6J_P!E]ZL4444444444445 M7K,UG1++7+"XL+Z"#4=/N(/L\]M*O@3XJN?B?\&+V:"ULP M;B?3;<$W%B/2`$?OX.>AKS[P'\0_V@/VKO$NL6>A^/X-%8"VF^P?VJ;&$CM] MG-OR?]0?S-9/Q<^'/@OPKKHLOC'\7_$?C3QC8V_V>?3]%@^T?8?^G?[1<5]= M?#C_`(*%>`?%NK:!X4T[0O&%WJ.H30Z?;SW5E!-S@8GG(GR![\U]?444457K M\W_^"B/QJM/'N@?#W2=(:^@L)_/UB>VU'2I["X_YX6_^O`];C\J^TOV9+>PT M[X!?#ZWTNX%UIPT.W\BX_P">W'^?SKU:J]S56#4[>YN)X(;B&X-N?WX_YXU: M^U>U'VKVJQ5>K%5[FK%%%%%%%%%5ZL44445Q^H_$GPEHFMPZ+J/BS1=.UAAG M[!=7\,,__?.";_`/M;1/`NAZ=J/_/S;6%>EVU% M%%6*/^6-%%%%%%3445#11111111111111111115>O!_VW?MO_#+_`(Y^Q>3N M^SP?:/M'3[/]H%?,?_!+7PH)]=\=>++BQQY$%OIUO<_^3%Q_[;U],_M`_LI^ M!?CGJ^D:YXGOM0T:YTF$P-<6-S#!YT![3DCD5Q<7[,'[-.GRWUPD/A[R;Z'[ M-]FGUSSA$<'B#,YQ-[BOE7]L?]F'2O@M/X?\9_#>;S_"]].+?_1[C[0;&_Q_ MHYMY^W?\J_3KP(-0/@O01KDPN-6^Q0?:+@P>3NFQSQVY[?XU^8_[+MP/&?[= MMOJNLV_G3S:KK%P//'2?_2*_5^BBBBBBBIJ*************AH_Y;4444444 M?\>\'TJO7S#\8OBI\*/V4M>\0>,1IL-QX_\`$<.#86!/VBYP`09O^>(]_:OG MLP_%+_@H==VTY-AX)^&^EWQMY[;[1]H_?C_T?,,_3GWKZ?\`A5^S/\*/V8=& MGUTVUN;BQ@\^Y\4:R_M7L7B^[^&O[`?PY@_P"$9TFQU'QC/BV@_M"? M_3M0S-_RWN?^6(YZ]/RKRG]FC]CQ?CE/J'Q)^*,,_P!GU>X_M"WTVW_T>/SKS[X>_" MW]H3]BJ;4M5T/PYI?C+1[_R/MVGZ;_I&/S_?U[)X%_X*8^#KJ,6/C7PYK?A/ M5NXM[;[1!^>:^EOAU\:_!OQ:@N9_"/B2Q\1"W_U_V8Y\CZUL>*_&VA?#_0KG M7/$.K66C:-`/W^H7,_`_&N>\"_M`?#WXC:M_9?ACQCI>MZCY'G_9[6?)Q7>_ M:O:BO@/]ARYAMOVL_C)8+``*-"L-;T\'SC;:A;^>,U\&_$W_@F1]H^TWWPQ\50W%N#./[.UD9SG_E MW^T#M7R%IX\9?!7XE7.G^'YYM/\`&.DSW&G&XT;_`$BX_P"GC[/7KFB_M^?& M[P3!_9-[KL&HW'_4:L/](KH-0_X*3?%;4+?4!;C0],N)Y_\`1[@0>>+?_1ZX M7Q%X_P#CY^T+?:?I.J7'B/4;;5I[?R+>WL?L^G?^2]?0GP9_X)D3?9X+CXDZ ML;;!Q_8OAV8\_P#7>X[U]X^$_"6D^`M&&D>'](L=%T^`?N;:P@%O!^E=)111 M1111111;]#1111115>BOAK]I#_@G^=;UF^\<_#"\BT768WS]*_0:K%%%%5Z_-C_`(*& M6MAJ/[4OP_L=:,QT"YL=/M[G[,?(N/(^WS_:/]([<8K[O^'WC;PEX@M[K0_" M^J6$[>&V&G7UAILV?L#0<"`_R^E>@53U#2X-4L+BRN,-;S0^1+^7_P!>OC^U M_P""?MQX"O\`4+[X8?%7Q'X$%_#^_MU((^M4-9_97_:"@-S_`&7\?+ZZMB?/ M@M[B>>"XKEQ\)OVS;<`_\)U!<^1_U%H/_D>O??V8;'X[:3875I\6I--OK:'/ MV>],PFU%^/XA"/)'X(OL\T$$.G:;_Q\3DG_ M`/77S];_`/!2CP7;SD:WX3\5>';8_P"HN+FW_P!?73V__!13X,W-CY_]K:I; M'SL>5<:3/N_E79^"OVO?A%X_MI_[,\=6%L;?K_:)^P?^E&*])T;QMH/B26:' M3->TS4;C_GWTZ^@G-;M6**********^=?VR[+XG:E\,K6/X5RRVUX+WSM5-O M/Y%P+?OC_/:OR>T7PEXE^*.K7$&B:3JOBO6;C_2)_L\%Q<7'_;Q7[=>`H;C1 M_!/AC2M3GL[?6;?3+>VGMX)NDX@`./R-?*7_``4.^*OQ5^&5OX=NO!NMC1_# MT[>1>W.GP[I[>X[&?T@Q6=^PQ^U7XD\9V_C'2?B#?S:AI^B0_P!K_P#"43D" M"R@_Y]YSZ@`G\#7IGP+_`&R%^/'Q3UGPYI'@^_M_"ME!Y]MX@/0GTG'_`"P/ MYUV7[1W[4/AS]G#1M)N-;M;W6+_59]MMI^G?>/\`]:OF+X2?\%"?''Q2^.'A M_P`-Q^#-+AT75Y_LQM;>X)G@'_/QY_2OKJ?]IKX7Z?XJ_P"$;G\OF[_@H3;_\8P:^ M/^GVQ_\`2@5S_P#P37\*#0_@#1_H^/_`"7KPO\`X*/? M$;7-0^)6C?#VPO9K73OL%O<3VPFQ;W\\]Q7SC^T]^SX/V<_$GA[2I;[^VKB^ MTJ"_N,V__'O<`X_I71_"+XU^,_V0_'G]DWWD:CX>_P!'N;_P[]H^T6_[^W^T M?:+?_IXK]>HO$UO=>&EUJQE^U6QL3>PX_P"6PP3_`(?G7YS_`/!.$0^+OVAO M&/B2:R^RW/\`94]S;V]O_P`>\'GW/-?I=5BBBBBBBIJ************AHHHH MHHHHHKY"_:7_`&P(?#NHS_#[X97$VM_$J^F@MX!!;_:(("3SSG_7>WT]*Q_@ M'^P]_9NM:CXR^,!L?&7BF^G\_P"S3`7$'3_7SYXG/3K79?M$?MJ>%/V<]5L/ M#5KI'_"1:Q_KKC3M/G$'V(>_'UXKYI\2>+O''_!0;QM/X=\)!O"WP_TR&VEO MX+^0L>IQ.<#B89/[@]/L]?3OC3QGX&_8/^#>GV.E:7#OY?/GP$_9]\2?M/\`Q%N/B[\4(/\`B0&8M8:+<_\`+<`CR(/^N`S7 MZ#:=_HUO_P`^U6:/LU+8>+?$E[XA%O\`\>XN*Y_P[;7]SJUO!I<%]>8^=J'B*W,%Q8V^/^>PZU][5\)_L=ZQ!K7[9WQKO8 M(H;>"87`\D]?^0AUK[THM^AHHH^T#THHHJ:BH:**.(![5Y[\*/ M%(^SFXTJQ:X@%P.#/_RQS^)%?*W_``3Y%M\,/V:O&?CG5+B$6$]]<:A_I'I! M;_\`UJ\8_8'T67XD?M5WWC%A!IYLHK_6)K;R.\_[CR/P\_/X5^D6L_#'PGXD MU8ZKJ_A31M2U(0>3]IO+"&>?'U(JEI_P;^'^F30S67@7PY;S^MOI5N#_`"KO M>(![4?\`+&BBBBBBBBBBBBBBBBBBBJ]'V7WKY(_;'_8U_P"%T8\5>$_*MO'4 M)A@G+S^1!?09.<\<3>A^E9/[*O[86JZKKT'PP^*EA<:;XX$_V>"^GM_(^T8' M`G])^.@K[-JQ1115>OQ^_;)\1#Q%^V#XA%C,-9\B_@T^"VGZ9@M[?-O_`.!% M>6_#/XQ>,_@[KVHZMX1U:?1=1OX/L\_^CV]Q/^T)X7\A M?;`'->_UR?Q6\.>)?%G@K4-*\(^)3X5UNX'^CZP(//\`(_"OFC3OAQ^UYX,) MF@^(7A;Q7Y^(/L^H9`@_'[/1)K/[8GABZN;VXTKPAXIM;,8_LZU)5I_Q'(-0 M77[9?QMT^',_[-VKCZ-7'A:YM[>:X\T7 M$]QY..@FS``"?K7UO17!CXR^!HM:&C#Q5HHOXA-YMJ;Z$,ODXSD9XQ^E7!\5 MO!D\_D1>,M",V/-P-4@Z?G71VES#>6HGM9?/M[C]]%-!R#4N?^F%-?C3;_%#4UU*Y\0V M[6UP+?[>1;^=;_Z@XKS3XD?\$X_"GQ)\?Z_XLN_&7B&WU'5IA<3VY$$P@/MD M=*9XJ_8#TRT^#3>!_!GBBXT:ZN-0_M#5-6OX?M%SJ/I;W'D[?W'M7HGP;^`* M?L]?!S4-*\(6]AJ/C>:RGN+C4;K]Q]OO\'[.9L<^3GCZ"OCKQ7^Q)\>_BQX< MG\8^+M<@U+QC!!B#1]0N!YX@]/M'^HS_`(50T+]C7XR>!/@YX@\3Z1"-'U_4 M0()M(M3G4#IY_P!?_P#P]?/GA3X7?$+3?$NC3Z7X%URYN+>_M[B"VN-!N/L] M?J=\$_VLM'^('C4?#[6+.?P_\1K&V_T_3_)S;F>#'VB&W)/.*^C:**FJ&IJ* M******AJ:H:FHJ&IJAHHHHHHHHHHJO7QG_P4Q\57NG?"/P]HEG=BWBU75<7T M6.9Q!!]H(S^`_2O0_P!A'1+?1OV7O!PA$N;X7&H3_:(?(/GFX]/PKSS]M#]C MK6/C5KG_``F?A2Y@;Q%!8PV$^CW`QYXSP//^A_2OGZV_8>^.OQ1\>:-/\0_/ M_L[_`(][_6KC5K>XN+>W_P"G>NUA_8"\9>/OV@-9U+Q9/!I_@8WX%M/!/!-< M7%C`<6UL>,C]Q[<5]9?M9ZG<>&_V;/B#?:7/-IT\&GDP7%OU[5\G_P#!+>XL MO^$O\;P+YW]H"QM_)S_S[>>?ZXK]'J*******FHHJ&IJ********AHHHHHHH MHKY)_;5_:CG^%>D_$1X6#W'C?78B5,$7_'E;\\]?]=Z?_JK4_9`_93TOX%> M#+;5]9TJ#_A.;X&XN)N+C[#_`-.]N:S/VIOVQ=,^&.FW'A3P->PZO\0KS_1[ M>WTZ+[1]B/.>/^>_3$'7Z=^7^!?_``3XTC2[;^W_`(K_`/%4^*+_`,^XGT]I M_/MH,]O^F_;KZU[+\3/'W@#]D+X3B>QTJQTZU)\C2M%L,6_VZX]!BOE?]G;X M`^(OVFOBCK'Q4^+>@_:/#M^"8+>X^T0>?_J#;F"#_GW,%?H;INEV^FZ?;V5C M"+:W@@\B&`#_`%/%6Z***\F_:&_9VTG]HWPKI^AZKJVI:+!8WHOX7T[@DC_] M=<_:_L5?!.WL;:`^`[*Y\C'[ZX\_,OUYKUOPA\-O"O@D?\2#PYIFC?\`7A8" MW_E7357N?^/:OA/]E?0M+$_MS?%K0=+L5T[3K>PN/L5M;CB`?:+?-?=E6** M****FHHHJ&BBO$_VA?BQ\.O`5GIOASXD0)?Z=XGE-K'8S6/VB"=@1CS_`&YA MZ^U?_$UQG_!,CPC?^'? M@YJ^KWD/V:#7=4,]CCK-;P?N,_\`CM?8M6*******************KUS%K\2 M_"NI>.=1\'6>NVMQXHL+<7%YIX.9X8#W_.NGHHHKYD_;,_9/@^-&A_\`"2^& MK(?\)_8+^X/GF#[=`,YMR?RKRS]E#]K6X\/ZE_PJGXIF^L/$\-]<6\&L:OU6**KT5^3%O=>&_'_P"W?XAUZ]G^T^#M M)U:_\0W]P(/^7>PM_M'_`*46]9OQLTWX)_%#Q+?Z[\/O&>J:=XAU[5?M!T_6 M;&XM]/S%KZ^LM1U"U-Q<37&GC]P3/.TYQ M^=>MT58HJO15BBBJ]6***KU8JO31IUO#<^?Y`^T8_P!?5JBO#_$?[''P;\17 MMQ?7GP_TK[3<3>?/8^./\`@FE\,O$VJK>Z3-J?A:$#YM.L&$]N M??$^:R?^':6AZ8UO/HWQ/\8Z)/!T*SP'^EH6?\` MI&GV\TMS"/M'X7'%?4GP,^&GC/X?:7J`\:_$*]\>ZC/,6BFN(/(A@'L*]9KR M[XX^/O&7@'P[:WW@OP-/X[U&:X$$VGV]\+?R8.?W_-?-LO[<7Q=T:46>I?LZ MZX\T/[B8VQN"/P_T>NGN?^"C?P_T/4+BQ\0^&/&?ARXM_P#EUU&P`G_]'T^# M_@IA\&;F>"#_`(J*#(_UYTGB"O:O@_\`'/P=\<].U"]\&ZC<:I;V,_V>X-S8 MSVYSZ?OP*]'K)A\-:3;:S/J\6FV8U@PXFO\`R!YY_3-;WV@>E%%%34444444 M4445#1111111111111115>OS"_X*EW./CAX=_P"Q:_\`;BXK]#OA5:C3OA?X M.LP;C]QI5N/]//\`I'^H[^]?#/Q`_P""E_B30/&7B#3]+\*:5=:-I]]/;075 MS/.+@UY+\3/^"AWQ1\?V&G6&ESP>"_(_U]QHW_+Q_P"!%?47[,7[?>G_`!5\ M1Z#X)\1:%<:=XAOH/)AU&VG^T6\\X'/3_4<5ZI^VUJ$VG_LO>/3!#DSV7D#$ M/3]^*\)_X)=>$[8Z)XN\4DW?]H7$\%@0Q_<8QY^1^8_/WK[OJQ1111114U%% M0U-11111114-%%%345#1117F\WP(\"S_`!('C^X\.6]QXPV[1J$X\XP?3TKY MP_:;_:-\3>+O$M]\'/A'9W&I^*+A?L^JZQ838_L\_P#/#D9!Q_RW[5W_`.S? M^QAX4^!>E:;?WMC8ZSXY_P"6^LW'6#_KAQQ73_M"_M'>&?@%X";R1.82.H M_P">!SX)^T7_P#H_P#I%Q]H_P"N M]?6OP2_;<^'GQJ\2:?X;TU=4L/$%Q;&>*UU"W.,?]=N1`+C_GXK1HHHHKYX_:O_`&6=)_:,T.WG6?[% MXHTJ">'2[@3'[/-D?ZB<=P3_`%KYP_9Z_:ZU[X!^)!\*/C%;S6VGZ3?!,)X9^D\%6ZKT7%S]G_UU?A)^(>K:7!/J/D?:-0G^S0?\N_VC_CX_P#)BN5_LVX^P?;O(G^S_P#/Q7[7 M_LO^`+;X;_`KP9I,-_/J,'V#[2+BXZ_O_P!__6O5JL4457H_Y>**L457HJQ< M=!5>K%%%%%%%%%%%%%%9FJ:-8:S;^1?65OJ%O_T\P>?FN=UKX3>"_$FE7&E: MKX3T74=/G'-M/80$5-X'^&OA3X8:5/8^%M#TSPY87$QGF@T^W$`E/J1ZUT]> M+_&S]FZ#XSZK;W__``G/BGPKY%D;>&WT2^^SV_U^M>;:S^S-\=='@M_^$8_: M"U6XQ_KCK=N#^5*[>;]^-/NKF$&#_KAY'7\:Z#X5_'']HCQ/XYT;3_$/P#VR>37UY17-^-O'NA?#?PW<:]XFU2#1](MAF:YN3@"O*_^&UO M@K_T4*P_[\S_`.%=3X!_:&^'/Q-EN+;PQXJTS4;B#K`'\HC\Z[O^W+'[1Y/V MR'[5Y/G>1YPSBKU3444445#11111111111115>ORO_X*6ZY9:Y\?8((YL76D MZ'#;3_3/V@?I<"OTY\)P?9_"VC12RFXQ9P#SIN_[GK_GUKY"_:I_8'TKQM9: MCXL^'UM_9GB<_P"D3:/;?N+>_P"OY3^]?GQX\UO7=;N-.T+6[?\`XF/AF#^Q MH+>Y@_TC_KWK]8OV7?V>/#GPR^'?A'5+GPGI^G>.#I4`U34!!_I!GQSG\=Y^NZA!:P8ASR#YW_`++6#_P3&@EM_@3XBF,$MO!- MXDN&@!/,P^SV_-?856*****FJ&BBBBIJ***AJ:BBBH:FJ&BBBBBBO!/VKK37 MM8\#:5X<$^-+#P7K^K7HMX)I[[[!1_M&_MY0Z<-7\&_"FWN?$'BK'VU@^./C??S^*?$$TYGBTBZF,]N#Q_KP1SU_U'08^M?: M=IID&G6UO;6EO#!;VXQ#!`/]35RK%5Z**+:BBBK'_+:J]?!G[(I_XSA^,7^C M_P!G_N-0_P!'^S_9\?Z?;U]]T444445-1114-%%?G%^P]HVK^//VJ_B%X[O% M\FWL#?BX`_Y[W%S@P?A]GS7F?[9_Q/U;Q'^UC;:5XBN)?#V@>%+ZW@A:T'GB M&#'VC[3_`-=ZEU#X4?![XCZ_\0?BM;B>YN/#\,'V?5Q-/"/)_U_.? M.)([9%6OV%_A@_Q`_:-N/%&A07GA[PKX=G-_L:<7&[[0/W%MY_?BOU:M^AHH MHHHHHHJI=W4&G6_G3S0V]OZS\57TW7+#4K8G3;Z"_P#>WN//_K7!?%[]H/P+ M\"H--_X2W7?[.GON(+81&:>?\!6I\,_C%X/^+NB'4_">MV6KVV.8+=OW\!/: M:'.1^5=Y5>K%%%%%5Z*L57JQ117A7[1O[,GA[X]^%[Z":*UT_P`3[=MCKQ@! MG7K^Y)QDPGCC./Z_*'PM_:8\<_LJ_$*#X8_%+/%U]#IVC`Z?8?Z1#Y_\`S\5ZK\>_VE/V?!X. M$Z9<^';;QWH&H3C6;2UTZ$Q6MN/F@\Z;IC&9_W..0.17VKHT]M>:=;3VFTV M,T(,&/\`GCC_`.O5VK%%%5Z*L444444?9QZT444444444444444457N+:K%% M%%%%35@^+/"&B>/M"N=%\0:7;ZOI-P,36MU%E6_"O!-6_P""?WP:US4+B\_L M*]T\S3?:#;Z?J$]O!GZ"N<\1_P#!-/X2ZC:V[:6^N:)"_\`M!'_`'^S M7/P_\$N/!]M/&TCP[\'M5\7:%!`9VU2T-P?./L(8&Q] M*\WM_P#@HAXHT/43I_B;X+Z[H\GDY6&.:`3#Q)>0K_P`\6TNX!_("O7_A1\:?!WQI MT.XU3PEJHU"TMV\B8^68C"?Q''YUW=%%%%%%%%%%%%5Z_)CXRZ;8?&/]NC6= M"\__`(EU_P");?3Y_M'_`$[V_P!GN/\`TGK]9K:V@M[<00_\>]+<7,%M!7G? MCOX.>!/%FKV_B76_!MCK6LV'^D6]QY'^D5YW^R]^UG%KG M0>#NN//S7@?_``51OIE/P]A$LJV&+^?('_+HHHHHHJ:H:***FHHHHHHHJ&BBBBBBBBBOFKXQ M_#*RNOCMX=^*OC'5-,L_!'@W2WG%M.1D7P)PW\O^_`KP'XF?M.>./VJ?$VK? M#7X0Z1!_PC-XOV>?6`29IH3U,P_Y80')&>O/O7T1^S5^R;H?[.6GW$WGC6O% M-SQ/K#)Y.(.T$`]./_U5]!T458JO_P`N]6*KT44?9?>BBBYKX;_9V\1-KO\` MP4"^+4Z03>3]GO[#BON2K%%%%345#14U0T445XO\"?V2/[(@U:W-O/<]?W]Q_H_ M_DO7EEMIL_V>VOYX)[C3O/\`L_VFOV8_93O/!VI?!#P_JG@/0K?P[H]^#<3: M9;9_*[[]H/2-;TRQO]-\/06]S/?W0.()[?'_' MN#_RW_TC[/\`^`]?K1;_`.HJ"K%%'_+:BBBBBJ]'_+O5BC[./6BO(?C]^SKX M:_:#\*0:5K7G6M_9'-CJ-M_Q\6YKXL^"_P`=O&_[&/BD?#'XCZ5<7'A1K[$& MI3Y6"PM_^>]OWG@_(@U^CFEZG8ZO:B^LIX+FVF_U-Q;S^<)A7SW_`,%!=9GT MS]ESQ28+[^SKBXGM[<'_`)[#[0./TK\Y?"GP>^)WB[X-6\OAW2M4UO0=5\29 M.FZ=!]H(G@M_^/BX_P"__P"E;/PR^!VJ:+^U%X=\'ZUHDUS:0>)+>"=KBQ_T M:XMK>XZU^R56*KU8JO5BBBBBJ]6******FHJ&IJAHHJO5BBBBBBBBBIJ*AHJ M:BBBBBBBBH:Q_$7A#0_%=HMOK6EV6KP0]%OK<3X_.N+\1?LY?#'Q'#/#?>`/ M#VZX',UMIT$,WY@5O?#7X3>%/A-H)T?PEI,&BZ<9O/\`L]N.,UUU<)\8OA1I M/QK\&?\`".ZW/J5O8--#<$Z;<>1/D'IGMWKYWUK_`()QZ%->_:-!^)'C#0SY M..+G[1_/%9OBW]CWXN>#_#=C%\/?CGXDN;JVF_<:?K%[Y,!'IQ_*L>Q^&G[: M/AJWA@A\U97AW]LSX.^);6>:'QY8:=Y'4ZG_H'_H_%=9X6 M^/OPW\77%S!HOC30]1N(/]>+>^'%=I;ZG!<#,-P+CS^8:T:JW%T+:WGF_P!> M8>U?EU^Q]J5C\8?VU[CQ7J=A!;W%Q]O\006WGY^SS_YN*_0CXW_%K3_@K\-M M8\97MO+J,%@/W5K;]9YN^-_I\'_7Q;U][?LJ?&K1?CEX$ MNO$=EI<.D>(#<>1KEM;XXN,?Z[W[U\1_\%,KF>Y^/&GV$_\`Q[P>&K?R/_`B MXK]//"V?["TSSO\`CX^PV^:VK?H:***FJ&IJ**************AHHHHHHHHK MY,_:I_9C\9?M(_$7PQ;_`-N6>C>!M.@^T7&5,]P;CV@/!KS3QW\:M)_9:T^W M^#/P7\,_VCXY\B"WOM7@@',_3_MXN/\`&OI_X`?$"_\`$?@K3]+\4>(]$U/X M@V-N#KEKIU];W!MS_P!L.G:O5Z**L457HHHJQ;]#15>JUU-?V]/B#KVBSSZA87^E37$-Q/;^1WMLU]_444445-1114-'V<>M% M>`_M,_'#QS\*Y?#]KX'^'>H>.KC5#AI[;SS!!]?)!-6_VF?'E]X%_9N\4>() M[&R.KK80VT]A<$S0`SL+?'T_?_I7AG_!.3X5V.I_`CQ0WB"RLM8T#7-6(&GW M$/GC]QQS7N6F^`_@6]Q?_".QTOPL93-_:=[X7`_?>=_SW(SG->H>!?!&A>`/ M#5MH/A_2K?1M'L1B"UM^D-=)111111163KF@V'B31[_2=3@6XL+V`P36Y/!A MY']:^/O%W_!,KX>C1;^XT'6?$,&I?9S]A@N+V"6V$X_U!P8.F?YUS'[(_P"P MAJOA+Q8/$GQ.TN#[3I4\%QI.GVU_]I_T@?\`+Q/[U%^TG^R5\8?B_P#'G^WK M>^T/5_#MOY)L%U"8P064'4P3V_5L]!= M/@^S3Z+;7\_V+>#_I_M_2WKV/_`(*6:IINN?`?P/JMA-8ZA!-K]O<6=Q;8N#/!]FG/[C\" M*]9_84\/7V@?LP>"(-1A$+SK/?VZ>D%Q<-<0?F"*^A****L4?\L:KT58JO5B MBBBBIJ*AJ:BH:FJ&BBBBBBBBBIJAJ:BBBBBBBH:FHHHHHHHHJ&BBBBBBWZ&B MN2\4?#;PSX^\C_A)O#>F>(O(/[C^U+&"X\C\Z\MU;]B?X-:U>3SGP+96YG') M@GGMR?RKGKC_`()T_!.YM_)_L&^QC_7_`-K3Y_G7"G_@FA86H\G0_BAXJT>U M_P"?<$5]HVUJ+:"WA_YX54UJZ@MM(U"XF(^S0P3^=7Y6_P#!.?\`Y.6T[_L$ MZA7Z#?M,?#B_^+_P1\4^$M%-G#K.H0X@-R.!^_\`_K?K7Y[_`+.'[6&J_LFW M6K^!_%/AJXN;!9S//IWD?9]0M[@__JKU+XV_\%%/!OC_`.$VL>&_#_AS5;C4 M==L;BPN/[8@@^S6/&/\`MO\`2NR_X)D^!]4\._#WQ1KU]87FGV&N7]N=/%S_ M`,O%O`"/M%?-7_!0RYO?^&E/$7F0"WMOL5AY&#_KX/(Y_7-?J[XUA;S_\^_\`\D7%?HA^QO\`!'QI\%_#.L+XY\13:CJ.K7IN M!8?:/M$$)S@S^=U,T^03SZ5](T4444444458JM<7`MK M/_\`@H5XYU[0)QJ.D7^D3^3O)/`_P"T[JO[%?CV?X4: MYH=GJ/A72/LXGN--/^D?:+C_`$BXN/\`R/\`ZCK7?:?\+_A5^V%\4-:\?_#[ MQOXH\+>)K":">]NK>+[/GL)X,^OD=>:^V=%T[^PM!L+&6\FOS!!%!]JN/]=. M?4_Y]:V************K_:O:BC_EWH_X]J*****L457HJQ115>BO+_CM^S_X M6^/OAN;2_$%GY%]M_P!!U>W@S<6)]0:_*[]ICX3>+/V>M>M_`NIZ[_;7AZ?_ M`(G&D_\`/O\`\^__`($5^H'[)^OZ1K_[//P\N-(=1:V^D0:>>/\`EXM_W%Q_ MY'!KV&BK%%%%%%%%%%%%%%35#4U%0U-4-%%%%%%%%%%%%3444445#4U%%%%% M%%0T44444444457HHHK&\:Z/#K_A+6=#EE-O!?V4]L9Q_P`L`8<9_K7YA?\` M!-\VX_:.S/!/<7`T&X\@G_MWK[K_`&J_B'XP^&/PDN]9\":&FMZA%/#;W#3Q M&%O'EO!!1<_\`D"DT MK]I;P;H^IV-[;_L_>"8[JQF\\.L\^5]QD$?G7Z:_L_\`QMTGX^_#:W\5Z793 MZ<3^XGTZY_Y83U^ MESZQ`/W^GB^4W$7_`&PZULT?\N]?`_PZ?-BWE(+0X MM[?O#QS[U^@%OT-%%%%%344445#117YD_P#!3;Q) MW_X^!]HGZ?\`DO;UL_\`!3CX.MIU]X>^)-I?`&`OB) M;?$O1/&.GPRVW@>Y-S;:I.9QY%P<'I[^>(?UK]2J+?H:*FHJ&BBBBWZ&BJ]% M%'VBWHJGJ6KVVFVYGO9H+:"$><6GGQ3M.NX-2MH+BRFAN+>?_EXM^]6J*Q/& MGC#3_A_X;U?Q%K<_V;1]*MS'K&![W7-,U;3X M=0GOK(?\>4!SU@_U_G8[8]*^I?#NNV/B;2;'5=,F%SI]]#Y\%QZBM2BJ]%6* M**RM:O);'2+J:WL_[1N+>'SH8`>9C7Y6?#3]OCX@^$OBO<:YXMU2\UGPK?3S M_;=%MQQ;8Z?9Q5__`(*%_$W0?BOJ/PXU[PO>C4-/NM*N#`1!][]^!Y!_+]*^ M_P#]GG0]!T?X)>!K?PM!]FT?^R;:YA80>1YWG0`B?'N#_GBO6J*KT58HHHHH MHJO]IQ_KJ^=?VN?VJ[[]FJR\,RZ7X?LO$(U4W"G[3??9Q%Y`!S^M>=_!'_@H MJWQ:^)N@^#KKP*-%DU68P+J,&J_:1GZ>0/YBOHWX;?M`^!OBOJNL:3X:UJ"Z MUC29O(NK"?\`I M(^G:N>\1_M'?#_XN?!+XDGP9XKAN9[#0K_[0L_G03V_^CGGD9]*^9?\`@EM" M)_'WCB8W_P!F,6E6X&G?\_'[\G[1^G_DQ7WO\0OB!X:^%_AJYU[Q/?0:-H]C MUN+D`8X_Y85\,?';_@HKX?J9@MM/@\2Z/YYN/^O>WK]1J ML444444444445-4-%3445#4U%0T44444445\E_M]_"CQE\3_``'X6MO!=E>Z MC]GU#_3]/MI\`P&`UT'[$OP*M_A#\*A>WNE2Z?XQUL_\3=;@\Y@GN/L^?P/Z MU]*457HHJQ5>C_EWHKY$^*W_``43\&?#'QIJ'ARRT&^U][";[-/=6LX@@$_I M7J^M_M0?#_P;\--"\8^(MWU:Q@OK>Q_UMS,"!T@'/IR/3VKX*_93N=3^ M,G[;L'BI/MEU:Q7VHZO<3W<_[^&WQ]GMQ[\3P5[Y_P`%%O%?Q(\!S^#M7\,Z MKJNC^%[?*W%SI\N/]/\`^7<3^U>[?LT?M':3^T?X*N+^QMYM.U>P\BWU"UN! M_J+BOFG7-7MO!W_!3#39M/E%U;Z[`(;@>?QF>`0#];>OT%HHHHJ:BBBBH:** M*_+_`/:B^(5CX?\`V^M.U>^@@_L_PR;":Y^SP?\`+`0&<_:/QGKU/]I?]HWX M%_'/X,Z;8WNOZKIJ7U]Y]C/;:3]HN;&Y@QR8/^V]?3G[-EAX>T[X$^"+;PSJ M@U?P_!I<`MM2$7D_:!CAL=OI7J/V<>M%%%%%%%%%?*O[5/[;VD_`V1O#_A^W MM/$/C$\3V^[]Q8_]?!'2NV_98_:!E_:'^&L_B*_T8Z-=V]]/82VT`F,/R]QD M>_ZU[97Y?_%?XS?M'P:U\0M;CUN]\)>$])U`P8N+"WM\P&Y\B`V_VBW[F`G\ M:3_@G*/'_B3XI7]_:>([N#P=8'[1KEL]P/\`3[BX^T>1C_MOFNY^"/[0_P`5 M?VA_VJKC_A']5^S^!K">>XN-(N(2(#IX/D#GR,^?GMFODSX_>/?B1XC^(>HV M/Q!U6]&L:3<7%O!;W'_+#_KWK]`_^"9VI:[<_`"X@U2#_2/M'_D"OEKX:?#FW^+'QGT?PKX?N+X:;JM]<06 M-SG@B>'_IW%>K4457HHHJ MQ1<=!5>BOE[_`(*0:D+;]F?4K?O?:I;6_P">?\*](^$G@GPUXU^"'PNN-2T* MRU#[#H6GW%E_:$`N#`?LXQUKY&_97\(:7\7/VRO'WQ"M]/7_`(1S1-2GETN\ ML#]GMI;@@VX..^8?.FQ_M5;LM`L?AU_P4TT^/1[T1Z;KWVFYGR?M'[^>"X\^ M#V_?V^?:OT/HJ:H:*FJ&BBBBBBBBIJ**AJ:BBBBBBBBBBBBBBBH:FJ&BBBBB MBBBBBJ]?G/\`\%&O@;XSU3QS;?$'2[#^T?#WV"#3YOL[;KB&?/!\COQC\Z^* M].U+5O"4^LV'GSZ=]O@_L^_M[C_KX_X][C_P'K[X_P""5VC36GAKX@:H?^7K M4+>U'_;N"?\`VO7K'[9?[-GB+]H3PUHG_".ZY;Z=?Z5/-.-/O@3;W&?8#B;W MKXKM?V#?CYX=U6VN+'0;+[18S_:(+BWU:`5ZWXB^(G[8OPWTNWTN?PV;F#[/ M_P`?&C:'!J`M_P`+>OKSX,^-?$>I_!/3O$?Q!TF;1_$:6$]Q?Z;/N\CR,?N:M4444444445-111114-%%%%%%%%%%5Z/^7BBBC[+[T445YA^T MWX@U3PK\`?'6K:!++!K%MI4YMKF`?Z@^M?,/[$7[,WPJ\?\`P3T_Q+K>A6WB MK79[Z<3C4AS8'_GAUZ?\M_\`MXKQ3XB?L#_%ZVNM9UN>?1-:,'VBX^TV]Z;< M?9_^N%=-_P`$[_@_XWN/&=K\1].U2'3_``:QN(+ZW\TF>^(Y\@P=!CKSZ5ZG M^U+^U-JOB>XU_P"%?P^\&:MJ.L_:?[(O=1N+`S6^.?/$`^A_UYZ&N\_8C_9C MU7]GK0-:N?$%Q!_;>N"V9M.M_P#CWMQ#D#'XS&O`M*M[?1?^"B_A:#2_!'_" MOM/\^Y$%@+>WM_M!^SW'^D'/A M%X;;6_%>J#2-)$HA-P\,TPR?7`SZ]JD7QUI5UX!_X3+3)AJ^BFR.I03VW/GP M>3G-?FW^R]X5D_:G^/GQ0UW7-/D.DZQIEZL\[PX^P37!'DX]PNX_A7S]XG^` MGCGP;XRO_"TGAS5+N^LI_(5M,L9[D7(]17ZX_LH^$M:\!?LY>"-!\0VTMAK- ME;[;BVGZQ'SR<'\#^M>QU-14-QT%%35#117S[^U;J_QAM?"=M8_"70KBYN;T M_P"FZS;7$'VFQ'3]Q;W!P37Y2^(/`7CEOB3/X5U+2M4NO'-Q/F?3[C_CXN)[ MC_2*_3_]E#1_'_PP_9OCL/%^A3-K.E?:)](T9?(^TBVQF"`_]-^)OSJU^SA\ M>/B!\6(_$1\:_#>_\)6VF6_GP33V\]M]H/\`SP\B<9SCWKX!^+O_``O/X]>, MC?ZWX3\83K-/FQT\Z3]>Y^$O&_Q[_P"%#^(O#7A;X&P>'M/@ ML/L$%SIQGM[B`'_CX_T>X_TBXGK`^%>M>+/V!/A9_P`)+XA\&?:-:\6ZM]GG MT^XU;[/]GM[>W_T?_P!N*\J^,?C[P/\`'W5C/X%^%.J0?$/7H/M%]?_EX^SV]O_P`?%?2/@;P9\9_@_P#L=VWA_P`)^%-2@\>7^NW$TWD7%O\` M:+&`\^?[G"^17RO\7?V=_9UCU%O#F>>;V%?'_[0W_! M0K0M0\`6T/PH\27NF^*/MT/G_:-*Q_HYMYSTN..OD?Y-?&/BCXB^,?B)\0M' MU7QG+>^(-8)@@@MM0M\?:("BBBK%5Z*L5YY\:_@UH M/QO\#W'AKQ`)5MSB:"YM^)[>89Q,/I73^#/"%AX(\-:1H>E0_9M.TNW^SP0> M@_S_`#KEOA%\$O!OP5T_4;#PCI(TV"_G^T3]_.-<#\+_`-CGP=\*OBGX@\<6 M\]QK&LZM?SWYK\>_BW^U9\8Y_'_`(AM)_'%]HZP7UQ: MG3M`N/)MX?L\^/W!/7CUKR#4=2T+4O!?GS_;KGQU/JUQ<3W'_+O/I_V?_P!* M/M%?IQ_P3B^P_P##-EM]B^S_`&[^U;C^T/L_7[1V\_\`[8?9_P!*^JZ**XGX MN^(['P7\+O%.OWTT\&G6&E7!G-O#FX'':OSO_P""9VB?:?V@+B?_`)\-"N+C M_P!)[>OU.HHHHHHHHHJ:H:*+?H:*FHHHHHHJ&BBBBBBBBBBC_EM5>BBK%5[: MBK%9FHZ;;ZG87%E<0BYMIX/(GMZ\P^`/[-WAO]G6PU:ST"]U/4(=3:$S?VC/ MNP1D9'YUZO=6T-W;&WEAAG@Q^^AQFJ7AGPUI7@_2(-*T73+/2+"`?N;:P@$$ M`_`#%;%5_LOO7Q'\6=(\K_@I#\-;F"?[/]NL89_KB#41_2ON2IJAJ:H:FHJ& MBIJ**^$_^"EGB/5M4NOAM\.-,D@6W\3:AB;/7S_/MH+?];@U['\2?$&@_LH_ MLN&Q6X.IKI.DC2+"WN9L7%]/@0`5^?/PKT/]H+X3_#7_`(3GP);ZII_A:^_X MF,]Q;_9[C_4?\_%O^=?>O[(/[5UC^T#X&QG2]*L M=/X\C_1H/(XK;H^R^]%%'V7WHMJL444457N/])%%>$?MB?!_7?C7\&9_#/AC M['_:)OH+C_2)O(''_P"NOR2^*OPNUWX.>++CPWXA^P_VS!!]HG_LZ?[15CX: M>%-5\:?%'P_H>BP07.L7U]F#[1/FWN/^V]?NI5BK%%%5ZL57JQ111111111; M]#1111114U0T444445-111111111111111111114-345#4U0T444452O+V#2 MK":]NY1!;PP^=-/TXKXWU3P5^RW=0>*OB[;7T%Q;CSS?W=O//<"">?\`TO@CXQ>"O!WA.[TRX\#^(Y?%.@ZA;3[I[^'R9[<]Q/!@9_(5^D_ M_!/WP]?^&OV=-'^W<+?WL]_;V_D&W,$!^G^N^OO[5].T45X]^UOJ$&E_LU?$ M&8G/GZ1<6X_>X_U_']:^4?\`@ECX;MVU?X@:X9YOM%O#;V)MSV\_G/\`Y+BO MT7HJ:H:*FHJ&BBBIJ*AX@'M14U%%%%%%0T444444<0#VHHHHJO1115BJ]%6* M****KU^?'C.WT70_^"B'@@VFD:K8-<3DWLVH"<&XG_TC$]ODD>1[]*_0^WZ& MBBIJ**AHJ:H:FJ&O@+QYXOTKXC_\%%O"VAZS;B>P\-3>18>3^_\`/N?L_P!H MY]/_`+GJ?_@J=KZKX;\#:6MY`G^G3WL]M_R\8$!Q_,U]1_LZ>"]4\#?`KP=X M"^U'3])@M[AH(0!C;S#^'2O+=*_89\-Z%^T'IWQ'T:Y_LBPMOWW_``C] MM`(;>"XQ]Z'``%?4M35#4U0T5-4-%%%%%%%%5S;?:*/^/:BBBK%5ZL57JQ15 M>BBBYKX*_;\^/OQ6^%/CG3[#PS?S^'_"MS8?N=0@M_\`7W'IY_:OG#]G/XL> M#?$/QRGU7XV6\'BJXU2"WM[?5]7`^SV,X_Y;3YX'I6K^P#IWVC]K/3OW$%Q; M007X_P#)>OUOJQ5>K%%5ZL57N:*L4444444?:!Z4444444444444445-4-34 M5#4U%%%%%%%%%%%%%%0T5-1114-%%%%%<-\8_#<_C+X2^,=!LS(NI:KI5S;0 M#_IL8#M_I7XZ?%OX'>./@=<0V_BS2Y='M]5AVPW%K8^AKS^X_U%O^X_ MU$%?M]\$?#4_@[X*^!M(O/)^T6&B6]O/Y`](!_A7DG@[_@H+\*O%OC.W\."? M5-.,\WV>WU#4;?[/;W!^M?3-?/?Q$E^.?_#1'A<>$[.Q'PSAA_XFK7,]M^^. M?WV`'OV?VTJZL!J4NO:A!;0$=("#YQG_#%8O_!,'P_# MI?P:U?7!@SZOJOV<_P#;"``?UK[-J:H:*FHJ&BBBIJ**AHHJ:BBBBH:***** M*******KT458JO15BBBBBBBOS_\`C9XUMM<_;_\`A<]C/#;W.FS6^DW/[Z&8 MG]]..G4?Z_ZU^@%%%%345#1Q`/:IJ***^=/`G['_`(4\"_'36?BD+Z^U'5K^ M>XN8;>X\GR+":X_UY&!GFODSX\VX^+/_``4'TO0AH4VH6MA?:?I][:_9O.\Z MV@_TB>>X'_/#_2`*_3&ULX-.MXK>"&*"WB&(881@#Z5=HHHJ&BIJAHJ:H:** M*******KT58HHHHHJO1117PA^V)^TWH4FM>*/A%XN\.ZUIWAR>"$?\)#:_\` M'Q]HSY_GP6__`"\0#&#[YKQW3?V";#4_A5K?C^S^(]GXAT>WTB?4;`Z/8?9Q M<^1;G_7_`&C_`%'2H/\`@FCX9&O?'Z?53/\`\@'0Y[G[/_S\>>?(_I7ZL6W^ MOJQ5>K%%5ZL44444457JQ;]#111111111114U0T4445-111111111114-344 M44445#14U%%%0T444445RWC'P!X9^(.E0:7XH\/V7B#3P?.BM]0MQ.(C^-?D MO^T=X(TK4?VJM0\%^$=*TOP]I_V_3]'L+?3[`6]O_P`N_I_T\5^OFF:78^'+ M"WLK"&&UTZQA$$%O;C_4BOSM_;R^`?PH\$^&SXC\,7%CH_BJ:_\`^1?MYL6U MQ_S\?Z/_`,L*\U^%?_!0KXC_``OTJVTJ^%CXKT^"#R(+;4/]'N(/K/WKZF_9 MY_X*!P?&'QYIO@[6_"O]BZCJH_T*YT^^%Q;D55_X*<:JMK\&?#NF#R?].UV' MO^_/DP3DUZ9^P=;BOHFWZ&IJAHHJ:H:*FHHHHHHJ& MIJAJ:H:*FJ&BBBBBBBBBBBBBBBBXZ"BBBBBBBBOA']H?3="M?VPO@[?Z;X6>\G MBM;=1_K93@5!+J<']G?;/,\ZV$/G">'N/:OS@_8;\;3_`!0_;)\5>+)O(MO[ M6L-0N/LP_P"OBWK],J**AHHJ:BBBH:FHJ&BBBBBBBBJ]6*******KT45YO\` M&[X&>&OCIX.N-"\168'!-CJ`Q]HL9^Q@_+_/;\_X?V:/B=^SLWQ(&JW'_%M3 MX;UBVFN+:^_T>_,]L8+?_1_^?CS_`"*[?_@F%X.TY-3\7>*X]7GFOH8/[/GL M39A1!#<$3B;S^^?(_P`\5^B-6*******************FJ&BBBBIJAHHHHJ: MBBBBBBBBBBBBBBBBBBBBH:*FJ&BBBBBBBBBOCZX_89;4_P!H(_$O5?%\^H6X MU<:Q]@^Q#S?W$VZW@S_='KBOIWQGX#/"5]'>Z+X3T31]1(_X^-/T^"";\P*\D M_:(_8YT/]HWQ%I.KZKKNIZ+>V-D;%3:0P'()SGGZUZ5\$O@YI7P,^'VG^%M' MEFN;>WS--?!75KJXUB*P_M!N)_WUKG,'$'7!]?QK[>M M^AHHHHJ:H:FHHHKX5_X*H^+I-/\`AQX-T(`>3?:I/_88TW4X9_LUUI_@N![?`\_\`TF>W`@/O^_85\_\`_!*_PP'O?'.N7&D! MA;PVUA;ZA[@SFX@_#_1Z_16BIJAHHHHJ:BBBBH:**/LX]:****KU8HJO15BB MBBBJ]%9?B3Q-I7@G0M0US6[V'3M'L8/M$]Q<'B`5^8G[2_[:OBOXU:?K&D^$ M+&XT;P+;_P"C7UR>M^/K_P`N]?0W_!,;3?L_P/\`$-]B'[1<:[U\C_IWMZ^R M:L444444444444444445-4-%OT-%%%%%%%%%%3445#14U%%0T5-111111111 M11114-%%%%%35#111111111114U%%%%%%%0U-111114-%3445#]H'I111111 M1115>K%%%5ZL4444444457KX:_;9'B/0_C#\)=;U.?2[_1X->\G2=-,,\!&3 M!_Q\7%?=M%%%%%35#4U%%?#7[W-Q;_\` M+N+@_P"HM^E?7?['WP4U'X%_".'1-:M[I[V:XOI[&;SA-R?).?ICCV]Z^ M@Z***AHHHHHJ:BBBBH:******KU8HHHJO15BBJ]%97BGPKI'C;0-1T/6[&'4 MM(O[?R+BUN!^XF![5RMA\"OAYIW@RY\'0^$]*'AB^F-Q/IWD?Z/-.>_Z5T?@ MSP-H7@'0H=)\,:39:-IT'_+M86_D"NDHHHHHHHJO5BBCB<>U%'V<>M%%%344 M5#1114U0T445-111114-%3445#14U%%%%%%0T45-114-%%%%%344445#1111 M14U0U-111114-%35#4U%%%%%%%0U-14-%%%%%%%%5Z**L457JQ1111111117 MR+^U@T^I_'SX!6=[8FVMH/%>8+CSO]?_`,>_:OKJBBBBIJ*AJ:BBBH:*FHHH MJ&BIJ*AHJ:BBBBBBH:FJ&IJAHHJO15BJ]%%6***********/^6-%%5Z*L444 M45-4-%%35#4U0T444445-14-34444445#4U0U-111114-%3445#4U0T44444 M445-14-%%%%%345#4U%%0U-4-%35#4U%%%%%%%0U-14-%%%%%5_^7>BK%%5Z M*L4444457JQ111117QI^VGJ<$?QM_9\L#JBZ>L.N_:)KC.9XAY]O7V711111 M4U%%0T5-4-35#114U%0U-4-35#4U0T45-114-%%%QT%5ZL57HJQ111111111 M5>K%%%%%%%%5Z*L4444?:!Z45-4-%%35#14U0T45-4-35#114U%%%%%%0T5- M111114-34445#14U0T44445-11114-'V<>M%%%34445#4U%0T445-11114-3 M444445#111115>K%%5Z3[5_Q\?\`3"K-%%%%%%5ZL444445\1_\`!0L06OC7 MX+7_`)$/VB'6,_:"?(Q^_MO^6_;Z5]N444445-114-%35#4U0U-4-345#4U% M0T5-11114-35#11111111111111111<=!5>K%%%%5[FK%%5Z**L44445-111 M114-%%35#11114U0U-11111111111111111114-%35#11114U%%%0T5-1114 M-%34444444445#4U0T4445-111114-%%%5Z*L444457HJQ1115>BK%%%%%%? M#?\`P4!/!]B(;TE?$NGS?:%A.!Q/\`\M^U M?6EM_P`>U6**FHJ&BIJ***AHJ:H:FHHHJ#'_`$VJ>BBH:FJ&IJ*********A MHHHHHJO_`,>U%6*******KU8HJO]I^S6_P"_K@/&?QW^'OPZOO[/\3>,=$T> M_*\6-Q;\.M=?1115;^T M8//\CSX?M'I5FBIJAJ:BBH:*FHHJ&IJAHJ:BH:FHHHHHHHHHHHHHHHJ&BBBB MBBBBBBBBIJAHHHJ:H:*FHHHHHHHHHHJ&IJ***AHHHJ:BBBBBBH:***KU8HJO M5BJ]6***********KT58M^AHKX0_X*56T^EP^`=;@UC4&VZB3!H\)_<&XA.[ M[0/^FPS@?2ON>V_X]JL4444445-114-%%3444445#14U%%%0U-111114-%%% M%%%%4-3DN+:QE^Q0Q7%QC,-O++Y(/MG%>$ZO\)_B_P"/V\7:7XI^(.F:/X0U M99H+>PT*P\ZYA@(QS//W_"O1OA7\)['X3:5/I5EJ^MZQ;3-YW_$ZOOM!A]A7 M?UEZ-]O_`+/M_MOD?;\?O_LW^HHOOM6VW^R?9\^<,^=_SP[UJ5YG\(/AA>_# MG_A*9M0UUM?OM*-8@'VJRFG&,C]*]5TNTET_2+>&>8W]Q#"(C.>#,? M\BLO5/`>A:MXITSQ+=:7;W&OZ9#+!97[#)@4]1_GWK@?B[^R]\.OC7J/V_Q1 MHDMQ?B#R/M]O,8&Q^=7?&SX":1\<='_L MO6M6URPM,#,&FWQ@A/U`%>-1U2^GG,L_ M'[\Y)!/^<5[+HNEC1M-@LA<7-UY(_P!??S>=.?J>]:U%0U-4-35#14U%%%0T M45-1114-3445#114U0T5-14-%%%%%%%%%%%35#111111114U0U-1114-3444 M44444445#4U0U-4-3444445#111111115?[5[44?\?-6***********+CH** MRM;\-V/B*U^S:G866H6W_/&^MQ/_`#K5HHHHHHHJ:BBBH:FHHHJ&BIJAJ:BB MBBBBBBBBBBH:**********/^6-%%%%%%%%%%%%%%%%%%34445#114U%%%0T5 M-4-345#1111111114U%0U-4-%%%%'V@>E%%%%%35#111111114U0U-111111 M1111111111114-34444445#11111115>K'V<>M5Z**L444444444457JQ111 M11111114U%%%%%0U-4-35#4U0U-11114-35#111111111115>K%%%%%%%%%% M%%%%%%%%%3444445#14U0T5-4-%34445#4U%0T5-4-%%3445#_RVHHHHHHHH MHHHHHHHHHHHHHHHJ:BH:FHHHHHHHHHHHHHJ&IJ*AJ:H:FHHHHHJ&BBBBBBJ_ M_'S11115BBBBJ]6**********************FHJ&BBIJ*********AHJ:H: M**FJ&BBBBBBBBBBBC[./6BBBBBBBBBBBBBIJ***AJ:BBBH:FJ&BBBBBBIJ** M***AHHHHJ:BH:*****/LX]:+?H:*KU8M^AHHHHHHHHHHHHHHJ:BBBBBBBBBB MBBBBBH:FHJ&IJ*******AHHHHHN.@JO1_P`O%'_'M5BJ]%%6*/LX]:K_`/+Q M15BBBBBBBBBBBBBBBBBBC[0/2BIJ*AJ:H:FHHHHHHHHHHHHHJ&BBBBBBBBBB MBBBBBBC[0/2BBBBBBBIJAHJ:H:FHHJ&BBBIJ*******AHJ:BBBBBBH:FHJ&B MBBIJAJ:H:*****/^6U%'_+:BBBBBBBBBBBBH[>!86:4C]]+UJ2BBIJ****** M***************AJ:BBH:******KT58JO115BBJ]6*************FJ&BX MZ"BBBXZ"BIJAJ:H:FHHJ&BBIJAJ:BH:FHHHHJ&BBBC[0/2BBBBBBBBBBBJ]6 M**************FHHJ&BIJ*******AJ:BBBBBBBBH:FJ&IJ*AHJ:BH:***** M******************FJ&IJ**************AJ:BBBBBBBBBH:*****/^6- M5Z***L46_0T44444444444445-14-%%%%35#114U%%%%%%%%%%0U-1111114 M-%%%%%%%%%%%5Z*L?9QZT44444444445-114-3445#1114U0U-14-%%%%344 M445#4U%%0_:!Z45-14-%%%%%%%%%%OT-%%%%%%%%%%%%%%%%%34444444444 M44444444444444445#11]H'I11_RQJO115BJ]6*KT458HJO5BBBBBBBBBBBB MBBBBBIJ**AHHHJ:BBBBBBBBBBBH:FHHHJ&BBBBBBBBBBBBBBBBBBBIJAJ:BB MH:*FJ&BWZ&IJ***AJ:H:*FHHJ&BBBIJ**AHHJ:H:FJ&BBBBBBBBC[./6BBBB MBBBBBBBBBBBBBBBBBIJ***AJ:BBBBBBBBBBBBBBBBBBBBBBH:*********KT M444458M^AHHHHHM^AHHHHHX@'M111111111111114U%%%0T5-1111111114- M%%OT-%%%%'V<>M'V<>M5ZL44444445-14-34445#4U0U-4-%34445#4U0T5- M14-35#14U%%%%0T5-114-%%%35#11111111111111_RVHHHHHHHHHHHJ:BBB MBBBBBH:FHHHHHHHHHHHHHHHHHJ&BXZ"BBBJ]6*KU8JO_`,>U6***KT458HHH MHHHHHHHHHHHHHHHHHHHHJ:BBBBH:***FHHHHHHHHHHHJ&BBBBBBBBBBBBBBB MIJ*AHHHHHHHHJ:BH:FHHJ&BIJ*AHJ:BH:FHHHHHHHJ&IJ**AHHHHHHHHHHHH MHHHHHHHHHHHHHHJ:H:**FHHHHHHHHJ&IJAJ:BBBBBBBBBBBBH:/^6-%%%%%% M%5ZL457HJQ5>BK%%%%%%QT%5ZL44444444444445-4-%%35#14U0T5-1114- M34444445#4U%0T4444444444?9QZT445-4-35#1114U0U-4-%34445#114U0 MT45-11111111114-%%%%%%OT-%%%%%%%%%%%%%%%5Z/LOO5BBBBBIJ*AHJ:B MBBBBBBBH:FHHHHHHHHHHHHHHHJ&BBBBBBC_EC15>YJQ15>BBBBK%%%%%QT%% M%%%%%%%%%%%%%%345#114U0T445-14-344445#4U%%%%%0T4444444444444 M446_0U-14-%%%3445#4U0U-1111114-344444444445#1114U0T4?\MJ*FHJ M&XZ"CB`>U%%'$`]J**************FHHJ&BBBIJ******AJ:BBBBBBBBBBB MBBBBH:**************KT458H_Y;444444446_0T4444445-11114-%%35# M1114U0T5-1111111114-345#111114U0T4?\L:**/M`]**FJ&BIJ**AHHJ:B MBH:**FHHJ&BIJ**************AHX@'M1111111111115>K%5ZL44444444 M445-111111111111111111111111111114-%%%%%%%%%%5Z+:K%%%5[FBBK% M%%'$X]J***KVU6***+CH****FHHJ&IJ*AHHHJ:BBBBBBH:FJ&IJ********A MHHHHHHJ:H:***FJ&BIJAHJ:BH:*FHHJ&IJAHHHJ:BBBBBBBBBBBBBBBBH:*F MJ&BBBBBBBBBBBBBBBBBBJ]6******FHHJ&IJ*****************AJ:BBBB MBBBH:***+CH*****KU8JO5BBJ]6**KU8HJO5BWZ&J]S5BBBBBBBBBBBBBIJ* M**AJ:BBH:*FHHHHHJ&BIJ****AJ:BH:FJ&BBBBIJ***AHM^AHHHJ:BBH:*FH MJ&IJAHHHHHHJ:BH:FHHJ&IJ*******AJ:BH:*********/\`EM1;]#111111 M111111111114U%0T5-11111114-%3444444444445#4U%%0T444444457JQ1 M11115?\`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`'M1_R\47-%%6 M*+?H:*******FJ&IJAHHHHHJ:BBBH:*****FJ&IJ*AHHHHHHHHHHHHHHJ:BB MBBBH:**FHJ&IJAHHHHJ:BBBBBH:FJ&IJ****AHHHHHHHJO\`9?>K%OT-%%%% M%%%%%%%5Z/\`CVHJQ11111Q`/:BBBBBBIJ****AHJ:BBBBBBBBBBBBBBH:** M*FHHHJ&BC_EM111111_RVHHHHJO5BBBBC_EC1115>C_EXHN?]?11;58H_P"6 M-%%%%%'_`"VHJ:BH;CH***FJ&BIJ****A_Y;5-1111114-%35#<=!1111111 M14U0T6_0T45-111111114-345#114U%%%%%%%%0U-11114-35#1_RQHHHHHH MJ:H:+?H:**********KW-%%6/^6-%%%%%OT-%%%%%%34445#4U0U-1111111 /1111114-%35#4U%0U__9 ` end EX-10 5 exhibit10-24.htm EXHIBIT 10.24 Exhibit 10.24

Exhibit 10.24

NONQUALIFIED INDUCEMENT STOCK OPTION AGREEMENT
(Shares not issued under the Equity Compensation Plan)

        THIS AGREEMENT is dated effective as of the grant date set forth on Exhibit A attached hereto, between MEDTOX Scientific, Inc., a Delaware corporation (the “Corporation”), and the individual listed on Exhibit A (“Grantee”).

        WHEREAS, the Corporation desires to grant and the Grantee desires to accept the Stock Options to purchase Common Stock of the Corporation (as defined below);

        NOW THEREFORE, in consideration of the premises and of the covenants and agreements set forth below, it is mutually agreed as follows:

        1.        Grant of Options. The Corporation hereby grants to Grantee an Inducement Option to purchase from the Corporation all or any part of an aggregate amount of the shares of the Common Stock of the Corporation, $.15 par value per share (the “Common Stock”), at the Option price and on other terms, as set forth in Exhibit A attached hereto and made a part hereof, and in accordance with (but not issued under) the Equity Compensation Plan of the Corporation adopted by the Directors and Shareholders of the Corporation effective as of October 26, 1993, and as subsequently amended. The date of this Agreement is the effective date of the grant. This Option is not intended to qualify as an Incentive Stock Option as described in Section 422 of the Internal Revenue Code of 1986 and is referred to as a Nonqualified Stock Option.

        2.        Incorporation of Plan by Reference. This option and any shares purchased upon the exercise of this option shall be subject to each and every provision of the Equity Compensation Plan. A copy of the Plan and all amendments is available from the Company upon request of the Grantee. All terms contained in this Agreement which are not defined in this Agreement shall have the same meaning given to such terms in the Plan.

        3.        Exercise Period. This Option shall vest and become exercisable in accordance with the schedule attached hereto as Exhibit A and made a part hereof. All vested Options must be exercised on or before the earlier of the end of the ninety (90) day period set out in Section 6 hereof or a date ten (10) years from the date of the grant. Vesting shall continue in accordance with Exhibit A notwithstanding the termination of Grantee’s employment by the Corporation.

        4.        Exercise of Option. The vested portion of this Option may be exercised only by written notice of intent to the Corporation at its office at 402 West County Road D, New Brighton, Minnesota 55112. Such notice shall state the number of shares of Common Stock in respect of which the Option is being exercised and shall be accompanied by payment for such Common Stock in cash, certified or cashier’s check or by personal check, if acceptable to the Corporation, or in such other manner as specified in the Plan. A form of Notice of Exercise is attached hereto.

        5.        Withholding. In the event that the Grantee elects to exercise this Option or any part thereof, and if the Corporation shall be required to withhold any amounts by reasons of any federal, state or local tax laws, rules or regulations in respect of the issuance of shares to the Grantee pursuant to the Option, the Corporation shall be entitled to deduct and withhold such amounts from any payments to be made to the Grantee. In any event, the Grantee shall make available to the Corporation, promptly when requested by the Corporation, sufficient funds or shares of Common Stock of the Corporation held for at least six months, to meet the requirements of such withholding; and the Corporation shall be entitled to take and authorize such steps as it may deem advisable in order to have such funds available to the Corporation out of any funds or property due or to become to the Grantee. In any event, the Grantee shall make available to the Corporation, promptly when requested by the Corporation, sufficient funds or shares of Common Stock of the Corporation held for at least six months, to meet the requirements of such withholding; and the Corporation shall be entitled to take and authorize such steps as it may deem advisable in order to have such funds available to the Corporation out of any funds or property due or to become to the Grantee.

        6.        Exercise Upon Death or Termination of Employment. Except as provided in Exhibit A, if the Grantee’s employment with the Company or any subsidiary terminates for any reason other than gross misconduct, the option shall remain in force for a period of ninety (90) days and remain subject to the terms of the Plan and this Agreement. If Grantee shall die while an employee of the Company or any subsidiary or within ninety (90) days after termination of employment, this option may be exercised (subject to the previous sentence), to the extent that the Grantee was entitled to do so at the date of death, by the person or persons to whom Grantee’s rights under this option pass by will or applicable law, or if no such person has such right, by his or her executors or administrators, subject to the terms of this Agreement. If Grantee is terminated for cause as described in the Agreement, this option shall terminate as of the date of such termination.

        7.        No Right of Employment. Nothing contained in this Agreement shall obligate the Company or any subsidiary of the Company to continue the employment of Grantee for any particular period or interfere with the right of the Company or any such subsidiary to terminate Grantee’s employment at any time.

        8.        No Shareholder Rights. Grantee shall have no rights as a stockholder with respect to any shares of Common Stock subject to this Option prior to the date of issuance of a certificate or certificates for such shares.

        9.        Investment Representation. Notice of the exercise of this Option may include a representation that any of the Option shares purchased shall be acquired as an investment and not with a view to, or for sale in connection with, any public distribution.

        10.      Compliance with Law and Regulations. The Grantee acknowledges that this Option may not be exercised until the Corporation has taken all actions then required to comply with all applicable federal and state laws, rules and regulations and any exchange on which the Common Stock may then be listed. The certificates representing the shares purchased upon the exercise of this Option may bear a legend in substantially the following form:

2

These shares have not been registered either under any applicable federal law and rules and resale will not be permitted under state law unless the shares are first registered under the Minnesota Securities law. Further, no sale, offer to sell, or transfer of these shares shall be made unless a registration statement under the federal Securities Act of 1933, as amended, with respect to such shares is then in effect or an exemption from the registration requirements of such Act is then in fact applicable to such shares.

        11.      Non-Transferability. This Option shall not be transferable other than by will or by laws of descent and distribution. During the lifetime of the Grantee, this Option shall be exercisable only by such Grantee.

        12.      Other Assistance. Upon the exercise of this Option the Grantee or other person exercising the Option must execute a shareholder’s agreement and make any representation or give any commitment which the Company, in its discretion, deems necessary or advisable by reason of the securities laws of the United States or any state, and execute any document or pay any sum of money in respect of taxes or undertake to pay or have paid any such sum which the Company, in its discretion, deems necessary be reason of the Code or any rule or regulation thereunder, or by reason of the tax laws of any state.

        13.      Dispute or Disagreement. As a condition of the granting of this option, the Grantee agrees that any dispute or disagreement which may arise under or as a result of or pursuant to this Agreement or the Plan shall be determined by the Company in its sole discretion, and that any interpretation by the Company of the terms of this Agreement or the Plan shall be final, finding and conclusive.

        14.      Binding Agreement. This Agreement shall be binding upon and inure to the benefit of the legal representatives, executors, administrators, successors and assigns of each party to this Agreement.

        15.      Complete Agreement. This Agreement sets forth the entire understanding of the parties hereto and shall not be amended, changed or terminated except by an instrument in writing signed by the parties to this Agreement.

        16.      Counterparts and Governing Law. This Agreement may be executed in counterparts, and its validity, construction and performance, shall be governed by the laws of the state of Minnesota.

        17.      Cause. Termination by the Company of the Grantee’s employment for “Cause” shall mean termination upon:

(1)
The willful and continued failure by the Grantee to substantially perform Grantee’s duties with the Company (other than any such failure resulting from Grantee’s incapacity due to physical or mental illness) after a written demand for substantial performance is delivered to the Grantee by the Company, which demand specifically identifies the manner in which the Company believes that Grantee has not substantially performed Grantee’s duties; or

3

(2)
the willful engaging by the Grantee in conduct which is demonstrably and materially injurious to the Company, monetarily or otherwise.

For purposes of this Section, no act, or failure to act, on the Grantee’s part shall be deemed “willful” unless done, or omitted to be done, by the Grantee not in good faith and without reasonable belief that the Grantee’s action or omission was in the best interest of the Company.

4

        IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the grant date set forth in Exhibit A attached hereto.

MEDTOX SCIENTIFIC, INC

By:     /s/   Richard J. Braun

           Richard J. Braun

Title:  CEO/President

GRANTEE

[Grantee's signature is set forth on Exhibit A

attached hereto and made a part hereof.]

5

NOTICE OF EXERCISE OF STOCK OPTION

MEDTOX Scientific, Inc.
402 West County Road D
New Brighton, Minnesota 55112

        The undersigned is the holder of a Stock Option (the “Option”) to purchase shares of Common Stock of MEDTOX Scientific, Inc. (the “Corporation “), pursuant to the terms of the Stock Option Agreement between the Corporation and the undersigned (the “Agreement”). The undersigned hereby irrevocably elects to exercise the Option to purchase _______ shares of Common Stock (the “Option Shares”). Enclosed herewith are (1) the original signed Agreement, and (2) payment for the Option Shares as required under the Agreement. The undersigned requests that the certificate representing the Option Shares be issued in the name of the undersigned and delivered to the address set forth below.

        In connection with the issuance of the Option Shares to the undersigned, the undersigned hereby certifies and represents to the Corporation that the undersigned is acquiring such shares for the purpose of investment and not with a view toward distribution. The undersigned understands that these securities have not been registered either under any applicable federal law and rules or applicable state law and rules and that resale will not be permitted under state law unless the securities are first registered or the sale is a transaction exempt from registration under the applicable state securities law.

        The undersigned further understands that no sale, offer to sell, or transfer of the Option Shares shall be made unless a registration statement under the federal Securities Act of 1933, as amended (the “Act”), with respect to the Option Shares is then in effect or an exemption from the registration requirements of the Act is then in fact applicable to the Option Shares. The undersigned understands that a legend reciting this investment restriction may be placed on any stock certificate that may be issued to the undersigned.

Dated:______________________

___________________________
                (Grantee Signature)

___________________________
                         (Address)

S.S. No._____________________

6

EXHIBIT A
TO NONQUALIFIED INDUCEMENT STOCK OPTION AGREEMENT
MEDTOX SCIENTIFIC, INC.

Name of Grantee: Robert C. Bohannon

Social Security #: ###-##-####

Date of Grant: December 3, 2003

Number of Shares Granted: 20,000

Exercise Price: $5.69 per share

Vesting: The Options shall vest pro rata on a daily basis during the period

commencing on December 3, 2003, and ending on December 2,

2006. All Options shall vest immediately upon the occurrence of

an Acceleration Event as described in the Plan, death of Grantee or

Grantee becomes Disabled

MEDTOX Scientific, Inc. Accepted and agreed to by

the undersigned Grantee

By:  s/s Richard J. Braun                s/s Robert C. Bohannon

        Richard J. Braun Signature

Title: CEO/President

[Please execute two copies of this Exhibit A
and return one copy to the Corporation.]

7

EX-10 6 exhibit10-25.htm EXHIBIT 10.25 Exhibit 10.25

Exhibit 10.25

RESTRICTED STOCK INDUCEMENT
AWARD AGREEMENT
(Shares not issued under the Equity Compensation Plan)

        THIS RESTRICTED STOCK AWARD AGREEMENT (the "Agreement") reflects the offer of an inducement award of Restricted Stock pursuant to the terms set forth herein as of this 3rd day of December, 2003, by MEDTOX Scientific, Inc. (formerly EDITEK, Inc.), a Delaware corporation, to Robert C. Bohannon (the "Participant").

        For valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

    1.        Defined Terms. Unless the context clearly requires otherwise, capitalized terms shall have the meaning specified in the MEDTOX Scientific, Inc. Equity Compensation Plan (the “Plan”).

    2.        Award. The Committee hereby offers to Participant 5,500 shares of MEDTOX Scientific, Inc. (the “Restricted Stock”). These shares of stock are not being offered as part of the Equity Compensation Plan. Unless this offer of Restricted Stock is accepted and a fully executed copy of this Agreement is delivered to the Committee within 60 days, this offer shall lapse.

    3.        Restriction Period. Except as otherwise provided herein, if the Participant’s employment with the Company terminates prior to the third anniversary of the offer date of this Agreement (the “Restriction Period”), all shares of Restricted Stock subject to this Agreement shall be forfeited by the Participant and shall revert to the Company.

    4.        Waiver of Restriction Period. All restrictions, including employment during the Restriction Period, shall be waived if one of the following events occurs:

               a.        an Acceleration Event;

               b.        death of the Participant;

               c.        Disability; or

               d.        the restrictions are waived in the sole discretion of the Chief Executive Officer of the Company or the Committee, in the case of an award to the Chief Executive Officer of the Company.

- 2 -

    5.        Non-Transferability, Possession and Delivery of Shares. A Participant may not sell, exchange, transfer, pledge, hypothecate or otherwise dispose of Restricted Stock during the Restriction Period. The certificates representing shares of Restricted Stock shall be held in custody by the Company until the Restriction Period expires or until restrictions thereon otherwise lapse, and the Participant shall deliver to the Company a stock power endorsed in blank relating to the Restricted Stock. If the Restriction Period expires without a prior forfeiture of the Restricted Stock or in the case of the occurrence of an Acceleration Event, unrestricted certificates for such shares shall be delivered to the Participant.

    6.        Taxes and Withholding. The Company may make such provisions and take such steps as it may deem necessary or appropriate for the withholding or payment of any taxes which the Company is required by any law or regulation of any governmental authority, whether federal, state or local, domestic or foreign, to withhold or pay in connection with all or any portion of this award. Participant agrees to give the Committee prompt written notice of any election made by such Participant under Section 83(b) of the Code, or any similar provision thereof.

    7.        Voting and Dividend Rights. During the Restriction Period, the Participant shall possess all of the rights of a shareholder of the Company, including the right to vote the shares to the extent, if any, such shares possess voting rights and the right to receive any dividends. In the event the Company declares a stock dividend on the Restricted Stock, such shares shall be subject to the same restrictions as the underlying Restricted Stock and shall be paid to the Company to be held in custody for the benefit of the Participant.

- 3 -

    8.        Miscellaneous. Nothing in the Plan or this Agreement shall confer upon any Participant any right to continue in the employ of the Company, or to serve as a director thereof, or interfere in any way with the right of the Company to terminate his or her employment at any time. No award granted shall be deemed salary or compensation for the purpose of computing benefits under any employee benefit plan or other arrangement of the Company for the benefit of its employees unless the Company shall determine otherwise. No Participant shall have any claim to an award until it is actually granted under the Plan. To the extent that any person acquires a right to receive payments from the Company under the Plan or this Agreement, such right shall, except as otherwise provided by the Committee, be no greater than the right of an unsecured general creditor of the Company.

        The grant of an award shall be subject to all applicable federal and state laws, rules, and regulations and to such approvals by any United States government or regulatory agency as may be required.

- 4 -

        This Agreement, the Plan and all actions taken hereunder shall be governed by the laws of the State of Delaware. If the provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any jurisdiction, or would disqualify the Agreement under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Agreement, it shall be stricken and the remainder of the Agreement shall remain in full force and effect.

    9.        Acceptance. The terms and provisions of this Agreement and the Plan shall be binding upon, and shall inure to the benefit of the Participant and his or her executors or administrators, heirs, and personal and legal representatives. Execution of this Agreement below shall signify the Participant’s acceptance of this Agreement together with the Plan and that they set forth all of the provisions, agreements, conditions, understandings, warranties and representations between the parties with respect to the Restricted Stock and that there are no premises, agreements, conditions, understandings, warranties, or representations, oral or written, express or implied, between the parties with respect to the Restricted Stock other than as set forth in the Agreement and Plan.

MEDTOX Scientific, Inc.

By:   /s/ Richard J. Braun
         Richard J. Braun
         Its:  CEO/President

Accepted by:

/s/ Robert C. Bohannon
Participant

Date: December 3, 2003

- 5 -

EX-10 7 exhibit10-26.htm EXHIBIT 10.26 Exhibit 10.26

Exhibit 10.26

PURCHASE AND SALE AGREEMENT

EFFECTIVE DATE: July 1, 2003

PARTIES: Cox Health, a Missouri corporation

1423 N. Jefferson

Springfield, MO 65802

Fax No. (417) 269-3092

Attn: David Stewart                                               ("Cox")

Medtox Laboratories, Inc., a Minnesota corporation

402 West County Road D

St. Paul, MN 55112

Fax No. (651) 628-6150

Attn: Kevin Wiersma                                             ("Medtox")

RECITALS:

       A.        Cox currently performs testing for drugs of abuse (the “Services”) to certain businesses (the “Customers”).

       B.        Medtox desires to purchase from Cox its Customer List (defined below), free and clear of any and all liabilities, liens, claims, charges, security interests, pledges, restrictions and encumbrances of every kind and character (collectively, the “Encumbrances”), subject to the terms and conditions of this Purchase and Sale Agreement (the “Agreement”).

       C.        Cox has agreed to sell the Customer List (defined below) to Medtox subject to the terms and conditions of this Agreement.

AGREEMENT:

        In consideration of the mutual promises set forth herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

      1.        Sale of Customer List.

           a.        Description of Customer List. Upon the terms and subject to the conditions of this Agreement, Cox shall sell, transfer, assign, convey, and deliver to Medtox, and Medtox shall purchase from Cox, free and clear of all Encumbrances, all of Cox’s right, title and interest in and to the list of all of the Customers (including such Customers’ contact information) attached hereto as Exhibit A (collectively, the “Customer List”).

1

           b.        Purchase Price. In consideration of the sale of the Customer List by Cox to Medtox, Medtox agrees to pay Cox as set forth on Schedule 1(b).

           c.        Reports and Payment. On or before the end of the fourth full calendar month following the Effective Date and within thirty (30) days after the end of each three (3) month period thereafter during the term of this Agreement, Medtox shall provide to Cox a written report itemizing the amounts invoiced to Customers and the Cash Revenues and shall deliver payment for the amounts then due to Cox; provided, however, Medtox shall be entitled to withhold any portion or all of the payments due Cox pursuant to Section 7.

           d.        Records. Medtox agrees to keep accurate written records in sufficient detail to enable the consideration payable under this Agreement by Medtox to be determined and verified. Medtox shall maintain such records during the term of this Agreement and for a period of not less than three (3) years thereafter; provided, however, the obligation of Medtox to maintain such records shall terminate upon breach by Cox of any covenant or agreement contained in this Agreement or any representation or warranty made by Cox shall prove to be materially untrue or misleading.

           e.        Audit of Records. Upon reasonable notice and during regular business hours, Medtox shall make its business records relating to the Customer List available for audit by an independent accountant selected by Cox to verify the accuracy of the reports provided and the payments made by Medtox to Cox under this Agreement. Such audits shall be at the expense of Cox; provided, however, (i) if any such audit reveals underpayment by more than five percent (5%) during the audit period, Medtox shall reimburse Cox for all expenses incurred by Cox to conduct such audit, and (ii) the obligation of Medtox to make its business records available to Cox shall terminate upon breach by Cox of any covenant or agreement contained in this Agreement or any representation or warranty made by Cox shall prove to be materially untrue or misleading.

      2.        No Assumption of Liabilities. Medtox is not assuming any liabilities, obligations or undertakings of Cox.

      3.        Transition of Customer Business.

           a.        Open Purchase Orders. Cox shall perform Services on any Customer order submitted prior to the Effective Date.

           b.        Outstanding Invoices. Cox shall retain all payments received by it under outstanding invoices for Services ordered prior to the Effective Date.

      4.        Representations and Warranties of Cox. Cox represents and warrants as follows:

2

           a.        Organization. Cox is a corporation duly organized, validly existing and in good standing under the laws of the state of Missouri. Cox has all corporate right, power and authority, and holds any and all privileges, franchises, immunities, licenses, permits, authorizations and approvals, and has made any and all qualifications, registrations and filings, which are required (by law, contract, agreement or otherwise) for it to own and operate its properties and assets, and to otherwise carry on and conduct the Business.

           b.        Authority. This Agreement has been duly authorized, executed and delivered by Cox and is valid and binding obligation of Cox enforceable against Cox in accordance with its terms except as such enforceability may be limited by applicable bankruptcy, insolvency, moratorium and similar laws affecting creditors rights generally and except as such enforceability may be limited by general principles of equity; and Cox has full corporate right and power to enter into and perform its obligations under this Agreement.

           c.        Qualifications. Cox is qualified to do business as a foreign corporation in each jurisdiction where the conduct of its business or its ownership of properties requires such qualifications.

           d.        Conflicts. Neither the execution, delivery or performance of this Agreement nor the consummation of the transactions contemplated hereby, does or will, after the giving of notice, or the lapse of time, or otherwise, (i) conflict with, result in a breach of, or constitute a default under, the Articles of Incorporation or By-laws of Cox, or any federal, state or local law, statute, code, ordinance, rule or regulation, or any federal, state or local court or administrative order or process, or any contract, agreement, arrangement, commitment or plan to which Cox is a party, or under which Cox may be obligated, or by which Cox may be subject or bound, (ii) result in the creation of any mortgage, pledge, lien, claim, charge, encumbrance or assessment upon, or otherwise adversely affect, any of the Customer List, or (iii) terminate, amend or modify, or give any party the right to terminate, amend, modify, abandon or refuse to perform or comply with, any contract, agreement, arrangement, commitment or plan to which Cox is a party, or under which Cox may be obligated, or by which Cox may be subject or bound.

           e.        Title to Customer List. Cox has good and marketable title to the Customer List, free and clear of any Encumbrances or other adverse interests of any kind.

           f.        Compliance with Law. Cox is not materially in default under or in violation of any applicable statute, law, ordinance, decree, order, rule, regulation, franchise, permit or license of any governmental body applicable to the Customer List or the Services.

           g.        Customer List. The Customer List does not contain individual names or any other potentially identifying information about the individuals who have been tested or will be tested in connection with the Services.

3

           h.        Consents. Cox is not required to obtain any consent or other approvals from any governmental agency or other person (including, without limitation, any Customer and any financial institution) as a result of the transactions contemplated hereby.

           i.        Privacy. Neither the creation, possession or use of the Customer List, nor the transfer of the Customer List to Medtox along with subsequent possession and use by Medtox, has violated or will violate any applicable law or regulation, including but not limited to, the Federal Trade Commission Act (FTC Act) or Health Insurance Portability and Accountability Act (HIPPA) and the regulations promulgated thereunder. Cox further represents and warrants that it has not adopted any privacy or similar policy and has not given any notices or made any statements regarding privacy, confidential information or the like to any of the Customers.

           j.        Non-Disclosure. Cox has not disclosed, granted a license to use, transferred or otherwise shared the Customer List with any person or entity engaged in the Business during the past three (3) years.

      5.        Representations and Warranties of Medtox. Medtox represents and warrants as follows:

           a.        Organization. Medtox is a corporation, duly organized and validly existing and in good standing under the laws of Minnesota.

           b.        Authority. This Agreement has been duly authorized, executed and delivered by Medtox and is a valid and binding obligation of Medtox enforceable against Medtox in accordance with its terms; and Medtox has full corporate right and power to enter into and perform its obligations under this Agreement.

6. Covenants of Cox.

           a.        Covenant Not to Compete. For a period of five (5) years commencing as of the Effective Date, anywhere in the United States, neither Cox nor any of its affiliates shall directly or indirectly, either for itself or any other person, (i) own, manage, control, participate in, permit is name to be used by, consult with, render services for or otherwise assist in any manner any entity that owns, invests in, manages, controls or engages in the Services (the “Restricted Business”), (ii) employ or attempt to employ or assist anyone else to employ any current or future employee of Medtox without the prior written consent of Medtox, or (iii) solicit any Customer or do business substantially identical to, or competitive with the Restricted Business. If, at the time of enforcement of this Section 6, the duration, scope or area restrictions stated herein are found to be unreasonable under circumstances then existing, the parties agree that the maximum duration, scope or area reasonable under such circumstances shall be substituted for the stated duration, scope or area. Cox agrees that Medtox shall have the right, in addition to any other rights and remedies existing in its favor, to enforce its rights and the obligations under this Section 6 not only by an action or actions for damages, but also by an action or actions for specific performance, injunction and/or other equitable relief without posting any bond or security to enforce or prevent any violations, whether anticipatory, continuing or future, of the provisions of this Section 6.

4

           b.        Confidentiality. From and after the Closing, neither Cox, nor any of its affiliates, or agents will use any the Customer List for itself or for any other person, firm, corporation, limited liability company, partnership or other entity unless such use (i) is approved for such use or disclosure by Medtox in writing, or (ii) is used or disclosed pursuant to applicable laws, statutes, rules, regulations or orders of governmental authorities or the order of any court of competent jurisdiction provided that Medtox is given reasonable prior notice of such disclosure.

           c.        Further Assurances. Cox shall deliver to Medtox such other documents and instruments as may be reasonably required to consummate the transactions contemplated hereby. All documents, instruments and opinions to be furnished by Cox pursuant hereto shall be in form and substance reasonably satisfactory to Medtox and its counsel.

      7.         Default; Remedies.

           a.        Withhold Payment. In addition to any other remedy available to Medtox, if Cox shall fail to observe or perform any of the terms, conditions, covenants or agreements required to be observed or performed by Cox under this Agreement or any representation or warranty made by Cox in this Agreement shall prove to have been untrue in any material respect or materially misleading as of the time such representation or warranty was made, Medtox may withhold any payments due to Cox under Section 1.

           b.        Specific Performance. It is understood that, in the event of a breach of this Agreement, the measure of damages at law to the affected party will be difficult to ascertain and the remedy at law may be inadequate. Accordingly, it is specifically agreed that both Cox and Medtox shall be entitled to the remedy of specific performance to enforce the terms and conditions of this Agreement

           c.        Arbitration. Except for (i) any claims for temporary or permanent injunctive relief or (ii) any causes of action brought in equity by either party hereto, any and all disputes, controversies, or claims arising out of or relating to this Agreement, or the breach, termination or invalidity thereof, shall be finally settled in accordance with this Section 7(c).

           i.        Either party may initiate negotiation proceedings by writing a letter to the other party setting forth the particulars of the dispute, the terms of the contract that are involved and the suggested resolution of the dispute. If the dispute is not resolved within thirty (30) days after delivery of the initial written letter setting forth the particulars of the dispute, either party may submit such dispute to binding arbitration conducted pursuant to the provisions of this Agreement and the commercial arbitration rules of the American Arbitration Association (“AAA”), unless such AAA rules are inconsistent with the provisions of this Supply Agreement, in which case the rules of this Agreement shall govern.

5

           ii.       The case shall be submitted to a single arbitrator who shall be a retired state or federal judge or an attorney who has practiced in the area of business litigation or in the substantive area of law related to this Agreement, for at least ten (10) years. Each party shall submit a list of three (3) arbitrators to the other party within ten (10) days after the initiating party has delivered a written notice to the other party demanding arbitration of the dispute. From the combined list, the parties shall mutually agree on the arbitrator. Should the parties be unable to agree on the choice of an arbitrator within thirty (30) days after delivery of the written notice demanding arbitration, the arbitration shall be conducted by a panel of three (3) arbitrators. Each party shall choose one arbitrator within ten (10) after the expiration of the above thirty (30) day period and the two selected shall choose a third arbitrator within five (5) days after their appointment.

           iii.      The site of the arbitration shall be in the metropolitan area of Minneapolis/St. Paul in the state of Minnesota. The exact location within such metropolitan area shall be designated by the arbitrator(s). The arbitrator(s) shall allow the parties to conduct limited discovery.

           iv.       The arbitration award shall be final and binding upon the parties and may be entered and enforced in any court having jurisdiction. Each party shall bear its own expenses and the costs of arbitration shall be borne equally by the parties.

      8.        Closing. The consummation of the transactions contemplated by this Agreement shall occur on the Effective Date (the “Closing”).

      9.        Bill of Sale. On the Effective Date, Seller shall execute and deliver to the Buyer a Bill of Sale, in the form attached as Exhibit B, conveying the Customer List to Medtox, free and clear of all Encumbrances.

      10.       General Provisions.

           a.        Expenses. Each party will pay its own legal, accounting and other expenses incurred in connection with this Agreement.

           b.        Brokerage. Neither party has engaged a broker or finder in connection with this transaction.

           c.        Nature and Survival of Representations. All statements contained in any certificate or other instrument delivered by or on behalf of a party pursuant hereto shall be deemed representations and warranties by the party making such statements. No party shall be deemed to have made any representations or warranties except as specifically provided in this Agreement. All representations and warranties of Cox contained herein and the covenants and agreements contained in Sections 5, 6, 7, 10(c) and 10(d) shall survive the consummation of the transactions contemplated by this Agreement and shall continue indefinitely.

6

           d.        Indemnification. Cox shall indemnify Medtox with respect to any claim arising from the Customer List, and any breach of any of Cox’s obligations under this Agreement, and shall hold Medtox harmless from, any out-of-pocket loss, cost, liability or expense (including, but not limited to reasonable legal fees) which Medtox may incur or suffer by reason of, or which results, arises out of, or is based upon the Customer List, the inaccuracy or breach of any representation or warranty made by Cox in this Agreement or the failure of Cox to comply with any of its covenants in this Agreement. If any damages as defined in this Section shall result in any tax saving or other monetary benefit to Medtox, the amount of such damages shall be reduced to reflect such benefit.

           e.        Notices. All notices, demands and other communications provided for in this Agreement shall be in writing and shall be given by personal delivery, via facsimile transmission (receipt telephonically confirmed), by nationally recognized overnight courier (prepaid), or by certified or registered first class mail, postage prepaid, return receipt requested, sent to each party, at its address as set forth at the beginning of this Agreement or at such other address or in such other manner as may be designated by such party in written notice to the other party. All such notices, demands and communications shall be effective when personally delivered, one (1) business day after delivery to the overnight courier, upon telephone confirmation of facsimile transmission or upon receipt after dispatch by mail to the party to whom the same is given or made.

           f.        Binding Nature. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their successors and assigns.

           g.        Entire Agreement. This Agreement, together with Exhibit A, contains the entire contract between the parties as to the subject matter hereof and supersedes any prior or contemporaneous written or oral agreements between the parties with respect to the subject matter hereof.

           h.        Severability. Any provision of the Agreement which is prohibited or unenforceable in any jurisdiction shall, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.

           i.        Captions. The captions or headings herein are for convenience only and in no way define, limit or describe the scope or intent of any provisions of this Agreement.

7

           j.        Modifications and Waivers. No purported amendment, modification or waiver of any provision of this Agreement shall be binding unless set forth in a written document signed by all parties (in the case of amendments and modifications) or by the party to be charged thereby (in the case of waivers). Any waiver shall be limited to the circumstance or event specifically referenced in the written waiver document and shall not be deemed a waiver of any other term or provision of this Agreement or of the same circumstance or event upon any recurrence thereof. The failure of any party at any time to require performance of any provisions hereof shall, in no manner, affect the right at a later date to enforce the same.

           k.        Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Minnesota, without application of its conflict of laws provisions.

           l.        Counterparts. This Agreement may be executed in any number of counterparts, and transmitted via facsimile, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[Signatures on the Following Page]

8

        IN WITNESS WHEREOF, the parties have executed this Agreement, in the manner appropriate to each, to be effective as of the date on the first page hereof.

COXHEALTH

By s/s Larry D. Wallis

    Its President and CEO

MEDTOX LABORATORIES, INC

By s/s Kevin J. Wiersma

    Its CFO, COO

9

EXHIBIT A

Customer List

Attached.

10

EXHIBIT B

Bill of Sale

Attached.

11

SCHEDULE 1(b)

Purchase Price

         In consideration of the sale of the Customer List by Cox to Medtox, Medtox agrees to pay Cox as follows:

           (i)        the sum of fifty thousand and no/100 dollars ($50,000.00) (the “Initial Payment”) at Closing (defined in Section 8); and

           (ii)       fifty percent (50%) of the Cash Revenues (defined below) (the “Initial Period Payments”), less the Initial Payment, for a period of one (1) year from the Effective Date (the “Initial Period”); and

           (iii)      six and one-half percent (6.5%) of the Cash Revenues (defined below) (the “Remaining Payments”), for a period of two years following the Initial Period; provided, however, in the event the Initial Period Payments do not equal or exceed the Initial Payment, the Remaining Payments shall be reduced by an amount equal to the Initial Payment less the Initial Period Payments.

For purposes of this Agreement, “Cash Revenues” shall mean the cash actually received by Medtox from the Customers for the amount invoiced by Medtox to the Customers, less the specimen collection costs and the Medical Review Officer (MRO) fees incurred by Medtox.

12

EX-10 8 exhibit10-27.htm EXHIBIT 10.27 Exhibit 10.27

Exhibit 10.27

August 15, 2003

THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND
SECURITY AGREEMENT

        This Amendment, dated as of August 15, 2003, is made by and between MEDTOX SCIENTIFIC, INC., a Delaware corporation (“Scientific”), MEDTOX LABORATORIES, INC., a Delaware corporation (“Laboratories”), MEDTOX DIAGNOSTICS, INC., a Delaware corporation (“Diagnostics”), and CONSOLIDATED MEDICAL SERVICES, INC., a Delaware corporation (“Consolidated”, and together with Scientific, Laboratories and Diagnostics, collectively, the “Borrowers”, and each a “Borrower”), and WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation formerly known as Norwest Business Credit, Inc. (the “Lender”).

Recitals

        The Borrowers and the Lender are parties to an Amended and Restated Credit and Security Agreement dated as of May 7, 2001 but effective as of March 31, 2001, as amended by a First Amendment to Amended and Restated Credit and Security Agreement dated as of October 24, 2001, and a Second Amendment to Amended and Restated Credit and Security Agreement dated as of May 10, 2002 (as so amended, the “Credit Agreement”). Capitalized terms used in these recitals have the meanings given to them in the Credit Agreement unless otherwise specified.

        The Borrowers have requested that certain amendments be made to the Credit Agreement, which the Lender is willing to make pursuant to the terms and conditions set forth herein.

        NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements herein contained, it is agreed as follows:

        1.        Defined Terms. Capitalized terms used in this Amendment which are defined in the Credit Agreement shall have the same meanings as defined therein, unless otherwise defined herein. In addition, Section 1.1 of the Credit Agreement is amended by adding or amending, as the case may be, the following definitions:

        “‘Debt Service Coverage Ratio’ means as of any date, the ratio of (i) the sum of (A) Pre-Tax Net Income, plus (B) year-to-date depreciation expense, plus (C) year-to-date amortization expense to (ii) the sum of (A) Current Maturities of Long Term Debt plus (B) Unfinanced Capital Expenditures.”

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 1 -

                  “‘Maximum Line’ means $8,000,000.”

        “‘Pre-Tax Net Income’ means fiscal year-to-date pre-tax net income from continuing operations, as determined in accordance with GAAP.”

        “‘Revolving Note’ means the Borrowers’ revolving promissory note, payable to the order of the Lender in substantially the form of Exhibit A to the Third Amendment and any note or notes issued in substitution therefor, as the same may hereafter be amended, supplemented or restated from time to time.

        “‘Third Amendment’ means that certain Third Amendment to Amended and Restated Credit and Security Agreement by and between the Borrowers and the Lender dated as of August 15, 2003.

                  “‘Unfinanced Capital Expenditures’ means as of any date, the difference of:

                  (i)        the difference of:

(A)         the amount of Capital Expenditures made during the year-to-date period, less,

(B)
the amount of cash proceeds (or seller credit in the form of a deferred purchase price) received by the Borrowers to finance such Capital Expenditures, less,

                  (ii)       the lesser of:

(A)         $300,000 or

(B)
the amount of Capital Expenditures made within the 90 days preceding such date for which the Borrowers are seeking financing, reduced by the amount of cash proceeds the Borrowers expect to receive from such financing.”

        2.        Financial Covenants. Sections 6.13 – 6.16 and 7.10 are amended to read as follows:

        “Section 6.13 Minimum Debt Service Coverage Ratio. The Borrowers will maintain, on a consolidated basis, during each year-to-date period described below, their Debt Service Coverage Ratio, determined as at the end of each period, at not less than the ratio set forth opposite such period:

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 2 -

Year-to-date period ending
Minimum Debt Service
Coverage Ratio

June 30, 2003 0.40 to 1.00

September 30, 2003 0.55 to 1.00

December 31, 2003 0.85 to 1.00

        “Section 6.14 Minimum Pre-Tax Net Income. The Borrowers will achieve as of each date listed below, on a consolidated basis, Pre-Tax Net Income of not less than the amount set forth opposite such date:

Date
Minimum Pre-Tax Net
Income

June 30, 2003 $(600,000)

September 30, 2003 $(275,000)

December 31, 2003 $(300,000)

March 31, 2004 $(350,000)

                  “Section 6.15 – Reserved.

                  “Section 6.16 – Reserved.

        “Section 7.10 Capital Expenditures. During each fiscal year-to-date period described below, the Borrowers and their Subsidiaries will not incur or contract to incur in the aggregate, Capital Expenditures of more than the amount set forth opposite such period:

Year-to-date period ending
Capital Expenditures

June 30, 2003 $2,500,000

September 30, 2003 $3,000,000

December 31, 2003 $3,000,000

March 31, 2004    $500,000

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 3 -

        3.        Changes to Exhibits. Exhibit B to the Credit Agreement is replaced by Exhibit B to this Amendment.

        4.        No Other Changes. Except as explicitly amended by this Amendment, all of the terms and conditions of the Credit Agreement shall remain in full force and effect and shall apply to any advance or letter of credit thereunder.

        5.        Amendment Fee. The Borrower shall pay the Lender as of the date hereof a fully earned, non-refundable fee in the amount of $5,000 in consideration of the Lender’s execution and delivery of this Amendment.

        6.        Conditions Precedent. This Amendment shall be effective when the Lender shall have received an executed original hereof, together with each of the following, each in substance and form acceptable to the Lender in its sole discretion:

    (a)        The Revolving Note, duly executed on behalf of the Borrowers.

(b)        A Certificate of the Secretary of each Borrower certifying as to (i) the resolutions of its board of directors approving the execution and delivery of this Amendment, (ii) the fact that its articles of incorporation and bylaws, which were certified and delivered to the Lender continue in full force and effect and have not been amended or otherwise modified except as set forth in the Certificate to be delivered, and (iii) that its officers and agents who have been certified to the Lender, as being authorized to sign and to act on its behalf continue to be so authorized or setting forth the sample signatures of each of its officers and agents authorized to execute and deliver this Amendment and all other documents, agreements and certificates on its behalf.

    (c)        Payment of the fee described in Paragraph 5.

    (d)        Such other matters as the Lender may require.

        7.        Representations and Warranties. Each Borrower hereby represents and warrants to the Lender as follows:

(a)        Each Borrower has all requisite power and authority to execute this Amendment and the Revolving Note and to perform all of its obligations hereunder, and this Amendment and the Revolving Note have been duly executed and delivered by the Borrower and constitute the legal, valid and binding obligation of each Borrower, enforceable in accordance with its terms.

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 4 -

(b)        The execution, delivery and performance by each Borrower of this Amendment and the Revolving Note have been duly authorized by all necessary corporate action and do not (i) require any authorization, consent or approval by any governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, (ii) violate any provision of any law, rule or regulation or of any order, writ, injunction or decree presently in effect, having applicability to any Borrower, or the articles of incorporation or by-laws of any Borrower, or (iii) result in a breach of or constitute a default under any indenture or loan or credit agreement or any other agreement, lease or instrument to which any Borrower is a party or by which it or its properties may be bound or affected.

(c)        All of the representations and warranties contained in Article V of the Credit Agreement are correct on and as of the date hereof as though made on and as of such date, except to the extent that such representations and warranties relate solely to an earlier date.

        8.        No Waiver. The execution of this Amendment and acceptance of any documents related hereto shall not be deemed to be a waiver of any Default or Event of Default under the Credit Agreement or breach, default or event of default under any Security Document or other document held by the Lender, whether or not known to the Lender and whether or not existing on the date of this Amendment.

        9.        Release. Each Borrower hereby absolutely and unconditionally releases and forever discharges the Lender, and any and all participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents and employees of any of the foregoing, from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which any Borrower has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment, whether such claims, demands and causes of action are matured or unmatured or known or unknown.

        10.        Costs and Expenses. The Borrowers hereby reaffirm their agreement under the Credit Agreement to pay or reimburse the Lender on demand for all costs and expenses incurred by the Lender in connection with the Loan Documents, including without limitation all reasonable fees and disbursements of legal counsel. Without limiting the generality of the foregoing, the Borrowers specifically agree to pay all fees and disbursements of counsel to the Lender for the services performed by such counsel in connection with the preparation of this Amendment and the documents and instruments incidental hereto. The Borrowers hereby agree that the Lender may, at any time or from time to time in its sole discretion and without further authorization by the Borrowers, make a loan to the Borrowers under the Credit Agreement, or apply the proceeds of any loan, for the purpose of paying any such fees, disbursements, costs and expenses and the fee required under paragraph 5 hereof.

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 5 -

        11.        Miscellaneous. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original and all of which counterparts, taken together, shall constitute one and the same instrument.

        IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first written above.

WELLS FARGO BUSINESS CREDIT, INC MEDTOX SCIENTIFIC, INC.

MEDTOX DIAGNOSTICS, INC

MEDTOX LABORATORIES, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Kimberly Leppanen

      Kimberly Leppanen

      Its Vice President By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - 3rd Amendment to Amended and
Restated Credit and Security Agreement

- 6 -

Exhibit A to Third Amendment to Amended and
Restated Credit and Security Agreement

REVOLVING NOTE

$8,000,000 Minneapolis, Minnesota

August 15, 2003

        For value received, the undersigned, MEDTOX SCIENTIFIC, INC., a Delaware corporation, MEDTOX LABORATORIES, INC., a Delaware corporation, MEDTOX DIAGNOSTICS, INC., a Delaware corporation, and CONSOLIDATED MEDICAL SERVICES, INC., a Delaware corporation (together, the “Borrowers”), hereby jointly and severally promise to pay as provided in the Credit Agreement (defined below), to the order of WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation (the “Lender”), at its main office in Minneapolis, Minnesota, or at any other place designated at any time by the holder hereof, in lawful money of the United States of America and in immediately available funds, the principal sum of Eight Million Dollars ($8,000,000) or, if less, the aggregate unpaid principal amount of all Revolving Advances made by the Lender to the Borrowers under the Credit Agreement together with interest on the principal amount hereunder remaining unpaid from time to time, computed on the basis of the actual number of days elapsed and a 360-day year, from the date hereof until this Note is fully paid at the rate from time to time in effect under the Amended and Restated Credit and Security Agreement dated as of May 7, 2001 but effective as of March 31, 2001 (as heretofore amended and as the same may hereafter be amended, supplemented or restated from time to time, the “Credit Agreement”) by and among the Lender and the Borrowers. The principal hereof and interest accruing thereon shall be due and payable as provided in the Credit Agreement. This Note may be prepaid only in accordance with the Credit Agreement.

        This Note is issued pursuant, and is subject, to the Credit Agreement, which provides, among other things, for acceleration hereof. This Note is the Revolving Note referred to in the Credit Agreement. This Note is secured, among other things, pursuant to the Credit Agreement and the Security Documents as therein defined, and may now or hereafter be secured by one or more other security agreements, mortgages, deeds of trust, assignments or other instruments or agreements. To the extent this Note evidences the Borrowers’ obligation to pay Revolving Advances made before the date hereof, this Note is issued in substitution for and replacement of but not in payment of the Borrowers’ promissory note dated as of January 14, 1998, payable to the order of the Lender in the original principal amount of $6,000,000.

Medtox - $8,000,000 Revolving Note

- 1 -

        The Borrowers hereby jointly and severally agree to pay all costs of collection, including attorneys’ fees and legal expenses in the event this Note is not paid when due, whether or not legal proceedings are commenced.

        Presentment or other demand for payment, notice of dishonor and protest are expressly waived.

MEDTOX SCIENTIFIC, INC.

MEDTOX LABORATORIES, INC

MEDTOX DIAGNOSTICS, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - $8,000,000 Revolving Note

- 2 -

Exhibit B to Third Amendment to Amended
and Restated Credit and Security Agreement

Compliance Certificate

To: Kimberly Leppanen

Wells Fargo Business Credit, Inc.

Date: __________________

Subject: Medtox Scientific, Inc.

Medtox Laboratories, Inc.

Medtox Diagnostics, Inc.

Consolidated Medical Services, Inc.

        Financial Statements

        In accordance with our Amended and Restated Credit and Security Agreement dated as of May 7, 2001, but effective as of March 31, 2001(as amended to date, the “Credit Agreement”), attached are the financial statements of MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Consolidated Medical Services, Inc. (together, the “Borrowers”) as of and for ________________ (the “Reporting Date”) and the year-to-date period then ended (the “Current Financials”). All terms used in this certificate have the meanings given in the Credit Agreement.

        I certify that the Current Financials have been prepared in accordance with GAAP, subject to year-end audit adjustments, and fairly present the Borrowers’ financial condition and the results of its operations as of the date thereof.

        Events of Default. (Check one):

|_| The undersigned does not have knowledge of the occurrence of a Default or Event of Default under the Credit Agreement not previously reported to the Lender.

|_| The undersigned has knowledge of the occurrence of a Default or Event of Default under the Credit Agreement and attached hereto is a statement of the facts with respect thereto.

Medtox - Compliance Certificate 7/2003

- 1 -

        Financial Covenants. I further hereby certify as follows:

      1.        Minimum Debt Service Coverage Ratio. Pursuant to Section 6.13 of the Credit Agreement, as of the Reporting Date, the Borrowers’ Debt Service Coverage Ratio was _____ to 1.00 which |_| satisfies |_| does not satisfy the requirement that such ratio be no less than ______ to 1.00 on the Reporting Date as set forth in table below:

Year-to-date period ending
Minimum Debt Service
Coverage Ratio

June 30, 2003 0.40 to 1.00

September 30, 2003 0.55 to 1.00

December 31, 2003 0.85 to 1.00

      2.        Minimum Pre-Tax Net Income. Pursuant to Section 6.14 of the Credit Agreement, the Borrowers’ Pre-Tax Net Income for the period ending on the Reporting Date, was $____________, which |_| satisfies |_| does not satisfy the requirement that such amount be not less than $_____________ for such period as set forth in table below:

Date
Minimum Pre-Tax Net Income

June 30, 2003 $(600,000)

September 30, 2003 $(275,000)

December 31, 2003 $(300,000)

March 31, 2004 $(350,000)

      3.        Capital Expenditures. Pursuant to Section 7.10 of the Credit Agreement, for the year-to-date period ending on the Reporting Date, the Borrowers have expended or contracted to expend for Capital Expenditures, $__________________ in the aggregate which |_| satisfies |_| does not satisfy the requirement that such expenditures not exceed $_____________ in the aggregate during such period as set forth below:

Medtox - Compliance Certificate 7/2003

- 2 -

Year-to-date period ending
Capital Expenditures

June 30, 2003 $2,500,000

September 30, 2003 $3,000,000

December 31, 2003 $3,000,000

March 31, 2004    $500,000

      4.        Salaries. As of the Reporting Date, the Borrowers |_| are |_| are not in compliance with Section 7.17 of the Credit Agreement concerning salaries.

        Attached hereto are all relevant facts in reasonable detail to evidence, and the computations of the financial covenants referred to above. These computations were made in accordance with GAAP.

MEDTOX SCIENTIFIC, INC.

MEDTOX LABORATORIES, INC

MEDTOX DIAGNOSTICS, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - Compliance Certificate 7/2003

- 3 -

EX-10 9 exhibit10-28.htm EXHIBIT 10.28 Exhibit 10.28

EXHIBIT 10.28

Wells Fargo Equipment Finance, Inc. Promissory Note

733 Marquette Avenue, Suite 700

MAC N9306-070

Minneapolis, MN 55402

Contract Number 56101-701 dated as of January 22, 2003

For Value Received, the undersigned hereby promises to pay to the order of Wells Fargo Equipment Finance, Inc. (the “Lender”) at its main office in Minneapolis, Minnesota, in lawful money of the United States of America, the principal sum of $964,672.81 together with interest on the unpaid balance hereof from the date the loan proceeds are disbursed hereunder at an annual rate (computed on the basis of actual number of days elapsed in a 360-day year) determined as set forth below.

The interest rate in effect on the date the loan proceeds are disbursed hereunder shall be 1.25% over the rate of interest then publicly announced by Wells Fargo Bank, N.A. (“the Bank”) as its base rate (the “Base”), and shall remain in effect through the last day of the calendar month in which the loan proceeds are disbursed hereunder. (The Bank may, in fact, charge some borrowers rates which are below the “Base”.) The interest rate in effect for each calendar month thereafter during the term of this Note shall be the same percentage over the Base as in effect on the last day of the preceding calendar month; provided, however, that notwithstanding any change in the Base after the maturity of this Note, this Note shall bear the same rate of interest after maturity as it bore at maturity.

The First Payment Due Date shall be the date that is one month after the date loan proceeds are disbursed hereunder. The undersigned agrees that the dates of the First Payment Due Date and the Final Installment Due Date may be left blank when this Note is executed and hereby authorizes Lender to insert such dates based upon the date the loan proceeds are disbursed.

Principal and interest shall be payable in 46 consecutive equal monthly installments of $23,307.33 each commencing on the First Payment Due Date and continuing on the same day of each month thereafter, and in a final installment of the entire unpaid balance of this Note on the Final Installment Due Date, provided; however, that annual adjustment payments shall be made as set forth below.

The amount of each monthly installment hereunder other than the final installment is the amount necessary to amortize this Note in equal monthly installments from the First Payment Due Date through the Final Installment Due Date at an interest rate of 5.50% per annum. On each annual anniversary of the First Payment Due Date, the undersigned shall pay Lender or Lender shall credit to the next installment or installments in the order of maturity, as the case may be, an amount necessary to make the unpaid principal balance of this Note on such anniversary date equal to what it would have been on such anniversary date had the interest rate hereon been the rate set forth in this paragraph throughout the previous 12 months. Payments shall be applied first to interest and then to principal.

This Note may not be prepaid, in whole or in part, during months 1-12. This Note may be prepaid, in whole or in part, at any time thereafter but only if accompanied by a prepayment premium of 2% of the principle amount prepaid in prepaid during months 13-24, 1% during months 25-36, and 0% thereafter. Any partial prepayment shall be applied to the last maturing installment or installments.

1

Each of the following shall constitute an Event of Default hereunder: (a) failure to pay any installment or other payment hereunder when due; (b) the occurrence of an Event of Default as defined in any security agreement or mortgage securing this Note; (c) the commencement of any bankruptcy or insolvency proceedings by or against the undersigned or any guarantor of this Note; and (d) any indebtedness the undersigned may now or hereafter owe to any affiliate of Lender shall be accelerated following a default thereunder or, if any such indebtedness is payable on demand, payment thereof shall be demanded. Upon the occurrence of an Event of Default, Lender may do any one or more of the following as it may elect, provided, however, that upon the occurrence of an Event of Default specified in (c) above, the entire unpaid balance of this Note shall automatically become and be due and payable without notice or demand of any kind: (i) upon written notice to the undersigned, declare the entire unpaid balance of this Note to be immediately due and payable and the same shall thereupon become and be immediately due and payable; (ii) exercise any one or more of the rights and remedies available to it under any security agreement or mortgage securing this Note or under any other agreement or by law.

The undersigned hereby waives presentment, notice of dishonor, and protest. The undersigned agrees to pay all costs of collection of this Note, including reasonable attorney’s fees. The holder hereof may change the terms of payment of this Note by extension, renewal or otherwise, and release any security for, or party to, this Note and such action shall not release any accommodation maker, endorser, or guarantor from liability on this Note.

Notwithstanding anything to the contrary contained herein, if the rate of interest, late payment fee, prepayment premium or any other charges or fees due hereunder are determined by a court of competent jurisdiction to be usurious, then said interest rate, fees and/or charges shall be reduced to the maximum amount permissible under applicable law and any such excess amounts shall be applied towards the reduction of the principal balance of this Note.

This Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Minnesota without regard to conflicts of law rules.

If this Note is signed by more than one person as Debtor, then the term “Debtor” shall refer to each of them separately and to all of them jointly, and each such person shall be liable hereunder individually in full and jointly with the others.

First Payment Due Date: March 13, 2003                                    Final Installment Due Date: December 13, 2006

See attached Annex A for signatures.

2

Wells Fargo Equipment Finance, Inc. Annex A

Investors Building, Suite 300

733 Marquette Avenue

Minneapolis, MN 55402

Annex A to Promissory Note dated as of January 22, 2003

By signing this agreement, each of the undersigned acknowledges that they are jointly and severally bound to perform all of the obligations of the Debtor under the note and the term “Debtor” shall refer to each of them separately and to all of them jointly.

In witness whereof, Debtor and Secured Party, intending to be legally bound hereby, have duly executed this Agreement, as of the day and year first aforesaid.

Debtor:      Medtox Scientific, Inc.

By: s/s Kevin J.Wiersma
Title: Secretary

Debtor:      Medtox Laboratories, Inc.

By: s/s Kevin J.Wiersma
Title: Secretary

Debtor:      Medtox Diagnostics, Inc.

By: s/s Kevin J.Wiersma
Title: Secretary

3

EX-10 10 exhibit10-29.htm EXHIBIT 10.29 Exhibit 10.29

EXHIBIT 10.29

Wells Fargo Equipment Finance, Inc. Promissory Note

733 Marquette Avenue, Suite 700

MAC N9306-070

Minneapolis, MN 55402

Contract Number 56101-702 dated as of June 06, 2003

For Value Received, the undersigned hereby promises to pay to the order of Wells Fargo Equipment Finance, Inc. (the “Lender”) at its main office in Minneapolis, Minnesota, in lawful money of the United States of America, the principal sum of $676,628.35 together with interest on the unpaid balance hereof from the date the loan proceeds are disbursed hereunder at an annual rate (computed on the basis of actual number of days elapsed in a 360-day year) determined as set forth below.

The interest rate in effect on the date the loan proceeds are disbursed hereunder shall be 1.25% over the rate of interest then publicly announced by Wells Fargo Bank, N.A. (“the Bank”) as its base rate (the “Base”), and shall remain in effect through the last day of the calendar month in which the loan proceeds are disbursed hereunder. (The Bank may, in fact, charge some borrowers rates which are below the “Base”.) The interest rate in effect for each calendar month thereafter during the term of this Note shall be the same percentage over the Base as in effect on the last day of the preceding calendar month; provided, however, that notwithstanding any change in the Base after the maturity of this Note, this Note shall bear the same rate of interest after maturity as it bore at maturity.

The First Payment Due Date shall be the date that is one month after the date loan proceeds are disbursed hereunder. The undersigned agrees that the dates of the First Payment Due Date and the Final Installment Due Date may be left blank when this Note is executed and hereby authorizes Lender to insert such dates based upon the date the loan proceeds are disbursed.

Principal and interest shall be payable in 42 consecutive equal monthly installments of $17,747.30 each commencing on the First Payment Due Date and continuing on the same day of each month thereafter, and in a final installment of the entire unpaid balance of this Note on the Final Installment Due Date, provided; however, that annual adjustment payments shall be made as set forth below.

The amount of each monthly installment hereunder other than the final installment is the amount necessary to amortize this Note in equal monthly installments from the First Payment Due Date through the Final Installment Due Date at an interest rate of 5.50% per annum. On each annual anniversary of the First Payment Due Date, the undersigned shall pay Lender or Lender shall credit to the next installment or installments in the order of maturity, as the case may be, an amount necessary to make the unpaid principal balance of this Note on such anniversary date equal to what it would have been on such anniversary date had the interest rate hereon been the rate set forth in this paragraph throughout the previous 12 months. Payments shall be applied first to interest and then to principal.

This Note may be prepaid, in whole or in part, at any time and from time to time without penalty. Any partial prepayment shall be applied to the last maturing installment or installments.

1

Each of the following shall constitute an Event of Default hereunder: (a) failure to pay any installment or other payment hereunder when due; (b) the occurrence of an Event of Default as defined in any security agreement or mortgage securing this Note; (c) the commencement of any bankruptcy or insolvency proceedings by or against the undersigned or any guarantor of this Note; and (d) any indebtedness the undersigned may now or hereafter owe to any affiliate of Lender shall be accelerated following a default thereunder or, if any such indebtedness is payable on demand, payment thereof shall be demanded. Upon the occurrence of an Event of Default, Lender may do any one or more of the following as it may elect, provided, however, that upon the occurrence of an Event of Default specified in (c) above, the entire unpaid balance of this Note shall automatically become and be due and payable without notice or demand of any kind: (i) upon written notice to the undersigned, declare the entire unpaid balance of this Note to be immediately due and payable and the same shall thereupon become and be immediately due and payable; (ii) exercise any one or more of the rights and remedies available to it under any security agreement or mortgage securing this Note or under any other agreement or by law.

The undersigned hereby waives presentment, notice of dishonor, and protest. The undersigned agrees to pay all costs of collection of this Note, including reasonable attorney’s fees. The holder hereof may change the terms of payment of this Note by extension, renewal or otherwise, and release any security for, or party to, this Note and such action shall not release any accommodation maker, endorser, or guarantor from liability on this Note.

Notwithstanding anything to the contrary contained herein, if the rate of interest, late payment fee, prepayment premium or any other charges or fees due hereunder are determined by a court of competent jurisdiction to be usurious, then said interest rate, fees and/or charges shall be reduced to the maximum amount permissible under applicable law and any such excess amounts shall be applied towards the reduction of the principal balance of this Note.

This Note shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of Minnesota without regard to conflicts of law rules.

If this Note is signed by more than one person as Debtor, then the term “Debtor” shall refer to each of them separately and to all of them jointly, and each such person shall be liable hereunder individually in full and jointly with the others.

First Payment Due Date: July 13, 2003                               Final Installment Due Date: December 13, 2006

See attached Annex A for signatures.

2

Wells Fargo Equipment Finance, Inc. Annex A

Investors Building, Suite 300

733 Marquette Avenue

Minneapolis, MN 55402

Annex A to 56101 dated as of June 6, 2003

By signing this agreement, each of the undersigned acknowledges that they are jointly and severally bound to perform all of the obligations of the Debtor under the note and the term “Debtor” shall refer to each of them separately and to all of them jointly.

In witness whereof, Debtor and Secured Party, intending to be legally bound hereby, have duly executed this Agreement, as of the day and year first aforesaid.

Debtor:      Medtox Scientific, Inc.

By: s/s Kevin J. Wiersma
Title: CFO

Debtor:      Medtox Laboratories, Inc.

By: s/s Kevin J. Wiersma
Title: CFO

Debtor:      Medtox Diagnostics, Inc.

By: s/s Kevin J. Wiersma
Title: CFO

3

EX-10 11 exhibit10-30.htm EXHIBIT 10.30 Exhibit 10.30

Exhibit 10.30

March 5, 2004

FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AND
SECURITY AGREEMENT

        This Amendment, dated as of March 5, 2004, is made by and between MEDTOX SCIENTIFIC, INC., a Delaware corporation (“Scientific”), MEDTOX LABORATORIES, INC., a Delaware corporation (“Laboratories”), MEDTOX DIAGNOSTICS, INC., a Delaware corporation (“Diagnostics”), and CONSOLIDATED MEDICAL SERVICES, INC., a Delaware corporation (“Consolidated”, and together with Scientific, Laboratories and Diagnostics, collectively, the “Borrowers”, and each a “Borrower”), and WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation formerly known as Norwest Business Credit, Inc. (the “Lender”).

Recitals

        The Borrowers and the Lender are parties to an Amended and Restated Credit and Security Agreement dated as of May 7, 2001 but effective as of March 31, 2001, as amended by a First Amendment to Amended and Restated Credit and Security Agreement dated as of October 24, 2001, a Second Amendment to Amended and Restated Credit and Security Agreement dated as of May 10, 2002, and a Third Amendment to Amended and Restated Credit and Security Agreement dated as of August 15, 2003 (as so amended, the “Credit Agreement”). Capitalized terms used in these recitals have the meanings given to them in the Credit Agreement unless otherwise specified.

        The Borrowers have requested that certain amendments be made to the Credit Agreement, which the Lender is willing to make pursuant to the terms and conditions set forth herein.

        NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements herein contained, it is agreed as follows:

        1.        Defined Terms. Capitalized terms used in this Amendment which are defined in the Credit Agreement shall have the same meanings as defined therein, unless otherwise defined herein. In addition, Section 1.1 of the Credit Agreement is amended by adding or amending, as the case may be, the following definitions:

        “‘2004 Capex Advances’ has the meaning given in Section 2.8.”

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 1 -

        “‘2004 Capex Note’ means the promissory note of the Borrowers, dated as of March ___, 2004, payable to the order of the Lender in the original principal amount $1,500,000 and in substantially the form of Exhibit A to the Fourth Amendment or any note or notes issued in substitution therefor, as the same may hereafter be amended, supplemented or restated from time to time.”

        “‘Availability’ means the difference of the (i) Borrowing Base and (ii) the sum of (A) the outstanding principal balance of the Revolving Note and (B) the L/C Amount.”

        “‘Debt Service Coverage Ratio’ means as of any date, the ratio of (i) the sum of (A) Pre-Tax Net Income, plus (B) year-to-date depreciation expense, plus (C) year-to-date amortization expense, plus (D) non-cash deferred compensation to (ii) the sum of (A) Current Maturities of Long Term Debt plus (B) Unfinanced Capital Expenditures.”

        “‘Fourth Amendment’ means that certain Fourth Amendment to Amended and Restated Credit and Security Agreement by and between the Borrowers and the Lender dated as of March 5, 2004.

        “‘Fourth Amendment Effective Date’ means the date upon which all conditions set forth in Paragraph 10 of the Fourth Amendment are satisfied.”

        “‘Maturity Date’ means March 31, 2006.”

        “‘Management Compensation Plan’ means an annual plan approved by the Borrowers’ compensation committee.

        “‘Term Advance’ means a 2000 Capex Advance, a 2000 Term Advance, a 2001 Capex Advance or a 2004 Capex Advance and “Term Advances” means the 2000 Capex Advances, the 2000 Term Advances, the 2001 Capex Advances and the 2004 Capex Advances.”

        “‘Term Floating Rate’ means an annual rate equal to the sum of the Prime Rate plus one and one-half of one percent (1.50%), which annual rate shall change when and as the Prime Rate changes.”

        “‘Term Note’ means the 2000 Term Note, the 2000 Capex Note, the 2001 Capex Note or the 2004 Capex Note and “Term Notes” means the 2000 Term Note, the 2000 Capex Note, the 2001 Capex Note and the 2004 Capex Note.”

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 2 -

        2.        Capex Advances.

       (a)        Section 2.1(b) is amended to read as follows:

                   (b)        Capex Advances.

               (i)        2000 Capex Advances. Before the date of this Agreement, the Lender made various term advances to the Borrowers to finance capital expenditures (the “2000 Capex Advances”), the Borrowers’ obligation to pay which is evidenced by the 2000 Capex Note. As of the Fourth Amendment Effective Date, the outstanding principal balance of the 2000 Capex Note was $827,530.61, with interest paid through February 29, 2004. No Borrower has any claim, defense or offset to enforcement of the 2000 Capex Note.

               (ii)       2001 Capex Advances. During the period from March 31, 2001 through March 31, 2002, the Lender made various term advances to the Borrowers to finance capital expenditures (the “2001 Capex Advances”), the Borrowers’ obligation to pay which is evidenced by the 2001 Capex Note. As of the Fourth Amendment Effective Date, the outstanding principal balance of the 2001 Capex Note was $660,428.18, with interest paid through February 29, 2004. No Borrower has any claim, defense or offset to enforcement of the 2001 Capex Note.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 3 -

        3.        2004 Capex Advances. Sections 2.8 and 2.9 of the Credit Agreement are amended to read as follows:

         Section 2.8 2004 Capex Advances. The Lender may, in its sole discretion, make advances to the Borrowers from time to time, from the Fourth Amendment Effective Date through December 31, 2004, in an aggregate amount not to exceed the lesser of $1,500,000 or eighty percent (80%) of the purchase price (less insurance, freight, delivery, interest, taxes, installation, licenses or any similar costs or expenses, and less any discounts, rebates, refunds or other reductions in price) of new Equipment other than leasehold improvements, office and recordkeeping equipment or furniture (the “2004 Capex Advances”). The Borrowers’ obligation to pay the 2004 Capex Advances shall be evidenced by the 2004 Capex Note and shall be secured by the Collateral as provided in Article III. The 2004 Capex Advances are term advances. Any 2004 Capex Advances that are prepaid may not be reborrowed.

         Section 3.1 Requests for 2004 Capex Advances. The Borrowers shall comply with the following procedures when requesting 2004 Capex Advances:

         (a)        Requests for a 2004 Capex Advance shall be made on an individual Borrower basis and shall be made in writing, by a person authorized under Section 2.3, specifying the amount of the 2004 Capex Advance, and the date it is to be made, which shall be at least five (5) Banking Days after the date of the request. The Borrowers shall be obligated to repay all 2004 Capex Advances notwithstanding the fact that the Person requesting the same was not in fact authorized to do so. Any request for a 2004 Capex Advance shall be deemed to be a representation by the Borrowers that the conditions set forth in Section 4.2 have been met as of the time of the request.

         (b)        Each request shall be accompanied by (i) the actual invoice and purchase order for the newly acquired Equipment, (ii) a description of such Equipment, (iii) evidence of (A) delivery of such Equipment to the applicable Borrower and its acceptance by the applicable Borrower, (B) title to such Equipment in the name of the applicable Borrower, (C) payment therefor or a letter from the applicable Borrower directing the Lender to disburse the 2004 Capex Advance proceeds to the Equipment vendor directly, (D) the Lender’s first priority security interest in such Equipment, (E) insurance on such Equipment in form and substance acceptable to the Lender; and (iv) such other documentation or information as the Lender may require.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 4 -

         (c)        Upon the Lender’s determination to make a 2004 Capex Advance, the Lender shall disburse the amount of the 2004 Capex Advance by crediting the same to the demand deposit account of the applicable Borrower, as specified in Section 2.2, unless the applicable Borrower and the Lender shall agree in writing to another manner of disbursement.

        4.        Payment on Term Notes. Section 2.10(d) is hereby added to the Credit Agreement:

         (d)        2004 Capex Note.

            (i)       The amount of each 2004 Capex Advance shall be due and payable beginning on the first day of the first month after the date on which that 2004 Capex Advance is made, and continuing on the first day of each month thereafter, in substantially equal monthly installments in an amount sufficient to fully amortize the principal balance of that 2004 Capex Advance in 48 equal monthly installments; the principal amount to be paid each month on the 2004 Capex Note shall be the sum of such monthly installments; and”

            (ii)       On the Termination Date, the entire unpaid principal balance of the 2004 Capex Note, and all unpaid interest accrued thereon, shall be due and payable in full.

        5.        Termination and Prepayment Fees. Section 2.17 is amended by amended subsections (a) and (b) to read as follows:

           (a)       Termination Fees. If the Credit Facility is terminated for any reason as of a date other than the Maturity Date, the Borrowers shall pay the Lender a fee equal to one percent (1%) of the Maximum Line.

           (b)        Prepayment Fees. If the Term Advances are prepaid for any reason, the Borrowers shall pay to the Lender a fee equal to one percent (1%) of the amount prepaid.

        6.        Financial Covenants. Sections 6.13, 6.14 and 7.10 are amended to read as follows:

           “Section 6.13 Minimum Debt Service Coverage Ratio. The Borrowers will maintain, on a consolidated basis, during the fiscal year 2004, their Debt Service Coverage Ratio, determined as at the end of such fiscal year, at not less than 1.10 to 1.00.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 5 -

           “Section 6.14 Minimum Pre-Tax Net Income. The Borrowers will achieve, on a consolidated basis, during each year-to-date period described below, Pre-Tax Net Income of not less than the amount set forth opposite such date:

Date
Minimum Pre-Tax Net
Income

March 31, 2004 $              0

June 30, 2004 $   650,000

September 30, 2004 $1,650,000

December 31, 2004 $2,000,000

March 31, 2005 $              0

           “Section 7.10 Capital Expenditures. During each fiscal year-to-date period described below, the Borrowers and their Subsidiaries will not incur or contract to incur in the aggregate, Capital Expenditures of more than the amount set forth opposite such period:

Year-to-date period ending
Capital Expenditures

March 31, 2004 $1,750,000

June 30, 2004 $3,000,000

September 30, 2004 $3,500,000

December 31, 2004 $3,500,000

        7.        Section 7.17 is amended to read as follows:

        “Section 7.17 Salaries. The Borrowers will not pay excessive or unreasonable salaries, bonuses, commissions, consultant fees or other compensation; or increase the salary, bonus, commissions, consultant fees or other compensation of any directors, shareholders owning 10% or more of the stock, consultant, or any member of their families, by more than 15% in any one year, either individually or for all such persons in the aggregate, or pay any such increase from any source other than profits earned in the year of payment; provided, however, that the Borrowers are permitted to pay annual cash bonuses pursuant to the Management Compensation Plan provided that no Default of Event of Default exists or will occur as a result of such payments.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 6 -

       8.        Consent to Payment of Subordinated Debt. Pursuant to the terms of the 10% Private Placement Subordinated Notes listed on Exhibit C to this Amendment (the “Subordinated Notes”), payment of principal and interest on the Subordinated Notes is subordinated to payment of the Obligations under the Credit Agreement, and the Borrower is required to make full payment of the Obligations under the Credit Agreement prior to any payment of principal and interest on the Subordinated Notes. Notwithstanding the foregoing, upon receipt from the Borrowers of a certificate in the form of Exhibit B stating that there are no Defaults or Events of Default under the Credit Agreement for the period ending September 30, 2004, the Lender consents to the Borrowers’ payment of all principal and interest on the Subordinated Notes, provided that (a) no Default or Event of Default exists or will occur as a result of such payment and (b) Availability shall not be less than $750,000 after such payment.

       9.        Changes to Exhibits. Exhibit B to the Credit Agreement is replaced by Exhibit B to this Amendment.

       10.      No Other Changes. Except as explicitly amended by this Amendment, all of the terms and conditions of the Credit Agreement shall remain in full force and effect and shall apply to any advance or letter of credit thereunder.

       11.      Amendment Fee. The Borrower shall pay the Lender as of the date hereof a fully earned, non-refundable fee in the amount of $10,000 in consideration of the Lender’s execution and delivery of this Amendment.

       12.      Conditions Precedent. This Amendment shall be effective when the Lender shall have received an executed original hereof, together with each of the following, each in substance and form acceptable to the Lender in its sole discretion:

            (a)        The 2004 Capex Note, duly executed on behalf of the Borrowers.

            (b)        A Certificate of the Secretary of each Borrower certifying as to (i) the resolutions of its board of directors approving the execution and delivery of this Amendment, (ii) the fact that its articles of incorporation and bylaws, which were certified and delivered to the Lender continue in full force and effect and have not been amended or otherwise modified except as set forth in the Certificate to be delivered, and (iii) that its officers and agents who have been certified to the Lender, as being authorized to sign and to act on its behalf continue to be so authorized or setting forth the sample signatures of each of its officers and agents authorized to execute and deliver this Amendment and all other documents, agreements and certificates on its behalf.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 7 -

            (c)        Payment of the fee described in Paragraph 11.

            (d)        Such other matters as the Lender may require.

       13.      Representations and Warranties. Each Borrower hereby represents and warrants to the Lender as follows:

            (a)        Each Borrower has all requisite power and authority to execute this Amendment and the 2004 Capex Note and to perform all of its obligations hereunder, and this Amendment and the 2004 Capex Note have been duly executed and delivered by the Borrower and constitute the legal, valid and binding obligation of each Borrower, enforceable in accordance with its terms.

            (b)        The execution, delivery and performance by each Borrower of this Amendment and the 2004 Capex Note have been duly authorized by all necessary corporate action and do not (i) require any authorization, consent or approval by any governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, (ii) violate any provision of any law, rule or regulation or of any order, writ, injunction or decree presently in effect, having applicability to any Borrower, or the articles of incorporation or by-laws of any Borrower, or (iii) result in a breach of or constitute a default under any indenture or loan or credit agreement or any other agreement, lease or instrument to which any Borrower is a party or by which it or its properties may be bound or affected.

            (c)        All of the representations and warranties contained in Article V of the Credit Agreement are correct on and as of the date hereof as though made on and as of such date, except to the extent that such representations and warranties relate solely to an earlier date.

       14.      No Waiver. The execution of this Amendment and acceptance of any documents related hereto shall not be deemed to be a waiver of any Default or Event of Default under the Credit Agreement or breach, default or event of default under any Security Document or other document held by the Lender, whether or not known to the Lender and whether or not existing on the date of this Amendment.

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 8 -

       15.      Release. Each Borrower hereby absolutely and unconditionally releases and forever discharges the Lender, and any and all participants, parent corporations, subsidiary corporations, affiliated corporations, insurers, indemnitors, successors and assigns thereof, together with all of the present and former directors, officers, agents and employees of any of the foregoing, from any and all claims, demands or causes of action of any kind, nature or description, whether arising in law or equity or upon contract or tort or under any state or federal law or otherwise, which any Borrower has had, now has or has made claim to have against any such person for or by reason of any act, omission, matter, cause or thing whatsoever arising from the beginning of time to and including the date of this Amendment, whether such claims, demands and causes of action are matured or unmatured or known or unknown.

       16.      Costs and Expenses. The Borrowers hereby reaffirm their agreement under the Credit Agreement to pay or reimburse the Lender on demand for all costs and expenses incurred by the Lender in connection with the Loan Documents, including without limitation all reasonable fees and disbursements of legal counsel. Without limiting the generality of the foregoing, the Borrowers specifically agree to pay all fees and disbursements of counsel to the Lender for the services performed by such counsel in connection with the preparation of this Amendment and the documents and instruments incidental hereto. The Borrowers hereby agree that the Lender may, at any time or from time to time in its sole discretion and without further authorization by the Borrowers, make a loan to the Borrowers under the Credit Agreement, or apply the proceeds of any loan, for the purpose of paying any such fees, disbursements, costs and expenses and the fee required under paragraph 11 hereof.

       17.      Miscellaneous. This Amendment may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original and all of which counterparts, taken together, shall constitute one and the same instrument.

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date first written above.

WELLS FARGO BUSINESS CREDIT, INC MEDTOX SCIENTIFIC, INC.

MEDTOX DIAGNOSTICS, INC

MEDTOX LABORATORIES, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Kimberly Leppanen

      Kimberly Leppanen

      Its Vice President By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - Fourth Amendment to Amended and
Restated Credit and Security Agreement

- 9 -

Exhibit A to Fourth Amendment to Amended and
Restated Credit and Security Agreement

2004 CAPEX NOTE

$1,500,000 Minneapolis, Minnesota

March 5, 2004

        For value received, the undersigned, MEDTOX SCIENTIFIC, INC., a Delaware corporation, MEDTOX LABORATORIES, INC., a Delaware corporation, MEDTOX DIAGNOSTICS, INC., a Delaware corporation, and CONSOLIDATED MEDICAL SERVICES, INC., a Delaware corporation (together, the “Borrowers”), hereby jointly and severally promise to pay as provided in the Credit Agreement (defined below), to the order of WELLS FARGO BUSINESS CREDIT, INC., a Minnesota corporation (the “Lender”), at its main office in Minneapolis, Minnesota, or at any other place designated at any time by the holder hereof, in lawful money of the United States of America and in immediately available funds, the principal sum of One Million Five Hundred Thousand Dollars ($1,500,000) or, if less, the aggregate unpaid principal amount of all 2004 Capex Advances made by the Lender to the Borrowers under the Credit Agreement together with interest on the principal amount hereunder remaining unpaid from time to time, computed on the basis of the actual number of days elapsed and a 360-day year, from the date hereof until this Note is fully paid at the rate from time to time in effect under the Amended and Restated Credit and Security Agreement dated as of May 7, 2001 but effective as of March 31, 2001(as amended to date and as the same may hereafter be amended, supplemented or restated from time to time, the “Credit Agreement”) by and among the Lender and the Borrowers. The principal hereof and interest accruing thereon shall be due and payable as provided in the Credit Agreement. This Note may be prepaid only in accordance with the Credit Agreement.

        This Note is issued pursuant, and is subject, to the Credit Agreement, which provides, among other things, for acceleration hereof. This Note is the 2004 Capex Note referred to in the Credit Agreement. This Note is secured, among other things, pursuant to the Credit Agreement and the Security Documents as therein defined, and may now or hereafter be secured by one or more other security agreements, mortgages, deeds of trust, assignments or other instruments or agreements.

        The Borrowers hereby jointly and severally agree to pay all costs of collection, including attorneys’ fees and legal expenses in the event this Note is not paid when due, whether or not legal proceedings are commenced.

Medtox - $1,500,000 2004 Capex Note

- 1 -

        Presentment or other demand for payment, notice of dishonor and protest are expressly waived.

MEDTOX SCIENTIFIC, INC.

MEDTOX LABORATORIES, INC

MEDTOX DIAGNOSTICS, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - $1,500,000 2004 Capex Note

- 2 -

Exhibit B to Fourth Amendment to Amended
and Restated Credit and Security Agreement

Compliance Certificate

To: Kimberly Leppanen

Wells Fargo Business Credit, Inc.

Date: __________________

Subject: Medtox Scientific, Inc.

Medtox Laboratories, Inc.

Medtox Diagnostics, Inc.

Consolidated Medical Services, Inc.

        Financial Statements

        In accordance with our Amended and Restated Credit and Security Agreement dated as of May 7, 2001, but effective as of March 31, 2001(as amended to date, the “Credit Agreement”), attached are the financial statements of MEDTOX Scientific, Inc., MEDTOX Laboratories, Inc., MEDTOX Diagnostics, Inc., and Consolidated Medical Services, Inc. (together, the “Borrowers”) as of and for ________________ (the “Reporting Date”) and the year-to-date period then ended (the “Current Financials”). All terms used in this certificate have the meanings given in the Credit Agreement.

        I certify that the Current Financials have been prepared in accordance with GAAP, subject to year-end audit adjustments, and fairly present the Borrowers’ financial condition and the results of its operations as of the date thereof.

        Events of Default. (Check one):

|_| The undersigned does not have knowledge of the occurrence of a Default or Event of Default under the Credit Agreement not previously reported to the Lender.

|_| The undersigned has knowledge of the occurrence of a Default or Event of Default under the Credit Agreement and attached hereto is a statement of the facts with respect thereto.

Medtox - Compliance Certificate

- 1 -

        Financial Covenants. I further hereby certify as follows:

      1.        Minimum Debt Service Coverage Ratio. Pursuant to Section 6.13 of the Credit Agreement, as of the Reporting Date, the Borrowers’ Debt Service Coverage Ratio was _____ to 1.00 which |_| satisfies |_| does not satisfy the requirement that such ratio be no less than 1.10 to 1.00 for fiscal year 2004.

      2.        Minimum Pre-Tax Net Income. Pursuant to Section 6.14 of the Credit Agreement, the Borrowers’ Pre-Tax Net Income for the period ending on the Reporting Date, was $____________, which |_| satisfies |_| does not satisfy the requirement that such amount be not less than $_____________ for such period as set forth in table below:

Date
Minimum Pre-Tax Net
Income

March 31, 2004 $              0

June 30, 2004 $   650,000

September 30, 2004 $1,650,000

December 31, 2004 $2,000,000

March 31, 2005 $              0

      3.        Capital Expenditures. Pursuant to Section 7.10 of the Credit Agreement, for the year-to-date period ending on the Reporting Date, the Borrowers have expended or contracted to expend for Capital Expenditures, $__________________ in the aggregate which |_| satisfies |_| does not satisfy the requirement that such expenditures not exceed $_____________ in the aggregate during such period as set forth below:

Year-to-date period ending
Capital Expenditures

March 31, 2004 $1,750,000

June 30, 2004 $3,000,000

September 30, 2004 $3,500,000

December 31, 2004 $3,500,000

      4.        Salaries. As of the Reporting Date, the Borrowers |_| are |_| are not in compliance with Section 7.17 of the Credit Agreement concerning salaries.

Medtox - Compliance Certificate

- 2 -

        Attached hereto are all relevant facts in reasonable detail to evidence, and the computations of the financial covenants referred to above. These computations were made in accordance with GAAP.

MEDTOX SCIENTIFIC, INC.

MEDTOX LABORATORIES, INC

MEDTOX DIAGNOSTICS, INC

CONSOLIDATED MEDICAL SERVICES, INC

By s/s Richard J. Braun

      Richard J. Braun

      Their Chief Executive Officer

Medtox - Compliance Certificate

- 3 -

Exhibit C to Fourth Amendment to Amended
and Restated Credit and Security Agreement

10% Private Placement Subordinated Notes

- 1 -

EX-21 12 exhibit21-1.htm EXHIBIT 21.1 Exhibit 21.1

EXHIBIT 21.1

SUBSIDIARIES OF REGISTRANT

The Company has a wholly owned subsidiary, New Brighton Business Center, LLC. The subsidiary operates real estate property in which the Company locates its corporate headquarters.

The Company has a wholly owned subsidiary, MEDTOX Diagnostics, Inc. in Burlington, North Carolina. The subsidiary manufactures and distributes diagnostic devices.

The Company has a wholly owned subsidiary, MEDTOX Laboratories, Inc. in St. Paul, Minnesota. The subsidiary performs forensic and clinical laboratory services.

EX-31 13 ex31-1.htm EXHIBIT 31.1 Exhibit 31.1

EXHIBIT 31.1

CERTIFICATIONS

Certification of Chief Executive Officer
Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002

I, Richard J. Braun, Chief Executive Officer, certify that:

1.     I have reviewed this report on Form 10-K of MEDTOX Scientific, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)    disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a)   all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)   any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:   March 18, 2004 By:   /s/ Richard J. Braun

Richard J. Braun

Chief Executive Officer

EX-31 14 ex31-2.htm EXHIBIT 31.2 Exhibit 31.2

EXHIBIT 31.2

Certification of Chief Financial Officer
Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002

I, Kevin J. Wiersma, Chief Financial Officer, certify that:

1.     I have reviewed this report on Form 10-K of MEDTOX Scientific, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.     The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)   disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.     The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a)   all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)   any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:   March 18, 2004 By:   /s/ Kevin J. Wiersma

Kevin J. Wiersma

Chief Financial Officer

EX-32 15 ex32-1.htm EXHIBIT 32.1 Exhibit 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the Annual Report of MEDTOX Scientific, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission (the “Report”), I, Richard J. Braun, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

     (1)        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

     (2)        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:   March 18, 2004 By:   /s/ Richard J. Braun

Richard J. Braun

Chief Executive Officer

EX-32 16 ex32-2.htm EXHIBIT 32.2 Exhibit 32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

        In connection with the Annual Report of MEDTOX Scientific, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2003 as filed with the Securities and Exchange Commission (the “Report”), I, Kevin J. Wiersma, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

     (1)        The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

     (2)        The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:   March 18, 2004 By:   /s/ Kevin J. Wiersma

Kevin J. Wiersma

Chief Financial Officer

~~~~-----END PRIVACY-ENHANCED MESSAGE-----~~~~


	MEDTOX SCIENTIFIC, INC



	By: /s/ Richard J. Braun
	Richard J. Braun

	Title: CEO/President

	GRANTEE

	[Grantee's signature is set forth on Exhibit A
	attached hereto and made a part hereof.]


Name of Grantee:	Robert C. Bohannon

Social Security #:	###-##-####

Date of Grant:	December 3, 2003

Number of Shares Granted:	20,000


Exercise Price:	$5.69 per share

Vesting:	The Options shall vest pro rata on a daily basis during the period
	commencing on December 3, 2003, and ending on December 2,
	2006. All Options shall vest immediately upon the occurrence of
	an Acceleration Event as described in the Plan, death of Grantee or
	Grantee becomes Disabled


MEDTOX Scientific, Inc.	Accepted and agreed to by
	the undersigned Grantee


By: s/s Richard J. Braun	s/s Robert C. Bohannon
Richard J. Braun	Signature

Title: CEO/President


EFFECTIVE DATE:	July 1, 2003

PARTIES:	Cox Health, a Missouri corporation
	1423 N. Jefferson
	Springfield, MO 65802
	Fax No. (417) 269-3092
	Attn: David Stewart ("Cox")

	Medtox Laboratories, Inc., a Minnesota corporation
	402 West County Road D
	St. Paul, MN 55112
	Fax No. (651) 628-6150
	Attn: Kevin Wiersma ("Medtox")


	COXHEALTH



	By s/s Larry D. Wallis
	Its President and CEO


	MEDTOX LABORATORIES, INC



	By s/s Kevin J. Wiersma
	Its CFO, COO

Year-to-date period ending	Minimum Debt Service Coverage Ratio
June 30, 2003	0.40 to 1.00
September 30, 2003	0.55 to 1.00
December 31, 2003	0.85 to 1.00

Date	Minimum Pre-Tax Net Income
June 30, 2003	$(600,000)
September 30, 2003	$(275,000)
December 31, 2003	$(300,000)
March 31, 2004	$(350,000)

Year-to-date period ending	Capital Expenditures
June 30, 2003	$2,500,000
September 30, 2003	$3,000,000
December 31, 2003	$3,000,000
March 31, 2004	$500,000


WELLS FARGO BUSINESS CREDIT, INC	MEDTOX SCIENTIFIC, INC.
	MEDTOX DIAGNOSTICS, INC
	MEDTOX LABORATORIES, INC
	CONSOLIDATED MEDICAL SERVICES, INC
By s/s Kimberly Leppanen
Kimberly Leppanen
Its Vice President	By s/s Richard J. Braun
	Richard J. Braun
	Their Chief Executive Officer


To:	Kimberly Leppanen
	Wells Fargo Business Credit, Inc.

Date:	__________________

Subject:	Medtox Scientific, Inc.
	Medtox Laboratories, Inc.
	Medtox Diagnostics, Inc.
	Consolidated Medical Services, Inc.


Wells Fargo Equipment Finance, Inc.	Promissory Note
733 Marquette Avenue, Suite 700
MAC N9306-070
Minneapolis, MN 55402


Wells Fargo Equipment Finance, Inc.	Annex A
Investors Building, Suite 300
733 Marquette Avenue
Minneapolis, MN 55402

Date	Minimum Pre-Tax Net Income
March 31, 2004	$ 0
June 30, 2004	$ 650,000
September 30, 2004	$1,650,000
December 31, 2004	$2,000,000
March 31, 2005	$ 0

Year-to-date period ending	Capital Expenditures
March 31, 2004	$1,750,000
June 30, 2004	$3,000,000
September 30, 2004	$3,500,000
December 31, 2004	$3,500,000


Dated: March 18, 2004	By: /s/ Richard J. Braun
	Richard J. Braun
	Chief Executive Officer


Dated: March 18, 2004	By: /s/ Kevin J. Wiersma
	Kevin J. Wiersma
	Chief Financial Officer

ITEM 6. SELECTED FINANCIAL DATA

MEDTOX SCIENTIFIC, INC. CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2003 AND 2002 (In thousands, except share and per share data)

MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF OPERATIONS YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001 (In thousands, except share and per share data)

MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (In thousands, except share data)

MEDTOX SCIENTIFIC, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001 (In thousands)

SCHEDULE II-VALUATION & QUALIFYING ACCOUNTS

RECITALS:

AGREEMENT:

(The signature page follows.)

EXHIBIT A

Description of the Nova Building

EXHIBIT B

Description of the Nypro Buildings

EXHIBIT C

Legal Description

EXHIBIT D

Zoning of the Premises

EXHIBIT E

Ongoing Repair and Maintenance Responsibilities

EXHIBIT F

The Expansion Property

NONQUALIFIED INDUCEMENT STOCK OPTION AGREEMENT (Shares not issued under the Equity Compensation Plan)

RESTRICTED STOCK INDUCEMENT AWARD AGREEMENT (Shares not issued under the Equity Compensation Plan)

PURCHASE AND SALE AGREEMENT

RECITALS:

AGREEMENT:

EXHIBIT A

Customer List

EXHIBIT B

Bill of Sale

SCHEDULE 1(b)

Purchase Price

THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT

REVOLVING NOTE

Compliance Certificate

EXHIBIT 10.28

EXHIBIT 10.29

2004 CAPEX NOTE

Compliance Certificate

10% Private Placement Subordinated Notes

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2003 AND 2002
(In thousands, except share and per share data)

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001
(In thousands, except share and per share data)

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share data)

MEDTOX SCIENTIFIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED DECEMBER 31, 2003, 2002, AND 2001
(In thousands)

NONQUALIFIED INDUCEMENT STOCK OPTION AGREEMENT
(Shares not issued under the Equity Compensation Plan)

RESTRICTED STOCK INDUCEMENT
AWARD AGREEMENT
(Shares not issued under the Equity Compensation Plan)

THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AND
SECURITY AGREEMENT

Certification of Chief Executive Officer
Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002

Certification of Chief Financial Officer
Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002